CENTRO DE INVESTIGAÇÃO
IPOPORTO
RESEARCH CENTER

# 2025 ACTIVITY REPORT

# TABLE OF CONTENTS

IDENTIFICATI ..... 1
Name of the R&D Unit ..... 1
Acronym ..... 1
Director/ Unit Coordinator ..... 1
Vice-Directors ..... 1
Host Institution ..... 1
Keywords ..... 1
Website ..... 1
Contacts ..... 1
R&D UNIT DESCRIPTION ..... 2
Overall Description ..... 2
Long-term goal ..... 3
Core Facilities and Operational Working Groups ..... 3
Research Team ..... 4
Human Resources (Externally funded) ..... 5
ONGOING PROJECTS ..... 8
MAJOR SCIENTIFIC OUTPUTS ..... 18
PUBLICATIONS OVERVIEW ..... 18
Number of Publications ..... 18
Impact Factor ..... 18
Publications by Area of Knowledge and Scimago classification categories ..... 19
Sum of publications' Impact Factors ..... 21
Publications' Internationalization ..... 21
EDUCATION, ADVANCED TRAINING AND SCIENTIFIC MEETINGS ..... 22
Education ..... 22
Advanced Courses ..... 30
Scientific educational programmes ..... 30
Scientific outreach activities ..... 31
Organisation/ Host of Scientific Meetings and Seminars ..... 31
CLINICAL RESEARCH OVERVIEW ..... 34
Clinical Studies ..... 34
IPO Porto's Precision Oncology Program ..... 34
Clinical Trials ..... 35
COMPETITIVE FUNDING GRANTED IN 2025 ..... 36

Research Projects ..... 36
European Agencies ..... 36
FCT & COMPETE 2030 Calls ..... 37
Other Funding ..... 38
Internal Funding Program for Integrative Research Projects- Dr. José Guimarães dos Santos Research Grants ..... 38
Human Resources ..... 39
MSCA Postdoctoral Fellowships 2025 – European Union ..... 39
FCT-Individual Call to Scientific Employment Stimulus – 7th Edition ..... 39
FCT-PhD Fellowships-Individual Call ..... 39
EXTERNAL FUNDING ..... 41
INTERNAL FUNDING ..... 42
RESEARCH GROUPS/UNITS ..... 43
CANCER BIOLOGY & EPIGENETICS GROUP ..... 44
CANCER GENETICS GROUP ..... 70
CLINICAL ONCOLOGY GROUP ..... 82
EPIDEMIOLOGY, OUTCOMES, ECONOMICS, & MANAGEMENT IN ONCOLOGY GROUP ..... 89
EXPERIMENTAL PATHOLOGY & THERAPEUTICS GROUP ..... 100
MEDICAL PHYSICS, RADIOBIOLOGY & RADIATION PROTECTION GROUP ..... 115
MOLECULAR ONCOLOGY & VIRAL PATHOLOGY GROUP ..... 125
PRECANCEROUS LESIONS & EARLY CANCER MANAGEMENT GROUP ..... 140
CLINICAL RESEARCH UNIT ..... 159
ONCOLOGY NURSING RESEARCH UNIT ..... 178
LIST OF PUBLICATIONS ..... 190
IPO PORTO RESEARCH CENTER @ NEWS ..... 221

## IDENTIFICATION OF THE R&D UNIT

### Name of the R&D Unit
IPO Porto Research Center /Centro de Investigação do IPO Porto

### Acronym
IPO Porto RC /CI-IPO Porto

### Director/ Unit Coordinator
Carmen Jerónimo, PhD
Email: carmenjeronimo@ipoporto.min-saude.pt

### Vice-Directors
Mário Dinis Ribeiro, MD, PhD
Rui Medeiros, PhD

### Host Institution
Portuguese Oncology Institute/Instituto Português de Oncologia do Porto Francisco Gentil, EPE (IPO Porto)

### Keywords
Cancer epigenetics
Cancer genetics
Clinical research
Epidemiology and outcomes research
Experimental therapy
Innovative Therapies
Medical physics
Molecular oncology
Radiation Protection
Radiobiology

### Website
[en] https://ipoporto.pt/en/eu-profissional/investigacao/

[pt] http://ipoporto.pt/centro-de-investigacao/

### Contacts
Director: Phone: +351 22508400 ext.3230
Email: centro.investigacao@ipoporto.min-saude.pt

Scientific Manager:
Phone: +351 22508400, ext.7400

Secretary: +351 22508400, ext.3241
Email: secretariado.dci@ipoporto.min-saude.pt

# R&D UNIT DESCRIPTION

## Overall Description

IPO Porto Research Center is a Department of the Portuguese Oncology Institute of Porto/Instituto Português de Oncologia do Porto Francisco Gentil, EPE (IPO Porto), Portugal's leading cancer care provider, treating over 10,000 new patients and conducting more than 50,000 follow-up appointments annually, dedicated to patient care, training, and research in Oncology (http://www.ipoporto.pt/). IPO Porto is a member of the Organization of European Cancer Institutes (OECI), being accredited since 2011 as a Comprehensive Cancer Center in collaboration with i3S—the Porto Comprehensive Cancer Center Raquel Seruca (Porto.CCC)—and coordinating the National Network of Comprehensive Cancer Centers.

IPO Porto Research Center is endowed with the mission of coordinating and developing the research activity of IPO Porto. It is a founding member of the Associated Laboratory Health Research Network (RISE-LA), coordinating the Thematic line 2 (TL2)- "Clinical & Translational Research in Oncology (R&D Unit 776) since 2021 and has been a Foundation for Science and Technology (FCT) R&D unit since 2004, rated as Excellent in the two last international evaluations (2019 and 2024).

Currently, the Research Center encompasses five translational research groups (Cancer Biology & Epigenetics; Cancer Genetics; Experimental Pathology & Therapeutics; Medical Physics, Radiobiology & Radiation Protection; and Molecular Oncology & Viral Pathology), and a group dedicated to responding to the growing needs in epidemiology of cancer, outcomes and quality of life in Oncology, as well as sustainability of health systems and value-based healthcare (Epidemiology, Outcomes, Economics & Management in Oncology). Clinical research is mainly driven by two dedicated groups: Precancerous Lesions & Early Cancer Management and the Clinical Oncology in close collaboration with the Clinical Research Unit supported by the Center for Therapeutic Innovation in Oncology, a cornerstone for the development and implementation of clinical trials, and the Oncology Nursing Research Unit, which contributes to advancing patient-centered research and care.

Additionally, the Research Center's activity is supported by the institutional Biobank that is integrated into Biobank.PT Consortium through the National Tumor Bank Network. Since 2021, IPO Porto Research Center has been a node of the GenomePT Consortium.

## Long-term goal

IPO Porto Research Center long-term objective is to enhance the delivery of Precision Cancer Medicine to Portuguese cancer patients, improving care and increasing cure rates, based on the significant advancement of knowledge accomplished by the Center's multidisciplinary team on the 3 major strategic research lines:

- Promote cancer prevention through the development of new hereditary cancer risk predictors aiming to implement effective preventive actions in specific risk groups;
- Develop new and more effective strategies for screening and early detection of the most prevalent cancers using non- or minimally invasive technologies;
- Expand access to Precision Oncology, leveraging the already ongoing program by mapping new molecular targets using multiple "omics" and other laboratory discoveries to implement innovative and more effective therapeutic approaches.

## Core Facilities and Operational Working Groups

IPO Porto Research Center's wet laboratory facilities are strewn in different buildings (Figure 1), including three translational research laboratories: **Laboratory 1 (RC-LAB1/CI-LAB1)** located in the E-Building on the 6$^{th}$ floor (sharing of equipment and laboratory space with the Service of Laboratorial Genetics); **Laboratory 2 (RC-LAB2/CI-LAB2)** located in the E-Building on the 1$^{st}$ floor and **Laboratory 3 (RC-LAB3/CI-LAB3)** located in the F-building on the 1$^{st}$ floor. Together, these facilities provide the infrastructure necessary to support a broad range of translational cancer research. To support the effective operation of these laboratories, the role of Lab Manager has been established. They will assist with laboratory management and research operations, including the implementation of experimental protocols, data analysis, team training, student supervision, funding applications, and the dissemination of scientific results. Moreover, one laboratory (**RC-LAB4/ CI-LAB4**), devoted to complex clinical data analysis and the coordination of clinical observational studies, is based on the 1$^{st}$ floor of the A-Building, while a clinical/ living laboratory is based on the 3$^{rd}$ floor. **Clinical facilities** and **the Center for Innovative Therapeutics in Oncology,** dedicated to clinical trials, are housed in the B-Building, on the 1$^{st}$ and 5$^{th}$ floors, whereas the Nursing Oncology Research Unit is located in the A-Building, on the 13$^{th}$ floor. The center's cutting-edge technological platforms include a Facility for Complex Data Analysis, Advanced Light Microscopy and Bioimaging, Flow Cytometry and FACS Sorting, Proteomics and Glycomics, *In vivo* CAM, Genomics and transcriptomics, Cytogenetics unit, Cell culture and *in vitro* models, Tissue histopathology, immunostaining, Tissue microarrays, and a Biobank.

To foster collaborative research amongst the 10 research groups/Units in data science, bioinformatics, and computational biology, while promoting knowledge sharing and skill development, the Computational Biology and Bioinformatics Working Group (**BCB$_{WG}$**) was established early in 2025.




**Figure 1** – IPO Porto Research Center facilities

## Research Team

In December 2025, IPO Porto Research Center comprised over 350 members, including 98 PhD researchers and 202 MSc graduates. The IPO Porto staff included 97 medical doctors, 18 nurses, 103 health/research technicians, 17 PhD researchers, and 24 PhD students. Additionally, 51 members were funded by external fellowships: 42 PhD Students, 7 Research Assistants, and 3 post-doctoral researchers. During this year, 34 MSc students conducted their dissertation projects under the supervision of IPO Porto researchers. The total of FTE (Full-time equivalent) for 2025 was 195.125 (Figure 2), with PhD students representing approximately 21% of the workforce and PhD researchers (including Associated and Affiliated Researchers) accounting for 31.75 FTE.




**Figure 2** – IPO Porto Research Center FTE (Full-time Equivalent) by category in 2025

## Human Resources (Externally funded)

At the end of 2025, the Centre employed 14 PhD researchers hired with external funding (Table 1; Figure 3), 5 of whom held permanent positions under the FCT TENURE program (1st Edition), representing a meaningful 267% increase in stable full-time positions.

**Table 1** – PhD Researchers hired by type of funding

| Category | No. | Funding Program |
|---|---|---|
| **Assistant Researcher** | 5 | FCT-TENURE 1st Edition (2023.14811.TENURE) |
| **Assistant Researcher** | 1 | ONCOSCREEN (ID: 101097036 HORIZON-MISS-2021-CANCER-02) |
| **Junior Researcher** | 1 | FCT Pluriannual Funding (UIDP/00776/2025) |
| **Junior Researcher** | 1 | Individual Stimulus of Scientific Employment – 4th ed. (2021.03835.CEECIND) |
| **Junior Researcher** | 1 | Individual Stimulus of Scientific Employment – 6th ed. (2023.06366.CEECIND) |
| **Junior Researcher** | 1 | EUCanScreen (ID: 101162959 EU4H-2023-JA-2-IBA) |
| **Junior Researcher** | 1 | EUNetCCC (ID: 101183407 EU4Health) |
| **Junior Researcher** | 1 | JANE-2 (ID: 101183265 EU4Health) |
| **Junior Researcher** | 1 | ONCOVALUE (ID: 101095245 HORIZON-HLTH-2022-TOOL-11) |
| **Junior Researcher** | 1 | PAINLESS (ID: 101057367 HORIZON-HLTH-2021-DISEASE-04) |




**Figure 3** – Number of PhD researchers with a fixed-term contract funded by external agencies in the last 5 years

Additionally, a PhD student was recruited through the European Union's Horizon 2020 Marie Skłodowska-Curie Actions. During the same period, twenty-four full-time technicians, including seven PhD holders, were also hired (Table 2). These fixed-term recruitments were made possible by competitive external funding obtained through research projects.

**Table 2** – PhD Student, Technicians & Technical Assistant hired by type of funding

| Category | No. | Funding Program |
|---|---|---|
| **PhD Student** | 1 | European Union's Horizon 2020 Marie-Sklodowska Curie grant-PROSTAMET |
| **Technician** | 1 | RISE-LA (LA/P/0053/2020) |
| **Technician (with PhD)** | 2 | RISE-LA (LA/P/0053/2020) |
| **Technician** | 2 | E-OEN-2024 |
| **Technician** | 2 | E-OEN-2025 |
| **Technician** | 2 | PI220-NOVARTIS-MTBnrp |
| **Technician** | 2 | TOGAS (ID: 101101252 EU4H-2022-PJ1) |
| **Technician (with PhD)** | 1 | AIDA (ID: 101095359 HORIZON-HLTH-2022-STAYHLTH-02) |
| **Technician (with PhD)** | 1 | CCI4EU (ID: 101103746 HORIZON-MISS-2022-CANCER-01-02) |
| **Technician** | 1 | CI-IPOP-19/2024 |
| **Technician** | 1 | CI-IPOP 28/2024 |
| **Technician** | 1 | EUNetCCC (ID: 101183407 EU4Health) |
| **Technician** | 1 | HENKO (Interreg Sudoe) |
| **Technician (with PhD)** | 1 | ONCOSCREEN (ID: 101097036 HORIZON-MISS-2021-CANCER-02) |
| **Technician** | 1 | PAINLESS (ID: 101057367 HORIZON-HLTH-2021-DISEASE-04) |
| **Technician** | 1 | PCM4EU (ID: 101079984 EU4H-2021-PJ15) |
| **Technician (with PhD)** | 1 | PI218-CI-IPOP-45-20244-UHN-miR371-STM |
| **Technician (with PhD)** | 1 | PI228-CI-IPOP-22-2025-WAYFIND-R |
| **Technician** | 1 | PRIME-ROSE (ID: 101104269 HORIZON-MISS-2022-CANCER-01) & EUNetCCC (ID: 101183407 EU4Health) |
| **Technical assistant** | 1 | PI228-CI-IPOP-22-2025-WAYFIND-R |

Moreover, 42 PhD students were funded through FCT fellowships secured under five institutional calls (Figure 4 & Table 3), three Postdoctoral Researchers and three Research Assistants were supported by fellowships awarded by the Portuguese League Against Cancer (LPCC-North Region), and three Research Assistants were funded through Research projects.




**Figure 4** – Number of PhD students with fellowship funded by FCT between 2021 and 2025

**Table 3** – PhD Students, Postdoctoral Researchers & Research Assistants hired by type of funding

| Category | No. | Funding Program |
|---|---|---|
| **PhD Student** | 35 | FCT Individual grants for up to 4 years |
| **PhD Student** | 7 | FCT R&D Unit fellowship for up to 4 years |
| **Postdoctoral Researcher** | 3 | LPCC-NRN2025 |
| **Research Assistant** | 1 | LPCC-NRN2025 |
| **Research Assistant** | 2 | LPCC-NRN 2025 ONCOVAC |
| **Research Assistant** | 1 | ONCOSCREEN (ID: 101097036 HORIZON-MISS-2021-CANCER-02) |
| **Research Assistant** | 1 | PI162-CI-IPOP-155-2021 |
| **Research Assistant** | 1 | PI218-CI-IPOP-45-2024-UHN-miR371-STM |

## ONGOING PROJECTS

In 2025, the IPO Porto Research Center registered 50 active scientific projects with competitive funding. Projects led by Principal Investigators (PIs) and Co-Principal Investigators (Co-PIs), primarily affiliated with the Center, are listed below; of these, 31 secured a 100% funding rate. The European Commission fully or partially supported 21 scientific projects (Table 4), while the FCT funded or co-funded 10 projects (Table 5). Other national funding agencies supported nine projects listed in Table 6.

Additionally, 10 projects received funding through the Dr José Guimarães dos Santos Research Grant, an internal competitive funding program designed to promote interdisciplinary and integrative research initiatives, support innovative ideas at early stages, and foster collaboration across research Groups/Units (Table 7).

Projects in basic /translational research supported by internal funding or without dedicated funding are described within each research group or unit's reports.

**Table 4** – Ongoing projects with competitive funding supported by the European Union (EU)

| Start | End | Acronym | CODE | Funding Agency [Funding Rate] | Title | Budget granted | PI/ Co-PI |
|---|---|---|---|---|---|---|---|
| 01/06/2022 | 31/05/2027 | **PAINLESS** | ID: 101057367 HORIZON-HLTH-2021-DISEASE-04 | EU [100%] | Pain relief in palliative care of cancer using home-based neuromodulation and predictive biomarkers WP1 | €5 952 323.75 (Total) € 342 250.00 (IPO Porto) | Sara Brazys (PI Santiago de Compostela Univ) Rui Medeiros (IPO Porto) |
| 01/11/2022 | 31/10/2025 | **CHIP-AML22** | ID: 101079988 EU4H-2021-PJ2 | EU [80%] | Improved diagnostics and survival for all children with Acute Myeloid Leukemia treated within the NOPHO-DB- SHIP consortium; a cross-European collaboration | € 2 394 522.13 (Total) € 193 481.68 (IPO Porto) | Coord. Elise Witthoff (Skåne University Hospital, SE) Vítor Costa (IPO Porto, PT) |
| 01/12/2022 | 30/11/2026 | **ONCOVALUE** | ID: 101095245 HORIZON-HLTH-2022-TOOL-11 | EU [100%] | Implementing value-based oncology care at European cancer hospitals: An AI-based framework for assessing real-life effectiveness of novel cancer therapies in real-time | € 6 953 003.50 (Total) € 424 434.75 (IPO Porto) | Coord. Johanna Mattson (Helsinki UHHospital, FI) Luísa Conceição Lopes (IPO Porto) |
| 01/01/2023 | 31/12/2026 | **ONCOSCREEN** | Nº 101097036 HORIZON-MISS-2021-CANCER-02 | EU [100%] | ONCOSCREEN- A European “shield” against colorectal cancer based on novel, more precise and affordable risk-based screening methods and viable policy pathways | € 12 972 076.00 (Total) € 382 500,00 (IPO Porto) | Mário Dinis-Ribeiro/ Luís Lima |
| 01/01/2023 | 31/12/2026 | **AIDA** | ID: 101095359 HORIZON-HLTH-2022-STAYHLTH-02 | EU [100%] | AIDA - An Artificially Intelligent Diagnostic Assistant for gastric inflammation | € 7 274 628.75 (Total) € 791 875.00 (IPO Porto) | Coord. Tania Fleitas (Instituto de Investigación Sanitaria – INCLIVA) Mário Dinis-Ribeiro (IPO Porto) |
| 01/01/2023 | 30/06/2025 | **PCM4EU** | ID: 101079984 EU4H-2021-PJ15 | EU [80%] | Personalised Cancer Medicine for all EU citizens | € 2 943 454.71 (Total) € 160 551.90 (IPO Porto) | Coord. Hans Gelderblom (LUMC, NL) Rui Henrique/ Júlio Oliveira (IPO Porto, PT) |

**Table 4 (cont.)** – Ongoing projects with competitive funding supported by the European Union (EU)

| Start | End | Acronym | CODE | Funding Agency [Funding Rate] | Title | Budget granted | PI/ Co-PI |
|---|---|---|---|---|---|---|---|
| 01/03/2023 | 28/02/2026 | **TOGAS** | ID: 101101252 EU4H-2022-PJ1 | EU [80%] | Towards Gastric Cancer Screening Implementation in the European Union | € 9 069 648.05 (Total) € 934 957.87 (IPO Porto) | Coord. (University of Latvia, LV) Mário Dinis Ribeiro (IPO Porto, PT) |
| 01/05/2023 | 30/04/2026 | **CCI4EU** | ID: 101103746 HORIZON-MISS-2022-CANCER-01-02 | EU [100%] | COMPREHENSIVE CANCER INFRASTRUCTURES 4 EUROPE | € 9 984 080.25 (Total) € 70 750.00 (IPO Porto) | Coord. (OECI) Rui Henrique (IPO Porto, PT) |
| 01/07/2023 | 30/06/2028 | **PRIME-ROSE** | ID: 101104269 HORIZON-MISS-2022-CANCER-01 | EU [100%] | PRecisIon Cancer MEdicine RepurpOsing SystEm Using Pragmatic Clinical Trials | € 5 968 725.00 (Total) € 142 375.00 (IPO Porto) | Coord. Kjeitel Tasken (Oslo Universitetssykehus HF, NO) Rui Henrique (IPO Porto, PT) |
| 01/01/2024 | 31/12/2027 | **PROSTAMET** | ID: 101120283 HORIZON-MSCA-2022-DN-01 | EU [100%] | A Comprehensive Translational Research and Training Pipeline Harnessing Lipid Metabolism to Improve Prostate Cancer Management and Educate Young Researchers in Tackling Complex Disease | € 2 398 219.20 (Total) € 243 403.20 € (IPO Porto) | Coord. Katholieke Universiteit Leuven, BE Carmen Jerónimo (IPO Porto, PT) |
| 01/01/2024 | 31/12/2026 | **HENKO-NET** | S1/4.5/E0091 – Interreg Sudoe | FEDER/EU [75%] | Innovation and Digital Technologies for Social and Health Palliative Care at Home | € 1 497 718.24 (Total) €146 114.61 (IPO Porto) | Coord. Fundación INTRAS, SP Maria Paula Silva (IPO Porto) |
| 01/06/2024 | 31/05/2027 | **EUCanScreen** | ID: 101162959 EU4H-2023-JA-2-IBA | EU [80%] | Implementation of cancer screening programmes | € 30 999 929.42 (Total) € 638 016.39 € (IPO Porto) | Coord. Latvijas Universitate - LU Mário Dinis Ribeiro (IPO Porto, PT) |
| 01/10/2024 | 30/08/2028 | **EUNetCCC** | ID: 101183407 EU4Health | EU [80%] | European Network Comprehensive Cancer Centers | € 89 609 998.55 (Total) € 1 077 847.33 € (IPO Porto) | Coord. Thomas DUBOIS (INCa, FR) Júlio Oliveira (IPO Porto, PT) |

**Table 4 (cont.)** – Ongoing projects with competitive funding supported by the European Union (EU)

| Start | End | Acronym | CODE | Funding Agency [Funding Rate] | Title | Budget granted | PI/ Co-PI |
|---|---|---|---|---|---|---|---|
| 31/10/2024 | 30/10/2028 | **JANE-2** | ID: 101183265 EU4Health | EU [80%] | Joint Action on Networks of Expertise on Cancer | € 40 471 453.41 (Total) € 200 989.65 € (IPO Porto) | Coord. Paolo G Casali (Fondazione Irccs Istituto Nazionale Dei Tumori, IT) Júlio Oliveira (IPO Porto, PT) |
| 01/05/2025 | 30/04/2029 | **eCAN Plus** | ID: 101219434 EU4H-2024-JA-IBA-02 | EU [80%] | Enhancing the digital capabilities of cancer centres in the European Union to improve prevention and care | € 24 993 336.10 (Total) € 292 118.61 (IPO Porto) | Coord. Marc Van den Bulcke (Sciensano, BE) Maria José Bento (IPO Porto) |
| 01/06/2025 | 31/05/2028 | **CHAFT** | S2/4.5/F0150 – Interreg Sudoe | FEDER/EU [75%] | Home monitoring and identification of cisplatin-induced hearing loss risk profiles | € 1 420 990.33 (Total) € 171 320.42 (IPO Porto) | Cood. Emanuele Murana (CHU de Montpellier, Département ORL et CMF, FR) Rita Félix Soares (IPO Porto) |
| 01/09/2025 | 31/08/2028 | **CancerWatch JA** | ID: 101219450 EU4H-2024-JA-IBA-03 | EU [80%] | Improving Quality and Timeliness of Cancer Registry Data feeding into the European Cancer Information System | € 16 249 841.06 (Total) € 129 917.26 (IPO Porto) | Coord. Norwegian Institute of Public Health – NW Maria José Bento (IPO Porto) |
| 01/10/2025 | 30/09/2029 | **HOPE4Kids** | ID: 101233078 EU4H-2024-JA-IBA-09 | EU [80%] | Holistic Oncological Palliative care 4 Europe's Kids | € 11 999 945.30 (Total) € 45 097.29 (IPO Porto) | Coord. Leontien Kremer (Princess Máxima Centrum voor kinderoncologie, NL) Silvia Silva. (IPO Porto) |

**Table 4 (cont.)** – Ongoing projects with competitive funding supported by the European Union (EU)

| Start | End | Acronym | CODE | Funding Agency [Funding Rate] | Title | Budget granted | PI/ Co-PI |
|---|---|---|---|---|---|---|---|
| 01/10/2025 | 30/09/2028 | **OPTIMIZE-RT** | 2025-1-MT01-KA220-HED-000356020 | EU [100%] | Education programme to OPTIMIZE imaging doses in RadioTherapy CBCTs | € 400 000.00 (Total) € 35 613.00 (IPO Porto) | Coord. Universita Ta Malta MT Bárbara Barbosa (IPO Porto) |
| 01/11/2025 | 31/10/2029 | **EURECA** | ID: 101226733 HORIZON-MSCA-2024-DN-01 | EU [100%] | EURopean Epitranscriptomics of Cancer Academy | € 4 157 935.20 (Total) € 279 445.32 (IPO Porto) | Coord. Elena Martens-Uzunova (ERASMUSMC, NL) Carmen Jerónimo (IPO Porto) |
| 01/11/2025 | 31/10/2029 | **JA PCM** | ID: 101233450 EU4H-2024-PJ-03-4 | EU [80%] | Joint Action Personalised Cancer Medicine | € 25 281 071.49 (Total) € 261 519.13 (IPO Porto) | Coord. Marc Van den Bulcke (Sciensano, BE) Beatrice Mainoli (IPO Porto) |

**Table 5** – Ongoing projects with competitive funding supported by Fundação para a Ciência e Tecnologia/Foundation for Science and Technology (FCT)

| Start | End | Acronym | CODE | Funding Agency [Funding Rate] | Title | Budget granted | PI/ Co-PI |
|---|---|---|---|---|---|---|---|
| 01/10/2021 | 31/12/2026 | **RISE2020** | LA/P/0053/2020 | FCT [100%] | Rede de Investigação em Saúde: do Laboratório à Saúde Comunitária - RISE | € 375 000.00 (Total) €107 494.72 (IPO Porto) | Fernando Schmitt (FMUP) Carmen Jerónimo (IPO Porto) |
| 01/01/2023 | 31/08/2026 | **UCIPredict** | TRANSCAN3/0001/2021 | TRANSCAN-3_ERA-NET; FCT-EU [100%] | Circulating Tumour Microenvironment Components as Urothelial Cancer Immunotherapy Response Predictors | € 607 630 .00 (Total) € 99 635.00€ (IPO Porto) | Coord. Marta Dueñas (CIBER, SP) Carmen Jerónimo (IPO Porto, PT) |
| 01/03/2023 | 31/12/2026 | **EpImmunePCa** | 2022.04809.PTDC | FCT [100%] | On the crossroads of Immuno-Epigenetics for targeting advanced Prostate Cancer | € 249,997.48 (Total) € 239 997.48 (IPO Porto) | Margareta P. Correia/ Rui Henrique |
| 12/03/2023 | 11/03/2025 | **PCaEVision** | 2022.05135.PTDC | FCT [100%] | Decoding the role of extracellular vesicles in prostate cancer bone metastasis | € 50 000.00 | Vera Constâncio / Hector Peinado (CNIO) |
| 21/12/2023 | 19/06/2025 | **PRUNE2-PRED** | 2023.01928.RESTART | FCT [100%] | PRUNE2 gene as a novel dual-role biomarker for prostate cancer inherited predisposition and therapy response | € 49 800.00 | Andreia Brandão |
| 01/01/2025 | 31/12/2027 | **GATE** | COMPETE2030-FEDER-00886200 \| Project 15198 2023.17753.ICDT | COMPETE2030-FEDER/ FCT [100%] | GenerAlizable and Trustable computer assisted upper gastrointestinal Endoscopy | € 249 480.00 (Total) € 31 665.60 (IPO Porto) | Coord. Miguel Coimbra (INESC TEC) Mário Dinis Ribeiro (IPO Porto) |
| 01/07/2025 | 30/06/2028 | **PROMISE** | COMPETE2030-FEDER-00843200 \| Project 14871 2023.16683.ICDT | COMPETE2030-FEDER/ FCT [100%] | Multiomic Profiling of Prostate Cancer Extracellular Vesicles to Uncover Molecular Signatures for Biomarker Discovery | € 249 350.40 | Carmen Jerónimo |
| 01/07/2025 | 30/06/2026 | **Radio4Breast** | COMPETE2030-FEDER-00728700 \| Project 16134 2023.18532.ICDT | COMPETE2030-FEDER/ FCT [100%] | Mapping the potential of human breast-on-a-chip models for personalized radiation therapy | € 247 104.00 (Total) € 48 470.40 (IPO Porto) | Vanessa Fernandes Cardoso (UM) Anabela Dias (IPO Porto) |

**Table 5 (cont.)** – Ongoing projects with competitive funding supported by Foundation for Science and Technology (FCT)

| Start | End | Acronym | CODE | Funding Agency [Funding Rate] | Title | Budget granted | PI/ Co-PI |
|---|---|---|---|---|---|---|---|
| 01/09/2025 | 31/08/2028 | **JANUS** | COMPETE2030-FEDER-00910400\| Project15422 2023.17087.ICDT | COMPETE2030-FEDER/ FCT [100%] | Reengineering cervical cancer screening for the 21st century: joint action for a novel up-to-date and sustainable screening program | € 249,480.00 (Total) € 59,400.00 (IPO Porto) | Nuno Lunet (ISPUP) Rui Henrique (IPO Porto) |
| 01/09/2025 | 31/08/2028 | **NeurONiche** | COMPETE2030-FEDER-00697400 \| Project 15860 2023.16317.ICDT | COMPETE2030-FEDER/ FCT [100%] | Advanced engineering of human innervated pre-metastatic niche: elucidating the impact of prostate cancer-derived extracellular vesicles on bone metastatic pathological neurotization | € 249,998.40 (Total) € 47,520.00 (IPO Porto) | Estrela Neto (i3S) Carmen Jerónimo (IPO Porto) |

**Table 6** – Ongoing projects funded by other national agencies

| Start | End | Acronym | CODE | Funding Agency [Funding Rate] | Title | Budget granted | PI/ Co-PI |
|---|---|---|---|---|---|---|---|
| 01/03/2025 | 30/04/2026 | **CART_cDNA** | Remission 2025 | SPH/APCL/LILLY [100%] | Circulating DNA as a prognostic marker for assessing response in R/R DLBCL patients' following CAR19 T-cell therapy | € 15 000 | Sérgio Chacim |
| 01/03/2025 | 28/02/2028 | **ONCATS** | COMPETE2030-FEDER-01453400 | COMPETE2030-FEDER [85%] | Federated Network of Real-World Health Data for the Evaluation of Health Technologies and Medicines in Oncology | € 1 199 702.09 (Total)<br>€ 300 057.48 (IPO Porto) | Coord. *Promptly Health*<br>Maria José Bento (IPO Porto) |
| 01/07/2025 | 30/06/2028 | **NeuroDevice** | COMPETE2030-FEDER-00699000 \|Project 15875 | COMPETE2030-FEDER [85%] | The Challenge in the Diagnostic Assessment of Neurodevelopmental Disorders: Innovative Neurochemical Tools | € 201 849.84 (Total)<br>€ 52 509.60 (IPO Porto) | Maria de Fátima de Sá Barroso (REQUIMTE)<br>Ana Luísa Teixeira (IPO Porto) |
| 01/09/2025 | 31/08/2028 | **Breast_To_Bone** | COMPETE2030-FEDER-00686000 \| Project 15753 | COMPETE2030-FEDER [85%] | The Influence of Triple Negative Breast Cancer Secretome in Bone Pre-Metastatic Reprogramming | € 212 498.64 (Total)<br>€ 47,520.00 (IPO Porto) | Joana Paredes (i3S)<br>Carmen Jerónimo (IPO Porto) |
| 01/09/2025 | 30/08/2028 | **PRECISER** | COMPETE2030-FEDER-00721400 \| Project 16066 | COMPETE2030-FEDER [85%] | Preclinical validation of the efficacy of combined inhibition of EGFR and STAT3 for ETS-rearranged prostate carcinomas | € 203 649.12 | Paula Paulo |
| 09/09/2025 | 07/09/2028 | **BeMIC-on.chip** | COMPETE2030-FEDER-00684200 \|Project 15736 | COMPETE2030-FEDER [85%] | Bioengineering an ex vivo microenvironment of triple-negative breast cancer on-chip: a new tool to uncover new avenues for therapeutic intervention | € 212 241.60 (Total)<br>€ 25 056.00 (IPO Porto) | Silvia Bidarra (i3S)<br>Anabela Dias (IPO Porto) |
| 0110/2025 | 29/09/2028 | **DeCode** | COMPETE2030-FEDER-00685900 \| Project 15736 | COMPETE2030-FEDER [85%] | Discovering new cancer vulnerabilities by Deciphering the m6A RNA Code | € 198 288.00 (Total)<br>€ 25 704.00 IPO Porto | Raquel Almeida (i3S)<br>Carmen Jerónimo (IPO Porto) |
| 01/11/2025 | 31/01/2028 | **CAR T-Matters** | COMPETE2030-FEDER-01477200 \| Project 18427 | COMPETE2030-FEDER [85%] | Transforming the CAR T-cell therapy landscape in Portugal | € 653 797.56 | Júlio Oliveira |

**Table 6 (cont.)** – Ongoing projects funded by other national agencies

| Start | End | Acronym | CODE | Funding Agency [Funding Rate] | Title | Budget granted | PI/ Co-PI |
|---|---|---|---|---|---|---|---|
| 01/12/2025 | 30/11/2026 | **EPITARGET** | NCH2025017 | AICIB [100%] | Exploring the epigenetic modulator KDM4C for the treatment of triple-negative breast cancer (TNBC) | €75 000 (Total) €15 000 (IPO Porto) | Fátima Baltazar (ICVS-UM) Carmen Jerónimo (IPO Porto) |

**Table 7** – Internal Funding Program for integrative research projects – Dr. José Guimarães dos Santos Research Grants

| Acronym | CODE | Title | Budget granted | PI |
|---|---|---|---|---|
| **Arrest** | PI235-CI-IPOP-03-2025 | The Use of Virtual Reality for Inpatients with Cancer at the IPO Porto [*Aplicação de realidade virtual em doentes oncológicos internados no IPO-Porto]* | € 10 000.00 | Álvaro Silva |
| **DEBILItAte** | PI240-CI-IPOP-36-2025 | Dissecting histopathological and epigenetic biomarkers of intraductal, indolent and aggressive prostate carcinomas | € 20 000.00 | João Lobo |
| **ImpReSario** – | PI236-CI-IPOP-33-2025 | Implementation of the RAD51-FFPE test as a biomarker for HRD in ovarian high-grade serous carcinoma" | € 10 000.00 | Carla Bartosch |
| **LIFT Trial** | PI237-CI-IPOP-34-2025 | A phase 2 study to evaluate the safety and efficacy of Low dose radIotherapy in combination with dose adjusted of Fludarabine followed by Tisagenlecleucel treatment in refractory/relapsed non-Hodgkin diffuse large B cell lymphoma | € 750 000.00 | Delfim Duarte |
| **MEliOrate** | PI242-CI-IPOP-89-2024 | Mapping Eloquent Brain Regions for Optimized SRS in Brain Metastases | € 10 000.00 | Mavilde Longarito |
| **ProTeCteD** | PI238-CI-IPOP-81-2024 | Therapeutic personalization and cost-effectiveness analysis of Dinutuximab Beta administration at the Portuguese Oncology Institute of Porto FG, EPE [*Personalização terapêutica e análise de custo efetividade na administração de Dinutuximab Beta no Instituto Português de Oncologia do Porto FG, EPE*] | € 4 300.00 | Henriqueta Sampaio |
| **RadGames** | PI241-CI-IPOP-37-2025 | Serious Game in Health Education for Radiodermatitis | € 10 000.00 | Marisa Matos |
| **Screen4Cancer** | PI243-CI-IPOP-38-2025 | A Prospective Multicentric Study Evaluating a Novel DNA Methylation Blood Test for Multi-Cancer Early Detection | € 20 000.00 | Rui Henrique |
| **SuHRBlaC** | PI239-CI-IPOP-35-2025 | Follow-up of patients with high-risk non-muscle-invasive bladder cancer: validation of a DNA methylation-based test in a real-world setting [*Vigilância de doentes com cancro da bexiga não músculo invasivo de alto risco: validação de um teste baseado em metilação do DNA num cenário Real*] | € 10 000.00 | João André Carvalho |
| **TRANSPIRE** | PI244-CI-IPOP-39-2025 | A Pragmatic Non-Randomized Trial of Prehabilitation for Cancer Surgery Preparation: Study Protocol for a Comparative Analysis of Delivery Modes | € 7 4952.46 | Pedro Martins |

# MAJOR SCIENTIFIC OUTPUTS

## PUBLICATIONS OVERVIEW

### Number of Publications

In 2025, the IPO Porto Research Center accounted for a total of 328 peer-reviewed scientific articles with a definite publication date in 2025 (PubMed and/or Scopus, Figure 5).




**Figure 5 –** Number of publications over the last 10 years.

### Impact Factor

In 2025, IPO Porto Research Center members published a total of 328 peer-reviewed scientific articles, with 297 of those published in journals with impact factors (IF). The mean impact factor of these published articles was 5.6 (IF Source Clarivate). Moreover, 77 articles were published in journals with an impact factor above 5, and 39 articles were published in journals with an impact factor above 10 (Figure 6).




**Figure 6** –Distribution of published articles by Impact factor and mean (>5 and >10) since 2018

## Publications by Area of Knowledge and Scimago classification categories

Publications were predominantly concentrated within the domains of Medicine and Biochemistry, Genetics and Molecular Biology, as indexed in SCOPUS (Figure 7).




**Figure 7** – Publications in scientific journals according to Scopus categories

Of all indexed publications with impact factor, 176 (59%) were classified within at least one first-quartile Q1 category according to the Scimago classification (Figure 8). Among these, 47 were assigned to the "Medicine" category, 34 to "Oncology", and 20 to the "Cancer Research" category.




**Figure 8** – 2025 Publications according to IF and the Scimago classification

With respect to publications featuring a 1st author or senior (last) author affiliated with the IPO Porto Research Center, 144 were published in scientific journals with an Impact Factor. Among these, 83 were published in the Q1 category, from which 6 were published in journals with an Impact factor higher than 10 (Figure 9).




**Figure 9** – 2025 Publications according to IF and Scimago classification with IPO Porto Research Center's researchers as first or senior authors

## Sum of publications' Impact Factors

Based on publications indexed in Scopus and PubMed databases, the cumulative impact factor of the 297 indexed publications in 2025 summed 1,655.5 (Figure 10).




**Figure 10** – Distribution of the Sum of publications' Impact Factors since 2018.

## Publications' Internationalization

The research maintained a high level of global engagement, with approximately 45% of the publications (n = 148) resulting from collaborations involving co-authors affiliated with foreign institutions (Figure 11).




**Figure 11** – Proportion of publications with international collaborations since 2018.

## EDUCATION, ADVANCED TRAINING AND SCIENTIFIC MEETINGS

Several Researchers were involved in teaching and/or supervision of pre-graduate and post-graduate students.

### Education

**PhD Programmes**

**UNIVERSITY OF PORTO**

- Biomedical Engineering (FEUP/UP)
- Biomedical Sciences (ICBAS)
- Biomedicine (FMUP)
- Cardiovascular Sciences (FMUP)
- Clinical and Health Services Research (FMUP)
- Experimental and Clinical Pharmacology and Toxicology (FMUP/FFUP)
- Health Data Science (FMUP)
- Medicine (FMUP)
- Molecular and Cellular Biology (ICBAS, IBMC)
- Molecular and Cellular Biotechnology Applied to Health Sciences (ICBAS/FFUP)
- Molecular Oncology and Medicine (FMUP/ICBAS)
- Pathology and Molecular Genetics (ICBAS/FMUP)
- Physical Activity and Health (FADEUP)

**INTERNATIONAL**

- Advanced Biotechnology, Health Biotechnology (University of Vigo)

**MSc Programmes**

**UNIVERSITY OF PORTO**

- Biochemistry (ICBAS/FCUP)
- Clinical Analysis and Public Health (E2S/IPP)
- Clinical and Health Psychology (FCS/UFP)
- Educational Sciences (FPCEUP)
- Integrated MSc in Bioengineering (ICBAS/FEUP)
- Integrated MSc in Dental Medicine (FCS/UFP)
- Integrated MSc in Dental Medicine (FMDUP/ICBAS)
- Integrated MSc in Medicine (FMUP)
- Integrated MSc in Medicine (ICBAS)
- Health Evidence and Decision (FMUP)
- Integrated MSc in Medicine (UFP)
- Integrated MSc in Medicine (UM)
- Integrated MSc in Pharmaceutical Sciences (FCS/UFP)
- Medical Physics (FCUP)
- Molecular Oncology and Medicine (FMUP)
- Oncology (ICBAS)

**OTHER UNIVERSITIES/POLYTECHNIC INSTITUTES**

- Biochemistry in Health (School of Health, Polytechnic Institute of Porto)
- Laboratory Techniques in Biopathology (E2S/IPP)
- Medical Technology and Healthcare Business (E2S/IPP)
- Pharmacy (School of Health, Polytechnic University of Porto)
- Technological, Comparative and Molecular Genetics (UTAD)

**INTERNATIONAL**

- Biomedical Sciences (University of Geneva, Switzerland)
- European Master's in Molecular Pathology (Côte d'Azur University)

Eleven PhD theses (Figure 12 & Table 8) and 30 MSc dissertations supervised by researchers affiliated with the center were publicly defended (Figure 13 & Table 9).




**Figure 12** – The evolution of the number of PhD theses completed since 2018




**Figure 13** – The evolution of the number of completed MSc Dissertations since 2018.

**Table 8 –** PhD Theses completed in 2025 supervised by Integrated PhD Researchers

| Name | Fellowship | Title | Program | Faculty/University | Supervising team | Date Public defence |
|---|---|---|---|---|---|---|
| Diana Montezuma Felizardo | NA | A new vision in Pathology: From clinical implementation of Digital Pathology to algorithm development in Computational Pathology | Medical Sciences | ICBAS – School of Medicine and Biomedical Sciences, University of Porto, Portugal | S: Jaime dos Santos Cardoso<br>Co-S: Rui Henrique and Carmen Jerónimo | 04/02/2025 |
| Joana Sofia Gonçalves Guerra | SFRH/BD/138670/2018 | Inherited predisposition to gastric cancer of different histological subtypes | Biomedical Sciences | ICBAS – School of Medicine and Biomedical Sciences, University of Porto, Portugal | S: Manuel Teixeira<br>Co-S: Carla Oliveira | 07/03/2025 |
| Tiago Terras Ferreira | 2020.04789.BD | Comprehensive characterization of canine mammary tumors: Insights into histopathological features, microRNA dynamics and bioengineering 3D models | Veterinary Sciences - Biomedical Science (field) | University of Trás-os-Montes e Alto Douro (UTAD) | S: Paula Oliveira<br>Co-S: Rui Medeiros & João Mano | 13/05/2025 |
| Maria Pedro Pessoa de Barros Pereira da Silva | SFRH/BD/132441/2017 | Germline variants in genes involved in the chromosome segregation machinery associated with inherited prostate cancer predisposition | Pathology and Molecular Genetics | ICBAS – School of Medicine and Biomedical Sciences, University of Porto, Portugal | S: Manuel Teixeira<br>Co-S: Paula Paulo<br>Co-S: Hélder Maiato | 16/06/2025 |
| Catarina Guimarães-Teixeira | 2020.06038.BD | Uncovering the role of epitranscriptomic alterations in kidney cancer | Pathology and Molecular Genetics | ICBAS – School of Medicine and Biomedical Sciences, University of Porto, Portugal | S: Carmen Jerónimo<br>Co-S: Rui Henrique and Vera Miranda-Gonçalves | 03/07/2025 |
| Vera Inês Salvado Constâncio | LCF/BQ/DR20/11790013 | A multimodal approach to decoding prostate cancer: bridging biology and clinical application | Biomedical Sciences | ICBAS – School of Medicine and Biomedical Sciences, University of Porto, Portugal | S: Carmen Jerónimo<br>Co-S: Hing Leung & Bruno Costa-Silva | 22/10/2025 |
| João Antunes | SFRH/BD/147776/2019 | Cracking frailty to improve its diagnosis in the cancer set | Physical Activity and Health | Faculty of Sport of the University of Porto | S: Daniel Moreira-Gonçalves<br>Co-S: Rita Maria Pinho Ferreira; Lúcio Lara Santos | 10/11/2025 |

*NA- Not applicable*

**Table 8(cont.) –** PhD Theses completed in 2025 supervised by Integrated PhD Researchers

| Name | Fellowship | Title | Program | Faculty/University | Supervising team | Date Public defence |
|---|---|---|---|---|---|---|
| Catarina Filipa Pereira Lopes | UI/BD/151488/2021 | A roadmap toward individualized screening and management of early gastric cancer | Molecular and Cellular Biotechnology Applied to Health Sciences | ICBAS – School of Medicine and Biomedical Sciences, University of Porto, Portugal | S: Mário Dinis-Ribeiro, Co-S: Carina Pereira | 04/12/2025 |
| Clara Daher Mota | UI/BD/150674/2020 | Impact of Preoperative Physical Fitness Assessment on Predicting Postoperative Outcomes in Cancer Patients | Physical Activity and Health | Faculty of Sport of the University of Porto | S: Daniel Moreira-Gonçalves<br>Co-S: Lúcio Lara Santos | 10/12/2025 |
| Dylan Gomes Ferreira | 2020.09384.BD | Exploring the Gastric Cancer Glycoproteome towards Glycan- targeted Chimeric Antigen Receptor (CAR)-T Cells Immunotherapy | Biomedical Sciences | ICBAS – School of Medicine and Biomedical Sciences, University of Porto, Portugal | S: José Alexandre Ferreira<br>Co-S: Lúcio Lara Santos; Juan José Lasarte | 10/12/2025 |
| Rita Canário | PD/BD/128001/2016 | High-grade serous tubo-ovarian carcinoma: insights from the Fallopian tube niche into pathogenesis and biomarkers identification | Basic and Applied Biology | ICBAS – School of Medicine and Biomedical Sciences, University of Porto, Portugal | S: Joana Paredes<br>Co-S: Carla Bartosch & Manuel Teixeira | 15/12/2025 |

*NA- Not applicable*

**Table 9** – MSc dissertations completed in 2025 supervised by IPO Porto Researchers

| Name | Fellowship | Title | Program | Faculty/University | Supervising team | Date Public defence |
|---|---|---|---|---|---|---|
| Renato Manuel da Silva Rodrigues | NA | Gal-3 inhibitors as radiosensitizers for prostate cancer | Molecular Biomedicine | University of Aveiro | S: Margarida Fardilha; Co-S: Carmen Jerónimo | 01/07/2025 |
| Miguel Bernardo Oliveira Alves | NA | Expression of ENPP1 in testicular germ cell tumors: exploring its role in the pathobiology of distinct histotypes and in prognosis | Medicine | ICBAS – School of Medicine and Biomedical Sciences, University of Porto | S: João Lobo; Co-S: Rui Henrique | 11/07/2025 |
| Mariana Magalhães | NA | Deciphering the Influence of CD276 glycocode in Gastric Cancer Immunoregulation. | Health Biochemistry | School of Health of Polytechnic Institute of Porto (E2S-P.Porto) | S: Andreia Peixoto; Co-S: José Alexandre Ferreira | 20/09/2025 |
| Mariana Moreira Pires | NA | The IGF-1 Axis in Cancer-Associated Thrombosis and Cachexia: Dual Modulation of Inflammation and Survival Pathways | Metabolism | Faculty of Medicine of the University of Porto (FMUP) | S: Rui Medeiros Co-S: Valéria Tavares & Tiago Ferreira | 09/10/2025 |
| Filipa Raquel Silva Correia | NA | Biofilmes bacterianos: implicações nas infeções protésicas | Pharmaceutical Sciences | Faculty of Health Sciences, University Fernando Pessoa | S: Fátima Cerqueira | 31/10/2025 |
| Maria Miguel Pinto Lima | NA | Overcoming prostate cancer resistance using a new homologous recombination inhibitor | Oncology | ICBAS – School of Medicine and Biomedical Sciences, University of Porto | S: Lucilia Saraiva; Co-S: Vera Miranda-Gonçalves | 12/11/2025 |
| Adriana Couto | NA | Radiomics and CT: Investigating the Need for Surgery After Chemoradiotherapy in Esophageal Cancer | Mathematical Engineering | Faculty of Sciences, University of Porto | S: Inês Domingues; Co-S: João Santos | 14/11/2025 |
| Marta Lopes Rodrigues | NA | MethylCytPREDICT - Unveiling the potential of DNA promoter methylation and cytokines as biomarkers to predict BCG response in bladder cancer patients | Oncology | ICBAS – School of Medicine and Biomedical Sciences, University of Porto | S: Carmen Jerónimo; Co-S: Sara Monteiro-Reis | 18/11/2025 |
| Susana Loureiro | NA | Non-Invasive Screening Strategies for Colorectal Cancer: Protocol Optimization and RNA Biomarker Identification | Pharmacy | School of Health of Polytechnic Institute of Porto (E2S-P.Porto) | S: Luís Lima | 18/11/2025 |
| Ana Raquel Conde Martins | NA | Atividade Antitumoral de novos compostos em linhas celulares representativas dos tumores mais prevalentes em Portugal | Pharmaceutical Sciences | Faculty of Health Sciences, University Fernando Pessoa | S: Fátima Cerqueira | 21/11/2025 |

**Table 9 (cont.)** – MSc dissertations completed in 2025 supervised by IPO Porto Researchers

| Name | Fellowship | Title | Program | Faculty/University | Supervising team | Date Public defence |
|---|---|---|---|---|---|---|
| Joana Beatriz Dias Nunes | NA | Anticancer Potential of Compounds from a Brazilian Native Plant Against the Most Relevant Cancers in Portugal | Biochemistry in Health | School of Health of Polytechnic Institute of Porto (E2S-P.Porto) | S: Fátima Cerqueira<br>Co-S: Rui Medeiros | 27/11/2025 |
| Vânia Catarina Moreira Dias | NA | Unveiling the Role of EV-derived miR-15b-5p, -1293, -376a-3p in Clear Cell Renal Cell Carcinoma Progression | Oncology | ICBAS – School of Medicine and Biomedical Sciences, University of Porto | S: Francisca Dias<br>Co-S: Ana Luisa Teixeira & Rui Medeiros | 27/11/2025 |
| Luis Gonçalo Teixeira Pereira | NA | Identification of Potential Biomarkers for Early Detection of Colorectal Cancer | Biostatistics and Bioinformatics Applied to Health | School of Health of Polytechnic Institute of Porto (E2S-P.Porto) | S: Luís Lima; Co-S: Andreia Brandão & Brígida Faria | 02/12/2025 |
| Camila de Magalhães Neto | NA | Discovering Infertility Bio(glyco)markers using Human Spermatozoa | Biochemistry | University of Aveiro (UA) | S: Ana Martins; Co-S: José Alexandre Ferreira | 03/12/2025 |
| Ana Margarida Ferreira Maia Gomes Cabral | NA | Therapeutic Decision Determinants and Outcomes in Gastrointestinal Stromal Tumors in the Tyrosine Kinase Inhibitors Era | Health Evidence and Decision | Faculty of Medicine of the University of Porto (FMUP) | S: Maria José Bento; Co-S: Luísa Lopes Conceição | 04/12/2025 |
| Bárbara Amorim-Fernandes | NA | Analytic Validation of DNA Methylation Biomarkers in a population-based Cervical Cancer Screening Program | Oncology | ICBAS – School of Medicine and Biomedical Sciences, University of Porto | S: Carmen Jerónimo; Co-S: Rui Henrique | 04/12/2025 |
| Catarina Rodrigues Carvalho | NA | MicroRNAs Associados às Vias de Biossíntese do Cortisol e da Aldosterona: Potenciais Biomarcadores com Implicações Médico-Legais | Legal Medicine | ICBAS – School of Medicine and Biomedical Sciences, University of Porto | S: Ana Luísa Teixeira<br>Co-S: Francisca Dias & Rui Medeiros | 5/12/2025 |
| Margarida Cunha Morais | NA | Dissecting Molecular Alterations in Prostate Cancer Metastasis | Oncology | ICBAS – School of Medicine and Biomedical Sciences, University of Porto | S: Carmen Jerónimo; Tutor: Vera Constâncio | 09/12/2025 |
| Anabela Bianca Moreira Costa | NA | Simultaneous detection of germline and somatic mutations in DNA repair genes by next-generation sequencing of cell-free DNA from metastatic prostate cancer patients | Oncology | ICBAS – School of Medicine and Biomedical Sciences, University of Porto | S: Manuel Teixeira; Co-S: Ana Barbosa | 11/12/2025 |

**Table 9 (cont.)** – MSc dissertations completed in 2025 supervised by IPO Porto Researchers

| Name | Fellowship | Title | Program | Faculty/University | Supervising team | Date Public defence |
|---|---|---|---|---|---|---|
| Jéssica Pedrosa Cordeiro | NA | Immune Profiling and Methylome Analysis of Peripheral Blood from Prostate Cancer Patients | Oncology | ICBAS – School of Medicine and Biomedical Sciences, University of Porto | S: Margareta P. Correia; Co-S: Carmen Jerónimo | 11/12/2025 |
| Manuela Cristina Dias Pinheiro | LPCC | Structural variant detection using targeted short read sequencing data from cancer patients | Bioinformatics and Computational Biology | Faculty of Sciences, University of Porto | S: Manuel Teixeira | 11/12/2025 |
| Marina Isabel Lourenço Reis | NA | Estudo genómico da predição fenotípica da cor dos olhos | Legal Medicine | ICBAS – School of Medicine and Biomedical Sciences, University of Porto | S: Rui Medeiros<br>Co-S: Ana Luísa Teixeira | 11/12/2025 |
| Anna Flávia Xavier | NA | The impact of Vitamin D and NGF on Cachexia: a Study of Polymorphic Variants in Oncology Patients | Molecular Oncology and Medicine | Faculty of Medicine of the University of Porto (FMUP) | S: Rui Medeiros<br>Co-S: Valéria Tavares | 15/12/2025 |
| Catarina Conceição da Costa Ribeiro | NA | ReSCue: Re-irradiation of the Spinal Cord – Radiobiological, Dosimetric Data and Outcomes | Oncology | ICBAS – School of Medicine and Biomedical Sciences, University of Porto | S: Isabel Bravo<br>Co-S: Maria José Bento | 15/12/2025 |
| Sandra Amélia Moreira Mendes | NA | RIBRAIM - Re-Irradiation of recurrent Brain Metastases | Oncology | ICBAS – School of Medicine and Biomedical Sciences, University of Porto | S: Isabel Bravo<br>Co-S: Maria José Bento | 15/12/2025 |
| Gabriela Assunção | NA | Characterization of the Endometrial Carcinoma Microenvironment: Comparison between Primary Tumors and Metastasis | Oncology | ICBAS – School of Medicine and Biomedical Sciences, University of Porto | S: Carla Bartosch; CO-S: Carmen Jerónimo | 16/12/2025 |
| Maria Inês Silva dos Reis | NA | Implementation of the RAD51-FFPE test as a biomarker for HRD in ovarian high-grade serous carcinoma | Oncology | ICBAS – School of Medicine and Biomedical Sciences, University of Porto | S: Carla Bartosch; Co-S: Vera Miranda-Gonçalves | 17/12/2025 |

**Table 9 (cont.)** – MSc dissertations completed in 2025 supervised by IPO Porto Researchers

| Name | Fellowship | Title | Program | Faculty/University | Supervising team | Date Public defence |
|---|---|---|---|---|---|---|
| Maria João Nunes | NA | Thermosensitive Chitosan/Pluronic Hydrogels for Smart Cancer Glycovaccines Delivery | Biochemistry | University of Aveiro (UA) | S: José Alexandre Ferreira; Co-S: Vítor Gaspar | 17/12/2025 |
| Luís Daniel Pinto Ferraz Ribeiro | NA | The role of IPO4 germline variants for breast cancer predisposition in patients without mutations in know genes | Oncology | ICBAS – School of Medicine and Biomedical Sciences, University of Porto | S: Manuel Teixeira; CO-S: Ana Peixoto | 18/12/2025 |
| Maria João Barreira | NA | Optimizing Polysacaride Hydrogels for Enhanced Immunogenic Delivery of Cancer Vaccines | Biotechnology | University of Aveiro (UA) | S: José Alexandre Ferreira; Co-S: Vítor Gaspar | 18/12/2025 |

*NA- Not applicable*

## Advanced Courses

- Applied Radiobiology to Medical Physics Residents, IPO Porto Oncology (EPOP/IPO Porto, 8h) – 2025
- Applied Radiobiology to Medical Residents in Radiation Oncology (EPOP/IPO Porto, 15h) – 2025
- Data Management in Scientific Research Using REDCap (EPOP/ IPO Porto, 6h) – 2025
- Endoscopy for oesophageal squamous cell carcinoma: Diagnosis and therapeutic procedures (webinar series, 8h), organisation within the project The African Initiative Against Oesophageal Cancer (AFROC), (June – September 2025)
- Endoscopy for oesophageal squamous cell carcinoma: Diagnosis and therapeutic procedures (job shadowing, 40h), organisation within the project The African Initiative Against Oesophageal Cancer (AFROC), (October 2025)
- EUCanScreen Course on Upper GI Endoscopy: How to Improve Your Cancer Detection Rate" (webinar series, 3h), organisation within the project Implementation Of Cancer Screening Programmes (EUCanScreen) (November – December 2025)
- Oncology Nursing Research Course (EPOP/ IPO Porto, 24h) – 2025
- Research Methodologies in Oncology (ICBAS/IPO Porto, 28h) – 2025
- Virus, Vaccines and Cancer (EPOP/IPO Porto, 21 h) – 2025

## Scientific educational programmes

- Giovanni Marco Bugelli (Malta) in the mission of Standing Committee on Research Exchange (SCORE) for the **International Federation of Medical Students' Associations (IFMSA)** organization within the research project of "EMBRACIVE: Non-invasive identification and characterization of extracellular vesicles in Bladder Cancer Patients" (July 2025).
- Niga Alhaydesi (Iraq – Kurdistan) in the mission of the Standing Committee on Research Exchange (SCORE) for the **International Federation of Medical Students' Associations (IFMSA)** organization within the research project of "UCIPREDICT – Circulating tumour microenvironment components as Urothelial Cancer Immunotherapy Response Predictors"(July 2025).
- Victoria Álvarez Mendez (Spain) in the mission of the Standing Committee on Research Exchange (SCORE) for **the International Federation of Medical Students' Associations (IFMSA)** organization within the research project of "UCIPREDICT – Circulating tumour microenvironment components as Urothelial Cancer Immunotherapy Response Predictors"(July 2025).
- Erik Carrier (Canada) in the mission of the Standing Committee on Research Exchange (SCORE) for the **International Federation of Medical Students' Associations (IFMSA)** organization within the research project of "MethylProCancer – Prostate Cancer Risk Stratification: Unveiling circulating DNA methylation-based biomarkers"(July 2025).
- Ahmed Triki (Tunisia) in the mission of the Standing Committee on Research Exchange (SCORE) for the **International Federation of Medical Students' Associations (IFMSA)** organization within the research project of "UCIPREDICT – Circulating tumour microenvironment components as Urothelial Cancer Immunotherapy Response Predictors"(August 2025).
- Vanesa Petrova (Bulgaria) in the mission of Standing Committee on Research Exchange (SCORE) for the **International Federation of Medical Students' Associations (IFMSA)** organization within the research project of "EMBRACIVE: Non-invasive identification and characterization of extracellular vesicles in Bladder Cancer Patients" (August 2025).

- Ahmed Reda Housini (Morocco) in the mission of the Standing Committee on Research Exchange (SCORE) for the **International Federation of Medical Students' Associations (IFMSA)** organization within the research project of "MethylProCancer – Prostate Cancer Risk Stratification: Unveiling circulating DNA methylation-based biomarkers"(August 2025).

## Scientific outreach activities

- **MOSTRA – UP**, in collaboration with RISE, in a scientific divulgation activity of the research center for the young community, *Multiusos de Gondomar*, Gondomar, Portugal (6th –9th March 2025)
- **Biomedical Youth School**, ICBAS – UP, in a scientific divulgation of the research center for high school students, IPO Porto, Porto, Portugal (24th and 30th July 2025)
- **Science happening at the IPO Porto Research Center**, in collaboration with i3S as part of European Researchers' Night, in a scientific divulgation of the research center for high school students, IPO Porto, Porto, Portugal (4th September 2025)
- **IV Biomedical Engineering Summit workshop,** in collaboration with the National Association of Biomedical Engineering Students as part of the IV Biomedical Engineering Summit, IPO Porto (5th September 2025)
- **2nd edition IPO Porto Research Center Open Day**, a scientific divulgation activity of the research center for the young community, IPO Porto, Porto, Portugal (8th October 2025)

## Organization/ Host of Scientific Meetings and Seminars

**INTERNATIONAL**

- **EPCA-European Prostate Cancer Alliance 2025 Web seminars series** (Scientific Committee member – Carmen Jerónimo)**: February 17th; December 15th**
- **EUROGIN 2025,** Porto, Portugal (Scientific Committee member – Rui Medeiros)16th – 19th March 2025
- **I UIEO International Seminar: "Research in Oncology Nursing"** Porto, Portugal (Organizing Committee & Scientific Committee – Ana Rodrigues, Carla Silva, Diana Ramada, Dr Rui Costa) 25th March 2025; https://ipoporto.pt/evento/1-o-seminario-internacional-da-ui-enfermagem-oncologica/
- **GRELL-ENCR 2025 Ascencion Meeting @ IPO Porto** (Porto, PT) (Organizing Committee – Maria José Bento, Rita Calisto, Ana Filipa Gonçalves, Teresa Garcia, Pedro Leite Silva & Ana Catarina Rodrigues) 27th-30th May 2025; https://www.lab52.pt/grell2025/
- **Webinar IPVS "Controversies in Anal Cancer Screening" @ IPVS 2025** (Virtual) (Organizer –Andreia Albuquerque) 9th April 2025 https://ipvsoc.org/event/ipvs-webinar-2025-anal-cancer-screening/
- **XIX Congress of the Iberian Society of Cytometry**. (Porto, Portugal) (Local Organising Committee – Carlos Palmeira; Scientific Committee – Lúcio Lara Santos). 14th-16th May 2025; https://sic2025.pt
- **"IMMUNO-model YRI Meeting – Young Researchers and Innovators on Immunotherapies: The Future is Now"** (Porto, Portugal) (Organizing Committee – Carmen Jerónimo, Catarina Rodrigues, Filipa D. dos Reis, Mariana L. da Costa, Andreia Peixoto; Scientific Committee – Catarina Rodrigues, Margareta P. Correia) 25th September 2025 https://www.immuno-model.eu/newss/immuno-model-yri-meetingyoung-researchers-and-innovators-on-immunotherapies-the-future-is-now/
- **2nd International Conference for Doctoral Students in Nursing,** Porto, Portugal (Scientific Committee – Isabel Rocha) 9th & 10th October 2025; http://sigarra.up.pt/icbas/pt/noticias_geral.ver_noticia?p_nr=73489
- **INSERM workshop 'Glycobiology, the sweet side of life in health and disease.** (Theoretical phase: Bordeaux, France; Practical phase: Lille or Nancy, France)( Organizing Committee – José Alexandre Ferreira) Theoretical phase15th -17th October 2025; Practical phase: 12th – 14th November 2025)

- **Second edition of the IPVS Human Papillomavirus Related Anogenital Diseases Course for Clinicians 2025 (IPVS PACC) @ IPVS 2025** (Bangkok, Thailand) (Chair and Organizer – Andreia Albuquerque) 22nd-23rd October 2025.
- **Second edition of the IPVC 2025 High-resolution Anoscopy Workshop @ IPVC 2025 (**Bangkok, Thailand) (Chair and Organizer – Andreia Albuquerque) 23rd October 2025.
- **2nd International Congress and 14th National Congress on Oncology Nursing – "Combining Science and Empathy to Provide Excellent Care""** (Évora, Portugal) (Organizing Comittee & Scientific Comittee – Carla Rodrigues Silva, Joana Lopes, Rui Costa) 7th & 8th November 2025

**NATIONAL**

- **9th Symposium of the Master in Oncology** (Porto, Portugal) (Organizing Committee – Prof. Carmen Jerónimo, Irina Amorim, Fernanda Fernandes-Pontes, Mariana L. da Costa, Bárbara Amorim-Fernandes, Jéssica P. Cordeiro, Margarida Morais, Marta Lopes-Rodrigues, Mariana Melo Costa, Sara Freitas; Scientific Committee – Prof. Carmen Jerónimo, Dr. Cláudia Vieira, Prof. Isabel Bravo, Prof. Rui Henrique) 7th March 2025 (IPO Porto & ICBAS-UP)
- **7th ENJIO – National Meeting of Young Researchers in Oncology** (Organizing. Committee – Prof. Rui Medeiros, Dr. Monica Gomes) 24th September 2025 (LPCC)
- **4th Beira Alta Wound Care Conference: "Surgical Wounds: From Incision to Healing: A Safe Journey on the Path to Recovery"** (Mortágua, Portugal) (Organizing Committee – Andreia Salvini) 26th September 2025
- **3rd Young Researcher Day** (Porto, Portugal) (Organizing Committee – Prof. Carmen Jerónimo, Dr. José Alexandre Ferreira, Dr. Leonardo Moço, Dr. Margareta P Correia, Dr. Paula Paulo, Dr. Sofia Salta; Scientific Committee – Dr. Ana Luísa Teixeira, Dr. Andreia Peixoto, Prof. Fátima Cerqueira, Dr. Vera Miranda-Gonçalves, Dr. Andreia Brandão, Dr. Carina Pereira, Dr. Luís Lima, Dr. Sara Monteiro-Reis, Dr. Alina Rosinha, Dr. Bruno Soares, Dr. Cláudia Moreira, Dr. Manuela Pinheiro, Dr. Sara Coelho) 22nd October (IPO Porto)
- **Prof. Claus Jørgensen's Seminar** (Porto, Portugal) (Organization – Prof. Carmen Jerónimo, Dr. Sofia Salta) – 27th October (IPO Porto)
- **Care at the Source: Hematology and Bone Marrow Transplantation Nursing Conference** (Porto, Portugal) (Organizing Committee – Isabel Rocha; Scientific Committee – Ana Cristina Rodrigues, Rui Costa) 28th November 2025
- **Portuguese Wound Management Association Congress**. **The art of (re)treatment: from sketch to masterpiece (Gondomar, Portugal)** (Organizing Committee & Scientific Committee – Marisa Matos) 14th November 2025
- **5th Scientific Conference – Nursing Research: Interdisciplinarity and Innovation** (Porto, Portugal) (Organizing Committee & Scientific Committee – Carla Silva e Rui Costa) 26th November 2025
- **Workshop "Multiomics for Systems Oncology** (Porto, Portugal) (Local Organizing Committee and Scientific Committee – Dr. Andreia Peixoto; Dr. Luís Lima, Dr. Alexandre Ferreira); 11th -12th December 2025 (IPO Porto).
- **2025 Cycle of Workshops – Transferable Skills for Researchers (Porto, Portugal)** (Organizing Committee: Prof. Carmen Jerónimo, Dr. Vera Constâncio, Dr. Andreia Peixoto, Catarina Rodrigues, Dr. Sofia Salta):
    - 18th February |Public Speaking and Presentation Techniques |Prof. Manuel Firmino Torres (FEUP)
    - 18th March | Grant Writing |Prof. Ana Paula Pêgo (i3S/ICBAS) & Sociedade Portuguesa de Inovação (SPI)
    - 29th April | Well-being and Resilience | Prof. Catarina Brandão (FPCE-UP)
    - 4th June | How to find funding | Sónia Pereira (Research and R&D Projects Service Reitoria UP)

- 1st July | Career Options Outside Academia |Fernanda Correia & Maria Inês Ferreira (Talent and Career Center Reitoria UP)
- 2nd September |Research Integrity | Prof. Rui Nunes (FMUP)
- 3rd November | Scientific Writting | Prof. Paula Silva (ICBAS)

- **Porto.CCC Raquel Seruca Immuno-Oncology Club** (Prof. Carmen Jerónimo, Dr. Margareta P. Correia, Dr. Sofia Salta), monthly @IPO Porto/ i3S
  - January 29th @IPO Porto| Theme: "Spatial Biology in Cancer: Mapping the Tumor Microenvironment". Presenters: Margareta Correia (IPO Porto) and Carolina Dantas (i3S); Round Table: Maria José Oliveira (i3S), Salomé Pinho (i3S), Nuno Mendes (i3S) and Nuno Coimbra (IPO Porto).
  - February 19th @i3S | Theme: "Evolution of cancer: heterogeneity and dynamics", Presenters: Luísa Pereira (i3S), José Carlos Machado (i3S) and Carmen Jerónimo (IPO Porto).
  - March 27th @IPO Porto | Theme: "Inflammation and Cancer: from basic to clinical applications". Sónia Melo (i3S), Sérgia Velho (i3S) Round Table: José Pedro Castro (i3S), Maria José Oliveira (i3S) and Margareta Correia (IPO Porto).
  - April 23rd@i3S |Theme: ""Metabolism and Cancer: from bench to bedside" Presenters: Joana Peixoto (i3S), Tiago Duarte (i3S) and Raquel Soares (i3S); Round Table: Susana Irving (IPO Porto) and Vera Miranda Gonçalves (IPO Porto).
  - May 28th @i3S |Theme: "Regeneration and Cancer: from basic to clinical applications" Presenters: Perpétua Pinto-do-Ó (i3S) and Catarina Leite Pereira (i3S).
  - June 26th @IPO Porto |" Moving Forward after Cancer" |Presenters: Fernando Ribas (IPO Porto Patients' Advisory Council), Magda Oliveira (IPO Porto).

- **IPO Porto Research Center Monthly Scientific Meetings**
  Organizing committee: Drs. J. Alexandre Ferreira, Margareta P. Correia and Paula Paulo

| Date | Speaker | Presentation Theme |
|---|---|---|
| **12/03/2025** | **Evangelos Giampazolias**<br>CRUK Manchester Institute, UK | Host Determinants of Cancer Immunity. Killing Cancer with Gut Instinct |
| **16/04/2025** | **Paula Paulo**<br>Cancer Genetics Group, IPO Porto Research Center | Linking Genetic Markers with Therapeutic Opportunities in Prostate Cancer |
| **07/05/2025** | **Mariana Silva**<br>Principal Scientist at Vor Bio, USA | Novel CD33/CLL-1-directed dual CAR-T cells mediate potent antigen-specific cytolytic activity in mouse models of Acute Myeloid Leukemia (AML) |
| **11/06/2025** | **Pedro Leite Silva & Anabela Faria de Sousa**<br>Epidemiology, Outcomes, Economics & Management in Oncology Group, IPO Porto Research Center | Unlocking the Potential of Cancer Registry in Oncological Research |
| **08/07/2025** | **Lorena Dieguez**<br>Medical Devices Research Group, International Iberian Nanotechnology Laboratory | Applying Nanotechnology to Cancer Diagnostics and Precision Medicine |
| **10/09/2025** | **Kirsteen Campbell**<br>CRUK Scotland Institute, Scotland, UK | Engaging the BCL-2 family to eliminate cancer cells |
| **15/10/2025** | **Adriana Carneiro**<br>Experimental Pathology & Therapeutics Group, IPO Porto Research Center | Isolation and Characterization of Circulating Tumour Cells and Clusters in Gastrointestinal Cancer: Towards Non-Invasive Biomarkers for Prognosis |
| **12/11/2025** | **Rita Fior**<br>Champalimaud Foundation, Lisbon | Zebrafish Avatars: a functional precision medicine platform to tailor cancer treatments & Study tumor innate immune evasion |

# CLINICAL RESEARCH OVERVIEW

## Clinical Studies

During 2025, 45 new observational clinical studies were initiated at IPO Porto Research Center adding to the 41 studies that were already ongoing.

## IPO Porto's Precision Oncology Program

The identification of molecular biomarkers has become standard practice for certain tumor types; however, the routine and systematic integration of genetic profiling into clinical care remains limited. To address this gap and facilitate the translation of molecular data into meaningful clinical outcomes, a multidisciplinary Molecular Tumor Board (MTB) was established at IPO Porto in 2021.

The MTB is coordinated by Dr. Júlio Oliveira, a Medical Oncologist and Clinical Pharmacologist who also leads the Early Phase Clinical Trials Unit. The board includes Dr. José Dinis, Medical Oncologist and Coordinator of the Clinical Research Unit; Dr. Deolinda Pereira, Medical Oncologist and Director of the Medical Oncology Service; Dr. José Mário Mariz, Clinical Hematologist and Director of the Onco-Hematology Service; Dr. Ana Maia Ferreira, Pediatric Oncologist and Director of the Pediatric Oncology Service; Prof. Lúcio Santos, Surgical Oncologist and Coordinator of the Pathology & Experimental Therapy Group; Prof. Manuel Teixeira, Oncogenetics Specialist, Coordinator of the Oncogenetics Group and Director of the Laboratory Genetics; Prof. Rui Henrique, Director of the Department of Pathology and Senior Researcher in the Cancer Biology & Epigenetics Group; and Dr. Joana Assis, Assistant Researcher in the Clinical Research Unit.

The IPO Porto Precision Oncology Program is a tumor-agnostic, prospective observational study assessing the feasibility of using multigene sequencing to guide personalized treatment in patients with advanced, refractory, rare, or hard-to-treat cancers. Consenting patients undergo next-generation sequencing (NGS) of tumor tissue or blood samples. Molecular results are systematically reviewed by the Molecular Tumor Board (MTB), which issues clinical recommendations and helps prioritize subsequent management strategies.

In line with the latest ESMO guidelines, the program seeks to identify patients who may benefit from targeted therapies when standard options are exhausted and to facilitate rapid enrollment in biomarker-driven trials. In 2025, the MTB reviewed molecular profiles from 276 patients, most with digestive tract cancers.

## Clinical Trials

In 2025, 166 clinical trials were active in the Clinical Trials Unit, of which 40 were initiated in that year, and 28 were closed (Figure 14).




**Figure 14** – Number of active Clinical trials and randomized patients

Moreover, an investigator-initiated trial was active in the same year: Neoadjuvant immunotherapy with durvalumab (MEDI4736) in non-surgical early-stage or locally advanced non-small cell lung cancer (NSCLC), followed by radical radiotherapy or chemoradiotherapy (CI-IPOP 74/2017 IDEAR, PI: Dr. Júlio Oliveira), with 10 patients accrued.

Additionally, two investigator-initiated trials were approved in 2025: LIFT Trial – A phase 2 study to evaluate the safety and efficacy of Low dose radiotherapy in combination with dose adjusted of Fludarabine followed by Tisagenlecleucel treatment in refractory/relapsed non-Hodgkin diffuse large B cell lymphoma (PI237-CI-IPOP-34-2025, PI: Prof. Delfim Duarte), and TRANSPIRE – A Pragmatic Non-Randomized Trial of Prehabilitation for Cancer Surgery Preparation: Study Protocol for a Comparative Analysis of Delivery Modes (PI244-CI-IPOP-39-2025, PI Dr. Pedro Martins).

## COMPETITIVE FUNDING GRANTED IN 2025

Overall, the center secured approximately 3.2 million euros (€ 3 212 218.02), from national and international agencies.

### Research Projects

#### European Agencies

| Code/ Agreement | Title | PIs | Funding Agency | Budget |
|---|---|---|---|---|
| 101219450 | **CancerWatch** – Improving Quality and Timeliness of Cancer Registry Data feeding into the European Cancer Information System | Maria José Bento (IPO Porto PI)<br>(Project Coordinator Norwegian Institute of Public Health – NW) | EU4Health Programme | IPO Porto<br>€ 129 917.26<br>Total<br>€ 16 249 841.06 |
| S2/4.5/F0150 | **CHAFT** – Home monitoring and identification of cisplatin-induced hearing loss risk profiles | Rita Félix Soares (IPO Porto PI)<br>(Project Coodinator. Emanuele Murana, CHU de Montpellier, Département ORL et CMF, FR) | Interreg Sudoe | IPO Porto<br>€ 171 320.42<br>Total€<br>1 894 653.77 |
| 101219434 | **eCAN Plus** – Enhancing the digital capabilities of cancer centres in the European Union to improve prevention and care | Maria José Bento<br>(IPO Porto PI)<br>(Project Coordinator: Marc Van den Bulcke, Sciensano, BE) | EU4Health Programme | IPO Porto<br>€ 292 118.61<br>Total<br>€ 24 993 336.10 |
| 101226733 | **EURECA** – EURopean Epitranscriptomics of Cancer Academy | Carmen Jerónimo (IPO Porto PI)<br>(Project Coordinator: Elena Martens-Uzunova (ERASMUSMC, NL) | Horizon Europe - Marie Skłodowska-Curie Actions (MSCA) HORIZON-MSCA-2024-DN-01 | IPO Porto<br>€ 279 445.32<br>Total<br>€ 4 157 935.20 |
| 101233078 | **HOPE4Kids** – Holistic Oncological Palliative care 4 Europe's Kids | Silvia Silva.<br>(IPO Porto PI)<br>(Project Coordinator: Leontien Kremer, Princess Máxima Centrum voor kinderoncologie, NL) | EU4Health Programme | IPO Porto<br>€ 45 097.29<br>Total<br>€14 999 931.58 |
| 101233450 | **JA PCM –** Joint Action Personalised Cancer Medicine | Beatrice Mainoli<br>(IPO Porto)<br>(Project Coordinator. Marc Van den Bulcke, Sciensano, BE) | EU4Health Programme | IPO Porto<br>€ 261 519.13<br>Total<br>€ 25 281 071.49 |
| 2025-1-MT01-KA220-HED-000356020 | **OPTIMIZE-RT** – Education programme to OPTIMIZE imaging doses in RadioTherapy CBCTs | Bárbara Barbosa (IPO Porto)<br>(Project Coordinator Universita Ta Malta MT) | ERASMUS+ | IPO Porto<br>€ 35 613.00<br>Total<br>€ 400 000.00 |

## FCT & COMPETE 2030 Calls

| Code/ Agreement | Title | PIs | Responsible Researcher @IPO Porto | Budget |
|---|---|---|---|---|
| COMPETE2030-FEDER-00684200 \|Project 15736 | **BeMIC-on.chip** – Bioengineering an ex vivo microenvironment of triple-negative breast cancer on-chip: a new tool to uncover new avenues for therapeutic intervention | Silvia Bidarra (i3S) | Anabela Dias (IPO Porto) | € 25 056.00 |
| COMPETE2030-FEDER-00686000 \| Project 15753 | **Breast_To_Bone** - The Influence of Triple Negative Breast Cancer Secretome in Bone Pre-Metastatic Reprogramming | Joana Paredes (i3S) | Carmen Jerónimo (IPO Porto) | € 47 520.00 |
| COMPETE2030-FEDER-01477200 \| Project 18427 | **CAR T-Matters –** Transforming the CAR T-cell therapy landscape in Portugal | Júlio Oliveira (IPO Porto) | NA | € 653 797.56 |
| COMPETE2030-FEDER-00685900 \| Project 15736 | **DeCode** – Discovering new cancer vulnerabilities by Deciphering the m6A RNA Code | Raquel Almeida (i3S) | Carmen Jerónimo (IPO Porto) | € 25 704.00 |
| COMPETE2030-FEDER-00886200 \|Project 15198 2023.17753.ICDT | **GATE** - GenerAlizable and Trustable computer assisted upper gastrointestinal Endoscopy | Miguel Coimbra (INESC TEC) | Mário Dinis-Ribeiro (IPO Porto) | € 31 666.00 |
| COMPETE2030-FEDER-00910400\| Project15422 2023.17087.ICDT | **JANUS** - Reengineering cervical cancer screening for the 21st century: joint action for a novel up-to-date and sustainable screening program | Nuno Lunet (ISPUP) | Rui Henrique (IPO Porto) | € 59 400.00 |
| COMPETE2030-FEDER-00699000 \|Project 15875 | **NeuroDevice** – The Challenge in the Diagnostic Assessment of Neurodevelopmental Disorders: Innovative Neurochemical Tools | Maria de Fátima de Sá Barroso (REQUIMTE) | Ana Luísa Teixeira (IPO Porto) | € 52 509.60 |
| COMPETE2030-FEDER-00697400 \| Project 15860 2023.16317.ICDT | **NeurONiche** - Advanced engineering of human innervated pre-metastatic niche: elucidating the impact of prostate cancer-derived extracellular vesicles on bone metastatic pathological neurotization | Estrela Neto (i3S) | Carmen Jerónimo (IPO Porto) | € 47 520.00 |
| COMPETE2030-FEDER-01453400 | **ONCATS –** Federated Network of Real-World Health Data for the Evaluation of Health Technologies and Medicines in Oncology | Promptly Health | Maria José Bento (IPO Porto) | € 300 057.48 |
| COMPETE2030-FEDER-00721400 \| Project 16066 | **PRECISER** - Preclinical validation of the efficacy of combined inhibition of EGFR and STAT3 for ETS-rearranged prostate carcinomas | Paula Paulo (IPO Porto) | NA | € 203 649.12 |
| COMPETE2030-FEDER-00843200 \| Project 14871 2023.16683.ICDT | **PROMISE** – Multiomic Profiling of Prostate Cancer Extracellular Vesicles to Uncover Molecular Signatures for Biomarker Discovery | Carmen Jerónimo (IPO Porto) | NA | € 249 350.40 |
| COMPETE2030-FEDER-00728700 \| Project 16134 2023.18532.ICDT | **Radio4Breast** – Mapping the potential of human breast-on-a-chip models for personalized radiation therapy | Vanessa Fernandes Cardoso (UM) | Anabela Dias (IPO Porto) | € 48 470.40 |
| 2024.13797.PEX | **SPECTRE** – Mining the ghost proteome in gastric cancer for novel vaccine glyconeoantigens | Andreia Peixoto (IPO Porto) | NA | € 60 000.00 |

| Code/ Agreement | Title | PIs | Responsible Researcher @IPO Porto | Budget |
|---|---|---|---|---|
| 2024.16499.PEX | **VISTA** – Validation of Innovative Stool Transcriptome-based Assay for colorectal cancer screening | Luís Lima (IPO Porto) | NA | € 59 981.55 |

## Other Funding

| Code/ Agreement | Title | PIs | Funding Agency | Budget |
|---|---|---|---|---|
| GECCP-2025 | **EPIDETECT-OR-S** – Validation of New Epigenetic Biomarkers for the Early Detection of Oral Cancer Using Saliva [*Validação de novos biomarcadores EPIgenéticos para Deteção Precoce do Cancro Oral através da Saliva]* | Óscar Rapado-González | Head and Neck Cancer Study Group Research Grant (GECCP) | € 5 000.00 |
| NCH2025017 | **EPITARGET -** Exploring the epigenetic modulator KDM4C for the treatment of triple-negative breast cancer (TNBC) | Fátima Baltazar (ICVS-UM)<br>Carmen Jerónimo (IPO Porto) | AICIB | € 15 000.00 |
| Nº1/2025 | Innovation in the early detection of gastric cancer through the identification of salivary biomarkers: the promising role of point-of-care devices | Mário Dinis Ribeiro | Portuguese Society of Gastroenterology (SPG) | € 22 407.59 |
| 22/2025 | **SNIFF:** Saliva-based non-invasive volatile organic compounds for gastric cancer detection | Catarina Lopes | Bial Foundation Ordem dos Médicos | € 30 000.00 |

## Internal Funding Program for Integrative Research Projects- Dr. José Guimarães dos Santos Research Grants

| Code/ Agreement | Title | PIs | Budget |
|---|---|---|---|
| PI235-CI-IPOP-03-2025 | **Arrest** – The Use of Virtual Reality for Inpatients with Cancer at the IPO Porto [*Aplicação de realidade virtual em doentes oncológicos internados no IPO-Porto]* | Álvaro Silva (PI) | € 10 000.00 |
| PI240-CI-IPOP-36-2025 | **DEBILItAte** – Dissecting histopathological and epigenetic biomarkers of intraductal, indolent and aggressive prostate carcinomas | João Lobo (PI) | € 20 000.00 |
| PI236-CI-IPOP-33-2025 | **ImpReSario** – Implementation of the RAD51-FFPE test as a biomarker for HRD in ovarian high-grade serous carcinoma" | Carla Bartosch (PI) | € 10 000.00 |
| PI237-CI-IPOP-34-2025 | **LIFT Trial** – A phase 2 study to evaluate the safety and efficacy of Low dose radIotherapy in combination with dose adjusted of Fludarabine followed by Tisagenlecleucel treatment in refractory/relapsed non-Hodgkin diffuse large B cell lymphoma | Delfim Duarte (PI) | € 750 000.00 |
| PI242-CI-IPOP-89-2024 | **MEliOrate** – Mapping Eloquent Brain Regions for Optimized SRS in Brain Metastases | Mavilde Longarito (PI) | € 10 000.00 |
| PI238-CI-IPOP-81-2024 | **ProTeCteD** – Therapeutic personalization and cost-effectiveness analysis of Dinutuximab Beta administration at the Portuguese Oncology Institute of Porto FG, EPE [*Personalização terapêutica e análise de custo efetividade na* | Henriqueta Sampaio (PI) | € 4 300.00 |

| Code/ Agreement | Title | PIs | Budget |
|---|---|---|---|
| | *administração de Dinutuximab Beta no Instituto Português de Oncologia do Porto FG, EPE*] | | |
| PI241-CI-IPOP-37-2025 | **RadGames** – Serious Game in Health Education for Radiodermatitis | Marisa Matos (PI) | € 10 000.00 |
| PI243-CI-IPOP-38-2025 | **Screen4Cancer**– A Prospective Multicentric Study Evaluating a Novel DNA Methylation Blood Test for Multi-Cancer Early Detection | Rui Henrique (PI) | € 20 000.00 |
| PI239-CI-IPOP-35-2025 | **SuHRBlaC** – Follow-up of patients with high-risk non-muscle-invasive bladder cancer: validation of a DNA methylation-based test in a real-world setting [*Vigilância de doentes com cancro da bexiga não músculo invasivo de alto risco: validação de um teste baseado em metilação do DNA num cenário Real*] | João André Carvalho (PI) | € 10 000.00 |
| PI244-CI-IPOP-39-2025 | **TRANSPIRE** – A Pragmatic Non-Randomized Trial of Prehabilitation for Cancer Surgery Preparation: Study Protocol for a Comparative Analysis of Delivery Modes | Pedro Martins (PI) | € 7 4952.46 |

## Human Resources

Specific funding for human resources was also attained. Namely, a two-year HORIZON-TMA-MSCA-PF-EF postdoctoral fellowship was funded by the European Union, and an FCT-CEEC three-year contract for an Assistant Research supported a second researcher.

### MSCA Postdoctoral Fellowships 2025 – European Union

| Code | Type of Action | Title | Researcher |
|---|---|---|---|
| 101271612 | HORIZON-TMA-MSCA-PF-EF | **GlycoIMPACT:** Glycoengineering for Immune Modulation in Precision Anti-Cancer Therapies | Andreia Peixoto |

### FCT-Individual Call to Scientific Employment Stimulus – 7th Edition

| Code | Title | Researcher | Category |
|---|---|---|---|
| 2024.08667.CEECIND | **GlycoVac:** Translating the non-canonical glycoproteome into cancer vaccines | Rita Azevedo | Assistant Researcher |

Moreover, 11 PhD students attained FCT individual fellowships for 4 years.

### FCT-PhD Fellowships-Individual Call

| Code | Title | Student | % | Supervisor | Co-Supervisor |
|---|---|---|---|---|---|
| 2025.03325.BD | Multi-Omics insights into the impact of postoperative physical activity on gastric cancer recurrence | Alessandro Nuccio | 30 | Rui Vitorino (UA) | Daniel Moreira-Gonçalves (FADEUP) & Lúcio Lara Santos (IPO Porto) |
| 2025.05389.BD | Molecular inhibition of PTEN-regulating microRNAs: a new extracellular vesicle-based therapeutic strategy to target | Ângela Maria Amorim Alves | 75 | Rui Medeiros (IPO Porto) | Francisca Dias (IPO Porto) & Sónia Melo (i3S) |

| Code | Title | Student | % | Supervisor | Co-Supervisor |
|---|---|---|---|---|---|
| | clear-cell renal cell carcinoma aggressiveness | | | | |
| 2025.05771.BD | IMPROVE - Integrating Molecular and Digital Biomarkers for Personalized Health Monitoring in Breast Cancer Survivors: Predicting and Managing Symptoms for Improved Quality of Life | Beatriz Matos | 60 | Cristina Mendes Santos (Fraunhofer Portugal/IPO Porto) | Maria Inês Almeida (i3S) & Lúcio Lara Santos (IPO Porto) |
| 2025.02046.BD | EpiPen-Dissecting the epigenetic features of Penile Cancer: investigating putative roles in HPV-associated and HPV-independent tumors | Fernanda Isabel Fernandes Pontes | 100 | João Lobo (IPO Porto) | Carmen Jerónimo (IPO Porto) & Rui M. Reis (ICVS) |
| 2025.06395.BD | Unravelling the pathobiological crosstalk between cancer associated thrombosis and cachexia: a multiomic biomarker signatures and translational insights in advanced malignancies | Joana Filipa Macedo Liz Pimenta | 100 | Rui Medeiros (IPO Porto) | Valéria Tavares (IPO Porto) |
| 2025.03036.BD | EpiPRISM - Prostate Cancer Immune Spatial Mapping and Epigenetic-Immune Crosstalk | Mariana Lima da Costa | 100 | Margareta P. Correia (IPO Porto) | Carmen Jerónimo (IPO Porto) & Noel FFC de Miranda (Leiden University) |
| 2025.02786.BD | NanoEpiCirc-mPCa – *Nanoparticle-Driven Targeting of Epigenetic–Circular RNA Networks in Metastatic Prostate Cancer* | Marta Amaral de Avelar | 100 | Carmen Jerónimo (IPO Porto) | Rui Henrique, (IPO Porto) & Cláudia Martins (i3S) |
| 2025.03463.BD | Self-sampling for human papillomavirus detection and novel triage biomarkers as tools for improving the sustainability of the Portuguese cervical cancer screening program | Patrícia Alexandra Rodrigues Sá | 12 | Nuno Lunet (ISPUP) | João Firmino-Machado (ISPUP) & Rui Henrique (IPO Porto) |
| 2025.06649.BDANA | GLYCOSHIELD: A Glycocode-Inspired Vaccine for Colorectal Cancer Prevention | Rafael Carneiro Lopes | 100 | José Alexandre Ferreira (IPO Porto) | Mário Dinis Ribeiro (IPO Porto) & Maria José Oliveira (i3S) |
| 2025.02935.BDANA | Proteomic and Glycomic Profiling for Non-Invasive Disease Biomarker Discovery: Colorectal Cancer as an example | Renato Manuel de Caldevilla Carvalho | 100 | Luís Carlos Oliveira Lima (IPO Porto) | Mário Dinis Ribeiro (IPO Porto) & José Alexandre Ferreira (IPO Porto) |
| 2025.06124.BD | Expanding the toolbox for Mental disorders diagnosis through bioinformatics, molecular biology and genosensor approaches | Tiago Manuel Moreira Barbosa | 25 | Fátima Barroso (REQUIMTE/ ISEP) | Ana Luísa Teixeira (IPO Porto) |

## EXTERNAL FUNDING

In 2025, the IPO Porto Research Center gained over 5 million Euros (5,056,398.28 €) to conduct R&D activities (Figure 15). Nearly 26% came from the FCT/ Ministry of Science and 160% from the European Commission. The pharma contributed to 55% of the total budget (2,770,543.21€).




**Figure 15** – Funding received by source since 2018.

Importantly, 21% of the amount received was granted exclusively to human resources (1,120,828.28€).

## INTERNAL FUNDING

Overall, approximately 1M€ internal funding was allocated to support R&D activities (Figure 16). The first edition of the Funding Program for Integrative Research-Dr. José Guimarães dos Santos Research Grants (in accordance with Article 11, paragraph 7, of the Internal Regulations of the IPO Porto Research Center), provided 250k€ to promote collaborative and integrative research projects. Additionally, 423,820.67 € was distributed among the Research Groups and Units based on the cumulative impact factor of their peer-reviewed publications indexed in 2024 (in accordance with Article 11, paragraph 5, of the Internal Regulations of the IPO Porto Research Center). This performance-based allocation aimed to recognize and support research excellence while fostering scientific productivity across the Research Center.




**Figure 16** – Internal Funding since 2018.

# RESEARCH GROUPS/UNITS

*This section outlines the specific outputs delivered by each group or unit in 2025.*

## CANCER BIOLOGY & EPIGENETICS GROUP

### Coordinator

Carmen Jerónimo, PhD

### Research team@31 December 2025

| Name | Academic degree | Professional situation | Category/position | Time % |
|---|---|---|---|---|
| Alice Manuela Santos Alves | MSc | External | Resident in Radiation Oncology; PhD Student | 30 |
| Amal Magdy Mohamed | MSc | Contract | PhD student; ITN-MSc PROSTAMET (GA: 101120283) | 100 |
| Ana Fernandes Rodrigues | MD, MSc | Contract | Medical Oncologist; PhD Student | 20 |
| Ana Isabel Atanásio Varelas | MD, MSc | Contract | Pathologist | 5 |
| Ana Luísa Peixoto da Costa e Cunha | MD, MSc | Contract | Pathologist | 5 |
| Ana Paula Marques Silva Lopes | BSc | Contract | Pathology Technician | 20 |
| Ana Rita Teixeira Marques | MSc | Fellowship | PhD student; FCT-2023.01232.BD | 100 |
| Anastasiia Ponosova | NA | Student | MSc Student | 30 |
| Ana Teresa Pinto Teixeira Martins | MSc | Contract | Pathology Technician | 5 |
| Ângelo de Jesus Rodrigues | MD, MSc | Contract | Pathologist | 5 |
| António Rui Azevedo Freitas | MD, MSc | Contract | Urologist; PhD Student | 30 |
| Bárbara Amorim Fernandes | BSc | Student | MSc Student | 100 |
| Bruno Miguel Oliveira Lopes | MSc | Student | PhD Student | 100 |
| Candy Paiva | BSc | Contract | Pathology Technician | 5 |
| Carina Raquel Carvalho Maia | MSc | Contract | Oncology Pharmacist; PhD Student | 20 |
| Carla Maria Magno Bartosch | PhD | Contract | Pathologist & Researcher | 30 |
| Carla Renata Dias | MD, MSc | Contract | Pathologist | 5 |
| Carlos Ochoa Leite | MSc | Contract | Physician in Occupational Medicine; PhD student | 30 |
| Carmen De Lurdes Fonseca Jerónimo | PhD, Aggregation | Contract | Assistant Researcher; Group Coordinator | 100 |
| Catarina Martins Lourenço | MSc | Fellowship | PhD Student; FCT-2021.06731.BD | 70 |
| Davide Gigliano | MD, MSc | Contract | Pathologist | 5 |
| Diana Almeida-Pereira | BSc | Student | MSc Student | 100 |
| Diana Montezuma Felizardo | MD, MSc | Hired (External) | Associate Researcher | 20 |
| Fernanda Isabel Fernandes Pontes | MSc | Fellowship | Research Technician; PhD Student | 100 |
| Fernanda Maria Ferreira da Silva | BSc | Contract | Pathology Technician | 5 |
| Filipa Domingues dos Reis | MSc | Fellowship | PhD Student; UI/BD/154816/2023 | 100 |
| Filipa Moreira Silva | MSc | Fellowship | PhD Student; FCT-2023.00300.BD | 100 |
| Gabriela Assunção | BSc | Student | MSc Student | 100 |
| Gonçalo Silva-Rodrigues | BSc | Student | MSc Student | 100 |
| Íris Carriço Rocha | MSc | Fellowship | PhD Student; UI/BD/154815/2023 | 100 |
| Isa Cristiana Silva Carneiro | MSc | Contract | Pathology Technician; PhD student | 10 |
| Isaac Braga | MD, MSc | Contract | Urologist; PhD Student | 30 |

| Name | Academic degree | Professional situation | Category/position | Time % |
|---|---|---|---|---|
| Jéssica Pedrosa Cordeiro | MSc | Student | MSc student | 100 |
| Jéssica Sousa | BSc | Student | MSc Student | 100 |
| João Álvaro Barbosa Martins | MSc | Contract | Medical Oncologist | 10 |
| João André Carvalho | MD, MSc | Contract | Urologist; PhD Student | 30 |
| João Lima Vaz Silva | MD, PhD | Contract | Resident in Pathology | 10 |
| João Martins da Gama | MD, MSc | External | Resident in Pathology; PhD Student | 20 |
| João Moura e Silva | MD, MSc | External | Resident in Pathology; PhD Student | 10 |
| João Pedro da Silva Machado Lobo | MD, PhD | Contract | Resident in Pathology; Junior Researcher | 30 |
| Jorge Silvério Torres Ferreira | MSc | Contract | Pathology Technician | 10 |
| José Pedro dos Santos Neves | MSc | External | Pathology Technician; PhD Student | 30 |
| José Pedro Leite Sequeira | MSc | Fellowship | PhD Student; FCT-2022.11060.BD | 100 |
| Júlia Azevedo | MD, MSc | Contract | Resident in Pathology | 10 |
| Lara Silva Cunha | NA | Student | MSc Student | 30 |
| Lígia Pires Gonçalves | MD | Contract | Radiologist; PhD Student | 20 |
| Liliana Raimundo | PhD | Contract | Pathology Technician | 30 |
| Maria Alzamora | MD, MSc | Contract | Resident in Pathology | 5 |
| Margareta Isabel Pereira Correia | PhD | Contract | Assistant Researcher; CEECINST/00091/2018 and 2023.14811.TENURE.001 | 100 |
| Margarida Cunha Morais | BSc | Student | MSc Student | 100 |
| María Gallardo Gómez | PhD | Fellowship | Foreigner Associated Researcher – IISGS (Vigo) | 100 |
| Maria Miguel Castro | MSc | Fellowship | PhD Student i3S/IPO Porto; FCT-2020.07439.BD | 30 |
| Mariana Filipa Silva Ferreira | MSc | Contract | Research Technician | 100 |
| Mariana Lima da Costa | MSc | Contract | Research Technician; PhD Student | 100 |
| Mariana de Melo Costa | BSc | Student | MSc Student | 100 |
| Mariana Rocha Carvalho | MSc | Fellowship | PhD Student; FCT-2022.09480.BD | 38 |
| Marta Avelar | MSc | Student | PhD Student | 100 |
| Marta Lopes Rodrigues | BSc | Student | MSc Student | 100 |
| Mónica Pires | MD | Contract | Gynaecologist; PhD Student | 20 |
| Nuno David Monteiro Coimbra | MD, MSc | Contract | Pathologist; PhD student | 10 |
| Nuno Tiago Fidalgo Tavares | MSc | Fellowship | PhD Student; FCT-2022.09566.BD | 100 |
| Óscar Rapado González | PhD | Fellowship | Foreigner Associated Researcher – IDIS (Santiago de Compostela) | 100 |
| Paula Cristina Monteiro Dias | BSc | Contract | Pathology Technician | 5 |
| Paula Cristina Monteiro | MD | Contract | Pathologist | 5 |
| Renata Lage Vieira | BSc | Contract | Pathology Technician | 5 |
| Rita Brasil Costa Cabral Botelho | BSc | Student | MSc student | 100 |
| Rita Manuela Guimarães | MSc | Contract | Pathology Technician; PhD Student | 5 |
| Rui Manuel Ferreira Henrique | MD, PhD, Aggregation | Contract | Senior Pathologist; Senior Researcher | 30 |
| Rui Miguel Silva Santos | MSc | Contract | Pathology Technician; PhD Student | 20 |

| Name | Academic degree | Professional situation | Category/position | Time % |
|---|---|---|---|---|
| Sanjana Vig | MSc | Contract | PhD Student LAQV/REQUIMTE /IPOPorto; EU-MSC-AIMED-GA 861138 | 25 |
| Sara Cristina Silva Cardoso | MSc | Contract | Clinical pathology technician | 5 |
| Sara Raquel Monteiro dos Reis | PhD | Contract | Junior Researcher; EU4H-JA-EUnetCCC | 100 |
| Sofia Paupério e Silva Paulino | MSc | Contract | Pathology Technician; PhD Student | 20 |
| Sofia Raquel Fernandes Salta | PhD | Contract | Invited Researcher | 30 |
| Sérgio Miguel Pereira Chacim | MD, MSc | External | Clinical Haematologist; PhD Student | 20 |
| Vera Inês Salvado Constâncio | PhD | Contract | Research Technician (PI218-CI-IPOP-45-2024-UHN-miR371-STM) | 100 |
| Vera Mónica Miranda Gonçalves | PhD | Contract | Junior Researcher NORTE-01-0145-FEDER-072678 FCT-UIDP/00776/2020-3C | 100 |

### Group description and objectives

The Cancer Biology & Epigenetics Group (CBE) is dedicated to elucidating the role of epigenetic alterations in cancer initiation and progression, translating these findings into clinically actionable tools for precision cancer medicine. While the group has historically focused on the molecular biology of urological malignancies, other prevalent cancers have also been addressed. Particular emphasis is now placed on the interplay between epigenetic regulation, tumour metabolism, and immune cell dynamics, addressing critical gaps in treatment response and therapeutic decision-making.

A central component of ongoing research is the development and optimisation of liquid biopsy approaches. A digital PCR–based pipeline for the detection of methylated DNA and microRNAs has already been established (doi: 10.3390/cancers14040858; 10.1002/ijc.34496), alongside a key contribution to the validation of miR-371a-3p as a clinical biomarker for testicular germ cell tumours (doi: 10.1098/rstb.2017.0338). Current efforts are directed toward the integration of more complex biomarker systems. In this context, the PROMISE project will employ multi-omics profiling of extracellular vesicles (EVs) derived from tumour tissue, plasma, and urine to identify signatures of early metastatic progression in prostate cancer and determine the most suitable biological fluid for biomarker detection (FCT-2023.16683.ICDT). Complementary studies include the development of EV-based blood biomarkers for the prediction of bone metastasis in prostate cancer (FCT-2022.05135.PTDC), as well as investigations into urinary and circulating biomarkers for predicting bladder cancer recurrence and response to immunotherapy, with a particular focus on tumour microenvironment dynamics (FCT-JCT-TRANSCAN3/0001/2021).

In parallel, previously established expertise in molecular pathway characterisation—initially applied to the identification of biomarkers associated with tumour aggressiveness and radiotherapy resistance (doi: 10.1038/s41419-020-03279-y)—is being extended to population-based screening and public health initiatives. In collaboration with the National Program for Oncological Diseases and health authorities, efforts are underway to validate epigenetic biomarkers for the early detection of prostate, lung, and cervical cancers. This strategic shift underscores the group's commitment to translating molecular discoveries into scalable screening solutions.

In 2025, the group intensified efforts to identify epigenetic vulnerabilities amenable to therapeutic targeting, particularly in hard-to-treat cancers. This research axis integrates tumour immunology and epigenetics, exploring strategies to enhance immune-mediated tumour recognition and improve the efficacy of CAR-T cell therapies (FCT-022.04809.PTDC). Participation in the PROSTAMET and EURECA European doctoral networks further supports investigations into metabolic reprogramming and epitranscriptomic regulation in advanced prostate cancer and other malignancies. Building on earlier work on clear cell renal cell carcinoma (doi: 10.3390/cells9041053), these studies aim to elucidate the regulatory role of epigenetics in cancer

metabolism and to develop novel approaches to sensitise tumours to hormone-based and radiotherapeutic interventions, ultimately improving outcomes in advanced disease.

## Active projects and funding

### Competitive Funding

#### International

- CCI4EU - "Comprehensive Cancer Infrastructures for the European Union", Funding Agency: 4EUROPE - HORIZON-MISS-2022-CANCER-01-02-101103746; Budget: 57K€ (2023-2026) [PI@IPO Porto: Prof. Rui Henrique, Coordinators: Carla Finocchiaro, Valentina Lungheu, and Maurizio Cicero - Organization of European Cancer Institutes (OECI-EEIG)].
- EURECA – "EURopean Epitranscriptomics of Cancer Academy", Funding Agency: European Commission - HORIZON-MSCA-2024-DN-01 (Grant agreement ID: 101226733), Budget: 279K€ (2025-2029) [PI@IPO Porto: Prof. Carmen Jerónimo, Coordinator: Dr. Elena Martens-Uzunova (ERASMUSMC, NL)].
- HENKO NET – "Innovation and Digital Technologies for Social and Health Palliative Care at home", co-funded by the European Commission, in the component FEDER, trough Interreg VI-B South-West Europe (S1/4.5/E0091); Budget: 158K€ (2024-2026) (Team members)
- PROSTAMET – "A Comprehensive Translational Research and Training Pipeline Harnessing Lipid Metabolism to Improve Prostate Cancer Management and Educate Young Researchers in Tackling Complex Disease", Funding Agency: European Commission - HORIZON-MSCA-2022-DN-01 (Grant agreement ID: 101120283), Budget: 243K€ (2024-2027) [IP@IPO Porto: Prof. Carmen Jerónimo, Coordinator: Prof. Johannes Swinnen (KU Leuven, BE)].
- UCIPredict – "UCIPredict: Circulating tumour microenvironment components as Urothelial Cancer Immunotherapy Response Predictors". In collaboration with CIEMAT (Spain); Funding Agency: TRANSCAN-3, ERA-NET: sustained collaboration of national and regional cancer research programs (JTC 2021) co-funded by the European Commission / DG Research & Innovation; Budget: 99K€ (2023-2026) [PI: Prof. Carmen Jerónimo, Coordinator: Dr. Marta Dueñas (CIBER, ES)].

#### National

- Breast_To_Bone – "The Influence of Triple Negative Breast Cancer Secretome in Bone Pre-Metastatic Reprogramming", Funding Agency: COMPETE2030/ Fundação para a Ciência e Tecnologia (COMPETE2030-FEDER-00686000, Project 15753), Budget: 47.5K€ (2025-2028) [PI@IPOPorto: Prof. Carmen Jerónimo; PI: Dr. Joana Paredes (i3S)]
- DeCode – "Discovering new cancer vulnerabilities by Deciphering the m6A RNA Code" (PI256-CI-IPOP-81-2025), Funding Agency: COMPETE2030 (COMPETE2030-FEDER-00685900 | Project 15736) Budget: 30K€ (2025-2028) [PI@IPOPorto: Prof. Carmen Jerónimo; PI: Dr. Raquel Almeida (i3S)]
- EpImmunePCa (II) – "On the crossroads of Immuno-Epigenetics for targeting advanced Prostate Cancer". In collaboration with INEB/i3S, Funding Agency: Fundação para a Ciência e Tecnologia (2022.04809.PTDC), Budget: 250K€ (2023-2026) [PI: Dr. Margareta Correia, Co-PI: Prof. Rui Henrique].
- EPITARGET - "Exploring the epigenetic modulator KDM4C for the treatment of triple-negative breast cancer (TNBC)", Funding Agency: AICIB, Budget: 15K€ (2025-2026)[PI@IPOPorto: Prof. Carmen Jerónimo; PI: Prof. Fátima Baltazar (ICVS)]
- JANUS – "Reengineering cervical cancer screening for the 21st century: joint action for a novel up-to-date and sustainable screening program", Funding Agency: COMPETE2030/ Fundação para a Ciência e Tecnologia (2023.17087.ICDT), Budget: 59.4K€ (2025-2028) [PI@IPOPorto: Prof. Rui Henrique; PI: Prof. Nuno Lunet (ISPUP)].
- PROMISE – "Multiomic Profiling of Prostate Cancer Extracellular Vesicles to Uncover Molecular Signatures for Biomarker Discovery", Funding Agency: COMPETE 2030/ Fundação para a Ciência e Tecnologia (2023.16683.ICDT), Budget: 249K€ (2025-2028) [PI: Prof. Carmen Jerónimo].
- NeurONiche – "Advanced engineering of human innervated pre-metastatic niche: elucidating the impact of prostate cancer-derived extracellular vesicles on bone metastatic pathological neurotization", Funding

Agency: COMPETE2030/ Fundação para a Ciência e Tecnologia (2023.16317.ICDT), Budget: 47.5K€ (2025-2028) [PI@IPOPorto: Prof. Carmen Jerónimo; PI: Dr. Estrela Neto (i3S)].

- PCaEVision – "Decoding the role of extracellular vesicles in prostate cancer bone metastasis". In collaboration with Fundação Champalimaud and CNIO (Spain), Funding Agency: Fundação para a Ciência e Tecnologia (2022.05135.PTDC), Budget: 50K€ (2023-2025) [PI: Dr. Vera Constâncio, Co-PI: Dr. Hector Peinado].

Internal

- DEBILItAte – "Dissecting histopathological and epigenetic biomarkers of intraductal, indolent and aggressive prostate carcinomas" (BJGS_PI239-CI-IPOP-35-2025), Budget: 20K€ (2025) [PI: Prof. João Lobo].
- ImpReSario – "Implementation of the RAD51-FFPE test as a biomarker for HRD in ovarian high-grade serous carcinoma" (BJGS_PI236-CI-IPOP-33-2025), Budget: 10K€ (2025) [PI: Dr. Carla Bartosch].
- Screen4Cancer - "A Prospective Multicentric Study Evaluating a Novel DNA Methylation Blood Test for Multi-Cancer Early Detection" (BJGS_PI243-CI-IPOP-38-2025), Budget: 20K€ (2025) (PI: Prof. Rui Henrique).
- SuHRBlaC – "Surveillance of high-risk non–muscle invasive bladder cancer patients: validation of a DNA methylation–based test in a real-world setting" (BJGS_PI239-CI-IPOP-35-2025), Budget: 10K€ (2025) [PI: Dr. João André Carvalho].
- DECODE-PCa – "Epigenetic regulation of non-coding RNAs in Prostate Cancer" (PI 157-CI-IPOP-121-2019), Budget: 35K€ (2021-2025). (PI: Prof. Carmen Jerónimo).
- DNAmeCERVIX – "DNA methylation biomarkers for triage of hrHPV positive cases in the Northern Portugal population-based cervical cancer screening program" (PI 142-CI-IPOP-130-2020), Budget: 45K€ (2020-2025) (PI: Prof. Carmen Jerónimo; Co-PI: Prof. Rui Henrique). In collaboration with ARS-Norte.
- EMBRACIVE – "A microfluidic assisted technology for non-invasive identification and characterization of extracellular vesicles in bladder cancer patients" (PI224-CI-IPOP-74-2024), Budget: 15K€ (2024-2025) (PI: Prof. Carmen Jerónimo).
- EpiLungScreen – "Epimarkers for Lung Cancer Screening in Liquid Biopsies" (PI248-CI-IPOP-29-2025), Budget: 5K€ (2025) (PI: Prof. Carmen Jerónimo; Prof. Rui Henrique).
- EpiMetaboK – "Epitranscriptomic alterations within renal cancer metabolism reprogramming: uncovering new therapeutic targets" (PI 112-CI-IPOP-92-2018), Budget: 50K€ (2022-2025) (PI: Prof. Carmen Jerónimo; Co-PI: Dr. Vera Miranda-Gonçalves).
- EpiPaRTy – "Advances in Epigenetic targeting for PCa: Dissecting the interplay between ncRNAs and chromatin remodelers and their role as biomarkers of RadioTherapy resistance" (PI-159-CI-IPOP-152-2021), Budget: 35K€ (2021-2025) (PI: Prof. Carmen Jerónimo).
- MethyProCancer – "Prostate Cancer Risk Stratification and monitoring approach: Unveiling circulating DNA methylation-based biomarkers" (PI189-CI-IPOP-22-2023), Budget: 25K€ (2023-2025) (PI: Prof. Carmen Jerónimo; Co-PI Prof. Rui Henrique).
- miREpiTestis – "Unveiling miR-371-373 cluster epigenetic reprogramming and downstream targets in testicular germ cell tumors" (PI190-CI-IPOP-23-2023), Budget: 25K€ (2023-2025) (PI: Prof. Carmen Jerónimo; Co-PI Dr. João Lobo).
- MiRVeBlad – "Identification of Exosomal-derived miRNAs as non-invasive high-risk BlCa biomarkers" (PI-160-CI-IPOP-153-2021), Budget: 45K€ (2021-2025). (PI: Prof. Carmen Jerónimo). In the context of Porto.CCC.
- PCaEXOBone – "Prostate Cancer pre-metastatic niche formation: Exosomal osteotropism" (PI 158-CI-IPOP-151-2021), Budget: 55K€ (2021-2025) (PI: Prof. Carmen Jerónimo)
- PlatiMethylPredict – "Promoter methylation of DNA repair genes as biomarker of response to platin-based chemotherapy" (PI247-CI-IPOP-162-2021), Budget: 15K€ (2021-2025) (PI: Prof. Carmen Jerónimo; Prof. Rui Henrique)

**Major achievements**

- ***Salta, S., Sequeira, J. P., Amorim-Fernandes, B., Lobo, J., Baldaque, I., Monteiro, P., Tavares, F., Taly, V., Henrique, R., & Jerónimo, C. Methylation-Specific Droplet Digital PCR: Testing a Novel Triage Tool for HrHPV-Positive Women in the Cervical Cancer Screening Program of Northern Portugal. MedComm. 2025, 6(7), e70203. (IF: 10.7) https://pubmed.ncbi.nlm.nih.gov/40529612/***

Current management for HrHPV-positive women with normal cytology often fluctuates between overtreatment and missed diagnoses. To fix this, our team validated a methylation-specific ddPCR assay targeting FAM19A4 and miR124-2 as a secondary triage tool. In a study of 750 HrHPV-positive women, the assay hit 88.5% sensitivity and 71.4% specificity for identifying CIN3+ lesions. Critically, this molecular triage outperformed standard HPV16/18 genotyping for predicting progression. With a strong correlation between methylation density and lesion severity ($p < 0.001$), the tool offers an objective metric to slash unnecessary colposcopy referrals while accurately flagging women with high-grade disease. (DOI: 10.1038/s41420-025-02597-4)

- ***Tavares, N. T., Lourenço, C., Constâncio, V., Fernandes-Pontes, F., Fonseca, D., Silva-Santos, R., Braga, I., Maurício, J., Henrique, R., Liu, M., Weiss, R. S., Bagrodia, A., Jerónimo, C., & Lobo, J. (2025). MicroRNA-371-373 cluster extracellular vesicle-based communication in testicular germ cell tumors. Cell communication and signaling. 2025, CCS, 23(1), 252. (IF: 8.9) https://pubmed.ncbi.nlm.nih.gov/40448114/***

While the miR-371-373 cluster is established as a hallmark of Testicular Germ Cell Tumors (TGCTs), this research clarified how these markers circulate via extracellular vesicles (EVs) to influence the tumor microenvironment. To do that, our team tracked the stability and biological activity of encapsulated miR-371a-3p by isolating EVs from both TGCT cell lines and patients' plasma samples. The core finding was that EV-packaged microRNAs remain protected and highly functional, directly modulating gene expression in recipient cells upon uptake. From a diagnostic standpoint, the data revealed that analyzing the EV-specific fraction of these microRNAs offers a sharper signal for detecting minimal residual disease compared to measuring total levels. These results reinforce the use of EV-based liquid biopsies as a more refined strategy for monitoring TGCT relapse and understanding tumor-host communication. (DOI: 10.1186/s12964-025-02250-8)

## Scientific output

### *a) Peer-reviewed indexed publications (final publication date in 2025)*

- Abrantes, R, Forcados, C, Warren, DJ, Santos-Ferreira, L, Fleten, KG, Senra, E, Costa, AF, Krpina, K, **Henrique, R**, Liberg, AM, Rawat, P, Gelebart, P, McCormack, E, Bjorge, L, Davidson, B, Greiff, V, Costea, DE, Pinto, F, Flatmark, K, Gomes, C, Inderberg, EM, Reis, CA and Walchli, S. *Pan-carcinoma sialyl-Tn-targeting expands CAR therapy to solid tumors.* Cell Rep Med. 2025;6(9): p. 102350 IF: 10.6
- Almeida, P, Alves, I, Fernandes, A**, Martins-Lima, C, Freitas, R, Braga, I,** Correia, J, **Jeronimo, C** and Pinho, SS. *"Mannose glycans as key players in trained immunity: A novel anti-tumoral catalyst".* Biochim Biophys Acta Gen Subj. 2025;1869(5): p. 130779. IF: 2.2
- Almeida, R, Boyaci, C, Braun, M, Pezzuto, F, Zens, P, **Lobo, J** and Tiniakos, D. *Breaking barriers in pathology: bridging gaps in multidisciplinary collaboration.* Virchows Arch. 2025;487(4): p. 733–6. IF:3.1
- Amaro, F, Carvalho, M**, Carvalho-Maia, C, Jeronimo, C, Henrique, R**, de Lourdes Bastos, M, de Pinho, PG and Pinto, J. *Metabolic signature of renal cell carcinoma tumours and its correlation with the urinary metabolome.* Metabolomics. 2025;21(2): p. 26. IF:3.3
- Bernardino, RM, Yin, LB, Lajkosz, K, Cockburn, JG, Wettstein, M, Sayyid, RK, **Henrique, R,** Pinheiro, LC, van der Kwast, T and Fleshner, NE. *Undetected Cribriform and Intraductal Prostate Cancer at biopsy is associated with adverse outcomes.* Prostate Cancer Prostatic Dis. 2025;28(1): p. 187–92.IF: 5.8
- Bernardino, RM, Yin, LB, Lajkosz, K, Winquist, E, Cockburn, JG, Jenjitranant, P, Veloso, R, C, OC, Benitez, AM, Nguyen, DD, Matthiesen, R, **Henrique, R,** Joshua, AM, van der Kwast, T and Fleshner, NE. *Intraductal Carcinoma Predicts Poor Response to Neoadjuvant Therapy in High-risk Prostate Cancer: A Retrospective Analysis of a Prospective Trial.* Eur Urol Open Sci. 2025;82: p. 52–8. IF:4.5

- **Brito-Rocha, T, Constancio, V**, Leite-Silva, P, **Carvalho-Maia, C, Sequeira, JP, Salta, S, Lobo, J, Machado, DI, Nunes, SP, Silva-Santos, R, Freitas, R,** Goncalves Dias, C, Vieira, C, Soares, M, **Henrique, R** and **Jeronimo, C.** *Multi-cancer early detection via a DNA methylation multiplex ddPCR-based blood test.* Int J Cancer. 2025;157(5): p. 1006–19. IF:4.7
- Canizo, CG, Guerrero-Ramos, F, Perez Escavy, M, Lodewijk, I, Suarez-Cabrera, C, Morales, L, **Nunes, SP,** Munera-Maravilla, E, Rubio, C, Sanchez, R, Rodriguez-Izquierdo, M, Martinez de Villarreal, J, Real, FX, Castellano, D, Martin-Arriscado, C, Lora Pablos, D, Rodriguez Antolin, A, Duenas, M, Paramio, JM and Martinez, VG. *Characterisation of the tumour microenvironment and PD-L1 granularity reveals the prognostic value of cancer-associated myofibroblasts in non-invasive bladder cancer.* Oncoimmunology. 2025;14(1): p. 2438291. IF:6.3
- Carapito, A, Amaro, F, **Teixeira-Marques, A, Henrique, R, Jeronimo, C,** Roque, ACA, Carvalho, F, Pinto, J, and Guedes de Pinho, P. *Influence of pre-analytical factors and biological variability on the urinary volatilome.* Anal Bioanal Chem. 2025;417(29): p. 6549–66. IF:3.8
- Castro, J, Azevedo, J, Lobo, C**, Rodrigues, A, Braga, I, Freitas, R, Silva-Santos, R,** Peixoto, A, **Henrique, R,** Leca, L and **Lobo, J**. *Cytological Features of the Emerging Entity Papillary Renal Neoplasm with Reverse Polarity: A Case Report Highlighting the Relevance of Fine-Needle Aspiration in Renal Masses.* Pathobiology. 2025;92(5): p. 288–93. IF:2.0
- Chavarriaga, J, Langleben, C, **Lobo, J**, Nappi, L, Yousef, GM, Ozcan, G, Khazamipour, N, **Tavares, NT**, Prassas, I, Dimitrakopoulos, L, Yuan, X, Bobrowski, A, Prendeville, S, Anson-Cartwright, L, **Jeronimo, C,** Jarvi, K, O'Malley, M, Leao, R, Lajkosz, K and Hamilton, RJ. *MicroRNA as a Liquid Biomarker to Detect Malignancy in Small Testicular Masses.* Eur Urol Oncol. 2025;8(6): p. 1575–82. IF:9.3
- **Constancio, V, Brito-Rocha, T, Henrique, R** and **Jeronimo, C**. *Reply to: Comment on "Multi-cancer early detection via a DNA methylation multiplex ddPCR-based blood test".* Int J Cancer. 2025;157(9): p. 1981–2. IF:4.7
- **Constancio, V, Lobo, J,** Gomez, A, **Ramalho-Carvalho, J, Carneiro, I, Freitas, R,** Esteller, M, **Henrique, R** and **Jeronimo, C.** *Large-scale DNA methylation profiling of urological cancers identifies shared and cancer-specific methylation signatures, and reveals differentially activated pathways for therapeutic targeting.* Clin Transl Med. 2025;15(10): p. e70488. IF:B6.8
- **Constancio, V, Lobo, J, Sequeira, JP, Henrique, R** and **Jeronimo, C.** *Prostate cancer epigenetics - from pathophysiology to clinical application.* Nat Rev Urol. 2025;22(7): p. 447–69. IF:14.6
- Costa, J, Le, VL, De Leo, A, Ravaioli, C, Velasco, V, Davidson, B, Skeie-Jensen, T, Devouassoux-Shisheboran, M, Trecourt, A, **Bartosch, C,** Rios, E, Genestie, C, Pautier, P, Lebreton, C, Guyon, F, Babin, G, Coindre, JM, Le Loarer, F, Saut, O and Croce, S. *Deep Learning Can Accurately Predict the Prognosis of Gynecologic Smooth Muscle Tumors of Uncertain Malignant Potential: A Multicenter Pilot Study.* Lab Invest. 2025;105(10): p. 104211. IF:4.2
- Cotton, S, Ferreira, D, Relvas-Santos, M, Brandao, A, Afonso, LP, Miranda, A, Ferreira, E, Santos, B, Goncalves, M, **Lopes, P**, Santos, LL, Silva, AMN and Ferreira, JA. *E-selectin affinity glycoproteomics reveals neuroendocrine proteins and the secretin receptor as a poor-prognosis signature in colorectal cancer.* Mol Oncol. 2025;19(3): p. 635–58. IF:4.5
- Dias, MR, Nicolau, C, Ferreira, H, **Chacim, S**, Oliveira, I, de Camara Negalha, G, Mariz, JM and Costa, JM. *Case Report: Effective methotrexate removal by combined hemodialysis and polymeric resin hemoadsorption.* Front Nephrol. 2025;5: p. 1644079. IF:NA
- Di Sciascio, L, Orsatti, A, Ambrosi, F, Franchini, E, Massari, F, Mollica, V, Bianchi, FM, Colecchia, M, De Leo, A, Acosta, AM**, Lobo, J,** Fiorentino, M and Ricci, C. *Characterization of testicular embryonic-type neuroectodermal tumor and embryonic-type neuroectodermal tissue admixed with mature neuro-glial tissue using a broad immunohistochemical panel.* Virchows Arch. 2025;487(1): p. 221–6. IF:5.4
- Dikland, FA, Fekih, C, Wellenstein, MRJ, Souza da Silva, R, Machado-Neves, R, Fraga, J, Oliveira, D, Montezuma, D, Pinto, IM and Woodburn, J. *A scoping review of TSR analysis in colorectal cancer: implications for automated solutions.* Oncol Rev. 2025;19: p. 1605383.
- **Dos Reis, FD**, Saidani, Y, Martin-Rubio, P, Sanz-Pamplona, R, Stojanovic, A and **Correia, MP.** *CAR-NK cells: harnessing the power of natural killers for advanced cancer therapy.* Front Immunol. 2025;16: p. 1603757. IF:5.9

- Elmaadawy, MM**, Pires-Goncalves, L,** Shimpi, T and Singla, V. *The Global Reading Room: Performing a Breast Localization Procedure.* AJR Am J Roentgenol. 2025;225(1): p. e2432282. IF:6.1
- **Estevao-Pereira, H, Guimaraes-Teixeira, C, Flores, BCT, Moreira-Silva, F, Tavares, NT, Guimaraes, R, Braga, I,** Mauricio, J, **Henrique, R, Jeronimo, C** and **Lobo, J.** *EHMT2/G9a and EZH2: Epimarkers in testicular germ cell tumors.* Andrology. 2025;13(2): p. 286–95. IF:3.4
- Felix, J, Matias, A and **Bartosch, C**. *Cellular dynamics of cervical remodelling: insights from preterm and term labour.* Arch Gynecol Obstet. 2025;311(6): p. 1553–60. IF:2.5
- **Fernandes-Pontes, F, Lobo, J, Jeronimo, C** and **Henrique, R.** *Identification of novel biomarkers in renal cell carcinoma.* Expert Rev Mol Diagn. 2025;25(8): p. 465–77. IF: 3.6
- Greig, A, **Henrique, R**, Xie, B, Thrasivoulou, C, Millar, M and Ahmed, A. *Super-Resolution Microscopy Reveals Alterations in Clathrin Structure in Human Cancer Tissue.* Am J Pathol. 2025;195(9): p. 1619–26. IF:3.6
- Klockner, P, Teixeira, J**, Montezuma, D**, Fraga, J, Horlings, HM, Cardoso, JS and Oliveira, SP. *H&E to IHC virtual staining methods in breast cancer: an overview and benchmarking.* NPJ Digit Med. 2025;8(1): p. 384. IF: 3.6
- Lagoa, M, Ramos, AS, **Leite, CO**, Bento, J and Pires, L. *Lymph node tuberculosis after occupational exposure in a Portuguese physician.* Rev Bras Med Trab. 2025;23(2): p. e20251361. IF: NA
- **Lobo, J**, He, H, Ahmed, R, Zein-Sabatto, B, Winokur, T, Wei, S, Harada, S, McKenney, JK, Myles, JL, Nguyen, JK, Przybycin, CG, Williamson, SR, Magi-Galluzzi, C and Alaghehbandan, R. *Primary Ewing Sarcoma of the Kidney: Clinicopathologic and Molecular Study of 24 Patients Including a Rare EWSR1::ETV4 Fusion.* Am J Surg Pathol. 2025;49(10): p. 1078–89. IF: 4.2
- **Lobo, J,** Ohashi, R and Moch, H. *Diagnosis of Papillary Renal Cell Carcinoma – the Current Perspective.* Kidney Cancer. 2025;9(1 Special Issue: Updates in Kidney Tumor Classification, Morphology, and Molecular Alterations): p. 16–26. IF: 1.1
- **Lobo, J, Tavares, NT, Fernandes-Pontes, F, Fonseca, D, Jeronimo, C, Henrique, R**, Ricci, C, de Leo, A, Collins, K, Idrees, MT, Ulbright, TM, Gupta, S and Acosta, AM. *Phenotypic and Molecular Features of Somatically Derived "Yolk Sac Tumors": Similarities and Differences With Counterparts of Germ Cell Origin.* Mod Pathol. 2025;38(9): p. 100807. IF:5.5
- **Lobo, J, Tavares, NT, Fonseca, D, Jeronimo, C, Henrique, R**, Wyvekens, N, Yang, Y, Snuderl, M, Maclean, F, Gordetsky, J, Fletcher, CD, Hirsch, MS, Hornick, JL, Idrees, MT, Collins, K, Warmke, L, Ulbright, TM and Acosta, AM. *MicroRNA-371-373 cluster and methylome analysis suggests that a subset of 'somatic-type' malignancies arising in germ cell tumors may originate in yolk sac tumor components.* J Pathol. 2025;266(2): p. 160–76. IF: 5.2
- **Lobo, J**, Zein-Sabatto, B, Lal, P and Netto, GJ. *Digital and Computational Pathology Applications in Bladder Cancer: Novel Tools Addressing Clinically Pressing Needs.* Mod Pathol. 2025;38(1): p. 100631.IF:5.5
- **Macedo-Silva, C, Albuquerque-Castro, A, Carrico, I**, Lencart, J, **Carneiro, I,** Altucci, L, **Lobo, J, Miranda-Goncalves, V, Henrique, R, Correia, MP** and **Jeronimo, C.** *Decoding MUC1 and AR axis in a radiation-induced neuroendocrine prostate cancer cell-subpopulation unveils novel therapeutic targets.* Cell Death Discov. 2025;11(1): p. 306. IF: 7.0
- **Machado, DI, Brito-Rocha, T, Salta, S**, Monjardino, T, **Henrique, R** and **Jeronimo, C**. *Circulating cell-free DNA methylation as biomarker for lung cancer detection: a systematic review and meta-analysis of diagnostic studies.* Syst Rev. 2025;14(1): p. 120. IF: 3.9
- **Marques-Magalhaes, A, Moreira-Silva, F, Graca, I**, Dias, PC, **Correia, MP, Alzamora, MA, Henrique, R,** Lopez, M, Arimondo, PB, **Miranda-Goncalves, V** and **Jeronimo, C.** *Combination of MLo-1508 with sunitinib for the experimental treatment of papillary renal cell carcinoma.* Front Oncol. 2025;15: p. 1399956. IF: 3.3
- Meleiro, M and **Henrique, R**. *Epigenetic Alterations in Glioblastoma Multiforme as Novel Therapeutic Targets: A Scoping Review.* Int J Mol Sci. 2025;26(12) IF:4.9
- Melotti, S, Ambrosi, F, Franceschini, T, Giunchi, F, Vasuri, F, Orsatti, A, Di Sciascio, L, Grillini, A, Franchini, E, Massari, F, Mollica, V, Marchetti, A, Mineo Bianchi, F, Colecchia, M, Acosta, AM, **Lobo, J,** Fiorentino, M and Ricci, C. *Immunohistochemical expression of EZH2 in germ cell tumors of the*

*testis: New insights into the genesis and epigenetic reprogramming of these fascinating tumors.* Am J Clin Pathol. 2025;164(5): p. 739–45. IF:1.9

- Meneses, O, **Alzamora, M**, Dias, C, Ortigao, R and Marques, D. *Immune-Related Esophagitis and Durable Response to Second-Line Treatment With Nivolumab in Stage IV Squamous Cell Esophageal Carcinoma.* Cureus. 2025;17(12): p. e98324.IF: 1.3
- Mesquita, P, Coelho, A, Ribeiro, AS, Povoas, LFC, de Oliveira, C, Leca, N, Silva, S, Ferreira, D, Padua, D, Coelho, R**, Jeronimo, C,** Paredes, J, Conde, C, Pereira, B and Almeida, R. *The RNA-binding protein YTHDF3 affects gastric cancer cell migration and response to paclitaxel by regulating EZRIN.* Gastric Cancer. 2025;28(5): p. 760–75. IF:5.1
- Mesquita, S, Azevedo, J, **Silva-Santos, R, Tavares, NT,** Santos, C, **Rodrigues, A, Henrique, R, Braga, I**, Acosta, AM, **Freitas, R** and **Lobo, J**. *Testicular adult granulosa cell tumour: discussing assessment of risk, microRNA-371a-3p levels and FOXL2 testing in a single case.* Histopathology. 2025;87(5): p. 773–6. IF: 4.1
- Michalova, K, Martinek, P, Mezencev, R, Gupta, S, Williamson, S, Wasco, M, Mohanty, S, Magi-Galluzzi, C, Canete-Portillo, S, Aron, M, Kandukuri, S**, Lobo, J,** Barkan, GA, Kilic, I, Strakova-Peterikova, A, Pivovarcikova, K, Michal, M, Michal, M, Ulbright, TM and Acosta, AM. *Renal Juxtaglomerular Cell Tumors Exhibit Distinct Genomic and Epigenomic Features and Lack Recurrent Gene Fusions: Comprehensive Molecular Analysis of a Multi-institutional Series.* Am J Surg Pathol. 2025;49(3): p. 217–26. IF: 4.2
- Mink, JN, Eckstein, M, Khalmurzaev, O, Pryalukhin, A, Geppert, C, Lohse, S, Bende, K, **Lobo, J, Henrique, R,** Loertzer, H, Steffens, J, **Jeronimo, C**, Wunderlich, H, Heinzelbecker, J, Bohle, RM, Stockle, M, Matveev, V, Hartmann, A and Junker, K. *Evaluation of Nectin-4 and Trop-2: Implications for Patient Outcomes and Therapy in Penile Cancer.* Mod Pathol. 2025;38(8): p. 100781. IF:5.5
- Monteiro, MV, **Moreira-Silva, F,** Lagarto, M, Ferreira, LP, Ramalhinho, C, Duarte, IF, **Jeronimo, C**, Gaspar, VM and Mano, JF. *Bioengineered Tumor-Stroma Prostate Cancer In Vitro Models for Screening Therapeutics.* Biotechnol Bioeng. 2025;122(6): p. 1541–53.IF: 3,6
- **Montezuma, D**, Oliveira, SP, Tolkach, Y, Boor, P, Haragan, A, Carvalho, R, Della Mea, V, Kiehl, TR, Leh, S, Yousif, M, Ameisen, D, Mircea-Sebastian, S, Zerbe, N and L'Imperio, V. *Annotation Practices in Computational Pathology: A European Society of Digital and Integrative Pathology (ESDIP) Survey Study.* Lab Invest. 2025;105(3): p. 102203. IF 4.2
- **Montezuma, D**, Porz, R, Ameisen, D, L'Imperio, V, Serbanescu, MS, Temprana-Salvador, J, Zerbe, N, Khalili, N, Zlobec, I, European Society of, D and Integrative, P. *Unbiased Artificial Intelligence: Addressing Bias in Computational Pathology.* Mayo Clin Proc Digit Health. 2025;3(4): p. 100302. IF:NA
- **Moreira-Silva, F**, Macedo-Silva, C**, Jeronimo, C** and Julio, MK. *Translating G9a epigenetics' role: From cell machinery to cancer therapy.* Gene. 2025;968: p. 149681. IF: 2.4
- Moura, R, Oliveira, D, **Carvalho, M**, Pirker, TM, Hammer, N, Parente, M and Vom Scheidt, A. *Experimental characterization of the non-linear viscoelastic properties of human female perineal tissue.* Sci Rep. 2025;15(1): p. 42483. IF:3.9
- Nunes, JD**, Montezuma, D**, Oliveira, D, Pereira, T and Cardoso, JS. *A survey on cell nuclei instance segmentation and classification: Leveraging context and attention.* Med Image Anal. 2025;99: p. 103360. IF: 11.8
- Nunes, JD, **Montezuma, D,** Oliveira, D, Pereira, T, Zlobec, I, Pinto, IM and Cardoso, JS. *Bridging Domain Gaps in Computational Pathology: A Comparative Study of Adaptation Strategies.* Sensors (Basel). 2025;25(9) IF:3,5
- **Oliveira-Lopes, B, Tavares, NT, Henrique, R, Jeronimo, C** and **Lobo, J**. *Testicular germ cell tumors and infertility: Exploring epigenetic dysregulation in the journey of the male germ cell towards new biomarkers and therapeutics.* Biochim Biophys Acta Rev Cancer. 2025;1880(5): p. 189437. IF:8.3
- Pang, KH, Fallara, G, **Lobo, J,** Alnajjar, HM, Sangar, V, von Stempel, C, Huang, DY, Parnham, A, Cazzaniga, W, Giganti, F, Haider, A, Sachdeva, A, Albersen, M, Alifrangis, C, Bandini, M, Castiglione, F, De Vries, HM, Fankhauser, C, Heffernan Ho, D, Nicol, D, Shamash, J, Thomas, A, Walkden, M, Freeman, A, Muneer, A, Penile, E-Y and Testis Cancer Working, G. *Management of Small Testicular Masses: A Delphi Consensus Study.* Eur Urol Oncol. 2025;8(1): p. 152–63. IF: 9.3

- Pereira, F, Pimenta, JL, Rei, M**, Dias, CR** and Pereira, D. *Metastatic Mammary-Like Adenocarcinoma of the Vulva Responding to Cyclin-Dependent Kinase (CDK) Inhibitor: A Case Report and Literature Review.* Cureus. 2025;17(9): p. e93598. IF: 1.3
- **Petronilho, S**, Poullot, E, Andre, A, Robe, C, Nouhoum, S, Fataccioli, V, Quintela, JM, Claudel, A, Briere, J, Lechapt, E, Lemonnier, F**, Henrique, R**, de Leval, L and Gaulard, P. *Follicular Helper T-cell Lymphoma With Hodgkin/Reed-Sternberg-Like Cells Versus Classic Hodgkin Lymphoma: A Comparative Study.* Am J Surg Pathol. 2025;49(3): p. 273–83. IF: 4.2
- Pinheiro, MR, Fernandes, LE**, Carneiro, IC, Carvalho, SD, Henrique, RM**, Tuchin, VV, Oliveira, HP and Oliveira, LM. *Optimized reconstruction of the absorption spectra of kidney tissues from the spectra of tissue components using the least squares method.* J Biophotonics. 2025;18(12): p. e202300466. IF:2.3
- **Pires-Goncalves, L.** *Invasive lobular carcinoma subgroup analysis of the MIPA study: real-world prospective data on preoperative MRI impact across the globe.* Eur Radiol. 2025;35(7): p. 3987–9. IF: 4.7
- **Pires-Goncalves, L**, Aguiar, AT, Leal, C, Guimaraes-Santos, A, Abreu, M and **Henrique, R**. *Prospective Evaluation of Contrast-enhanced Mammography for Early Prediction of Pathologic Response after Neoadjuvant Therapy.* Radiol Imaging Cancer. 2025;7(3): p. e240117. IF:6.3
- Pires, AM, Barreto, JP, Caetano, J, Soares, MJ, Geraldes, C, Fernandes, B, Coucelo, M, **Chacim, S,** Coelho, H, Correia, C, Cruz, AP, Cunha, M, Cunha, MR, Cunha, N, Ferraz, P, Freitas, JG, **Henrique, R**, Lisboa, S, Lucio, P, Paiva, A, Pedrosa, C, Ramos, I, Sarmento-Ribeiro, AB, Seabra, P, Sevilha, J, Sousa, MJR, Sousa, S, Sousa, T, Tavares, M, Trigo, F, Roque, A, Bergantim, R, Joao, C and On Behalf Of The Portuguese Multiple Myeloma, G. *Multiple Myeloma Laboratory Diagnostics Made Simple: Practical Insights and Key Recommendations.* J Clin Med. 2025;14(19) IF:2.9
- Pires, AM, Barreto, JP, Caetano, J, Soares, MJ, Geraldes, C, Fernandes, B, Coucelo, M, **Chacim, S,** Coelho, H, Correia, C, Cruz, AP, Cunha, M, Cunha, MR, Cunha, N, Ferraz, P, Freitas, JG**, Henrique, R,** Lisboa, S, Lucio, P, Paiva, A, Pedrosa, C, Ramos, I, Sarmento, AB, Seabra, P, Sevilha, J, Rego de Sousa, MJ, Sousa, S, Sousa, T, Tavares, M, Trigo, F, Bergantim, R, Roque, A and Joao, C. *[Diagnosis and Laboratory Follow-Up of Patients with Multiple Myeloma: Guidelines from the Portuguese Multiple Myeloma Group].* Acta Med Port. 2025;38(10): p. 654–68. IF: 1.0
- **Rapado-Gonzalez, O**, Sevilla-Garcia, CI, Pizcueta-Leiros, J, Salgado-Barreira, A, Pineiro-Lamas, M, De Carlos-Villafranca, F, Lopez-Lopez, R and Suarez-Cunqueiro, MM. *Association of DNA Methylation and Oral Cancer Risk: A Systematic Review and Meta-Analysis.* J Evid Based Dent Pract. 2025;25(4): p. 102169. IF: 4.0
- **Rodrigues, A, Henrique, R, Jeronimo, C** and Araujo, A. *Management of typical and atypical metastatic lung carcinoids: present and future perspectives.* Clin Transl Oncol. 2025;27(3): p. 816–23. IF:2.5
- **Rodrigues, A,** Pina, M, Calisto, R, Leite-Silva, P, Medeiros, P, Silva, C, Silva, AS, Redondo, P, **Ramalho-Carvalho, J,** Santos, SF and Bento, MJ. *Characterization of the Population, Treatment Patterns, and Outcomes of Patients with Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) with Epidermal Growth Factor Receptor Mutation (EGFRm): A Retrospective Cohort Study from IPO Porto.* Curr Oncol. 2025;32(8) IF:3.4
- Rodrigues, PR, Lopes-Conceicao, L, Sousa, V, Coutada, A, Bento, MJ, **Coimbra, N**, Leal, C, Pereira, D and Magalhaes Ferreira, A. *The clinicopathological characteristics, oncologic outcomes and costs of "HER2-low" early breast cancer compared to HER2-zero and HER2-positive: a single-centre retrospective analysis.* Front Oncol. 2025;15: p. 1579602. IF:3.3
- Rodrigues, RM, **Felgueiras, J**, Jones, S, **Camilo, V**, Matos, B, **Jeronimo, C**, Howl, J and Fardilha, M. *Exploring the feasibility of protein phosphatase 1-docking motif-mimetic cell-penetrating peptides for modulating prostate carcinogenesis.* JNCI Cancer Spectr. 2025;9(6) IF:4.1
- **Salta, S, Sequeira, JP, Amorim-Fernandes, B, Lobo, J,** Baldaque, I**, Monteiro, P,** Tavares, F, Taly, V, **Henrique, R** and **Jeronimo, C.** *Methylation-Specific Droplet Digital PCR: Testing a Novel Triage Tool for HrHPV-Positive Women in the Cervical Cancer Screening Program of Northern Portugal.* MedComm (2020). 2025;6(7): p. e70203. IF: 10.7

- **Silva-Ferreira, M,** Cruz, S, Luis, MS, Silva, MC, **Monteiro-Reis, S, Henrique, R, Jeronimo, C**, Lefevre, SC, Laplaud, A, Frasca, M, Pollet, L, Zurbanobeaskoetxea, L, Barbastro, RA, Garcia, MIH, Galan, BJ, Palau, FG, Marques, DF and Duran, RL. *Mapping study on AI-based technologies in palliative care - a scoping study.* BMC Palliat Care. 2025;24(1): p. 274. IF: 3.0
- Spies, S, Nazarian, E, Bremmer, F, Gonzalez, IA, **Lobo, J,** Reyes-Mugica, M, Zambrano, E, Hulsker, CCC, Mavinkurve-Groothuis, AMC, de Krijger, RR and Groot, ML. *Multi-Observer Study on the Assessment of Pediatric Gonadal Tumors Using Higher Harmonic Generation Microscopy as Compared to Conventional Histology.* Cancers (Basel). 2025;17(10) IF: 4.4
- **Tavares, NT, Henrique, R, Jeronimo, C** and **Lobo, J.** *Current Role of MicroRNAs in the Diagnosis and Clinical Management of Germ Cell Tumors.* Surg Pathol Clin. 2025;18(1): p. 91–100. IF: NA
- **Tavares, NT, Lourenco, C, Constancio, V, Fernandes-Pontes, F, Fonseca, D, Silva-Santos, R, Braga, I,** Mauricio, J**, Henrique, R**, Liu, M, Weiss, RS, Bagrodia, A, **Jeronimo, C** and **Lobo, J.** *MicroRNA-371-373 cluster extracellular vesicle-based communication in testicular germ cell tumors.* Cell Commun Signal. 2025;23(1): p. 252. IF:8.9
- Tavares, V, Lopes, C, **Macedo-Silva, C**, Farinha, M, Costa, J, Vilas-Boas, MI, Pinelas, S, Assis, J, Dinis-Ribeiro, M, Pereira, D, Pereira, C and Medeiros, R. *Genetic markers of thrombophilia as predictors of outcome in colorectal cancer.* J Thromb Thrombolysis. 2025;58(5): p. 663–78. IF:2.2
- Tripepi, M, da Costa, AG, Albergaria, D, Costa, A, Catarino, A, Duarte, AL**, Bartosch, C**, Schuler, V, Oliveira, J, Lima, J and Casanova, J. *Case Report: Hypercalcemic small-cell carcinoma of the ovary during pregnancy: diagnostic and therapeutic challenges.* Front Oncol. 2025;15: p. 1648580. IF: 3.3

### b) Peer-reviewed indexed publications within a consortium

- Downes, M, Lopez-Beltran, A, Contieri, R, Hansel, D, Paner, G, Shen, S, van Rhijn, B, Al-Ahmadie, H, Amin, M, Brunelli, M, Comperat, E, Cookson, S, Faltas, B, Guo, C, Hartmann, A, Kamat, A, Mertens, L, Ross, J, van der Kwast, T, Warrick, J, Kristiansen, G, Cheng, L, Raspollini, M and **Members of the ISUP GU Cancer Precursor Consensus Panel**. *International Society of Urological Pathology Consensus Meeting 2024 - Working Group 2 Preneoplastic and Precursor Lesions of the Urinary Bladder*. Am J Surg Path. 2025;49(12):e46-e57. IF: 4.2
- Iczowski, K, De Marzo, A, Agarwal, N, Berman, D, Cimadamore, A, Fine, S, Greenland, N, Khani, F, Loda, M, Lotan, T, Varma, M, Chinnaiyan, A, Giannarini, G, Huang, J, Montironi, R, Netto, G, Osunkoya, A, Ratliff, T, Kristiansen, G, Cheng, L, van Leenders, G and **Members of the ISUP GU Cancer Precursor Consensus Panel**. *International Society of Urological Pathology Consensus Meeting 2024 - Working Group 1 The Prostate.* Am J Surg Path. 2025;49(12):e33-e45. IF: 4.2
- Longoni, M, Fankhauser, C, Negri, F, Salonia, A, Basile, G, Johnstone, PA, Bandini, M and **EAU-YAU Penile and Testis Cancer Working Group**. *Treatment strategies in human papillomavirus-related advanced penile cancer*. Nat Rev Urol. 2025;22(7):427-438. IF: 14.6
- Rodler, S, Cei, F, Ganjavi, C, Checcucci, E, De Backer, P, Rivero Belenchon, I, Taratkin, M, Puliatti, S, Veccia, A, Piazza, P, Baekelandt, L, Kowalewski, KF, Gómez Rivas, J, Fankhauser, CD, Moschini, M, Gandaglia, G, Campi, R, De Castro Abreu, A, Russo, GI, Cocci, A, … **YAU Collaborators**. GPT-4 generates accurate and readable patient education materials aligned with current oncological guidelines: A randomized assessment. PloS one. 2025; 20(6), e0324175. IF: 2.6

## Other outputs

### Book Chapters

- Apolónio, J, **Lobo, J**, Fernandes, MT, Jesus, TT, Paredes, J and Leão, R. Fisiopatologia oncológica: mecanismos moleculares. In book: Fisiopatologia – Bases da Medicina Clínica (2025) ISBN: 978-989-752-935-1
- **Rapado-González O**, **Henrique R**, **Jerónimo C**. Chapter 1 – Salivary Epigenetic Biomarkers in Oral Cancer. In book: Advancements in Oral Cancer – Modern Diagnostics, Altered Molecular Profile and Therapeutic Strategies (2025). DOI: 10.5772/intechopen.1009835

### *Oral Communications by Invitation*

#### *International*

- Henrique R. (2025). DNA methylation as a triage marker for colposcopy referral in HPV-based cervical cancer screening, EUROGIN 2025. (March) Porto, Portugal
- Silva-Ferreira M (2025). HENKO NET State of the Art, The Patient Pathway in Palliative Care – Innovations and Digital solutions in France, Spain and Portugal. (January) Limoges, France
- Henrique R. (2025). M371-Test® and bladder epicheck®: Novel biomarkers in liquid biopsy", ESMO Sarcoma and Rare Cancers Annual Congress. (March) Lugano, Switzerland
- Henrique R. (2025). Cómo alinear los indicadores de los laboratorios de anatomia patológica con los indicadores de los gestores sanitarios, para poder introducir la innovación en los laboratorios de anatomía patológica, Sakura FE- TDx Summit Iberia. (April) Valencia, Spain
- Silva-Ferreira M (2025). Overview: Results of a Study on the Perception of Palliative Care Professionals Regarding Innovation, Barriers, and Facilitators, Innovating Palliative Care in the Community – Digital Tools for a Comprehensive Approach to Needs. (May) Bilbao, Spain
- Jerónimo C. (2025). Unlocking Urological Cancer: Epigenetic Insights from Lab to Clinic. International Society for Molecular and Clinical Epigenetics (isMOCLEP) drop-in webinar series. (May) Virtual
- Jerónimo C. (2025). Liquid biopsies: Shifting the cancer screening paradigm. Presented within the PANDORA – A Pan-European Educational Platform, Session: Liquid Biopsies: Searching for cancer biomarkers. (June) Virtual
- Lobo J. (2025). Liquid biopsy revolution: miRNA as the new diagnostic frontier. UROonco25. (June) Seville, Spain
- Lobo J. (2025) Intraoperative frozen section: Optimising decision-making in organ-sparing surgery or just intraoperative delay? UROonco25. (June) Seville, Spain
- Lobo J. (2025) Beyond imaging: miRNA as the missing piece in stage II decision-making. UROonco25. (June) Seville, Spain
- Lobo J, Acosta A. (2025) Testicular germ cell tumors. British Association of Urological Pathology (BAUP) monthly webinar series. (July) Virtual
- Lobo J. (2025) MicroRNA 371~373 cluster and testicular germ cell tumors: insights on clinical application and biology. XLX Reunión Anual de la Academia de Investigación en Biología de la Reproducción (AIBIR). (August) Virtual
- Lobo J. (2025) Molecular updates in testicular germ cell tumor pathology. Symposium "Update on molecular and AI advances in GU tumours. 37th European Congress of Pathology. (September) Vienna, Austria
- Lobo J (2025). Molecular and Histopathological Biomarkers in testicular germ cell tumors. XIII Reunión del grupo Gallego de Uropatología. (October) Vigo, Spain
- Lobo J. (2025) Applications of Digital and Computational Pathology in Uropathology. XIII Reunión del Grupo Gallego de Uropatología. (October) Vigo, Spain
- Lobo J (2025). miRNAs for testis cancer: From diagnosis to monitoring of disease. Plenary Session "Innovations and collaborative approaches in testicular cancer: From molecular insights to multidisciplinary strategies". 17th European Multidisciplinary Congress on Urological Cancers. (November) Prague, Czech Republic
- Henrique R. (2025). From tumor biopsy to targeted therapy: Decoding molecular signatures for Precision Oncology, XXXVI Congress of the Society Hungarian of Oncologists. (November) Siófok, Hungary
- Jerónimo C. (2025) Urinary biomarkers for monitoring of non-muscle-invasive bladder cancer (NMIBC). Presented at the European Multidisciplinary Urological Cancer Congress (EMUC25), (November) Prague, Czech Republic
- Jerónimo C. (2025). The DNA Methylation Landscape of Prostate Cancer. Presented at the 34th ARTP Annual Meeting, Session II – Epigenetic and transcriptomic drivers of prostate cancer. (November) Paris, France

- Montezuma D. (2025). The role of Pathologists in the development of Computational Pathology tools. 12th Digital Pathology & AI Congress: Europe. (December) London, UK

### *National*

- Constâncio V (2025). Epigenetic Mechanisms in Oncology, 3rd Edition of the Oncobiology Course – Liga Portuguesa Contra o Cancro. (January) Porto, Portugal
- Henrique R. (2025). Carcinoma urotelial: implicações clínicas do perfil morfológico e da classificação molecular, 2ª Jornadas de Urologia Oncológica - CUF. (January) Lisbon, Portugal
- Lobo J. (2025) RCC with sarcomatoid features: perspectives from the Pathologist. XXX Workshop of Uro-oncology. Grupo Português Génito-Urinário. (March) Lisbon, Portugal
- Montezuma D. (2025) Digital and Computational Pathology: a sneak peak into the field. RISE Health Bioinformatics Day. (April) Porto, Portugal
- Lobo J. (2025) Application of liquid biopsies in testicular cancer – focus on microRNAs. Meeting "Conectados pelo conhecimento", Rede D'Or. (April) Virtual
- Lobo J. (2025) Testicular cancer – the role of cancer biomarkers: How to improve diagnostic performance? 1st Portuguese Congress of Urologic Oncology. (May) Coimbra, Portugal
- Henrique R. (2025). Basic concepts of immunotherapy, [Conceitos básicos de imunoterapia], 6th Course on Oncology Pulmonology. (May) Vila Nova de Gaia, Portugal
- Henrique R. (2025). Bladder Cancer: Innovations in Molecular Markers [Cancro da bexiga: Inovação em marcadores moleculares], 1st Portuguese Congress on Oncological Urology. (May) Figueira da Foz, Portugal
- Lobo J. (2025) Sample selection and preparation. Summer Academy on Precision Oncology: a hands-on course. 1st International Forum Precision Cancer Medicine. (September) Porto, Portugal
- Henrique R. (2025). Building a CCI in the North of Portugal focusing on Precision Cancer Medicine: lessons learned and the way ahead, 1st International Forum in Precision Cancer Medicine. (September) Porto, Portugal
- Jerónimo C. (2025). Bridging distances, enhancing competencies: strategic support for health research. 4th National Meeting of the Training Centers of the National Health Service (SNS), (September) Terceira Island, Azores, Portugal
- Monteiro-Reis S (2025). Budget and Funding in Clinical Research, 2nd Edition of the Clinical Research Course, Portuguese Society of Surgery (September) Porto, Portugal
- Constâncio V (2025). Translating Molecular Complexity into Clinical Opportunity: A Multimodal Strategy to Decode Prostate Cancer Onset and Progression. iBiMED – DCM Seminars | Autumn Series (September) Aveiro, Porto
- Correia MP (2025). Translational research and evidence-based decisions in immune-oncology. Hot Topics in Immune Checkpoint Inhibitors' Toxicities. (September) Porto, Portugal
- Coimbra N. (2025). Translational research and evidence-based decision in immuno-oncology. Curso Hot Topics in Immune Checkpoint Inhibitors' Toxicities, IPO Porto. (September) Porto, Portugal
- Lobo J. (2025) Challenges in testicular cancer – Early diagnosis. Gynecological and Urological cancers – prevention, treatment and challenges. (September) Lisbon, Portugal
- Jerónimo C. (2025). Cancer Epigenetics. Course on *Fundamentals of Genetics, Development and Neoplasia*, ICVS, University of Minho (October) Braga, Portugal
- Coimbra N. (2025). HER2-low/HER2-ultralow Breast Carcinoma: The State of the Art in Pathology and Clinical Implications. [Carcinoma da Mama HER2-low/HER2-ultralow: O estado da arte na Anatomia Patológica e implicações clínicas]. Follow HER Story 2025 | HER2-low Clinical Cases Forum | 2nd edition. (October) Vila Nova de Gaia, Portugal
- Coimbra N. (2025). Evolution in Classification—From Histology to the Integration of Genomics and Immunohistochemistry. [Evolução na Classificação – da Histologia à Integração da Genómica e Imunohistoquímica.] Course on the Basics of Lung Cancer, IPO Porto. (October) Porto, Portugal
- Coimbra N. (2025). Integration of Molecular Testing into the Diagnosis and Treatment of HR+/HER2 Breast Cancer. [Integração da Testagem Molecular no Diagnóstico e Tratamento do Cancro da Mama HR+/HER2]. PI3KCA Workshop for Pathologists. (October) Porto, Portugal

- Montezuma D. (2025) ARABESC: an innovative project in colorectal pathology. Leica Science Days (October) Matosinhos, Portugal
- Coimbra N. (2025). Biomarcadores Preditivos / Companion Diagnostics. Leica Day, IMP Laboratory. (October) Porto, Portugal
- Coimbra N. (2025). Understanding HER2 Ultra-Low in Advanced Breast Cancer: How Can We Overcome the Challenges? Biomarkers On Spot, Astrazeneca Portugal. (October) Lisboa, Portugal
- Salta S (2025). Molecular Oncology, Decoding Cancer: The Era of Molecular Oncology - Science Month 25 – AE-ESTeSC (November), Virtual
- Montezuma D. (2025) Digitizing a laboratory. [Digitalização de um laboratório]. Pre-congress course of the 20th Congress of the Portuguese Society of Surgical Pathology (November) Tomar, Portugal
- Coimbra N. (2025). Tailoring Immuno-Oncology in Resectable NSCLC: Personalized approaches for improved outcomes: Practical aspects of Anatomopathology in the treatment of patients with lung cancer. SPCCTV Congress. (November) Albufeira, Portugal
- Coimbra N. (2025). Lung cancer after neoadjuvant treatment: Standardized approach, challenges and clinical relevance. 23rd SPAP National Congress . (November) Tomar, Portugal
- Jerónimo C. (2025). Epigenetic Biomarkers in Urological Cancer: promises and pitfalls. 22nd National Oncology Congress of the Portuguese Society of Oncology. (November) Braga, Portugal.
- Montezuma D. (2025) From traditional pathology to digital and computational pathology [Da patologia tradicional à patologia digital e computacional]. Telemedicine and e-Health Lectures from the Master's Program in Medical Informatics at the University of Porto (December) Porto, Portugal
- Correia MP (2025). Immunophenomics: Charting the Immune Complexity with High-Dimensional Profiling. Workshop: Multiomics for Systems Oncology. (December) Porto, Portugal
- Mainoli B, Assis J, Coimbra N, Lobo J, Coelho S. (2025) IPO Porto Molecular Tumor Board Session. Multiomics for Systems Oncology. (December) Porto, Portugal
- Jerónimo C. (2025). Large-Scale Epigenetic Profiling and Emerging Therapeutic Opportunities in Prostate Cancer. Workshop: *Multiomics for Systems Oncology*, IPO Porto. Session: Urological oncology – translational and clinical perspectives (December) Porto, Portugal

### *Oral Communications in International Scientific Meetings*

- Salta S, Sequeira JP, Teixeira-Marques A, Amorim-Fernandes B, Carvalho-Machado D, Saraniero S, Lobo J, Sousa A, Sousa H, Baldaque I, Monteiro P, Tavares F, Taly V, Henrique R, Jerónimo C. (2025) Droplet Digital PCR & Methylation: A New Approach For HPV-Positive Women Triage. EUROGIN 2025 – International Multidisciplinary HPV Congress. (18th March); Porto, Portugal
- Lobo J, Tavares NT, Fonseca D, Constâncio V, Marques A, Henrique R, Jerónimo C, Michalova K, Cornejo K, Colecchia M, Ricci C, Idrees M, Contreras F, Fernandez I, Anderson W, Maclean F, Osunkoya AO, Kao CS, Ulbright T, Acosta A. (2025) Comprehensive microRNA Profiling of Testicular Leydig Cell Tumors Supports the Existence of a Signature Predictive of Malignant Behavior. 114th USCAP Annual Meeting (24th March). Boston, USA
- Lobo J, Tavares NT, Fonseca D, Henrique R, Jerónimo C, Ricci C, De Leo A, Ulbright T, Sounak G, Acosta A. (2025) Analysis of microRNA 371-373 Cluster and 12p Status in Somatic Carcinomas with Phenotypic Similarities to Yolk Sac Tumor. 114th USCAP Annual Meeting (24th March). Boston, USA
- Correia, MP (2025). Targeting Immunoepigenetics to Unlock NK-Mediated Killing of Prostate Cancer Cells. NK2025-21st Meeting of the Society for Natural Immunity (11th June); Hobart, Tasmania, Australia
- Moreira-Silva F, Zimmerli M, Chouvardas P, Roth B, Jerónimo C, Kruithof-de Julio M. (2025) G9a epigenetic targeting upregulates androgen and p53 signaling in advanced prostate cancer. 81. Jahresversammlung, Schweizerische Gesellschafr für Urologie (3rd-5th September); Basel, Switzerland.
- Lobo J, Tavares NT, Lourenço C, Constâncio V, Fernandes-Pontes F, Silva-Santos R, Braga I, Maurício J, Henrique R, Liu M, Weiss RS, Bagrodia A, Jerónimo C. (2025) MicroRNA 371~373 cluster is released in testicular germ cell tumors via extracellular vesicles. 37th European Congress of Pathology (9th September); Vienna, Austria

- Lourenço C, Tavares NT, Constâncio V, Monteiro-Reis S, Carvalho Â, Jerónimo C. (2025) Unlocking the Potential of Urinary Extracellular Vesicles as Bladder Cancer Biomarkers. 3rd MOVE Symposium (8th October); Tartu, Estonia.
- Rapado González Ó, Costa Fraga N, Díaz Lagares Á, López Cedrún JL, Araújo C, Capelo R, Lima M, Pereira JC, Vieira C, Cardoso A, Nogueira S, Guimarães J, Diz-Lobo Ribeiro CM, Henrique R, López López R, Muinelo Romay L, Jerónimo C, Suárez Cunqueiro MM. (2025) Genome-wide discovery and validation of novel DNA methylation markers for oral cancer detection using saliva. 10th Trends in Head & Neck Oncology (THNO-2025). European Organisation for Research and Treatment of Cancer (EORTC). (11th – 15th November) Faro, Portugal.

### *Oral Communications in National Scientific Meetings*

- Lopes-Rodrigues M, Martins-Lima C, Carvalho JA, Freitas R, Correia J, Díaz-Lagares A, Dueñas M, Monteiro-Reis S, Jerónimo C. (2025) Unveiling the potential of DNA promoter methylation and cytokines as biomarkers to predict BCG response in bladder cancer patients. 9th Symposium of the MSc in Oncology. (9th March); Porto, Portugal.
- Amorim-Fernandes B, Salta S, Baldaque I, Monteiro P, Henrique R, Jerónimo C. (2025). Analytic validation of DNA methylation biomarkers in a population-based cervical cancer screening program. 9th Symposium of the MSc in Oncology. (9th March); Porto, Portugal.
- Morais M, Constâncio V, Miranda-Gonçalves V, Costa-Silva B, Henrique R, Leung H, Jerónimo C. (2025). Decoding the Impact of ITGA6 in Prostate Cancer Progression. 9th Symposium of the MSc in Oncology. (9th March); Porto, Portugal.
- da Costa ML, dos Reis FD, Cantante M, Henrique R, Jerónimo C, Correia MP (2025). Spatial Mapping the Immune Landscape of Prostate Cancer Throughout Disease Progression. IJUP 2025 (7-9th May); Porto, Portugal
- Rapado-González Ó, Araújo C, Cardoso A, Henrique R, Jerónimo C, Suárez-Cunqueiro MM. Discovery of novel DNA methylation markers for saliva-based detection of oral cancer. (2025) Reunião Anual APMO. (26 – 27th September); Gandra, Portugal.
- Lourenço C, Constâncio V, Tavares NT, Monteiro-Reis S, Silva-Santos R, Lobo F, Lobo J, Osório H, Carvalho Â, Jerónimo C. (2025) The Impact of Direct Contact: A Proteomic Liquid Biopsy Strategy Using Urinary Extracellular Vesicles for Bladder Cancer Diagnosis. Pitch Presentation. 3rd Young Researchers' Day. (22nd October); Porto, Portugal.
- Sequeira JP, Silva-Rodrigues G, Freitas R, Diaz-Lagares Á, Henrique R, Jerónimo C. (2025) Can Pathology-Guided Biomarker Assessment Improve Pre-treatment Risk Stratification in Prostate Cancer for biomarker selection? A Retrospective Validation Study from the Portuguese Oncology Institute of Porto. Oral Presentation. 3rd Young Researchers' Day. (22nd October); Porto, Portugal.
- Magdy A, Sequeira JP, Constâncio V, Fernandes-Pontes F, Díaz-Lagares Á, Henrique R, Swinnen J, Jerónimo C. (2025). *Epigenetic deregulation contributes to metabolic reprogramming and therapy resistance in prostate cancer*. Oral Presentation. 3rd Young Researchers' Day. (22nd October); Porto, Portugal.

### *Posters in international conferences*

- Teixeira-Marques A, Sequeira JP, Monteiro-Reis S, Freitas R, Dueñas M, Henrique R, Jerónimo C. Bacille Calmette-Guérin immunotherapy failure in bladder cancer patients: unlocking the world of miRNAs derived from urinary extracellular vesicles. ISEV2025 Annual Meeting, (24-27th April); Vienna, Austria
- dos Reis FD, da Costa ML, Lobo J, Carneiro I, Freitas R, Henrique R, Jerónimo C, Correia MP (2025). Exploring the Role of Immuno-Epigenetics in Prostate Cancer. 3rd IMMUNO-model Annual Conference (13-14th May); Warsaw, Poland
- da Costa ML, dos Reis FD, Cantante M, Henrique R, Jerónimo C, Correia MP (2025). Spatial Mapping the Immune Landscape of Prostate Cancer Throughout Disease Progression. 3rd IMMUNO-model Annual Conference (13-14th May); Warsaw, Poland

- dos Reis FD, da Costa ML, Lobo J, Carneiro I, Freitas R, Henrique R, Jerónimo C, Correia MP (2025). Targeting Immunoepigenetics to Unlock NK-Mediated Killing of Prostate Cancer Cells. NK2025-21st Meeting of the Society for Natural Immunity (11th June); Hobart, Tasmania, Australia
- Lourenço C, Constâncio V, Tavares NT, Monteiro-Reis S, Silva-Santos R, Lobo F, Lobo J, Osório H, Carvalho Â, Jerónimo C. (2025) Proteomic profiling of bladder cancer patients-derived extracellular vesicles. 2025 Annual Congress of the European Association for Cancer Research (EACR 2025) (16-19th June); Lisbon, Portugal
- Fernandes-Pontes F, Constâncio V, Lobo J, Alzamora M, Silva-Santos R, Henrique R, Miranda-Gonçalves V, Jerónimo C (2025). Promoter methylation regulates CDHR5 and UPB1 expression in clear cell Renal Cell Carcinoma with sarcomatoid differentiation.2025 Annual Congress of the European Association for Cancer Research (EACR 2025) (16-19th June); Lisbon, Portugal
- Constâncio V, Lobo J, Gomez A, Ramalho-Carvalho J, Carneiro I, Freitas R, Esteller M, Henrique R, Jerónimo C (2025). High-throughput DNA methylation profiling of urological malignancies: defining epigenetic signatures in prostate, bladder and kidney cancer. EACR 2025, (16-19th June); 2025. Lisbon, Portugal
- Rapado-González Ó, Costa-Fraga N, Rodríguez-Casanova A, López-Cedrún JL, Constâncio V,
- Díaz-Lagares Á, López-López R, Henrique R, Suárez-Cunqueiro MM, Jerónimo C. Genome-wide DNA methylation profiling reveals a novel DNA methylation signature for early detection of oral cancer using saliva based liquid biopsy. 2025 Annual Congress of the European Association for Cancer Research (EACR 2025) (16-19th June); Lisbon, Portugal
- Carvalho M, Martins-Lima C, Monteiro-Reis S, Correia MP, Jerónimo C, Ferreira J (2025). An easy-to-use semi-automated image segmentation algorithm for scratch wound healing assays. 30th Congress of the European Society of Biomechanics (ESB 2025) (6-9th July); Zürich, Switzerland
- Moreira-Silva F, Zimmerli M, Chouvardas P, Roth B, Jerónimo C, Kruithof-de Julio M. (2025) G9a epigenetic targeting upregulates androgen and p53 signaling in advanced prostate cancer. 81. Jahresversammlung, Schweizerische Gesellschafr für Urologie (3rd–5th September); Basel, Switzerland
- Constâncio V, Carvalho T, Sequeira R, P. Nunes S, Morais M, Monteiro M, Miranda-Gonçalves V, Elzanowska J, Henrique R, Leung H, Costa-Silva B, Jerónimo C. (2025). A novel immunocompetent model reveals key mechanisms underlying prostate cancer bone metastasis. Cancer Core Europe Summer School in Translational Cancer Research 2025 (5-10th October); Faro, Portugal
- Magdy A, Sequeira JP, Constâncio V, Fernandes-Pontes F, Díaz-Lagares Á, Henrique R, Swinnen J, Jerónimo C. (2025). Epigenetic deregulation contributes to metabolic reprogramming and therapy resistance in prostate cancer. Oral Presentation. 34th Annual Meeting of the French Association for Assisted Reproductive Technology (ARTP) (19th November); Paris, France
- dos Reis FD, da Costa ML, Lobo J, Carneiro I, Freitas R, Henrique R, Jerónimo C, Correia MP. (2025). Epigenetic Modulation of Anti-tumor Immune Responses in Prostate Cancer. IV ASEICA-ASPIC International Meeting, New Therapies and Challenges, topics from basic to clinical (20-21 November); Santiago de Compostela, Spain
- Miranda-Gonçalves, V*, Guimarães-Teixeira, C*, Nunes P. S, Bueno-Costa, A, Duarte F. I, Carriço R. I, Lobo, J, Henrique R, Esteller, M, Jerónimo C (2025). FTO-mediated m6A demethylation drives metabolic reprogramming and immune evasion in papillary renal cell carcinoma. IV ASEICA-ASPIC International Meeting, New Therapies and Challenges, topics from basic to clinical (20-21 November); Santiago de Compostela, Spain
- Constâncio V, Lourenço C, Lobo J, Tavares N, Rodrigues Â, Peinado H, Costa-silva B, Leung H, Henrique R, Jerónimo C (2025). Extracellular Vesicle Proteomics Identifies Biological Matrix-Specific Signatures of Prostate Cancer. IV ASEICA-ASPIC International Meeting, New Therapies and Challenges, topics from basic to clinical (20-21st November); Santiago de Compostela, Spain
- da Costa ML, dos Reis FD, Cantante M, Henrique R, Jerónimo C, Correia MP. (2025). Spatial Immune Profiling of Prostate Cancer Throughout Disease Progression. IV ASEICA-ASPIC International Meeting, New Therapies and Challenges, topics from basic to clinical (20-21st November); Santiago de Compostela, Spain

- Cordeiro JP, dos Reis FD, da Costa ML, Jerónimo C, Correia MP. (2025). "Peripheral Blood Immune Cell Phenotype and DNA Methylation Profiling in Prostate Cancer Patients". IV ASEICA-ASPIC International Meeting, New Therapies and Challenges, topics from basic to clinical (20-21st November); Santiago de Compostela, Spain
- Lopes-Rodrigues M, Martins-Lima C, Constâncio V, Gómez MG, Carvalho JA, Freitas R, Correia J, Díaz-Lagares A, Dueñas M, Monteiro-Reis S, Jerónimo C. "Urinary Cytokines and DNA Methylation as Predictive Biomarkers of BCG Response in Bladder Cancer". IV ASEICA-ASPIC International Meeting, New Therapies and Challenges, topics from basic to clinical (20-21st November); Santiago de Compostela, Spain
- Rapado-González Ó, Costa-Fraga N, López-Cedrún JL, Araújo C, Constâncio V, Díaz Lagares Á, López-López R, Muinelo-Romay L, Suárez-Cunqueiro MM, Jerónimo C. "A Novel Salivary Epigenetic Signature for Oral Cancer Non-Invasive Early Detection". IV ASEICA-ASPIC International Meeting, New Therapies and Challenges, topics from basic to clinical (20-21st November); Santiago de Compostela, Spain

### *Posters in national conferences*

- Fernandes-Pontes F, Constâncio V, Lobo J, Alzamora M, Silva-Santos R, Henrique R, Miranda-Gonçalves V, Jerónimo C (2025). CDHR5 and UPB1 Promoter Methylation: Emerging Biomarkers for Sarcomatoid Clear Cell Renal Cell Carcinoma. IJUP 2025 (7-9th May); Porto, Portugal
- Teixeira-Marques A, Sequeira JP, Gallardo-Gómez M, Salta S, Freitas R, Carvalho JA., Ferreira J, Monteiro-Reis S, Correia MP., Dueñas M, Henrique R, Jerónimo C (2025). BCG therapy failure in bladder cancer patients: unlocking extracellular vesicles' miRNAs as predictive biomarkers. One Health PhD Forum. ICBAS-UP, (12th May); Porto, Portugal
- Teixeira-Marques A, Sequeira JP, Gallardo-Gómez M, Salta S, Freitas R, Carvalho JA., Ferreira J, Monteiro-Reis S, Correia MP., Dueñas M, Henrique R, Jerónimo C (2025). BCG immunotherapy response in bladder cancer patients: the value of extracellular vesicles' miRNAs as predictive biomarkers. (26th and 27th June), Faro, Portugal
- Cordeiro JP, dos Reis FD, da Costa ML, Jerónimo C, Correia MP. (2025). "Immune Cell Phenotype and DNA Methylation Landscape in Peripheral Blood of Prostate Cancer Patients". 3rd Young Researcher's Day: From discovery to Disruption – Empowering Young innovators in Oncology; Porto, Portugal
- Amorim-Fernandes B, Salta S, Baldaque I, Monteiro P, Henrique R, Jerónimo C. (2025). "Analytic validation of DNA methylation biomarkers in a population-based cervical cancer screening program". 3rd Young Researcher's Day: From discovery to Disruption – Empowering Young innovators in Oncology; Porto, Portugal
- Morais M, Constâncio V, Miranda-Gonçalves V, Costa-Silva B, Henrique R, Leung H, Jerónimo C. (2025). "Dissecting Molecular Alterations in Prostate Cancer Progression". 3rd Young Researcher's Day: From discovery to Disruption – Empowering Young innovators in Oncology; Porto, Portugal
- Lopes-Rodrigues M, Martins-Lima C, Constâncio V, Gómez MG, Carvalho JA, Freitas R, Correia J, Díaz-Lagares A, Dueñas M, Monteiro-Reis S, Jerónimo C. "DNA Methylation Predictive Value in BCG Response for Bladder Cancer". 3rd Young Researcher's Day: From discovery to Disruption – Empowering Young innovators in Oncology; Porto, Portugal
- R. Carriço I, Macedo-Silva C, A. M. Santos J, Jerónimo C, Miranda-Gonçalves V. (2025). "Decoding Radioresistance in Prostate Cancer Through Epigenetic and Metabolic Lenses". 3rd Young Researcher's Day: From discovery to Disruption – Empowering Young innovators in Oncology; Porto, Portugal
- Carvalho M, Martins-Lima C, Monteiro-Reis S, Correia MP, Jerónimo C, Ferreira J. (2025) "Wound Profiler: A Practical Tool for Semi-Automated Scratch Assay Image Segmentation". 3rd Young Researcher's Day: From discovery to Disruption – Empowering Young innovators in Oncology; Porto, Portugal
- Lourenço C, Constâncio V, Tavares NT, Monteiro-Reis S, Silva-Santos R, Lobo F, Lobo J, Osório H, Carvalho Â, Jerónimo C. (2025) Identificação De Biomarcadores Em Vesiculas Extracelulares

Derivadas Do Cancro Da Bexiga: A Perspetiva Proteómica Da Célula À Urina. 7th Encontro Nacional De Jovens Investigadores Em Oncologia (ENJIO). (24th September); Porto, Portugal

- Tavares NT, Fonseca D, Amorim-Fernandes, B, Gumauskaite S, Constâncio V, Lobo J, Leite-Silva P, Rosinha A, Henrique R, Jerónimo C. (2025) Promoter hypermethylation in genes as a biomarker for predicting response to cisplatin-based chemotherapy in bladder cancer [Hipermetilação do promotor em genes como biomarcador de predição de resposta à quimioterapia com cisplatina em cancro da bexiga]. 7th National Meeting of Young Researchers in Oncology (ENJIO). (24th September); Porto, Portugal

### *Editorial Board Positions*

| Journal | Publishing Company | Position | Researcher |
|---|---|---|---|
| Clinical Epigenetics | BMC-Springer Nature | Section Editor: Cancer epigenetics & diagnostics | Carmen Jerónimo |
| Pathobiology | Karger | Editorial Board Member | João Lobo |
| Plos ONE | Public Library of Science | Associate Editor | Rui Henrique |
| Frontiers in Cell and Developmental Biology | Frontiers | Associate Editor of the Section of Epigenomics and Epigenetics | Carmen Jerónimo, Rui Henrique |
| Frontiers in Genetics | Frontiers | Associate Editor of the Section of Epigenomics and Epigenetics | Carmen Jerónimo, Rui Henrique |
| Frontiers in Molecular Medicine | Frontiers | Associate Editor | João Lobo |
| Frontiers in Oncology | Frontiers | Topic Editor in Epigenetic Insights into Diagnostic and Therapeutic Applications | Carmen Jerónimo |
| Frontiers in Oncology | Frontiers | Academic Editor | João Lobo |
| Frontiers in Urology | Frontiers | Review Editor | João Lobo |
| Journal of Clinical Medicine | MDPI | Guest Editor | João Lobo, Óscar Rapado-González |
| Life | MDPI | Guest Editor | João Lobo |
| Tumori Journal | Public Library of Science | International Editorial Board Member | Carmen Jerónimo, Rui Henrique |

### *Peer Review*

BMC Cancer; Communications; Cancer Letters; Cells; Cell Reports; Clinica Chimica Acta; Expert Reviews in Molecular Diagnosis; Journal of Translational Medicine; Clinical Epigenetics; European Urology; European Urology Oncology; European Urology Focus; Frontiers Immunology; Frontiers in Oncology; International Journal of Cancer; IScience; Journal of Advanced Research; Journal of Experimental & Clinical Cancer; Molecular Cancer; Molecular Medicine; Molecular Oncology; npj Digital Medicine; Scientific Reports; The Journal of Pathology; The Lancet Obstetrics, Gynaecology, & Women's Health; The Lancet Oncology; Translational Oncology; Virchows Archiv; Nature Reviews in Urology;

### *Grant Reviewer*

| Agency | Call | Country | Date | Researcher |
|---|---|---|---|---|
| Fonds de la Recherche Scientifique (FNRS) | FNRS Quinquennial Scientific Prizes: Joseph Maisin Scientific Prize in Basic Biomedical Science | Belgium | 2025 | Carmen Jerónimo |
| Institut National Du Cancer (InCa), France | SIRIC 2022-Integrated Cancer Research Site Designation mid-term evaluation | France | 2025 | Carmen Jerónimo |

| Agency | Call | Country | Date | Researcher |
|---|---|---|---|---|
| Ministero dell'Università e della Ricerca (MUR), Italy | FIS 3 Call-Italian Science Fund (Fondo Italiano per la Scienza) 2024–2025, Life Sciences, | Italy | 2025 | Carmen Jerónimo |
| Swiss Cancer Research Foundation | 2025 Call | Switzerland | 2025 | Carmen Jerónimo |
| Prémio Dr Mário Fonseca 2025/Dr Mário Fonseca Prize 2025 | Projects | Portugal | 2025 | Carmen Jerónimo, Rui Henrique |
| European Science Foundation (ESF) | Postdoctoral Fellowship (FWO) | France | 2025 | Margareta P. Correia |
| Swiss National Science Foundation (SNSF) | 2025 call | Switzerland | 2025 | Rui Henrique |
| Austrian Science Fund (FWF) | Projects | Austria | 2025 | Rui Henrique |
| Israel Science Foundation (ISF) | Projects | Israel | 2025 | Rui Henrique |
| University of Malta | Projects | Malta | 2025 | Rui Henrique |

### *Participation as Opponent in MSc Evaluation Committees*

| Student | Title | Program | Researcher |
|---|---|---|---|
| Inês Sofia da Costa Ferreira | *Evolutionary Insights into Colorectal Cancer Tumor Suppressor Genes: Signatures of Positive Selection in Mammals* | Applications in Biotechnology and Synthetic Biology, FCUP | Carmen Jerónimo |
| Pedro Dias Moreira | Medical Education at the School of Medicine and Biomedical Sciences of the University of Porto: Student Trends and Perspectives | Integrated Master's in Medicine, ICBAS | Rui Henrique |

### *Participation as Opponent in PhD/Aggregation Evaluation Committees*

| Student | Title | Program | Researcher |
|---|---|---|---|
| Antero José Pena Afonso de Abrunhosa | Health Sciences | Aggregation in Health Sciences-Biomedical Sciences, Faculty of Medicine, University of Coimbra | Carmen Jerónimo |
| Ana Rita Gomes | Design, synthesis, and biological activity of functionalized steroids as anticancer agents | PhD in Pharmaceutical Sciences, Pharmaceutical Chemistry, Faculty of Pharmacy, University of Coimbra | Carmen Jerónimo |
| Iris Adriana Maria Lodewijk | *CD44v6 as a novel target in precision medicine approaches for advanced bladder cancer* | PhD in Molecular Biosciences, Autonomous University of Madrid, Spain (External Evaluator) | Carmen Jerónimo |

### *Participation in Academic Recruitment Committees*

| Call/Jury | Researcher |
|---|---|
| Faculty of Sciences, University of Lisbon 2022/052023.15441.TENURE.Call for the recruitment of an Assistant Professor in the scientific area of Genetics (1 job). Public Notice No. 2025/1129 | Carmen Jerónimo |

### *Teaching Activity: Coordination of Curricular Units/Courses*

| Member | Curricular Units | Program | Position | Faculty/University |
|---|---|---|---|---|
| Carmen Jerónimo | Laboratory Oncology, Project – _Research Seminars, Epigenetics | MSc in Oncology | Co-Director, Coordination and teaching | ICBAS; UP |
| Carmen Jerónimo | Research Methodologies in Biopathology | Integrated MSc in Medicine | Coordination and teaching | ICBAS; UP |
| Carmen Jerónimo | Oncobiology | MSc in Bioengineering | Coordination and teaching | FE/ICBAS; UP |
| Carmen Jerónimo | Oncobiology | MSc in Biochemistry | Teaching | FC/ICBAS; UP |

| Member | Curricular Units | Program | Position | Faculty/University |
|---|---|---|---|---|
| Carmen Jerónimo | Epigenetics and Cancer I & II | MSc & PhD Programme in Molecular Medicine and Oncology | Coordination and teaching | FMUP & ICBAS/FM; UP |
| Carmen Jerónimo | Techniques in Molecular Biology, Epigenetic Mechanisms in Oncology | PhD Programme in Pathology and Molecular Genetics | Coordination and teaching | ICBAS/FM; UP |
| Carmen Jerónimo | Pathology I Pathology II | Integrated MSc in Medicine | Teaching | ICBAS; UP |
| Carmen Jerónimo | Biopathology I, Biopathology II | Integrated MSc in Dental Medicine | Teaching | FMD; UP |
| Carmen Jerónimo | Biology of Disease | MSc in Health, Communication and Society | Coordination and teaching | ICBAS; UP |
| Rui Henrique | Pathology I, Pathology II, Anatomic Pathology | Integrated MSc in Medicine | Deputy Director, Coordination, and teaching | ICBAS; UP |
| Rui Henrique | Biopathology I, Biopathology II | Integrated MSc in Dental Medicine | Coordination and teaching | FMD; UP |
| Rui Henrique | Oncobiology | MSc in Biochemistry | Coordination and teaching | FC/ICBAS; UP |
| Rui Henrique | Oncobiology | MSc in Bioengineering | Coordination and teaching | FC/ICBAS; UP |
| Rui Henrique | Pathological Oncology | MSc in Oncology | Coordination and teaching | ICBAS; UP |
| Rui Henrique | Pathology of Neoplasia | PhD Programme in Pathology and Molecular Genetics | Coordination and teaching | ICBAS/ FM; UP |
| Ana T. Martins, Isa Carneiro, João Lobo, Paula Lopes, Paula Monteiro Sérgio Lopes | Laboratory Oncology, | MSc in Oncology | Teaching | ICBAS; UP |
| Ana Varelas, David Gigliano, João Lobo | Biopathology I, Biopathology II | Integrated MSc in Dental Medicine | Teaching | FMD; UP |
| Ângelo Rodrigues, Carla Bartosch, Nuno Coimbra | Pathology I, Pathology II | Integrated MSc in Medicine | Teaching | ICBAS; UP |
| João Lobo | Biopathology I Biopathology II | MSc in Dental Medicine | Teaching | FMDUP |
| Ana T. Martins, Isa Carneiro, João Lobo, Paula Lopes, Paula Monteiro Sérgio Lopes | Laboratory Oncology, | MSc in Oncology | Teaching | ICBAS; UP |
| Margareta P. Correia, Sara Monteiro-Reis, Vera Miranda-Gonçalves | Epigenetics | MSc in Oncology | Teaching | ICBAS; UP |
| Margareta P. Correia, Sara Monteiro-Reis, | Research Practices in Oncology | MSc in Oncology | Teaching | ICBAS; UP |

| Member | Curricular Units | Program | Position | Faculty/University |
|---|---|---|---|---|
| Vera Miranda-Gonçalves | | | | |
| Margareta P. Correia, Sara Monteiro-Reis, Vera Miranda-Gonçalves | Epigenetic Mechanisms in Oncology | PhD Programme in Pathology and Molecular Genetics | Teaching | ICBAS/FM; UP |
| Margareta P. Correia, Vera Miranda-Gonçalves | Epigenetics and Cancer I & II | MSc & PhD Programme in Molecular Medicine and Oncology | Teaching | FMUP & ICBAS/FM; UP |
| Margareta P. Correia, Sara Monteiro-Reis, Vera Miranda-Gonçalves | Oncobiology | MSc in Biochemistry | Teaching | FCUP; UP |
| Margareta P. Correia, Sara Monteiro-Reis, Vera Miranda-Gonçalves | Oncobiology | Integrated MSc in Bioengineering | Teaching | FEUP; UP |
| Margareta P. Correia; Sara Monteiro-Reis, Vera Miranda-Gonçalves | Biology of Disease | MSc in Health, Communication and Society | Teaching | ICBAS; UP |
| Margareta P. Correia; Sara Monteiro-Reis, Vera Miranda-Gonçalves | Research Methodologies in Oncology | Continuing Training Unit | Teaching | ICBAS; UP |
| Mariana Carvalho | Industrial Drawing | BSc in Industrial Engineering and Management | Teaching | FEUP; UP |
| Mariana Carvalho | Mechanical Engineering Drawing | BSc in Mechanical Engineering | Teaching | FEUP; UP |
| Vera Constâncio | Advanced Techniques in Molecular Biology | MSc in Laboratory Techniques in Molecular Biology | Teaching | ESS-P.Porto |

### *International Internships*

| Period | Researcher/student | Position/Program | Country |
|---|---|---|---|
| Oct. 2024-Sept. 2025 | María Gallardo Gómez | Postdoctoral Xunta de Galicia – GAIN 2024 call: Axudas de apoio à etapa de formación posdoutoral<br>Translational Molecular Oncology Unit<br>Instituto de Investigación Sanitaria Galicia Sur | Vigo, Spain. |
| June 2025 – Sept. 2025 | Ilknur Yildiz | Erasmus+ | Faculty of Life and Natural Sciences, Abdullah Gül University, Republic of Türkiye |
| Mar 2025- May 2025 | John Buchanan | Medical Student Elective | University of Birmingham, UK. |

### Prizes, Honors and Awards

| Researcher | Prize designation | Institution | Date | Amount |
|---|---|---|---|---|
| Fernanda Fernandes-Pontes | Best Poster in Health Sciences | IJUP 2025 | May 2025 | NA |
| Mariana L. da Costa | Best Oral Communication in Health Sciences | IJUP 2025 | May 2025 | NA |
| Nuno Tiago Tavares | Fulbright Grant for Research with the Support of FCT | Fulbright Portugal Grants | September 2025 | NA |
| Catarina Lourenço | Best Pitch Presentation | 3rd Young Researchers Day | October 2025 | NA |
| José Pedro Sequeira | Honourable Mention for Oral Presentation | 3rd Young Researchers Day | October 2025 | NA |
| Vera Constâncio | Honourable Mention for Poster Presentation | 9th Cancer Core Europe Summer School in Translational Cancer Research | October 2025 | NA |
| Carmen Jerónimo | World's Top 2% Scientists List | | 2025 | |
| Rui Henrique | World's Top 2% Scientists List | | 2025 | |

### Scientific Appointments

| Organization | Researcher |
|---|---|
| Chair of the European Association of Urology Section of Translational Research (EAU) | Carmen Jerónimo |
| President of the ASPIC- Portuguese Association for Cancer Research (Associação Portuguesa de Investigação em Cancro- EACR affiliated) | Carmen Jerónimo |
| Management Committee member COST ACTION (CA21135-IMMUNO-model) - Modelling immunotherapy response and toxicity in cancer | Carmen Jerónimo |
| Member of the Scientific Advisory Board of the International Society for Molecular and Clinical Epigenetics | Carmen Jerónimo |
| Member of the Digital & Computational Pathology (DCP) Working Group of the European Society of Pathology (ESP) | Diana Montezuma |
| Member of the Pathology and Pathogenomics Working Group of the European Interdisciplinary Society of Artificial Intelligence for Cancer Research (ESAC) | Diana Montezuma |
| Board member and chair of the Scientific Committee of the European Society of Digital and Integrative Pathology (ESDIP) | Diana Montezuma |
| Member of the Steering Committee of the European Master's in Molecular Pathology (EMMP) | João Lobo<br>Rui Henrique |
| European Society of Pathology – Member of the Uropathology, Molecular Pathology, Pulmonary Pathology and Alumni Working Groups | João Lobo |
| Member of the Testis Cancer Guideline Panel of the European Association of Urology (EAU) | João Lobo |
| Board member of the EAU Section of Uropathology (ESUP) | João Lobo |
| Member of the EAU Oncology Section (ESOU) Working Group on Testicular / Penile Cancer | João Lobo |
| Malignant Germ Cell International Consortium (MaGIC) - Vice-chair of the Young Investigator Subcommittee, Member of the Pathology Subcommittee and Membership Committee | João Lobo |
| Young Academic Urologists (YAU) - Member of Penile & Testis Working Group | João Lobo |
| Member of the Young Cancer Professionals (YCP) – European Cancer Organisation | João Lobo |
| Fellow da European Academy of Cancer Sciences | Rui Henrique |
| Member of the Organisation of European Cancer Institutes (OECI) Extended Designation Board | Rui Henrique |

### National collaborations

| Title | Researchers | Collaborators | Funding | Period |
|---|---|---|---|---|
| EMBRACIVE – _A microfluidic assisted technology for non-invasive identification and characterization of plasma extracellular vesicles in bladder cancer patients PhD Project of Catarina Lourenço | Carmen Jerónimo | Ângela Carvalho (Biocomposites Group) INEB/i3S | FCT: 2021.06731.BD | 2022-2026 |
| ExtraVesiBle - "Extracellular Vesicles in Bladder cancer Bacille Calmette-Guerin treated patients: from exploration of non-coding biomarkers towards biological function" PhD project of Ana Teixeira-Marques | Carmen Jerónimo | Celso Reis (Glycobiology in Cancer Group) IPATIMUP/i3S | FCT: 2023.01232.BD | 2023-2027 |
| EpImmunePCa - "On the crossroads of Immuno-Epigenetics for targeting advanced Prostate Cancer" | Margareta P. Correia,<br>Rui Henrique<br>Carmen Jerónimo | Maria José Oliveira (Tumor and Microenvironment Interactions) INEB/i3S | FCT: 2022.04809.PTDC | 2023-2026 |
| PCaEVision – "Decoding the role of extracellular vesicles in prostate cancer bone metastasis" | Vera Constâncio,<br>Carmen Jerónimo | Bruno Costa-Silva (Systems Oncology Group) CF | FCT: 2022.05135.PTDC | 2023-2025 |
| NeurONiche - "Advanced engineering of human innervated pre-metastatic niche: elucidating the impact of prostate cancer-derived extracellular vesicles on bone metastatic pathological neurotization" | Carmen Jerónimo | Estrela Neto (Neuro & Skeletal Circuits Group) i3S | FCT: 2023.16317.ICDT | 2025-2028 |
| Breast_to_bone - "The Influence of Triple Negative Breast Cancer Secretome in Bone Pre-Metastatic Reprogramming" | Carmen Jerónimo | Joana Paredes (Cancer Mestastasis Group) i3S | FCT: COMPETE2030-FEDER-00686000, Project 15753 | 2025-2028 |
| JANUS - "Reengineering cervical cancer screening for the 21st century: joint action for a novel up-to-date and sustainable screening program" | Rui Henrique | Nuno Lunet (ISPUP) | FCT: 2023.17087.ICDT | 2025-2028 |
| Overcoming Prostate Cancer Resistance using a New Homologous Recombination Inhibitor | Carmen Jerónimo<br>Vera Miranda-Gonçalves | Lucília Saraiva (REQUIMTE) | 2024.13556.PEX | 2025-2026 |
| Stroke&Cancer - "Stroke in translation: biomarkers for diagnosis and management of acute ischemic stroke" | Carmen Jerónimo<br>Rui Henrique<br>Sara Monteiro-Reis<br>João Lobo<br>Vera Constâncio<br>José Pedro Sequeira | Luís F. Maia (ULS de Santo António, E.P.E.) | Research Project Grant (BPI) from the Department of Teaching and Training, ULSSA | 2025-2026 |

### International collaborations

| Title | Researchers | International Team | Institution | Country | Funding |
|---|---|---|---|---|---|
| CCI4EU – Comprehensive Cancer Infrastructures for the European Union | Carmen Jerónimo; José Pedro Sequeira; Rui Henrique; Vera Contâncio | Carla Finocchiaro, Valentina Lungheu and Maurizio Cicero | Carla Finocchiaro, Valentina Lungheu and Maurizio Cicero | The Netherlands | EU (4 EUROPE-HORIZON-MISS-2022-CANCER-01-02, ID: 101103746) |
| EURECA - EURopean Epitranscriptomics of Cancer Academy | Carmen Jerónimo | Elena Martens-Uzunova | Erasmus MC | Netherlands | EU: 101226733 HORIZON-MSCA-2024-DN-01 |
| EpImmunePCa - "On the crossroads of Immuno-Epigenetics for targeting advanced Prostate Cancer" | Margareta P. Correia, Rui Henrique Carmen Jerónimo Filipa Domigues Reis Rui Freitas | Adelheid Cerwenka; Ana Stojanovic; Gabri van der Pluijm | Mannheim Institute for Innate Immunoscience; Leiden University Medical Centre | Germany Netherlands | FCT: 2022.04809.PTDC |
| ExtraVesiBle - Extracellular Vesicles in Bladder cancer Bacille Calmette-Guerin treated patients: from exploration of non-coding biomarkers towards biological function | Ana Teixeira-Marques, Marta Rodrigues, Sara Monteiro-Reis, Carmen Jerónimo | Marta Dueñas | Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT) Fundación para la Investigación Biomédica Hospital 12 Octubre | Madrid, Spain | FCT: 2023.01232.BD |
| HENKO NET – Innovation and Digital Technologies for Social and Health Palliative Care at home | Carmen Jerónimo, Mariana Silva Ferreira, Rui Henrique, Sara Monteiro-Reis | Raquel Losada Durán, Raquel Losada Durán | Fundación INTRAS | Castilla y León,Valladolid, Spain | EU and European Regional Development Fund (ERDF) |
| MethylProCancer – Prostate Cancer Risk Stratification and monitoring approach: Unveiling circulating DNA methylation-based biomarkers; PhD Project of José Pedro Sequeira | José Pedro Sequeira, Rui Henrique, Carmen Jerónimo | Ángel Diaz-Lagares | Epigenomics Unit, Translational Medical Oncology Group (Oncomet), Health Research Institute of Santiago (IDIS) | Spain | FCT: 2022.11060.BD |
| MiREpiTestis: "Unveiling mir-371-373 cluster epigenetic reprogramming and downstream targets in testicular germ cell tumours"; PhD project of Nuno Tiago Tavares | João Lobo, Carmen Jerónimo | Aditya Bagrodia | University of California – San Diego | USA | FCT: 2022.09566.BD |
| ProEpiCare: Prospects of using Epi-Drugs as a Tailored Approach in Prostate Cancer; PhD Project of Filipa Moreira Silva | Carmen Jerónimo | Marianna Kruithof-de Julio | University of Bern | Switzerland | FCT: 2023.00300.BD |

| Title | Researchers | International Team | Institution | Country | Funding |
|---|---|---|---|---|---|
| PCaEVision – "Decoding the role of extracellular vesicles in prostate cancer bone metastasis" | Vera Constâncio, Carmen Jerónimo | Hector Peinado; Hing Leung | Spanish National Cancer Research Centre (CNIO) | Spain; United Kingdom | FCT: 2022.05135.PTDC |
| PCM4EU – Personalised Cancer Medicine for Europe | Rui Henrique | Hans Gelderblom | Leiden University Medical Centre (LUMC)+15 | Leiden, The Netherlands | EU4Health, ID: 101079984 EU4H-2021-PJ15 |
| PRIME-ROSE | Rui Henrique | Kjetil Taskén | Institute for Cancer Research Oslo University Hospital | Oslo, Norway | EU ID: 101104269 HORIZON-MISS2022-CANCER-01 |
| PROMISE – Multiomic Profiling of Prostate Cancer Extracellular Vesicles to Uncover Molecular Signatures for Biomarker Discovery | Carmen Jerónimo, Vera Constâncio, Sara Monteiro-Reis, Catarina Lourenço, Nuno Tavares | Maija Puhka; Ángel Diaz-Lagares, Hector Peinado; Elena Martens-Uzunova | University of Helsinky; IDIS; Centro Nacional de Biotecnología (CNB-CSIC); Erasmus University Medical Center (Erasmus MC) | Finland; Spain; Netherlands | FCT: 2023.16683.ICDT |
| PROSTAMET - A Comprehensive Translational Research and Training Pipeline Harnessing Lipid Metabolism to Improve Prostate Cancer Management and Educate Young Researchers in Tackling Complex Disease | Carmen Jerónimo, Vera Miranda-Gonçalves, Amal Magdy | Johannes Swinnen; Alejandro Sifrim | Katholieke Universiteit Leuven (KU Leuven); Institut national de la santé et de la recherche médicale (INSERM) | Belgium; France | EU: 101120283 HORIZON-MSCA-2022-DN-01 |
| Strategies for determination of methylation biomarkers in liquid biopsies: saliva and blood for oral cancer diagnosis and monitoring | Carmen Jerónimo Rui Henrique Vera Constâncio Bárbara Amorim Fernandes | Óscar Rapado-González María Mercedes Suárez-Cunqueiro Rafael López-López | Translational Medical Oncology Group (ONCOMET), Health Research Institute of Santiago (IDIS), | Santiago de Compostela, Spain. | CRIS Out-Back Programme |
| UCI Predict- Circulating tumour microenvironment components as Urothelial Cancer Immunotherapy Response Predictors- | Ana Teixeira-Marques, Sara Monteiro-Reis; Margareta Correia Rui Henrique Rui Freitas, Carmen Jerónimo | Marta Dueñas | Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT) and Fundación para la Investigación Biomédica Hospital 12 Octubre | Madrid, Spain | TRANSCAN3/0001/2021 |
| Uncovering regulatory networks underlying the miR-371-373 cluster and novel therapeutics in testicular germ cell tumors: insights from epigenetics"; PhD project of Nuno Tiago Tavares | João Lobo, Carmen Jerónimo | Robert S. Weiss | Cornell University | Attica, USA | FCT: 2022.09566.BD |

### International Consortia

| Organization | Researcher |
|---|---|
| MC Substitute-COST ACTION INTERNATIONAL NUCLEOME CONSORTIUM-CA18127-INC | Carmen Jerónimo |
| Management Committee member COST ACTION (CA21135-IMMUNO-model) - Modelling immunotherapy response and toxicity in cancer | Carmen Jerónimo |
| Member-COST ACTION Modelling immunotherapy response and toxicity in cancer; Action CA21135-IMMUNO-model | Margareta P. Correia; Filipa Domingues dos Reis; Mariana L. da Costa; Jéssica P. Cordeiro |
| Member of COST ACTION (CA24115 – CINNAMON) - Connecting an International Network of Academic Manufacturers of ONcoimmunotherapies | Margareta P. Correia |
| PROSTAMET - A comprehensive translational research and training pipeline harnessing lipid metabolism to improve prostate cancer management (Horizon Europe MSCA-Doctoral Network, Grant No. 101120283) | Carmen Jerónimo; Amal Magdy |
| EURECA - EURopean Epitranscriptomics of Cancer Academy (Horizon Europe MSCA-Doctoral Network, Grant agreement ID: 101226733) | Carmen Jerónimo |

### Patents Submitted

| Description | File number | Status | National/ international |
|---|---|---|---|
| Lourenço C, Constâncio V, Carvalho Â, Jerónimo C. Bladder Cancer Biomarkers, Methods and Kit | PT20252007037390 | Provisional | National |
| Jerónimo C. A panel of eight volatile compounds as biomarkers for the early detection of bladder cancer in urine | PT20252007296028 | Provisional | National |

## CANCER GENETICS GROUP

### Coordinator

Manuel Teixeira, MD, PhD

### Research team @31 December 2025

| Name | Academic degree | Professional situation | Category/position | Time % |
|---|---|---|---|---|
| Ana de Fátima Fernandes Barbosa | PhD | Contract | Clinical biologist | 30 |
| Ana Luísa Peixoto de Moura | PhD | Contract | Oncology pharmacits | 30 |
| Anabela Bianca Moreira Costa | BSc | Student | MSc student | 100 |
| Andreia Filipa Moreira Aguiar Brandão | PhD | Contract | Junior researcher - 2021.03835.CEECIND | 100 |
| Beatriz Monteiro Pinheiro | MSc | Contract | Clinical biologist | 20 |
| Beatriz Namorado | BSc | Student | MSc student | 100 |
| Carla Alexandra Cavaco Pinto | MSc | Contract | Clinical biologist | 20 |
| Carla Patrícia Brandão Gomes Paulo Escudeiro | MSc | Contract | Clinical biologist | 20 |
| Catarina Gomes Rodrigues Santos | MSc | Contract | Clinical biologist | 20 |
| Cecília Maria Gaspar Guedes Figueiredo e Correia | MSc | Contract | Clinical biologist | 20 |
| Elsa Gomes Paiva | MSc | Fellowship | PhD student FCT UI/BD/154819/2023 | 100 |
| Inês Isabel Pereira de Sá | BSc | Student | MSc student | 100 |
| Isabel Maria da Silva Veiga dos Santos | MSc | Contract | Clinical biologist | 20 |
| Joana Virgínia Pinto Valejo de Magalhães Vieira | MSc | Contract | Clinical biologist | 20 |
| João Fernando Pinho Silva | MD, MSc | Contract | Genetician | 20 |
| Luís Daniel Pinto Ferraz Ribeiro | BSc | Student | MSc student | 100 |
| Manuel António Rodrigues Teixeira | PhD, Aggregation | Contract | Research Coordinator | 100 |
| Manuela Cristina Dias Pinheiro | PhD | Fellowship | Postdoc Researcher (LPCC-NRN2025) | 100 |
| Maria de Lurdes Eiras Torres | MSc | Contract | Clinical biologist | 20 |
| Maria Gabriela Oliveira dos Reis Soares | MD, BSc | Contract | Geneticist | 20 |
| Mariana Gonçalves Eiras | MSc | Fellowship | PhD Student FCT 2024.04511.BD | 15 |
| Marta Ribeiro José Cardoso | PhD | Contract | Clinical biologist | 20 |
| Patrícia Margarida Ferreira Saraiva Baptista Arinto | MSc | Contract | Clinical biologist | 100 |
| Patrícia Maria Carvalho Rocha | MSc | Contract | Clinical biologist | 20 |
| Paula Cristina Martins dos Santos Paulo | PhD | Contract | Assistant Researcher (2023.14811.TENURE.003) | 100 |
| Roberto Miguel Pais Pinto | MSc | Fellowship | PhD Student FCT 2024.04316.BDANA | 20 |
| Sofia de Melo Feiteira Maia | MD, PhD | External | Associate Researcher | 30 |
| Susana de Campos Bizarro | MSc | Contract | Clinical biologist | 20 |
| Susana Lisboa Fernandes | MSc | Contract | Clinical biologist | 20 |
| Tatiana da Cruz Almeida | MSc | Fellowship | PhD Student FCT 2024.00816.BD | 30 |

### Group description and objectives

The general objective of the Cancer Genetics Group is to study the interplay between inherited cancer predisposition and the pattern of acquired genetic alterations that give rise to cancer, in order to understand the mechanisms of tumor initiation and progression and their role in therapy response and resistance. Several biologically and clinically relevant tumor models are studied, as they can provide transversal input, but with emphasis in prostate cancer (PrCa). To make possible tailor-made therapy specifically directed towards the altered metabolism of tumor cells, exact knowledge about the inherited and acquired genomic abnormalities of individual patients, not just about diagnostic categories, is becoming a decisive factor in the selection of optimal therapy. In fact, the fields of germline and somatic genetics are progressively more interconnected, as exemplified by shared mutation signatures that might have similar predictive value for targeted cancer therapy.

The main lines of research for the period 2024-2026 are the following:

1. To further characterize the contribution to carcinogenesis of the *PRUNE2*, *BUB1B* and *IPO4* genes, which we have recently uncovered as candidate PrCa predisposition genes contributing to explain the missing heritability of this disease. Besides providing the possibility for a molecular diagnosis of inherited predisposition for these families, this research findings may allow pre-symptomatic testing. This will enable offering targeted screening to high-risk carriers, since it is likely that this will result in increased positive predictive value for prostate biopsy as compared to population-based studies. Pre-symptomatic testing for high-risk genes will also avoid unspecific PrCa screening in non-carriers of a known high-risk family mutation, thereby avoiding the risk of overdiagnosis and overtreatment in men that have the population risk despite belonging to a high-risk family.
2. To understand the polygenic basis of hereditary predisposition to prostate cancer using a multi-omics integrative approach combining genomic and transcriptomic strategies. The project is divided in three main goals: to identify rare and low-frequency germline alterations (SNVs and CNVs) associated with particular gene clusters/pathways playing a role in the inherited predisposition to PrCa; to characterize tumor transcriptomic variation and understand its impact in inherited PrCa, by performing RNA-seq in prostate carcinomas from familial PrCa cases previously analyzed by WES; and to clarify the possible correlation between the genetic variability (germline and somatic) and gene expression levels, and its association with the hereditary predisposition to PrCa.
3. To use cell-based strategies to screen genetic variants and compounds targeting cilia-related genes for prostate cancer development and therapy. This project proposes four interrelated, yet independent aims: to determine the impact of germline mutations in ciliary genes for PrCa development; to identify the most effective compounds, concentrations and potential synergistic combinations that restore cilia function in PrCa cells; to restore primary cilia formation in PrCa 3D spheroid models to reduce cancer-associated phenotypes; and to determine the molecular pathways underlying cilia-dependent tumorigenesis.
4. To evaluate the potential utility of anti-EGFR therapies in ETS-positive subtypes of prostate cancer. The identification of the molecular subtypes ERG, ETV1 and ETV4, representing approximately 50%, 10% and 5% of metastatic PrCa cases, may provide therapeutic opportunities for drug repurposing. The main questions to be addressed in this project are: to clarify the potential of combined EGFR/STAT3 inhibition in ETS-subtypes of PrCa, exploring the molecular pathways involved and understanding how these targeted therapies affect the oncogenic properties of ETS-positive tumors; to assess the inflammatory profile of PrCa ETS-subtypes, using previously obtained transcriptomic profile of prostate carcinomas harboring different ETS rearrangements; to determine the impact of the tumor microenvironment on combined EGFR/STAT3 inhibition efficacy in PrCa cells by evaluating how the microenvironment modulates treatment responses and, subsequently, identify a molecular signature that can predict treatment efficacy.

## Active projects and funding

### Competitive Funding

#### National

- PRUNE2 – "PRUNE2 gene as a novel dual-role biomarker for prostate cancer inherited predisposition and therapy response" (2023.01928.RESTART), Budget: 49.8K€ (2023-2025) (PI: Andreia Brandão).
- PRECISER – "Preclinical validation of the efficacy of combined inhibition of EGFR and STAT3 for ETS-rearranged prostate carcinomas" (COMPETE2030-FEDER-00721400), Budget: 203.649 € (2025-2028) (PI: Paula Paulo).

### Internal

- HPC – "Inherited predisposition to prostate cancer" (PI 63-CI-IPOP-24-2015), Budget: 75K€ (2011-2026) (PI: Manuel Teixeira).
- ctDNA-BRCA – "Identification of somatic and germline mutations in circulating tumor DNA in ovarian cancer patients and in germline BRCA1/BRCA2 mutation carriers undergoing cancer screening" (PI 71-CI-IPOP-35-2016), Budget: 90K€ (2016-2026) (PI: Manuel Teixeira).
- ctDNA-Lynch – "Detection of cancer specific genetic alterations in circulating free tumor DNA as a tool for early cancer diagnosis and follow up in Lynch syndrome patients" (PI 72-CI-IPOP-36-2016), Budget: 20K€ (2016-2026) (PI: Manuel Teixeira).
- InCyte – "Analysis of T315" (PI 81-CI-IPOP-52-2017), Budget: 41K€ (2016-2026) (PI: Manuel Teixeira).
- ctDNA-Cancer – "Validation of liquid biopsies for predictive biomarker testing, therapy response monitoring, and resistance mechanism identification in cancer patients" (PI 82-CI-IPOP-54-2017), Budget: 35K€ (2017-2026) (PI: Manuel Teixeira).
- CaGaGen – "Identification of germline mutations by gene-panel next generation sequencing in familial tubular and mixed tubular-diffuse gastric cancer" (PI 84-CI-IPOP-56-2017), Budget: 90K€ (2017-2026) (PI: Manuel Teixeira).
- STOP-TKI – "The role of immune system for treatment-free remission in CML patients who stopped TKI therapy" (PI 126-CI-IPOP-120-2019), Budget: 12K€ (2019-2026) (PI: Manuel Teixeira).
- LUNG-ctDNA – "Characterization of targeted therapy resistance mechanisms in EGFR/ALK/ROS1/BRAF-positive NSCLC by gene panel NGS in circulating cell-free DNA" (PI 138-CI-IPOP-126-2019), Budget: 15K€ (2021-2026) (PI: Manuel Teixeira).
- VATER – "Landscape of somatic and germline genetic alterations in ampullary carcinomas" (PI 140-CI-IPOP-128-2020), Budget: 15K€ (2019-2026) (PI: Manuel Teixeira).
- MetPC – "Simultaneous detection of germline and somatic mutations in DNA repair genes by next generation sequencing of tumor samples and cell-free DNA from metastatic prostate cancer patients" (PI 141-CI-IPOP-129-2020), Budget: 75K€ (2021-2026) (PI: Manuel Teixeira).
- PATHSEARCH – "Understanding the polygenic basis of hereditary predisposition to prostate cancer: a multi-omics integrative approach combining genomics and transcriptomics" (PI 161-CI-IPOP-154-2021), Budget: 10K€ (2022-2028) (PI: Andreia Brandão).
- TREATCILIA – "Theragnostic exploitation of ciliogenesis defects in prostate cancer – building bridges" (PI 162-CI-IPOP-155-2021), Budget: 45K€ (2022-2026) (PI: Paula Paulo).
- POLYRISK – "Impact of multigene next generation sequencing and polygenic risk score for breast cancer predisposition" (PI 163-CI-IPOP-156-2021), Budget: 10K€ (2022-2026) (PI: Manuel Teixeira).
- ETS-EGFR-CRC – "Identification of markers of resistance to anti-EGFR therapy in colorectal carcinoma" (PI 205-CI-IPOP-08-2023), Budget: 8K€ (2023-2026) (PI: Paula Paulo).
- HLEU – "Inherited predisposition to hematological malignancies" (PI 206-CI-IPOP-29-2023), Budget: 5K€ (2023-2026) (PI: Manuel Teixeira).
- ETS-EGFR-PC – "In vitro exploitation of the therapeutic potential of EGFR pathway inhibitors in prostate cancer cells harboring ETS rearrangements" (PI 207-CI-IPOP-30-2023), Budget: 55K€ (2023-2026) (PI: Paula Paulo).

## Major achievements

- ***Guerra, J, Estrada-Florez, AP, Lott, PC, Pinto, C, Pinheiro, M, Chiu, KA, Montoya, DJ, Zhang, H, Polanco-Echeverry, GM, Pinto, P, Peixoto, A, Santos, C, Barbosa, A, Silva, J, Suarez-Olaya, J, Castro-Valencia, F, Molina, G, Corvalan, AH, Della Valle, A, Castelao, JE, Fernandez-Fernandez, N, Cid, L, Rios-Sarabia, N, Medrano, R, Mantilla, A, Echeverry de Polanco, MM, Rivera-Herrera, AL, Riano-Moreno, J, Parra-Medina, R, Gonzalez-Castrillon, LM, Dominguez, R, Isidoro, AR, Silva, F, Morgan, DR, Cock-Rada, AM, Sanabria-Salas, MC, Bohorquez, MH, Torres, J, Teixeira, MR, & Carvajal-Carmona, LG, on behalf of Consorcio Galicia and the Hispanic Gastric Cancer Genetics Collaborative Group. The role of multi-organ cancer predisposition genes in the risk of inherited and histologically diverse gastric cancer. EBioMedicine. 2025, 116: 105759. (IF: 10.8) https://pubmed.ncbi.nlm.nih.gov/40446793/***

This work aimed to estimate the frequency of known cancer predisposition gene variants in GC cases with and without a cancer family history, diverse histological subtypes, and varied age of onset. We evaluated the contribution of pathogenic or likely pathogenic (P/LP) variants in well-established moderate-to-high penetrance multi-organ cancer predisposition genes for GC risk in a large international multi-centre retrospective cohort study involving 750 patients with GC of early-onset or family history of cancer, either by panel sequencing or whole exome sequencing (WES). We identified 45 patients (6%) with P/LP variants in *ATM*, *BRCA2*, *MLH1*, *TP53*, *BRCA1*, *PALB2*, *RAD51D*, *CHEK2*, *RAD51C* and *PMS2*, all of which were mutually exclusive. The P/LP variant prevalence was higher in intestinal (9.8%) than in diffuse (4.3%) or mixed GC (4.5%) (p-value = 0.023), without difference per mutated gene by histological subtypes. Our findings indicate that a broader panel of cancer predisposition genes, beyond *CDH1* and *CTNNA1*, should be included in gene panels to investigate germline variants in patients with GC. This would be especially beneficial when there is a family history of cancer, irrespective of histology subtype, as it would increase the chance of identifying patients who could benefit from risk reduction, targeted treatment, and surveillance of other cancer types. (DOI: 10.1016/j.ebiom.2025.105759)

- ***Paiva, EG, Orr, B, Azeredo, A, Brandao, A, Teixeira, MR, & Paulo, P. EGFR-STAT3 activation provides a therapeutic rationale for targeting aggressive ETV1-positive prostate cancer. Mol Oncol. 2025, 19(11): 3287-3304. (IF: 4.5) https://pubmed.ncbi.nlm.nih.gov/40808640/***

Genomic rearrangements involving the ETS transcription factors *ERG* or *ETV1* are among the most frequent genetic alterations in PCa; however, their clinical utility remains elusive. Using PCa cells overexpressing ETV1 or ERG, representing early and advanced disease stages, we unveiled a positive feedback loop between ETV1 and EGFR, with STAT3 acting as a downstream effector of ETV1-EGFR signaling. Analysis of external datasets revealed that both EGFR and STAT3 are significantly upregulated in ETV1-positive PCa, consistent with ChIP-seq data identifying them as direct ETV1 targets. Accordingly, combined inhibition of EGFR and STAT3 using Erlotinib and TTI-101, respectively, led to a significant reduction in 2D and 3D cell growth of early and advanced PCa cells overexpressing ETV1. Collectively, our findings highlight EGFR-STAT3 activation as a novel ETV1-regulated oncogenic pathway, providing a rationale for repurposing EGFR inhibitors in combination with STAT3 inhibitors as a therapeutic strategy for the 8-10% of prostate carcinomas characterized by *ETV1* rearrangements/overexpression. (DOI: 10.1002/1878-0261.70069)

## Scientific output

### *a. Peer-reviewed indexed publications (final publication date in 2025)*

- Almeida, E, Martins, ML, Marques, D, Delas, R, **Almeida, T**, Chaves, J, Libanio, D, Renna, F, Coimbra, MT and Dinis-Ribeiro, M. *Artificial intelligence for endoscopic grading of gastric intestinal metaplasia: advancing risk stratification for gastric cancer.* Endoscopy. 2025;57(11): p. 1254–60. IF: 12.8
- Almeida, M, Gandini, F, Rito, T, Foody, MG, **Brandao, A**, Oliveira, M, Olivieri, A, Fichera, A, Oteo-Garcia, G, Zainuddin, Z, Eng, KK, Pomat, W, Bryk, J, Pereira, L, Farr, H, Pala, M, Oppenheimer, SJ, Richards, MB and Soares, P. *Leveraging known Pacific colonisation times to test models for the ancestry of Southeast Asians*. Sci Rep. 2025;15(1): p.37044. IF: 3.9
- Alves, A, Ferreira, M, **Eiras, M**, Lima, L, Medeiros, R, Teixeira, AL and Dias, F. *Exosome-derived hsa-miR-200c-3p, hsa-miR-25-3p and hsa-miR-301a-3p as potential biomarkers and therapeutic targets*

*for restoration of PTEN expression in clear cell renal cell carcinoma.* Int J Biol Macromol. 2025;302: p. 140607. IF: 8.5

- Barnes, DR, Tyrer, JP, Dennis, J, Leslie, G, Bolla, MK, Lush, M, Aeilts, AM, Aittomaki, K, Andrieu, N, Andrulis, IL, Anton-Culver, H, Arason, A, Arun, BK, Balmana, J, Bandera, EV, Barkardottir, RB, Berger, LPV, Berrington de Gonzalez, A, Berthet, P, Bialkowska, K, Bjorge, L, Blanco, AM, Blok, MJ, Bobolis, KA, Bogdanova, NV, Brenton, JD, Butz, H, Buys, SS, Caligo, MA, Campbell, I, Castillo, C, Claes, KBM, Colonna, SV, Cook, LS, Daly, MB, Dansonka-Mieszkowska, A, de la Hoya, M, deFazio, A, DePersia, A, Ding, YC, Doherty, JA, Domchek, SM, Dork, T, Einbeigi, Z, Engel, C, Evans, DG, Foretova, L, Fortner, RT, Fostira, F, Foti, MC, Friedman, E, Frone, MN, Ganz, PA, Gentry-Maharaj, A, Glendon, G, Godwin, AK, Gonzalez-Neira, A, Greene, MH, Gronwald, J, Guerrieri-Gonzaga, A, Hamann, U, Hansen, TVO, Harris, HR, Hauke, J, Heitz, F, Hogervorst, FBL, Hooning, MJ, Hopper, JL, Huff, CD, Huntsman, DG, Imyanitov, EN, Izatt, L, Jakubowska, A, James, PA, Janavicius, R, John, EM, Kar, S, Karlan, BY, Kennedy, CJ, Kiemeney, L, Konstantopoulou, I, Kupryjanczyk, J, Laitman, Y, Lavie, O, Lawrenson, K, Lester, J, Lesueur, F, Lopez-Pleguezuelos, C, Mai, PL, Manoukian, S, May, T, McNeish, IA, Menon, U, Milne, RL, Modugno, F, Mongiovi, JM, Montagna, M, Moysich, KB, Neuhausen, SL, Nielsen, FC, Nogues, C, Olah, E, Olopade, OI, Osorio, A, Papi, L, Pathak, H, Pearce, CL, Pedersen, IS, **Peixoto, A**, Pejovic, T, Peng, PC, Peshkin, BN, Peterlongo, P, Powell, CB, Prokofyeva, D, Pujana, MA, Radice, P, Rashid, MU, Rennert, G, Richenberg, G, Sandler, DP, Sasamoto, N, Setiawan, VW, Sharma, P, Sieh, W, Singer, CF, Snape, K, Sokolenko, AP, Soucy, P, Southey, MC, Stoppa-Lyonnet, D, Sutphen, R, Sutter, C, Tan, YY, **Teixeira, MR**, Terry, KL, Thomsen, LCV, Tischkowitz, M, Toland, AE, Van Gorp, T, Vega, A, Velez Edwards, DR, Webb, PM, Weitzel, JN, Wentzensen, N, Whittemore, AS, Winham, SJ, Wu, AH, Yadav, S, Yu, Y, Ziogas, A, Berchuck, A, Couch, FJ, Goode, EL, Goodman, MT, Monteiro, AN, Offit, K, Ramus, SJ, Risch, HA, Schildkraut, JM, Thomassen, M, Simard, J, Easton, DF, Jones, MR, Chenevix-Trench, G, Gayther, SA, Antoniou, AC and Pharoah, PDP. *Genome-wide association study of 398,238 women unveils seven loci associated with high-grade serous ovarian cancer*. NPJ Genom Med. 2025;10(1): p.73. IF: 4.8
- Caldevilla, R, **Eiras, M**, Santos, DAR, Almeida, J, Oliveira, B, Loureiro, S, Soares, J, Gonzalez-Santos, M, Ramos, N, Videira, PA, Santos, LL, Dinis-Ribeiro, M and Lima, L. *Advancing Non-Invasive Colorectal Cancer Screening: Exploring the Potential of Monoclonal Antibody L2A5.* Int J Mol Sci. 2025;26(7) IF: 4.9
- Cotton, S, Ferreira, D, Relvas-Santos, M, **Brandao, A**, Afonso, LP, Miranda, A, Ferreira, E, Santos, B, Goncalves, M, Lopes, P, Santos, LL, Silva, AMN and Ferreira, JA. *E-selectin affinity glycoproteomics reveals neuroendocrine proteins and the secretin receptor as a poor-prognosis signature in colorectal cancer*. Mol Oncol. 2025;19(3): p.635-658. IF: 4.5
- Ferreira, D, Marinho-Santos, B, Relvas-Santos, M, **Orr, B**, **Brandao, A**, Afonso, LP, Santos, LL and Ferreira, JA. *Trimmed N-glycans define aggressive gastric cancer and predict clinical outcomes*. Theranostics. 2025;15(18): p.9375-9398. IF: 13.3
- Galama, R, Ribeiro, C, **Silva, J** and de Sousa, JA. *Epidemiological profile of women with moderate-risk breast cancer mutations*. Cir Esp (Engl Ed). 2025;103(1): p.55-56. IF: 1.3
- **Guerra, J**, Estrada-Florez, AP, Lott, PC, **Pinto, C**, ***Pinheiro, M***, Chiu, KA, Montoya, DJ, Zhang, H, Polanco-Echeverry, GM, **Pinto, P**, **Peixoto, A**, **Santos, C**, **Barbosa, A**, **Silva, J**, Suarez-Olaya, J, Castro-Valencia, F, Molina, G, Corvalan, AH, Della Valle, A, Castelao, JE, Fernandez-Fernandez, N, Cid, L, Rios-Sarabia, N, Medrano, R, Mantilla, A, Echeverry de Polanco, MM, Rivera-Herrera, AL, Riano-Moreno, J, Parra-Medina, R, Gonzalez-Castrillon, LM, Dominguez, R, Isidoro, AR, Silva, F, Morgan, DR, Cock-Rada, AM, Sanabria-Salas, MC, Bohorquez, MH, Torres, J, **Teixeira, MR**, Carvajal-Carmona, LG, Consorcio, G and Hispanic Gastric Cancer Genetics Collaborative, G. *The role of multi-organ cancer predisposition genes in the risk of inherited and histologically diverse gastric cancer*. EBioMedicine. 2025;116: p.105759. IF: 10.8
- Lobo, J, Castro, J, Azevedo, J, Lobo, C, Rodrigues, A, Braga, I, Freitas, R, Silva-Santos, R, **Peixoto, A**, Henrique, R, Leca, L and Lobo, J. *Cytological Features of the Emerging Entity Papillary Renal Neoplasm with Reverse Polarity: A Case Report Highlighting the Relevance of Fine-Needle Aspiration in Renal Masses*. Pathobiology. 2025;92(5): p.288-293. IF: 2.0
- Lopes, C, **Brandao, A**, **Teixeira, MR**, Dinis-Ribeiro, M and Pereira, C. *Saliva-derived transcriptomic signature for gastric cancer detection using machine learning and leveraging publicly available*

*datasets*. Sci Rep. 2025;15(1): p.18491. IF: 3.9

- Meireles, AM, Calisto, R, Bento, MJ, Gouveia, PM, **Bizarro, S**, **Teixeira, M**, Moreira, C, Santo, AE and Mariz, M. *Epidemiological characterization of chronic myeloid leukaemia patients at an oncologic centre: A retrospective observational study*. Hematol Transfus Cell Ther. 2025;47(3): p.103935. IF: 1.6
- Mesquita, S, Azevedo, J, Silva-Santos, R, Tavares, NT, **Santos, C**, Rodrigues, A, Henrique, R, Braga, I, Acosta, AM, Freitas, R and Lobo, J. *Testicular adult granulosa cell tumour: discussing assessment of risk, microRNA-371a-3p levels and FOXL2 testing in a single case*. Histopathology. 2025;87(5): p.773-776. IF: 4.1
- **Paiva, EG**, **Orr, B**, **Azeredo, A**, **Brandao, A**, **Teixeira, MR** and **Paulo, P**. *EGFR-STAT3 activation provides a therapeutic rationale for targeting aggressive ETV1-positive prostate cancer*. Mol Oncol. 2025;19(11): p.3287-3304. IF: 4.5
- Peixoto, A, Ferreira, D, Miranda, A, Relvas-Santos, M, Freitas, R, Veth, TS, **Brandao, A**, Ferreira, E, **Paulo, P**, **Cardoso, M**, Gaiteiro, C, Cotton, S, Soares, J, Lima, L, Teixeira, F, Ferreira, R, Palmeira, C, Heck, AJR, Oliveira, MJ, Silva, AMN, Santos, LL and Ferreira, JA. *Multilevel plasticity and altered glycosylation drive aggressiveness in hypoxic and glucose-deprived bladder cancer cells*. iScience. 2025;28(2): p.111758. IF: 4.1
- Pires, AM, Barreto, JP, Caetano, J, Soares, MJ, Geraldes, C, Fernandes, B, Coucelo, M, Chacim, S, Coelho, H, **Correia, C**, Cruz, AP, Cunha, M, Cunha, MR, Cunha, N, Ferraz, P, Freitas, JG, Henrique, R, **Lisboa, S**, Lucio, P, Paiva, A, Pedrosa, C, Ramos, I, Sarmento, AB, Seabra, P, Sevilha, J, Rego de Sousa, MJ, Sousa, S, Sousa, T, Tavares, M, Trigo, F, Bergantim, R, Roque, A and Joao, C. *Diagnosis and Laboratory Follow-Up of Patients with Multiple Myeloma: Guidelines from the Portuguese Multiple Myeloma Group*. Acta Med Port. 2025;38(10): p.654-668. IF: 1.0
- Pires, AM, Barreto, JP, Caetano, J, Soares, MJ, Geraldes, C, Fernandes, B, Coucelo, M, Chacim, S, Coelho, H, **Correia, C**, Cruz, AP, Cunha, M, Cunha, MR, Cunha, N, Ferraz, P, Freitas, JG, Henrique, R, **Lisboa, S**, Lucio, P, Paiva, A, Pedrosa, C, Ramos, I, Sarmento-Ribeiro, AB, Seabra, P, Sevilha, J, Sousa, MJR, Sousa, S, Sousa, T, Tavares, M, Trigo, F, Roque, A, Bergantim, R, Joao, C and On Behalf Of The Portuguese Multiple Myeloma, G. *Multiple Myeloma Laboratory Diagnostics Made Simple: Practical Insights and Key Recommendations*. J Clin Med. 2025;14(19): p.7115. IF: 2.9
- Pires, C, Marques, IJ, Saramago, A, Moura, MM, Pojo, M, Cabrera, R, **Santos, C**, Rosario, F, Lousa, D, Vicente, JB, Bandeiras, TM, **Teixeira, MR**, Leite, V and Cavaco, BM. *Identification of novel candidate predisposing genes in familial nonmedullary thyroid carcinoma implicating DNA damage repair pathways*. Int J Cancer. 2025;156(1): p.130-144. IF: 4.7
- Relvas-Santos, M, Ferreira, D, **Brandao, A**, Afonso, LP, Santos, LL, Silva, AMN and Ferreira, JA. *Glycomics and Glycoproteomics Reveal Distinct Oligomannose Carriers Across Bladder Cancer Stages*. Int J Mol Sci. 2025;26(10): p.4891. IF: 4.9
- Santos, DAR**, Eiras, M,** Gonzalez-Santos, M, Santos, M, Pereira, C, Santos, LL, Dinis-Ribeiro, M and Lima, L. *A preliminary assessment of a stool-based microRNA profile for early colorectal cancer screening.* Sci Rep. 2025;15(1): p. 28597. IF:3.9
- Selemane, C, Ferreira, D, **Veiga, I**, **Rocha, P**, Jamisse, L, Buane, L, Guisseve, A, Carrilho, C, Ismail, M, **Teixeira, MR** and Santos, LL. *Molecular characterisation of Mozambican patients diagnosed with colorectal adenocarcinoma*. J Gastrointest Oncol. 2025;16(3): p.1025-1037. IF: 2.0

### *b. Other outputs*

#### *Oral Communications by Invitation*

- Paulo P (2025). Loss of primary cilia in prostate cancer: genetic markers and therapeutic opportunitites. Conferências em Oncobiologia 2024-25 (26th March); Porto, Portugal.
- Pinto C (2025). Cancer genetics diagnosis and cases studies. 8th Course of Basics in Human Genetic Diagnostics, (8th - 12th September); Figueira da Foz, Portugal.
- Paulo P (2025). High Content Screening Applications in Translational Research in Oncology. Cell Analysis Day (12th November); Lisbon, Portugal.

- Silva MP (2025). *BUB1B* monoallelic germline variants contribute to prostate cancer predisposition by triggering chromosomal instability. 29th Annual Meeting of the Portuguese Society of Human Genetics (20th-22nd November); Coimbra, Portugal.
- Teixeira MR (2025). The evolving role of liquid biopsy in NSCLC: Characterising resistance mechanisms. 29th Annual Meeting of the Portuguese Society of Human Genetics (20th-22nd November); Coimbra, Portugal.
- Teixeira MR (2025). Introduction to FGFR(3) Biology. 20th National Congress of the Portuguese Society of Anatomic Pathology (19th-22nd November); Tomar, Portugal.
- Pinto C (2025). "Post-Congress Course | Molecular Pathology". 20th National Congress of the Portuguese Society of Anatomic Pathology (19th-22nd November); Tomar, Portugal.

### *Oral Communications in International Scientific Meetings*

- Paiva EG, Namorado B, Teixeira MR, Paulo P (2025). Targeting EGFR and STAT3 in ETV1-positive prostate cancer: insights from 2D and 3D co-culture models. IMMUNO-model Meeting: Young Researchers and Innovators on Immunotherapies: The Future is Now. COST Action (CA21135) (25th September); Porto, Portugal.
- Cardoso M, Corado M, Paulo P, Henrique R Orr B, Teixeira M, Brandão A (2025). Exploring the tumor suppressor role of PRUNE2 in prostate cancer. ESHG 2025 (24-27th May); Milan, Italy.

### *Oral Communications in National Scientific Meetings*

- Eiras M, Santos D, Gonzalez-Santos M, Soares J, Lara-Santos L, Dinis-Ribeiro M, Pereira C, Brandão A, Lima L (2025). Looking beyond DEGs: Hidden Small RNAs as Candidate Markers for Early Colorectal Cancer Detection. 3rd Young Researchers' Day (22nd October); Porto, Portugal.
- Lopes C, Brandão A, Paulino S, Dinis-Ribeiro M, Pereira C (2025). Molecular tool for early gastric cancer detection and surveillance: Developing a novel gene expression signature. RISE Day 2025 (20th October). Aveiro, Portugal.
- Peixoto A, Ferreira D, Miranda A, Relvas-Santos M, Freitas R, Veth TS, Brandão A, Ferreira E, Paulo P, Cardoso M, Gaiteiro C, Cotton S, Soares J, Lima L, Teixeira F, Ferreira R, Palmeira C, Heck AJR, Oliveira MJ, Silva AMN, Santos LL, Ferreira JA (2025). Multilevel plasticity and altered glycosylation drive aggressiveness in hypoxic and glucose-deprived bladder cancer cells. 3rd Young Researchers' Day (22nd October); Porto, Portugal.
- Ribeiro L, Barbosa A, Pinheiro M, Brandão A, Pinto C, Santos C, Guerra J, Silva J, Peixoto A, Teixeira M (2025). The role of *IPO4* germline variants for breast cancer predisposition in patients without mutations in known genes. 3rd Young Researchers' Day (22nd October); Porto, Portugal.

### *Posters in international conferences*

- Cardoso M, Corado M, Paulo P, Henrique R, Orr B, Teixeira M, Brandão A (2025). Investigating the impact of PRUNE2 deregulation on prostate cancer. EACR 2025 Congress (16-19th June); Lisbon, Portugal.
- Costa S, Orr B, Teixeira M, Paulo P (2025). EGFR targeting restores primary cilia loss upon ETS-driven oncogenic transformation in prostate cells. EACR 2025 Congress (16-19th June); Lisbon, Portugal.
- Paiva EG, Orr B, Brandão A, Teixeira MR, Paulo P (2025). EGFR-STAT3 activation provides a therapeutic rationale for targeting aggressive ETV1-positive prostate cancer. EACR 2025 Congress (16-19th June); Lisbon, Portugal.
- Lopes C, Brandão A, Paulino S, Costa J, Marques de Sá I, Küttner-Magalhães R, Marcos-Pinto R, Libânio D, Dinis-Ribeiro M, Pereira C (2025). Early gastric cancer clues in saliva: Exploring a tissue-based signature for non-invasive detection. IV ASEICA-ASPIC International Meeting (20th-21st November); Santiago de Compostela, Spain.
- Lopes C, Brandão A, Paulino S, Dinis-Ribeiro M, Pereira C (2025). Stratifying risk beyond diagnosis: A gene expression signature for early gastric cancer and metachronous lesion prediction. UEG Week 2025 (4-7th October); Berlin, Germany.

- Paiva EG, Namorado B, Teixeira MR, Paulo P (2025). A targeted therapy for the treatment of ETV1/ETV4-positive prostate cancer: insights from 2D and 3D co-culture models. IV ASPIC–ASEICA International Meeting (20-21st November); Santiago de Compostela, Spain.
- Paiva EG, Namorado B, Teixeira MR, Paulo P (2025). Combined EGFR and STAT3 inhibition in ETV1/ETV4-overexpressing prostate cancer: insights from 2D and 3D co-culture models. Annual Pathology Conference of the Victor Babeș Institute (12-14th November); Bucharest, Romania. Best Poster Prize.
- Soares J, Ferreira D, Dourado-Gonçalves M, Miranda A, Relvas-Santos M, Brandão A, Paulo P, Cotton S, Freitas R, Ferreira E, Afonso, LP, Silva A, Palmeira C, Amado F, Santos LL, Ferreira JA (2025). CD276 immature glycosylation drives colorectal cancer aggressiveness and T cell mediated immune escape. SIC2025: Congress of the Iberian Society of Cytometry (14-16th May); Porto, Portugal.

### *Posters in national conferences*

- Carvalho E, Brandão A, Schmitt F, Vale N (2025). Integrative Analysis of microRNA Pathways Underlying Hormone Receptor Heterogeneity in HER2-Low Breast Cancer. 3rd Young Researchers' Day (22nd October); Porto, Portugal.
- Costa AB, Barbosa A, Gonçalves C, Guerra J, Pinheiro M, Pinto C, Santos C, Peixoto A, Teixeira M (2025). Evaluating ctDNA sequencing as an alternative approach to tumor tissue testing in metastatic prostate cancer for PARP inhibitors eligibility. 3rd Young Researchers' Day (22nd October); Porto, Portugal.
- Costa AB, Barbosa A, Gonçalves C, Guerra J, Pinheiro M, Peixoto A, Teixeira M (2025). Evaluating ctDNA sequencing as an alternative approach to tumor tissue testing in metastatic prostate cancer for PARP inhibitors eligibility. ENJIO (24th September); Porto, Portugal.
- Malta M, Pereira L, Lisboa S, Torres L, Vieira J, Peixoto A, Correia C, Teixeira M (2025). *PAX5::AUTS2* fusion in pediagtric B-cell acute lymphoblastic leukemia: A relapse-prone genetic subtype. 29th Annual Meeting of the Portuguese Society of Human Genetics (20th-22nd November); Coimbra, Portugal.
- Martins R, Pinto C, Pinheiro M, Barbosa A, Santos C, Dias R, Bartosh C, Peixoto A, Teixeira MR (2025). Clinical relevance of *POLE* exonuclease domain mutations: Insights from routine testing with an automated qPCR assay. 29th Annual Meeting of the Portuguese Society of Human Genetics (20th-22nd November); Coimbra, Portugal.
- Martins R, Malta M, Pereira L, Pinheiro M, Pinto C, Barbosa A, Santos C, Guerra J, Bartoch C, Peixoto A, Teixeira M (2025). Implementation of a digital PCR assay for detection of POLE oncogenic variants. 10th Advanced Gynecological Oncology Course (3rd-4th July); Porto, Portugal.Mendes AC, Santos C, Peixoto A, Frutuoso C, Saraiva JM, Maia S, Teixeira MR (2025). Retrospective analysis of patients who underwent tumour and germline testing for ovarian cancer. 29th Annual Meeting of the Portuguese Society of Human Genetics (20th-22nd November); Coimbra, Portugal.
- Paiva EG, Miranda-Gonçalves V, Brandão A, Jerónimo C, Orr B, Teixeira MR, Paulo P. EGFR and STAT3 co-inhibition as a targeted therapeutic approach for PEA3-positive prostate cancer (2025). 2nd One Health PhD Forum (ICBAS-School of Medicine and Biomedical Sciences) (12th June); Porto, Portugal.
- Pereira L, Malta M, Lisboa S, Torres L, Bizarro S, Vieira J, Rocha P, Peixoto A, Correia C, Teixeira M (2025). Acute myeloid leukemia: Diagnostic and post-transplant challenges. 29th Annual Meeting of the Portuguese Society of Human Genetics (20th-22nd November); Coimbra, Portugal.
- Pinto R, Ferreira D, Marinho-Santos B, Brandão A, Santos LL, Ferreira JA (2025). Unsupervised Machine Learning Reveals Molecular Subgroups in Gastric Cancer. 3rd Young Researchers' Day (22nd October); Porto, Portugal.
- Ribeiro L, Barbosa A, Pinheiro M, Brandão A, Pinto C, Santos C, Guerra J, Silva J, Peixoto A, Teixeira M (2025). Prevalence of germline variants in the *IPO4* gene in individuals with breast or ovarian cancer. ENJIO (24th September); Porto, Portugal.
- Ribeiro L, Pinheiro M, Barbosa A, Peixoto A, Pinto C, Santos C, Guerra J, Teixeira MR (2025). The role of *IPO4* germline variants for breast/ovarian cancer predisposition in patients without mutations in known genes. Investigação Jovem da Universidade do Porto (7-9th May); Porto, Portugal.

- Costa S, Orr B, Teixeira MR, Paulo P (2025). EGFR targeting restores primary cilia loss upon ETS-driven oncogenic transformation in prostate cells – involvement of the stroma components. IV ASPIC-ASEICA International Meeting (20th-21st November); Santiago de Compostela, Spain.
- Costa S, Orr B, Teixeira MR, Paulo P (2025). EGFR targeting restores primary cilia loss upon ETS-driven oncogenic transformation in prostate cells (16th-19th June). EACR 2025; Lisbon, Portugal.
- Namorado BA, Paiva EG, Teixeira MR, Paulo P (2025). EGFR and STAT3 as Therapeutic Targets in ETV1-Positive Prostate Cancer: Insights from 2D and 3D Co-culture Models [EGFR e STAT3 como alvos terapêuticos no cancro da próstata ETV1- positivo: contributos de modelos de co-cultura 2D e 3D]. ENJIO (24th September); Porto, Portugal.

### *Editorial Board Positions*

| Journal | Publishing Group | Position | Researcher |
|---|---|---|---|
| Cancers | MDPI | Editorial Board Member | Manuel Teixeira |
| Cells | MDPI | Section Board Member | Manuel Teixeira |
| Current Issues in Molecular Biology | MDPI | Section Board Member | Paula Paulo |
| Current Issues in Molecular Biology | MDPI | Special Issue Guest Editor | Paula Paulo |
| Frontiers in Genetics | Frontiers | Review Editor | Andreia Brandão |
| Genes | MDPI | Special Issue Guest Editor | Andreia Brandão |
| Genes Chromosomes and Cancer | Wiley | Editorial Board Member | Manuel Teixeira |
| International Journal of Molecular Sciences | MDPI | Topical Advisory Panel | Paula Paulo |

### *Peer Review*

Cancers (Andreia Brandão); Cancer Investigation (Paula Paulo); Cells (Paula Paulo); Genes (Andreia Brandão); Genes, Chromosomes and Cancer (Manuel Teixeira); MedComm (Manuel Teixeira); Molecules (Paula Paulo); Proceedings of the National Academy of Sciences (Paula Paulo).

### *Grant Reviewer*

| Agency | Call | Country | Date | Researcher |
|---|---|---|---|---|
| Prostate Cancer UK | 2025 Career Acceleration Fellowships | UK | 2025 | Manuel Teixeira |
| IDIBAPS | Research Groups Evaluation Call | Spain | 2025 | Manuel Teixeira |

### *Teaching Activity: Coordination of Curricular Units/Courses*

| Member | Curricular Units | Program | Position | Faculty/University |
|---|---|---|---|---|
| Manuel Teixeira | Medical Genetics | Integrated MSc in Medicine | Coordination and teaching | ICBAS; UP |
| Manuel Teixeira | Oncobiology | MSc in Oncology | Coordination and teaching | ICBAS; UP |
| Manuel Teixeira | Genes and Cancer | PhD Programme in Pathology and Molecular Genetics | Coordination and teaching | ICBAS/FM; UP |
| Manuel Teixeira | Molecular Cytogenetics I | MSc in Molecular Medicine and Oncology | Coordination and teaching | ICBAS/FM; UP |
| Manuel Teixeira | Molecular Cytogenetics II | PhD Programme in Molecular Medicine and Oncology | Coordination and teaching | ICBAS/FM; UP |
| Manuel Teixeira | Pathology II | Integrated MSc in Medicine | Teaching | ICBAS; UP |

| Member | Curricular Units | Program | Position | Faculty/University |
|---|---|---|---|---|
| Manuel Teixeira | Oncobiology | MSc in Biochemistry | Teaching | FC/ICBAS; UP |
| Manuel Teixeira | Oncobiology | MSc in Bioengineering | Teaching | FE/ICBAS; UP |
| Manuel Teixeira | Techniques in Molecular Biology | PhD Programme in Pathology and Molecular Genetics | Teaching | ICBAS/FM; UP |
| Ana Peixoto, Carla Pinto, Catarina Santos, Cecília Correia, Joana Vieira, Lurdes Torres, Susana Bizarro, Susana Lisboa | Laboratory Oncology | MSc in Oncology | Teaching | ICBAS; UP |
| Carla Pinto | Molecular Analysis and Diagnosis | MSc in Laboratory Techniques in Biopathology | Teaching | ESS; IPP |
| Carla Pinto | Biosafety and Management in Biopathology Laboratories | MSc in Laboratory Techniques in Biopathology | Teaching | ESS; IPP |
| Carla Pinto | Pathology and Molecular Genetics I | MSc in Laboratory Techniques in Biopathology | Teaching | ESS; IPP |
| Carla Pinto | Pathology and Molecular Genetics II | MSc in Laboratory Techniques in Biopathology | Teaching | ESS; IPP |
| Carla Pinto | Quality Control in Molecular Pathology | MSc in Laboratory Techniques in Biopathology | Teaching | ESS; IPP |
| Carla Pinto | Advanced Techniques in Molecular Biology I | MSc in Laboratory Techniques in Biopathology | Teaching | ESS; IPP |
| Carla Pinto | Advanced Techniques in Molecular Biology II | MSc in Laboratory Techniques in Biopathology | Teaching | ESS; IPP |
| Carla Pinto | Dissertation or Internship | MSc in Laboratory Techniques in Biopathology | Teaching | ESS; IPP |
| Andreia Brandão | Research Practices in Oncology | MSc in Oncology | Teaching | ICBAS; UP |
| Paula Paulo | Research Practices in Oncology | MSc in Oncology | Teaching | ICBAS; UP |
| Manuel Teixeira | Oncogenetics | Research Methodologies in Oncology (Edition 1) | Teaching | ICBAS; UP |
| Andreia Brandão | Bioinformatics and computational biology applied to omics sciences | Research Methodologies in Oncology (Edition 1) | Teaching | ICBAS; UP |
| Paula Paulo | High-throughput confocal screening applications | Research Methodologies in Oncology (Edition 1) | Teaching | ICBAS; UP |

### *International Internships*

| Period | Researcher/student | Position/Program | Country |
|---|---|---|---|
| Mar. - Jun. 2025 | Javier Manuel Galego Carro | PhD student in Galician Foundation of Genomic Medicine, Santiago de Compostela | Spain |

### Prizes, Honors and Awards

| Researcher | Prize designation | Institution | Date | Amount |
|---|---|---|---|---|
| Maria Pedro Silva | Prize of the Portuguese Society of Human Genetics, for the best Portuguese scientific publication in Human Genetics in 2024 | SPGH | November 22nd, 2025 | |
| Elsa Gomes Paiva | Top 5 Poster Pitch Selection | 2nd One Health PhD Forum (ICBAS-School of Medicine and Biomedical Sciences) | June 12th, 2025 | - |
| Elsa Gomes Paiva | Best Poster Award | Annual Pathology Conference of the Victor Babeș Institute | November 12–14th, 2025 | - |

### Scientific Appointments

| Organization | Researcher |
|---|---|
| Representant of Porto Comprehensive Cancer Center in the European Reference Network Genetic Tumour Risk Syndromes (GENTURIS) | Manuel Teixeira |

### National collaborations

| Title | Researchers | Collaborators | Funding | Period |
|---|---|---|---|---|
| Characterization of targeted therapy resistance mechanisms in EGFR/ALK/ROS1/BRAF-positive NSCLC by gene panel NGS in circulating cell-free DNA | Carla Escudeiro, Manuel Teixeira (PI) | 10 Portuguese hospitals | CI-IPOP-126-2019; Roche Diagnostica | 2020-2026 |
| Germline mutations in genes involved in the chromosome segregation machinery associated with inherited prostate cancer predisposition; PhD project of Maria Pedro Silva | Maria Pedro Silva, Paula Paulo, Manuel Teixeira (PI) | Hélder Maiato (Chromosome Instability & Dynamics), i3S | FCT: SFRH/BD/ 132441/2017 | 2018-2025 |
| Inherited predisposition to gastric cancer: novel susceptibility genes and a minimally invasive screening strategy in germline mutation carriers; PhD project of Joana Guerra | Joana Guerra, Manuel Teixeira (PI) | Carla Oliveira (Expression Regulation in Cancer), IPATIMUP/i3S | FCT: SFRH/BD/ 138670/2018 | 2019-2025 |
| BRCA-STEM: Exploring stemness in high grade serous carcinoma of the ovary using hereditary breast-ovarian cancer syndrome as a model system; PhD project of Rita Canário | Ana Peixoto, Ana Barbosa, Manuel Teixeira | Joana Paredes (Epithelial Interactions in Cancer) IPATIMUP/i3S | FCT: PD/BD/128001/2016 | 2017-2025 |

### International collaborations

| Title | Researchers | International Team | Institution | Country | Funding |
|---|---|---|---|---|---|
| Inherited predisposition to gastric cancer: novel susceptibility genes and a minimally invasive screening strategy in germline mutation carriers; PhD project of Joana Guerra | Joana Guerra, Manuel Teixeira | Luis G Carvajal-Carmona | UC Davis Genome Center | California, USA | UC Davis; CI-IPOP56-2017; SFRH/BD/138670/2018 |
| The IMPACT Study: Identification of Men with a genetic predisposition to | Sofia Maia, Marta Cardoso, Manuel Teixeira | Rosalind Eeles (coordinator, | Institute of Cancer Research | UK | Institute of Cancer Research; FCT: |

| Title | Researchers | International Team | Institution | Country | Funding |
|---|---|---|---|---|---|
| Prostate Cancer: Targeted screening in men at higher genetic risk and controls (ClinicalTrials.gov Identifier: NCT00261456) | | world-wide study) | | | SFRH/BD/116557/2016 |
| PRUNE2 gene as a novel dual-role biomarker for prostate cancer inherited predisposition and therapy response | Andreia Brandão, Paula Paulo, Manuel Teixeira | Rosalind Eeles | Institute of Cancer Research | UK | Institute of Cancer Research |

### *International Consortia*

| Organization | Researcher |
|---|---|
| The Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) | Manuel Teixeira, Ana Peixoto, Andreia Brandão |
| Prostate Cancer Association Group to Investigate Cancer Associated Alterations in the Genome (PRACTICAL) | Manuel Teixeira, Paula Paulo, Andreia Brandão |
| The Breast Cancer Association Consortium (BCAC) | Manuel Teixeira, Ana Peixoto, Manuela Pinheiro |
| Evidence-based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) | Manuel Teixeira, Ana Peixoto |
| European Reference Network (ERN) for GENetic TUmour RIsk Syndromes (GENTURIS) | Manuel Teixeira |

## CLINICAL ONCOLOGY GROUP

### Coordinator

Ana Espírito Santo, MD PhD

### Research team @31 December 2025

| Name | Academic Degree | Professional Situation | Category/position | Time % |
|---|---|---|---|---|
| Alba Regueira Iglesias | PhD | External - Associate Researcher | International Researcher | 100 |
| Alina Rosinha | MD, MSc | Contract | Medical Oncologist | 20 |
| Ana Alexandra Ferreira | MD, BSc | Contract | Medical Oncologist | 20 |
| Ana Filipa Carneiro | MD, BSc | Contract | Medical Oncologist | 20 |
| Ana Isabel Vieira do Espírito Santo | MD, PhD | Contract | Hemato-oncologist | 30 |
| Ana Raquel Teixeira | MD, MSc | Contract | Medical Oncologist Resident | 10 |
| Ana Rita Lopes | MD, MSc | Contract | Medical Oncologist | 20 |
| Ana Sofia Patrão | MD, MSc | Contract | Medical Oncologist | 20 |
| Andreia Guimarães da Cruz | MD, MSc | Contract | Medical Oncologist | 20 |
| António Miguel Abreu | MD, PhD | Contract | Medical Oncologist | 30 |
| Cátia Faustino | MD, BSc | Contract | Medical Oncologist | 10 |
| Cláudia Paiva Agostinho | MD, MSc | Contract | Medical Oncologist Resident | 20 |
| Cláudia Sílvia da Rocha Moreira | MD, MSc | Contract | Hemato-oncologist | 20 |
| Dânia Sofia Marques Santos | MD, MSc | Contract | Medical Oncologist | 20 |
| Dulcineia Alves Pereira | MD, BSc | Contract | Hemato-oncologist | 20 |
| Hugo Nascimento Ferreira | MD, MSc | Contract | Nephrologist | 20 |
| Inês Baptista Freitas | MD, MSc | Contract | Medical Oncologist Resident | 20 |
| Joana Bordalo e Sá | MD, MSc | Contract | Medical Oncologist | 20 |
| João Pedro Gouveia da Fonseca | MD, MSc | Contract | Medical Oncologist Resident | 20 |
| João Pedro Jacinto Pina Barreto | MD, MSc | Contract | Clinical Pathology Resident | 20 |
| Joaquim Castro Silva | MD, PhD | Contract | Otorhinolaryngologist | 30 |
| Jorge Marinho | MD, PhD | Contract | Stomatologist | 30 |
| José Brito da Silva | MD, MSc | Contract | Medical Oncologist Resident | 20 |
| José Manuel Ferrer Martinez | BSN, MSc | Contract | Nurse Specialist, PhD student | 20 |
| Leonardo Ferreira Maia Moço | MD, MSc | Contract | Hemato-oncologist Resident | 20 |
| Magda Andrea Silva Oliveira | PhD | Contract | Psychologist | 30 |
| Maria Cândida Tiago da Silva | MD, MSc | Contract | Palliative Care Physician | 20 |
| Maria Deolinda de Sousa Pereira | MD, PhD | Contract | Medical Oncologist | 30 |
| Maria Gabriela Martins | MD, BSc | Contract | Clinical Pahtologist | 20 |
| Maria Isabel Vilas-Boas | MD, MSc | Contract | Medical Oncologist | 20 |
| Maria Joaquina Maurício | MD, MSc | Contract | Medical Oncologist | 20 |
| Maria Cassiano Neves | MD, MSc | Contract | Medical Oncologist | 20 |
| Marta Alexandra Silva Soares | MD, BSc | Contract | Medical Oncologist | 20 |
| Marta Isabel Ribeiro Ferreira | MD, MSc | Contract | Medical Oncologist | 10 |
| Mavilde Longarito | MD, PhD | Contract | Neuroradiologist | 30 |
| Michael Sapateiro Luís | MD, MSc | Contract | Medical Oncologist | 20 |
| Nuno Borges Gonçalves | MD, BSc | Contract | Clinical Pahtologist | 10 |
| Olga Sousa de Meneses | MD, MSc | Contract | Medical Oncologist | 20 |
| Paula Cristina Ferreira | MD, BSc | Contract | Medical Oncologist | 20 |

| Name | Academic Degree | Professional Situation | Category/position | Time % |
|---|---|---|---|---|
| Rita Amorim e Costa | MD, MSc | Contract | Medical Oncologist | 20 |
| Rita Ribeiro Silva | MD, PhD | Associate Researcher | Hemato-oncologist | 20 |
| Rute Ribeiro Fernandes | MD, MSc | Contract | Medical Oncologist Resident | 20 |
| Sara Neves de Carvalho | MD, MSc | Contract | Medical Oncologist Resident | 20 |
| Sara Marina Carneiro Coelho | MD, MSc | Contract | Medical Oncologist Resident | 20 |
| Susana Sousa Almeida | MD, MSc | Contract | Psychiatrist | 30 |
| Vitor Costa | MD, BSc | Contract | Pediatrician | 20 |

### Group description and objectives

The Clinical Oncology Research Group, created in 2021, comprises a team of dedicated oncology healthcare professionals committed to a multidisciplinary approach to cancer research. Our foremost objective is to bridge the gap between clinical practice and translational research, with a steadfast dedication to conducting studies that elevate patient outcomes and elevate the standard of care.

Central to our mission is the augmentation of investigator-initiated clinical studies, alongside fostering participation in collaborative endeavors with other research groups, and through partnerships with national and international organizations. We have already made significant contributions to various observational and minimally invasive studies, and we seek to further amplify our involvement and leadership in such initiatives over time. These studies are designed to address unmet needs, encompass real-world data collection, and include pharmacoeconomic analyses.

Although the group is newly established, our team has been expanding annually. Moreover, several team members are in their clinical training at renowned cancer centers like MD Anderson Cancer Center and Gustave Roussy. Further, efforts will be made to increase the number of clinical PhD students.

Another pivotal aim is to sustain our current level of activity, both in spearheading and conducting clinical trials, as well as in providing training for medical residents and other health care professionals. By delving into diverse facets of cancer biology, we endeavor to gain deeper insights to facilitate the transfer of knowledge aimed at enhancing cancer patients' care. Furthermore, we are engaged in academic studies focusing on quality of life and patient perspectives. Moreover, our research endeavors in the realm of oncology precision medicine are rapidly expanding, with the goal of offering the most innovative and effective treatments to IPO Porto patients.

### Active projects and funding

### Competitive Funding

International

- CHIP-AML22: Improved diagnostics and survival for all children with Acute Myeloid Leukemia treated within the NOPHO-DB- SHIP consortium; a cross-European collaboration; 193 481,68€ (2022-2025); Dr. Vítor Costa (PI at IPO Porto).
- HENKO_NET: Innovation and Digital Technologies for Social and Health Palliative Care at Home; an Interreg collaboration; 157 886,96€ (2024-2026); Dra. Cândida Silva / Dr. Michael Luis (Investigators at IPO Porto).
- CHAFT: Home monitoring and identification of cisplatin-induced hearing loss risk profile; 171 320.42€ Dr. Rita Félix Soares (PI at IPO Porto)

### Internal

- The LIFT Trial: A phase 2 study to evaluate the safety and efficacy of Low dose radIotherapy in combination with dose adjusted of Fludarabine followed by Tisagenlecleucel treatment in refractory/relapsed non-Hodgkin diffuse large B cell lymphoma (PI237-CI-IPOP-34-2025) Dr Guimaraes dos Santos Grant; 75000€ (2025-2026); Dr Delfim Duarte (PI)
- MEliOrate: Mapping Eloquent Brain Regions for Optimized SRS in Brain Metastases PI242-CI-IPOP-89-2024 Dr Guimaraes dos Santos Grant; 10000€ (2025-2026); Dra Mavilde Arantes (PI)

## Scientific output

### a. Peer-reviewed indexed publications (final publication date in 2025)

- Aguiar, JM, Machado da Silva, J, Fonseca, C and **Marinho, J.** *An Assessment of the Sensory Function in the Maxillofacial Region: A Dual-Case Pilot Study.* Sensors (Basel). 2025;25(11) OF:3.5
- Azevedo, C, Fonseca, AC**, Barreto, JP**, Pires, AM, Faria, C, Pinto, A, Sousa, ME, Palmeira, C, Prudêncio, C, Fernandes, B, **Martins, G** and Ferraz, R. *Evaluating the heavy/light chain immunoglobulin biomarker for early relapse detection in multiple myeloma: A comparative study with conventional methods.* Clinical Immunology Communications. 2025;8: p. 105–8. IF: NA
- Cardoso, F, Jacot, W, Kuemmel, S, Gupta, S, Cruz, F, Balaraman, R, **Ferreira, A**, Ahola, T, Chapko, Y, Zhukova, L, Chiang, W, Li, Z, Ji, Y, Kaakiou, N, Bolotova, N and Sparano, JA. *600- vs 400-mg First-Line Ribociclib in Hormone Receptor-Positive/ERBB2-Negative Advanced Breast Cancer: The AMALEE Randomized Clinical Trial.* JAMA Oncol. 2025;11(11): p. 1356–63. IF: 20.1
- Costa, MT, Neto, BV, **da Silva, JB**, Carvalho, L, Salgado, L, **Pereira, D**, Adega, F, Tavares, V and Medeiros, R. *Venous Thrombogenesis and Cervical Cancer: Plasma MicroRNAs as Prognostic Indicators of Tumor Behavior.* Int J Mol Sci. 2025;26(19) IF: 4.9
- Dauccia, C, Martins-Branco, D, Moreau, M, Ameye, L, Agostinetto, E, Arecco, L, Lobo-Martins, S, Skoporc, A, **Vilas-Boas, I,** Auprih, M, Awada, A, Debien, V and de Azambuja, E. *Characteristics, Treatment Patterns and Clinical Outcomes of Women with Maghreb Origin and Diagnosis of Breast Cancer: A Single-Center, Retrospective Cohort Study.* Clin Breast Cancer. 2025;25(8): p. e1092–e9 e11. IF:2.5
- Dias, MR, Nicolau, C, **Ferreira, H**, Chacim, S, Oliveira, I, de Camara Negalha, G, Mariz, JM and Costa, JM. *Case Report: Effective methotrexate removal by combined hemodialysis and polymeric resin hemoadsorption.* Front Nephrol. 2025;5: p. 1644079. IF: NA
- Estevao-Pereira, H, Guimaraes-Teixeira, C, Flores, BCT, Moreira-Silva, F, Tavares, NT, Guimaraes, R, Braga, I, **Mauricio, J**, Henrique, R, Jeronimo, C and Lobo, J. *EHMT2/G9a and EZH2: Epimarkers in testicular germ cell tumors.* Andrology. 2025;13(2): p. 286–95. IF: 3.4
- Fernandes, I, Macedo, D, Gouveia, E, **Ferreira, A**, Lima, J, Lopez, D, Melo-Alvim, C, Carvalho, A, Tavares, P, Rodrigues-Santos, P, Cardoso, P, Magalhaes, M, Vieira, P, Brito, J, Mendes, C, Rodrigues, J, Netto, E, Oliveira, V, Sousa, C, Henriques Abreu, M, Pina, F and Vasques, H. *[Practical Guidance on the Detection of NTRK Fusions in Sarcomas: Current Status and Diagnostic Challenges].* Acta Med Port. 2025;38(4): p. 266–75. IF:1.0
- Fernandes, N, Soares, S, **Arantes, M** and Arantes, J. *Time perception of attractive male faces and voices: The role of women's menstrual cycle.* PLoS One. 2025;20(4): p. e0321956. IF: 2.6
- Ferreira, A, **Ferreira, H** and Costa, JM. *Hypercalcemia in a patient with small bowel gastrointestinal stromal tumor: a quiz.* J Nephrol. 2025;38(5): p. 1525–7. IF: 2.6
- Ferreira, A, Reis, M, Chuva, T**, Ferreira, H**, Coelho, I, Paiva, A and Costa, JM. *Pharmacological nephrotoxicity profile in a comprehensive cancer center: What changed in two decades and predictors for the need for haemodialysis and mortality.* Nefrologia (Engl Ed). 2025;45(6): p. 501332. IF: 2.6
- Guedes, AP, Fernandes, CL, **Freitas, IB**, Ferreira, PC and **Vilas Boas, MI.** *Prolonged Responses to Cemiplimab in Advanced Cutaneous Squamous Cell Carcinoma: A Case Series.* Cureus. 2025;17(9): p. e92346. IF:1.3
- Jansen, F, Eerenstein, SE, Taylor, KJ, Amdal, CD, Bjordal, K, Astrup, GL, Herlofson, BB, Duprez, F, Gama, RR, Jacinto, AA, Hammerlid, E, Scricciolo, M, Fanetti, G, Guntinas-Lichius, O, Inhestern, J, Dragan, T, Fabian, A, Boehm, A, Wohner, U, Kiyota, N, Kruger, M, Bonomo, P, Pinto, M, Nuyts, S, **Silva, JC**, Stromberger, C, Specenier, P, Tramacere, F, Bushnak, A, Perotti, P, Plath, M, Paderno, A, Stempler, N, Kanellopoulou, A, Singer, S and Verdonck-de Leeuw, IM. *Unmet supportive care needs among head and neck cancer survivors beyond 5 years after diagnosis: a multinational cohort study.* Lancet Reg Health Eur. 2025;59: p. 101495. IF: 13
- **Luís, MS**. *Asthenia*. Medical Oncology Compendium2025. p. 709–13. IF: NA
- Madeira, N, Franca, G, Jesus, G, Fernandes, JM, **Almeida, SS** and Filipe, CN. *Attention Deficit/Hyperactivity Disorder in Adults: Position of Portuguese Experts on Diagnosis and Treatment.* Acta Med Port. 2025;38(3): p. 187–96. IF: 1.0

- **Maia Moco, L,** Hortas, AM, Ramos, I, Fontoura, A, de Camara Negalha, G, Bras, G and Mariz, M. *Sodium 2-Mercaptoethanesulfonate (MESNA), Ifosfamide, Mitoxantrone, and Etoposide (MINE) in Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Is the Old Regimen Still Gold?* Cureus. 2025;17(7): p. e87128. IF:1.3
- **Meireles, AM,** Calisto, R, Bento, MJ, Gouveia, PM, Bizarro, S, Teixeira, M, **Moreira, C, Santo, AE** and Mariz, M. *Epidemiological characterization of chronic myeloid leukaemia patients at an oncologic centre: A retrospective observational study.* Hematol Transfus Cell Ther. 2025;47(3): p. 103935. IF: 1.6
- **Meireles, AM**, Oliveira Rodrigues Amarante, ACD, Marques Catita, BMC, Abilheira Monjardino, M, de Abreu Gouveia, PMG, Rocha Moreira, CSD, Jesus Leite, LC, Coutinho, R, Santos Ferreira, RB, Bras, GP, Guerreiro, M, Vaz, CP and Mariz, JM. *Effects of fludarabine dosage on transplant-related outcomes in hematopoietic stem cell transplantation.* Leuk Lymphoma. 2025;66(10): p. 1942–6. IF:2.2
- **Meneses, O**, Alzamora, M, Dias, C, Ortigao, R and **Marques, D**. *Immune-Related Esophagitis and Durable Response to Second-Line Treatment With Nivolumab in Stage IV Squamous Cell Esophageal Carcinoma.* Cureus. 2025;17(12): p. e98324. IF:1.3
- Mor, E, Apte, S, Mitchell, C, Nessim, C, Almond, M, Vincenzi, B, Lopez, JAG, Cranmer, L, Wagner, MJ, Nissan, A, **Abreu, MH**, Albertsmeier, M, Knoblauch, M, Barlow, A, Keung, EZ, Grignani, G, Hornick, JL, Gronchi, A and Gyorki, DE. *Natural History of Primary Retroperitoneal Extra-Visceral Perivascular Epithelioid Cell Tumors (PEC): A Study from Transatlantic and Australasian Retroperitoneal Sarcoma Working Group (TARPSWG).* Ann Surg Oncol. 2025;32(10): p. 7817–28. IF:3.5
- **Oliveira, MA, Almeida, SS, Martins, G,** Godinho, I, Palmeira, C, Sousa, ME, Fernandes, L, Medeiros, R and Guerra, MP. *The Inflammatory Footprint of Anti-Breast Cancer Treatments and Psychosocial Factors in Women Undergoing Chemotherapy.* Biomedicines. 2025;13(10) IF: 3.9
- Pereira, F, Pimenta, JL, Rei, M, Dias, CR and **Pereira, D.** *Metastatic Mammary-Like Adenocarcinoma of the Vulva Responding to Cyclin-Dependent Kinase (CDK) Inhibitor: A Case Report and Literature Review.* Cureus. 2025;17(9): p. e93598. IF:1.3
- Pereira, JL, Arede, L, Ferreira, F, Matos, A, **Pereira, D**, Santos, RF, Carmo, AM, Oliveira, MJ, Machado, JC, Duarte, D and Dos Santos, NR. *Antibody blockade of the PSGL-1 immune checkpoint enhances T-cell responses to B-cell lymphoma.* Leukemia. 2025;39(1): p. 178–88. IF:13.4
- Perez-Fidalgo, A, Schmalfeldt, B, George, A, Gourley, C, Pignata, S, Lorusso, D, Barretina-Ginesta, MP, Romero, I, Grimm, C, Van Gorp, T, Rossing, M, Collins, DC, Fernebro, J, Bjorge, L, Leary, A, Rouge, TM, Harter, P, Kurzeder, C, **Savva-Bordalo, J** and You, B. *Consensus on drivers of maintenance treatment choice and patterns of care in advanced ovarian cancer.* Int J Gynecol Cancer. 2025;35(7): p. 101863. IF:4.7
- Pires-Goncalves, L, Aguiar, AT, Leal, C, Guimaraes-Santos, A, **Abreu, M** and Henrique, R. *Prospective Evaluation of Contrast-enhanced Mammography for Early Prediction of Pathologic Response after Neoadjuvant Therapy.* Radiol Imaging Cancer. 2025;7(3): p. e240117. IF: 6.3
- Pires, AM**, Barreto, JP**, Caetano, J, Soares, MJ, Geraldes, C, Fernandes, B, Coucelo, M, Chacim, S, Coelho, H, Correia, C, Cruz, AP, Cunha, M, Cunha, MR, Cunha, N, Ferraz, P, Freitas, JG, Henrique, R, Lisboa, S, Lucio, P, Paiva, A, Pedrosa, C, Ramos, I, Sarmento-Ribeiro, AB, Seabra, P, Sevilha, J, Sousa, MJR, Sousa, S, Sousa, T, Tavares, M, Trigo, F, Roque, A, Bergantim, R, Joao, C and On Behalf Of The Portuguese Multiple Myeloma, G. *Multiple Myeloma Laboratory Diagnostics Made Simple: Practical Insights and Key Recommendations.* J Clin Med. 2025;14(19) IF:2.9
- Pires, AM, **Barreto, JP**, Caetano, J, Soares, MJ, Geraldes, C, Fernandes, B, Coucelo, M, Chacim, S, Coelho, H, Correia, C, Cruz, AP, Cunha, M, Cunha, MR, Cunha, N, Ferraz, P, Freitas, JG, Henrique, R, Lisboa, S, Lucio, P, Paiva, A, Pedrosa, C, Ramos, I, Sarmento, AB, Seabra, P, Sevilha, J, Rego de Sousa, MJ, Sousa, S, Sousa, T, Tavares, M, Trigo, F, Bergantim, R, Roque, A and Joao, C. *[Diagnosis and Laboratory Follow-Up of Patients with Multiple Myeloma: Guidelines from the Portuguese Multiple Myeloma Group].* Acta Med Port. 2025;38(10): p. 654–68. IF:1.0
- Rocha, EM, Costa, PT**, Arantes, M**, Aguiar, A, Pires, A and Conde, S. *Volumetric and Linear Imaging Response After Stereotactic Radiotherapy for Vestibular Schwannoma.* Cureus. 2025;17(12): p. e98252. IF: 1.3

- Rodrigues, I, **Fernandes, R, Ferreira, A, Pereira, D**, Fernandes, R, Soares, R and Luis, C. *Is Progesterone Receptor a Neglected Feature in Breast Cancer? A Retrospective Study Analysing the Clinicopathological Characteristics of Breast Cancer Based on Progesterone Receptor Status.* Clin Breast Cancer. 2025;25(4): p. e331–e40. IF: 2.5
- Rodrigues, PR, Lopes-Conceicao, L, Sousa, V, Coutada, A, Bento, MJ, Coimbra, N, Leal, C, **Pereira, D** and **Magalhaes Ferreira, A**. *The clinicopathological characteristics, oncologic outcomes and costs of "HER2-low" early breast cancer compared to HER2-zero and HER2-positive: a single-centre retrospective analysis.* Front Oncol. 2025;15: p. 1579602. IF: 3.3
- Rodrigues, PR, Mata, D, **Brito-da-Silva, J,** Duque, CP and **Ferreira, A.** *A Rare Case of Benign Phyllodes Tumor of the Breast Responding to Anastrozole.* Cureus. 2025;17(1): p. e77277. IF: 1.3
- Roxo, F, Duarte, D and **Abreu, MH**. *Immune-Mediated Thrombocytopenia Induced by Niraparib: A Clinically Relevant Case.* Cureus. 2025;17(11): p. e97299.
- Silva-Ferreira, M, Cruz, S, **Luis, MS, Silva, MC,** Monteiro-Reis, S, Henrique, R, Jeronimo, C, Lefevre, SC, Laplaud, A, Frasca, M, Pollet, L, Zurbanobeaskoetxea, L, Barbastro, RA, Garcia, MIH, Galan, BJ, Palau, FG, Marques, DF and Duran, RL. *Mapping study on AI-based technologies in palliative care - a scoping study.* BMC Palliat Care. 2025;24(1): p. 274. IF: 3.0.
- Soldin, I, **Teixeira, R**, Ortigao, R, Lapa, A and Lima, S. *Immune Checkpoint Inhibitor-Induced Hepatitis: A Case Report of Challenging Management.* Cureus. 2025;17(1): p. e77331. IF: 1.3
- Tavares, NT, Lourenco, C, Constancio, V, Fernandes-Pontes, F, Fonseca, D, Silva-Santos, R, Braga, I, **Mauricio, J**, Henrique, R, Liu, M, Weiss, RS, Bagrodia, A, Jeronimo, C and Lobo, J. *MicroRNA-371-373 cluster extracellular vesicle-based communication in testicular germ cell tumors.* Cell Commun Signal. 2025;23(1): p. 252. IF: 8.9
- Tavares, V, Lopes, C, Macedo-Silva, C, Farinha, M, Costa, J, **Vilas-Boas, MI,** Pinelas, S, Assis, J, Dinis-Ribeiro, M, **Pereira, D**, Pereira, C and Medeiros, R. *Genetic markers of thrombophilia as predictors of outcome in colorectal cancer.* J Thromb Thrombolysis. 2025;58(5): p. 663–78. IF:2.2
- Tavares, V, **Savva-Bordalo, J**, Rei, M, Liz-Pimenta, J, Assis, J, **Pereira, D** and Medeiros, R. *Heritable Genetic Variability in Ovarian Tumours: Exploring Venous Thromboembolism Susceptibility and Cancer Prognosis in a Hospital-Based Study.* Gene. 2025;950: p. 149378. IF: 2.4
- Taylor, KJ, Amdal, CD, Bjordal, K, Astrup, GL, Herlofson, BB, Duprez, F, Gama, RR, Jacinto, A, Hammerlid, E, Scricciolo, M, Jansen, F, Verdonck-de Leeuw, IM, Fanetti, G, Guntinas-Lichius, O, Inhestern, J, Dragan, T, Fabian, A, Boehm, A, Wohner, U, Kiyota, N, Kruger, M, Bonomo, P, Pinto, M, Nuyts, S, **Silva, JC**, Stromberger, C, Specenier, P, Tramacere, F, Bushnak, A, Perotti, P, Plath, M, Paderno, A, Stempler, N, Kouri, M, Gregoire, V, Tribius, S, Singer, S, Group, EQoL, the, EH and Neck, G. *Toxicities in long-term survivors of head and neck cancer-A multi-national cross-sectional analysis.* Int J Cancer. 2025;157(10): p. 2061–70. IF: 4.7
- **Teixeira, AR, Agostinho, C**, Dias, C, Soares, R, Pina, M, Dinis, J, Lopes-Conceicao, L and Vieira, C. *Treatment of Locally Advanced and Metastatic Salivary Gland Cancer: A 10-year Experience of an Oncology Center in Portugal.* Acta Med Port. 2025;38(10): p. 608–18. IF: 1.0
- **Teixeira, AR**, Mata, D, **Ferreira, H,** Paiva, A, Pelayo, MJ, Rafael, **C, Mauricio, J**, Calisto, R and **Cassiano Neves, M**. *Short Hydration Regimen in Cisplatin-Based Chemotherapy and Its Impact on Nephrotoxicity: A Unicentric Prospective Study.* Cureus. 2025;17(2): p. e79774. IF: 1.3

### b. Other outputs

#### Oral Communications by Invitation

- Catarina Bastos, Ana Almeida, Maria José Bento, Magda Oliveira, Rui Costa. (2025) "Reduce the stress of family caregiver of pediatric patients undergoing bone marrow transplantation". 9th Symposium of the MSc in Oncology. IPO Porto, Portugal.
- Magda Oliveira. (2025) "Improving the care and quality of life for cancer survivors". IPO Porto Research Center
- Sónia Castro, Magda Oliveira (2025) "Clinical Communication in Oncology and Palliative Care – Skills Training [Comunicação Clínica em Oncologia e Cuidados Paliativos – Treino de Competências]", 2nd IPO Porto Medical Conference

- Magda Oliveira. (2025) "Innovative Research Projects in Hematology and Bone Marrow Transplantation [Projetos de Investigação Inovadores em Hematologia e Transplante de Medula Óssea]". Cuidar na Raiz: Jornadas de Enfermagem de Hematologia e Transplantação de Medula Óssea
- Ana Espírito Santo (2025): "CAR-T cells: What's the Current Status? [CAR-T cells: qual o ponto de situação]". 7º ENJIO, LPCC-NRN
- Ana Espírito Santo (2025): "The past, the present and the future of CART cell Therapy in Portugal". Beyond 6

### *Oral Communications in International Scientific Meetings*

- Joaquim Castro Silva: "Transoral Laser Microsurgery for Locally Advanced Glottic Tumors: Reducing Morbidity, Preserving Survival", 15th Congress of the European Laryngogical Society, 2025

### *Oral Communications in National Scientific Meetings*

- Joaquim Castro Silva: " Surgery for Oral Cavity Tumors: Quality Parameters and Optimization of Outcomes [Cirurgia dos tumores da cavidade oral: parâmetros de qualidade e otimização de resultados]", 72th National Congress of the Portuguese Society of ENT and Head and Neck SurgeryNational Congress of the Portuguese Society of ENT and Head and Neck Surgery, Viseu

### *Posters in national conferences*

- Leonardo Maia Moço, Ana Amarante, Ana Maria Hortas, Alice Fontoura Alves, Gonçalo de Câmara Negalha, Inês Clara, Inês Ramos, Paula Alves, Ana Espírito Santo, Delfim Duarte, Susana Couto Irving, José Mário Mariz: For CAR T CELL, size does seem to matter! Annual Meeting of the Portuguese Society of Hematology, Lisbon, 2025

### *Teaching Activity: Coordination of Curricular Units/Courses*

| Member | Curricular Units | Program | Position | Faculty/University |
|---|---|---|---|---|
| Ana Espirito Santo | FoM1/FM3 (Fundamentals and Foundations in Medicine) | Integrated MSc in Medicine | Teaching | Faculty of Medicine, University of Minho |
| Ana Espirito Santo | PCPA1 (Clinical Practice and Academic Profile) | Integrated MSc in Medicine | Teaching | Faculty of Medicine, University of Minho |
| Ana Espirito Santo | TPP (Professional Practice Transition) | Integrated MSc in Medicine | Teaching | Faculty of Medicine, University of Minho |
| Ana Espirito Santo | PCM (Complementary Medicine Pathways) | Integrated MSc in Medicine | Teaching | Faculty of Medicine, University of Minho |
| Ana Espirito Santo | Introductory notes to the clinical cases in liquid tumours | Integrated MSc in Medicine | Teaching | University Fernando Pessoa |
| Ana Espirito Santo | Main Types of Cell-Based Therapies | Integrated MSc in Medicine | Teaching | University Fernando Pessoa |
| Ana Raquel Teixeira | Clinical cases of breast cancer | Postgraduate Course in Medical Oncology and Radioncology | Teaching | University Fernando Pessoa |
| Maria Deolinda de Sousa Pereira | Clinical Practice of Oncology | Integrated MSc in Medicine | Teaching | ICBAS; UP |
| Maria Deolinda de Sousa Pereira | Clinical Practice of Oncology | Integrated MSc in Medicine | Coordination & Teaching | ICBAS; UP |
| Maria Deolinda de Sousa Pereira | Supervised Laboratory / Clinical Practice | MSc in Oncology | Coordination & Teaching | ICBAS; UP |
| Maria Deolinda de Sousa Pereira | Monitoring Seminars Dissertation / Internship | MSc in Oncology | Teaching | ICBAS; UP |
| Mavilde Arantes | Neuroanatomy | Integrated MSc in Medicine | Teaching | FMUP |

| Member | Curricular Units | Program | Position | Faculty/University |
|---|---|---|---|---|
| Mavilde Arantes | Functional Neuroanatomy | Integrated MSc in Medicine | Teaching | FMUP |
| Mavilde Arantes | Anatomy II | Integrated MSc in Medicine | Teaching | FMUP |
| Mavilde Arantes | Radiology and Medical Imaging I: Radiological Anatomy | Integrated MSc in Medicine | Teaching | FMUP |
| Magda Oliveira | Pediatric Palliative Care | Postgraduate Studies in Palliative Care | Teaching | ESSSM (Escola Superior de Saúde Santa Maria) |
| Magda Oliveira | Family Care and Grief Support – Unique Aspects of Grief in Children and Adolescents | Postgraduate Studies in Palliative Care | Teaching | ESSSM (Escola Superior de Saúde Santa Maria) |
| Magda Oliveira | Psychoneuroimmunology and Cancer: Risk and Protective Factors for the Onset and Development of Cancer | Advanced Postgraduate Specialization in Oncological Psychology | Teaching | INSPSIC (Instituto Português de Psicologia) |
| Magda Oliveira | Psychological Intervention for Mental Disorders in Oncology | Advanced Postgraduate Specialization in Oncological Psychology | Teaching | INSPSIC (Instituto Português de Psicologia) |
| Magda Oliveira | Psychological Approaches to the Continuum of Emotional Suffering: Theories and Interventions | MSc in Oncology | Teaching | ICBAS; UP |
| Magda Oliveira | Challenges of Coping with Cancer: Areas of Intervention and Their Specific Characteristics | MSc in Clinical Phsycology and health | Teaching | FPCE-UP |
| Magda Oliveira | Challenges of Coping with Cancer: Areas of Intervention and Their Specific Characteristics – Clinical Case: Psychological Intervention | MSc in Clinical Phsycology and health | Teaching | FPCE-UP |

### *Scientific Appointments*

| Organization | Researcher |
|---|---|
| EORTC Head and Neck Group | Joaquim Castro Silva |
| EORTC Quality of life Group | Joaquim Castro Silva |

## EPIDEMIOLOGY, OUTCOMES, ECONOMICS, & MANAGEMENT IN ONCOLOGY GROUP

### Coordinator

Maria José Bento, MD, PhD

### Research team @31 December 2025

| Name | Academic degree | Professional situation | Category/Position | Time % |
|---|---|---|---|---|
| Álvaro José Silva | MD, MSc | Contract | Physician in Palliative Care | 10 |
| Ana Catarina Rodrigues | MD, MSc | Contract | Physician in Public health | 50 |
| Ana Cláudia Ferreira | MSc | Contract | Data manager | 100 |
| Ana Filipa Gonçalves | PhD | Contract | Data manager | 30 |
| Ana Margarida Cabral | MD, MSc | External | Master student | 20 |
| Ana Sofia Oliveira | BSc | Contract | Management Technician | 10 |
| Carlos Matos | MSc | External | Physician in Public health/ PhD student | 10 |
| Cláudia Teixeira | MSc | Contract | Data analyst | 10 |
| Débora Abreu | MSc | Fellowship | PhD student FCT 2023.05410.BDANA | 40 |
| Diana Lopes Alves | MSc | Contract | Data manager | 100 |
| Flávia Castro | MSc | Contract | Data manager | 100 |
| Francisca Mendes | MSc | Contract | Data manager | 100 |
| Henriqueta Sampaio | BSc | Contract | Assistant Pharmacist | 10 |
| Joana Moreira | MSc | External | Invited Researcher | 100 |
| Luisa Lopes Conceição | PhD | Contract | Junior Researcher | 100 |
| Maria José Bento | PhD | Contract | Group Coordinator / Physician in Public Health | 30 |
| Mariana Pinto Sousa | MSc | Fellowship | PhD Student FCT UI/BD/154828/2023 | 60 |
| Marta Rangel | MSc | Contract | Management Technician | 10 |
| Ofélia Godinho | PhD | Contract | Statistician | 30 |
| Pedro Leite Silva | MSc | Contract | Statistician | 30 |
| Rita Calisto | MSc | Contract | Statistician | 30 |
| Rita Rb-Silva | MD, PhD | External | Clinical Hematologist | 20 |
| Rui Pedro Pereira | MSc | Contract | Data manager | 100 |
| Silvia Torres | MSc | Contract | Data manager | 100 |
| Susana Pinto | PharmD, MSc | Contract | Oncology pharmacists | 10 |
| Teresa Garcia | MD, MSc | Contract | Public health specialist, PhD student | 50 |
| Virgínia Sousa | MSc | Contract | Management Technician | 20 |

### Group description and objectives

Epidemiology, Outcomes, Economics & Management in Oncology Group (EOEMOG) research activity encompasses research at population level (North Region Cancer Registry of Portugal – RORENO and Portuguese National Cancer Registry - RON) and hospital level (IPOP) and in several areas of knowledge, meeting the level of challenges that health systems face globally and assuming that the management of health care should have a strong component of clinical results (Value-Based Health Care). Thus, the group has contributed to increase the knowledge about the epidemiology of cancer, including geographic distribution of incidence, influence of socioeconomic determinants, and assessment of the impact of the disease on the population by quantifying the global burden of disease. In addition, the group has produced knowledge in the areas of management, health outcomes and health care economics.

The group intends to have a local and global impact on health care by incorporating a multidisciplinary perspective in the production of knowledge in the following areas:

- Cancer epidemiology, including cancer etiology and socioeconomic determinants;

- Clinical epidemiological research into predictive and prognostic factors of patient survival;
- Health care management, outcome research and health economics.

Being IPO Porto Research Center a department of the Portuguese Oncology Institute of Porto, the role of EOEMOG in these areas can be leveraged by strong integration with clinical practice.

In the future, the group aims to increase national and international partnerships in projects, support observational studies and publish and communicate.

## Active projects and funding

### Competitive Funding

#### International

- ONCOVALUE – "Implementing value-based oncology care at European cancer hospitals: An AI-based framework for assessing real-life effectiveness of novel cancer therapies in real-time" (CI-IPOP-11-2022; 101095245 HORIZON-HLTH-2022-TOOL-11), Budget: 424 435 € (2022–2026) [Local PI@IPO Porto: Luísa Lopes-Conceição; Researchers: Virgínia Sousa, Teresa Garcia, Maria José Bento].
- ONCATS – "Rede Federada de Dados de Saúde de Mundo Real para Avaliação de Tecnologias de Saúde e Medicamentos em Oncologia" (COMPETE2030-FEDER-01453400; Portugal 2030), Budget: 1 487 113,28 € (2025–2028) [Local PI@IPO Porto: Maria José Bento].
- Cancer Watch JA – "Improving Quality and Timeliness of Cancer Registry Data feeding into the European Cancer Information System" (EU4Health Programme; Ref: CR-g-24-40), Total Budget: 16 249 841,00 € (2025–2028) [Local PI@IPO Porto: Maria José Bento].
- PAINLESS – "Pain relief in palliative care of cancer using home-based neuromodulation and predictive biomarkers" (101057367 HLTH-2021-DISEASE-04-01), Budget: 342 250 € (2022–2027) [Researcher: Luísa Lopes-Conceição].
- CCI4EU – "Comprehensive Cancer Infrastructures for the European Union", Budget: 9 984 080,00 € [Researcher@IPO Porto: Maria José Bento].
- EUnetCCC JA – "European Network of Comprehensive Cancer Centres Joint Action" (EU4Health Programme), Budget: 112 000 000 € (2024–2028) [Researcher@IPO Porto: Maria José Bento].
- eCAN Plus JA – "Enhancing the digital capabilities of cancer centres in the European Union to improve prevention and care" (EU4Health Programme; Ref: 101219434), Budget: 24 993 336,10 € (2025–2029) [Researcher@IPO Porto: Maria José Bento].

#### National

- CO(r)RECT Me – "Metastatic COloREctal Cancer Treatment Pathway" (CI-IPOP-53-2023), Budget: 13 500 € (2023–2025) [PI: Teresa Garcia].
- ISCCP – "Incidence and survival for childhood cancer in Portugal from 2010 to 2020: a nationwide population-based study" (CI-IPOP-54-2023), Budget: 15 000 € (2023–2025) [PI: Catarina Rodrigues].
- RISK – "New mRNA signatures as risk markers in cancers triggered by tobacco smoking" (EXPL/SAU-PUB/1073/2021), Budget: 50 000 € (2021–2027) [co-PI: Maria José Bento].

### Internal

- ProTeCteD – Therapeutic personalization and cost-effectiveness analysis of Dinutuximab Beta administration at the Portuguese Oncology Institute of Porto FG, EPE [*Personalização terapêutica e análise de custo efetividade na administração de Dinutuximab Beta no Instituto Português de Oncologia do Porto FG, EPE*] Dr Guimaraes dos Santos Grant; (BolsaJGS-PI238-CI-IPOP-81-2024-TeCteD), Budget: 4 300 € (2025–2026) [PI: Henriqueta Sampaio; Researchers: Virgínia Sousa].
- Arrest; The Use of Virtual Reality for Inpatients with Cancer at the IPO Porto [*Aplicação de realidade virtual em doentes oncológicos internados no IPO-Porto*]; Dr Guimaraes dos Santos Grant; (BolsaJGS - PI235-CI-IPOP-03-2025), Budget: 10 000€ (2025-2026); [PI: Dr Álvaro dos Santos]

### Other consortia projects

- BENCHISTA – "International benchmarking of population-based childhood cancer survival by stage at diagnosis" (IPOP-CES 35/022), Overall Budget: 349 746,50 £ (2021–2026) [Researchers: Maria José Bento, Catarina Rodrigues].
- Costs analysis, effectiveness and safety associated with CAR-T cell therapy – "Results from a Portuguese Comprehensive Cancer Center" (IPOP-CES 188/020), Budget: n.a. (2019–2025) [Researchers: Maria José Bento, Teresa Monjardino, Patrícia Redondo, Marta Rangel].
- ULCER2C – "Evaluation of the cost for treating pressure ulcers in cancer patients" (PI-173-CI-IPOP-07-2022), Budget: 3 527,40 € (2021–2026) [PI: Luísa Lopes-Conceição; Researcher: Virgínia Sousa].
- German Cancer Research Center collaboration – "Comparative analysis of colorectal cancer incidence, detection, stage at diagnosis and survival: an international population-based study", Budget: n.a. [Researchers: Maria José Bento, Rita Calisto].
- Second primary tumors study – "Comparison of incidence, survival and healthcare utilization between patients with second primary tumors and patients with a single primary tumor" (IPOP-CES 50/019), Budget: n.a. (2019–2025) [Researchers: Virgínia Sousa, Maria José Bento].
- Chronic Myeloid Leukemia at IPOP – "Epidemiological characterization of patients treated at IPO Porto" (IPOP-CES 79/023), Budget: 15 000 € (2022–2025) [Researcher: Rita Calisto].
- EUonQoL – "Quality of Life in Oncology: measuring what matters for cancer patients and survivors in Europe" (PI216-CI-IPOP-50-2023-OECI_3rdParty_EUonQoL), Budget: 30 000 € (2023–2026) [Local PI@IPO Porto: Maria José Bento; Local co-PI: Luísa Lopes-Conceição; Researchers: Diana Lopes, Ana Catarina Rodrigues].
- IDEAL4OMOP – "Comparative Analysis of the Natural History and Outcomes of Early-Onset and Late-Onset Colorectal Cancer", Budget: 16 925 € (2025) [Local PI: Catarina Rodrigues; co-PI: Rita Rb-Silva; Researchers@IPO Porto: Maria José Bento].
- OEN –Oncology Evidence Network projects [Researchers: Ana Catarina Rodrigues, Luísa Lopes-Conceição, Joana Moreira, Maria José Bento]:
    - "ROS1-positive NSCLC real-world outcomes in Europe and Canada" (CI-IPOP-32-2024), Budget: n.a. (2023–2025) [co-PI: Luísa Lopes-Conceição].
    - "ESR1 mutations in ER+/HER2- advanced breast cancer treated with everolimus" (CI-IPOP-72-2024), Budget: n.a. (2024–2025) [Researcher: Luísa Lopes-Conceição].
    - "VECTOR – Indirect treatment comparison for VERITAC-2 using real-world data" (CI-IPOP-73-2024), Budget: n.a. (2024–2025).
    - "External Control Arm Study to support HTA submissions for T-DXd" (CI-IPOP-15-2025), Budget: n.a. (2025) [PI: Ana Catarina Rodrigues].
    - "ESPERANZA-C – Real-world outcomes by HER2 status in solid tumours" (CI-IPOP-89-2025), Budget: n.a. (2025–2026) [Researchers: Ana Catarina Rodrigues, Maria José Bento, Luísa Lopes-Conceição, Joana Moreira].

### Major achievements

- ***Sousa, MP***, ***Monjardino, T***, *Costa Santos, C, Lara, L and* ***Bento, MJ****. Completeness Evaluation of Adult-Population-Based Cancer Registries: A Systematic Review. Cancers. 2025;17:1123. (IF: 4.4)* https://www.mdpi.com/2072-6694/17/7/1123

Accurate population-based cancer data is essential for understanding trends, guiding healthcare policies, and ensuring effective resource allocation. However, population-based cancer registries face challenges in ensuring their data is complete and reliable. The objective of this study was to evaluate what statistical methods are used worldwide to estimate cancer registry completeness, highlighting the strengths and limitations of these methods. Eighty-three studies from 31 countries were identified, with most studies meeting high-quality standards. Overall, the choice of which method to use is highly dependent on the registries' data quality. By identifying the most effective approaches, our results emphasize the importance of continuous refinement of these assessment methods to improve the reliability and global comparability of cancer registry data. This research helps to support better decision-making in cancer prevention, treatment, and policy development, ultimately benefiting both researchers and patients. (DOI: 10.3390/cancers17071123)

- ***Taveira-Barbosa, J**, **Garcia, TM**, Lebre, A, Fontes, F, Brandão, M, **Calisto, R**, Turé, R, **Bento, MJ**, Lunet, N, Morais, S and **Lopes-Conceição, L**. Characteristics and Mortality of Patients With Cancer Diagnosed With SARS-CoV-2 in Northern Portugal. Anticancer Res. 2025;45(4):1749–1760. (IF: 1.7) https://ar.iiarjournals.org/content/45/4/1749.long*

This study provides robust real-world evidence that SARS-CoV-2 infection is associated with a significantly increased risk of mortality among cancer patients. By comparing infected and non-infected patients across multiple tumor types within a large oncology center, it demonstrates that COVID-19 had a lasting negative impact on cancer outcomes beyond the acute phase of infection. Importantly, the study identifies particularly vulnerable subgroups, patients living outside the metropolitan area, those with lung cancer, and patients undergoing surgery as first-line treatment, who experienced substantially higher mortality risks. These findings underline the need for targeted prevention strategies, tailored clinical management, and equitable access to care for cancer patients during infectious disease outbreaks, reinforcing the relevance of integrating pandemic preparedness into oncologic care planning. (DOI: 10.21873/anticanres.17555)

## Scientific output

### *a. Peer-reviewed indexed publications (final publication date in 2025)*

- Brito-Rocha, T, Constâncio, V, **Leite-Silva, P**, Carvalho-Maia, C, Sequeira, JP, Salta, S, Lobo, J, Machado, DI, Nunes, SP, Silva-Santos, R, Freitas, R, Gonçalves Dias, C, Vieira, C, Soares, M, Henrique, R and Jerónimo, C. *Multi-cancer early detection via a DNA methylation multiplex ddPCR-based blood test. I*nt J Cancer. 2025;157(5):1006–1019. IF: 4.7
- Costa, SPF, Sousa, F, **Leite-Silva, P**, Gomes, D and Sousa, O. *Stereotactic body radiation therapy for lung metastases from colorectal cancer: outcomes and prognostic factors in a series of 109 patients*. Rep Pract Oncol Radiother. 2025;29(6):700–709. IF: 2.0
- Ferraz-Gonçalves, JA, Lima, Á, Silva, ÁJ and **Calisto, R**. *Factors Associated With Prolonged Survival in Colorectal Cancer Patients Admitted to Palliative Care: An Exploratory Study*. Am J Hosp Palliat Med. 2025;42(12):1278–1283. IF: 1.4
- Gonçalves, E, Fontes, F, **Rodrigues, JR**, **Calisto, R**, **Bento, MJ** and Lunet, N. *Risk and survival of third primary cancers in a population-based cohort of patients with a cervical, endometrial, or ovarian cancer*. J Obstet Gynaecol Res. 2025;51(5):e16297. IF: 1.5
- Machado, DI, Brito-Rocha, T, Salta, S, **Monjardino, T,** Henrique, R and Jeronimo, C. *Circulating cell-free DNA methylation as biomarker for lung cancer detection: a systematic review and meta-analysis of diagnostic studies.* Syst Rev. 2025;14(1): p. 120. IF: 3.9
- Meireles, AM, **Calisto, R**, **Bento, MJ**, Martinho Gouveia, P, Bizarro, S, Teixeira, M, Moreira, C and Espírito Santo, A. *Epidemiological characterization of chronic myeloid leukaemia patients at an oncologic centre: A retrospective observational study.* Hematol Transfus Cell Ther. 2025;47(3):103935. IF: 1.6
- Montenegro, MA, Domingues, TD, **Garcia, TM**, Ferreira, RQ, Furtado, IT and Simão, DC. *Male breast cancer in Portugal: a descriptive analysis of a 20-year cohort*. Eur J Breast Health. 2025;21(2):154–161. IF: 1.7
- Rodrigues, A, Pina, M, **Calisto, R**, **Leite-Silva, P**, **Medeiros, P**, Silva, C, Silva, AS, **Redondo, P**, Ramalho-Carvalho, J and Santos, SF. *Characterization of the Population, Treatment Patterns, and Outcomes of Patients with Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) with Epidermal Growth Factor Receptor Mutation (EGFRm): A Retrospective Cohort Study from IPO Porto.* Curr Oncol. 2025;32(8):414. IF: 3.4
- Rodrigues, ED, **Bento, MJ**, **Calisto, R**, **Rodrigues, J**, Almeida, P, López, E and Teixeira, L. *Utilisation patterns of radiotherapy among older patients: Insights from Portuguese National Cancer Registry data*. J Cancer Policy. 2025;43:100522. IF: 2.0
- Rodrigues, PR, **Lopes-Conceição, L**, **Sousa, V**, Coutada, A, **Bento, MJ**, Coimbra, N, Leal, C, Pereira, D and Magalhães Ferreira, A. *The clinicopathological characteristics, oncologic outcomes and costs of "HER2-low" early breast cancer compared to HER2-zero and HER2-positive: a single-centre retrospective analysis*. Front Oncol. 2025;15:1579602. IF: 3.3

- Silva, JC, **Leite-Silva, P**, Tavares, F, **Bento, MJ**, Libânio, D and Dinis-Ribeiro, M. *Impact of a FIT Based Colorectal Cancer Screening Program on Gastric Cancer Incidence, Early Diagnosis and Patients' Survival*. Helicobacter. 2025;30(5):e70071. IF: 4.3
- **Sousa, MP**, **Monjardino, T**, Costa Santos, C, Lara, L and **Bento, MJ**. *Completeness Evaluation of Adult-Population-Based Cancer Registries*: A Systematic Review. Cancers. 2025;17:1123. IF: 4.4
- **Sousa, MP**, Pereira, AC, Correia, B, do Carmo, A, Matos, AM, Cruz, MT and Moreira, FTC. *Cellulose-Based Colorimetric Test Strips for SARS-CoV-2 Antibody Detection.* Biosensors (Basel). 2025;15(6) IF: 5.6
- **Taveira-Barbosa, J**, **Garcia, TM**, Lebre, A, Fontes, F, Brandão, M, **Calisto, R**, Turé, R, **Bento, MJ**, Lunet, N, Morais, S and **Lopes-Conceição, L**. *Characteristics and Mortality of Patients With Cancer Diagnosed With SARS-CoV-2 in Northern Portugal.* Anticancer Res. 2025;45(4):1749–1760. IF: 1.7
- **Taveira-Barbosa, J**, Morais, S, **Garcia, TM**, **Bento, MJ** and Lunet, N. *Second primary cancers among males with a first primary prostate cancer: a population-based study in Northern Portugal*. Clin Exp Med. 2025;25(1):122. IF: 3.5
- Teixeira, AR, Agostinho, C, Dias, C, Soares, R, Pina, M, Dinis, J, **Lopes-Conceição, L** and Vieira, C. *Treatment of Locally Advanced and Metastatic Salivary Gland Cancer: A 10-year Experience of an Oncology Center in Portugal.* Acta Med Port. 2025;38(10):608–618. IF: 1.0
- Teixeira, AR, Mata, D, Ferreira, H, Paiva, A, Pelayo, MJ, Rafael, C, Maurício, J, **Calisto, R** and Cassiano Neves, M. *Short Hydration Regimen in Cisplatin-Based Chemotherapy and Its Impact on Nephrotoxicity: A Unicentric Prospective Study.* Cureus. 2025;17(2):e79774. IF: 1.3

### b. Peer-reviewed indexed publications within a consortitum

- Allemani C, Minicozzi P, Morawski B, Lima CA, Bennett D, Pongnikorn D, Petrova D, Innos K, Girardi F, Galán Alvarez Y, Schaffar R, Dal Maso L, Molinié F, Valkov M, Phillips K, Siesling S, Schultz A, Daubisse-Marliac L, Marcos-Gragera R, Di Carlo V and **VENUSCANCER Working Group**. *Global variation in patterns of care and time to initial treatment for breast, cervical, and ovarian cancer from 2015 to 2018 (VENUSCANCER): a secondary analysis of individual records for 275 792 women from 103 population-based cancer registries in 39 countries and territories*. Lancet. 2025 Nov 15;406(10517):2325-2348. doi: 10.1016/S0140-6736(25)01383-2. IF: 88.5
- Bernasconi A, Toss A, Zattarin E, Mousavi SM, Blum M, Kuehni CE, Katalinic A, Trallero J, Rapiti E, Maso LD, Botta L, Rossi S, Peccatori F, Trama and **EUROCARE-6 Study Group**. *Prognosis of Breast Cancer in European female adolescents and young adults (AYAs): EUROCARE-6 retrospective cohort results*. Breast. 2025;82:104472. IF: 7.9
- Botta L, Capocaccia R, Vener C, Bernasconi A, Trama A, Didoné F, Demuru E, De Angelis R, Rossi S, Mousavi SM, Peters F, Bennet D, Mayer-da-Silva A, Jooste V; **EUROCARE-6 Working Group**. *Estimating cure and risk of death from other causes of adolescent and young adult cancer patients in Europe*. Eur J Cancer. 2025 Jun 3;222:115443. doi: 10.1016/j.ejca.2025.115443. IF: 7.1
- Botta L, Capocaccia R, Bernasconi A, Rossi S, Galceran J, Dal Maso L, Lepage C, Molinié F, Bouvier AM, Marcos-Gragera R, Vener C, Guevara M, Murray D, Ragusa R, Gatta G, Jooste V**; EUROCARE-6 Working Group**. *The impact of cancer survivors' extra risk of noncancer mortality on net survival estimation*. Am J Epidemiol. 2025 Nov 4;194(11):3316-3324. doi: 10.1093/aje/kwaf148. IF: 4.8
- Crocetti E, Bennett D, Jooste V, Rossi S, Maso LD, Marcos-Gragera R, Smits S, Zagar T, Troussard X, Mayer-da-Silva A, Daubisse-Marliac L, Lourenço A, Katalinic A, Sanchez MJ, Vener C, Mousavi M, Ziliani V, Gatta G; **EUROCARE-6 Working Group**. *Skin melanoma survival is improving in Europe but regional differences persist: Results of the EUROCARE-6 study*. Eur J Cancer. 2025 Dec 9;231:116061. doi: 10.1016/j.ejca.2025.116061. IF: 7.1
- Gatta G, Calleja-Agius J, Sandrucci S, Bennet D, Azzopardi MJ, Capocaccia R and **EUROCARE WG**. *Incidence and survival of rare female genital tract cancers in Europe: The EUROCARE-6 study.* Eur J Surg Oncol. 2025;51(4):109996. IF: 2.9
- Gatta G, Luttmann S, Trama A, Rossi S, Galceran J, Innos K, Guevara M, Licitra L, Bennet D, Redondo-Sánchez D, Capocaccia R; **EUROCARE Working Group**. *Epithelial head and neck cancer survival in*

*Europe: Geographical variation, time trends and long term survival*. Eur J Cancer. 2025 Oct 16;229:115692. doi: 10.1016/j.ejca.2025.115692. IF: 7.1

- Hoogendijk R, Capocaccia R, van der Lugt J, Kranendonk MEG, Hoving EW, Wesseling P, Visser O, van Vuurden DG, Gatta G, Karim-Kos HE and **EUROCARE Working Group**. *Long-term survival and cure fraction estimates for paediatric central nervous system tumours in 31 European countries (EUROCARE-6): a population-based study.* Lancet Oncol. 2025;26(8):1091–1099. IF: 35.9
- McCabe M, Rossi S, Cerza F, Massimino M, Gianno F, Spycher BD, Marcos-Gragera R, Bennett D, Lasalvia P, Didonè F, El Karoui NJ, Ragusa R, Mayer-da-Silva A, Mousavi SM, Trama A; **EUROCARE-6 Working Group**. *Survival of European adolescents and young adults diagnosed with central nervous system tumours and comparison with younger and older age groups: EUROCARE-6 results*. Eur J Cancer. 2025 Sep 9;227:115661. doi: 10.1016/j.ejca.2025.115661. IF: 7.1
- Trama A, Geerdes EE, Demuru E, De Angelis R, Karim-Kos HE, Troussard X, Bennett D, Marcos-Gragera R, Kuehni CE, Liu H, Bernasconi A, Vener C, Guevara M, Zwaan CM, Mayer-da-Silva A, Paapsi K, Ragusa R, Smith OP; **EUROCARE-6 Working Group**. *Survival of European children, adolescents and young adults diagnosed with haematological malignancies in the period 2000-2013: Results from EUROCARE-6, a population-based study*. Eur J Cancer. 2025 Jun 3;222:115336. doi: 10.1016/j.ejca.2025.115336. IF: 7.1
- Trama A, Rossi S, Bennet D, Stiller C, Paapsi K, Troussard X, Giudici F, Karim-Kos HE, Cerza F, Trallero J, Ragusa R, Blum M, Mayer-da-Silva A, Peters F, Didonè F, Botta L; **EUROCARE-6 Working Group**. *Comparative analysis of 5-year relative survival in adolescents and young adults with cancer relative to both children and adults in Europe (EUROCARE-6): Results from a population-based study*. Eur J Cancer. 2025 Aug 26;226:115535. doi: 10.1016/j.ejca.2025.115535. IF: 7.1

### *c. Other outputs*

#### *Oral Communications by Invitation*

- **Bento MJ.** National Epidemiology 2021. Cancer in Portugal [Epidemiologia Nacional 2021. Doença Oncológica em Portugal.]. World Cancer Day 2025 (4th February); IPO do Porto, Portugal
- **Bento MJ.** Public Health at the IPO in Porto [A Saúde Pública no IPO do Porto]. Introduction to Public Health (6th February), online.
- **Garcia TM**. Let´s talk about: Young patients and BC. Old problems increasing? 7th Breast Cancer Weekend (7-8th February); Porto, Portugal.
- **Garcia TM**, **Calisto R**, **Coutinho C**, **Godinho O**. Tendências do padrão de apresentação da doença na era da vacinação. 10º Curso Avançado Ginecologia Oncológica (3-4th July); Porto, Portugal.
- **Garcia TM**, Gomes AC, **Calisto R**, **Bento MJ**, Associação entre exposição ao radão no interior das cases e incidência de vários tipos de cancro em Portugal Continente – Um estudo multinível - XLIII Reunião Anual da Sociedade Espanhola de Epidemiologia (SEE) e o XX Congresso da Associação Portuguesa de Epidemiologia (APE) (2-5 September) Las Palmas de Gran Canaria, Spain
- **Calisto R**, **Garcia TM**, **Coutinho C**, **Bento MJ**, The influence of wildfires in Cancer incidence - XLIII Reunião Anual da Sociedade Espanhola de Epidemiologia (SEE) e o XX Congresso da Associação Portuguesa de Epidemiologia (APE) (2-5 September) Las Palmas de Gran Canaria, Spain
- **Coutinho C**, **Calisto R**, **Garcia TM**, Alves SM, **Bento MJ**. Occupational Cancer in Portugal: What can Municipality Workforce Reveal? XLIII Reunião Anual da Sociedade Espanhola de Epidemiologia (SEE) e o XX Congresso da Associação Portuguesa de Epidemiologia (APE) (2-5 September) Las Palmas de Gran Canaria, Spain
- **Bento MJ**. Tumores Hereditários: Estado da Arte e Epidemiologia, Curso Tumores Hereditários. LPCC- Nucleo Regional do Centro (3 October), Coimbra, Portugal.
- **Bento MJ.** Registo Nacional Oncológico (RON): Fatores críticos de sucesso. Workshop Futuro dos Dados em Saúde: Como desenvolver e melhorar registos nacionais? (21 November), Lisboa, Portugal
- **Bento MJ**. RON: Opportunities in Survivorship Investigation, Survivorship: investigation to care plan. Congresso Nacional de Oncologia (28 november), Braga, Portugal.

### Oral Communications in International Scientific Meetings

- Fernandes AL, Silvano P, Guimarães N, **Rb-Silva R**, Munna TA, Cunha LF, Leal A, Campos R, Jorge A. Human Experts vs. Large Language Models: Evaluating Annotation Scheme and Guidelines Development for Clinical Narratives. Text2Story 2025 - 8th International Workshop on Narrative Extraction from Texts held in conjunction with the 47th European Conference on Information Retrieval, ECIR 2025 (6-10 April); Lucca, Italy.
- **Calisto R**, **Garcia TM**, **Coutinho C**, **Bento MJ**, Do wildfires impact the incidence of cancer? GRELL & ENCR 2025 Scientific Meeting (27-30 May) Porto, Portugal
- Leite M, **Rb-Silva R**, Guimarães N, Stork L, Jorge A. Knowledge-Aware Clinical Narrative Extraction Using Ontologies and Knowledge Graphs. In book: Progress in Artificial Intelligence - 24th EPIA Conference on Artificial Intelligence, EPIA 2025, Faro, Portugal (October 1–3, 2025). DOI: 10.1007/978-3-032-05179-0

### Oral Communications in National Scientific Meetings

- **Rodrigues CA**, **Garcia T**, **Lopes-Conceição L**, **Leite-Silva P**, **Godinho O**, Monteiro LS, **Bento MJ**, Santos LL, Costa M (2025). Oral cancer survival in Portugal: A population-based overview (2015-2020). 7º encontro Statistics on Health Decision Making (10th -11th July); Aveiro, Portugal.

### Posters in international conferences

- **Taveira-Barbosa J**, **Garcia T**, Lebre A, Fontes F, Brandão M, **Calisto R**, Turé R, **Bento MJ**, Lunet N, Morais S, **Lopes-Conceição L** (2025). Characteristics and Mortality of Patients With Cancer Diagnosed With SARS-CoV-2 in Northern Portugal. 49th Annual Meeting of the Group for Cancer Epidemiology and Registration in Latin Language Countries (GRELL 2025) & European Network of Cancer Registries (ENCR) meeting (27th - 30th May); Porto, Portugal.
- **Sousa MP**, **Monjardino T**, Costa Santos C, Lara L, **Bento MJ** (2025). Completeness Evaluation of Adult-Population-Based Cancer Registries: A Systematic Review. GRELL & ENCR 2025 Scientific Meeting (27-30 May); Porto, Portugal
- **Garcia TM**, **Calisto R**, **Godinho O**, **Coutinho C**, **Bento MJ** (2025). HPV Vaccination and the incidence of Invasive Cervical Cancer: using cancer registry data to assess impact. GRELL & ENCR 2025 Scientific Meeting (27-29th May); Porto, Portugal.
- **Rb-Silva R**, Newby D, Rodrigues CA, Okegunna Y, Wu P, Schumann L. Comparative Analysis of the Natural History and Outcomes of Early-Onset and Late-Onset Colorectal Cancer. OHDSI Europe Symposium 2025 (5-7th July); Hasselt, Belgium.
- Fernandes AL, Silvano P, Leal A, Guimarães N, **Rb-Silva R**, Cunha LF, Jorge A. The Incremental Process of Building an Annotation Scheme for Clinical Narratives in Portuguese: the Contribution of Human Variation Analysis. 19th Linguistic Annotation Workshop (LAW-XIX-2025), July 2025, Vienna, Austria.
- Wu P, Newby D, Costelloe C, Rodrigues CA, Okegunna Y, Schumann L, Dulskas A, **Rb-Silva R**. Natural History and Outcomes in Early- and Late-Onset Colorectal Cancer: A Comparative Analysis. OHDSI UK 2025 (26th September), London, United Kingdom
- Chouaid C, Lee A, Bote De Cabo H, Christopoulos P, Correia B, Deshayes S, Estival Gonzalez A, Girard N, **Lopes-Conceição L**, Mella M, Moreira J , Rizzi S, Han M, Winter M, Calvet CY, Emanuel G, Glassberg MB, Rault C, Yuan Y, Cheung WY (2025). Real-world treatment patterns and survival in patients with ROS1-positive locally advanced or metastatic non-small cell lung cancer in Canada and Europe. 2025 European Society for Medical Oncology (ESMO) Annual Meeting (17th-21st October); Berlin, Germany.
- Bocquet F, Campone M, Cottu PH, Callens C, Patrão AS, **Lopes-Conceição L**, Alva Bianchi M, Sanchez Bayona R, Fasching PA, Uhrig S, Huebner H, Quinlan M, Quinlan P, Lee C, Turcan C, MacDougall F, Maissenhaelter B, Rudolph A (2025). Prevalence of ESR1 mutations in ER+/HER2- advanced breast cancer (aBC) patients treated with everolimus after CDK4/6 inhibitors. 2025 European Society for Medical Oncology (ESMO) Annual Meeting (17th-21st October); Berlin, Germany.

- Soares B.M.M., Magalhães Ferreira A, **Rangel M**, **Teixeira C**, **Garcia T**, **Bento MJ**, Brás D, Esteves J, Domingues M, **Calisto R**. ERNEST study: Prognostic factors and invasive disease-free survival in hormone receptor-positive, HER-2-negative breast cancer. ESMO 2025 (17th-21st October); Berlin, Germany
- Rodrigues A, Pina M, **Calisto R**, **Bento MJ**, **Leite-Silva P**, **Medeiros P**, Ramalho Carvalho J, Ferreira Santos S, Mariano J, Silva C, Silva AS, **Redondo P**. Healthcare Resource Utilization in Patients With Non-Small Cell Lung Cancer (NSCLC) and Epidermal Growth Factor Receptor Mutation (eGFRm): A Retrospective Cohort Study in a Portuguese Comprehensive Cancer Center. ISPOR Europe 2025 (9-12th November), Glasgow, Scotland
- Rosinha AR, **Calisto R**, **Rangel M**, **Teixeira C**, **Leite-Silva P**,·**Bento MJ**, Silva C, Correia I, Fialho AC, Ribeiro Dias S (2025). Prostate-specific antigen (PSA) response with apalutamide in patients with metastatic castration-sensitive prostate cancer in real-world: A retrospective cohort study - PSAPA study. European Multidisciplinary Congress on Urological Cancers (EMUC) 13 November 2025 - 16 November 2025, Brussels, Belgium
- Patrão A, **Bento MJ**, Ferreira CM, Domingues D, Brás D. Real-World Outcomes and Economic Impact of Ribociclib in HR+/HER2- Advanced Breast Cancer: Evidence from the Portuguese REASSURE Cohort. ISPOR Europe 2025 (9th - 12th November); Glasgow, Scotland.
- Roncadori A, **Lopes-Conceicao L**, **Garcia TM**, Lähteenmaa J, Tittel K, Bjerrum A, Massa I (2025).One Research Objective, Many Realities: Mapping Data Availability and Governance Diversity in Oncology Research. ISPOR Europe 2025 (9th - 12th November); Glasgow, Scotland.
- **Sousa MP**, Ramos H, Carvalho C, Soares MI, Ciucci A, Santos L, **Bento MJ**, Sette C, Pinho e Melo TMVD, Saraiva L (2025). Functional reactivation of p53 as a promising therapeutic strategy in the treatment of ovarian cancer. 4th ASEICA-ASPIC Joint Meeting (20-21 November); Santiago Compostela, Spain.

### *Posters in national conferences*

- **Sousa MP**, Ramos H, Carvalho C, Soares MI, Ciucci A, Santos L, **Bento MJ**, Sette C, Pinho e Melo TMVD, Saraiva L (2025). Functional reactivation of p53 as a promising therapy for the treatment of ovarian cancer [Reativação funcional da p53 como terapêutica promissora no tratamento do cancro do ovário]. 7.º National Meeting of Young Researchers in Oncology (ENJIO 2025) (24th September); Porto, Portugal
- Oliveira Ramos I, Mariz JM , **Ferreira AC**, **Alves Rodrigues C,** **Rangel M**, **Medeiros P**, **Calisto R**, **Bento MJ**. Real-World Treatment Patterns and Survival Outcomes of Diffuse Large B Cell Lymphoma, Annual Meeting of the Portuguese Society of Hematology, (6-8 November) Lisboa, Portugal
- Meireles AT, Batista M, Magalhães R, Cardoso S, Silva V, Braga F, **Garcia TM**, **Pinto S**, Fernandez-Llimos F. Influence of Body Mass Index on Response to Neoadjuvant Targeted Therapy in Early HER2-Positive Breast Cancer (2025) XVIII Congresso da APFH. 27th-29th November; Porto, Portugal
- Soares B.M.M., Magalhães Ferreira A, **Rangel M**, **Teixeira C**, **Garcia TM**, **Bento MJ**, Brás D, Esteves J, Domingues M, **Calisto R**. ERNEST study: Prognostic factors and invasive disease-free survival in hormone receptor-positive, HER-2-negative breast cancer. Congresso Nacional de Oncologia 2025 (26-28 November); Braga, Portugal

### *Editorial Board Positions*

| Journal | Publishing Company | Position | Researcher |
|---|---|---|---|
| Portuguese Journal of Surgery | | Statistical Consultant | Pedro Leite Silva |

### Participation as Opponent in PhD/Aggregation Evaluation Committees

| Student | Title | Program | Researcher |
|---|---|---|---|
| Edna Darlene Rodrigues Pinto | Geriatric evaluation of older adults proposed for Radiotherapy | PhD Thesis in Medical Sciencies, ICBAS, UP | Maria José Bento |
| Carlos David Ferreira Alone Selemane | Colorectal Cancer in Mozambique: Clinical, Pathological, and Molecular Characterization of the Disease, and Definition of an Efficient Action Plan | PhD Thesis in Medical Sciences, ICBAS, UP | Maria José Bento |

### Teaching Activity: Coordination of Curricular Units/Courses

| Member | Curricular Units | Program | Position | Faculty/University |
|---|---|---|---|---|
| Catarina Rodrigues | Epidemiology | MSc in Oncology | Teaching | ICBAS; UP |
| Luisa Lopes-Conceição | Research Practices in Oncology | MSc in Oncology | Teaching | ICBAS; UP |
| Luisa Lopes-Conceição | Statistical methods with application in epidemiology and analysis of health outcomes in oncology | Research Methodologies in Oncology / Introduction to Research Activity Course | Teaching | ICBAS; UP/ IPO Porto |
| Maria José Bento | Epidemiology and analysis of health outcomes in oncology | Research Methodologies in Oncology / Introduction to Research Activity Course | Teaching | ICBAS; UP/ IPO Porto |
| Maria José Bento | Epidemiology, Research Methodologies and Biostatistics I, Cancer Screening & Prevention | MSc in Oncology | Coordination and teaching | ICBAS; UP |
| Maria José Bento | Project - Research Seminars | MSc in Oncology | Teaching | ICBAS; UP |
| Maria José Bento | Oncobiology | MSc in Biochemistry | Teaching | FC/ICBAS; UP |
| Maria José Bento | Pathology and Molecular Genetics | MSc in Laboratory Techniques in Biopathology | Teaching | ESTSP |
| Maria José Bento | Epidemiology and Public Health, Medical Epidemiology | Integrated MSc in Medicine | Teaching | ICBAS; UP |
| Maria José Bento | Pathology II | Integrated MSc in Medicine | Teaching | ICBAS; UP |
| Maria José Bento | Principles of Medical Sciences I | Integrated MSc in Medicine | Coordination and teaching | Universidade Fernando Pessoa |
| Ofélia Godinho | Molecules, Cells and Disease III | Integrated MSc in Medicine | Teaching | Universidade Fernando Pessoa |
| Ofélia Godinho | Principles of Medical Sciences I | Integrated MSc in Medicine | Teaching | Universidade Fernando Pessoa |
| Pedro Leite Silva | Epidemiology and Data Analysis | Postgraduate in Cytotechnology | Teaching | P.PORTO - ESS |
| Rita Calisto | Research methodologies and biostatistics I | MSc in Oncology | Teaching | ICBAS; UP |
| Rita Calisto | Research methodologies and biostatistics II | MSc in Oncology | Teaching | ICBAS; UP |

| Member | Curricular Units | Program | Position | Faculty/University |
|---|---|---|---|---|
| Teresa Garcia | Introduction to Epidemiology | Integrated Master's Degree in Medicine | Teaching | FMUP; UP |

### Prizes, Honors and Awards

| Researcher | Prize designation | Institution | Date | Amount |
|---|---|---|---|---|
| Susana Pinto | First prize in APFH 2025 Poster | XVIII Congresso da Associação Portuguesa de Farmacêuticos Hospitalares (APFH) | November 2025 | n/a |
| Luisa Lopes-Conceição | Best Poster | 2025 European Society for Medical Oncology (ESMO) Annual Meeting | September 2025 | n/a |

### Scientific Appointments

| Organization | Researcher |
|---|---|
| Scientific Committee of the National Cancer Registry | Maria José Bento |

### National collaborations

| Title | Researchers | Collaborators | Funding | Period |
|---|---|---|---|---|
| Publication: National Oncological Registry of All Tumors in the Resident Population in Portugal, in 2022/ Publicação: Registo Oncológico Nacional de Todos os Tumores na População Residente em Portugal, em 2022 | Maria José Bento, Teresa Garcia, Catarina Rodrigues, Pedro Leite Silva, Ofélia Godinho | National Cancer Registry [Registo Oncológico Nacional] | NA | 2025 |
| Publication: Overall Survival, Patients Diagnosed in 2018, Portugal / Publicação: Sobrevivência Global, Doentes diagnosticados em 2018, Portugal | Maria José Bento, Teresa Garcia, Catarina Rodrigues, Pedro Leite Silva, Rita Calisto, Ofélia Godinho | National Cancer Registry [Registo Oncológico Nacional] | NA | 2025 |

### International collaborations

| Title | Researchers | International Team | Institution | Country | Funding |
|---|---|---|---|---|---|
| OEN – Oncology Evidence Network | Maria José Bento, Luisa Lopes-Conceição, Joana Moreira, Ana Catarina Rodrigues, Ofélia Godinho, Pedro Silva, Teresa Garcia | NA | IQVIA | NA | NA |
| DigiCore - DiGital Institute for Cancer Outcomes REsearch | Maria José Bento, Ana Catarina Rodrigues, Rita Silva | NA | NA | NA | NA |
| GRELL - Group for Cancer Epidemiology and Registration in Latin Language Countries | Rita Calisto, Maria José Bento | NA | NA | NA | NA |
| RARECAREnet - Surveillance of Rare Cancers in Europe | Maria José Bento, Pedro Leite Silva | NA | Istituto Nazionale Tumori di Milano | Italy | NA |

| Title | Researchers | International Team | Institution | Country | Funding |
|---|---|---|---|---|---|
| EUROCARE - Survival of cancer patients in Europe | Maria José Bento<br>Rita Calisto | NA | Istituto Nazionale Tumori di Milano & the Italian National Institute of Health | Italy | NA |
| CONCORD - Global surveillance of cancer survival | Maria José Bento<br>Pedro Leite Silva | Claudia Alemani | London School of Hygiene & Tropical Medicine | England | NA |
| WASABY - WAter & Soil contamination and Awareness on Breast cancer risk in Young women | Maria José Bento<br>Rita Calisto | NA | Instituto Nazionale Tumori di Milano | Italy | NA |
| IICC - International Incidence of Childhood Cancer | Maria José Bento,<br>Pedro Leite Silva | NA | International Agency for Research on Cancer (IARC) & the International Association of Cancer Registries (IACR) | France | NA |
| CRICCS - Cancer Risk in Childhood Cancer Survivors: understanding the causes to target prevention | Pedro Leite Silva | NA | International Association of Cancer Registries (IACR) | France | NA |
| EURECCA - EUropean REgistry of Cancer CAre or EURopEan CanCer Audit | Pedro Leite Silva,<br>Maria José Bento | NA | ESSO (European Society of Surgical Oncology) | Belgium | NA |

### *International Consortia*

| Organization | Researcher |
|---|---|
| UNCAN.eu, a European initiative to UNderstand CANcer | Maria José Bento |
| OECI Working Group on Cancer Economics and Benchmarking | Maria José Bento |

## EXPERIMENTAL PATHOLOGY & THERAPEUTICS GROUP

### Coordinator

Lúcio Santos, MD, PhD

### Research team @31 December 2025

| Name | Academic degree | Professional situation | Category/Position | Time % |
|---|---|---|---|---|
| Adriana Filipa Ribeiro Carneiro | MSc | Fellowship | PhD Student (FCT 2021.05593.BD) | 20 |
| Alessandro Nuccio | MSc | Fellowship | PhD Student FCT 2025.03325.BD | 25 |
| Ana Carolina Fernandes Vieira de Castro | MSc | Fellowship | PhD Student / FCT 2022.13379.BD | 100 |
| Ana Rita Pereira Azevedo | PhD | Contract | Associate Researcher | 100 |
| Andreia Filipa Ferreira Peixoto | PhD | Contract | Junior researcher (2023.06366.CEECIND) | 100 |
| Andreia Rafaela Linhares Miranda | MSc | Student | PhD Student (FCT 2022.12980.BD) | 75 |
| Beatriz da Silva Matos | MSc | Student | PhD student | 100 |
| Beatriz Marinho Santos | MSc | Student | PhD Student FCT 2024.00895.BD | 100 |
| Carlos Alberto Palmeira de Sousa | PhD | Contract | Clinical Biologist | 30 |
| Catarina Alexandre da Rocha Rodrigues | MSc | Fellowship | PhD Student (FCT UI/BD/153103/2022) | 75 |
| Catarina Alves Pinto | MSc | Fellowship | PhD Student (FCT 2023.04484.BD) | 50 |
| Clara Alice Gentil Daher Mota | MSc | Fellowship | PhD Student (FCT UI/BD/150674/2020) | 100 |
| Cristina Patrícia Mendes Santos | PhD | External | Associate Researcher | 30 |
| Daniel Mateus Gonçalves | MSc | Fellowship | PhD Student (FCT 2022.12633.BD= | 20 |
| Daniela Rocha Santos | MSc | Fellowship | PhD Student (FCT-UI/BD/154820/2023) | 70 |
| Dora Maria Barrocas Bernardo | MSc | Contract | Oncology Pharmacists | 20 |
| Dylan Gomes Ferreira | PhD | Associate Researcher | Invited PhD Researcher; Professor UPF | 100 |
| Eduardo da Silva Ferreira | MSc | Student | PhD Student (2024.04043.BDANA) | 100 |
| Eliana Janine de Paiva Soares | PhD | Fellowship | Research Assistant (LPCC_NRN 2025) | 100 |
| Elisabete Cristina Nunes Fernandes | PhD | External | Associate Researcher | 30 |
| Gilberto Isidouro Jacinto Raimundo | MSc | Fellowship | PhD Student / (FCT 2024.18463.PRT) | 30 |
| Inês de Almeida Neves | BSc | Student | MSc Student | 100 |
| José Alexandre Ribeiro de Castro Ferreira | PhD | Contract | Assistant Researcher (2023.14811.TENURE.005) | 100 |
| Leonardo Ferreira Matos | BSc | Student | MSc Student | 100 |
| Lisandra Gabriela Fernandes Cruz | BSc | Student | MSc Student | 100 |
| Lúcio José de Lara Santos | MD, PhD | Contract | Group Coordinator/ Oncological Surgeon | 30 |
| Luís Carlos Oliveira Lima | PhD | Contract | Assistant researcher (PI177-CI-IPOP-01-2023-HORIZON-ONCOSCREEN) | 100 |
| Luís Pedro Fernandes Afonso | MD, MSc | Contract | Pathologist | 20 |

| Name | Academic degree | Professional situation | Category/Position | Time % |
|---|---|---|---|---|
| Lícia Beatriz Alves Araújo | MSc | Student | MSc student | 100 |
| Mafalda Alves Ribeiro | BSc | Student | MSc Student | 100 |
| Mafalda Barbosa Pedrosa | MSc | Fellowship | PhD Student (FCT 2023.03444.BD) | 20 |
| Maria de Fátima Sousa e Santos | MD, MSc | Contract | Anaesthesiologist; PhD student | 20 |
| Maria do Céu dos Santos Silva Costa | PhD | External | Associate Researcher | 30 |
| Maria do Rosário Lima Viseu de Carvalho Pinto Leite | PhD | External | Associate Researcher | 30 |
| Maria João Barreira | BSc | Student | MSc Student | 100 |
| Maria João Nunes | BSc | Student | MSc Student | 100 |
| Mariana Gonçalves Eiras | MSc | Fellowship | PhD student (FCT 2024.04511.BD) | 70 |
| Mariana Macedo Alves Peyroteo Gomes | MD, MSc | Contract | Physician: Surgical oncology | 20 |
| Mariana Magalhães | MSc | Student | MSc Student | 100 |
| Mariana Pinto Sousa | MSC | Fellowship | PhD Student (FCT UI/BD/154816/2023) | 40 |
| Marta Filipa Relvas dos Santos | MSc | Student | PhD Student | 100 |
| Melissa João Vieira Borralho | BSc | Student | MSc student | 100 |
| Michelle Castanheira | MSc | Student | PhD student (FCT 2023.05159.BDANA) | 20 |
| Miguel González dos Santos | PhD | Contract | Higher Technician (PI177-CI-IPOP-01-2023-HORIZON-ONCOSCREEN_TS2) | 100 |
| Nuno Henrique Oliveira Jorge | MSc | Student | PhD student | 100 |
| Otília Lopes | DDS, PhD | External | Associate Researcher | 30 |
| Pamela Cristina Carvalho Borges | PhD | External | Afilliated Researcher | 20 |
| Pedro Carvalho Martins | MD, MSc | Contract | Physician: Surgical oncology | 20 |
| Pedro Miguel dos Reis Cruz | MD, MSc | Student | PhD Student | 30 |
| Rafael Carneiro Lopes | MSc | Student | PhD Student (FCT 2025.06649.BDANA) | 100 |
| Renato Manuel de Caldevilla Carvalho | MSc | Fellowship | Research Assistant (PI177-CI-IPOP-01-2023-HORIZON-ONCOSCREEN_BI4) | 100 |
| Roberto Miguel Pais Pinto | MSc | Student | PhD Student (FCT 2024.04316.BDANA) | 80 |
| Samuel da Silva Barbosa | MSc | Fellowship | PhD Student (2023.03394.BDANA) | 20 |
| Sara Francisca Ribeiro Freitas | BSc | Student | MSc Student | 100 |
| Sofia do Rosário Alves Pereira | PhD | External | Associate Researcher | 30 |
| Susana Sofia Macedo Loureiro | BSc | Student | MSc student | 100 |

### Group description and objectives

The Experimental Pathology & Therapeutics Group, established in 2008 as one of the research groups of the IPO PORTO FG EPE, is coordinated by Professor Lúcio Santos (MD, PhD), also the head of the surgical department of IPO Porto. The group comprises four senior researchers, one postdoc researcher, three research technicians, along with sixteen PhD and nine MSc students. Additionally, the team includes diverse experts such as a surgeon, pathologist, psychologist, immunologist, and four external invited researchers from other universities, bringing relevant expertise in animal models, pathology, physiology, and genetics.

Exploring frontiers in health, the group focuses its efforts across five fundamental areas: experimental pathology, neglected diseases, pre-clinical studies, translational medicine, and clinical research. It also provides a solid platform for training and higher education in cancer research. In line with this commitment, over the past five years, it has welcomed numerous graduate and post-graduate students from both national and international institutions, including those from African countries with Portuguese as the official language. This aligns with its mission to contribute to societal development. The group has also actively engaged in international networks with the aim of training the next generation of highly skilled European researchers. This commitment is exemplified by its participation in GlyCoCan consortium (2015-2019; DOI: 10.3030/676421), a Marie Curie European Training composed of 15 leading European partners in the fields of glycobiology, glyco-immunology and biomarker research. Furthermore, it plays leadership roles in various international competitive projects, including relevant multimillions EU funded project. This includes projects like "DC Matters – Combination of dendritic cell vaccine with immune checkpoint inhibitors as first-line therapy in patients with solid malignancies (NORTE-01-0247-FEDER-047212)" aimed to deliver disruptive vaccine based therapies for cancer. It also participates in the ONCOSCREEN (DOI:10.3030/101097036) project, involving a large 38-partners network ground-breaking set of technologies and methods for colorectal cancer screening.

The group is organized in four teams that collaborate closely, in an interactive manner, to deliver advances in healthcare:

The Experimental Pathology and Clinical Translation team, led by Prof. Lúcio Santos addresses the molecular complexities of cancer utilizing cutting-edge animal models and organoids. The primary objective is to establish the foundation for more precise and effective clinical interventions, thereby facilitating future clinical trials. The team places particular emphasis on investigating carcinogenesis induced by infectious agents and overlooked malignancies, reflecting a commitment to global equity. The main mission is to implement innovative approaches for diagnosing, treating, and preventing often neglected cancers. Additionally, the team focus on defining personalized risk mitigation programs in oncology. Its clinical dimension aims to translate relevant molecular findings into tangible clinical applications and healthcare advancements, namely through clinical trials. This integrated approach seamlessly connects research with clinical practice, ensuring the translation of research into direct socio-economic benefits through improved healthcare. As an example, the team has been actively engaged in enhancing the clinical approach for high-risk patients by offering safer and more patient-centered treatment options. To achieve this, the team plans to optimize surgical risk prediction through prospective validation of the IPOscore platform and implement prehabilitation programs before surgery. A randomized study funded by FCT (PTDC/SAU-DES/7945/2020) is comparing the efficacy of structured exercise prehabilitation *versus* non-structured exercise in reducing post-operative burden. The team intends to educate cancer care providers and patients about the benefits of prehabilitation and advocate for its incorporation as a standard of care. Additionally, they are actively involved in organizing a postgraduate course on perioperative care accredited by the University of Porto.

The Translational Glycooncology and Glycoengineering team led by Dr. José Alexandre Ferreira, has specialized in decoding cancer-associated protein glycosylation changes for early detection, prognosis, and personalized therapeutics. It crosses disciplinary frontiers between glycobiology, proteomics, oncology, immunology, and translational nanomedicine, elucidating the glycoproteome's role in cancer dissemination, identifying unforeseen targetable nodes, and establishing new paradigms for cancer treatment and prevention. The team is a trailblazer in cancer glyconeoantigen discovery, utilizing innovative glycoproteogenomics approaches to build knowledge banks for precision oncology. In recent years, the focus has also been on translating this knowledge into groundbreaking cancer vaccines, harnessing novel biomaterials and glycoengineering for cancer specificity and treatment efficacy. It provides a stimulating environment for high-standard postgraduate training, innovation, and entrepreneurship in glycooncology.

The Clinical Cancer Biomarkers team, led by Dr. Luis Lima, is devoted to biomarkers discovery and validation from a broad range of sources of biomarkers (DNA, mRNA, ncRNA, proteins) in liquid biopsies (blood, stools, saliva, urine), focusing on key clinical problems. One of the main goals is to determine the clinical relevance of circulating tumor cells (CTC) in gastrointestinal tumors using an innovative microfluidics device. Another major goal is to find a reliable set of biomarkers that could improve colorectal cancer screening, to do so we are focusing on biological samples such as stools and blood.

The Cancer Immunology team, led by Prof. Carlos Palmeira involves the issue of understanding and overcoming the resistance to immunotherapy with immune checkpoint inhibitors (ICIs). One of the objectives

is to evaluate new therapeutic synergies, using therapies that activate the immune system, such as phototherapy and Laser-induced thermotherapy (through the destruction of tumour cells and consequent release of tumour antigens) associated with ICIs, namely anti-PD1, anti-PDL1 and CTLA4. By using preclinical animal models, namely syngeneic models of poorly immunogenic, it has been possible to find experimental conditions that support the change to a more immunogenic tumor microenvironment that enhances the immune response. In addition, potential biomarkers associated with the immune system have been studied, with the aim of verifying patients' eligibility for therapy and monitoring immune responses by analyzing immune profiles. T and B lymphocytes subsets, natural killer (NK) cells, myeloid-derived suppressor cells, monocytes, dendritic cells, among others, have been evaluated in peripheral blood samples before and after ICIs, namely in patients with NSCLC, with the aim of finding an immunological fingerprint of the patient, called a peripheral "immunogram". For these projects, the group has obtained support from clinical trials ongoing in the institution, entities associated with the industry and grants from the Portuguese League Against Cancer.

The Experimental Pathology and Therapeutics group will devote the efforts of the next years to both basic and translational cancer research with the purpose of identifying biomarkers for early detection of the disease, prognosis, drug response and to guide therapeutic decision. Ultimately it will also focus on translating this knowledge into novel therapeutics.

## Active projects and funding

### Competitive Funding

#### International

- ONCOSCREEN - “A European “shield” against colorectal cancer based on novel, more precise and affordable risk-based screening methods and viable policy pathways” (101097036), Budget: IPO: 382.500€, Total: 13M€ (Co-PI: Luís Lima)

#### National

- CAR T-Matters - Shaping the future of CAR T-cell therapies in Portugal (FEDER, COMPETE2030-FEDER-01477200) Budget total: 1 482 725,60€ (2025) (Participants: José Alexandre Ferreira, Lucio Lara Santos, Andreia Peixoto)
- PROTECT- “Prehabilitation to enhance cancer treatment in patients with adenocarcinoma of the gastroesophageal junction and the stomach” (PTDC/SAU-DES/7945/2020), Budget: IPO-135,695.00€, Total-250K€ (2021) (PI: Lúcio Lara Santos).
- AFRICA- “Sub-Saharan panel of tumor lines: from patientderived cells to specialized population-based cancer treatment in African ancestry.” (PTDC/BIA-MOL/3986/2021), Budget: 25K€ (2021), (PI: Lúcio Lara Santos).
- RESOLVE- “Rational design of multivalent glycocode-inspired nanovaccine for gastric cancer immunotherapy” (PTDC/MED-OUT/2512/2021), Budget: 250K€ (2022) (PI:José Alexandre Ferreira).
- REVERENT - “PRE-CLINICAL VALIDATION OF A GLYCOCODE-INSPIRED VACCINE FOR BLADDER CANCER IMMUNOTHERAPY” (2022.03621.PTDC), Budget: 50K€, (PI: Andreia Peixoto; Co-PI: José Alexandre Ferreira)
- BioFaeC - “Novel faecal biomarkers for early detection of precancerous lesions and cancer - Improving the current model for colorectal cancer screening” (2022.09051.PTDC), Budget: 50K€, (Co-PI: Luís Lima)
- IDEAR – “Neoadjuvant Immunotherapy with Durvalumab (MEDI4736) in Non-Surgical Early Stage or Located Advanced Non-Small Cell Lung Cancer (NSCLC) followed by Radical Radiotherapy or Chemotherapy (Phase II, single arm, clinical trial)”. CI-IPOP, i3S e AstraZeneca, Budget: 50K€ (Co-PI: Lúcio Lara Santos)

### Internal

- OptimizingLiverMet - "Immunological and circulating tumour cells evaluation in colorectal cancer liver metastasis" (PI 77-CI-IPOP-47-2016), Budget: 38K € (2016) (PI: Lúcio Lara Santos; Co-PI: Luís Lima).
- GlycoBodies - "Development of monoclonal antibodies for chemoresistant bladder cancer based on glycobiomarkers" (CI-IPOP-58-2020), Budget: 28K€ (2020) (PI: Lúcio Lara Santos; Co-PI: José Alexandre Ferreira).
- TRANSPIRE – A Pragmatic Non-Randomized Trial of Prehabilitation for Cancer Surgery Preparation: Study Protocol for a Comparative Analysis of Delivery Modes (PI244-CI-IPOP-39-2025) Budget: 75K€ PI: Pedro Martins

### Major achievements

- **Ferreira D, Marinho-Santos B, Relvas-Santos M, Orr B, Brandão A, Afonso LP, Santos LL, Ferreira JA. Trimmed *N*-glycans define aggressive gastric cancer and predict clinical outcomes. Theranostics. 2025 Aug 22;15(18):9375-9398 https://pubmed.ncbi.nlm.nih.gov/41041068/ [IF: 13.3]**

This study provides the first comprehensive characterization of the N-glycome and glycoproteome of gastric cancer, identifying trimmed (paucimannosidic) N-glycans as robust markers of tumor aggressiveness and poor clinical outcome. Using integrated glycomics, glycoproteomics, tissue profiling, and large-scale TCGA validation, the work demonstrates that paucimannose enrichment increases with disease stage and outperforms established clinical biomarkers in prognostic accuracy. The study further links this glycosylation phenotype to dysregulated glycan-trimming enzymes and to aberrant modification of clinically relevant proteins such as MMP9, highlighting altered N-glycosylation as a key, previously underexplored driver of gastric cancer progression with clear translational relevance.

- **Santos D.A.R., Eiras, M., Gonzalez-Santos, M., Santos, M., Pereira, C., Santos, L.L., Dinis-Ribeiro, M., Lima, L. (2025). A preliminary assessment of a stool-based microRNA profile for early colorectal cancer screening. Scientific Reports, 15(1), 28597. https://pubmed.ncbi.nlm.nih.gov/40764826/ [IF: 3.9]**

Colorectal cancer screening methods are well established worldwide as a fundamental pilar in CRC management, namely through non-invasive faecal occult blood testing. However, the limited sensitivity of faecal occult blood test for detecting precancerous lesions highlights the need to search for alternative tools, such as microRNAs (miRs). The main aim of this study was to identify stool-based miR profiles for early colorectal cancer detection. A panel with miR-21-5p, miR-199a-5p, and age showed a moderate performance for colorectal cancer detection (sensitivity: 88%). Additionally, miR-451a, miR-21-5p, miR-199a-5p, age, and gender showed high performance for discriminating high-grade dysplasia lesions (sensitivity: 91%). Moreover, when we obtained a positive result in either panel, we achieved a sensitivity of 96% for high-grade dysplasia lesions identification. Finally, when a negative result was obtained in these panels after a positive faecal occult blood test result, we accurately identified individuals without lesions. These findings demonstrate the potential of miR panels as non-invasive biomarkers for colorectal cancer and high-grade dysplasia lesions detection and could constitute a secondary screening method following a positive faecal occult blood test.

### Scientific output

#### *a. Peer-reviewed indexed publications (final publication date in 2025)*

- Alves, A, Ferreira, M, **Eiras, M, Lima,** L, Medeiros, R, Teixeira, AL and Dias, F. *Exosome-derived hsa-miR-200c-3p, hsa-miR-25-3p and hsa-miR-301a-3p as potential biomarkers and therapeutic targets for restoration of PTEN expression in clear cell renal cell carcinoma.* Int J Biol Macromol. 2025;302: p. 140607. IF: 8.5

- Azevedo, C, Fonseca, AC, Barreto, JP, Pires, AM, Faria, C, Pinto, A, Sousa, ME**, Palmeira, C**, Prudêncio, C, Fernandes, B, Martins, G and Ferraz, R. *Evaluating the heavy/light chain immunoglobulin biomarker for early relapse detection in multiple myeloma: A comparative study with conventional methods.* Clinical Immunology Communications. 2025;8: p. 105–8. IF: NA
- Borges, P, Spencer, HB, Furtado, S, Costa, V, Barbosa, C and **Santos, LL**. *Breast cancer in Cape Verde: a 24-year retrospective study of clinical presentation, treatment and outcomes at Agostinho Neto University Hospital.* Ecancermedicalscience. 2025;19: p. 1826. IF: 1.3
- Branco, H, **Rodrigues, CA**, Oliveira, J, Mendes, N, Antunes, C, Amorim, I, **Santos, LL**, Vasconcelos, MH and Xavier, CPR. *Preclinical studies on the antitumor and non-toxic effect of combining pirfenidone with vinorelbine and carboplatin in non-small cell lung cancer.* Int J Cancer. 2025;156(9): p. 1756–69. IF: 4.7
- **Caldevilla, R, Eiras, M, Santos, DAR**, **Almeida, J**, Oliveira, B, Loureiro, S, Soares, J, Gonzalez-Santos, M, Ramos, N, Videira, PA, **Santos, LL**, Dinis-Ribeiro, M and **Lima, L**. *Advancing Non-Invasive Colorectal Cancer Screening: Exploring the Potential of Monoclonal Antibody L2A5.* Int J Mol Sci. 2025;26(7) IF: 4.9
- **Carneiro, A**, Aranda Palomer, M, Esteves, M, Rodrigues, C, Fernandes, JM, Oliveira, F, Teixeira, A, Honrado, C, Dieguez, L, Abalde-Cela, S and Xavier, M. *Advanced Microfluidics for Single Cell-Based Cancer Research.* Adv Sci (Weinh). 2025;12(41): p. e00975. IF:14.1
- **Cotton, S, Ferreira, D, Relvas-Santos, M,** Brandao, A, **Afonso, LP, Miranda, A, Ferreira, E, Santos, B, Goncalves, M,** Lopes, P**, Santos, LL**, Silva, AMN and **Ferreira, JA.** *E-selectin affinity glycoproteomics reveals neuroendocrine proteins and the secretin receptor as a poor-prognosis signature in colorectal cancer.* Mol Oncol. 2025;19(3): p. 635–58. IF:4.5
- **Cruz, P,** Lam, JM, Abdalla, J, Bell, S, Bytyci, J, Brosh-Nissimov, T, Gill, J, Haidar, G, Hoerger, M, Maor, Y, Pagliuca, A, Raffi, F, Samuels, F, Segev, D, Ying, Y, Lee, LYW and Global Immunocompromised Health, C. *Immunobridging Trials: An Important Tool to Protect Vulnerable and Immunocompromised Patients Against Evolving Pathogens.* Vaccines (Basel). 2024;13(1) IF:3.4
- Dos Santos, CS, Magalhaes, AC, Pinto, RJ, Carrilho, C, Pereira, C, Miguel, F, Borges, P, **Santos, LL** and Pereira, L. *Addressing Ancestral Underrepresentation in Oncobiology: The Need for Sub-Saharan African-Specific In Vitro Models.* Genes (Basel). 2025;16(12) IF: 2.8
- **Ferreira, D, Marinho-Santos, B, Relvas-Santos, M,** Orr, B, Brandao, A, Afonso, LP, **Santos, LL** and **Ferreira, JA.** *Trimmed N-glycans define aggressive gastric cancer and predict clinical outcomes.* Theranostics. 2025;15(18): p. 9375–98. IF:13.3
- Ferreira Pinto, P, **Peyroteo, M**, Baia, C, Marques, M, Cardoso, MJ, Videira, JF and Abreu de Sousa, J. *Early-Stage Colon Cancer Surveillance: Pattern and Timing of Recurrence and the Role of 5-Year Surveillance.* GE Port J Gastroenterol. 2025;32(2): p. 109–17. IF:0.6
- **Freitas, R, Peixoto, A, Santos, LL** and **Ferreira, JA.** *Glycan-based therapeutic approaches for bladder cancer: Overcoming clinical barriers.* Biochim Biophys Acta Rev Cancer. 2025;1880(3): p. 189327. IF: 8.3
- Juliao, I, Costa, T, Antunes, L, Almeida, P, Salamanca, P, Borges, H and **Santos, LL**. *Supporting the early development of decentralised oncology units in Portuguese-speaking African countries: initial results of the GONCO program in Angola and Cape Verde.* Ecancermedicalscience. 2025;19: p. 2050. IF:1.3
- Marques, M, **Martins, P**, Lencastre, L, Videira, F and de Sousa, JA. *Laparoscopic colorectal bypass for colorectal anastomosis stricture-A video vignette.* Colorectal Dis. 2025;27(12): p. e70351. IF:2.7
- Oliveira, MA, Almeida, SS, Martins, G, Godinho, I, **Palmeira, C**, Sousa, ME, Fernandes, L, Medeiros, R and Guerra, MP. *The Inflammatory Footprint of Anti-Breast Cancer Treatments and Psychosocial Factors in Women Undergoing Chemotherapy.* Biomedicines. 2025;13(10) IF: 3.9
- Peixoto, A, Ferreira, D, Miranda, A, Relvas-Santos, M, Freitas, R, Veth, TS, Brandao, A, Ferreira, E, Paulo, P, Cardoso, M, Gaiteiro, C, Cotton, S, Soares, J, Lima, L, Teixeira, F, Ferreira, R, Palmeira, C, Heck, AJR, Oliveira, MJ, Silva, AMN, Santos, LL and Ferreira, JA. *Multilevel plasticity and altered glycosylation drive aggressiveness in hypoxic and glucose-deprived bladder cancer cells.* iScience. 2025;28(2): p. 111758.
- **Peixoto, A, Ferreira, D, Miranda, A, Relvas-Santos, M, Freitas, R,** Veth, TS, Brandao, A**, Ferreira, E,** Paulo, P, Cardoso, M, **Gaiteiro, C, Cotton, S, Soares, J, Lima, L,** Teixeira, F, Ferreira, R, **Palmeira, C,**

Heck, AJR, Oliveira, MJ, Silva, AMN, **Santos, LL** and **Ferreira, JA.** *Multilevel plasticity and altered glycosylation drive aggressiveness in hypoxic and glucose-deprived bladder cancer cells.* iScience. 2025;28(2): p. 111758. IF:4.1

- Pelc, Z, Sedlak, K, Mlak, R, Endo, Y, Gockel, I, van Sandick, J, Baiocchi, GL, Wijnhoven, B, Gisbertz, S, Pera, M, Morgagni, P, Framarini, M, Hoelscher, A, Moenig, S, Kolodziejczyk, P, Piessen, G, Eveno, C, da Costa, PM, Baker, C, Davies, A, Allum, W, Romario, UF, Rosati, R, Reim, D, **Santos, LL**, D'Ugo, D, de Manzoni, G, Kielan, W, Schneider, P, Pawlik, TM, Polkowski, W and Rawicz-Pruszynski, K. *Impact of prognostic nutritional index on oncological outcomes and mortality among advanced gastric cancer patients: European GASTRODATA registry analysis.* Int J Cancer. 2025;157(8): p. 1734–45. IF:4.7
- **Pinto-Pinho, P**, Impens, F, Dufour, S, Van Haver, D, **Pinto-Leite, R**, Howl, J, Fardilha, M and Colaco, B. *The surface proteome of rabbit spermatozoa.* Anim Reprod Sci. 2025;276: p. 107834. IF:3.3
- **Pinto-Pinho, P**, Quelhas, J, Impens, F, Dufour, S, Van Haver, D, Lopes, G, Rocha, A, **Pinto-Leite, R,** Fardilha, M and Colaco, B. *The Surface Proteome of Bovine Unsexed and Sexed Spermatozoa.* Animals (Basel). 2025;15(4) IF: 2.7
- Pinto, RJ, **Ferreira, D**, Salamanca, P, Miguel, F, Borges, P, Barbosa, C, Costa, V, Lopes, C, **Santos, LL** and Pereira, L. *Coding and regulatory somatic profiling of triple-negative breast cancer in Sub-Saharan African patients.* Sci Rep. 2025;15(1): p. 10325. IF:3.9
- **Relvas-Santos, M, Ferreira, D,** Brandao, A, **Afonso, LP, Santos, LL**, Silva, AMN and **Ferreira, JA**. *Glycomics and Glycoproteomics Reveal Distinct Oligomannose Carriers Across Bladder Cancer Stages.* Int J Mol Sci. 2025;26(10) IF: 4.9
- **Santos, DAR, Eiras, M, Gonzalez-Santos, M,** Santos, M, Pereira, C, **Santos, LL,** Dinis-Ribeiro, M and **Lima, L.** *A preliminary assessment of a stool-based microRNA profile for early colorectal cancer screening.* Sci Rep. 2025;15(1): p. 28597. IF:3.9
- Sedlak, K, Kobialka, S, Pelc, Z, Endo, Y, Gockel, I, van Sandick, J, Baiocchi, GL, Wijnhoven, B, Gisbertz, S, Pera, M, Morgagni, P, Framarini, M, Hoelscher, A, Moenig, S, Kolodziejczyk, P, Piessen, G, Eveno, C, da Costa, PM, Davies, A, Allum, W, Romario, UF, Rosati, R, Reim, D, **Santos, LL**, D'Ugo, D, De Manzoni, G, Kielan, W, Schneider, PM, Pawlik, TM, Polkowski, W and Rawicz-Pruszynski, K. *Staging Laparoscopy in Gastric Cancer Patients Treated with Curative Intent: A European GASTRODATA Cohort Study.* Ann Surg Oncol. 2025;32(10): p. 7615–26. IF:3.5
- Selemane, C, **Ferreira, D,** Veiga, I, Rocha, P, Jamisse, L, Buane, L, Guisseve, A, Carrilho, C, Ismail, M, Teixeira, MR and **Santos, LL**. *Molecular characterisation of Mozambican patients diagnosed with colorectal adenocarcinoma.* J Gastrointest Oncol. 2025;16(3): p. 1025–37. IF:2.0
- **Sousa, MP,** Monjardino, T, Santos, CC, **Lara, L** and Bento, MJ. *Completeness Evaluation of Adult-Population-Based Cancer Registries: A Systematic Review.* Cancers (Basel). 2025;17(7) IF: 4.4
- **Sousa, MP**, Pereira, AC, Correia, B, do Carmo, A, Matos, AM, Cruz, MT and Moreira, FTC. *Cellulose-Based Colorimetric Test Strips for SARS-CoV-2 Antibody Detection.* Biosensors (Basel). 2025;15(6) IF:5.6

### *b. Other outputs*

#### *Book Chapters*

- **Relvas-Santos, M.**; Silva, A. M. N.; **Ferreira, J. A.** in Carbohydrate Chemistry Chemical and Biological Approaches Volume 47, ed. A. Pilar Rauter, Y. Queneau, and A. S. Palma, Royal Society of Chemistry, 2025, pp. 201-247.

#### *Oral Communications by Invitation*

- **Soares J.** (2025) Bioinformatics approaches applied to cancer research. XI Reuniões Científicas em Farmácia. (March) Virtual.
- **Lima, L.** (2025) Strategies for Discovery and Validation: Colorectal Cancer Screening as an Example [Estratégias para a descoberta e validação: o rastreio de cancro colorretal com exemplo]. Conferences on Oncobiology. (March).

- **Miranda A.** (2025) Interrogating the gastric cancer glycoproteome and the immune landscape towards cancer neoantigens and immune checkpoints. Translational Immunology Meeting. (March 10) Amsterdam, The Netherlands.
- **Ferreira JA.** Glycoengineered Cells and GlycoAvatars: Unraveling the Glycocalyx and Cancer-Immune Cell Interactome for New Therapeutic Strategies. IMMUNOmodel COST ACTION Third Annual Conference: Modeling Immunotherapy for Cancer – Bridging Research to Clinical Application. (May 14-15) Warsaw, Poland.
- **Ferreira JA.** Turning the glycocalyx into cancer vaccines: From biomarker discovery, preclinical models and validation. XIX Congress of the Iberian Society of Cytometry. (May 16) Porto, Portugal.
- **Ferreira JA.** Harnessing the Cancer Glycocode for Safe and Effective Cancer Vaccines. Hot Topics in Immune Checkpoint Inhibitors' Toxicities. (September 26) Porto, Portuga
- **Ferreira JA.** Glycoproteome mapping of the cancer glycocode: From Biomarker Discovery to Precision Oncology. Workshop EATRIS- Biomarkers in preclinical and early clinical development: challenges and Health Innovation. (October 9) Covilhã, Portugal.
- **Lima, L.** (2025) Cancer Screening: Research. [Rastreios na Luta contra o Cancro: Investigação]. 6th National Congress on Cancer Prevention and Patients' Rights . (November).
- **Ferreira JA.** Mapping the Tumour Glycocalyx through Glycoproteomics for Precision Oncology. 22nd National Oncology Congress (CNO) of the Portuguese Society for Oncology. (November 27) Braga, Portugal.
- **Lima, L.** (2025) Translating Transcriptomics into clinical impact: RNA biomarkers for colorectal cancer detection. Multiomics for Systems Oncology. (December).

### *Oral Communications in International Scientific Meetings*

- **Relvas-Santos, M.**; Ferreira, D.; Peixoto, A.; Azevedo, R.; Freitas, R.; Miranda, A.; Afonso, L. P.; Santos, L. L.; Silva, A. M. N.; Ferreira, J. A. (2025) Glycoengineered Cells and Targeted O-Glycoproteomics for Immunogenic Glycopeptides Discovery in Bladder Cancer. Gordon Research Seminar on Glycobiology (23rd March); Lucca, Italy.
- **Miranda A**, Ibáñez-Molero S, Garcia-Vallejo J, Lara-Santos, Ferreira A, van Kook Y. Deciphering advanced gastric cancer glycoproteome and immune landscape towards cancer neoantigens and novel immune checkpoints. Annual PhD Symposium (27-28th march 2025), Leiden, The Netherlands.
- Soares J, Ferreira D, Gonçalves M, Miranda A, Relvas-Santos M, Brandão A, Paulo P, Cotton S, Freitas R, Magalhães M, Ferreira E, Marinho-Santos B, Afonso LP, Silva AMN, Palmeira C, Amado F, **Peixoto A**, Santos LL, Ferreira JA. (2025) CD276 immature glycosylation drives colorectal cancer aggressiveness and T-cell-mediated immune escape. IMMUNO-model Workshop: Harmonizing in vivo models of immunotherapy, past, present and future directions of WG (7th April); Bergen, Norway.

### *Oral Communications in National Scientific Meetings*

- **Pedrosa, M.**, Barbosa, S., Jorge, N., Aires, I., Antunes, J., Castro, C., Cabral, S., Almeida, S., Romano, O., Fonseca, S., Teixeira, F. G., Braga, S. P., Martins, P. C., Ferreira, R., Moreira-Gonçalves, D., Santos, L. L. (2025). The Effect of Exercise Versus Physical Activity on Body Composition and Musculoskeletal Function in Patients with Gastric Cancer Undergoing Neoadjuvant Chemotherapy with FLOT [Efeito do exercício físico versus atividade física na composição corporal e músculo-esquelética em doentes com cancro gástrico submetidos a quimioterapia neoadjuvante com FLOT]. *XIII Perspectives in Oncology.* (20th February); Porto, Portugal.
- **Barbosa, S.**, Aires, I., Pedrosa, M., Antunes, J., Castro, C., Jorge, N., Cabral, S., Almeida, S., Romano, O., Fonseca, S., Teixeira, F. G., Martins, P. C., Ferreira, R., Moreira-Gonçalves, D., Santos, L. L. (2025). Impact of pre-rehabilitation on adipose tissue in patients with gastric cancer during chemotherapy [Impacto da pré-habilitação no tecido adiposo de doentes com cancro gástrico durante a quimioterapia]. *XIII Perspectives in Oncology.* (20th February); Porto, Portugal.
- **Peixoto, A.** (2025). IPO Porto Research Center Pathology and Experimental Therapeutics Group [Grupo de Patologia e Terapêutica Experimental do CI-IPOP]. *X Biochemistry Conference: The Biochemist of the Future: Unveiling Tomorrow.* (4th April); Porto, Portugal.

- **Soares, J.** (2025) Integrative Analysis of Non-Coding RNA Reveals Biomarkers for the Detection of Precancerous and Cancerous Lesions in Colorectal Cancer [Análise Integrativa de RNA não codificantes revela Biomarcadores para a deteção de lesões pré-cancerígenas e cancerígenas em cancro Colorectal]. *ENJIO* (24th September); Porto, Portugal.
- **Barbosa, S.**, Pedrosa, M., Moreira-Gonçalves, D., Santos, L. L. (2025). Admission criteria for the intermediate care surgical unit following elective abdominal cancer surgery [Critérios de admissão na unidade cirúrgica de cuidados intermédios após cirurgia abdominal eletiva oncológica]. *21st National Congress on Gastrointestinal Cancer.* (1st October); Figueira da Foz, Portugal.
- **Caldevilla, R.** (2025) Pitch Presentation: Proteomic and Glycomic Profiling for Non-Invasive Disease Biomarker Discovery: Colorectal Cancer as an example. *3rd Young Researchers Day*. (22nd October); Porto, Portugal.
- **Eiras, M.**, A.R. Santos, D., Gonzalez-Santos, M., Soares, J., Lara-Santos, L., Dinis Ribeiro, M., Pereira, C., Brandão, A., Lima, L. (2025). Looking beyond DEGs: Hidden Small RNAs as Candidate Markers for Early Colorectal Cancer Detection. *3rd Young Researchers Day*. (22nd October); Porto, Portugal.
- **Ferreira, D.**, Santos B., Fernandes E., Gonçalves M., Ferreira E., Diéguez L., Afonso LP., Peixoto A., Santos LL., Ferreira JA. Prognostic sialoglycan signature in gastric cancer reveals CEACAM5 as a potential tumor-specific glycoprotein marker. *3rd Young Researchers Day*. (22nd October); Porto, Portugal.
- **Miranda A**, Ibáñez-Molero S, Ferreira D, Clayton G, Garcia-Vallejo J, Lara-Santos, Ferreira A, van Kook Y. Multi-Omics Analysis of Advanced Gastric Tumors to Identify Neoantigens and Novel Immune Checkpoints. *3rd Young Researchers Day*, Porto, Portugal (22nd October).
- **Peixoto, A.**, Ferreira, D., Miranda, A., Relvas-Santos, M., Freitas, R., Veth, T. S., Brandão, A., Ferreira, E., Paulo, P., Cardoso, M., Gaiteiro, C., Cotton, S., Soares, J., Lima, L., Teixeira, F., Ferreira, R., Palmeira, C., Heck, A. J. R., Oliveira, M. J., Silva, A. M. N., Ferreira, J. A. (2025). Multilevel plasticity and altered glycosylation drive aggressiveness in hypoxic and glucose-deprived bladder cancer cells. *3rd Young Researchers Day*. (22nd October); Porto, Portugal.

### *Posters in international conferences*

- **Relvas-Santos, M.**; Ferreira, D.; Peixoto, A.; Azevedo, R.; Freitas, R.; Miranda, A.; Afonso, L. P.; Santos, L. L.; Silva, A. M. N.; Ferreira, J. A. (2025) Glycoengineered Cells and Targeted O-Glycoproteomics for Immunogenic Glycopeptides Discovery in Bladder Cancer. *Gordon Research Seminar on Glycobiology* (22nd-23rd March); Lucca, Italy.
- **Relvas-Santos, M.**; Ferreira, D.; Peixoto, A.; Azevedo, R.; Freitas, R.; Miranda, A.; Afonso, L. P.; Santos, L. L.; Silva, A. M. N.; Ferreira, J. A. (2025) Glycoengineered Cells and Targeted O-Glycoproteomics for Immunogenic Glycopeptides Discovery in Bladder Cancer. *Gordon Research Conference on Glycobiology* (23rd -28th March); Lucca, Italy.
- **Soares J**, Ferreira D, Gonçalves M, Miranda A, Relvas-Santos M, Brandão A, Paulo P, Cotton S, Freitas R, Magalhães M, Ferreira E, Marinho-Santos B, Afonso LP, Silva AMN, Palmeira C, Amado F, Peixoto A, Santos LL, Ferreira JA. (2025) CD276 immature glycosylation drives colorectal cancer aggressiveness and T-cell-mediated immune escape. *SIC2025: Congress of the Iberian Society of Cytometry* (14th May); Porto, Portugal.
- **Miranda A**, Ibáñez-Molero S, Garcia-Vallejo J, Lara-Santos, Ferreira A, van Kook Y. Deciphering advanced gastric cancer glycoproteome and immune landscape towards cancer neoantigens and novel immune checkpoints. *AI&I 8th Annual Symposium Explores the Future of Medicine* (22nd may 2025), Amsterdam, The Netherlands.
- **Eiras, M.**, Pinto, D., Santos, D.A.R., Soares, J., Gonzalez-Santos, M., Dinis-Ribeiro, M., Lima, L. (2025) Novel Blood-Based mRNA Biomarkers: A Promising Approach for Non-Invasive Colorectal Cancer Screening. *EACR 2025*, Lisbon, Portugal.
- **Santos, D.A.R.**, Santos, L.L., Vieira, C., Dinis-Ribeiro, M., Lima, L. (2025) The Small Solution for a Big Problem: Can MicroRNAs Predict Treatment Outcomes in Colorectal Cancer Patients?. *UEG Week 2025*, Berlin, Germany.

- **Santos, D.A.R.**, Loureiro, S., Eira, M., Caldevilla, R., Santos, L.L., Dinis-Ribeiro, M., Lima, L. (2025) Circulating MicroRNAs and Their Potential for Improve the Early Colorectal Cancer Screening. *UEG Week 2025*, Berlin, Germany.

### *Posters in national conferences*

- **Loureiro, S.**, Santos, D.A.R., Caldevilla, R., Eiras, M., Soares, J., Gonzalez-Santos, M., Dinis-Ribeiro, M., Lima, L. (2025) Plasma microRNA profiles enhance the detection of colorectal lesions [Perfis de microRNAs plasmáticos potenciam a deteção de lesões colorretais]. 7th National Meeting of Young Researchers in Oncology, (24th September), Porto, Portugal.
- **Barreira, M. J.**, Nunes M., Ferreira, E., Borralho M., Peixoto, A., Miranda A., Ferreira D., Marinho B., Freitas R., Sarmento B., Oliveira, M.J., Palmeira C., Silva, A. M. N., Santos, L. L., Ferreira J. A. 2025 Optimizing polysaccharide hydrogels for enhanced immunogenic delivery of cancer vaccines. *3rd Young Researchers' Day*. (22nd October); Porto, Portugal.
- **Ferreira, E.**, Freitas, R., Miranda, A., Ferreira, D., Barreira, M. J., Nunes, M. J., Palmeira, C., Oliveira, M. J., Sarmento, B., Peixoto, A., Silva, A. M. N., Santos, L. L., & Ferreira, J. A. 2025. Engineering PLGA nanoparticles for aggregation control and supramolecular adjuvant delivery in glycovaccine formulations. *3rd Young Researchers' Day*. (22nd October); Porto, Portugal.
- **Nunes M.**, Barreira, M. J., Ferreira, E., Borralho M., Peixoto, A., Miranda A., Ferreira D., Marinho B., Freitas R., Sarmento B., Oliveira, M.J., Palmeira C., Silva, A. M. N., Santos, L. L., Ferreira J. A. 2025 Thermosensitive Pluronic/Chitosan hydrogels for smart cancer glycovaccines delivery. *3rd Young Researchers' Day*. (22nd October); Porto, Portugal.
- **Santos, D.A.R.**, Santos, L.L., Vieira, C., Dinis-Ribeiro, M., Lima, L. (2025) MicroRNAS as Predictive Biomarkers of Therapeutic Response in Colorectal Cancer: A Systematic Review and Study Design. *3rd Young Researchers' Day* (22nd October); Porto, Portugal.

### *Editorial Board Positions*

| Journal | Publishing Group | Position | Researcher |
|---|---|---|---|
| Journal of Cancer Metastasis and Treatment | OAE Publishing Inc. | Editorial board | Lúcio Lara Santos |
| Revista Portuguesa de Cirurgia | SPC | Chief editor | Lúcio Lara Santos |
| ecancermedicalscience | ecancer | Editorial board | Lúcio Lara Santos |
| International Journal of Molecular Sciences | MDPI | Guest Editor | Luís Lima |

### *Peer Review*

Advanced Science; Biochimica et Biophysica Acta - Molecular Basis of Disease; Biomedicines; BMC Gastroenterology (Springer Nature); Cancer Communications; Cancers; Carbohydrate Polymers; Cell Communication and Signaling journal; Discover Oncology (Springer Nature); Discovery Medicine (Springer Nature); Heliyon; Journal of Clinical Medicine; Journal of Integrative Medicine (Elsivier); Nature Chemical Biology; Nature Communications; Scientific Reports (Springer Nature); Theranostics

### *Grant Reviewer*

| Agency | Call | Country | Date | Researcher |
|---|---|---|---|---|
| Croatian Science Foundation | Installation Research Projects | Croatia | 2025 | José Alexandre Ferreira |
| European Research Executive Agency (REA) | HORIZON MSCA Postdoctoral Fellowships | Belgium | 2025 | José Alexandre Ferreira |
| European Health and Digital Executive Agency (HaDEA) | HORIZON-HLTH-2025-03-IND-03-two-stage | Belgium | 2025 | José Alexandre Ferreira |
| European Research Executive Agency (REA) | HORIZON-EIC-2025-PATHFINDEROPEN | Belgium | 2025 | José Alexandre Ferreira |

| Agency | Call | Country | Date | Researcher |
|---|---|---|---|---|

### Participation as Opponent in MSc Evaluation Committees

| Student | Title | Program | Researcher |
|---|---|---|---|
| Joana Beatriz Dias Nunes | Anticancer Potential of Compounds from a Brazilian Native Plant Against the Most Relevant Cancers in Portugal | Biochemistry in health (E2S-IPP) | Luís Lima |
| Bárbara Alexandra Campos Ferreira | Development of Stratified 3D Models of the Pancreatic Ductal Adenocarcinoma Immunosuppressive Microenvironment | University of Aveiro | José Alexandre Ferreira |

### Teaching Activity: Coordination of Curricular Units/Courses

| Member | Curricular Units | Programme | Position | Faculty/University |
|---|---|---|---|---|
| Lúcio Lara Santos | Clinical Anatomy | Integrated MSc in Medicine | Coordination and teaching | ICBAS; Porto University |
| Lúcio Lara Santos | Oncology | Integrated MSc in Dental Medicine | Coordination and teaching | Faculty of Health; Fernando Pessoa University |
| Lúcio Lara Santos | Pathological Anatomy | Integrated MSc in Dental Medicine | Coordination and teaching | Faculty of Health; Fernando Pessoa University |
| Lúcio Lara Santos | Medical Specialities II | Integrated MSc in Dental Medicine | Coordination and teaching | Faculty of Health; Fernando Pessoa University |
| Lúcio Lara Santos | Integrated Clinic for Special Patients | Integrated MSc in Dental Medicine | Teaching | Faculty of Health; Fernando Pessoa University |
| Lúcio Lara Santos | General Pathology | Integrated MSc in Dental Medicine | Teaching | Faculty of Health; Fernando Pessoa University |
| Carlos Palmeira | Pathological Anatomy | Integrated MSc in Dental Medicine | Coordination and teaching | Faculty of Health; Fernando Pessoa University |
| Carlos Palmeira | Medical Informatics in the Presentation and Analysis of Laboratory Data | Higher Technical Professional Course | Teaching | Health School; Fernando Pessoa |
| Carlos Palmeira | Support Techniques in Precision Medicine | Biomedical Laboratory Science | Teaching | Health School; Fernando Pessoa |
| Carlos Palmeira | Medical Specialities II | Integrated MSc in Dental Medicine | Teaching | Faculty of Health; Fernando Pessoa University |
| Carlos Palmeira | Molecules, Cells and Disease I | Integrated MSc in medicine | Coordination and teaching | Medical School and Biomedical Sciences Fernando Pessoa |
| Luís Lima | Molecules, Cells and Disease I | Integrated MSc in medicine | Teaching | Medical School and Biomedical Sciences Fernando Pessoa |
| José Alexandre Ferreira | Molecules, Cells and Disease I | Integrated MSc in medicine | Teaching | Medical School and Biomedical Sciences Fernando Pessoa |
| Luís Lima | Research Practices in Oncology | MSc in Oncology | Teaching | ICBAS; University of Porto |
| José Alexandre Ferreira | Research Practices in Oncology | MSc in Oncology | Teaching | ICBAS; University of Porto |

| Member | Curricular Units | Programme | Position | Faculty/University |
|---|---|---|---|---|
| José Alexandre Ferreira | Research Methodology in Oncology | Continuing Education Course | Teaching | ICBAS, University of Porto |
| Lúcio Lara Santos | Clinical Procedures and Practices III | Integrated MSc in medicine | Coordination and teaching | Medical School and Biomedical Sciences Fernando Pessoa |

### *Prizes, Honors and Awards*

| Researcher | Prize designation | Institution | Date | Amount |
|---|---|---|---|---|
| Andreia Peixoto | Honorable mention for oral presentation | IPO Porto Research Center | October 2025 | N/A |
| Andreia Peixoto | OECI travel grant | Organization of European Cancer Institutes - OECI | October 2025 | N/A (travel and accommodation expenses) |
| Andreia Peixoto | IMMUNO-model Cost Action Travel Grant | Bergen University | April 2025 | N/A (travel and accommodation expenses) |
| Daniela Santos | Honorable mention for poster presentation | IPO Porto Research Center | October 2025 | N/A |
| Andreia Miranda | Honorable mention for oral presentation | IPO Porto Research Center | October 2025 | N/A |
| Eduardo Ferreira | Best poster presentation | IPO Porto Research Center | October 2025 | N/A |

### *Scientific Appointments*

| Organization | Researcher |
|---|---|
| Scientific Organizer and Instructor, Pre-Congress Course 03 at the XIX Congress of the Iberian Society of Cytometry (May 2025) | Andreia Miranda |
| Board member of IARC (Representative of Portugal) | Lúcio Lara Santos |
| PROCURA OMICS - Portuguese Association of Proteomics (Board of Directors) | José Alexandre Ferreira |

### National collaborations

| Title | Researchers | Collaborators | Funding | Period |
|---|---|---|---|---|
| NextGenGlycoVacs: Next generation glycovaccines for immunologically cold tumours | Andreia Peixoto | Maria José Oliveira (I3s) | FCT 2023.06366.CEECIND | 2024-2030 |
| RESOLVE | José Alexandre Ferreira | Maria José Oliveira e Bruno Sarmento (I3s), Francisco Amado (UA), Andre Silva (REQUIMTE) | | 2021-2025 |
| Glycoproteogenomics Characterization in Colorectal Cancer using Deep Learning Approaches | José Alexandre Ferreira | Daniel Mateus Gonçalves IST), Rui Henriques (IST), Rafael Costa (FCT-UNL) | 2022.12633.BD | 2022-2026 |
| Challenging invasive fungal infections: Development of innovative electrochemical nanogenosensors to detect Aspergillus spp, Candida spp, and Zygomycetes. Phd project: Michelle Castanheira | Luís Lima | Fátima Barroso (REQUIMTE/LAQV-ISEP), Marlene Santos (ESS-IPP) | 2023.05159.BDANA | 2023-2027 |
| Understanding and overcoming immunotherapy resistance: a step toward response biomarkers and novel combinatory approaches; PhD Project: Catarina A. Rodrigues | Lúcio Lara Santos Carlos Palmeira | Cristina Xavier, M. Helena Vasconcelos (i3S) | FCT: UI/BD/153103/2022 | 2022-2026 |
| REVERENT: Pre-clinical Validation of a Glycocode-inspired Vaccine for Bladder Cancer | Andreia Peixoto | Maria José Oliveira (I3s)<br>Flávia Castro (I3s) | 2022.03621.PTDC | 2023-2025 |
| Introducing molecular analysis of Circulating Tumour Cells in the clinic: Their significance in clonal evolution and immune escape in gastrointestinal cancers; PhD Project: Adriana Carneiro | Luís Lima | Lorena Dieguez (Medical Devices Group) INL | FCT: 2021.05593.BD | 2022-2025 |

### International collaborations

| Title | Researchers | International Team | Institution | Country | Funding |
|---|---|---|---|---|---|
| Interrogating the Gastric Cancer Glycoproteome Towards Cancer Neoantigens and Novel Immune Checkpoints | José Alexandre Ferreira<br>Lúcio Lara Santos<br>Andreia Miranda | Yvette van Kooyk | Amsterdam University Medical Center | The Netherlands | FCT: 2022.12980. BD |
| SweetEScape: Tumour Microenvironment and Aberrant Glycosylation: A partnership driving immune escape | Andreia Peixoto, José Alexandre Ferreira, Andreia Miranda | Hérve Luche<br>Magali Grange | CIPHE: Immunophenomique Center from Inserm (US012), the CNRS (UMS3367) and Aix Marseille University (AMU). | France | CIPHE institutional funding |
| Glycoproteogenomics discovery of neoantigens towards multi-antigen-targeted T-cell immunotherapy for pancreatic cancer<br>PhD project; Beatriz Marinho | José Alexandre Ferreira<br>Beatriz Marinho | Noortje de Haan<br>Juan Lasarte | Center for Proteomics and Metabolomics (CPM-LUMC)<br>CIMA at University of Navarra | The Netherlands<br>Spain | FCT - 2024.00895. BD |
| CV-POC- Cape Verde Personalized Oncology Care | Lúcio Lara Santos | PI – Pamela Borges | HUAN | Cape Verde | F. Calouste Gulbenkian e Fundação La Caja |
| Molecular Biology Laboratory Implementation at Agostinho Neto Hospital, Cape Verde - Breast Cancer Diagnosis and Research | Lucio Lara Santos | Pi- Pamela Borges | HUAN | Cape Verde | F. Calouste Gulbenkian |

### International Consortia

| Organization | Researcher |
|---|---|
| ONCOSCREEN European consortium | Luís Lima, Lúcio Lara Santos |
| CARE4UTI European consortium, WP leader | Luís Lima |
| RADIANT European consortium | Luís Lima |
| Member of IMMUNO-model Cost Action (CA21135) | Andreia Peixoto |

## MEDICAL PHYSICS, RADIOBIOLOGY & RADIATION PROTECTION GROUP

### Coordinator

João Santos, PhD

### Research team @31 December 2025

| Name | Academic degree | Professional situation | Category/position | Time % |
|---|---|---|---|---|
| Alexandre Baptista Mendes Pereira | BSc | Contract | Medical Physicist | 20 |
| Ana Catarina Santos Souto | MSc | Contract | Medical Physicist | 30 |
| Anabela Gregório Dias | PhD | Contract | Medical Physicist | 30 |
| António Luís Soares | BSc | Contract | Medical Physicist | |
| Bárbara Adélia Meireles Barbosa | MSc | Contract | Radiotherapy Tehcnician, PhD student | 20 |
| Carla Isabel Vaz Tavares Figueiredo Capelo | BSc | Contract | Oncology pharmacist | 20 |
| Diana Jorge Pimparel Alves Nuno Pinto | BSc | Contract | Medical Physicist | 20 |
| Diana Lopes Silva | MSc | Contract | Medical Physicist | 100 |
| Filipe Augusto Madeira Dias | MSc | Contract | Medical Physicist | 20 |
| Inês Campos Monteiro Sabino Domingues | PhD | External | Associate Researcher | 20 |
| Inês Magalhães da Silva de Lucena e Sampaio | MD, BSc | Contract | Physician in Nuclear Medicine | 20 |
| Isabel Maria Guedes Bravo | PhD | Contract | Assistant Researcher, Radiobiologist | 100 |
| Joana Borges Lencart e Silva | BSc | Contract | Medical Physicist | 20 |
| João António Miranda dos Santos | PhD | Contract | Medical Physicist/ Group Coordinator | 30 |
| José Mesquita | BSc | Student | MSc student | 100 |
| Luís Hugo da Silva Trindade Duarte | MD, BSc | Contract | Physician in Nuclear Medicine | 20 |
| Luís Paulo Teixeira Cunha | MSc | Contract | Medical Physicist | 20 |
| Maria Alice Ramos Machado de Oliveira | BSc | Student | MSc Student | 100 |
| Maria Celina Ribeiro Lourenço | MSc | Contract | Medical Physicist | 20 |
| Olga Maria Teixeira de Sousa de Sá Pinto | MD, BSc | Contract | Radioncologist | 10 |
| Pedro Filipe Conde Andrade Silva | MSc | Contract | Radiotherapy Tehcnician | 20 |
| Pedro Peixoto Teles | PhD | External | Associate Researcher | 50 |
| Rafaela Rodrigues Carvalhais | BSc | Student | MSc Student | 100 |
| Rita Correia da Silva Alçada Albergueiro | BSc | Student | MSc Student | 50 |
| Rogéria Maria Craveiro Pereira | MSc | Contract | Radiobiologist | 20 |
| Sara Filipa Coelho Guerreiro | MSc | Student | PhD student | 20 |
| Sara Patrícia de Almeida Pinto | MSc | Contract | Medical Physicist | 20 |
| Sofia Isabel de Castro e Silva | PhD | Contract | Medical Physicist | 30 |
| Susana Margarida Oliveira Gonçalves | MSc | Contract | Radiotherapy Tehcnician | 20 |
| Vera Catarina Marques Antunes | MSc | Contract | Medical Physicist | 20 |

## Group description and objectives

The Medical Physics, Radiobiology & Radiation Protection Group was formed in the beginning of 2008 housed by the IPO Porto Research Center. Its members are mainly physicists and radiobiologists but also include other expertises such as radiopharmacy and clinical practitioners. It is the only Medical Physics and Radiobiology research group in Portugal whose activities are developed entirely in a hospital environment. The work of the group focuses on the application of the methodology of physics and radiobiology to solve specific problems related to health care, especially in the area of ionizing radiation, both from the perspective of the patient procedures optimization or in the perspective of the protection in the event of professional exposure to ionizing radiation. Being focused in the interaction of ionizing radiation and biological tissues, the question of radiation protection arises immediately. The group embraced already critical personal exposure due to highly heterogeneous radiation fields during the project "Dose distribution mapping and Monte Carlo simulations in CT-fluoroscopy" (PTDC/SAU-ENB/115792/2009) and patient exposure during intra-operatory radiotherapy during the project "IORT: the effect of shielding on dose distributions in intra-operative electron radiotherapy: a Monte Carlo simulations study." (PTDC/SAU-ENB/117631/2010). Both these studies were complemented by Monte Carlo (MC) simulations. This methodology, with increasing computer power over the last years, is becoming a benchmark method to simulate "difficult-to-execute-in-practice" procedures in ionizing radiation physics, where exposure of subjects must be very well justified. Over the year of 2017, the group extended this methodology to external radiotherapy using Penelope based PRIMO software, which has become one of the main strategic lines of research. Monte Carlo methods are being used also in the field of Nuclear Medicine, both for imaging and radiation spectrum analysis and optimization.

The group is involved in several national and international collaborations such as Faculdade de Ciências da Universidade do Porto, Instituto de Ciências Biomédicas Abel Salazar da Universidade do Porto, Instituto Superior Técnico (IST/CTN), INESC Porto, Universidade de Aveiro (Dep. Eng. Mecânica), Universidade de Coimbra (Centro de Informática e Sistemas da Universidade de Coimbra; LIP), Faculdade de Ciências da Universidade de Lisboa, Universidade do Minho (MEMS), Institute of Nuclear Physics PAN, Radzikowskiego 152, PL 31-342 Krakow, Radiation Chemistry and Dosimetry Laboratory, Bijenička c. 54, HR-10000 Zagreb, Croatia, Greek Atomic Energy Commission (EEAE), Dosimetry and Calibration Department P.O. Box 60092, 153 10 Agia Paraskevi, Athens, Greece, SCK•CEN | Belgian Nuclear Research Centre, Unit Research in Dosimetric Applications, Boeretang 200 - BE-2400 Mol, among others.

The group has two Full Members (J.A.M. Santos and P.P. Teles) in the European Radiation Dosimetry Group (Eurados), and two Associated Members (J. Lencart and A.G. Dias), in the Workgroup 9, WG9 (Radiation Protection in Radiotherapy).

## Active projects and funding

### Competitive Funding

#### International

- 2025-1-MT01-KA20-HRD-0003566020 – Optimize RT – "Education program to OPTIMIZE imaging doses in Radiotherapy CBCTs". (Erasmus$^{+}$) Budget: 35 613,00€ (2025-2028) (Project Coodinator: Guilherme Couto, Univ. Malta)
- 2019-2022 Manager for work package (WP7) - digital skills for SAFE EUROPE- Safe and Free Exchange of EU Radiography Professionals across Europe- project under the Erasmus+ Sector Skill Alliances programme

National

- Radio4Breast – "Mapping the potential of human breast-on-a-chip models for personalized radiation therapy". (FCT) Budget: 48 470,40€ (2025-2028) (Co-PI: Anabela Dias in collaboratoion with CMES, Minho).
- BeMIC-on-chip- "Bioengineering an ex vivo microenvironment of triple-negative breast cancer on-chip: a new tool to uncover new avenues for therapeutic intervention". (FCT) Budget: 25 056,00€ (Co-PI: Anabela Dias in collaboration with i3S)

**Internal**

- DOSAU-RT – "Desenvolvimento de metodologia e implementação de um programa de auditorias dosimétricas em Radioterapia". (PI222-CI-IPOP-75-2024) Budget: 47 000.00€ (PI: Anabel Dias/Co-PI: Catarina Souto)
- TBI-VMAT- "Implementation of total body irradiation using volumetric modulated arc therapy as part of an institutional hemotopoietic stem cell transplantation program". (PI2023-CI-IPOP-39-2023) Budget: 20 000.00 (PI: Anabela Dias/Co-PI: Susana Gonçalves)
- TIPTOP – "Artificial intelligence applied to image based oncological prognosis" (PI-145-CI-IPOP-133-2020), (2020)
- Obra3HT - "Optimizing Breast Cancer treatment planning workflow: from 3DCRT to hybrid techniques" (PI-199-CI-IPOP-35-2023), (2023)
- DoMiRe - "Development and implementation of a MRI-only guided radiotherapy workflow" (PI-200-CI-IPOP-36-2023), (2023)
- RaAITo - "Development of a Chatbot for Radiotherapy using Artificial Intelligence Tools" (PI-201-CI-IPOP-37-2023), 2023
- LuPET - "Lu-177 radiotherapy outcome prediction using image data from Ga-68 PET/CT scans" (PI-202-CI-IPOP-38-2023), 2023

**Major achievements**

- ***Sara F.C. Guerreiro, Filipa Leal, Anabela G. Dias, Pedro L. Granja, Juliana R. Dias Dias AG, Polycaprolactone (PCL)-Gelatin Eletrospun Meshes for Accelerated gastric Wound Healing, Colloids and Surfaces B: Biointerfaces 250 (2025) 114572. https://doi.org/10.1016/j.colsurfb.2025.114572 & Sara F.C. Guerreiro, Anabela G. Dias, Pedro L. Granja, Juliana R. Dias Dias AG, In situ radiotherapy for gastric cancer: The role of gold and other inorganic nanoparticles, Acta Biomaterialia 202 (2025) 27-44, https://doi.org/ 10.1016/j.actbio.2025.06.044***

The article "In situ radiotherapy for gastric cancer: The role of gold and other inorganic nanoparticles" reviews the emerging use of high-atomic-number inorganic nanoparticles, particularly gold, as radiosensitizers in gastric cancer treatment. These nanoparticles enhance local radiation dose deposition through increased photoelectric interactions, generating secondary electrons that intensify tumour damage while potentially sparing surrounding healthy tissue. The paper discusses mechanisms of tumour targeting, modulation of the tumour microenvironment, and the concept of in situ radiotherapy as a strategy to stimulate systemic anti-tumour immune responses. It also addresses key translational challenges, including toxicity, biodistribution, and clinical implementation.
The study "Polycaprolactone (PCL)-Gelatin Electrospun Meshes for Accelerated Gastric Wound Healing" presents the development of electrospun nanofibrous scaffolds combining polycaprolactone and gelatin to promote gastric tissue repair. By mimicking the extracellular matrix, these meshes support cell adhesion, proliferation, angiogenesis, and tissue regeneration in the harsh gastric environment. Experimental results demonstrate accelerated wound healing, reduced inflammation, and improved tissue organisation compared with conventional approaches. The work highlights the potential of bioengineered scaffolds as therapeutic tools for gastrointestinal repair and regenerative medicine.

- ***Albergueiro, R.; Antunes, V.; Santos, J. Effect of OSEM Reconstruction Iteration Number and Monte Carlo Collimator Modeling on 166Ho Activity Quantification in SPECT/CT. Appl. Sci. 2025, 15, 1589.***

***https://doi.org/10.3390/app15031589 & Rita Albergueiro, Rafael Silva, João Santos. Post-therapeutic dosimetric evaluation of 166Ho radioembolization for liver malignancies: Impact of software on tumor and liver doses. Advances in Radiotherapy & Nuclear Medicine 2025, 3(3), 55–64, https://doi.org/10.36922/ARNM025220023]***

These two studies address complementary stages of the same clinical objective: achieving accurate patient-specific dosimetry in holmium-166 radioembolization for liver malignancies. The first investigates how SPECT/CT reconstruction parameters — specifically the number of OSEM iterations and the use of Monte Carlo-based collimator modelling — influence activity quantification. Since absorbed dose calculations in radionuclide therapy depend directly on reconstructed activity distributions, the study demonstrates that reconstruction choices can introduce significant biases in estimated activity, thereby affecting subsequent dosimetric assessments.
The second study extends this framework into the clinical domain by analysing post-therapeutic dosimetry and examining how different software platforms impact calculated tumour and liver doses. Variations in segmentation methods, dose calculation algorithms, and processing workflows were shown to produce meaningful differences in reported absorbed doses, with potential implications for treatment evaluation and outcome prediction. Together, the two works form a coherent pathway from quantitative imaging optimisation to reliable clinical dosimetry, highlighting that accurate reconstruction and standardised analysis tools are both essential to ensure consistent, evidence-based planning and assessment of ^166Ho radioembolization therapies.

## Scientific output

### *a) Peer-reviewed indexed publications (final publication date in 2025)*

- **Albergueiro, R, Antunes, V** and **Santos, J**. *Effect of OSEM Reconstruction Iteration Number and Monte Carlo Collimator Modeling on 166Ho Activity Quantification in SPECT/CT.* Applied Sciences. 2025;15(3) IF: 2.5
- **Barbosa, B,** Oliveira, C, Couto, JG, **Bravo, I**, Antunes, L, McFadden, S, Hughes, C, McClure, P and **Dias, AG**. *Digital proficiency and educational needs of Portuguese radiation therapists.* Radiography (Lond). 2025;31(6): p. 103176. IF:2.8
- Batista, S, Couceiro, M, Filipe, R, Rachinhas, P, Isidoro, J and **Domingues, I**. *Private Data Incrementalization: Data-Centric Model Development for Clinical Liver Segmentation.* Bioengineering (Basel). 2025;12(5) IF:3.7
- Campilho, B, Silva, S, Pinto, S, Conde, P, **Lencart, J, Mendes, B** and **Santos, J.** *Minimizing 3T MRI Geometric Distortions for Stereotactic Radiosurgery via Anterior–Posterior Phase Encoding–A Phantom Study.* Applied Sciences. 2025;15(18)IF:2.5
- Costa, SPF, Sousa, F, Leite-Silva, P, Gomes, D and **Sousa, O**. *Stereotactic body radiation therapy for lung metastases from colorectal cancer: outcomes and prognostic factors in a series of 109 patients.* Rep Pract Oncol Radiother. 2024;29(6): p. 700–9. IF:2.0
- **Domingues, I.** *Predicting Grades in the "Introduction to Clinical Databases" Course: Dataset Creation, Pipeline Design, and Model Evaluation*. Artificial Intelligence in Education Technologies: New Development and Innovative Practices. Lecture Notes on Data Engineering and Communications Technologies. 2282025. p. 255–67. IF:NA
- **Guerreiro, SFC, Dias, AG,** Dias, JR and Granja, PL. *In situ radiotherapy for gastric cancer: The role of gold and other inorganic nanoparticles.* Acta Biomater. 2025;202: p. 27–44.IF:9.6
- **Guerreiro, SFC**, Leal, F, **Dias, AG**, Granja, PL and Dias, JR. *Polycaprolactone (PCL)-Gelatin Electrospun Meshes for Accelerated Gastric Wound Healing.* Colloids Surf B Biointerfaces. 2025;250: p. 114572. IF:5.6
- Jasieniecka, A and **Domingues, I.** *CRISPR-Cas9 and Its Bioinformatics Tools: A Systematic Review.* Curr Issues Mol Biol. 2025;47(5) IF: 3.0
- Lopes, R, **Teles, P** and Santos, J. *A systematic review of the effectiveness of leaded glasses for ensuring safety among healthcare professionals in fluoroscopy.* J Med Imaging Radiat Sci. 2025;56(2): p. 101848. IF:2.0
- Lopes, R, **Teles, P** and Santos, J. *A systematic review on the occupational health impacts of ionising radiation exposure among healthcare professionals.* J Radiol Prot. 2025;45(2) IF:1.8

- Macedo-Silva, C, Albuquerque-Castro, A, Carrico, I, **Lencart, J**, Carneiro, I, Altucci, L, Lobo, J, Miranda-Goncalves, V, Henrique, R, Correia, MP and Jeronimo, C. *Decoding MUC1 and AR axis in a radiation-induced neuroendocrine prostate cancer cell-subpopulation unveils novel therapeutic targets.* Cell Death Discov. 2025;11(1): p. 306. IF:7.0
- Morais, P, **Domingues, I** and Bernardino, J. *Deep Learning Techniques for Detecting Morphed Face Images: A Literature Review.* IEEE Access. 2025;13: p. 105952–81. IF:3.6
- Oliveira, MAM, Calado, ML, **Guerreiro, SFC**, Dias, JR, Campos, MJ, Murray, PG and Novais, SC. *Improved biosynthesis and characteristics of silver nanoparticles using marine endophytic fungi exposed to hypo-osmotic stress.* Sci Rep. 2025;15(1): p. 16327. IF:3.9
- **Oliveira, S,** Fernandes, R, Baylina, P, Santos, J, Vieira, G, Faria, I and Pereira, N. *The Impact of a Rectal Spacer in VMAT Dosimetry in the Treatment of Prostate Cancer.* Applied Sciences. 2025;15(17) IF:2.5
- Rodrigues, AC, de Almeida, JG, Rodrigues, N, Moreno, R, Castro Verde, AS, Mascarenhas Gaivao, A, Bilreiro, C, Santiago, I, Ip, J, Beliao, S, Silva, S, **Domingues, I,** Tsiknakis, M, Marias, K, Regge, D, Papanikolaou, N and Pro, C-IC. *Improving Clinically Significant Prostate Cancer Detection with a Multimodal Machine Learning Approach: A Large-Scale Multicenter Study.* Radiol Imaging Cancer. 2025;7(5): p. e240507. IF:6.3
- Souto, C, Aguilar, B, Dias, V, Pascual, E, Farinha, G, Marcelino, C, Rodrigues, C, **Teles, P**, Perez-Rozos, A, Sallabanda, M and Sallabanda, K. *Beam data commissioning, validation and clinical implementation of SRS gyroscopic system.* Phys Med. 2025;133: p. 104952.IF:2.7
- **Teles, P,** Costa, R, Bettio, T, Pinheiro, T, Loupa, T, Santos, J, Pinto, F, Gil, OM, Ferrari, P and Zankl, M. *Local DRL estimation and effective dose calculation in paediatric interventional cardiology using measurements and Monte Carlo simulations.* Phys Med. 2025;135: p. 105023. IF:2.7
- Wadas, I and **Domingues, I.** *Systematic Review of Phylogenetic Analysis Techniques for RNA Viruses Using Bioinformatics.* Int J Mol Sci. 2025;26(5) IF:4.9

### b. Other outputs

#### Oral Communications by Invitation

- Teles P. (2025) Reinforcement learning – a case-study for the use of machine learning in radiation transport. EUGLOH Summer School "Biomedical Data Processing and Artificial Intelligence "BEATRICE"
- Bárbara Barbosa (2025) AI-driven innovations in radiotherapy. European Society of Radiology (February); Vienna, Austria.
- Bárbara Barbosa (2025) Digital Transformation in Radiotherapy. Portuguese Association of Radiotherapists-ART (January); Webinar
- Inês Lucena Sampaio (2025) PET-PSMA: The New Gold Standard in Staging? [*PET-PSMA: o novo gold standard no estadiamento?]*. "Prostate Cancer I | New Approaches and Challenges" (16th May)
- Inês Lucena Sampaio (2025) Safety of Innovative Treatments in Nuclear Medicine *[Segurança dos Tratamentos Inovadores em Medicina Nuclear]* Active Pharmacovigilance: Monitor, Detect, Act INFARMED,I.P. (29th May)
- Inês Lucena Sampaio, New Options in Nuclear Medicine [*Novas opções no âmbito da medicina nuclear*] 21st National Congress on Gastrointestinal Cancer, (1st-3rd October) Figueira da Foz, Portugal

#### Oral Communications in International Scientific Meetings

- Couto, J. Santos, B. Mendes, and I. Domingues, "Multimodal Prediction of Complete Response to Chemoradiotherapy in Esophageal Cancer Using Clinical Data, Radiomics, and Deep Embeddings," in 2025 14th International Symposium on Image and Signal Processing and Analysis (ISPA), 2025, pp. 1–6.
- Mendes, I. Domingues, and J. Santos, "Assessing the Impact of Automatic vs. Manual Segmentation on Radiomic Feature Analysis: A Prostate Cancer Study," in 2025 14th International Symposium on Image and Signal Processing and Analysis (ISPA), 2025, pp. 22–26.

- P. Morais and I. Domingues, “Composite Heatmaps: Interpreting Deep Models in Morph Attack Detection,” in 2025 14th International Symposium on Image and Signal Processing and Analysis (ISPA), 2025, pp. 1–6.
- Rodrigues, N. Rodrigues, J. G. Almeida, A. M. Gaivão, C. Bilreiro, I. Santiago, J. Ip, S. Beli˜ao, M. Tsiknakis, K. Marias, D. Regge, P.-I. Consortium, N. Papanikolaou, and I. Domingues, “Uplift Modeling for Treatment Effect Estimation in the Prostate Cancer Treatment Landscape,” in 12th
- Ruben Sousa, Íris R. Carriço, Ângela Albuquerque Castro, Joana Lencart, António Soares, Pedro Leite-Silva, Catarina Macedo Silva, Isabel Bravo, Bárbara Barbosa, Ana Ferreira, Catarina Ribeiro, João Santos, Carla Castro, Carmen Jerónimo, Vera Miranda Gonçalves (2025) Devemos apostar na cronoradioterapia em cancro da próstata localizado? Uma abordagem segundo o ritmo circadiano”. Symposium “Innovative Approaches in Oncology Care,” CNART 2025 (February); Lisboa, Portugal.

### *Oral Communications in National Scientific Meetings*

- Lourenço C, Santos JA (2025), Existing approaches to screening of radiation protective equipment: a systematic review, XI Congresso SPPCR (8-12$^{th}$ September); Coimbra, Portugal

### *Posters in international conferences*

- Sara F. C. Guerreiro; Anabela G. Dias; Pedro L. Granja; Juliana R. Dias, A radiosensitizing electrospun patch for enhanced radiotherapy and gastric wall repair in stomach cancer treatment, TERMIS EU 2025 - Tissue Engineering International & Regenerative Medicine Society, maio 2025, Freiburg, Germany. Poster com apresentação e discussão].
- Dias AG, Lencart J, Silva D, Souto C, Development of a dosimetric audit methodology based on the revision of the IAEA TRS 398 protocol, ICARO 4 – International Conference on Advances in Radiation Oncology, junho 2025, Viena, Austria. Poster com apresentação e discussão].
- Souto C, Silva D, Lencart J, Dias AG, Establishment of an uncertainty budget for reference dosimetry, ICARO 4 – International Conference on Advances in Radiation Oncology, junho 2025, Viena, Austria. Poster com apresentação e discussão].
- Gonçalves S, Cunha LT, Lencart J, Dias AG, Modeling and validation of a rotative over-couch support transmission and attenuation properties for TBI VMAT, Radiotherapy and Oncology 206, Supplement 1 (2025) S2599, p. 2606. DOI: 10.1016/S0167-8140(25)00843-6
- Rita Albergueiro, Ana Luísa Carvalho e João Santos. “Optimizing Quantitative $^{177}$Lu SPECT-CT: Effects of OSEM Parameters and Deadtime” no Congresso Europeu de Medicina Nuclear (EANM’25)
- Rita Albergueiro, Ana Luísa Carvalho, Luís Cunha, Catarina Souto e Joana Vale “Establishing DRLs in [$^{18}$F]FDG PET-CT: A Digital-Analog Comparison” no Congresso Europeu de Medicina Nuclear (EANM’25)
- Gonçalves S, Cunha LT, Pinto D, Lencart J, **Dias AG**, Modeling and validation of rotative over-couch support transmission and attenuation properties for TBI VMAT, ESTRO 2025, May 2025, Viena, Austria. Poster com apresentação e discussão].
- Luís Cunha, Barbara Barbosa, Bruno Mendes, Susana Gonçalves, Cristina Santos, André Soares, Pedro Dias, Marisa Matos. 2025. “Chat iPERTO: empowering radiotherapy patients through artificial intelligence”. ESTRO 2025 (02- 06$^{th}$ May);

### *Posters in national conferences*

- J. Maurício, I. Domingues, and H. Oliveira, “Diagnosing Ulcerative Colitis Severity through Image Analysis Using Ordinal Classification,” in Portuguese Conference on Pattern Recognition (RecPad), 2025.
- A. Couto, B. Mendes, J. Santos, and I. Domingues, “Multimodal prediction of complete response to chemoradiotherapy in esophageal cancer,” in Portuguese Conference on Pattern Recognition (RecPad), 2025.
- B. Mendes, I. Domingues, and J. Santos, “Automatic vs. manual segmentation in prostate cancer radiomics,” in Portuguese Conference on Pattern Recognition (RecPad), 2025.
- P. Morais and I. Domingues, “Interpreting morph attack detection with composite heatmaps,” in Portuguese Conference on Pattern Recognition (RecPad), 2025.

### Editorial Board Positions

| Journal | Publishing Company | Position | Researcher |
|---|---|---|---|
| Brazilian Journal of Radiation Sciences | Sociedade Brasileira de Proteção Radiológica - SBP | Editor | Pedro Teles |
| IEEE Access | IEEE | Associate Editor | Inês Domingues |
| Computer Methods in Biomechanics and Biomedical Engineering: Imaging & Visualization | Taylor & Francis | Associate Editor | Inês Domingues |

### Peer Review

Physica Medica, Radiation Oncology, Radiation Protection Dosimetry, Int. J Cancer. Medical Physics, Brit. J Cancer, Bioengineering, Diagnostics, Frontiers in Oncology, J. Radiot. Practice, J. Clin. Med., Computational and artificial intelligence, Computer Methods in Biomechanics and Biomedical Engineering, Radiography; Technical Innovations and Patient Support in Radiation Oncology (tipsRO); Applied Sciences; Diagnostics; ECAI - European Conference on Artificial Intelligence Electronics; Frontiers in Education; Iberian Conference on Information Systems and Technologies; Iberian Conference on Pattern Recognition and Image Analysis; IEEE Frontiers in Education Conference; IEEE International Conference on Computer Vision and Machine Intelligence; IEEE International Joint Conference on Biometrics; IEEE International Symposium on Biomedical Imaging (ISBI); International Workshop on Biometrics and Forensics (IWBF); International Conference in Computer Analysis of Images and Patterns (CAIP); International Conference on Medical Image Computing and Computer Assisted Intervention – MICCAI; International Symposium on Image and Signal Processing and Analysis (ISPA); Journal of Imaging; Life; Pattern Analysis and Applications; Portuguese Conference on Pattern Recognition; RISTI - Revista Iberica de Sistemas E Tecnologias de Informacao

### Participation as Opponent in MSc Evaluation Committees

| Student | Title | Program | Researcher |
|---|---|---|---|
| Rita Isabel Almeida Campino Martins do Vale | GAN-Based Data Augmentation and Anonymisation for Medical Image Classification | Master in Mathematics and Applications, University of Aveiro | Inês Domingues |
| João Vieitas | ML-Based Wind Speed Downscaling in Iberian Peninsula | Master in Computational Engineering, University of Aveiro | Inês Domingues |
| Vasco Daniel Tomás Gomes | Correction of wind speed forecasts via Machine Learning approaches | Master in Computational Engineering University of Aveiro | Inês Domingues |
| Maria Vaz de Salvador | Next-Generation Synthetic Face Data with Diffusion Models | Master in Computational Statistics and Data Analysis, Faculty of Sciences of University of Porto and INESCTEC | Inês Domingues |
| Rita Marques | Sperm Motility Analysis from Microscopic Videos | Master in Bioengineering - Biomedical Engineering, Faculty of Engineering of University of Porto | Inês Domingues |
| Filipe Gonçalves | Prediction Models for the Redistribution of the Fleet in a Vehicle Sharing System | Master in Robotics and Intelligent Systems, University of Aveiro | Inês Domingues |
| Pedro Rafael Ferreira Tavares | Enhancing Textile Defect Detection through Markers and Segmentation | Master in Data Science and Engineering, Faculty of Engineering of University of Porto | Inês Domingues |

| Student | Title | Program | Researcher |
|---|---|---|---|
| Ana Sofia Coelho Saraiva | Automatic Segmentation and Reconstruction of the Mandible from CT Scans | Master in Bioengineering - Biomedical Engineering, Faculty of Engineering of University of Porto | Inês Domingues |
| Tiago Daniel dos Santos Leitão e Sousa | Deep learning strategies for UAV-based inspection of photovoltaic panels | Master's Degree in Electrical and Computer Engineering, Faculty of Engineering, University of Porto | Inês Domingues |
| Lúcia José Araújo Fernandes | Análise de risco em Medicina Nuclear | MSc in Medical Physics | Pedro Teles |

### *Participation as Opponent in PhD/Aggregation Evaluation Committees*

| Student | Title | Program | Researcher |
|---|---|---|---|
| Tong Liu | Information Security-Oriented Tamper Detection and Self-Recovery Technology | dual degree of Doctor of Philosophy in Computer Applied Technology, Macao Polytechnic University and Doutoramento em Engenharia Informática (Doctor of Philosophy in Informatics Engineering), University of Coimbra | Inês Domingues |
| Nicolás Jesús Gallego Molina | Explainable Graph and Signal Processing methods for Multimodal EEG-NIRS Brain Network Modelling in Language Disorders | Universidad de Málaga | Inês Domingues |
| Zewei Wu | Mitigating Representation Ambiguity in Multi-Object Tracking via Leveraging Contextual Clues Behind Detections | Dual degree of Doctor of Philosophy in Computer Applied Technology, Macao Polytechnic University and Doutoramento em Engenharia Informática (Doctor of Philosophy in Informatics Engineering), University of Coimbra | Inês Domingues |
| Joana Maria Neves da Rocha | Explainable Artificial Medical Intelligence for Automated Thoracic Pathology Screening | Faculty of Engineering, University of Porto | Inês Domingues |
| Ana Carolina Rodrigues | Bi-parametric MRI Radiomics in the Spectrum of Prostate Cancer Treatment – Assessing the Trustworthiness of AI | HEADS - PhD in Health Data Science, Porto University | João Santos |

### *Teaching Activity: Coordination of Curricular Units/Courses*

| Member | Curricular Units | Program | Position | Faculty/University |
|---|---|---|---|---|
| Bárbara Barbosa | Digital skills of RT radiographers in Europe | MSc in Digital Health and BSc in Science in Radiography - year 3 | Visiting lecture | University of Malta |
| Bárbara Barbosa | Research Process from Idea to Thesis Submission | BSc in Science in Radiography - year 2 | Visiting lecture | University of Malta |
| Bárbara Barbosa | Tips and Reflections on Embarking and Enduring a PhD Journey | Public talk (professionals, MSc and BSc students) | Visiting lecture | University of Malta |
| Isabel Bravo | Radiobiology and Biophysics | MSc in Medical Physics | Coordinator and Lecturer | FCUP |

| Member | Curricular Units | Program | Position | Faculty/University |
|---|---|---|---|---|
| Isabel Bravo | Radiobiology | BSc in Medical Imaging and Radiotherapy | Coordinator and Lecturer | E2S-IPP |
| Isabel Bravo | Radiobiology and Biophysics | MSc in Medical Physics | Coordinator and Lecturer | FCUP |
| Pedro Teles | Signal and Image Processing in Medical Physics; Computational Methods in Medical Physics; Dosimetry and Radiological Protection; Radiation Physics; Seminar; Dissertation; Project | MSc in Medical Physics | Director, Assistant Professor | FCUP |
| Pedro Teles | Computational Physics; Mechanics | BSc in Physics / Engineering Physics | Assistant Professor | FCUP |
| Pedro Teles | Forensic Sciences | MSc in Criminology | Assistant Professor (invited) | FDUP |
| Pedro Teles | Nuclear, Radiation and Particle Engineering Physics | PhD in Physical Engineering | Assistant Professor | PRODEF (FCUP/FEUP) |

### *Scientific Appointments*

| Organization | Researcher |
|---|---|
| Chair of the Symposium: “Innovative Approaches in Oncology Care”, CNART 2025 | Bárbara Barbosa |
| Member of the Scientific Advisory Group (SAG) for Radiotherapy (ESTRO) | Bárbara Barbosa |
| Abstract reviewer for ESTRO 2025 | Bárbara Barbosa |
| Chair of the Session: “Future in ART”, CNATARP 2025 | Bárbara Barbosa |
| Chair of Medical Physics Division of the Portuguese Physics Society | Pedro Teles |
| EURADOS Voting Member representative | João Santos |

### International collaborations

| Title | Researchers | International Team | Institution | Country | Funding |
|---|---|---|---|---|---|
| European project. "ECHOES - ExChange of ExpertiSe in healthcare professionals' education." | Bárbara Barbosa | | -University of Malta; PMF Research; Royal College of Surgeons, Ireland; INHWE -International Network for Health Workforce Education; Tampere University of Applied Sciences. University of Galway; Heimerer College; University of Graz; University of Paderborn; Ulster University; Buckinghamshire New University; | Malta Italy Ireland Filand Ireland Germany Austria Germany United Kingdom (North Ireland) United Kingdom (England) | Erasmus+ 2021-2027; Project No: 2023-1-MT01-KA220-HED-000156744 |
| European project "OPTIMIZE-RT - Education Program to OPTIMIZE Imaging Doses in RadioTherapy CBCTs" | Bárbara Barbosa, Anabela Dias | | European Federation of Radiographers Societies – EFRS; INSTITUTO POLITECNICO DO PORTO; UNIDADE LOCAL DE SAÚDE DE SÃO JOÃO EPE; Ministry for Health and Active Ageing - Government ofMalta; UNIVERSITA TA MALTA; EUROPEAN SOCIETY FOR RADIOTHERAPY AND ONCOLOGY; European Federation of Organisations for Medical Physics; Fondazione IRCCS San Gerardo dei Tintori | Netherlands Portugal Malta Belgium Netherlands Italy | Erasmus+, Grant Agreement Number: 2025-1-MT01-KA220-HED-000356020 |

### International Consortia

| Organization | Researcher |
|---|---|
| European Consortium in the project "ECHOES -ExChange of ExpertiSe in healthcare professionals' education." Representing IPO-Porto as an associated partner. | Bárbara Barbosa |
| European Consortium in the project "OPTIMIZE-RT - Education Program to OPTIMIZE Imaging Doses in RadioTherapy CBCTs ." Leader of Work Package 4 (WP4). | Bárbara Barbosa, Anabela Dias |
| EURADOS | João Santos, Pedro Teles, Joana Lencart, Pedro Teles |

## MOLECULAR ONCOLOGY & VIRAL PATHOLOGY GROUP

### Coordinator

Rui Medeiros, PharmD, PhD

### Research team @31 December 2025

| Name | Academic Degree | Professional Situation | Category/position | Time % |
|---|---|---|---|---|
| Ângela Maria Amorim Alves | MSc | PhD Fellowship | PhD Student (FCT 2025.05389.BD) | 100 |
| Ana da Conceição Saraiva e Sousa | MSc | External | Associate Researcher, PhD Student | 20 |
| Ana Luísa Pereira Teixeira | PhD | Contract | Junior Researcher | 100 |
| Andreia Filipa Rosário | MSc | PhD Fellowship | PhD Student (FCT UI/BD/154821/2023) | 100 |
| Anna Flávia Xavier | MD | MSc student | MSc student | 30 |
| Áurea Lima | MD, PhD | Contract | Medical Oncologist | 30 |
| Bruno Miguel Pinheiro Pires | MSc | PhD Fellowship | PhD Student IPO Porto/UBI (FCT 2024.02748.BD) | 100 |
| Carina Sofia Teixeira Fernandes | PhD | Pos-doc Researcher | Pos-doc Researcher | 30 |
| Carla Manuela Moutinho Silva Campos | MSc | Contract | Clinical Pathology Technician, PhD student | 20 |
| Catarina Rodrigues Carvalho | BSc | Student | Master Student | 100 |
| Francisca Guilherme Carvalho Dias | PhD | External | Associate Researcher/Assistant Professor | 30 |
| Eduarda Almeida Rufo Pereira | MSc | PhD Fellowship | PhD Student | 25 |
| Guido Andre Nchowela | MSc | PhD Fellowship | PhD St. IPO Porto/UnEduardoMondlane (FCT:BD2023.18580.PRT) | 50 |
| Hugo Manuel Lopes Sousa | MD, PhD | External | Associate Researcher | 30 |
| Inês Cristina Guerra de Melo | MSc | Fellowship | PhD Student. Research Fellowship LPCC-NRN 2025 | 100 |
| Izamara Gomes Maocha | MSc | PhD Fellowship | PhD Student IPO Porto/UBI (FCT:PRT/BD/154597/2022) | 25 |
| Isabel Patrícia Dias Meireles | MSc | PhD Fellowship | PhD Student (FCT 2024.04184.BDANA) | 100 |
| Maria de Fátima Araújo Magalhães Cerqueira | PhD | External | Associate Researcher | 30 |
| Mariana Filipa Couto Ferreira | MSc | Fellowship | PhD Student. Research Fellowship LPCC-NRN 2025 | 100 |
| Mariana Isabel Cruz Rei | MD, PhD | Contract | Gynecologist | 30 |
| Mariana Gomes Morais | PhD | External | Associate Researcher | 30 |
| Mariana Moreira Pires | BSc | Student | MSc Student | 100 |
| Mariana Teixeira Costa | BSc | Student | MSc Student | 100 |
| Marina Isabel Lourenço Reis | BSc | Student | MSc Student | 100 |
| Marlene Elisabete Moreira Santos | PhD | External | Associate Researcher | 30 |
| Rui M. Gil da Costa | PhD | External | Afilliated Researcher | 30 |
| Rui Medeiros | PharmD, PhD | Contract | Group Coordinator | 100 |
| Tânia Rôlo Dias | MSc | Fellowship | PhD student (FCT.2022.11431.BD) | 100 |

| Name | Academic Degree | Professional Situation | Category/position | Time % |
|---|---|---|---|---|
| Tiago Terras Ferreira | MSc | PhD Fellowship | PhD student (FCT.2020.04789.BD) | 25 |
| Valéria Delgado Tavares | PhD | Fellowship | Research Fellowship LPCC-NRN 2025 | 100 |
| Vânia Catarina Moreira Dias | BSc | Student | MSc student | 100 |

## Group description and objectives

The Molecular Oncology & Viral Pathology Group, established in 2002, focuses on understanding molecular mechanisms underlying cancer onset, progression, and therapeutic response. Its core mission is to identify and validate molecular biomarkers that improve patient stratification, guide therapeutic decisions, and enhance clinical outcomes, particularly within the frameworks of Precision Medicine and Molecular Epidemiology. Following the pioneer work developed, technological development and understanding the relevance of extracellular vesicles in the precision Medicine field, our group is also currently focused on the study of biomarkers that are carried inside these nanovesicles to established new prognosis biomarkers based on liquid biopsies approaches.

Molecular Oncology & Viral Pathology Group Key Research Pillars

-**Precision Medicine & Pharmacogenomics & Personalized Therapy** : The group studies a broad spectrum of molecular biomarkers—genetic polymorphisms, mRNAs, microRNAs, lncRNAs, viral genomes and, more recently, extracellular vesicle (EV)-derived biomarkers. These markers support early diagnosis, prognosis, and therapy optimization, including identifying responders vs. non-responders and preventing adverse drug reactions. Research integrates individualized genetic and epigenetic profiles to understand their influence on drug efficacy, toxicity, therapy resistance, and patient-specific treatment outcomes.

-**Tumor Heterogeneity & 3D Cancer Models**: To better replicate human disease, the group develops advanced 3D cancer models that capture intratumoral complexity and enable translational studies linking molecular profiles to clinical phenotypes.

-**Cancer-Associated Systemic Phenotypes**: Ongoing work addresses systemic manifestations such as pain, cachexia, and thromboembolic events, refining biological and clinical markers to support better patient management. This includes leadership participation in European initiatives such as PAINLESS.

-**Viral Pathology & Oncogenic Viruses**: The group investigates the role of viruses—particularly Human Papillomavirus (HPV), Cytomegalovirus (CMV), and Epstein-Barr Virus (EBV)—in carcinogenesis. Research explores host–virus interactions, immune heterogeneity, and clinically relevant risk stratification in infection and vaccine response.

Strategic Objectives (2025–2029): 1)Reinforce translational research integrating advanced experimental platforms with clinical applications.; 2)Expand development of 3D tumor models coupled with EV-based and molecular biomarker profiling.; 3)Deepen investigation of systemic cancer phenotypes affecting quality of life.;4)Strengthen expertise in viral oncology, immune response dynamics, and precision risk stratification.

## Active projects and funding

### Competitive Funding

International

- PAINLESS - “Pain relief in palliative care of cancer using home-based neuromodulation and predictive biomarkers” (Grant Agreement N°101057367; HLTH-2021-DISEASE-04-01), Budget: 273,4K€ (2022-2026) (PI: Maria Teresa Carrilho/ Rui Medeiros).

National

- NeuroDevice - “Challenging the Analytical Diagnosis of Neurodevelopmental Disorders: Pioneering Neurochemical Devices” (COMPETE2030-FEDER-00699000 (operation nº 15875), Budget: 61.776K€ (2025-2028)(PI: Fátima Barroso/ Ana Luísa Teixeira)
- OnCOVacB – “Evaluation of the Immunologic Response to COVID-19 Vaccination in Oncological Patients”, Budget: 500K€ (AstraZeneca) (2022-2024)(PI: Júlio Oliveira/ Rui Medeiros).

**Internal**

- EVmiRs4PC- “Extracellular vesicles derived miRNA microRNAs as mediators of drug resistance using 3D spheroid in vitro models for prostate cancer” (CI-IPOP 13-2022), Budget: 5K€ (2022-2023) (PI: Ana Luísa Teixeira).
- EXOmiRs4RCC - “Renal cell carcinoma-derived exosome: the microRNA content as a new disease predictive biomarker and an opportunity to invasive/metastatic disease management under the genetic background” (CI-IPOP-21-2015), Budget 87.5K€ (2016-2025)(PI: Ana Luísa Teixeira, Co-PI: Francisca Dias).
- EUPICPHARMADCP - “Pharmacogenomic determinants of therapeutic response of urogynecological cancer” (CI-IPOP-22-2015), Budget 62.5K€ (2016-2025) (PI: Rui Medeiros).
- GWASPHARMAGEN – “GWAS and Data Science as putative approaches for identifying pharmacogemomics determinants of response to therapy”, Budget 37.5K€, (CI-IPOP-91-2018) (2019-2025) (PI:Rui Medeiros).
- VIRCIRCDNA- "Circulating viral genomes in the blood of cervical cancer patients", Budget 33K€, (CI-IPOP-37-2016) (2026-2025) (PI: Rui Medeiros).
- ViRALmiRNA – "microRNA-mediated viral regulation of the tumor microenvironment", Budget 55K€ (CI-IPOP-66-2017) (2018-2025) (PI: Rui Medeiros).
- NeutroSAC– “Cachexia Anorexia Syndrome and its Clinical, Pharmacogenomic and Biochemistry”, Budget 40K€ (CI-IPOP-118-2019) (2020-2025)(PI: Rui Medeiros).

**Major achievements**

- ***Alves Â, Ferreira M, Eiras M, Lima L, Medeiros R, Teixeira AL, Dias F. Exosome-derived hsa-miR-200c-3p, hsa-miR-25-3p and hsa-miR-301a-3p as potential biomarkers and therapeutic targets for restoration of PTEN expression in clear cell renal cell carcinoma. Int J Biol Macromol. 2025 Apr;302:140607. Doi: 10.1016/j.ijbiomac.2025.140607. (IF: 8.5)***
  ***https://pubmed.ncbi.nlm.nih.gov/39900161/***

- ***Tavares I, Morais M, Dias F, Ferreira M, Martins G, Fernandes R, Bidarra SJ, Medeiros R, Teixeira AL. Extracellular vesicles derived-microRNAs predicting enzalutamide-resistance in 3D spheroid prostate Cancer model. Int J Biol Macromol. 2025 Jan; 284(Pt 1):137993. Doi: 10.1016/j.ijbiomac.2024.137993. (IF: 8.5)*** ***https://pubmed.ncbi.nlm.nih.gov/39592052/***

Clear cell renal cell carcinoma (ccRCC) and advanced prostate cancer represent two of the most challenging malignancies in terms of therapy resistance and disease progression. The group’s recent research has made significant contributions by unveiling the role of exosome-derived microRNAs as both biomarkers and regulators of treatment response in these cancers. In ccRCC, the discovery that exosomal miR-200c-3p, miR-25-3p, and miR-301a-3p directly modulate PTEN—a key tumor suppressor frequently silenced in cancer—offers new diagnostic and therapeutic perspectives. These findings highlight the potential of targeting these microRNAs to restore PTEN expression, reinforcing the concept of *miRNA-based precision medicine* in renal cancer. Complementing these insights, the group demonstrated in a 3D spheroid model of prostate cancer that specific extracellular vesicle-associated microRNAs can predict resistance to the antiandrogen enzalutamide. This pioneering work introduces a powerful experimental tool for modeling drug resistance *in vitro* and emphasizes extracellular vesicle-derived microRNAs as promising predictive biomarkers for

therapeutic response in advanced prostate cancer. Together, these studies underscore the central role of tumor-derived extracellular vesicles as mediators of intercellular communication, therapeutic resistance, and biomarker discovery—paving the way for novel translational approaches in genitourinary oncology research.

**Scientific output**

***a. Peer-reviewed indexed publications (final publication date in 2025)***

- Alencar, A, Abreu, F and **Fernandes, C**. *Sleep, fatigue, and altered cognition in healthcare professionals: Evidence from Portugal using the fatigue and altered cognition scale.* Sleep Epidemiology. 2025;5 IF:NA
- **Alves, A, Ferreira, M**, Eiras, M, Lima, L**, Medeiros, R, Teixeira, AL** and **Dias, F**. *Exosome-derived hsa-miR-200c-3p, hsa-miR-25-3p and hsa-miR-301a-3p as potential biomarkers and therapeutic targets for restoration of PTEN expression in clear cell renal cell carcinoma.* Int J Biol Macromol. 2025;302: p. 140607. IF:8.5
- Azevedo, T, Silva-Reis, R, **Medeiros-Fonseca, B,** Goncalves, M, Mendes, G, Roboredo, M, Rocha, MJ, Peixoto, F, Pinto, ML, Matos, M, Sousa, JR, Oliveira, PA and Coimbra, AM. *Do (xeno)estrogens pose a risk to earthworms? Soy isoflavones and estradiol impact gonad structure and induce oxidative stress in Eisenia fetida.* Chemosphere. 2025;377: p. 144315. IF: NA
- Barbosa, T, Morais, SL, Carvalho, R, Magalhães, JMCS, Domingues, VF, Delerue-Matos, C, Ferreira-Fernandes, H, Pinto, GR, **Santos, M** and Barroso, MF. *Vitamin K Epoxide Reductase Complex (VKORC1) Electrochemical Genosensors: Towards the Identification of 1639 G>A Genetic Polymorphism.* Chemosensors. 2025;13(7) IF:3.7
- Barbosa, T, Morais, SL, Pereira, E, Magalhaes, J, Domingues, VF, Ferreira-Fernandes, H, Pinto, G, **Santos, M** and Barroso, MF. *Warfarin Pharmacogenomics: Designing Electrochemical DNA-Based Sensors to Detect CYP2C9*2 Gene Variation.* Genes (Basel). 2025;16(4) IF:2.8
- **Costa, MT, Neto, BV,** da Silva, JB, Carvalho, L, Salgado, L, Pereira, D, Adega, F, **Tavares, V** and **Medeiros, R**. *Venous Thrombogenesis and Cervical Cancer: Plasma MicroRNAs as Prognostic Indicators of Tumor Behavior.* Int J Mol Sci. 2025;26(19) IF:4.9
- de Carvalho, CG, Casseb, SG, **Silva, M-RG**, Castro, B, Szumilewicz, A, Davenport, MH and Santos-Rocha, R. *Translation and cross-cultural adaptation of the Get Active Questionnaire for Pregnancy ("Questionário Seja Ativa durante a Gravidez") into Portugal and Brazil Portuguese.* Apunts Sports Medicine. 2025;60(228) IF:1.3
- **Dias, V, Alves, A, Medeiros, R, Teixeira, AL** and **Dias, F.** *Unveiling the TGF-beta/Smad signaling in renal carcinoma progression: Prognostic and therapeutic insights.* Biochim Biophys Acta Rev Cancer. 2025;1880(4): p. 189372. IF:8.3
- Dores, AR, Peixoto, M, **Fernandes, C,** Marques, A and Barbosa, F. *The Effects of Social Feedback Through the "Like" Feature on Brain Activity: A Systematic Review.* Healthcare (Basel). 2025;13(1) IF:2.7
- Duarte, N, Martins, JP, Garcia-Domingo, M, Garcia-Pedraza, JA and **Santos, M.** *Medication review improves pain management and quality of life in chronic pain: a pilot randomized controlled study.* Sci Rep. 2025;15(1): p. 44689. IF:3.9
- Duarte, N, Martins, JP, Garcia-Pedraza, JA and **<** *Ten-year analgesic utilization patterns and economic implications in Portugal.* Br J Clin Pharmacol. 2025;91(3): p. 866–81. IF:3.0
- Ferraz-Goncalves, JA**, Lima, A**, Silva, AJ and Calisto, R. *Factors Associated With Prolonged Survival in Colorectal Cancer Patients Admitted to Palliative Care: An Exploratory Study.* Am J Hosp Palliat Care. 2025;42(12): p. 1278–83. IF:1.4
- **Ferreira, T, Dias, F, Alves, A,** Gama, A, Mano, JF, Oliveira, PA and **Medeiros, R**. *Let-7b, miR-29b, and miR-125b as Potential Biomarkers for Differentiating Canine Mammary Carcinoma Histological Types.* Animals (Basel). 2024;15(1) IF: 2.7
- **Ferreira, T**, Machado, AT, **Medeiros, R,** Mano, JF, Oliveira, PA and Gama, A. *Hormone receptor discrepancy and molecular subtype changes in canine mammary carcinomas and synchronous lymph node metastasis.* Res Vet Sci. 2025;194: p. 105816. IF:1.8
- Garcia, LOR, Moreira, R and **Silva, MG.** *Occupational Stress and Sleep of Military Police Officers From Rio de Janeiro, Brazil.* Am J Hum Biol. 2025;37(1): p. e24184. IF:1.7

- Gribben, JG, Quintanilla-Martinez, L, Crompton, S, Arends, J, Bardin, C, Becker, H, Castinetti, F, Csaba, DL, D'Anastasi, M, Frese, T, Geissler, J, Matuzeviciene, R, Mayerhoefer, ME, **Medeiros, R,** Morgan, K, Narbutas, S, Nier, S, Ricardi, U, Arjona, ET, Ungan, M, Warwick, L and Zucca, E. *European Cancer Organisation Essential Requirements for Quality Cancer Care: Hematological malignancies.* Hemasphere. 2025;9(4): p. e70108. IF:14.6
- Inácio, Â, Aguiar, L, Caldeira, J, Gato, M, Carrilho, R, Pires, P, Ferreira, J, Coelho, L, **Medeiros, R**, Bicho, M and Clara Bicho, M. *Investigating the role of neurotransmitter system and neurotrophic factor-related genes in human papillomavirus-associated cervical lesions.* Eurasian Journal of Medicine and Oncology. 2025;9(2): p. 250–60. IF:NA
- Jakubowska, M, Costa, VM, Krzeptowski, W, Dominkus, PP, **Santos, M,** Demirdogen, BC, Genc, S, Trougakos, IP, Kanninen, KM, Winklhofer-Roob, BM, Copple, IM, Cuadrado, A, Dolzan, V and Morgenstern, C. *Altered NRF2 signalling in systemic redox imbalance: Insights from non-communicable diseases.* Redox Biol. 2025;87: p. 103891. IF:11.9
- Jesus, TM, Azevedo, T, Silva-Reis, R, Ferreira, T, Nascimento-Goncalves, E, Medeiros, C, Ferreira, J, Gama, A, Gaivao, I, Pires, MJ, Lanzarin, G, Felix, L, Venancio, C, **Medeiros, R**, Bastos, M, Finimundy, TC, Barros, L, Gil, DACRM and Oliveira, PA. *Exploring the Chemopreventive and Antioxidant Effects of Spearmint Leaf Hydroethanolic Extract in HPV16-transgenic Mice.* In Vivo. 2025;39(3): p. 1303–13. IF: 1.8
- **Lopes, I, Meireles, I, Rocha, R, Medeiros, R** and **Cerqueira, F**. *An Overview of the Therapeutic Potential of Dimeric Flavonoids for Targeting Cancer Hallmarks.* BioChem. 2025;5(1) IF: NA
- Lopes, LR, Machado, DE, Goes, RA, Amaral, MVG, **Dias, F, Tavares, V, Medeiros, R** and Perini, JA. *Implications of tendinopathy on the sports career: Epidemiological and clinical profile of high-performance athletes.* Phys Ther Sport. 2025;72: p. 59–68. IF: 2.4
- Lopes, LR, **Medeiros, R, Tavares, V, Dias, F,** Amaral, MVG, Goes, RA, Matheus Guimaraes, JA and Perini, JA. *A Systematic Review and Meta-Analysis on Aerobic Fitness Dynamics in Post-COVID-19 Athletes: Implications in the Return-to-Play Performance.* Sports (Basel). 2025;13(2) IF:2.9
- Lourenco, AC, Nogueira, HG, Rodrigues, D, Gama, A, Machado-Rodrigues, AM, **Silva, MRG** and Padez, C. *Neighborhood Socioeconomic Deprivation and Gender Disparities in Children with Excessive Body Weight in a Southern European Municipality.* Children (Basel). 2025;12(3) IF:2.1
- Manave, EC, **Nchowela, GA**, Miguel, AR, Matuassa, CC, Muadica, AS, Machanja, B, Fernandes, L, Mavilingue, OM, Simbine, I, Tsamba, P, Manuel, IF, Muchanga, IJ, Deta, T, Ualema, EM, Cortes, H and Alfredo, C. *High burden and multi-parasite profile of gastrointestinal infections in cattle from Limpopo District, Southern Mozambique: Epidemiology, risk factors, and One Health implications.* Vet World. 2025;18(12): p. 3994–4008.
- Marrufo, TJ, Capece, BPS and **Silva, MRG**. *Influence of Artisanal Mining and Environmental Pollutants on Food Security in Southern Africa: A Systematic Review.* Food and Energy Security. 2025;14(2) IF: 4.5
- Martins, AM, Valero Juan, LF, **Santos, M** and Martins, JP. *Immunogenicity as a Predictor of Influenza Vaccine Efficacy: A Systematic Review.* Vaccines (Basel). 2025;13(8)IF:3.4
- Moreira, F, Jesus, A, Pinho, C, **Santos, M**, Serdoura, M and Cruz, A. *Ensuring safety in cytotoxic drug preparation: A systematic review of guidelines addressing education for pharmacy professionals.* J Am Pharm Assoc (2003). 2025;65(3): p. 102352. IF:2.5
- Nunes, J, **Medeiros, R,** Melonio, MC, da Rocha, CQ and **Cerqueira, F.** *The Potential of Parkia platycephala from Use to Cure.* Compounds. 2025;5(4) IF: 2.3
- Oliveira, MA, Almeida, SS, Martins, G, Godinho, I, Palmeira, C, Sousa, ME, Fernandes, L, **Medeiros, R** and Guerra, MP. *The Inflammatory Footprint of Anti-Breast Cancer Treatments and Psychosocial Factors in Women Undergoing Chemotherapy.* Biomedicines. 2025;13(10) IF: 3.9
- Oliveira, PA, Hajri, L, Moreno, AVP, Santos, CED, Brito, HO, Bastos, M, **Medeiros, R,** Ghodbane, S, Ammari, M, **Gil da Costa, RM** and Faustino-Rocha, AI. *Pennisetum glaucum (L.) Oral Supplementation Mitigates Multi-Organic Dysfunction Associated with Carcinogenesis in HPV16-Transgenic Mice.* Curr Issues Mol Biol. 2025;47(10) IF: 3.0

- Pereira, F, Pimenta, JL, **Rei, M,** Dias, CR and Pereira, D. *Metastatic Mammary-Like Adenocarcinoma of the Vulva Responding to Cyclin-Dependent Kinase (CDK) Inhibitor: A Case Report and Literature Review.* Cureus. 2025;17(9): p. e93598. IF:1.3
- **Rei, M,** Bernardes, JF and Costa, A. *Ultrasound in endometrial cancer: evaluating the impact of pre-surgical staging.* Oncol Rev. 2025;19: p. 1446850. IF: 5.2
- Rojo, AI, Buttari, B, Cadenas, S, Carlos, AR, Cuadrado, A, Falcao, AS, Lopez, MG, Georgiev, MI, Grochot-Przeczek, A, Gumeni, S, Jimenez-Villegas, J, Horbanczuk, JO, Konu, O, Lastres-Becker, I, Levonen, AL, Maksimova, V, Michaeloudes, C, Mihaylova, LV, Mickael, ME, Milisav, I, Miova, B, Rada, P, **Santos, M,** Seabra, MC, Strac, DS, Tenreiro, S, Trougakos, IP and Dinkova-Kostova, AT. *Model organisms for investigating the functional involvement of NRF2 in non-communicable diseases.* Redox Biol. 2025;79: p. 103464. IF: 11.9
- Santos, DAR, Eiras, M, Gonzalez-Santos, M, **Santos, M**, Pereira, C, Santos, LL, Dinis-Ribeiro, M and Lima, L. *A preliminary assessment of a stool-based microRNA profile for early colorectal cancer screening.* Sci Rep. 2025;15(1): p. 28597. IF: 3.9
- **Satari, S, Mota, INR**, Silva, ACL, Brito, HO, Oliveira, PA**, Gil da Costa, RM** and Medeiros, R. *Hallmarks of Cancer Cachexia: Sexual Dimorphism in Related Pathways.* Int J Mol Sci. 2025;26(9) IF:4.9
- Sessa, C, Travado, L, Calaminus, G, Cunha, TM, Delgado Bolton, RC, van Driel, W, Fernandes, A, Hutka, M, Lemley, B, Luczak, N, **Medeiros, R**, Oberst, S, Ottevanger, N, Papadia, A, Pereira, P, Rodrigues, M, Stolnicu, S, Vandecasteele, K, Costa, A, Poortmans, P and Peccatori, F. *European Cancer Organisation Essential Requirements for Quality Cancer Care for ovarian cancer: Focus on the multidisciplinary team.* Tumori. 2025;111(1): p. 11–9. IF:3.1
- **Silva, MG**, Rodrigues, D, Machado-Rodrigues, AM, Nogueira, H, Gama, A and Padez, C. *Sociodemographic Characteristics Associated With Food-Insecure Households With Preschool and School Children: Findings From the ObesInCrisis Study.* Am J Hum Biol. 2025;37(6): p. e70080. IF:1.7
- Silva, MP, Silva, B, Costa, I, Coutinho, PJG**, Cerqueira, F,** Pinto, E and Dias, AM. *Domino synthesis of a new class of red-shifted and antimicrobial imidazole-based azo dyes from 5-aminoimidazole-4-carboxamidrazones.* Org Biomol Chem. 2025;23(20): p. 4983–96. IF:2.7
- **Tavares, I, Morais, M, Dias, F, Ferreira, M,** Martins, G, Fernandes, R, Bidarra, SJ, **Medeiros, R** and **Teixeira, AL.** *Extracellular vesicles derived-microRNAs predicting enzalutamide-resistance in 3D spheroid prostate Cancer model.* Int J Biol Macromol. 2025;284(Pt 1): p. 137993. IF:8.5
- **Tavares, V**, Lopes, C, Macedo-Silva, C, Farinha, M, Costa, J, Vilas-Boas, MI, Pinelas, S, Assis, J, Dinis-Ribeiro, M, Pereira, D, Pereira, C and **Medeiros, R**. *Genetic markers of thrombophilia as predictors of outcome in colorectal cancer.* J Thromb Thrombolysis. 2025;58(5): p. 663–78. IF:2.2
- **Tavares, V,** Savva-Bordalo, J, **Rei, M**, Liz-Pimenta, J, Assis, J, Pereira, D and **Medeiros, R**. *Heritable Genetic Variability in Ovarian Tumours: Exploring Venous Thromboembolism Susceptibility and Cancer Prognosis in a Hospital-Based Study.* Gene. 2025;950: p. 149378. IF:2.4
- **Teixeira, AL, Dias, F** and **Gil da Costa, RM**. *Editorial: Exploring HPV's role in genitourinary cancers beyond cervical cancer.* Front Oncol. 2025;15: p. 1658619. IF:3.3

### *b) Other outputs*

#### *Book Chapters*

- Martins, A.M., Juan, L.F.V., **Santos, M.,** Martins, J.P. (2025). Sources of Bias When Assessing Seasonal Influenza Vaccine Performance: A Narrative Review. In: Henriques-Rodrigues, L., Menezes, R., Machado, L.M., Faria, S., de Carvalho, M. (eds) New Frontiers in Statistics and Data Science. SPE 2021. Springer Proceedings in Mathematics & Statistics, vol 469. Springer, Cham. https://doi.org/10.1007/978-3-031-68949-9_16. ISBN: 978-3-031-68948-2.

### *Oral Communications by Invitation*

- **Dias F**. (2025) Tiny Messengers, Big Impact: How extracellular vesicles are revolutionizing cancer care. XIV In4Med. (21st February) Coimbra, Portugal.
- **Teixeira AL**. (2025) Aspectos Éticos en investigacion. Encuentro Epilepsia: investigación e innovación compartida - GENOPSYSEN thematic network, CYTED Network. (19th May) Santiago, Spain
- **Teixeira AL.** (2025) Aspectos Éticos en investigacion. Encuentro Epilepsia: investigación e innovación compartida - GENOPSYSEN thematic network, CYTED Network. (21th May) Vigo, Spain
- **Melo, I. G.** (2025). Endothelial Dysfunction: Beyond the Clot. ICT 2025: 29th International Congress on Thrombosis. (7th November) Porto, Portugal.
- **Tavares, V.** (2025). Genetic Markers of Cancer-Associated Thrombosis. ICT 2025: 29th International Congress on Thrombosis. (7th November) Porto, Portugal.
- Santos, M (2025). The Neuroscience-based-Nomenclature massive open online course (MOOC). Neuroscience-based Nomenclature Session. Oct 13th. 38th ECNP Congress. Amsterdam, The Netherlands.
- **Medeiros, R.** (2025). "Genetics on the Path to Personalized Medicine." XXIV Conference of the College of Clinical Analysis and Human Genetics, Specialty College of Clinical Analysis and Human Genetics of the Portuguese Pharmaceutical Society. February 16th, Lisbon, Portugal
- **Medeiros, R.** (2025). "New Approaches in HPV DNA Cervical Cancer Screening." XIV National Congress of Clinical Pathology. March 15th , Braga, Portugal
- - **Medeiros, R.** (2025). "Eradication of HPV-Related Diseases in the Lusophone World: Biology, History and Societal Impact." EUROGIN 2025 International Multidisciplinary HPV Congress – Lusophone Workshop. March 16th, Porto, Portugal
- **Medeiros, R.** (2025). "HPV Research at the Portuguese Oncology Institute of Porto." EUROGIN 2025 International Multidisciplinary HPV Congress – Lusophone Workshop. March 16th, Porto, Portugal
- **Medeiros, R.** (2025). "Eliminating HPV-Associated Cancers: An Utopia?" Update in Medicine 2025. May 1st, Coimbra, Portugal
- **Medeiros, R.** (2025). "Targeted Therapies: A New Era in Personalized Treatment." "Research and Development of New Drugs." i9 Digital Health – Fundação Oriente. May 31st, Lisbon, Portugal
- **Medeiros, R.** (2025). "The Pharmaceutical Sciences expert in the Oncologic Patient Journey." V Community Pharmacy Conference 2025 – Excellence, Innovation and Longevity. Specialty College of Community Pharmacy of the Portuguese Pharmaceutical Society. May 31st, Lisbon, Portugal
- **Medeiros, R.** (2025). "Cancer Control in Europe: Maintaining Momentum, Prioritising Action." The Economist's 10th Annual World Cancer Series Europe – The Economist Group. June 11th, Brussels, Belgium
- **Medeiros, R.** (2025). "EU4Health Projects on HPV: Final Results. What's Next?" PERCH Meeting, ISTITUTO SUPERIORE DI SANITÀ – National Center for Global Health. June 12th, Rome, Italy
- **Medeiros, R.** (2025). "Essential Requirements for Quality Cancer Care in Ovarian Cancer – The European Perspective." 10th Edition of the Gynecology Oncology Advanced Meeting, IPO Porto. July 3rd, 2025, Porto, Portugal
- **Medeiros, R.** (2025). "How to Reduce the Risk of Cancer Development in Women Infected with HPV." VIII Brazilian Symposium of ABPTGIC and I International "Online" Symposium – HPV & Cancer. Webinar of the Brazilian Society of Lower Genital Tract Pathology and Colposcopy. July 5th, 2025, Brasília, Brazil
- **Medeiros, R.** (2025). "Strategies for Identifying and Genotyping HPV in Cervical Cancer Screening." Multidisciplinary Meeting of GIN–Gynecology, Women and Children Unit of ULS São João – São João Hospital Center. July 9th, 2025, Porto, Portugal
- **Medeiros, R.** (2025). "Portugal's Experience as a Best Practice Example – Accelerating Progress Toward the EU's HPV Cancer Elimination Goal: A Path to the Finish Line." European Parliament, Brussels. July 15th, 2025, Brussels, Belgium

- **Medeiros, R.** (2025). "Oncology, Pharmacogenomics and Personalized Medicine: Citizenship vs One Health." Fiocruz One Health Program (Translational Research Program – One Health – FIO-One Health), Oswaldo Cruz Foundation / Oswaldo Cruz Institute. August 27th, 2025, Rio de Janeiro, Brazil
- **Medeiros, R.** (2025). "Pharmaceutical Sciences expert in Oncology: Brazil–Portugal Collaboration (UERJ–IPO)." 6th Pharmacy Symposium "Pharmacist: One Professional, Millions of Possibilities." UERJ – State University of Rio de Janeiro. August 27th, 2025, Rio de Janeiro, Brazil
- **Medeiros, R.** (2025). "Overview of Cancer Research: From Screening to Pharmacogenomics and Personalized Medicine." INCA Postgraduate Program. National Cancer Institute (INCA). August 29th, 2025, Rio de Janeiro, Brazil
- **Medeiros, R.** (2025). "Precision Oncology: The Future is Now." Session 2 Moderator. 1st International Forum of Precision Cancer Medicine, September 18–19th, 2025, Porto
- **Medeiros, R.** (2025). "Essential Requirements for Quality Cancer Care in Precision Cancer Medicine." Community 365 Roundtable: "Sustaining Our Oncology Professions: Meeting Their Needs." European Cancer Organization, October 23rd, 2025, Brussels.
- **Medeiros, R.** (2025). "Precision Oncology: The Future is Now." Session 2 Moderator. 1st International Forum of Precision Cancer Medicine, September 18–19th, 2025, Porto
- **Medeiros, R.** (2025). "Pharmaceutical Competence in Oncology: What Challenges?" XX Scientific Congress AEFFUP ANF. November 15th, 2025, Porto
- **Medeiros, R.** (2025). "Cancer-Associated Thrombosis: Pathophysiological Complexity." 29th ICT International Congress on Thrombosis. November 6–8th, 2025, Porto
- **Medeiros, R.** (2025). "Strategies to Eliminate Cervical Cancer." 206th Meeting of the Portuguese Society of Gynecology, November 14–15th, 2025, Porto

### *Oral Communications in International Scientific Meetings*

- **I. Maocha**; J. Lopes-Nunes; J. Rolo; B. Pires; E. Gallardo; A. Palmeira-de-Oliveira; J. Martinez-de-Oliveira; R. Palmeira-de-Oliveira; **R. Medeiros**; C. Tomaz; J. Castro-de-Sousa; C. Cruz. "Targeted Therapy for HPV-Associated Lesions Using Imiquimod-Loaded Lipid Nanoparticles." EUROGIN – International Multidisciplinary HPV Congress, Porto, Portugal, 16–19th March 2025.

### *Oral Communications in National Scientific Meetings*

- Rodrigues Cardoso, C., Lopes Henriques, I., Moreira, F., & **Santos, M.** (2025). Analysis of the technique for handling monoclonal antibodies in cancer treatments: Compliance of the information presented in RCM and guidelines [*Análise da técnica de manipulação de anticorpos monoclonais em tratamentos oncológicos: Conformidade da informação apresentada em RCM e guidelines]* 11th Scientific Meetings on Pharmacy, School of Health Sciences, Polytechnic Institute of Porto, Porto, Portugal.
- **Ferreira, M., Morais, M., Alves, Â., Tavares, I., Dias, F.**, Bidarra, S., **Medeiros, R., Teixeira, A.L**. (2025). *miRNA downregulation dynamics during acquisition of enzalutamide resistance: Implications for early detection and RNA-based therapeutic approaches.* 18th Edition of Young Researchers Meeting of the U.Porto (IJUP). Porto, Portugal
- **Alves, Â., Ferreira, M.**, Eiras, M., Lima, L., **Medeiros, R., Teixeira, A.L., Dias, F.** (2025). *Hsa-miR-200c-3p, hsa-miR-25-3p and hsa-miR-301a-3p as potential biomarkers and therapeutic targets for restoration of PTEN expression in clear cell renal cell carcinoma.* 18th Edition of Young Researchers Meeting of the U.Porto (IJUP)., Porto, Portugal

### *Posters in international conferences*

- Alves Â, Ferreira M, Eiras M, Lima L, Medeiros R, Teixeira AL, Dias F.(2025). Hsa-miR-200c-3p, hsa-miR-25-3p and hsa-miR-301a-3p as potential biomarkers and therapeutic targets for restoration of PTEN expression in clear cell renal cell carcinoma. EACR 2025 Congress (16-19th June); Lisbon, Portugal.

- Dias V, Alves Â, Maurício J, Morais A, Medeiros R, Teixeira AL, Dias F. (2025). Unveiling the Role of EVs-derived miR-15b, -1293, -376a in Clear Cell Renal Cell Carcinoma Progression. EACR 2025 Congress (16-19th June); Lisbon, Portugal.
- Dias TR, Almeida B, Cruz P, Sousa-Pimenta M, Soares B, Teixeira AL, Oliveira J, Dias F, Medeiros R. (2025). MicroRNAs humoral and cellular immune response profile to COVID-19 vaccine boost in cancer patients. EACR 2025 Congress (16-19th June); Lisbon, Portugal.
- Ferreira M, Morais M, Alves Â, Tavares I, Dias F, Bidarra S, Medeiros R, Teixeira AL (2025). Extracellular Vesicle-Associated miRNA downregulation dynamics during acquisition of enzalutamide resistance: implications for early detection and RNA-based therapeutic opportunities. EACR 2025 Congress (16-19th June); Lisbon, Portugal.
- Alves Â, Ferreira M, Eiras M, Lima L, Medeiros R, Teixeira AL, Dias F.(2025). Combined Inhibition of PTEN-Regulating MiRNAs as a promising therapeutic Strategy for clear cell renal cell carcinoma. IV ASPIC-ASEICA International Meeting (20-21st November); Santiago de Compostela, Spain.
- Ferreira M, Morais M, Alves Â, Tavares I, Dias F, Bidarra S, Medeiros R, Teixeira AL (2025). Tracking EV-derived miRNA dynamics to detect and overcome enzalutamide resistance in Prostate cancer. IV ASPIC-ASEICA International Meeting (20-21st November); Santiago de Compostela, Spain.
- Lopes LR, Machado DE, Goes RA, Sousa E, Tavares V, Dias F, Medeiros R, Perini J. The development of musculoskeletal injury in high-performance athletes: ACE2 genetic polymorphisms and a risk score. GENETICA 2025 - International Congress of the Brazilian Genetics Society (13th August); Brazil.
- Lopes LR, Medeiros R, Dias F, Tavares V, Goes RA, Sousa E, Machado DE, Perini J. Multifactorial Risk Score and the Risk of Musculoskeletal Injuries in High-Performance Athletes: Analysis of Polymorphisms in the ACE2 Gene [Escore de risco multifatorial e o risco de lesões musculoesqueléticas em atletas de alto desempenho: análise de polimorfismos no gene ACE2.] 2nd Annual Research and Innovation Conference of the National Institute of Traumatology and Orthopedics (INTO) (27th November); Brazil.
- Silva, D.; Moreira, F.; Santos, M. (2025) Efficacy and Safety of Tocilizumab in the Treatment of Rheumatoid Arthritis: An Umbrella Review, in Abstracts of the 3rd International Electronic Conference on Biomedicines. Med. Sci. Forum 2025, 34, 1. https://doi.org/ 10.3390/msf2025034001
- Santos, M.; Santos, A.; Jesus, A. (2025) Exploring the Role of Oral Antidiabetic Medications as Adjuncts in Depression Treatment, in Abstracts of the 3rd International Electronic Conference on Biomedicines. Med. Sci. Forum 2025, 34, 1. https://doi.org/ 10.3390/msf2025034001
- Tomé, P.; Moreira, F.; Santos, M. (2025) Pharmacological Approaches in Amyotrophic Lateral Sclerosis: A Systematic Review of Clinical Trials on Efficacy, Survival, and Safety Profiles, in Abstracts of the 3rd International Electronic Conference on Biomedicines. Med. Sci. Forum 2025, 34, 1. https://doi.org/ 10.3390/msf2025034001

### *Posters in national conferences*

- Pires MM, Tavares V, Ferreira T, Silva ACL, Medeiros R. (2025). The Role of IGF-1 Signalling in Cancer-Associated Thrombosis and Cachexia. X Jornadas da Bioquímica. (10th April), Porto, Portugal
- Mendes L, Lopes C, Tavares V, Dinis-Ribeiro M, Pereira C. (2025) Validation of genome-wide association studies (GWAS)-derived polymorphisms as susceptibility biomarkers for gastric cancer: a study design. 18th Edition of Young Researchers Meeting of the U.Porto (IJUP). (7-9th May), Porto, Portugal
- Costa MT, Tavares V, Adega F, Medeiros R. (2025) Circulating Levels of miR-145 Link Mucin-Driven Thrombosis and Survival Outcomes in Cervical Cancer: Implications for Patient Monitoring. 10th Advanced Course in Gynaecologic Oncology. (3-4th July), Porto, Portugal

- Melo IG, Tavares V, Savva-Bordalo J, Rei M, Liz-Pimenta J, Pereira D, Medeiros R. Heparanase in Ovarian Cancer: Beneficial After All? Encontro Ciência 2025. (9-11th July), Lisbon, Portugal
- Melo IG, Tavares V, Savva-Bordalo J, Rei M, Liz-Pimenta J, Pereira D, Medeiros R. Heparanase in Ovarian Cancer: An Immunotherapy Opportunity? 10th Advanced Course in Gynaecologic Oncology. (3-4th July), Porto, Portugal
- Pires MM, Tavares V, Ferreira T, Silva ACL, Melo IG, Medeiros R. Rethinking the Insulin Growth Factor 1 Axis in Ovarian Cancer: Genetic Predictors of Survival. 10th Advanced Course in Gynaecologic Oncology. (3-4th July), Porto, Portugal
- Pires MM, Tavares V, Ferreira T, Silva ACL, Melo IG, Medeiros R. (2025) The Role of IGF-1 Signalling in Cancer-Associated Thrombosis and Cachexia. Encontro Ciência 2025. (9-11th July), Lisbon, Portugal
- Tavares V, Melo IG, Savva-Bordalo J, Rei M, Liz-Pimenta J, Assis J, Pereira D, Medeiros, R. (2025) Targeting the Tissue Factor Pathway in Ovarian Carcinoma: Prognostic Value of Plasma microRNAs and Implications for Novel Therapies. Encontro Ciência 2025. (9-11th July), Lisbon, Portugal
- Tavares V, Melo IG, Savva-Bordalo J, Rei M, Liz-Pimenta J, Assis J, Pereira D, Medeiros, R. Targeting the Tissue Factor Pathway in Ovarian Carcinoma: Prognostic Value of Plasma microRNAs and Implications for Novel Therapies. 10th Advanced Course in Gynaecologic Oncology. (3-4th July), Porto, Portugal
- Lopes I, Meireles I, Rocha AC, Dias F, Cerqueira M, Cunha J, da Costa Ataide G, Cerqueira F. (2025). *Adenocalymma magnificum*: flower extract inhibits the migration of prostate tumor cells [*Adenocalymma magnificum:* extrato de flor inibe a migração de células tumorais de próstata] 7th National Meeting of Young Researchers in Oncology (ENIO) (24th September), Porto, Portugal
- Nunes J, Lopes I, Meireles I, Melônio M, Quinto da Rocha C, Gil da Costa R, Brito H, Medeiros R, Cerqueira F. (2025). The Promise of Parkia platycephala Leaves in Cancer Treatment [A promessa da folha de Parkia platycephala no tratamento de cancro]. 7th National Meeting of Young Researchers in Oncology (ENIO) (24th September), Porto, Portugal
- Nunes J, Lopes I, Meireles I, Melônio M, Quinto da Rocha C, Gil da Costa R, Brito H, Medeiros R, Cerqueira F. (2025). Antitumor activity of Parkia platycephala flower extracts [Atividade antitumoral de extratos de flor de Parkia Platycephala]. 7th National Meeting of Young Researchers in Oncology (ENIO) (24th September), Porto, Portugal
- Martins A, Lopes I, Meireles I, Quintinho da Rocha C, Gil da Costa R, Brito H, Medeiros R, Cerqueira F. (2025). Friderica platyphylla: a ray of hope in the fight against pancreatic cancer [Friderica platyphylla: uma esperança no combate ao cancro do pancreas]. 7th National Meeting of Young Researchers in Oncology (ENIO) (24th September), Porto, Portugal
- Martins A, Lopes I, Meireles I, Quintinho da Rocha C, Gil da Costa R, Brito H, Medeiros R, Cerqueira F. (2025). Study of the Antitumor Activity of Clusia grandiflora [Estudo da atividade antitumoral de Clusia grandiflora]. 7th National Meeting of Young Researchers in Oncology (ENIO) (24th September), Porto, Portugal
- Martins AS, Ferreira M, Vieira C, Romano O, Rodrigues R, Moreira AP, Rubal-Oter L, Brozoz-Vásquez, Álvarez-Rodríguez M, Pérez IF, Dumitrescu EA, Gheorghe A, Dah C, Arendt-Nielsen L, Carrillo-de-la-Pena MT, Teixeira AL, Medeiros R. Validation of Central Pain Processing Biomarkers to Predict Chronic Pain in Cancer Patients: Insights from the PAINLESS WP1 Longitudinal Study. 3rd Young Researchers´Day 2025 (22nd October), Porto, Portugal
- Ferreira T, Machado AT, Medeiros R, Oliveira PA, Gama A. (2025) Molecular subtype changes in canine mammary tumours: primary tumour versus lymph node metastasis. II Thematic Meeting Al4animals - Comparative, Translational Medicine and Biotechnology. (28th November), Porto, Portugal

### Editorial Board Positions

| Journal | Publishing Company | Position | Researcher |
|---|---|---|---|
| Frontiers in Cellular and Infection Microbiology | Frontiers | Associate Editor | Rui M. Gil da Costa |
| Frontiers in Oncology | Frontiers | Associate Editor | Rui M. Gil da Costa |
| International Journal of Molecular Sciences | MDPI | Topical Advisory Panel; Guest Editor | Marlene Santos |
| International Journal of Molecular Sciences | MDPI | Topical Advisory Panel | Valéria Tavares |
| Frontiers in Nutrition | Frontiers | Guest Associate Editor | Marlene Santos |
| Depression and Anxiety | Wiley/ Hindawi | Academic Editor | Marlene Santos |
| Cancers | MDPI | Special Issue Editor | Francisca Dias |
| Frontiers in Oncology | Frontiers | Guest Associate Editor | Francisca Dias |
| Frontiers in Oncology | Frontiers | Review Editor | Ana Luísa Teixeira |
| Cancers | MDPI | Special Issue Editor | Ana Luísa Teixeira |
| Frontiers in Genetics | Frontiers | Review Editor | Ana Luísa Teixeira |
| Frontiers in Cellular and Infection Microbiology | Frontiers | Review Editor | Ana Luísa Teixeira |
| Frontiers in Oncology | Frontiers | Guest Associate Editor | Ana Luísa Teixeira |
| Extracellular Vesicles and Circulating Nucleic Acids | OAE Publishing | Junior Editor | Ana Luísa Teixeira |
| Pharmaceutics | MDPI | Special Issue Editor | Ana Luísa Teixeira |
| Pharmaceutics | MDPI | Special Issue Editor | Mariana Morais |
| Cancers | MDPI | Special Issue Editor | Mariana Morais |
| Antibiotics | MDPI | Special Issue Editor | Fátima Cerqueira |
| Molecules | MDPI | Special Issue Editor | Fátima Cerqueira |
| Pharmaceutics | MDPI | Special Issue Editor | Fátima Cerqueira |
| RISE Health Research Journal | Wolters Kluwer | Associate Editor | Fátima Cerqueira |
| Viruses | MDPI | Guest Editor | Rui Medeiros |
| Cancers | MDPI | Guest Editor | Rui Medeiros |
| International Journal of Molecular Science | MDPI | Editorial Board Member | Rui Medeiros |
| Frontiers in Genetics: Applied genetic Epidemiology | Frontiers | Editorial Board Member | Rui Medeiros |
| Frontiers in Health Services:Health policy and Management | Frontiers | Editorial Board Member | Rui Medeiros |
| Oncology Letters | Spandidos Pub | Editorial Board Member | Rui Medeiros |
| Rise Health Research Journal | Wolters Kluwer | Associate Editor | Rui Medeiros |
| eLife | aLifeSciences | Editorial Board Member | Rui Medeiros |

### Peer Review

Advanced Science; Alternative Therapies in Health and Medicine; Animals; Annals of Medicine; Antioxidants; Biomarkers - Taylor& Francis; Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease; Biomedicines; Biochimica et Biophysica Acta (BBA) - Reviews on Cancer; Biology; Biomarkers in Medicine; Biomedicines; Bioengineering, BMC cancer; BMC – Cardiovascular Disorders; British Journal of Cancer; Cancer Letters; Cancers; Cancer Communications; Cancer Informatics; Cancer Medicine; Cancer Reports; Cells; Ciência Rural; Clinical Case Reports; Clinical Chemistry; Clinical Epidemiology; Clinical Epigenetics; Communications Biology; Computational and Structural Biotechnology Journal; Current Issues in Molecular Biology; Current Oncology; Diagnostics; Discovery Oncology; E CNS Neuroscience & Therapeutics; Biomedicine; Epigenetics; Epigenomics; European Journal of Medical Research; European Urology; Extracellular Vesicles and Circulating Nucleic Acids; FEBS Open Bio; Frontiers in Genetics; Frontiers in Oncology; Frontiers In Psychiatry; Genes; Hematology – Taylor& Francis; Histology & Histopathology; International Journal of Cancer; International Journal of Molecular Sciences; International Journal of Women's Health; iScience; Journal of Experimental & Clinical Cancer Research; Journal of Extracellular Biology; Journal of Fungi; Journal of Personalized Medicine; Journal of Pharmaceutical and Biomedical Analysis; Journal of Urology; Human Pathology; Lancet; Life; Medicina; Metabolites; Molecular and Cellular Probes; Mol Cancer; Mol Oncology; Molecules; Nanomaterials; Nanomedicine; Nature Reviews in Urology; Neoplasia; Nutrients; Oncotarget; Pharmaceutics; Pharmaceuticals; Pharmacological Reports; PLOS One; Postgraduate Medicine; Prostate; Porto Biomedical Journal; Reports of Practical Oncology and Radiotherapy; Scientific Reports; Therapeutic Advances in Medical Oncology; Therapeutics and Clinical Risk Management; Theranostics; Thrombosis Journal; Toxins; Veterinary Medicine and Science; Veterinary Sciences; Virchows Archiv, Journal Medical Virology, etc.,

### Participation as Opponent in MSc Evaluation Committees

| Student | Title | Program | Researcher |
|---|---|---|---|
| Mariana Moura Magalhães | Deciphering the influence of CD276 glycocode in colorectal cancar immunoregulation | Master in Biochemistry in Health - IPP | Francisca Dias |
| Ana Raquel Conde Martins | Atividade antitumoral de novos compostos em linhas celulares representativas dos tumores mais prevalentes em Portugal | Integrated Master in Pharmaceutical Sciences – FCS-UFP | Francisca Dias |
| Susana Sofia Macêdo Loureiro | Non-Invasive Screening Strategies for Colorectal Cancer: Protocol Optimization and RNA Biomarker Identification | Master in Pharmacy – ESS, IPP | Ana Luísa Teixeira |

### Teaching Activity: Coordination of Curricular Units/Courses

| Member | Curricular Units | Programme | Position | Faculty/University |
|---|---|---|---|---|
| Ana Luísa Teixeira | Forensic biology and Antropology | MSc in Legal Medicine | Teaching | ICBAS-UP |
| Ana Luísa Teixeira | Molecules, Cells and Disease III | Integrated MSc in Medicine | Teaching | EMCB-UFP |
| Ana Luísa Teixeira | Scientific Reading and Writing | Integrated MSc in Medicine | Teaching | EMCB-UFP |
| Ana Luísa Teixeira | Research Practices in Oncology | MSc in Oncology | Teaching | ICBAS-UP |
| Carina Fernandes | Cognitive Psychology I | BSc in Psychology | Teaching | FCHS-UFP |
| Carina Fernandes | Cognitive Psychology II | BSc in Psychology | Teaching | FCHS-UFP |
| Carina Fernandes | Neuropsychology | BSc in Psychology | Teaching | FCHS-UFP |
| Carina Fernandes | Neurocognitive Assessment and Intervention | MSc in Clinical and Health Psychology | Teaching | FCHS-UFP |
| Francisca Dias | Scientific Reading and Writing | Integrated MSc in Medicine | Teaching | EMCB-UFP |

| Member | Curricular Units | Programme | Position | Faculty/University |
|---|---|---|---|---|
| Francisca Dias | Molecules, Cells and Disease II | Integrated MSc in Medicine | Teaching | EMCB-UFP |
| Francisca Dias | Molecules, Cells and Disease III | Integrated MSc in Medicine | Teaching | EMCB-UFP |
| Francisca Dias | Immunology | MSc in Biomedicine | Teaching | EMCB-UFP/UTAD |
| Francisca Dias | Scientific Methodology and Communication in Science | MSc in Biomedicine | Teaching | EMCB-UFP/UTAD |
| Fátima Cerqueira | Virology | Integrated MSc in Pharmaceutical Sciences | Teaching | FCS-UFP |
| Fátima Cerqueira | Parasitology and Micology | Integrated MSc in Pharmaceutical Sciences | Teaching | FCS-UFP |
| Fátima Cerqueira | Molecules, Cells and Disease III | Integrated MSc in Medicine | Teaching | EMCB-UFP |
| Fátima Cerqueira | Immunology | MSc in Biomedicine | Teaching | EMCB-UFP/UTAD |
| Fátima Cerqueira | NA | MSc in Biomedicine | Assistant coordinator of the program | EMCB-UFP/UTAD |
| Fátima Cerqueira | Clinical Virology | Bachelor's degree in biomedical laboratory sciences | Teaching | ESS-FP |
| Fátima Cerqueira | Clinical Parasitology and Micology | Bachelor's degree in biomedical laboratory sciences | Teaching | ESS-FP |
| Fátima Cerqueira | General Microbiology | Integrated MSc in Dental Medicine | Teaching | FCS-UFP |
| Hugo Sousa | Basic Pathology | BScH Nursing | Coordination of Curricular Unit | ISAVE |
| Hugo Sousa | Basic Pathology | BScH Phyiotherapy | Coordination of Curricular Unit | ISAVE |
| Hugo Sousa | Medical Pathology | BScH Nursing | Coordination of Curricular Unit | ISAVE |
| Hugo Sousa | CLINICAL VIROLOGY | MSc in Clinical Analysis | Teaching | Faculty of Pharmacy, University of Porto |
| Marlene Santos | Pharmacology II | BSc in Pharmacy | Coordination of Curricular Unit | ESS-IPP |
| Marlene Santos | Laboratory in Pharmacy II | BSc in Pharmacy | Coordination of Curricular Unit | ESS-IPP |
| Marlene Santos | Simulated Practices in Pharmacotherapy II | BSc in Pharmacy | Coordination of Curricular Unit | ESS-IPP |
| Marlene Santos | Applied Pharmacology and Therapeutics | BSc in Clinical Physiology | Coordination of Curricular Unit | ESS-IPP |
| Marlene Santos | Pharmacogenomics | MSc in Pharmacy/ MSc Biochemistry in Health | Coordination of Curricular Unit | ESS-IPP |
| Marlene Santos | R&D New Medicines and Health Products | MSc in Pharmacy | Coordination of Curricular Unit | ESS-IPP |
| Rui Medeiros | Virology/Parasitology | PharmD Pharmaceutical Sciences | Coordination and teaching | FCS-UFP |
| Rui Medeiros | Pharmacogenomics | MSc in Oncology | Coordination and teaching | ICBAS/IPO-Porto |

| Member | Curricular Units | Programme | Position | Faculty/University |
|---|---|---|---|---|
| Rui Medeiros | Pharmacogenomics and Molecular Epidemiology | PhD Pathology and Molecular Genetics | Coordination and teaching | ICBAS/IPO-Porto |
| Rui Medeiros | Pharmacogenomics and Molecular Epidemiology | MSc Medicine and Molecular Oncology | Coordination and teaching | FMUP-UP |
| Rui Medeiros | Scientific Reading and Writing | Integrated MSc in Medicine | Coordination and teaching | EMCB-UFP |
| Rui Medeiros | Clinical Virology | Bachelor's degree in biomedical laboratory sciences | Coordination and teaching | ESS-FP |
| Rui Medeiros | Clinical Parasitology and Micology | Bachelor's degree in biomedical laboratory sciences | Coordination and teaching | ESS-FP |
| Valéria Delgado Tavares | Molecules, Cells and Disease III | Integrated MSc in Medicine | Teaching | EMCB-UFP |

### *International Internships*

| Period | Researcher/student | Position/Program | Country |
|---|---|---|---|
| Nov. 024 – March 2025 | Juliane Raeck | Erasmus+ Student | Germany |

### *Prizes, Honors and Awards*

| Researcher | Prize designation | Foundation/ Company | Date | Amount |
|---|---|---|---|---|
| Mariana Moreira Pires | Second-best Poster | 10th Advanced Course in Gynecologic Oncology | July 2025 | 400€ |
| Ana Luísa Teixeira | ASPIC Grant (Top scoring abstract), EACR 2025 | EACR 2025 Congress | June 2025 | - |
| Marlene Santos | Certificate of Merit for Scientific Publication (PAPRE 2025) for work published in the scientific journal Redox Biology, ranked in the top 10% of the respective scientific area in the Web of Science | PAPRE 2025 - IPP | | |

### Scientific Appointments

| Organization | Researcher |
|---|---|
| Member Board of Directors of the ECO European Cancer Organization | Rui Medeiros |
| Member of The Neuroscience-based-Nomenclature (NbN) taskforce in representation of the ECNP | Marlene Santos |
| Supervision Council, Pharmaceutical Order | Rui Medeiros |
| Board Member of LPCC, Portuguese League Against Cancer | Rui Medeiros |

### International collaborations

| Title | Researchers | International Team | Institution | Country | Funding |
|---|---|---|---|---|---|
| Pain relief in palliative care of cancer using home-based neuromodulation and predictive biomarkers (PAINLESS) | Rui Medeiros Ana Luisa Teixeira, Ana Sofia Martins, Mariana Ferreira | María T. Carrillo-de-la-Peña (Coord) | USC, University of Santiago Compostela (IPO Porto-Rui Medeiros chair WP1) | Belgium, Czechia, Denmark, France, Germany, Israel, Portugal, Romania, Spain, and Switzerland | PAINLESS is a Horizon Europe Initiative HORIZON-HLTH-2021-DISEASE-04 (2022-2027) |

### International Consortia

| Organization | Researcher |
|---|---|
| Management Committee Member and WG1 Leader - Management Committee Member and WG1 Leader | Marlene Santos |
| GenoPsySEN thematic network – Ibero-American Program of Science and Technology for Development CYTED | Ana Luísa Teixeira |
| Biomarkers of central pain processing and modulation as predictive tools of chronic pain in patients with cancer (PAINLESS WP1) | Rui Medeiros |
| Consortium Agreement on Science and Teaching by IPO Porto/Faculty of Medicine of University of Maranhão | Rui Medeiros |
| Consortium Agreement on Science and Teaching by IPO Porto/UERJ, State University of Rio de Janeiro | Rui Medeiros |

## PRECANCEROUS LESIONS & EARLY CANCER MANAGEMENT GROUP

### Coordinator

Mário Dinis Ribeiro, MD PhD

### Research team @31 December 2025

| Name | Academic Degree | Professional Situation | Category/position | Time % |
|---|---|---|---|---|
| Adriana Serra | MSc | Contract | Research Assistant | 100 |
| Ana Carina Pereira | PhD | Contract | Assistant Researcher / Senior Researcher | 100 |
| Ana Paula Santos | PhD | Contract | Endocrinologist / Junior Researcher | 30 |
| Andreia Albuquerque | PhD | External | Associate Researcher | 30 |
| Catarina Brandão | MD, MSc | Contract | Gastroenterologist | 10 |
| Catarina Lopes | PhD | Contract | Research Assistant | 100 |
| Daniela Rocha Santos | MSc | Fellowship | PhD Student | 30 |
| Diogo Libânio | MD, PhD | Contract | Gastroenterologist / Senior Researcher | 30 |
| Filipa Fontes | PhD | External | Associate Researcher | 20 |
| Inês Marques de Sá | MD, MSc | Contract | Gastroenterologist / PhD Student | 20 |
| Mariana Gonçalves Eiras | MSc | Fellowship | PhD student | 30 |
| Mário Dinis-Ribeiro | MD, PhD, Aggregation | Contract | Department of Medicine Director /Group Coordinator | 30 |
| Miguel Areia | MD, PhD | External | Associate Researcher | 30 |
| Mylene Costa | MD, MSc | Contract | Clinical Pathology Resident | 70 |
| Patrícia Alves | PhD | Contract | Junior Research | 100 |
| Pedro Pimentel-Nunes | MD, PhD | External | Associate Researcher | 30 |
| Rafael Lopes | MSc | Fellowship | PhD student | 30 |
| Raquel Ortigão | MD | Contract | Gastroenterologist | 20 |
| Raquel Ramos | MSc | Contract | Research Assistant | 100 |
| Renato Caldevilla | MSc | Fellowship | PhD Student | 30 |
| Ricardo Kuttner-Magalhães | MD, PhD | External | Associate Researcher | 30 |
| Ricardo Marcos-Pinto | MD, PhD | External | Associate Researcher | 30 |
| Ruben Alves | BSc | Student | MSc Student | 20 |
| Tatiana Cruz Almeida | MSc | Fellowship | PhD student | 100 |

### Group description and objectives

The PRECAM group represents a unique network in the field of clinical and translational research in Early Cancer, with a greater focus on Gastrointestinal Oncology, bringing together researchers from different leading cancer institutions, such as the IPO of Porto, IPO of Coimbra and the University Hospital Centre of Porto.

This multidisciplinary team focuses on the main mission of creating new knowledge and evaluating new and disruptive technologies in a comprehensive and integrative vision, to improve the diagnosis and follow-up of patients with precursor lesions and early cancer, through the personalization of healthcare. It is also our priority to understand groups' perceptions on cancer screening/management to guide the development of effective healthcare strategies that better meet the needs of both citizens/patients and providers.

Specifically, the PRECAM group will focus on:

- Assessing the feasibility and effectiveness of screening programs in digestive cancers in Portugal and Europe.
- Developing non-invasive, accessible and scalable diagnostic tests, like liquid biopsies.
- Enhancing minimally invasive diagnostic techniques, such as endoscopy, with improved quality and leveraging AI.
- Improving clinical management by creating decision-making tools, intervention strategies, and conducting cost-effectiveness studies to enhance patient outcomes and healthcare efficiency.
- Understanding citizens', patients' and healthcare providers' perceptions towards screening and management of precancerous lesions in gastrointestinal tract, including their preferences, knowledge and intention to adhere, and contributing to the promotion of cancer screening adherence.
- Developing capacity and fostering sustainable change in gastrointestinal cancer screening and early diagnosis by contributing to the advancement of lifelong medical education.

## Active projects and funding

### Competitive Funding

#### International

- EUCanScreen – "Implementation of cancer screening programmes" (101162959), Budget @IPO Porto: 638 016,39€ (2024) (PI @IPO Porto: Mário Dinis-Ribeiro).
- TOGAS – "Towards Gastric cancer Screening implementation in the European Union" (101101252), Budget @IPO Porto: 934 957,00€ (2023) (PI @IPO Porto: Mário Dinis-Ribeiro).
- AIDA – "An Artificially Intelligent Diagnostic Assistant for gastric inflammation" (101095359), Budget @IPO Porto: 791 875,00€ (2022) (PI @IPO Porto: Mário Dinis-Ribeiro).
- ONCOSCREEN- "A European "shield" against colorectal cancer based on novel, more precise and affordable risk-based screening methods and viable policy pathways" (101097036), Budget @IPO Porto: 382 500,00€ (2022) (PI @IPO Porto: Mário Dinis-Ribeiro)

#### National

- GATE – "GenerAlizable and Trustable computer assisted upper gastrointestinal Endoscopy" (COMPETE2030-FEDER-00886200), Budget @IPO Porto: 31 666.00€ (PI@IPO Porto: Mário Dinis-Ribeiro)
- EndoRadiomics – **"**A Radiomics Approach to Gastric Lesion Characterization in Endoscopic Images" (04/C05-i08.01/2024.P2024.07584.IACDC/2024), Budget: 124 995€ (PI@IPO Porto: Mário Dinis-Ribeiro)
- IMAGE – "Individualized gastric adenocarcinoma early diagnosis and improved patients' survival: from liquid biopsies to a comprehensive management approach" (NORTE-01-0145FEDER-000050), Budget: 601 320,91€ (2021) (PI: Mário Dinis-Ribeiro; Co-PI: Pedro Pimentel-Nunes & Diogo Libânio)
- CAGED – "Computer assisted gastric cancer diagnosis" (EEE/5557/2020), Budget: 249 460€ (2021) (Co-PI: Mário Dinis-Ribeiro)
- BioFaec – "Novel faecal biomarkers for early detection of precancerous lesions ans cancer: Improving the current model for colorectal cancer screening" (2022.09051.PTDC), Budget: 50 000€ (2023) (PI: Mário Dinis-Ribeiro)
- "Glycans as novel players in the development of colitis-associated colorectal cancer: an opportunity to identify biomarkers for cancer surveillance" (FCTEXPL/MED-ONC/0496/2021), Budget: 50 000€ (2021) (PI: Ricardo Marcos-Pinto)
- "The Glyco-immuno code in colorectal cancer: an opportunity for novel immunotherapeutic strategies for cancer prevention" (LPCC-NRN), Budget: 13 500€ (2023) (PI: Ricardo Marcos-Pinto)
- "The Glyco-immuno code in colorectal cancer: an opportunity for novel immunotherapeutic strategies for cancer prevention" (SPG), Budget: 6 000€ (2023) (PI: Ricardo Marcos-Pinto)

### Major achievements

- ***Garrido, M., Almeida., T. C., Kuttner-Magalhães, R., Marcos-Pinto, R., Archer, S., Pinho, R., Estevinho, M. M., Santos-Antunes, J., Morais, R., Barreiro, P., Simão, I., Bourke, M., Wang, H., Amaro, P., Gravito-Soares, E., Kuvaev, R., Kashin, S., Areia, M., Viegas, M. I., Koch, A. D., Spaander, M. C. W., Provoost, N., Manfredi, G., Esposito, G., Losurdo, G., Lemmers, A., Fernández-Esparrach, G., Santiago, E. R., Dinis-Ribeiro, M., Libânio, D. External multicenter validation of the FAMISH score for predicting metachronous gastric lesions after endoscopic submucosal dissection. Scand J Gastroenterol. 2025, 1-9. (IF: 1.7) https://pubmed.ncbi.nlm.nih.gov/40587228/***

Surveillance after gastric endoscopic submucosal dissection (ESD) is crucial due to the high risk of metachronous gastric lesions (MGL), although this risk may differ between patients. We sought to validate the FAMISH score - a prediction score to estimate MGL risk after gastric ESD - within a multicentric framework**.** Surveillance after gastric endoscopic submucosal dissection (ESD) is crucial due to the high risk of metachronous gastric lesions (MGL), although this risk may differ between patients. We sought to validate the FAMISH score - a prediction score to estimate MGL risk after gastric ESD - within a multicentric framework. A total of 855 individuals were included, with 20% of them considered low-risk according to the FAMISH score. After a mean follow-up time of 5 years (SD ± 2 years), 168 patients (19.6%) developed MGL. At 3 years of follow-up, the score achieved 90.4% sensitivity and 93.9% NPV. At 5 years follow-up, the score achieved 89.1% sensitivity and 85.3% NPV. The FAMISH risk score achieved a fair diagnostic accuracy with an AUC of 0.618 at 3 years ($p < 0.001$) and 0.597 ($p = 0.006$) at 5 years of follow-up. The progression to MGL at 5 years of follow-up was significantly lower for the low-risk group (9.6% vs. 18.2%, $p = 0.029$). The FAMISH score achieved an acceptable diagnostic accuracy in a multicentric validation cohort from Western countries. This score is a useful tool to identify patients with low risk for MGL allowing to safely extend surveillance intervals and reduce the burden of care.

- ***Lopes, C., Brandão, A., Teixeira, M.R., Dinis-Ribeiro, M., Pereira, C. Saliva-derived transcriptomic signature for gastric cancer detection using machine learning and leveraging publicly available datasets. Sci Rep. 2025, 15(1): 18491. (IF: 3.9) https://pubmed.ncbi.nlm.nih.gov/40425785/***

Saliva, a non-invasive, self-collected liquid biopsy, holds promise for early gastric cancer (GC) screening. This study aims to assess the potential of saliva as a proxy for malignant gastric transformation and its diagnostic value through transcriptomic profiling. Leveraging transcriptomic data from the Gene Expression Omnibus (GEO), we constructed and validated predictive models through machine learning algorithms within the tidymodels framework. Tissue-based models were validated on independent tissue datasets, and subsequently applied to saliva. Additionally, an independent saliva-derived model was created and evaluated using sensitivity, specificity, accuracy, area under the curve (AUC), and likelihood ratio (LR) metrics. Tissue-derived models demonstrated excellent performance, with AUC values exceeding 0.9, but did not translate effectively to saliva, suggesting distinct molecular landscapes between tissue and saliva in GC. The saliva-specific model using support vector machine (SVM) achieved the highest performance, with an AUC of 0.87 (95% CI 0.72-0.97), a sensitivity of 0.79 (95% CI 0.58-0.95) and a specificity of 0.70 (95% CI 0.40-0.90). While saliva may not mirror tissue gene expression profile, it represents a promising non-invasive predictive tool for the early detection of GC. Further research is warranted to optimize saliva-derived molecular signatures, increasing their sensitivity and specificity for early cancer detection and advance the use of liquid biopsies in personalized medicine for improved screening, diagnostic and prognostic capabilities.

### Scientific output

#### *a. Peer-reviewed indexed publications (final publication date in 2025)*

- **Albuquerque, A** and **Fontes, F**. *Recent Guidelines on Anal Cancer Screening: A Systematic Review.* J Low Genit Tract Dis. 2025;29(2): p. 180–5. IF:2.1
- **Albuquerque, A** and Rao, SSC. *Controversies in fecal incontinence.* World J Gastroenterol. 2025;31(3): p. 97963. IF:5.4
- Almeida, E, Martins, ML, Marques, D, Delas, R, **Almeida, T, Chaves, J, Libanio, D,** Renna, F, Coimbra, MT and **Dinis-Ribeiro, M.** *Artificial intelligence for endoscopic grading of gastric intestinal*

*metaplasia: advancing risk stratification for gastric cancer.* Endoscopy. 2025;57(11): p. 1254–60. IF: 12.8

- Alves, A, Ferreira, M**, Eiras, M**, Lima, L, Medeiros, R, Teixeira, AL and Dias, F. *Exosome-derived hsa-miR-200c-3p, hsa-miR-25-3p and hsa-miR-301a-3p as potential biomarkers and therapeutic targets for restoration of PTEN expression in clear cell renal cell carcinoma.* Int J Biol Macromol. 2025;302: p. 140607. IF:8.5
- **Areia, M**, Esposito, G, Leclercq, P, Romanczyk, M, Zessner-Spitzenberg, J, Delgado Guillena, PG, Monged, A, Honrubia Lopez, R, Uchima, H, Ruiz Ballesteros, EJ, Panarese, A, Reis de Oliveira, LA, Afify, S, Bisschops, R, Ferlitsch, M and External Voting, P. *Performance measures for upper gastrointestinal endoscopy: a European Society of Gastrointestinal Endoscopy (ESGE) Quality Improvement Initiative - Update 2025.* Endoscopy. 2025;57(11): p. 1268–97. IF:12.8
- Borges-Canha, M, Centelles-Lodeiro, J, Leite, AR, Chaves, J, Lourenco, IM, Von-Hafe, M, Vale, C, Martins, D, Silva, C, Ferreira, AC, Falony, G, Liberal, R, Fragao-Marques, M, Barros, A, Miranda, I, Leite-Moreira, A, **Pimentel-Nunes, P**, Vieira-Silva, S and Neves, JS. *Gut dysbiosis is linked to severe steatosis and enhances its diagnostic performance in MASLD.* eGastroenterology. 2025;3(3): p. e100204. IF:NA
- Caldevilla, R, **Eiras, M, Santos, DAR**, Almeida, J, Oliveira, B, Loureiro, S, Soares, J, Gonzalez-Santos, M, Ramos, N, Videira, PA, Santos, LL, **Dinis-Ribeiro, M** and Lima, L. *Advancing Non-Invasive Colorectal Cancer Screening: Exploring the Potential of Monoclonal Antibody L2A5.* Int J Mol Sci. 2025;26(7) IF:4.9
- Cunha Neves, JA, Baddeley, R, Pohl, H, Pioche, M, Lorenzo-Zuniga, V, Albeniz Arbizu, E, Mihai Voiosu, A, Rommele, C, Donnelly, L, Elli, L, Lopez-Munoz, P, Henniger, D, Khalaf, K, Bruno, MJ, Arvanitakis, M, Bisschops, R, Hassan, C, Messmann, H, Gralnek, IM, Siersema, PD, Thomas-Gibson, S, Hayee, B, Rodriguez de Santiago, E and **Dinis-Ribeiro, M**. *Endoscopic Sustainability PrimAry Reporting Essentials (E-SPARE): European Society of Gastrointestinal Endoscopy (ESGE) Position Statement.* Endoscopy. 2025;57(6): p. 674–88. IF:12.8
- Cunha Neves, JA, **Chaves, J, Dinis-Ribeiro, M** and **Libanio, D**. *X-Tackling the Path to Closure: Post-Endoscopic Submucosal Dissection Defect Resolution Strategies.* GE Port J Gastroenterol. 2025;32(2): p. 127–30. IF:0.6
- **Dinis-Ribeiro, M.** *Professor Lars Aabakken: A Visionary in GI Endoscopy and Medical Education.* United European Gastroenterol J. 2025;13(8): p. 1597–9. IF:6.7
- **Dinis-Ribeiro, M** and **Areia, M.** *How to improve the quality of upper gastrointestinal diagnostic endoscopy?* Clin Endosc. 2025;58(5): p. 633–7. IF:2.3
- **Dinis-Ribeiro, M, Libanio, D**, Uchima, H, Spaander, MCW, Bornschein, J, Matysiak-Budnik, T, Tziatzios, G, Santos-Antunes, J, Areia, M, Chapelle, N, Esposito, G, Fernandez-Esparrach, G, Kunovsky, L, Garrido, M, Tacheci, I, Link, A, Marcos, P, **Marcos-Pinto, R,** Moreira, L, **Pereira, AC, Pimentel-Nunes, P,** Romanczyk, M**, Fontes, F,** Hassan, C, Bisschops, R, Feakins, R, Schulz, C, Triantafyllou, K, Carneiro, F and Kuipers, EJ. *Management of epithelial precancerous conditions and early neoplasia of the stomach (MAPS III): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG) and European Society of Pathology (ESP) Guideline update 2025.* Endoscopy. 2025;57(5): p. 504–54. IF:12.8
- Enjo-Barreiro, JR, **Fontes, F**, Tualufo, S, Silva-Matos, C, Damasceno, A and Lunet, N. *Regional differences in the daily consumption of smoked and smokeless tobacco among adults (25-64 years) in Mozambique: 2005 versus 2014/2015.* Cad Saude Publica. 2025;40(12): p. e00029024. IF:1.8
- Esposito, G, **Areia, M,** Ching, HL, Afify, S, Guillena, PGD, Lopez, RH, Leclercq, P, Monged, A, Panarese, A, Reis De Oliveira, LA, Romanczyk, M, Ballesteros, EJR, Uchima, HI, Zessner-Spitzenberg, J, Eross, B, Hopper, A, Lux, T, McGettigan, N, Oguntoye, OO, Tai, FWD, Gralnek, IM, Hassan, C, Bisschops, R, Ferlitsch, M and External voting, p. *STAndardization of Reports (the STAR project) Upper gastrointestinal endoscopy: European Society of Gastrointestinal Endoscopy (ESGE) Quality Improvement Initiative.* Endoscopy. 2025;57(11): p. 1298–308. IF: 12.8
- Esposito, G, Dilaghi, E, Costa-Santos, C, Ligato, I, Annibale, B, **Dinis-Ribeiro, M, Areia, M** and Investigators, G. *The Gastroscopy RAte of Cleanliness Evaluation (GRACE) Scale: an international reliability and validation study.* Endoscopy. 2025;57(4): p. 312–20. IF: 12.8

- Facciorusso, A, Ramai, D, Dhar, J, Samanta, J, Chandan, S, Gkolfakis, P, Crino, SF, Maida, M, Anderloni, A, Boskoski, I, Triantafyllou, K, **Dinis-Ribeiro, M**, Hassan, C, Fuccio, L and Arvanitakis, M. *Effects of Glucagon-Like Peptide-1 Receptor Agonists on Upper Gastrointestinal Endoscopy: A Meta-Analysis.* Clin Gastroenterol Hepatol. 2025;23(5): p. 715–25 e3. IF:12.0
- Fernandes, C and **Dinis-Ribeiro, M**. *Reply to Gao et al.* Endoscopy. 2025;57(11): p. 1321–2. IF:12.8
- Fernandes, C, Estevinho, M, Marques Cruz, M, Frazzoni, L, Rodrigues, PP, Fuccio, L and **Dinis-Ribeiro, M.** *Adenoma detection rate by colonoscopy in real-world population-based studies: a systematic review and meta-analysis.* Endoscopy. 2025;57(1): p. 49–61. IF:12.8
- **Fontes, F,** Kapteijn, NEA, Hassan, C, Deane, C, Cristiano, M, Fernandes-Mendes, H, Luzko, I, Cavlina Sevo, M, Kelly, O, Esposito, G, Holster, IL, van der Horst, MPJ, Kweldam, CF, Voiosu, A, Pinto, RM, Almeida, N, O'Morain, C, Moreira, L, Bornschein, J, Spaander, MCW and **Dinis-Ribeiro, M.** *Adherence to clinical practice guidelines for Management of epithelial precancerous conditions and lesions in the stomach in Europe.* Endoscopy. 2025;57(12): p. 1338–47. IF:12.8
- **Fontes, F,** Morais, AG, Nhampule, J, Navarro, S, Sitoe, N, Amisse, L, Tulsidas, S, Lorenzoni, C, Carrilho, C and Lunet, N. *External Radiotherapy in Mozambique: Report of the First Five Years of Activity of the Radiotherapy Service of the Maputo Central Hospital.* Cancer Med. 2025;14(17): p. e71199. IF: 3.1
- Gallio, N, Preti, M, Casetta, E**, Albuquerque, A,** Vieira-Baptista, P, Borella, F, Bevilacqua, F, Cavallero, C, Mistrangelo, M and Revelli, A. *Imiquimod for Anal High Grade Intraepithelial Neoplasia: A Systematic Review.* Curr Oncol Rep. 2025;27(7): p. 833–43. IF:5.0
- Garrido, M, **Almeida, TC, Kuttner-Magalhaes, R, Marcos-Pinto, R,** Archer, S, Pinho, R, Estevinho, MM, Santos-Antunes, J, Morais, R, Barreiro, P, Simao, I, Bourke, M, Wang, H, Amaro, P, Gravito-Soares, E, Kuvaev, R, Kashin, S, Areia, M, Viegas, MI, Koch, AD, Spaander, MCW, Provoost, N, Manfredi, G, Esposito, G, Losurdo, G, Lemmers, A, Fernandez-Esparrach, G, Santiago, ER, **Dinis-Ribeiro, M** and **Libanio, D**. *External multicenter validation of the FAMISH score for predicting metachronous gastric lesions after endoscopic submucosal dissection.* Scand J Gastroenterol. 2025;60(8): p. 1–9. IF:1.7
- Goncalves, AR, Azevedo Silva, M, Sequeira, C, Mascarenhas, A, Costa, M, Pinto Pais, T, Barreiro, P, Almeida, N, Rama, N, Fernandes, A, Eliseu, L, Dinis-Ribeiro, M and Vasconcelos, H. *Applicability of the Scottish screen-detected polyp cancer study (SSPoCS) algorithm in a multicentric cohort in the management of malignant colorectal polyps.* Scand J Gastroenterol. 2025;60(1): p. 122–9.
- Goncalves, E, **Fontes, F,** Rodrigues, JR, Calisto, R, Bento, MJ, Lunet, N and Morais, S. *Risk and survival of third primary cancers in a population-based cohort of patients with a cervical, endometrial, or ovarian cancer.* J Obstet Gynaecol Res. 2025;51(5): p. e16297.
- Goncalves, N, **Chaves, J, Marques-Sa, I, Dinis-Ribeiro, M** and **Libanio, D.** *Early diagnosis of gastric cancer: Endoscopy and artificial intelligence.* Best Pract Res Clin Gastroenterol. 2025;75: p. 101979. IF:4.0
- Grozinsky-Glasberg, S, Hofland, J, Alband, S, de Lima, YC, Croitoru, A, Geilvoet, W, Igaz, P, Kos-Kudla, B, Krejs, GJ, Laviano, A, Panzuto, F, Sadanandam, A, **Santos, AP,** Welin, S and Srirajaskanthan, R. *Controversies in NEN: An ENETS position statement on nutritional support in neuroendocrine neoplasms.* J Neuroendocrinol. 2025;37(12): p. e70062. IF: 4.1
- Gupta, S, Mandarino, FV, Shahidi, N, Hourigan, LF, Messmann, H, Wallace, MB, Repici, A, **Dinis-Ribeiro, M,** Haber, GB, Taylor, ACF, Waxman, I, Siersema, PD, Pouw, RE, Lemmers, A, Bisschops, R, Mosko, JD, Teshima, C, Ragunath, K, Rosch, T, Pech, O, Beyna, T, Sharma, P, Lee, EYT, Burgess, NG, Bourke, MJ and study working, g. *Can optical evaluation distinguish between T1a and T1b esophageal adenocarcinoma: an international expert interobserver agreement study.* Endoscopy. 2025;57(3): p. 200–7. IF:12.8
- Hollenbach, M, Heise, C, Abou-Ali, E, Gulla, A, Auriemma, F, Soares, K, Leung, G, Schattner, MA, Jarnagin, WR, Wang, T, Caillol, F, Giovannini, M, Dahel, Y, Hackert, T, Paik, WH, Zerbi, A, Nappo, G, Napoleon, B, Arnelo, U, Haraldsson, E, Halimi, A, Waldthaler, A, Will, U, Saadeh, R, Masaryk, V, van der Wiel, SE, Bruno, MJ, Perez-Cuadrado-Robles, E, Deprez, P, Sauvanet, A, Bolm, L, Keck, T, Souche, R, Fabre, JM, Musquer, N, Kahler, G, Seyfried, S, Petrone, MC, Mariani, A, Zaccari, P, Belfiori, G, Crippa, S, Falconi, M, Partelli, S, Yilmaz, B, Demir, IE, Ceyhan, GO, Satoi, S, Regimbeau, JM, Gagniere, J, Repici, A, Anderloni, A, Vollmer, C, Casciani, F, Del Chiaro, M, Oba, A, Schulick, RD, Berger, A,

Maggino, L, Salvia, R, Schemmer, P, Wichmann, D, Inoue, Y, **Dinis-Ribeiro, M**, Laranjo, A, **Libanio, D,** Kleemann, T, Sandru, V, Ilie, M, Ahola, R, Laukkarinen, J, Schumacher, B, Albers, D, Curdia Goncalves, T, Barbier, L, Salame, E, Weismuller, TJ, Heling, D, Alves, A, Karam, E, Regenet, N, Dugic, A, Muehldorfer, S, Truant, S, Caca, K, Meier, B, Miutescu, BP, Tantau, M, Birnbaum, D, Miksch, RC, Wedi, E, Salzmann, K, Bruzzi, M, Lupinacci, RM, David, P, De Ponthaud, C, Schmidt, A, Regner, S, Gaujoux, S and group, Es. *Endoscopic papillectomy versus surgical ampullectomy for adenomas and early cancers of the papilla: a retrospective Pancreas2000/European Pancreatic Club analysis.* Gut. 2025;74(3): p. 397–409. IF:25.8

- Honing, J and **Dinis-Ribeiro, M**. *Preface to special edition: Screening and Early diagnosis of upper gastrointestinal neoplastic lesions.* Best Pract Res Clin Gastroenterol. 2025;75: p. 101983. IF: 4.0
- Lazaridis, N, Rimondi, A, Chacchi-Cahuin, R, Lemmers, A, Costa, D, Bucalau, AM, Mandair, D, Gupta, S, Tantau, M, Pioche, M, Rivory, J, Santos-Antunes, J, Marques, M, Ramos Zabala, F, Barbaro, F, **Pimentel-Nunes, P**, Uchima, H, Albeniz, E, **Dinis-Ribeiro, M**, Costamagna, G, Spada, C, Bourke, M, Caplin, M, Toumpanakis, C, Despott, EJ and Murino, A. *Endoscopic submucosal dissection for gastric neuroendocrine neoplasms: A multicenter retrospective study.* J Neuroendocrinol. 2025;37(9): p. e70064. IF:4.1
- **Lopes, C,** Brandao, A, Teixeira, MR, **Dinis-Ribeiro, M** and **Pereira, C.** *Saliva-derived transcriptomic signature for gastric cancer detection using machine learning and leveraging publicly available datasets.* Sci Rep. 2025;15(1): p. 18491. IF: 3.9
- **Lopes, C** and **Pereira, C**. *Advances towards gastric cancer screening: Novel devices and biomarkers.* Best Pract Res Clin Gastroenterol. 2025;75: p. 102009. IF:4.0
- Maida, M, Ramai, D, Mori, Y, **Dinis-Ribeiro, M**, Facciorusso, A, Hassan, C and and the, AICWG. *The role of generative language systems in increasing patient awareness of colon cancer screening.* Endoscopy. 2025;57(3): p. 262–8. IF:12.8
- Marcos, P, Goncalves, N, Gama, J, **Areia, M** and **Dinis-Ribeiro, M.** *Standardizing endoscopic protocols increases detection of gastric cancer during surveillance of patients with precancerous conditions: a systematic review and meta-analysis.* Dig Liver Dis. 2025;57(8): p. 1588–602.
- Mendes, RR, Mascarenhas, A, Correia, J, Estevinho, MM, Pereira Rodrigues, J, Conceicao, D, Saraiva, S, Mao De Ferro, S, Nascimento, CN, Loureiro, R, Costa, MS, Gravito-Soares, E, **Chaves, J, Libanio, D, Dinis Ribeiro, M,** Archer, S, Kuttner Magalhaes, R, Bronze, S, Noronha Ferreira, C, Tarrio, I, Araujo, T and Barreiro, P. *Colorectal Endoscopic Full-Thickness Resection: A Portuguese Multicenter Experience Based on a Retrospective Cohort.* GE Port J Gastroenterol. 2025;32(4): p. 264–72. IF:0.6
- Meneses, O, Alzamora, M, Dias, C, **Ortigao, R** and Marques, D. *Immune-Related Esophagitis and Durable Response to Second-Line Treatment With Nivolumab in Stage IV Squamous Cell Esophageal Carcinoma.* Cureus. 2025;17(12): p. e98324. IF:1.3
- Morais, R, Afonso, J, Sousa, N, Sousa-Pinto, B, **Libanio, D,** Marinho, B, Sacramento, ML, Simplicio, M, Faria-Ramos, I, Azevedo, L, Marques, M, Silveira, H, Gullo, I, Carneiro, F, Santos-Antunes, J and Macedo, G. *Cost-utility and clinical impact of endoscopic screening for esophageal and gastric neoplasia in patients with head and neck neoplasms.* Eur J Gastroenterol Hepatol. 2025;37(7): p. 815–25. IF:1.8
- Mourato, MB, Pratas, N, Branco Pereira, A, Chanca, R, Fronteira, I, Dinis, R and **Areia, M**. *Effectiveness of Gastric Cancer Endoscopic Screening in Intermediate-Risk Countries-A Systematic Review and Meta-Analysis.* United European Gastroenterol J. 2025;13(9): p. 1715–29. IF:6.7
- Mourato, MB, Pratas, N, Branco Pereira, A, Costa Pinto, F, Dinis, R, Fronteira, I and **Areia, M**. *Gastric Cancer Endoscopic Screening in an Intermediate-Risk Country-A Dual-Center Pilot Program.* Helicobacter. 2025;30(4): p. e70061. IF:4.3
- Nathan, M, Chatzistamatiou, K, Gallio, N, Cappello, C, Loughlin, P, Bock, S, Blanco, JL, Sendagorta, E, Etienney, I, **Albuquerque, A,** Vieira-Baptista, P, Schmidt, PT, Gultekin, M, Surmont, M, Ahmad, S, Bowring, J, Lyons, D, Cuming, T, Preti, M, Cruickshank, ME and Group, AS. *Current practices in HPV-related anogenital neoplasia care in Europe - a survey analysis.* BMC Cancer. 2025;25(1): p. 1223. IF:3.4
- Rodriguez-Carrasco, M, Esposito, G, Dilaghi, E, Manfredi, G, Alicante, S, Buscarini, E, Annibale, B and **Dinis-Ribeiro, M.** *Endoscopic grading of gastric intestinal metaplasia using blue light imaging in a*

*low-risk population: Multicenter cross-sectional validation study.* Endosc Int Open. 2025;13: p. a25003748. IF:2.3

- Rosa, B, Curdia Goncalves, T, Moreira, MJ, Dias de Castro, F, Sousa-Pinto, B, **Dinis-Ribeiro, M** and Cotter, J. *Reply to Mussetto et al.* Endoscopy. 2025;57(4): p. 426–7. IF: 12.8
- **Santos, DAR, Eiras, M**, Gonzalez-Santos, M, Santos, M, **Pereira, C,** Santos, LL, **Dinis-Ribeiro, M** and Lima, L. *A preliminary assessment of a stool-based microRNA profile for early colorectal cancer screening.* Sci Rep. 2025;15(1): p. 28597. IF: 3.9
- Shah, SC and **Dinis-Ribeiro, M**. *Endoscopic stratification of gastric intestinal metaplasia: where are we, where do we want to go and how do we get there?* Gut. 2025;74(5): p. 867–8. IF:25.8
- Silva, JC, **Dinis-Ribeiro, M** and **Libanio, D.** *Author's reply: "Improving screening participation: The need for socioeconomic considerations and psychological interventions in colorectal cancer programs".* Dig Liver Dis. 2025;57(6): p. 1333–4. IF: 3.8
- Silva, JC, **Dinis-Ribeiro, M**, Tavares, F **and Libanio, D**. *Adherence, risk perception, and attitudes towards colorectal cancer screening: A road to individualized screening?* Dig Liver Dis. 2025;57(6): p. 1162–70. IF:3.8
- Silva, JC, **Dinis-Ribeiro, M**, Tavares, F and **Libanio, D**. *Exploring the Perceived Risk of Complications in Endoscopic Screening Procedures.* GE Port J Gastroenterol. 2025;32(6): p. 404–13. IF:0.6
- Silva, JC, Leite-Silva, P, Tavares, F, Bento, MJ, **Libanio, D** and **Dinis-Ribeiro, M**. *Impact of a FIT Based Colorectal Cancer Screening Program on Gastric Cancer Incidence, Early Diagnosis and Patients' Survival.* Helicobacter. 2025;30(5): p. e70071. IF:4.3
- Soldin, I, Teixeira, R**, Ortigao, R,** Lapa, A and Lima, S. *Immune Checkpoint Inhibitor-Induced Hepatitis: A Case Report of Challenging Management.* Cureus. 2025;17(1): p. e77331. IF: 1.3
- Tavares, V, **Lopes, C,** Macedo-Silva, C, Farinha, M, Costa, J, Vilas-Boas, MI, Pinelas, S, Assis, J, **Dinis-Ribeiro, M,** Pereira, D, **Pereira, C** and Medeiros, R. *Genetic markers of thrombophilia as predictors of outcome in colorectal cancer.* J Thromb Thrombolysis. 2025;58(5): p. 663–78. IF:2.2
- Taveira-Barbosa, J, Garcia, T, Lebre, A, **Fontes, F,** Brandao, M, Calisto, R, Ture, R, Bento, MJ, Lunet, N, Morais, S and Lopes-Conceicao, L. *Characteristics and Mortality of Patients With Cancer Diagnosed With SARS-CoV-2 in Northern Portugal.* Anticancer Res. 2025;45(4): p. 1749–60. IF:1.7
- Tesselaar, MET, Partelli, S, Braat, A, Croitoru, A, **Soares Santos, AP**, Schrader, J, Welin, S, Christ, E, Falconi, M and Bartsch, DK. *Controversies in NEN: An ENETS position statement on the management of locally advanced neuroendocrine neoplasia of the small intestine and pancreas without distant metastases.* J Neuroendocrinol. 2025;37(12): p. e70083. IF: 4.1
- Viegas, MI, **Areia, M**, Elvas, L, Marcos-Pinto, R, Fernandes-Mendes, H, Alves, S, Brito, D, Saraiva, S, Cadime, AT, Cano-Catala, A, Parra, P, Moreira, L, Megraud, F, O'Morain, C, O, PN, Gisbert, JP and Hp-EuReg, i. *Effectiveness of First-Line Empirical Treatment in Portugal: Data from the European Registry on Helicobacter pylori Management.* GE Port J Gastroenterol. 2025;32(5): p. 339–49. IF:0.6
- Vieira, D, Barreira, S, **Dinis-Ribeiro, M** and Monteiro, E. *Self-perception of oropharyngeal cancer patients regarding the impacts of chemoradiotherapy treatments on swallowing and voice functions.* Revista de Logopedia, Foniatría y Audiología. 2025;45(2) IF:NA
- Vieira, D, Sousa, ECT, Laranja, A, Soares, A, **Dinis-Ribeiro, M** and Monteiro, E. *Patient and Healthcare Professional Perceptions*. Holistic Approaches to Health Recovery2025. p. 291–320. IF:NA

### b) Peer-reviewed indexed publications within a consortium

- Higgins K, Nyssen OP, Southern J, Laponogov I, AIDA CONSORTIUM, Veselkov D, Gisbert JP, Fleitas Kanonnikoff T, Veselkov K. *The* Helicobacter pylori *AI-clinician harnesses artificial intelligence to personalise H. pylori treatment recommendations***.** Nat Commun. 2025 Jul 14;16(1):6472. IF: 15.7
- Vu Trung, K, Abou-Ali, E, Gulla, A, Soares, K, Caillol, F, Paik, WH, Napoleon, B, Halimi, A, Masaryk, V, Bruno, MJ, Pérez-Cuadrado-Robles, E, Bolm, L, Seyfried, S, Petrone, MC, Yilmaz, B, Vollmer, C, Berger, A, Maggino, L, Schemmer, P, Wichmann, D, Karam, E, Dugic, A, Kunovsky, L, Regner, S, Gaujoux, S, Hollenbach, MH, for the ESAP Study Group. *Development and validation of the SDLD score: a simplified tool to predict successful endoscopic papillectomy in ampullary lesions*. Gastrointest Endosc. 2025 Oct;102(4):602-606. IF: 7.5

### *Other outputs*

#### *Book Chapters*

- Chaves, J, **Pimentel-Nunes, P**. Doença ulcerosa péptica. In book: Fisiopatologia – bases da medicina clínica. Lidel. ISBN: 9789897529351. 2025.
- Mansinho H, Santos LL, Gonçalves A, Marques AF, Raimundo A, Sepodes B, Castanheira B, Louro BS, **Brandão C**, Veiga F, Vilhais G, Faustino I, Ferreira IC, Santos J, Pinto JM, Santos JG, Machado M, Duarte M, Silva OL, Jacinto P, Chinita P, Costa PM, Vasconcelos PM, Marques R, Aranha R, Bento S, Lopes SR, Almeida V. 100 Perguntas chave no: Cancro Gástrico (2025). Permanyer. ISBN-13: 979-1387774325
- Menezes I, **Alves P**. Chapter 2 - O doutoramento em Educação: um título ou um percurso para a construção de uma cidadania académica? (pp. 29-43) In book: El doctorado en educación ¿Reproducir o transformar (2025). Peter Lang. ISBN: 978-3-631-93140-0
- Pimentel-Nunes P. Capítulo 9.2 – Gastrites e doença ulcerosa péptica. In book: Gastrenterologia Fundamental - 2a edição. Lidel. ISBN: 978-989-752-973-3. 2025
- von Hafe M, **Pimentel-Nunes P**. Doença do refluxo gastroesofágico. In book: Fisiopatologia – bases da medicina clínica. Lidel. ISBN: 9789897529351. 2025

#### *Oral Communications by Invitation*

- Brandão C. (2025) Hereditary – Digestive [Hereditário – Digestivo]. 9th SPO Oncology Course / Curia Course (February); Aveiro, Portugal.
- Dinis-Ribeiro M. (2025) Early Diagnosis of Gastrointestinal Cancer: What's Next? [Diagnóstico precoce do cancro digestivo: como evoluir?] 5th SAMS Endoscopy Conference (February); Lisboa, Portugal.
- Albuquerque A. (2025) HPV screening and treatment of anal precancerous lesions. EUROGIN (March); Porto, Portugal.
- Brandão C. (2025) Lynch Syndrome [Síndroma de Lynch] – 2nd Course on Gastrointestinal Tumors at the IPO in Porto (March); Porto, Portugal.
- Pimentel-Nunes P. (2025) How to perform a proper gastric investigation? LIVE SPED 2025 (March); Porto, Portugal.
- Areia M. (2025) How to be a top reviewer and reap the benefits. ESGE Days 2025 (April); Barcelona, Spain.
- Dinis-Ribeiro M. (2025) Guideline session UGI MAPS III: What's new? ESGE Days 2025 (April); Barcelona, Spain.
- Pimentel-Nunes P. (2025) What is image-enhanced endoscopy (IEE)? ESGE Days 2025 (April); Barcelona, Spain.
- Albuquerque A. (2025) Eradicating HPV-related cancers: a pipe dream? [Eliminação dos cancros associados ao HPV: uma utopia?] Medicine Update (May); Coimbra, Portugal.
- Areia M. (2025) Feeding Ostomies: Dietary Guidelines. Training [Ostomias de Alimentação: Padrão alimentar. Formação] "Nutrition for People with an Ostomy" (May); Coimbra, Portugal.
- Areia M. (2025) Colorectal Cancer Screening in the Central Region. [Rastreio do cancro colorretal na região Centro]. 10th Course on Oncological Gastroenterology (May); Coimbra, Portugal.
- Areia M. (2025) IPO Coimbra - 60 years to Provide Healthcare in Oncology: Quality as a Strong Commitment. National Meeting – HOPE 2025 (May); Coimbra, Portugal.
- Marcos-Pinto R. (2025) H. pylori in 2025: What Do We Need to Change? [H. pylori em 2025: o que temos que mudar?] Digestive Health Week 2025 (May); Porto, Portugal.
- Pimentel-Nunes P. (2025) Non-neoplastic gastric pathology – endoscopic aspects [Patologia não neoplásica gástrica – aspetos endoscópicos]. Course on Digestive Pathology 25 (May); Lisbon, Portugal.
- Albuquerque A. (2025) Epidemiologic side of transplants. IANS Meeting (June); London, UK.
- Dinis-Ribeiro M. (2025) How to improve my lesion recognition skills - How to assess what I find - Premalignant stomach and early gastric cancer. 13th Nottingham Upper GI Endoscopy & Barret's Endotherapy Course (June); Nottingham, UK.

- Dinis-Ribeiro M. (2025) Management algorithms of early neoplasia in the Upper GI Tract: When to choose EMR, when to choose ESD and when to choose neither of the two – Evidence based practice vs. current clinical guidelines recommendations. 13th Nottingham Upper GI Endoscopy & Barrett's Endotherapy Course (June); Notthingham, UK.
- Albuquerque A. (2025) Morphofunctional anatomy of the pelvic floor. [Anatomia morfofuncional do pavimento pélvico]. Digestive Motility Course (July); Porto, Portugal.
- Albuquerque A. (2025) Anal HPV Infection: Clinical Aspects and Associated Diseases. [Infeção anal por HPV: aspetos clínicos e doenças associadas]. Webinar IST (September); Virtual.
- Albuquerque A. (2025) Anal lesions: screening, diagnosis and treatment. ECSVD (September); Hamburg, Germany.
- Albuquerque A. (2025) Anal cytology. [Citologia anal]. Graduate Program in Cytology (September); Virtual.
- Dinis-Ribeiro M. (2025) Endoscopic diagnosis, staging and treatment of early gastric cancer. ESMO Preceptorship on gastric cancer (September); Madrid, Spain.
- Dinis-Ribeiro M. (2025) Supportive Care: Endoscopic options for treatment of gastric outlet obstruction and nutritional difficulties. ESMO Preceptorship on gastric cancer (September); Madrid, Spain.
- Pimentel-Nunes P. (2025) Atrophic gastritis and intestinal metaplasia: current approaches in the diagnosis and management. GastroEndo 2025 (September); Buenos Aires, Argentina.
- Pimentel-Nunes P. (2025) Endoscopic treatment of gastric cancer: in which cases to indicate it? GastroEndo 2025 (September); Buenos Aires, Argentina.
- Santos AP. (2025) "Neuroendocrine Tumors – A World Apart" - Interactive Clinical Case | Multidisciplinary Discussion – Endocrinology. *SPCENDO Congress 2025* (September); Porto, Portugal.
- Albuquerque A. (2025) Anal cancer screening. IPVC 2025 (October); Bangkok, Thailand.
- Albuquerque A. (2025) Anal cytology and HPV testing. IPVC 2025 (October); Bangkok, Thailand.
- Albuquerque A. (2025) New guidelines and what to do with them. IPVC 2025 (October); Bangkok, Thailand.
- Areia M. (2025) Stoma Therapy Course: Feeding Ostomies—PEG and Surgical Approaches [Curso de Estomaterapia: Ostomias de Alimentação Abordagem por PEG e Cirúrgica] IPO Coimbra Stoma Therapy Clinic (October); Coimbra, Portugal.
- Dinis-Ribeiro M. (2025) Cracking the code: Tools for premalignant and early gastric cancer detection. UEG Week 2025 (October); Berlin, Germany.
- Dinis-Ribeiro M. (2025) Screening for gastric cancer Is it viable in Europe? UEG Week 2025 (October); Berlin, Germany.
- Santos AP. (2025) Comorbidity Management in Palliative Care. Diabetes in Palliative Care. Challenges of Care Congress – Advances, Evidence and Strategies in Palliative Care (October); Porto, Portugal
- Albuquerque A. (2025) Constipation and fecal incontinence [Obstipação e incontinência fecal. APNUG Meeting (November); Costa da Caparica, Portugal.
- Diogo Libânio. (2025) Gastritis and Helicobacter pylori. [Gastrites e Helicobacter pylori] 2nd IPO Porto Medical Conference (November); Porto, Portugal.

### *Oral Communications in International Scientific Meetings*

- **Lopes C, Almeida TC, Marques-de-Sá I**, Chaves J, **Ortigão R**, Archer S, **Küttner- Magalhães R, Marcos-Pinto R, Libânio D, Dinis-Ribeiro M, Pereira C**. (2025). Exploring salivary proteomics: Advancing non-invasive screening for gastric cancer in an intermediate-risk population. The Festival of Genomics & Biodata (29-30 January); London, United Kingdom.
- Garrido M, **Almeida TC, Kuttner-Magalhães R, Marcos-Pinto R**, Archer S, Pinho R, Estevinho MM, Santos-Antunes J, Morais R, Barreiro P, Simão I, Bourke M, Wang H, Amaro P, Gravito-Soares E, Kuvaev R, Kashin S, **Areia M**, Viegas MI, Koch AD, Spaander MCW, Provoost N, Manfredi G, Esposito G, Losurdo G, Lemmers A, Fernández-Esparrach G, Santiago ER, **Dinis-Ribeiro M, Libânio D.** (2025)

External multicenter validation of the FAMISH score for predicting metachronous gastric lesions after endoscopic submucosal dissection. ESGE Days 2025 Congress (3-5 April); Barcelona, Spain.

- **Alves P, Pereira AC, Dinis-Ribeiro M** (2025). A Conceptualised Continuing Medical Education Curriculum to Increase Cancer Detection Rate. European Conference on Educational Research (ECER) (9-12 September 2025); Belgrade, Sérvia.
- Kirrout I, Nafria B, Pérez-Aísa Á, Tepes B, Voynovan I, Martínez-Domínguez SJ, Lucendo AJ, Vologzhanina L, Abdulkhakov S, Tejedor-Tejada J, Ilchishina T, Starostin B, Sarsenbaeva A, Pavoni M, Zaytsev O, Huguet JM, Gravina AG, Garre A, Perona M, Alekseenko S, Marcos MS, Pabón-Carrasco M, Núñez Martínez O, Andreev A, **Areia M**, Barrio J, Moreno A, Gómez Rodríguez BJ, Bogomolov P, Denkovski M, Bakulin I, Ortiz Polo I, Bakulina N, Domínguez Cajal M, Bordin DS, Gasbarrini A, Pinto R, Sánchez Alonso M, Pajares Villarroya R, Arteagoitia I, Jiménez-Moreno M, Parra P, Nyssen OP, Bujanda L, Cano-Català A, Moreira Ruiz L, Mégraud F, O'Morain C, Montes N, Gisbert JP; on behalf of the Hp-EuReg investigators. (2025) Literature-based *Helicobacter pylori* resistance data integrated into the European Registry on H. pylori Management (Hp-EuReg): limited usefulness for predicting first-line empirical treatment effectiveness. UEG Week 2025 (4-7 October); Berlin, Germany.
- Nyssen OP, Ortega GJ, Jonaitis L, Pérez-Aísa Á, Tepes B, Lucendo AJ, Tejedor-Tejada J, Bumane R, Garre A, Huguet JM, Perona M, Núñez Martínez O, Pabón-Carrasco M, Castro-Fernández M, **Areia M**, Barrio J, Moreno A, Butler T, Marcos MS, Keco-Huerga A, Domínguez Cajal M, Denkovski M, Pavoni M, Buzás GM, Lerang F, Losurdo G, Wolfe García PM, Phull PS, Martínez-Domínguez SJ, Kupcinskas J, Leja M, Pinto R, Smith S, Gasbarrini A, Papp V, Gómez-Rodríguez BJ, Sánchez Alonso M, Pajares Villarroya R, Pazo Mejide P, Jiménez-Moreno M, Pascual-Mato M, Bravo-Pache C, Montes M, Cano-Català A, Parra P, Moreira Ruiz L, Mégraud F, O'Morain C, Bujanda L, Gisbert JP; on behalf of the Hp-EuReg investigators. (2025) Long-term effect of macrolide consumption on Helicobacter pylori eradication treatments: data from the European Registry on H. pylori Management (Hp-EuReg). UEG Week 2025 (4-7 October); Berlin, Germany.
- Vasconcelos AC, Domingues Â, **Brandão C, Pimentel-Nunes P, Dinis-Ribeiro M, Libânio D.** (2025) Predictive factors for non-curative resection following gastric endoscopic submucosal dissection. UEG Week 2025 (Moderated Poster Session; 4–7 October); Berlin, Germany.

### *Oral Communications in National Scientific Meetings*

- Gil-Santos S, Fernandes A, **Santos AP**, Torres I, Ferreira G, Sampaio IL. (2025) Treatment of Lung Neuroendocrine Tumors with 177Lu-DOTATATE: Experience of a Tertiary Oncology Center. Portuguese Congress of Endocrinology – 76th Annual Meeting of SPEDM. (31 January); Porto, Portugal.
- Vasconcelos AC, Chaves J, **Ortigão R**, Azevedo R, **Brandão C, Libânio D, Sá I.** (2025) Expanding the Indications for Endoscopic Vacuum Therapy: A Case Series [Expandindo indicações da terapia de vácuo endoscópica: uma série de casos]. 21st Galician-Portuguese Conference (7–8 March); Vigo, Spain.
- Gonçalves N, Chaves J, Vasconcelos AC, **Brandão C**, Villas-Boas MI, **Ortigão R.** (2025) Immunotherapy-related hepatitis – an increasing concern among patients with oncological disseminated disease. APEF 2025 (27-29 March); Figueira da Foz, Portugal.
- Martins M, Morais R, Mendes F, Coelho R, Craciun A, Gonçalves TC, **Brandão C, Pimentel-Nunes P**, Santos-Antunes J, Lopes S, Trindade I, Macedo G. (2025) Nationwide cross-sectional survey study on the psychological effects experienced by Portuguese gastroenterologists following endoscopic adverse events. Semana Digestiva 2025 (28–30 May); Porto, Portugal.
- Rodrigues C, Vasconcelos AC, Garrido M, **Brandão C.** (2025) Pancreatic Cancer Screening in Lynch Syndrome: A Real-World Cohort. [Rastreio do cancro do pâncreas na síndrome de Lynch: uma coorte de vida real]. Digestive Health Week 2025 (28–30th May); Porto, Portugal.
- Vasconcelos AC, Domingues Â, **Brandão C, Pimentel-Nunes P, Dinis-Ribeiro M, Libânio D.** (2025) Predictors of Bleeding Following Endoscopic Gastric Submucosal Dissection [Fatores preditores de hemorragia após disseção endoscópica da submucosa gástrica]. Digestive Health Week 2025 (28–30th May); Porto, Portugal.

- Viegas MI, Regatia R, Costa M, Alves S, Elvas L, **Areia M**, Brito D, Saraiva S, Cadime AT. (2025) When a rare disease raises the pressure: Mahvash disease and portal hypertension. Digestive Health Week 2025 (28–30th May); Porto, Portugal.
- **Alves P**, Proença R, **Dinis-Ribeiro M**, Henrique R, Menezes I (2025). I Have a Ph.D.—Now What? An Exploratory Study on Postdoctoral Transitions in the Portuguese Context [Sou doutor/a, e agora? Um estudo exploratório sobre transições pós-doutoramento no contexto português]. 2025 Education Biennial: The Future Is Education. People, Life, and School. (16–20th June 2025), Braga, Portugal.
- Menezes I, Lopes A, Cruz-Correia R, **Alves P** (2025). The Interaction Between the Supervisory Relationship, the Academic/Scientific Context, Motivation, and Emotions in Doctoral Education. 2025 Education Biennial: The Future Is Education. People, Life, and School. (16–20th June 2025), Braga, Portugal.
- **Caldevilla R**. (2025) Pitch Presentation: Proteomic and Glycomic Profiling for Non-Invasive Disease Biomarker Discovery: Colorectal Cancer as an example. 3rd Young Researchers Day. (22 October); Porto, Portugal.
- Silva D, Gil-Santos S, Barbosa D, Vasconcelos N, Marão R, Duarte H, Souteiro P, **Santos AP**, Sampaio IL. (2025) Multi-line refractory metastatic pNET: Could [225Ac] Ac-DOTATATE change the therapeutic paradigm? 2025 Neuroendocrine Tumor Study Group Meeting. (20 October); Porto, Portugal.
- **Lopes C,** Brandão A, Paulino S, **Dinis-Ribeiro M, Pereira C.** (2025) Molecular tool for early gastric cancer detection and surveillance: Developing a novel gene expression signature. RISE Day 2025 (29 October). Aveiro, Portugal.

### *Posters in international conferences*

- Viegas MI, Elvas L, **Areia M**, Costa MS, Alves S, Brito D, Saraiva S, Cadime AT. (2025). Checkpoint inhibitor-induced gastritis: endoscopic insights for an accurate diagnosis. ESGE Days 2025 (3-5 April); Barcelona, Spain.
- Viegas MI, Elvas L, Saraiva S, Costa MS, Alves S, Brito D, **Areia M**, Cadime AT. (2025). Lynch syndrome screening interval: are we "scoping" enough? A single centre 19-year experience. ESGE Days 2025 (3-5 April); Barcelona, Spain
- Viegas MI, Elvas L, Brito D, Costa MS, **Areia M**, Alves S, Saraiva S, Cadime AT. (2025). A mediastinal cystic lesion: not everything is what seems. ESGE Days 2025 (3-5April); Barcelona, Spain
- Garrido M, **Almeida TC, Kuttner-Magalhães R, Marcos-Pinto R**, Archer S, Pinho R, Estevinho MM, Santos-Antunes J, Morais R, Barreiro P, Simão I, Bourke M, Wang H, Amaro P, Gravito-Soares E, Kuvaev R, Kashin S, **Areia M**, Viegas MI, Koch AD, Spaander MCW, Provoost N, Manfredi G, Esposito G, Losurdo G, Lemmers A, Fernández-Esparrach G, Santiago ER, **Dinis-Ribeiro M, Libânio D**. (2025) External multicenter validation of the FAMISH score for predicting metachronous gastric lesions after endoscopic submucosal dissection. Digestive Disease Week (3-6 May); San Diego, CA, USA.
- **Lopes C, Almeida TC, Marques-de-Sá I,** Chaves J, **Ortigão R**, Archer S, **Küttner-Magalhães R, Marcos-Pinto R, Libânio D, Dinis-Ribeiro M, Pereira C**. (2025) Unveiling salivary proteomics: A step towards non-invasive screening for gastric cancer in an intermediate-risk population. Digestive Disease Week (DDW) 2025 (3-6 May); San Diego, CA, USA.
- Santos S, Martins Fernandes A, **Santos AP,** Ferreira G, Lucena I (2025). Treatment of lung neuroendocrine tumors with 177Lu-DOTATATE: experience from a tertiary oncology centre. Joint Congress of ESPE and ESE 2025 (10-13 May); Copenhagen, Denmark.
- **Alves P,** Proença R, **Dinis-Ribeiro M,** Henrique R, Menezes I (2025). Post-PhD processes: an exploratory study on transitions after doctoral studies. EARLI 2025, Realising Potentials through Education: Shaping the Minds and Brains for the Future (25–29 August), Graz, Austria
- Cantú-Germano E, Moreira Ruiz L, Jonaitis L, Pérez-Aísa Á, Tepes B, Mahmudov U, Martínez-Domínguez SJ, Babayeva G, Tejedor-Tejada J, Lucendo AJ, Abdulkhakov S, Vologzhanina L, Bogomolov P, Mammadov E, Gómez Rodríguez BJ, Perona M, Denkovski M, Moreno A, Voynovan I, Pabón-Carrasco M, Butler T, Hasanov R, Núñez Martínez O, Ilchishina T, Guliyev F, Gasbarrini A, Huguet JM, **Areia M,** Gravina AG, Alekseenko S, Soledad Marcos M, Barrio J, Bermejo F, Andreev D, Bujanda L, Kupcinskas J, Leja M, Bordin DS, Smith S, Pinto R, Sánchez Alonso M, Pajares Villarroya R, Jiménez-

Moreno M, Arteagoitia I, Cano-Catala A, Parra P, Nyssen OP, Mégraud F, O'Morain C, Gisbert JP; on behalf of the Hp-EuReg investigators. (2025). Effectiveness of repeated use of amoxicillin–clarithromycin triple therapy and bismuth quadruple therapy after prior failure: preliminary results from the European Registry on Helicobacter pylori management (Hp-EuReg). UEG Week 2025 (4-7 October); Berlin, Germany.

- Cantú Germano E, Moreira Ruiz L, Pérez-Aísa Á, Martínez-Domínguez SJ, Voynovan I, Bujanda Fernández de Piérola L, Jonaitis LV, Tepes B, Garre A, Lucendo AJ, Lerang F, Butler T, Mahmudov U, Huguet JM, Tejedor-Tejada J, Bogomolov P, Beales I, Phull P, Pabón-Carrasco M, Castro-Fernández M, Alekseenko S, Pavoni M, Zaytsev O, Bumane R, Denkovski M, Domínguez Cajal M, Ilchishina T, **Areia M**, Keco-Huerga A, Babayeva G, Bermejo F, Simsek H, Losurdo G, Bordin DS, Kupcinskas J, Smith S, Gasbarrini A, Leja M, Pinto R, Simsek C, Gómez Rodríguez BJ, Pazo Mejide P, Pajares Villarroya R, Sánchez Alonso M, Cano-Catala A, Parra P, Mégraud F, O'Morain C, Nyssen OP, Gisbert JP; on behalf of the Hp-EuReg investigators. (2025). Factors associated with the lack of follow-up in Helicobacter pylori eradication treatment: results from the European Registry on Helicobacter pylori management (Hp-EuReg). UEGWeek 2025 (4-7 October); Berlin, Germany.
- Gonçalves N, Domingues Â, Corte-Real F, Correia F, Garrido M, **Brandão C.** (2025). Colonoscopy in Lynch syndrome – clinical audit and quality measures assessment. UEG Week 2025 (4–7 October); Berlin, Germany.
- Gonçalves N, Corte-Real F, Garrido M, Correia F, Domingues Â, **Brandão C.** (2025). Colorectal cancer surveillance program in Lynch syndrome: a clinical audit in a reference center. UEG Week 2025 (4–7 October); Berlin, Germany.
- **Lopes C,** Brandão A, Paulino S, **Dinis-Ribeiro M, Pereira C.** (2025) Stratifying risk beyond diagnosis: A gene expression signature for early gastric cancer and metachronous lesion prediction. UEG Week 2025 (4-7 October); Berlin, Germany.
- Martins M, Morais R, Mendes F, Coelho R, Craciun A, Gonçalves TC, **Brandão C, Pimentel-Nunes P**, Santos-Antunes J, Lopes S, Trindade I, Macedo G. (2025). Nationwide cross-sectional survey study on the psychological effects experienced by Portuguese gastroenterologists following endoscopic adverse events. UEG Week 2025 (4–7 October); Berlin, Germany.
- Nyssen OP, Jonaitis L, Pérez-Aísa Á, Pavoni M, Martínez-Domínguez SJ, Tepes B, Vologzhanina L, Fiorini G, Voynovan I, Lucendo AJ, Tejedor-Tejada J, Pabón-Carrasco M, Bujanda L, Huguet JM, Ortiz Polo I, Lerang F, Barrio J, Bermejo F, Losurdo G, Gómez Rodríguez BJ, Butler T, **Areia M**, Sarsenbaeva A, Núñez Martínez O, Beales I, Fernandes-Mendes H, Abdulkhakov S, Gasbarrini A, Denkovski M, Keco-Huerga A, Perona M, Phull PS, Kamtoh G, Alekseenko S, Smith SM, Marlicz W, Kupcinskas J, Bordin DS, Leja M, Pinto R, Pajares Villarroya R, Jiménez-Moreno M, Arteagoitia I, Sánchez Alonso M, Cano-Catala A, Parra P, Moreira Ruiz L, Mégraud F, O'Morain C, Gisbert JP; on behalf of the Hp-EuReg investigators. (2025). Empirical second-line treatments in Europe: data from 9,000 cases from the European Registry on Helicobacter pylori management (Hp-EuReg). UEG Week 2025 (4-7 October); Berlin, Germany.
- Parra P, Jonaitis L, Pérez-Aísa Á, Mahmudov U, Tepes B, Voynovan I, Vologzhanina L, Martínez-Domínguez SJ, Lucendo AJ, Babayeva G, Abdulkhakov S, Pavoni M, Tejedor-Tejada J, Denkovski M, Ilchishina T, Mammadov E, Fadieienko G, Starostin B, Sarsenbaeva AS, Zaytsev O, Bujanda L, Garre A, Huguet JM, Gravina AG, Perona M, Hasanov R, Guliyev F, Pabón-Carrasco M, Alekseenko S, Soledad Marcos M, Núñez Martínez O, Andreev D, Verdiyev E, **Areia M**, Barrio J, Gridnyev O, Gasbarrini A, Kupcinskas J, Bordin DS, Leja M, Pinto R, Pajares Villarroya R, Arteagoitia I, Sánchez Alonso M, Cano-Catala A, Moreira Ruiz L, Nyssen OP, Mégraud F, O'Morain C, Gisbert JP; on behalf of the Hp-EuReg investigators. (2025). Trends in the prescription of eradication treatments and their effectiveness in naïve patients over 12 years (2013–2024) in Europe: data from the European Registry on Helicobacter pylori management (Hp-EuReg). UEG Week 2025 (4-7 October); Berlin, Germany.
- Parra P, Pérez-Aísa Á, Tejedor-Tejada J, Martínez-Domínguez SJ, Lucendo AJ, Perona M, Núñez Martínez O, Gravina AG, Soledad Marcos M, Moreno A, Huguet JM, Bermejo F, Ortiz Polo I, Gasbarrini A, Gómez-Rodríguez BJ, Pavoni M, Pabón-Carrasco M, Barrio J, **Areia M**, Fernandes-Mendes H, Losurdo G, Kamtoh G, Pajares Villarroya R, Iyo Miyashiro E, Pozo Blanco AB, Velayos B, Planella M, Szredzki P, Domínguez Cajal M, Alcaide N, Fernández-Salazar L, Mata-Romero P, Flores V, Compare

D, Keco-Huerga A, Suárez Matías M, Rosania R, Garre A, Pinto R, Venerito M, Marlicz W, Jiménez-Moreno M, Sánchez Alonso M, Perelló A, Cano-Catala A, Moreira Ruiz L, Nyssen OP, Mégraud F, O'Morain C, Gisbert JP; on behalf of the Hp-EuReg investigators. (2025). Effectiveness and safety of single-capsule bismuth quadruple therapy in 12,500 patients from the European Registry on Helicobacter pylori management (Hp-EuReg). UEGWeek 2025 (October); Berlin, Germany.

- **Santos DAR**, Santos LL, Vieira C, **Dinis-Ribeiro M,** Lima L (2025). The Small Solution for a Big Problem: Can MicroRNAs Predict Treatment Outcomes in Colorectal Cancer Patients? UEG Week 2025 (4-7 October); Berlin, Germany.
- **Santos DAR,** Loureiro S, **Eira M, Caldevilla R,** Santos LL, **Dinis-Ribeiro M**, Lima L (2025). Circulating MicroRNAs and Their Potential to Improve Early Colorectal Cancer Screening. UEG Week 2025 (4-7 October); Berlin, Germany.
- Vasconcelos AC, Domingues Â, **Brandão C, Pimentel-Nunes P, Dinis-Ribeiro M, Libânio D.** (2025). Predictive factors for bleeding following gastric endoscopic submucosal dissection. UEG Week 2025 (4-7 October); Berlin, Germany.
- Vasconcelos AC, Domingues Â, **Brandão C, Pimentel-Nunes P, Dinis-Ribeiro M, Libânio D.** (2025). Predictive factors for non-curative resection following gastric endoscopic submucosal dissection. UEG Week 2025 (4-7 October); Berlin, Germany.
- **Lopes C**, Brandão A, Paulino S, Costa J, **Marques de Sá I, Küttner-Magalhães R, Marcos-Pinto R, Libânio D, Dinis-Ribeiro M, Pereira C.** (2025) Early gastric cancer clues in saliva: Exploring a tissue-based signature for non-invasive detection. IV ASEICA-ASPIC International Meeting (20-21 November); Santiago de Compostela, Spain.

### *Posters in national conferences*

- Corte-Real F, Garrido M, Correia F, Domingues Â, **Brandão C.** (2025) Colorectal Cancer Screening Program for Lynch Syndrome: Clinical Audit at a Referral Center [Programa de vigilância de cancro colorretal na síndrome de Lynch: auditoria clínica num centro de referência]. Digestive Health Week 2025. (28–30 May); Porto, Portugal.
- Domingues Â, Corte-Real F, Correia F, Garrido M, **Brandão C.** (2025) Colonoscopy in Lynch Syndrome—Clinical Audit with Evaluation of Quality Measures [Colonoscopia na síndrome de Lynch – auditoria clínica com avaliação das medidas de qualidade]. Digestive Health Week 2025. (28–30 May); Porto, Portugal.
- Regatia R, Viegas MI, Saraiva S, **Areia M**, Sarmento Costa M, Elvas L, Alves S, Brito D, Cadime AT. (2025) Efficacy and Adverse Events of Helicobacter pylori Eradication Therapies: An 11-Year Prospective Cohort Study [Eficácia e eventos adversos das terapêuticas de erradicação do Helicobacter pylori: estudo de coorte prospetivo a 11 anos]. Digestive Health Week 2025. (28-30 May); Porto, Portugal
- Regatia R, Viegas MI, Saraiva S, **Areia M**, Sarmento Costa M, Elvas L, Alves S, Brito D, Cadime AT. (2025) Recurrence and Complications Following Fragmented Colorectal Mucosectomy: A 12-Year Prospective Cohort Study. [Recorrência e complicações após mucosectomia fragmentada colorretal: estudo de coorte prospetivo a 12 anos]. Digestive Health Week 2025. (28-30 May); Porto, Portugal
- Vasconcelos AC, Domingues Â, **Brandão C, Pimentel-Nunes P, Dinis-Ribeiro M, Libânio D.** (2025) Predictors of non-curative resection following endoscopic dissection of the gastric submucosa. [Fatores preditores de resseção não curativa após disseção endoscópica da submucosa gástrica]. Digestive Health Week 2025. (28–30 May); Porto, Portugal.
- Viegas MI, Regatia R, Costa M, Saraiva S, Elvas L, **Areia M**, Alves S, Brito D, Cadime AT. (2025) Risk factors and lifestyle characteristics of early-onset vs. late-onset colorectal cancer: a single centre case-control study. Semana Digestiva 2025 (28-30 May); Porto, Portugal
- Viegas MI, Regatia R, Costa M, Saraiva S, Elvas L, **Areia M**, Alves S, Brito D, Cadime AT. (2025) Early-onset colorectal cancer: a two-year retrospective cohort study. Digestive Health Week 2025. (28-30 May); Porto, Portugal
- Pereira M, **Lopes C,** Pinho D, **Dinis-Ribeiro M, Pereira C**, Fernandes E. (2025) Advancing Early Detection of Gastric Cancer: Saliva Biomarkers and Point-of-Care Technology. VI Chemical and Biological Engineering Doctoral Symposium (2-3 October); Braga, Portugal.

- **Santos, DAR**, Santos, LL, Vieira, C**, Dinis-Ribeiro, M**, Lima, L. (2025) MicroRNAS as Predictive Biomarkers of Therapeutic Response in Colorectal Cancer: A Systematic Review and Study Design. 3rd Young Researchers' Day (22 October); Porto, Portugal.
- Gonçalves N, **Brandão C**, Azevedo R. (2025) A rare event of pagetoid migration of urothelial carcinoma to rectal mucosa. XXXIV National Congress of Coloproctology . (20–21 November); Braga, Portugal.

### *Editorial Board Positions*

| Journal | Publishing Group | Position | Researcher |
|---|---|---|---|
| Endoscopy | Thieme | Co-Editor-in-chief | Mário Dinis-Ribeiro |
| Digestive Endoscopy | Wiley | Advisory board | Mário Dinis-Ribeiro |
| Endocrine Insights | Karger | Associate Editor | Ana Paula Santos |
| CVIR Oncology | Springer Nature | Editorial Board - Neuroendocrine | Ana Paula Santos |
| BMC Gastroenterology | BMC Spinger Nature | Editorial Board | Andreia Albuquerque |
| European Journal of Medical Research | BMC Springer Nature | Associate Editor | Andreia Albuquerque |
| World Journal of Gastrointestinal Oncology | Baishideng Publishing Group Inc | Editorial Board | Andreia Albuquerque |
| Endoscopy | Thieme | Editorial Board | Miguel Areia |
| GE – Portuguese Journal of Gastroenterology | Karger | Co-Editor | Miguel Areia |
| United European Gastroenterology Journal | Wiley | Trainee Editor | Diogo Libânio |
| GE – Portuguese Journal of Gastroenterology | Karger | Editor-in-Chief | Diogo Libânio |
| Gastrointestinal Endoscopy | Elsevier | International Editorial Board | Diogo Libânio |
| GE – Portuguese Journal of Gastroenterology | Karger | Editorial Board | Pedro Pimentel-Nunes |

### *Peer Review*

Annals of Internal Medicine; BMC Gastroenterology; Current Oncology; Discover Oncology; Eur J Gastroenterol Hepatol; Gastroenterology; Gut; International Journal of Cancer; Journal of Integrative Medicine; Journal of the National Cancer Institute; Lancet Gastroenterology and Hepatology; Reports; Revista Portuguesa de Educação; Scand J Gastroenterol; Scientific Reports; World J Gastroenterol.

### *Participation as Opponent in MSc Evaluation Committees*

| Student | Title | Program | Researcher |
|---|---|---|---|
| Beatriz Leandro Fontão | RKIP-regulated miRNAs in Gastrintestinal Stromal Tumor (GIST) | Health Sciences – ICVS/UM | Ana Carina Pereira |

### Teaching Activity: Coordination of Curricular Units/Courses

| Member | Curricular Units | Program | Position | Faculty/ University |
|---|---|---|---|---|
| Ana Carina Pereira | Research Practices in Oncology | MSc in Oncology | Teaching | ICBAS; UP |
| Ana Paula Santos | - Neuroendocrine Tumors- Thyroid Tumors | MSc in Oncology | Teaching | ICBAS; UP |
| Ana Paula Santos | Molecules, Cells and Diseases 3 - Atherosclerosis - OncoEndocrinology | MSc in Medicine | Teaching | EMCB; UFP |
| Andreia Albuquerque | Clinical Medicine I | Integrated MSc in Medicine (MIMED) | Teaching | Medical Sciences Department, Aveiro University |
| Andreia Albuquerque | Clinical Medicine II | Integrated MSc in Medicine (MIMED) | Teaching | Medical Sciences Department, Aveiro University |
| Mário Dinis-Ribeiro | Evidence and Decision | MSc in Health Evidence and Decision (MEDS) | Teaching | FMUP |
| Mário Dinis-Ribeiro | Scientific Communication and Publication | MSc in Health Evidence and Decision (MEDS) | Coordination | FMUP |
| Mário Dinis-Ribeiro | Thesis, Project and Traineeship protocols I | MSc in Health Evidence and Decision (MEDS) | Coordination and Teaching | FMUP |
| Mário Dinis-Ribeiro | Diagnostic Studies | MSc in Health Evidence and Decision (MEDS) | Coordination | FMUP |
| Mário Dinis-Ribeiro | Thesis, Project and Traineeship protocols II | MSc in Health Evidence and Decision (MEDS) | Teaching | FMUP |
| Mário Dinis-Ribeiro | Evidence and Decision Making | PhD in Clinical and Health Services Research (PDICSS) | Teaching | FMUP |
| Mário Dinis-Ribeiro | PhD Thesis Project I | PhD in Clinical and Health Services Research (PDICSS) | Coordination and Teaching | FMUP |
| Mário Dinis-Ribeiro | PhD Thesis Project II | PhD in Clinical and Health Services Research (PDICSS) | Coordination and Teaching | FMUP |
| Mário Dinis-Ribeiro | Diagnostic Studies | PhD in Clinical and Health Services Research (PDICSS) | Coordination and Teaching | FMUP |
| Patrícia Alves | Advanced Issues on Methodologies of Research in Education | MSc in Educational Sciences (MCED) | Teaching | FPCEUP |
| Pedro Pimentel-Nunes | Animal Models and Experimental Echocardiography | Doctoral Programm in Cardiovascular sciences (PDCCV) | Teaching | FMUP |
| Pedro Pimentel-Nunes | Thesis | Doctoral Program in Cardiovascular sciences (PDCCV) | Teaching | FMUP |
| Pedro Pimentel-Nunes | Physiology I & II | Integrated MSc in Medicine (MIMED) | Teaching | FMUP |

| Member | Curricular Units | Program | Position | Faculty/ University |
|---|---|---|---|---|
| Pedro Pimentel-Nunes | Oncological Gastroenterology | Integrated MSc in Medicine (MIMED) | Teaching | FMUP |
| Pedro Pimentel-Nunes | Gastrointestinal Physiology and Physiopathology from Semiology to therapeutic (FFGST) | Continuing Training Unit for interns of Gastroenterology | Coordination and teaching | FMUP |

### *Prizes, Honors and Awards*

| Researcher | Prize designation | Institution | Date | Amount |
|---|---|---|---|---|
| Catarina Lopes | Prémio Maria de Sousa | Fundação Bial \| Ordem dos Médicos | November 2025 | 30 000€ |
| Catarina Lopes | Best Oral Communication | RISE-Health Research Network Associated Laboratory | October 2025 | Chaperone Gift Card |
| Catarina Lopes | Travel Grant UEG Week 2025 | United European Gastroenterology | October 2025 | 750€ |
| Daniela Santos | Honorable mention for poster presentation | IPO Porto Research Center | October 2025 | N/A |
| Miguel Areia | Best original article published in "GE - Portuguese Journal of Gastroenterology" em 2024 | Sociedade Portuguesa de Gastrenterologia | May 2025 | 1000 € |
| Pedro Pimentel Nunes | World's Top 2% Scientists List | | 2025 | |
| Mário Dinis-Ribeiro | World's Top 2% Scientists List | | 2025 | |

### *Scientific Appointments*

| Organization | Researcher |
|---|---|
| Sub-Director @ IPO Porto Research Center | Mário Dinis-Ribeiro |
| Secretary General of World Endoscopy Organization (WEO) | Mário Dinis-Ribeiro |
| European Initiative for Colorectal Cancer, JRC | Mário Dinis-Ribeiro |
| Advisory Board of European Neuroendocrine tumors Society (ENETS) | Ana Paula Santos |
| Member of ENETS MEN1 Task Force | Ana Paula Santos |
| Member of ENETS Women in NET Task Force | Ana Paula Santos |
| Scientific Committee Member for the Portuguese Congress of Endocrinology 2025 | Ana Paula Santos |
| Full Board Member of the International Papillomavirus Society (IPVS) | Andreia Albuquerque |
| Chair Social Media Committee IPVS | Andreia Albuquerque |
| Member Educational Committee IPVS | Andreia Albuquerque |
| Member of IPVS Industry subcommittee IPVS | Andreia Albuquerque |
| Chair of Scientific Committee for IPVC 2025 | Andreia Albuquerque |
| Chair of ESGE Quality Improvement committee for Quality in upper GI endoscopy | Miguel Areia |
| Coordinator of the institutional accreditation project by OECI "Organization of European Cancer Institutes for IPO Coimbra | Miguel Areia |
| Assistant Clinical Director at IPO Coimbra (responsible for Quality) | Miguel Areia |
| Member of the Scientific Committee for Upper GI in ESGE Days 2025 | Miguel Areia |
| Member of the European Society of Gastrointestinal Endoscopy (ESGE) curriculum working Group | Pedro Pimentel Nunes |
| Head of Cancer Risk Unit of Centro Hospitalar Universitário do Porto (CHUP) | Ricardo Marcos-Pinto |

| Organization | Researcher |
|---|---|
| Coordinator, Scientific Committee Member of Sociedade Portuguesa de Endoscopia Digestiva (SPED) | Ricardo Marcos-Pinto |
| Clinical Director of the Institute of Digestive Endoscopy of the North (Endonorte) | Ricardo Marcos-Pinto |
| CEO & Co-founder of Glyco4Clinics (startup) | Ricardo Marcos-Pinto |

### *National collaborations*

| Title | Researchers | Collaborators | Funding | Period |
|---|---|---|---|---|
| GATE - GenerAlizable and Trustable computer assisted upper gastrointestinal Endoscopy | Mário Dinis-Ribeiro | Francesco Renna (INESC TEC), Miguel Coimbra (INESC TEC) | FCT: COMPETE2030 -FEDER-00886200 | 2025-2028 |
| Non-invasive early screening and surveillance of gastric cancer | Carina Pereira, Catarina Lopes, Mário Dinis-Ribeiro | Andreia Brandão (IPO Porto Research Center), Manuel Teixeira (IPO Porto Research Center), Elisabete Fernandes (INL) | FCT: UI/BD/151488/ 2021 | 2021-2025 |
| ONCOSCREEN- A European “shield” against colorectal cancer based on novel, more precise and affordable risk-based screening methods and viable policy pathways | Mário Dinis-Ribeiro, Carina Pereira | Lúcio Lara-Santos (IPO Porto Research Center), Luís Lima (CI-IPOP) | HORIZON: 101097036 | 2023-2026 |
| Innovation in the early detection of gastric cancer biomarkers: The promising role of point-of-care devices | Mário Dinis-Ribeiro, Catarina Lopes, Carina Pereira | Maria Pereira (UM), Diana Pinho (UM), Elisabete Fernandes (INL) | *Sociedade Portuguesa de Gastrenterologia* (SPG) Nº1/2025 | 2025-2026 |
| Characterization of a multicenter series of pancreatic neuroendocrine neoplasms: the prognostic power of the ATRX/DAXX immunohistochemical profile and telomere status by FISH and qPCR. (TELNET) | Ana Paula Santos | João Vinagre (i3S), Sara Coelho (IPOP), Sara Gil-Santos (IPOP), Isabel Azevedo (IPOP) | | 2024-2027 |
| Revolutionizing Precision Medicine of Adrenocortical Carcinoma: using non-invasive liquid biopsy and artificial intelligence tools for early diagnosis. | Ana Paula Santos | Pedro Souteiro (IPOP), Duarte Pignatelli (ULS S. João/i3S), Sofia S. Pereira (UMIB/ICBAS), Diana Sousa, Sofia S. Oliveira, Madalena Costa, Marta Guimarães (ULS DV/ICBAS), Valeriano Leite (IPO Lisboa), Mariana | | 2024-… |

| Title | Researchers | Collaborators | Funding | Period |
|---|---|---|---|---|
| | | Monteiro (ICBAS); Elisabete Rios, Sandra Rebelo, Juan Falcon Perez, Isabel Ramos, João Tavares | | |
| Prevalence of Pituitary Tumors in Portugal: A Population Study for the Development of a National Registry | Ana Paula Santos | Pedro Souteiro (IPO), Raquel Calheiros (IPOP), Luís Miguel Cardoso (i3S) | | 2024-… |
| Perspectives on Liquid Biopsies for Gastric and Colorectal Cancer Screening and Surveillance: Voices of the Community, Patients and Physicians | Patrícia Alves, Mário Dinis-Ribeiro, Ruben Alves, Ana Carina Pereira, Catarina Lopes, Tatiana Almeida, Raquel Ramos | Sofia Pais (FPCEUP) | | 2025-2026 |
| Post-PhD processes: an exploratory study on transitions after doctoral studies | Patrícia Alves, Mário Dinis-Ribeiro, Rosa Proença, Rui Henrique | Isabel Menezes (FPCEUP) | | 2025-2026 |

### *International collaborations*

| Title | Researchers | International Team | Institution | Country | Funding |
|---|---|---|---|---|---|
| Comprehensive Analysis of Common Genetic Variants On Inflammatory Genes in Gastric Cancer: From Bench to Bedside | Ana Carina Pereira<br>Mário Dinis-Ribeiro | Johannes Schumacher | Institute of Human Genetics at University of Marburg | Germany | |
| MATCH - Molecular Biomarkers Towards Chemoprevention of Metachronous Gastric Lesions | Adriana Serra, Ana Carina Pereira, Mário Dinis-Ribeiro | Markus Gerhard, Raquel Luque | Technical University of Munich | Germany | |
| SNIFF: Saliva-based non-invasive volatile organic compounds for gastric cancer detection | Catarina Lopes, Mário Dinis-Ribeiro, Ana Carina Pereira | Tomasz Wasilewski, Damian Neubauer | Medical University of Gdańsk | Poland | Prémio Maria de Sousa 2025 |
| NET-Bile Study | Mª Leonor Lopes<br>Ana Paula Santos<br>Raquel Calheiros | Hans Hofland | Erasmus Medical Center – ENETS Center of Excellence | Netherlands | |

### International Consortia

| Organization | Researcher |
|---|---|
| EUCanScreen European Consortium | Mário Dinis-Ribeiro, Patrícia Alves, Ana Carina Pereira, Diogo Libânio; Catarina Brandão; Raquel Ramos |
| AFROC - The African Initiative Against Oesophageal Cancer | Mário Dinis-Ribeiro, Patrícia Alves; Raquel Ramos |
| AIDA European Consortium | Mário Dinis-Ribeiro, Ana Carina Pereira, Diogo Libânio, Catarina Lopes |
| TOGAS European Consortium | Mário Dinis-Ribeiro, Ana Carina Pereira, Diogo Libânio, Tatiana Almeida, Adriana Serra, Raquel Ramos |
| ONCOSCREEN European consortium | Mário Dinis-Ribeiro, Ana Carina Pereira, Diogo Libânio |
| European registry on the management of H. pylori infection (Hp-EuReg) | Miguel Areia, Ricardo Marcos-Pinto |
| EPoS, European Polyp Surveillance Trial (EPoS) | Miguel Areia |
| staR - European Network on the Germline Genetics of Gastric Cancer | Mário Dinis-Ribeiro, Ana Carina Pereira |

### Patents Submitted

| Description | File number | Status | National/ international |
|---|---|---|---|
| Dinis-Ribeiro M, Pereira C, Lopes C. Non-invasive biomarker, method and kit for early detection and surveillance of gastric cancer | PT20252007324896 | Provisional | National |

## CLINICAL RESEARCH UNIT

### Coordinators

José Dinis, MD and Claúdia Vieira, MD, PhD

### Research team @31 December 2025

| Name | Academic Degree | Professional Situation | Category/position | Time % |
|---|---|---|---|---|
| Alexandra Silva | BSc | Contract | Nurse Specialist | 100 |
| Alice Monteiro | BSc | Contract | Nurse Specialist | 100 |
| Alina Rosinha | MD, BSc | Contract | Medical Oncologist | 10 |
| Ana Filipa Carneiro | MD, BSc | Contract | Medical Oncologist | 10 |
| Ana Magalhães Ferreira | MD, BSc | Contract | Medical Oncologist | 20 |
| Ana Maia Ferreira | MD, BSc | Contract | Medical Oncologist | 10 |
| Ana Rita Lopes | MD, BSc | Contract | Medical Oncologist | 20 |
| Ana Rodrigues | MD, BSc | Contract | Medical Oncologist | 20 |
| António Eliseu de Carvalho Pereira Osório | MSc | Contract | Clinical Trials Assistant | 100 |
| António Miguel Abreu | MD, PhD | Contract | Medical Oncologist | 30 |
| Alexandra Silva | BSc | Contract | Nurse | 100 |
| Alice Monteiro | BSc | Contract | Nurse | 100 |
| Alina Rosinha | MD, BSc | Contract | Medical Oncologist | 10 |
| Ana Filipa Carneiro | MD, BSc | Contract | Medical Oncologist | 10 |
| Ana Magalhães Ferreira | MD, BSc | Contract | Medical Oncologist | 20 |
| Ana Maia Ferreira | MD, BSc | Contract | Medical Oncologist | 10 |
| Beatrice Mainoli | MD, BSc | Contract | Clinical Pharmacologist | 90 |
| Berta Reis | BSc | Contract | Nurse Specialist | 100 |
| Bruna Soares | BSc | Contract | Nurse Specialist | 100 |
| Cândida Carvalho | BSc | Contract | Nurse Specialist | 100 |
| Cátia Couto | MSc | Contract | Study Coordinator | 100 |
| Cátia Faustino | MD, BSc | Contract | Medical Oncologist | 10 |
| Cecília Carina Saraiva do Nascimento | MSc | Contract | Clinical Trials Assistant | 100 |
| Cláudia Martins Lima | PhD | Contract | Research Technician (LA/P/0053/2020) | 100 |
| Cláudia Moreira | MD, BSc | Contract | Clinical Hematologist | 10 |
| Claudia Vieira | MD, PhD | Contract | Medical Oncologist | 30 |
| Cristiana Ribeiro | BSc | Contract | Nurse Specialist | 100 |
| Daniela Alexandra Rocha Santos | MSc | Fellowship | PhD Student / FCT UI/BD/154820/2023 | 15 |
| Dânia Santos | MD, MSc | Contract | Medical Oncologist | 20 |
| Delfim Duarte | MD, PhD | Contract | Clinical Hematologist Resident | 10 |
| Diana Meira Alves | BSc | Contract | Nurse Specialist | 100 |
| Diana Ramada | BSN, MSc | Contract | Nurse Specialist | 10 |
| Dulcineia Pereira | MD, BSc | Contract | Clinical Hematologist | 20 |
| Elsa Pousada | BSc | Contract | Clinical Trials Assistant | 100 |
| Filipa Rocha | 12th Grade | Contract | Clinical Trials Assistant | 100 |
| Inês Capelo | MSc | Contract | Study Coordinator | 100 |
| Isabel Urraca | MD, MSc | Contract | Clinical Pharmacologist | 100 |

| Name | Academic Degree | Professional Situation | Category/position | Time % |
|---|---|---|---|---|
| Jéssica Rodrigues Almeida | MSc | Contract | Oncology pharmacists/Data enter | 100 |
| Joana Harper Maia | BSc | Contract | Manager of Good Clinical Practices and Quality | 100 |
| Joana Assis | PhD | Contract | Assistant Researcher (2023.14811.TENURE.006) | 100 |
| Joana Ferreira | BSc | Contract | Clinical Trials Assistant | 100 |
| Joana Margarida Dias Moreira dos Santos | MSc | Contract | Research Technician (PI188-CI-IPOP-21-2023-HORIZON-PRIME-ROSE) | 100 |
| Jorge André Anacleto Ribeiro | BSc | Contract | Study Coordinator | 100 |
| José Dinis Bastos Lima da Silva | MD, BSc | Contract | Senior Researcher, Oncologist | 20 |
| José Estácio | BSc | Contract | Other Support Personnel – Administrative Financial Support | 100 |
| José Mário Mariz | MD, BSc | Contract | Clinical Hematologist | 100 |
| Juliana Maria Salsa Ferreira | BSc | Contract | Study Coordinator | 100 |
| Júlio Oliveira | MD, MSc | Contract | Medical Oncologist | 10 |
| Leonel Bento | 12th grade | Contract | Clinical Trials Assistant | 100 |
| Liliana Maria Almeida Azevedo | BSc | Contract | Study Coordinator | 100 |
| Luísa Prada | MD, BSc | Contract | Clinical Pharmacologist | 100 |
| Maria Cassiano Neves | MD, MSc | Contract | Medical Oncologist | 20 |
| Maria Isabel Vilas-Boas | MD, MSc | Contract | Medical Oncologist | 20 |
| Maria Novaes Veloso | MSc | Contract | Oncology pharmacist | 100 |
| Maria Miguel Oliveira | MSc | Contract | Junior Manager of Good Clinical Practices and Quality | 100 |
| Mariana Sacramento | MSc | Contract | Study Coordinator | 100 |
| Marta Sofia da Silva Correia | PhD | Contract | Study Coordinator (PI228-CI-IPOP-22-2025-WAYFIND-R) | 100 |
| Marta Ferreira | MD, MSc | Contract | Medical Oncologist | 10 |
| Marta Moreira | BSc | Contract CEI | Trainee for Clinical Trials Assistant | 100 |
| Marta Soares | MD, BSc | Contract | Medical Oncologist | 10 |
| Nuno Sousa | MD, MSc | Contract | Medical Oncologist | 10 |
| Pedro Figueiredo | BSc | Contract | Nurse Specialist | 100 |
| Pedro Calvão | BSc | Contract | Clinical Trials Technician | 100 |
| Pedro Neves | 12th grade | Contract | Clinical Trials Assistant | 100 |
| Ruben Leite | MSc | Contract | Data enter | 100 |
| Rui Fonseca | BSc | Contract | Study Coordinator | 100 |
| Rute Silva | BSc | Contract | Study Coordinator | 100 |
| Sara Alves | MD, BSc | Contract | Medical Oncologist | 20 |
| Sara Pinto Coelho | MD, MSc | Contract | Medical Oncologist | 20 |
| Susana Ramada | BSc | Contract | Nurse Specialist | 100 |
| Susana Silva | BSc | Contract | Nurse Specialist | 100 |
| Tatiana Vieira | BSc | Contract | Nurse Specialist | 100 |
| Vítor Miguel Ribeiro | 12th grade | Contract | Contract Clinical Trials Assistant | 100 |

### Group description and objectives

The Clinical Research Unit, scientifically coordinated by a medical oncologist, directs both investigator-initiated and pharma clinical trials at IPO Porto. Comprising a committed full-time team of 1 assistant researcher, 1 clinical Pharmacologist, 2 Research Technicians (1 with a PhD), 5 clinical trial assistants, 9 study coordinators (1 with a PhD), 2 good clinical practices & quality managers and 2 oncology pharmacists, that daily perform clinical trials recruitment, ensuring protocol adherence, and assisting in all related procedures alongside the institution's multidisciplinary professionals. This collaborative effort also involves several part-time medical doctors, including 2 holding PhDs, nurses, pharmacists, and various technicians with different expertise. The unit collaborates with several IPO Porto clinical departments and research groups, aiding their participation in international clinical trials sponsored by entities such as the European Organization for Research and Treatment of Cancer, EU collaborative groups, and pharmaceutical companies.

The main objectives for the 2025-2029 years are:

1) The expansion of investigator-initiated early clinical trials to test the best-in-class targeted therapies, including those developed by the translational research groups. By participating in innovative clinical trials, researchers endeavor to uncover valuable insights that can enhance patient care and treatment outcomes.
2) To expand Precision Oncology Program (POP-IPOP) and increase the opportunities of biomarker driven clinical trial access.
3) To drive scientific collaboration with academic/non-commercial partners, biotech and pharma companies, focusing on clinical research and early drug development.

### Active projects and funding

### Competitive Funding

#### International

- PCM4EU – “Personalised Cancer Medicine for all EU citizens” (ID: 101079984 EU4H-2021-PJ15) Budget: 161K€ (2023-2026)(PI@IPO Porto: Júlio Oliveira)
- PRIME-ROSE – “PRecisIon Cancer MEdicine RepurpOsing SystEm Using Pragmatic Clinical Trials” (ID: 101104269 HORIZON-MISS-2022-CANCER-01) Budget: 142K€ (2023-2028) (PI@IPO Porto: Júlio Oliveira)
- HOPE4Kids – “Holistic Oncological Palliative care 4 Europe's Kids” (ID: 101233078 EU4H-2024-JA-IBA-09) Budget: 45K€ (2025-2029) (PI: Sílvia Silva)
- JA PCM – “Joint Action Personalised Cancer Medicine” (ID: 101233450 EU4H-2024-PJ-03-4) Budget: 262k€ (2025-2029) (PI: Beatrice Mainoli)

#### National

- IDEAR – “Neoadjuvant Immunotherapy with Durvalumab (MEDI4736) in Non-Surgical Early Stage or Located Advanced Non-Small Cell Lung Cancer (NSCLC) followed by Radical Radiotherapy or Chemotherapy (Phase II, single arm, clinical trial)”. (CI-IPOP 74-2017) Budget: 91K€ (2017-2023), (PI: Júlio Oliveira) in collaboration with i3S e AstraZeneca
- OnCOVacB – “Evaluation of the Immunologic Response to COVID-19 Vaccination in Oncological Patients, Budget: 200K€ (2022-2024) (PI: Júlio Oliveira/ Rui Medeiros)
- CAR T-MATTERS – “Transforming the CAR T-cell therapy landscape in Portugal” (COMPETE2030-FEDER-01477200 | Project 18427) Budget: 654K€ (2025-2028) (PI: Júlio Oliveira)

## Major achievements

**Overall, 133 patients were accrued for institutional clinical trials.**

| | Number of accruing trials | Number of patients recruited |
|---|---|---|
| **Phase I** | 13 | 7 |
| **Phase II** | 28 | 13 |
| **Phase III** | 123 | 113 |
| **Prospective interventional trials (without Phase I-III classification)** | 3 | 0 |
| **Total** | 167 | 133 |

**Six early phase clinical trials started in 2025 and 4 were closed, while 22 were ongoing, being one investigator-initiated Phase II trial.**

## Early phase clinical trials started in 2025

- A phase 2 study evaluating the efficacy, safety, tolerability, and pharmacokinetics of AMG 193 in subjects with methylthioadenosine phosphorylase (MTAP)-deleted previously treated advanced non-small cell lung cancer (NSCLC) (20230153 MTAPESTRY201, Principal Investigator Dr. Maria Cassiano Neves)
- A phase 1b/2 pan-tumor, open-label study to evaluate the efficacy and safety of ifinatamab deruxtecan (I-DXd) in subjects with recurrent or metastatic solid tumors (DS7300-203 IDeate-PanTumor02, Principal Investigator Dr. Sara Alves)
- A phase 1/2, open-label, platform study to evaluate safety and efficacy of the BCL-2 inhibitor ABBV-453 given as monotherapy or in combination with antimyeloma regimens in subjects with multiple myeloma (M25-275, Principal Investigator Dr. Cláudia Moreira)
- A phase 1/2 open label, dose escalation and expansion study of MDNA11, IL-2 superkine, administered alone or in combination with an immune checkpoint inhibitor in patients with advanced solid tumors (MDNA11-01 ABILITY-1, Principal Investigator Dr. Sara Coelho)
- A randomized phase ii study to evaluate the safety and efficacy of trastuzumab deruxtecan versus CDK4/6 inhibitor-based endocrine therapy as first-line therapy of HR-positive and HER2-low/ultralow advanced breast cancer patients classified as non-luminal subtype according to gene expression profiling (MEDOPP556 PONTIAC, Principal Investigator Dr. Ana Ferreira)
- A phase 2 study of alisertib in combination with endocrine therapy in patients with HR+, HER2-negative recurrent or metastatic breast cancer (PUMA-ALI-1201 ALISCA™-Breast1, Principal Investigator Dr. Ana Sofia Patrão)

## Early phase clinical trials ongoing in 2025

- An open label, first-in-human study of BAY 2927088 in participants with advanced non-small cell lung cancer (NSCLC) harboring an EGFR and/or HER2 mutation (21607, Principal Investigator Dr. Marta Soares)
- A phase 2, randomized, open-label, platform study utilizing a master protocol to evaluate novel immunotherapy combinations in participants with previously untreated, locally advanced/metastatic, programmed death ligand 1-selected non-small-cell lung cancer (213824, Principal Investigator Dr. Marta Soares)
- A phase 2, randomized, open-label, platform study using a master protocol to evaluate novel immunotherapy combinations as first-line treatment in participants with recurrent/metastatic PD-L1 positive squamous cell carcinoma of the head and neck (219885, Principal Investigator Dr. José Dinis)
- A phase 1 study evaluating the safety, tolerability, pharmacokinetics, and efficacy of AMG 509 in subjects with metastatic castration-resistant prostate cancer (20180146, Principal Investigator Dr. Alina Rosinha)
- A phase 1, multicenter, open-label, first-in-human study of the safety and pharmacokinetics of AMX-818 alone and in combination with pembrolizumab in participants with locally advanced or metastatic HER2-expressing cancers (AMX-818-001, Principal Investigator Dr. Júlio Oliveira)
- An open-label phase II randomized trial of BNT113 in combination with pembrolizumab versus pembrolizumab monotherapy as a first line therapy in patients with unresectable recurrent, or metastatic head and neck squamous cell carcinoma (HNSCC) which is positive for human papilloma virus 16 (HPV16+) and expresses PD-L1 (BNT113-01, Principal Investigator Dr. José Dinis)
- Tumor-agnostic precision immuno-oncology and somatic targeting rational for you (TAPISTRY) phase II platform trial (BO41932 TAPISTRY, Principal Investigator Dr. Júlio Oliveira)
- A phase Ib dose finding study assessing safety and activity of [177Lu]Lu-DOTA-TATE in newly diagnosed glioblastoma in combination with radiotherapy with or without temozolomide and in recurrent glioblastoma as single agent (CAAA601A52101, Principal Investigator Dr. Filipa Carneiro)
- A phase Ib dose finding study assessing safety and activity of [177Lu]Lu-NeoB in combination with ribociclib and fulvestrant in participants with ER-positive, HER-2 negative and GRPR-positive breast cancer experiencing early relapse from (neo)adjuvant endocrine therapy (CAAA603B12101 NeoB BC, Principal Investigator Dr. Ana Ferreira)
- Phase Ib dose finding study assessing safety and activity of [177Lu]Lu-NeoB in combination with radiotherapy and temozolomide in subjects with newly diagnosed glioblastoma and as a single agent in recurrent glioblastoma (CAAA603C12101, Principal Investigator Dr. Filipa Carneiro)
- A phase I/II, open-label, multi-center trial of [177Lu]Lu-NeoB in combination with capecitabine in adult patients with gastrin releasing peptide receptor positive, estrogen receptor-positive, human epidermal growth receptor-2 negative metastatic breast cancer after progression on previous endocrine therapy in combination with CDK4/6 inhibitor (CAAA603D12101, Principal Investigator Dr. Ana Ferreira)
- Neoadjuvant immunotherapy with durvalumab (MEDI4736) in non-surgical early stage or locally advanced non-small cell lung cancer (NSCLC) followed by radical radiotherapy or chemoradiotherapy (CI-IPOP 74 2017 IDEAR, Principal Investigator Dr. Júlio Oliveira)
- A phase II, open-label, multicentre, randomised study of neoadjuvant and adjuvant treatment in patients with resectable, early-stage (II to IIIB) non-small cell lung cancer (D9077C00001 NeoCOAST-2, Principal Investigator Dr. Marta Soares)
- Integration of trastuzumab, with or without pertuzumab, into perioperative chemotherapy of HER-2 positive stomach cancer: the INNOVATION-TRIAL (EORTC-1203-GITCG INNOVATION, Principal Investigator Dr. Cátia Faustino)
- A phase II study of adjuvant palbociclib as an alternative to chemotherapy in elderly patients with high-risk ER+/HER2- early breast cancer (EORTC-1745-ETF-BCG APPALACHES, Principal Investigator Dr. Inês Pousa)
- A randomized, double-blind, multicenter, phase 2 study of retifanlimab in combination with INCAGN02385 (anti–LAG-3) and INCAGN02390 (anti–TIM-3) as first-line treatment in participants

with PD-L1–positive (CPS ≥ 1) recurrent/metastatic squamous cell carcinoma of the head and neck (INCAGN 2385-203, Principal Investigator Dr. Cláudia Vieira)
- Immunogenicity profile of neoadjuvant Keytruda in combination with anthracycline versus carboplatin/paclitaxel containing chemotherapy regimen for the treatment of early-stage, TILs-positive, triple-negative breast cancer (KeyPARTNER, Principal Investigator Dr. Miguel Abreu)
- A multicenter, open-label, phase 2 basket study to evaluate the safety and efficacy of MK 2140 as a monotherapy and in combination in participants with aggressive and indolent B-cell malignancies (MK2140-006, Principal Investigator Dr. Cláudia Moreira)
- A phase I/II study of pembrolizumab (MK-3475) in children with advanced melanoma or a PD-L1 positive advanced, relapsed, or refractory solid tumor or lymphoma (MK3475-051 KEYNOTE-051, Principal Investigator Dr. Ana Maia Ferreira)
- A clinical trial of pembrolizumab (MK-3475) evaluating predictive biomarkers in subjects with advanced solid tumors (MK3475-158 KEYNOTE-158, Principal Investigator Dr. Sara Coelho)
- A phase 2 study to evaluate the efficacy and safety of belzutifan (MK-6482, formerly PT2977) monotherapy in participants with advanced pheochromocytoma/paraganglioma (PPGL), pancreatic neuroendocrine tumor (pNET), von Hippel-Lindau (VHL) disease-associated tumors, advanced gastrointestinal stromal tumor (wt GIST), or advanced solid tumors with HIF-2α related genetic alterations (MK6482-015 LITESPARK-015, Principal Investigator Dr. Sara Coelho)
- A phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib (E7080/MK-7902) in combination with pembrolizumab (MK-3475) versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) that have progressed after platinum therapy and immunotherapy (PD-1/PD-L1 inhibitors) (MK7902-009 LEAP-009, Principal Investigator Dr. Cláudia Vieira)

### Early phase clinical trials closed in 2025

- A phase 1, open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability pharmacokinetics immunogenicity, and antitumor activity of MEDI5752 in subjects with advanced solid tumors (D7980C00001, Principal Investigator Dr. Júlio Oliveira)
- A phase II basket study of the oral TRK inhibitor LOXO-101 in subjects with NTRK fusion-positive tumors (LOXO-TRK-15002 NAVIGATE, Principal Investigator Dr. Nuno Sousa)
- A randomized, double-blind trial to evaluate the safety and efficacy of apraglutide in subjects with Grade II to IV (MAGIC) steroid refractory gastrointestinal (GI) acute graft versus host disease on best available therapy (TA799-101 STARGAZE, Principal Investigator Dr. Carlos Pinho Vaz)
- A phase 1b/2, open-label, randomized study of vudalimab in combination with chemotherapy or pembrolizumab in combination with chemotherapy as first-line treatment in patients with advanced non-small cell lung cancer (XmAb717-06, Principal Investigator Dr. Ana Rodrigues)

**In 2025, 34 Phase IIb/Phase III Clinical trials were started joining to the 78 already ongoing, while 24 were closed, 2 of which started in the same year.**

### Phase IIb/Phase III clinical trials started in 2025

- A phase 3 open-label, randomized, active-controlled, multicenter trial to evaluate the efficacy and safety of orally administered BAY 2927088 compared with standard of care as a first-line therapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with HER2-activating mutations (22615 SOHO-02, Principal Investigator Dr. Marta Soares)
- Phase 3 randomized, controlled study of blinatumomab alternating with low-intensity chemotherapy versus standard of care for older adults with newly diagnosed philadelphia-negative B-cell precursor acute lymphoblastic leukemia with safety run-in (20190360 Golden Gate, Principal Investigator Dr. José Mário Mariz)

- A randomized, double-blind study evaluating the efficacy, safety, and immunogenicity of ABP 206 compared with OPDIVO® (nivolumab) in subjects with treatment-naïve unresectable or metastatic melanoma (20210031 ZINNIA, Principal Investigator Dr. Sara Coelho)
- A phase 2b, open-label, two-cohort study of subcutaneous amivantamab in combination with lazertinib as first-line treatment, or subcutaneous amivantamab in combination with platinum-based chemotherapy as second-line treatment, for common EGFR-mutated locally advanced or metastatic non-small cell lung cancer (61186372NSC2012 COPERNICUS, Principal Investigator Dr. Sara Alves)
- A phase 3 randomized, double-blind, placebo-controlled, study of bleximenib, venetoclax and azacitidine for the treatment of participants with newly diagnosed acute myeloid leukemia harboring KMT2A rearrangements or NPM1 mutations who are Ineligible for intensive chemotherapy (75276617AML3001 cAMeLOT-2, Principal Investigator Prof. Ana Espírito Santo)
- A phase 3, double-blind, randomized, placebo-controlled trial of quizartinib administered in combination with induction and consolidation chemotherapy and administered as maintenance therapy in adult patients with newly diagnosed FLT3-ITD negative acute myeloid leukemia (AC220-168 QUANTUM-WILD, Principal Investigator Dr. Dulcineia Pereira)
- A multicenter, randomized, double-blind, phase 2/3 study of ficerafusp alfa (BCA101) or placebo in combination with pembrolizumab for first-line treatment of PD-L1-positive, recurrent or metastatic head and neck squamous cell carcinoma (BCA101X301 FORTIFI-HN01, Principal Investigator Dr. Cláudia Vieira)
- A phase 3, randomized, open-label, multicenter study to compare the efficacy and safety of BMS-986393, a GPRC5D-directed CAR-T cell therapy, versus standard regimens in adult participants with relapsed or refractory and lenalidomide-refractory multiple myeloma (CA088-1007 QUINTESSENTIAL-2, Principal Investigator Dr. José Mário Mariz)
- A phase 3, randomized, open-label study of nivolumab + relatlimab fixed-dose combination with chemotherapy versus pembrolizumab with chemotherapy as first-line treatment for participants with non-squamous (NSQ), stage IV or recurrent non-small cell lung cancer and with tumor cell PD-L1 expression ≥ 1% (CA224-1093 RELATIVITY 1093, Principal Investigator Dr. Maria Cassiano Neves)
- IZABRIGHT-Breast01: A randomized, open-label, inferentially seamless phase 2/3 study of izalontamab brengitecan (BMS-986507) versus treatment of physician's choice in patients with previously untreated, locally advanced, recurrent inoperable, or metastatic triple-negative breast cancer (TNBC) or ER-low, HER2-negative BC who are Ineligible for anti-PD1/PD-L1 treatment (CA244-0008 IZABRIGHT-Breast01, Principal Investigator Dr. Ana Afonso)
- A randomized, double-blind, parallel-group study to compare pharmacokinetics, efficacy, safety, and immunogenicity of JPB898 (proposed nivolumab biosimilar) and US-licensed and EU-authorized Opdivo® in combination with Yervoy® in participants with untreated advanced (unresectable/metastatic) melanoma (CJPB898A12301 NivoReach, Principal Investigator Dr. Paula Ferreira)
- A phase IIIb study to characterize the efficacy and safety of Adjuvant ribociclib plus endocrine therapy in a close-to-clinical practice patient population with HR+ HER2− early breast cancer (CLEE011O12001 Adjuvant WIDER, Principal Investigator Dr. Ana Ferreira)
- A phase III, randomized, open-label study evaluating the efficacy and safety of divarasib and pembrolizumab versus pembrolizumab and pemetrexed and carboplatin or cisplatin in patients with previously untreated, KRAS G12C-mutated, advanced or metastatic non-squamous non-small cell lung cancer (CO45042 Krascendo-2, Principal Investigator Dr. Marta Soares)
- A phase III, randomized, double-blind, multicenter, global study of rilvegostomig or pembrolizumab monotherapy for the first-line treatment of patients with PD-L1-high metastatic non-small cell lung cancer (D702GC00001 ARTEMIDE-Lung04, Principal Investigator Dr. Marta Soares)
- A phase III, open-label, randomised study to assess the efficacy and safety of camizestrant (AZD9833, a next generation, oral selective estrogen receptor degrader) versus standard endocrine therapy (aromatase inhibitor or tamoxifen) as adjuvant treatment for patients with ER+/HER2- early breast cancer and an intermediate-high or high risk of recurrence who have completed

definitive locoregional treatment and have no evidence of disease (D8535C00001 CAMBRIA-2, Principal Investigator Dr. Marta Ferreira)

- A multicenter, global, interventional, open-label study of trastuzumab deruxtecan (T-DXd), an anti-HER2-antibody drug conjugate (ADC), in subjects who have unresectable and/or metastatic HER2-low or HER2 immunohistochemistry (IHC) 0 breast cancer (BC) (DS8201-0001-CIS-MA DESTINY-Breast15, Principal Investigator Dr. Cristina Oliveira)
- A multicenter, randomized, open-label, phase 3 trial of trastuzumab deruxtecan (ENHERTU®) plus chemotherapy plus or minus pembrolizumab versus chemotherapy plus trastuzumab plus or minus pembrolizumab as first-line treatment in participants with unresectable, locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) cancer (DS8201-724 DESTINY-Gastric05, Principal Investigator Dr. Cátia Faustino)
- A phase 3 randomized, controlled study of IMC-F106C plus nivolumab versus nivolumab regimens in HLA-A*02:01-positive participants with previously untreated advanced melanoma (IMC-F106C-301 PRISM-MEL-301, Principal Investigator Dr. Sara Coelho)
- A phase 3, randomized, open-label study of axatilimab versus best available therapy in participants with chronic graft-versus-host disease after at least 2 prior lines of systemic therapy (INCA034176-355 AGAVE-355, Principal Investigator Dr. Manuel Guerreiro)
- A global pivotal study in participants with KRAS G12C-mutant, locally advanced or metastatic non-small cell lung cancer comparing first-line treatment of LY3537982 and pembrolizumab vs placebo and pembrolizumab in those with PD-L1 expression ≥50% or LY3537982 and pembrolizumab, pemetrexed, platinum vs placebo and pembrolizumab, pemetrexed, platinum regardless of PD-L1 expression (J3M-MC-JZQB SUNRAY-01, Principal Investigator Dr. Cristina Oliveira)
- A phase 3, multicenter, double-blind, placebo-controlled study assessing the efficacy and safety of olomorasib in combination with standard of care immunotherapy in participants with resected or unresectable KRAS G12C-mutant, non-small cell lung cancer (J3M-MC-JZQH SUNRAY-02, Principal Investigator Dr. Marta Soares)
- Relapsed or refractory diffuse large B-cell lymphoma: phase 3 study to evaluate the safety and efficacy of epcoritamab plus lenalidomide compared to rituximab plus gemcitabine and oxaliplatin (M22-128, Principal Investigator Dr. Rita Coutinho)
- A phase 3 open-label, randomized, controlled study to evaluate the efficacy and safety of petosemtamab compared with Investigator's choice monotherapy treatment in previously treated patients with incurable, metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02, Principal Investigator Dr. Cláudia Vieira)
- A phase 3 randomized, open-label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03, Principal Investigator Dr. José Dinis)
- A randomized, open-label, multicenter, phase 3 study of zilovertamab vedotin (MK-2140) in combination with R-CHP versus R-CHOP in participants with previously untreated diffuse large B-cell lymphoma (DLBCL) (MK2140-010 waveLINE-010, Principal Investigator Dr. Mário Pimenta)
- An open-label, randomized phase 3 study of MK-2870 as a single agent and in combination with pembrolizumab versus treatment of physician's choice in participants with HR+/HER2- unresectable locally advanced or metastatic breast cancer (MK2870-010 TroFuse-010, Principal Investigator Dr. Ana Sofia Patrão)
- A phase 3, randomized, open-label study to evaluate the efficacy and safety of sac-TMT (sacituzumab tirumotecan, MK-2870) followed by carboplatin/paclitaxel vs chemotherapy, both in combination with pembrolizumab as neoadjuvant therapy for high-risk, early-stage, triple-negative breast cancer or hormone receptor-low positive/human epidermal growth factor receptor-2 negative breast cancer (MK2870-032 TroFuse-032, Principal Investigator Dr. Susana Amaral)
- A phase 3 study of the selective anaplastic lymphoma kinase (ALK) inhibitor NVL-655 compared to alectinib in first-line treatment of patients with ALK-positive advanced non-small cell lung cancer (NVL-655-04 ALKAZAR, Principal Investigator Dr. Marta Soares)

- Randomized, controlled, open-label, phase IIb/III study of lurbinectedin in combination with doxorubicin versus doxorubicin alone as first-line treatment in patients with metastatic leiomyosarcoma (PM1183-C-010-22 SaLuDo, Principal Investigator Dr. Miguel Abreu)
- Elacestrant versus standard endocrine therapy in women and men with node-positive, estrogen receptor-positive, HER2-negative, early breast cancer with high risk of recurrence - a global, multicenter, randomized, open-label phase 3 study (STML-ELA-0422 ELEGANT, Principal Investigator Dr. Inés Pousa)
- TACTI-004, a double-blinded, randomized phase 3 trial in patients with advanced/metastatic non-small cell lung cancer (NSCLC) receiving eftilagimod alfa (MHC class II agonist) in combination with pembrolizumab (PD-1 antagonist) and chemotherapy (TACTI-004, Principal Investigator Dr. Cristina Oliveira)
- A phase 2, randomized, double-blind, placebo- and active-comparator- controlled clinical study of V940 (mRNA-4157) plus pembrolizumab versus placebo plus pembrolizumab in participants with first-line advanced Melanoma (V940-012 INTerpath-012, Principal Investigator Dr. Paula Ferreira)
- zAvatar test-guided therapeutic decision vs standard of care, in relapsed ovarian cancer and in metastatic breast cancer - a multicentric randomized clinical study with intervention (zAvatar-FLUIDS, Principal Investigator Dr. Ana Ferreira)
- zAvatar test-guided therapeutic decision vs standard of care, in relapsed ovarian cancer and in metastatic breast cancer - a multicentric randomized clinical study with intervention (zAvatar-FLUIDS, Principal Investigator Dr. Miguel Abreu)

## Ongoing Phase IIb/Phase III clinical trials

- Phase 2b clinical study evaluating efficacy and safety of TAR-200 in combination with cetrelimab, TAR-200 alone, or cetrelimab alone in participants with high-risk non-muscle invasive bladder cancer (NMIBC) unresponsive to intravesical Bacillus Calmette-Guerin (BCG) who are ineligible for or elected not to undergo radical cystectomy (17000139BLC2001 SunRISe-1, Principal Investigator Dr. António Morais)
- A randomized, double-blind, placebo-controlled phase 3 study to evaluate dostarlimab as sequential therapy after chemoradiation in participants with locally advanced unresected head and neck squamous cell carcinoma (221530 JADE, Principal Investigator Dr. Cláudia Vieira)
- A randomized, multi-center, double-blind, placebo-controlled phase 3 study of bemarituzumab plus chemotherapy versus placebo plus chemotherapy in subjects with previously untreated advanced gastric or gastroesophageal junction cancer with FGFR2b overexpression (20210096 FORTITUDE-101, Principal Investigator Dr. Alina Rosinha)
- A phase 3 randomized study comparing teclistamab in combination with daratumumab sc and lenalidomide (Tec-DR) and talquetamab in combination with daratumumab sc and lenalidomide (Tal-DR) versus daratumumab SC, lenalidomide, and dexamethasone (DRd) in participants with newly diagnosed multiple myeloma who are either ineligible or not intended for autologous stem cell transplant as initial therapy (64007957MMY3005 MajesTEC-7, Principal Investigator Dr. Luísa Viterbo)
- A phase 3 randomized study comparing teclistamab monotherapy versus pomalidomide, bortezomib, dexamethasone (PVd) or carfilzomib, dexamethasone (Kd) in participants with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of therapy, including an anti-CD38 monoclonal antibody and lenalidomide (64007957MMY3006 MajesTEC-9, Principal Investigator Dr. Cláudia Moreira)
- A randomized, open-label phase 3 study of combination amivantamab and carboplatin-pemetrexed therapy, compared with carboplatin-pemetrexed, in patients with EGFR Exon 20ins mutated locally advanced or metastatic non-small cell lung cancer (61186372NSC3001 PAPILLON, Principal Investigator Dr. Isabel Azevedo)
- A phase 3 randomized study comparing bortezomib, lenalidomide and dexamethasone (VRd) followed by ciltacabtagene autoleucel, a chimeric antigen receptor T cell (CAR-T) therapy directed against BCMA versus bortezomib, lenalidomide, and dexamethasone (VRd) followed by lenalidomide and dexamethasone (Rd) therapy in participants with newly diagnosed multiple myeloma for whom

hematopoietic stem cell transplant is not planned as initial therapy (68284528MMY3004 CARTITUDE-5, Principal Investigator Dr. José Mário Mariz)

- A phase 3, randomized study of amivantamab and lazertinib combination therapy versus osimertinib versus lazertinib as first-line treatment in patients with EGFR-mutated locally advanced or metastatic non-small cell lung cancer (73841937NSC3003 MARIPOSA, Principal Investigator Dr. Maria Cassiano Neves)
- A randomized phase 3 study of MRTX849 versus docetaxel in patients with previously treated non-small cell lung cancer with KRAS G12C mutation (849-012 KRYSTAL-12, Principal Investigator Dr. Cristina Oliveira)
- PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer (ABGSG 42 PALLAS, Principal Investigator Dr. Miguel Abreu)
- A phase 3, randomized, double-blind, placebo-controlled study of acalabrutinib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in subjects ≤65 years with previously untreated non-germinal center diffuse large B-cell lymphoma (ACE-LY-312 (D8227C00001) ESCALADE, Principal Investigator Dr. Nélson Domingues)
- A randomized, open label, phase III trial to evaluate the efficacy and safety of palbociclib + anti-HER2 therapy + endocrine therapy vs. anti-HER2 therapy + endocrine therapy after induction treatment for hormone receptor positive (HR+)/HER2-positive metastatic breast cancer (AFT-38 PATINA, Principal Investigator Dr. Cláudia Vieira)
- A phase 3 randomized, open-label, multicenter study comparing zanubrutinib (BGB-3111) plus rituximab versus bendamustine plus rituximab in patients with previously untreated Mantle Cell Lymphoma who are ineligible for stem cell transplantation (BGB-3111-306 MANGROVE, Principal Investigator Dr. Ângelo Martins)
- A phase 3 randomized, open-label, multicenter study of zanubrutinib (BGB-3111) plus anti-CD20 antibodies versus lenalidomide plus rituximab in patients with relapsed/refractory follicular or marginal zone lymphoma (BGB-3111-308 MAHOGANY, Principal Investigator Dr. Dulcineia Pereira)
- An open-label, multicenter extension study of trastuzumab emtansine administered as a single agent or in combination with other anti-cancer therapies in patients previously enrolled in a Genentech and /or F. Hoffmann-La Roche Ltd. - sponsored trastuzumab emtansine study (BO25430, Principal Investigator Dr. Inés Pousa)
- A phase III randomized, double-blind, placebo-controlled, multicenter study evaluating the efficacy and safety of GDC-9545 combined with palbociclib compared with letrozole combined with palbociclib in patients with estrogen receptor-positive, HER2-negative locally advanced or metastatic breast cancer (BO41843 PersevERA, Principal Investigator Dr. Maria Cassiano Neves)
- A phase III, randomized, open-label, multicenter study evaluating the efficacy and safety of divarasib versus sotorasib or adagrasib in patients with previously treated KRAS G12C-positive advanced or metastatic non-small cell lung cancer (BO45217 Krascendo 1, Principal Investigator Dr. Rita Félix)
- A phase 3, randomized, double-blind, placebo-controlled study of talazoparib with enzalutamide in metastatic castration-resistant prostate cancer (C3441021 TALAPRO-2, Principal Investigator Dr. Alina Rosinha)
- An open-label continuation study for participants continuing from encorafenib/binimetinib clinical studies (C4221026 FLOTILLA, Principal Investigator Dr. Paula Ferreira)
- A phase 3, two-stage, randomized, multicenter, open-label study comparing mezigdomide (CC-92480), bortezomib and dexamethasone (MeziVd) versus pomalidomide, bortezomib and dexamethasone (PVd) in subjects with relapsed or refractory multiple myeloma (RRMM) (CA057-001 SUCCESSOR-1, Principal Investigator Dr. Ângelo Martins)
- A phase 3, multicenter, randomized, double-blind, placebo-controlled study comparing the efficacy and safety of golcadomide plus R-CHOP chemotherapy vs placebo plus R-CHOP chemotherapy in participants with previously untreated high-risk large B-cell lymphoma (CA073-1020 GOLSEEK-1, Principal Investigator Dr. Cláudia Moreira)

- An open label, multi-center asciminib roll-over study to assess long-term safety in patients who have completed a Novartis sponsored asciminib study and are judged by the investigator to benefit from continued treatment (CABL001A2001B, Principal Investigator Dr. Isabel Oliveira)
- A phase III, multi-center, open-label, randomized study of oral asciminib versus investigator selected TKI in patients with newly diagnosed philadelphia chromosome positive chronic myelogenous leukemia in chronic phase (CABL001J12301 ASC4FIRST, Principal Investigator Dr. Isabel Oliveira)
- A phase III, randomized, double-blind, placebo-controlled study of alpelisib (BYL719) in combination with fulvestrant for men and postmenopausal women with HR-positive, HER2-negative advanced breast cancer with a PIK3CA mutation, who progressed on or after aromatase inhibitor and a CDK4/6 inhibitor (CBYL719C2303 EPIK-B5, Principal Investigator Dr. Ana Ferreira)
- A phase 3, two-stage, randomized, multicenter, open-label study comparing iberdomide, daratumumab and dexamethasone (IberDd) versus daratumumab, bortezomib, and dexamethasone (DVd) in subjects with relapsed or refractory multiple myeloma (RRMM) (CC-220-MM-002 EXCALIBER-RRMM, Principal Investigator Dr. Catarina Campos Costa)
- A phase 3, multicenter, randomized, open-label, parallel-group study of the efficacy and safety of lenalidomide (REVLIMID®) versus chlorambucil as first-line therapy for previously untreated elderly patients with B-cell chronic lymphocytic leukemia (The ORIGIN Trial) (CC-5013-CLL-008 ORIGIN, Principal Investigator Dr. Nelson Domingues)
- A post-trial access roll-over study to allow access to ribociclib (LEE011) for patients who are on ribociclib treatment in Novartis-sponsored study (CLEE011A2412B, Principal Investigator Dr. Inés Pousa)
- A phase III, randomized, open-label study evaluating efficacy and safety of giredestrant compared with fulvestrant, both combined with a CDK4/6 inhibitor, in patients with estrogen receptor-positive, HER2-negative advanced breast cancer with resistance to prior adjuvant endocrine therapy (CO44657 PionERA, Principal Investigator Dr. Cláudia Vieira)
- A randomised, double-blind, parallel group, placebo-controlled multi-centre phase III study to assess the efficacy and safety of olaparib versus placebo as adjuvant treatment in patients with germline BRCA1/2 mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy (D081CC00006 OLYMPIA, Principal Investigator Dr. Miguel Abreu)
- Roll over study for patients who have completed a previous oncology study with olaparib and are judged by the investigator to clinically benefit from continued treatment (D0817C00098 ROSY-O, Principal Investigator Dr. Marta Ferreira)
- A phase III, open-label, randomised study to assess the efficacy and safety of extended therapy with camizestrant (AZD9833, a next generation, oral selective estrogen receptor degrader) versus standard endocrine therapy (aromatase inhibitor or tamoxifen) in patients with ER+/HER2- early breast cancer and an intermediate or high risk of recurrence who have completed definitive locoregional therapy and at least 2 years of standard adjuvant endocrine-based therapy without disease recurrence (D8531C00002 CAMBRIA-1, Principal Investigator Dr. Ana Afonso)
- A randomised, multicentre, double-blind, phase III study of AZD9833 (an oral SERD) plus palbociclib versus anastrozole plus palbociclib for the treatment of patients with estrogen receptor-positive, HER2-negative advanced breast cancer who have not received any systemic treatment for advanced disease (D8532C00001 SERENA-4, Principal Investigator Dr. Ana Ferreira)
- A phase III, double-blind, randomised study to assess switching to AZD9833 (a next generation, oral SERD) + CDK4/6 inhibitor (palbociclib or abemaciclib) vs continuing aromatase inhibitor (letrozole or anastrozole) + CDK4/6 inhibitor in HR+/HER2- MBC patients with detectable ESR1 mutation without disease progression during 1L treatment with aromatase inhibitor + CDK4/6 inhibitor (D8534C00001 SERENA-6, Principal Investigator Dr. Inés Pousa)
- A randomized phase 3 study of datopotamab deruxtecan (Dato-DXd) and pembrolizumab, with or without platinum chemotherapy, in subjects with no prior therapy for advanced or metastatic PD-L1 TPS <50% non-squamous non-small cell lung cancer without actionable genomic alterations (DS1062-A-U303 TROPION-Lung07, Principal Investigator Dr. Marta Soares)

- A randomized, open-label, phase 3 trial of Dato-DXd plus pembrolizumab vs pembrolizumab alone in treatment-naïve subjects with advanced or metastatic PD-L1 high (TPS ≥50%) non-small cell lung cancer without actionable genomic alterations (DS1062-A-U304 Tropion-Lung08, Principal Investigator Dr. Maria Cassiano Neves)
- A phase 3, multicenter, randomized, open-label, active-controlled study of trastuzumab deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in subjects with high-risk HER2-positive primary breast cancer who have residual invasive disease in breast or axillary lymph nodes following neoadjuvant therapy (DS8201-A-U305 DESTINY-Breast05, Principal Investigator Dr. Miguel Abreu)
- A phase 3, multicenter, 2-arm randomized, open-label study of trastuzumab deruxtecan in subjects with HER2-positive metastatic and/or unresectable gastric or gastro-esophageal junction (GEJ) adenocarcinoma subjects who have progressed on or after a trastuzumab-containing regimen (DS8201-A-U306 DESTINY-Gastric04, Principal Investigator Dr. Cátia Faustino)
- A phase 3 randomized, open-label, multicenter study assessing the clinical benefit of isatuximab (SAR650984) in combination with bortezomib (Velcade®), lenalidomide (Revlimid®) and dexamethasone versus bortezomib, lenalidomida and dexamethasone in patients with newly diagnosed multiple myeloma not eligible for transplant (EFC12522 IMROZ, Principal Investigator Dr. Ângelo Martins)
- A phase 3, randomized, double-blind, placebo-controlled multicenter study of itolizumab in combination with corticosteroids for the initial treatment of acute graft versus host disease (EQ-100-02 EQUATOR, Principal Investigator Dr. Luís Cláudio Leite)
- A phase III, open-label, randomized study to investigate the efficacy and safety of atezolizumab (anti-PD-L1 antibody) compared with best supportive care following adjuvant cisplatin-based chemotherapy in PD-L1-selected patients with completely resected stage IB–IIIA non-small cell lung cancer (GO29527, Principal Investigator Dr. Júlio Oliveira)
- A phase III, randomized, open-label, multicenter study evaluating the efficacy and safety of adjuvant giredestrant compared with physician's choice of adjuvant endocrine monotherapy in patients with estrogen receptor-positive, HER2-negative early breast cancer (GO42784 lidERA, Principal Investigator Dr. Maria Cassiano Neves)
- A randomized, open-label, phase 3 study of abemaciclib combined with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone in patients with high risk, node positive, early stage, hormone receptor positive, human epidermal receptor 2 negative, breast cancer (I3Y-MC-JPCF MonarchE, Principal Investigator Dr. Miguel Abreu)
- A phase 3, two-stage, randomized, multi-center, controlled, open-label study comparing iberdomide maintenance to lenalidomide maintenance therapy after autologous stem cell transplantation (ASCT) in participants with newly diagnosed multiple myeloma (NDMM) (IM048-022 EXCALIBER-Maintenance, Principal Investigator Dr. Catarina Campos Costa)
- International study for treatment of standard risk childhood relapsed ALL 2010: A randomized phase III study conducted by the Resistant Disease Committee of the International BFM study group (IntReALL SR 2010, Principal Investigator Dr. Vitor Costa)
- An open-label randomized trial of the efficacy and safety of zanidatamab with standard-of-care therapy against standard-of-care therapy alone for advanced HER2-positive biliary tract cancer (JZP598-302 HERIZON-BTC-302, Principal Investigator Dr. Isabel Vilas-Boas)
- A phase 2/3 randomized, controlled, open-label study of KRT-232 in subjects with primary myelofibrosis (PMF), post-polycythemia vera MF (Post-PV-MF), or post-essential thrombocythemia MF (Post-ET-MF) who are relapsed or refractory to Janus Kinase (JAK) inhibitor treatment (KRT-232-101 BOREAS, Principal Investigator Dr. Isabel Oliveira)
- An adaptive phase 3, randomized, open-label, multicenter study to compare the efficacy and safety of axicabtagene ciloleucel versus standard of care therapy as first-line therapy in subjects with high-risk large B-cell lymphoma (KT-US-484-0136 ZUMA-23, Principal Investigator Dr. José Mário Mariz)
- A phase 3 open-label, randomized study of pirtobrutinib (LOXO-305) versus bendamustine plus rituximab in untreated patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (LOXO-BTK-20023 BRUIN-CLL-313, Principal Investigator Dr. Dulcineia Pereira)

- A phase 3 open-label, randomized, controlled, global study of telisotuzumab vedotin (ABBV-399) versus docetaxel in subjects with previously treated c-Met overexpressing, EGFR wildtype, locally advanced/metastatic non-squamous non-small cell lung cancer (M18-868 Teliso-V, Principal Investigator Dr. Cristina Oliveira)
- A phase 3, randomized, open-label study to evaluate safety and efficacy of epcoritamab in combination with R-CHOP compared to R-CHOP in subjects with newly diagnosed diffuse large B-cell lymphoma (DLBCL) (M20-621 EPCORE, Principal Investigator Dr. Catarina Dantas)
- A phase 3, multicenter, randomized, open-label trial to evaluate the safety and efficacy of epcoritamab + rituximab and lenalidomide (R2) compared to chemoimmunotherapy in previously untreated follicular lymphoma (M22-003 EPCORE™FL-2, Principal Investigator Dr. Ângelo Martins)
- A phase 3, multicenter, randomized, open-label study of ABBV-383 compared with standard available therapies in subjects with relapsed or refractory multiple myeloma (3L+ RRMM monotherapy study) (M22-574 CERVINO, Principal Investigator Dr. Cláudia Moreira)
- A phase 3, randomized study to compare nemtabrutinib versus comparator (investigator's choice of ibrutinib or acalabrutinib) in participants with untreated chronic lymphocytic leukemia/small lymphocytic lymphoma (MK1026-011 BELLWAVE-011, Principal Investigator Dr. Isabel Oliveira)
- A phase 3, randomized, open-label, study to compare the efficacy and safety of adjuvant MK-2870 in combination with pembrolizumab (MK-3475) versus treatment of physician's choice (TPC) in participants with triple-negative breast cancer (TNBC) who received neoadjuvant therapy and did not achieve a pathological complete response (pCR) at surgery (MK2870-012 TroFuse-012, Principal Investigator Dr. Maria Cassiano Neves)
- A phase 3 randomized open-label study of adjuvant pembrolizumab with or without MK-2870 in participants with resectable stage II to IIIB (N2) NSCLC not achieving pCR after receiving neoadjuvant pembrolizumab with platinum-based doublet chemotherapy followed by surgery (MK2870-019, Principal Investigator Dr. Isabel Azevedo)
- A phase 3, randomized, open-label, active-comparator-controlled clinical study to evaluate the safety and efficacy of bomedemstat (MK-3543/IMG-7289) versus best available therapy (BAT) in participants with essential thrombocythemia who have an inadequate response to or are intolerant of hydroxyurea (MK3543-006, Principal Investigator Dr. José Mário Mariz)
- A phase 3 randomized, open-label study of OP-1250 monotherapy adjuvant immunotherapy with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo after complete resection of high-risk stage III melanoma: A randomized, double-blind phase 3 trial of the EORTC Melanoma Group (MK3475-054 EORTC 1325, Principal Investigator Dr. Paula Ferreira)
- A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC after resection and completion of standard adjuvant therapy (MK3475-091 PEARLS, Principal Investigator Dr. Marta Soares)
- A multicenter, open-label, phase 3 study to evaluate the long-term safety and efficacy in participants who are currently on treatment or in follow-up in studies that include pembrolizumab (MK3475-587, Principal Investigator Dr. Sara Coelho)
- A phase 3, randomized, comparator-controlled clinical trial to study the efficacy and safety of pembrolizumab (MK-3475) in combination with Bacillus Calmette-Guerin (BCG) in participants with high-risk non-muscle invasive bladder cancer (HR NMIBC) that is persistent or recurrent following BCG induction (MK3475-676 KEYNOTE-676, Principal Investigator Dr. Rui Freitas)
- A phase III, randomized, open-label study to evaluate pembrolizumab as neoadjuvant therapy and in combination with standard of care as adjuvant therapy for stage III-IVA resectable locoregionally advanced head and neck squamous cell carcinoma (LA HNSCC) (MK3475-689 KEYNOTE-689, Principal Investigator Dr. Cláudia Vieira)
- A randomized, double-blind, phase III study of pembrolizumab versus placebo in combination with neoadjuvant chemotherapy and adjuvant endocrine therapy for the treatment of high-risk early-stage estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2–) breast cancer (MK3475-756 KEYNOTE-756, Principal Investigator Dr. Marta Ferreira)

- A randomized, double-blind, placebo-controlled phase 3 trial of pembrolizumab (MK-3475) versus placebo in participants with esophageal carcinoma receiving concurrent definitive chemoradiotherapy (MK3475-975 KEYNOTE-975, Principal Investigator Dr. Dânia Marques)
- A randomized, double-blind, placebo-controlled, phase 3 study of pembrolizumab plus chemotherapy versus placebo plus chemotherapy for the treatment of chemotherapy-candidate hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) locally recurrent inoperable or metastatic breast cancer (MK3475-B49 KEYNOTE-B49, Principal Investigator Dr. Inés Pousa)
- Open-label phase 3 study of MK-7684A (coformulation of vibostolimab with pembrolizumab) in combination with concurrent chemoradiotherapy followed by MK-7684A versus concurrent chemoradiotherapy followed by durvalumab in participants with unresectable, locally advanced, stage III NSCLC (MK7684A-006 KeyVibe 006, Principal Investigator Dr. Marta Soares)
- A phase 3 multicenter, randomized, double-blinded, active-controlled, clinical study to evaluate the safety and efficacy of lenvatinib (E7080/MK-7902) with pembrolizumab (MK-3475) in combination with transarterial chemoembolization (TACE) versus TACE in participants with incurable/non-metastatic hepatocellular carcinoma (MK7902-012 LEAP-012, Principal Investigator Dr. Dânia Marques)
- A single-arm open-label multi-centre extension study of pertuzumab administered as a single agent or in combination with other anti-cancer therapies in patients previously enrolled in a Hoffmann-La Roche-sponsored pertuzumab study (MO29406 PereX, Principal Investigator Dr. Ana Ferreira)
- A phase 3 randomized, open-label study of OP-1250 monotherapy vs standard of care for the treatment of ER+, HER2– advanced or metastatic breast cancer following endocrine and CDK 4/6 inhibitor therapy (OP-1250-301 OPERA-01, Principal Investigator Dr. Marta Ferreira)
- A phase 3b, multicenter, open-label, PCI-32765 (ibrutinib) long-term extension study (PCI-32765CAN3001, Principal Investigator Prof. Ana Espírito Santo)
- A randomized, open-label, multicenter phase 3 trial of domvanalimab, zimberelimab, and chemotherapy versus nivolumab and chemotherapy in participants with previously untreated locally advanced unresectable or metastatic gastric, gastroesophageal junction, and esophageal adenocarcinoma (STAR-221, Principal Investigator Dr. Nuno Sousa)
- A phase 3, randomized, double-blind, placebo- and active-comparator-controlled clinical study of adjuvant V940 (mRNA-4157) plus pembrolizumab versus adjuvant placebo plus pembrolizumab in participants with high-risk stage II-IV melanoma (V940-001, Principal Investigator Dr. Paula Ferreira)
- A phase 3, randomized, double-blind, placebo- and active-comparator-controlled clinical study of adjuvant V940 (mRNA-4157) plus pembrolizumab versus adjuvant placebo plus pembrolizumab in participants with resected stage II, IIIA, IIIB (N2) non-small cell lung cancer (V940-002, Principal Investigator Dr. Ana Rodrigues)
- A phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of GDC-0074 plus palbociclib and fulvestrant versus placebo plus palbociclib and fulvestrant in patients with PIK3CA-mutant, hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer (WO41554 INAVO120, Principal Investigator Dr. Joana Bordalo e Sá)
- A phase III, randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of adjuvant atezolizumab or placebo and trastuzumab emtansine for HER2-positive breast cancer at high risk of recurrence following preoperative therapy (WO42633 ASTEFANIA, Principal Investigator Dr. Ana Ferreira)
- A phase III, randomized, open-label study evaluating the efficacy and safety of giredestrant in combination with Phesgo versus Phesgo after induction therapy with Phesgo-taxane in patients with previously untreated HER2-positive, estrogen receptor-positive locally-advanced or metastatic breast cancer (WO43571 heredERA, Principal Investigator Dr. Miguel Abreu)
- A phase 3, randomized, open-label, controlled study of cabozantinib (XL184) in combination with atezolizumab vs second novel hormonal therapy (NHT) iin subjects with metastatic castration-resistant prostate cancer (XL184-315 CONTACT-02, Principal Investigator Dr. Alina Rosinha)

- A phase III, randomized, double-blind, placebo-controlled study of atezolizumab with or without tiragolumab (anti-TIGIT antibody) in patients with unresectable locally advanced esophageal squamous cell carcinoma (YO42137 SKYSCRAPER-07, Principal Investigator Dr. Paula Ferreira)
- A randomized, multicenter, phase 3 study of zanidatamab in combination with chemotherapy with or without tislelizumab in subjects with HER2-positive unresectable locally advanced or metastatic gastroesophageal adenocarcinoma (GEA) (ZWI-ZW25-301 HERIZON-GEA-01, Principal Investigator Dr. Filipa Carneiro)

## Clinical Trials Phase IIb/ Phase III Closed in 2025

- A phase 1b/3 study of bemarituzumab plus chemotherapy and nivolumab versus chemotherapy and nivolumab alone in subjects with previously untreated advanced gastric and gastroesophageal junction cancer with FGFR2b overexpression (20210098 FORTITUDE-102, Principal Investigator Dr. Alina Rosinha)
- A phase 3, global, multi-center, double-blind, randomized, efficacy study of zolbetuximab (IMAB362) plus CAPOX compared with placebo plus CAPOX as first-line treatment of subjects with claudin (CLDN) 18.2-Positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma (8951-CL-0302 GLOW, Principal Investigator Dr. Cátia Faustino)
- A phase 3, open-label, randomized study to compare the efficacy and safety of luspatercept (ACE-536) versus epoetin alfa for the treatment of anemia due to IPSS-R very low, low or intermediate risk myelodysplastic syndromes (MDS) in ESA naïve subjects who require red blood cell transfusions (ACE-536-MDS-002 COMMANDS, Principal Investigator Dr. Gil Brás)
- A phase 3, randomized, controlled, multicenter, open-label study to compare tivozanib in combination with nivolumab to tivozanib monotherapy in subjects with renal cell carcinoma who have progressed following one or two lines of therapy where one line has an immune checkpoint inhibitor (AV-951-20-304 TiNivo-2, Principal Investigator Dr. Cátia Faustino)
- Randomized, multicenter, phase III, open label study of alectinib versus crizotinib in treatment naïve anaplastic lymphoma kinase-positive advanced non-small cell lung cancer (BO28984 ALEX, Principal Investigator Dr. Júlio Oliveira)
- A phase III, randomized, open-label study of pralsetinib versus standard of care for first-Line treatment of RET fusion-positive, metastatic non-small cell lung cancer (BO42864 AcceleRET-Lung, Principal Investigator Dr. Ana Rodrigues)
- A randomized, double-blind, placebo-controlled, phase III study evaluating the efficacy and safety of pembrolizumab plus platinum-based doublet chemotherapy with or without canakinumab as first line therapy for locally advanced or metastatic non-squamous and squamous non-small cell lung cancer subjects (CACZ885U2301 CANOPY-1, Principal Investigator Dr. Marta Soares)
- A phase III, multi-center, randomized (1:1), open-label, active-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with olaparib as compared to single agent cytotoxic chemotherapy, in participants with no germline BRCA mutation detected, platinum-resistant or refractory, high-grade serous ovarian cancer (CBYL719K12301 EPIK-O, Principal Investigator Dr. Miguel Abreu)
- A randomized, double-blind, parallel-group study to compare pharmacokinetics, efficacy, safety, and immunogenicity of JPB898 (proposed nivolumab biosimilar) and US-licensed and EU-authorized Opdivo® in combination with Yervoy® in participants with untreated advanced (unresectable/metastatic) melanoma (CJPB898A12301 NivoReach, Principal Investigator Dr. Paula Ferreira)
- A randomized, double-blind, placebo-controlled phase III multi-center study of azacitidine with or without MBG453 for the treatment of patients with intermediate, high or very high risk myelodysplastic syndrome (MDS) as per IPSS-R, or chronic myelomonocytic leukemia-2 (CMML-2) (CMBG453B12301 STIMULUS MDS 2, Principal Investigator Dr. Ana Espírito Santo)
- A phase III randomized, open-label, multicenter study to determine the efficacy and safety of durvalumab in combination with tremelimumab and enfortumab vedotin or durvalumab in

combination with enfortumab vedotin for perioperative treatment in patients ineligible for cisplatin undergoing radical cystectomy for muscle invasive bladder cancer (D910PC00001 VOLGA, Principal Investigator Dr. Joaquina Maurício)

- A randomized, double-blind, multicenter, phase 3 study to evaluate efficacy and safety of belumosudil in combination with corticosteroids versus placebo in combination with corticosteroids in participants at least 12 years of age with newly diagnosed chronic graft versus host disease (cGVHD) (EFC17757 ROCKnrol-1, Principal Investigator Dr. Gil Brás)
- A phase III, open-label, randomized study of atezolizumab and tiragolumab compared with durvalumab in patients with locally advanced, unresectable stage III non-small cell lung cancer who have not progressed after concurrent platinum-based chemoradiation (GO41854 SKYSCRAPER-03, Principal Investigator Dr. Maria Cassiano Neves)
- A phase III, multicenter, randomized, open-label, controlled study to evaluate the efficacy, safety, and pharmacokinetics of atezolizumab given in combination with cabozantinib versus docetaxel monotherapy in patients with metastatic non-small cell lung cancer previously treated with an anti-PD-L1/PD-1 antibody and platinum-containing chemotherapy (GO41892 Contact-1, Principal Investigator Dr. Isabel Azevedo)
- Open-label, global, multicenter, randomized, phase 3 study of sacituzumab govitecan versus docetaxel in patients with advanced or metastatic non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy and anti-PD-1/PD-L1 immunotherapy (GS-US-577-6153 EVOKE-01, Principal Investigator Dr. Ana Rodrigues)
- A randomized, open-label, phase 3 study of mirvetuximab soravtansine vs. Investigator's choice of chemotherapy in platinum-resistant advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression (IMGN853-0416 MIRASOL, Principal Investigator Dr. Joana Bordalo e Sá)
- A randomized open-label phase III study of sacituzumab govitecan versus treatment of physician's choice in subjects with metastatic or locally advanced unresectable urothelial cancer (IMMU-132-13 TROPiCS-04, Principal Investigator Dr. Filipa Carneiro)
- A phase 3, randomized, open-label study of axatilimab versus best available therapy in participants with chronic graft-versus-host disease after at least 2 prior lines of systemic therapy (INCA034176-355 AGAVE-355, Principal Investigator Dr. Manuel Guerreiro)
- A phase III, randomized, double-blind study to evaluate pembrolizumab plus chemotherapy vs placebo plus chemotherapy as neoadjuvant therapy and pembrolizumab vs placebo as adjuvant therapy for triple negative breast cancer (TNBC) (MK3475-522, Principal Investigator Dr. Marta Ferreira)
- A phase 3, randomized, double-blind study of MK-7684A in combination with etoposide and platinum followed by MK-7684A vs atezolizumab in combination with etoposide and platinum followed by atezolizumab for the first-line treatment of participants with extensive-stage small cell lung cancer (MK7684A-008 KeyVibe 008, Principal Investigator Dr. Isabel Azevedo)
- An open-label, phase IIIB, single arm multicenter safety study of atezolizumab (Tecentriq) plus nabpaclitaxel or paclitaxel in the treatment of unresectable locally advanced or metastatic triple-negative breast cancer (MO39874 EL1SSAR, Principal Investigator Dr. Miguel Abreu)
- A phase II/III, randomised, multicentre study of MOR00208 with bendamustine versus rituximab with bendamustine in patients with relapsed or refractory diffuse large B-cell lymphoma (R-R DLBCL) who are not eligible for high-dose chemotherapy (HDC) and autologous stem-cell transplantation (ASCT) – B-MIND (MOR208C204 B-MIND, Principal Investigator Dr. Gil Brás)
- A multicenter, randomized, double-blind, placebo-controlled phase 3 study of the Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib, in combination with rituximab versus placebo in combination with rituximab in treatment naïve subjects with follicular lymphoma (PCYC-1141-CA, Principal Investigator Dr. José Mário Mariz)
- A phase III, multicenter, open-label study of ribociclib vs. palbociclib in patients with advanced hormone receptor-positive/HER2-negative/HER2-enriched breast cancer (SOLTI-2101 HARMONIA, Principal Investigator Dr. Ana Ferreira)

## Scientific output

### a. Peer-reviewed indexed publications (final publication date in 2025) derived clinical trials studies

- **Alves, I, Moreira, AP, Sousa, T**, Teles, P, **Magalhaes, BM**, Goncalves, F and Fernandes, CS. *Impact of Exergames on the Rehabilitation of Cancer Patients Undergoing Major Abdominal Surgery: A Randomized Controlled Trial.* Cancer Nurs. 2025;48(3): p. 239–44. IF:2.5
- Cardoso, F, Jacot, W, Kuemmel, S, Gupta, S, Cruz, F, Balaraman, R, **Ferreira, A**, Ahola, T, Chapko, Y, Zhukova, L, Chiang, W, Li, Z, Ji, Y, Kaakiou, N, Bolotova, N and Sparano, JA. *600- vs 400-mg First-Line Ribociclib in Hormone Receptor-Positive/ERBB2-Negative Advanced Breast Cancer: The AMALEE Randomized Clinical Trial.* JAMA Oncol. 2025;11(11): p. 1356–63. IF: 20.1
- Cibula, D, Marnitz, S, Jarkovsky, J, Kocian, R, Dundr, P, Klat, J, Zapardiel, I, Arencibia, O, Landoni, F, Presl, J, Raspagliesi, F, Zikan, M, van Lonkhuijzen, LR, Torne, A, Slama, J, Minar, L, Ostojich, M, Pilka, R, **Petiz, AF,** Petzel, A, Burgetova, A, Fischerova, D, Nemejcova, K and Kohler, C. *Sentinel lymph node biopsy without systematic pelvic lymphadenectomy in females with early-stage cervical cancer: final outcome of the SENTIX prospective, single-arm, noninferiority, international trial.* Nat Cancer. 2025;6(9): p. 1585–94. IF:28.5
- **Cruz, P**, Lam, JM, Abdalla, J, Bell, S, Bytyci, J, Brosh-Nissimov, T, Gill, J, Haidar, G, Hoerger, M, Maor, Y, Pagliuca, A, Raffi, F, Samuels, F, Segev, D, Ying, Y, Lee, LYW and Global Immunocompromised Health, C. *Immunobridging Trials: An Important Tool to Protect Vulnerable and Immunocompromised Patients Against Evolving Pathogens.* Vaccines (Basel). 2024;13(1) IF: 3.4
- Fayette, J, Licitra, L, Harrington, K, Haddad, R, Siu, LL, Liu, YC, Tahara, M, Machiels, JP, Rischin, D, Seiwert, TY, Ferris, RL, Keilholz, U, Psyrri, A, Keam, B, Bossi, P, Metcalf, R, Hsieh, CY, Clement, PMJ, Isaev, P, Mudunov, A, **Dinis, J**, Hoeben, A, Kasper, S, Klinghammer, K, Hwang, M, Blando, J, Serrano, O, Ruscica, D, Cohen, RB and investigators, I-. *INTERLINK-1: A Phase III, Randomized, Placebo-Controlled Study of Monalizumab plus Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma.* Clin Cancer Res. 2025;31(13): p. 2617–27. IF: 10.2
- Haddad, R, Fayette, J, Teixeira, M, Prabhash, K, Mesia, R, Kawecki, A, Dechaphunkul, A, **Dinis, J**, Guo, Y, Masuda, M, Hsieh, CY, Ghi, MG, Vaz de Melo Sette, C, Harrington, K, Tahara, M, Saba, NF, Lau, A, Jiang, T, Yan, Y, Ballinger, M, Kaul, M, Matheny, C, Cuchelkar, V and Wong, DJ. *Atezolizumab in High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck: A Randomized Clinical Trial.* JAMA. 2025;333(18): p. 1599–607. IF: 55.0
- Shitara, K, Van Cutsem, E, Gumus, M, Lonardi, S, de la Fouchardiere, C, Coutzac, C, Dekervel, J, Hochhauser, D, Shen, L, Mansoor, W, Liu, B, Fornaro, L, Ryu, MH, Lee, J, **Faustino, C,** Metges, JP, Tabernero, J, Franke, F, Janjigian, YY, Souza, F, Jukofsky, L, Zhao, Y, Kamio, T, Zaanan, A, Pietrantonio, F and Investigators, DE-GT. *Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer.* N Engl J Med. 2025;393(4): p. 336–48. IF: 78.5
- Yang, JC, Lu, S, Hayashi, H, Felip, E, Spira, AI, Girard, N, Kim, YJ, Lee, SH, Ostapenko, Y, Danchaivijitr, P, Liu, B, Alip, A, Korbenfeld, E, Mourao Dias, J, Besse, B, Passaro, A, Lee, KH, Xiong, H, How, SH, Cheng, Y, Chang, GC, Yoshioka, H, Thomas, M, Nguyen, D, Ou, SI, Mukhedkar, S, Prabhash, K, D'Arcangelo, M, Alatorre-Alexander, J, Vazquez Limon, JC**, Alves, S**, Stroyakovskiy, D, Peregudova, M, Sendur, MAN, Yazici, O, Califano, R, Gutierrez Calderon, V, de Marinis, F, Kim, SW, Gadgeel, SM, Owen, S, Xie, J, Sun, T, Mehta, J, Venkatasubramanian, R, Ennis, M, Fennema, E, Daksh, M, Roshak, A, Man, J, Knoblauch, RE, Bauml, JM, Baig, M, Shah, S, Sethi, S, Cho, BC and Investigators, M. *Overall Survival with Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC.* N Engl J Med. 2025;393(17): p. 1681–93. IF:78.5

### b. Other peer-reviewed indexed publications (final publication date in 2025)

- Arede, L, Coutinho, R, Duarte, TL, Lopes, M, Simoes, RV, Silva, S, Baptista, P, Lopes, JM, Faria, R and **Duarte, D.** *Recapitulation of clinical features in a patient-derived xenograft mouse model of VEXAS syndrome.* Rheumatology (Oxford). 2025;64(9): p. 5189–92.IF: 4.4
- Bogas, M, Antas, J, Magalhaes, C, Revige, M, Guerra, L, Ribeiro, C, Eca, RC, Nunes, F, Lopes, A, Costa, L, Goncalves, M, Pedrosa, J, Capela, A, Gregorio, T, Dias, P, Alfaro, T, Pais, A, Soares, R, Queiros, A, Torres, T, **Assis, J, Maia, J,** Ferreira, M, Horta, L, Carreiro, R, Almeida, J, Meireles, MJ, Loucao, C, Antonio, S, Lopes, C, Coelho, P, Costa, R, Santana, M and Sousa, N. *Assessment of competencies of*

*clinical research professionals and proposals to improve clinical research in Portugal.* Front Pharmacol. 2025;16: p. 1578955. IF: 4.8

- Branco, H, Rodrigues, CA, **Oliveira, J,** Mendes, N, Antunes, C, Amorim, I, Santos, LL, Vasconcelos, MH and Xavier, CPR. *Preclinical studies on the antitumor and non-toxic effect of combining pirfenidone with vinorelbine and carboplatin in non-small cell lung cancer.* Int J Cancer. 2025;156(9): p. 1756–69. IF: 4.7
- Brito-Rocha, T, Constancio, V, Leite-Silva, P, Carvalho-Maia, C, Sequeira, JP, Salta, S, Lobo, J, Machado, DI, Nunes, SP, Silva-Santos, R, Freitas, R, Goncalves Dias, C, **Vieira, C, Soares, M,** Henrique, R and Jeronimo, C. *Multi-cancer early detection via a DNA methylation multiplex ddPCR-based blood test.* Int J Cancer. 2025;157(5): p. 1006–19. IF:4.7
- Dias, MR, Nicolau, C, Ferreira, H, Chacim, S, Oliveira, I, de Camara Negalha, G, **Mariz, JM** and Costa, JM. *Case Report: Effective methotrexate removal by combined hemodialysis and polymeric resin hemoadsorption.* Front Nephrol. 2025;5: p. 1644079. IF: NA
- Haj Mohammad, SF, van der Pol, H, Vrdoljak, E, Lassen, U, Ojamaa, K, Jalkanen, K, Verlingue, L, Stenzinger, A, Patocs, A, Curigliano, G, Baltruskeviciene, E, Helland, A, Russnes, HG, Lugowska, I, **Mainoli, B**, Edsjo, A, Lonardi, E, Tasken, K and Gelderblom, H. *A comprehensive assessment of the existing landscape of personalized cancer medicine in the European Union, on behalf of the PCM4EU consortium.* ESMO Open. 2025;10(11): p. 105872. IF: 8.3
- Maia Moco, L, Hortas, AM, Ramos, I, Fontoura, A, de Camara Negalha, G, Bras, G and **Mariz, M**. *Sodium 2-Mercaptoethanesulfonate (MESNA), Ifosfamide, Mitoxantrone, and Etoposide (MINE) in Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Is the Old Regimen Still Gold?* Cureus. 2025;17(7): p. e87128. IF: 1.3
- Meireles, AM, Calisto, R, Bento, MJ, Gouveia, PM, Bizarro, S, Teixeira, M, Moreira, C, Santo, AE and **Mariz, M.** *Epidemiological characterization of chronic myeloid leukaemia patients at an oncologic centre: A retrospective observational study.* Hematol Transfus Cell Ther. 2025;47(3): p. 103935. IF: 1.6
- Meireles, AM, Oliveira Rodrigues Amarante, ACD, Marques Catita, BMC, Abilheira Monjardino, M, de Abreu Gouveia, PMG, Rocha Moreira, CSD, Jesus Leite, LC, Coutinho, R, Santos Ferreira, RB, Bras, GP, Guerreiro, M, Vaz, CP and **Mariz, JM**. *Effects of fludarabine dosage on transplant-related outcomes in hematopoietic stem cell transplantation.* Leuk Lymphoma. 2025;66(10): p. 1942–6. IF:2.2
- Pereira, JL, Arede, L, Ferreira, F, Matos, A, Pereira, D, Santos, RF, Carmo, AM, Oliveira, MJ, Machado, JC, **Duarte, D** and Dos Santos, NR. *Antibody blockade of the PSGL-1 immune checkpoint enhances T-cell responses to B-cell lymphoma.* Leukemia. 2025;39(1): p. 178–88. IF:13.4
- Roxo, F, **Duarte, D** and Abreu, MH. *Immune-Mediated Thrombocytopenia Induced by Niraparib: A Clinically Relevant Case.* Cureus. 2025;17(11): p. e97299. IF:1.3
- Samarao, L, **Mariz, JM,** Goncalves, J, Martins, A and Castro, C. *Breast Primary Follicular Lymphoma: Two Cases of a Rare Entity Treated With Radical Radiotherapy and Rituximab.* Cureus. 2025;17(11): p. e95870. IF: 1.3
- **Santos, DAR**, Eiras, M, Gonzalez-Santos, M, Santos, M, Pereira, C, Santos, LL, Dinis-Ribeiro, M and Lima, L. *A preliminary assessment of a stool-based microRNA profile for early colorectal cancer screening.* Sci Rep. 2025;15(1): p. 28597. IF: 3.8
- **Soldin, I**, Teixeira, R, Ortigao, R, Lapa, A and Lima, S. *Immune Checkpoint Inhibitor-Induced Hepatitis: A Case Report of Challenging Management.* Cureus. 2025;17(1): p. e77331. IF: 1.3
- Tavares, V, Lopes, C, Macedo-Silva, C, Farinha, M, Costa, J, Vilas-Boas, MI, Pinelas, S, **Assis, J,** Dinis-Ribeiro, M, Pereira, D, Pereira, C and Medeiros, R. *Genetic markers of thrombophilia as predictors of outcome in colorectal cancer.* J Thromb Thrombolysis. 2025;58(5): p. 663–78. IF: 2.2
- Tavares, V, Savva-Bordalo, J, Rei, M, Liz-Pimenta, J**, Assis, J,** Pereira, D and Medeiros, R. *Heritable Genetic Variability in Ovarian Tumours: Exploring Venous Thromboembolism Susceptibility and Cancer Prognosis in a Hospital-Based Study.* Gene. 2025;950: p. 149378. IF: 2.4
- Teixeira, AR, Agostinho, C, Dias, C, Soares, R, Pina, M, Dinis, J, Lopes-Conceicao, L and **Vieira, C.** *Treatment of Locally Advanced and Metastatic Salivary Gland Cancer: A 10-year Experience of an Oncology Center in Portugal.* Acta Med Port. 2025;38(10): p. 608–18. IF: 1.0

## Other outputs

### Oral Communications by Invitation

- Assis J. (2025) The POP-IPOP and the MTB @IPO Porto. International Forum Precision Cancer Medicine - Summer Academy on Precision Oncology: a hands-on course. (18th-19th September) Porto, Portugal
- Assis J (2025) IPO Porto Molecular Tumour Board session. Workshop Multiomics for Systems Oncology - (11-12th December) Porto, Portugal

### Posters in international conferences

- **Santos, D.A.R.**, Santos, L.L., **Vieira, C**., Dinis-Ribeiro, M., Lima, L. (2025) The Small Solution for a Big Problem: Can MicroRNAs Predict Treatment Outcomes in Colorectal Cancer Patients? *UEG Week 2025*, Berlin, Germany.
- **Santos, D.A.R.**, Loureiro, S., Eira, M., Caldevilla, R., Santos, L.L., Dinis-Ribeiro, M., Lima, L. (2025) Circulating MicroRNAs and Their Potential for Improve the Early Colorectal Cancer Screening. *UEG Week 2025*, Berlin, Germany.

### Posters in national conferences

- Tavares V, Melo IG, Savva-Bordalo J, Rei M, Liz-Pimenta J, **Assis J,** Pereira D, Medeiros, R. (2025) Targeting the Tissue Factor Pathway in Ovarian Carcinoma: Prognostic Value of Plasma microRNAs and Implications for Novel Therapies. Encontro Ciência 2025. (9-11th July), Lisbon, Portugal
- Tavares V, Melo IG, Savva-Bordalo J, Rei M, Liz-Pimenta J, **Assis J**, Pereira D, Medeiros, R. Targeting the Tissue Factor Pathway in Ovarian Carcinoma: Prognostic Value of Plasma microRNAs and Implications for Novel Therapies. 10th Advanced Course in Gynaecologic Oncology. (3-4th July), Porto, Portugal
- **Santos, D.A.R.**, Santos, L.L., **Vieira, C**., Dinis-Ribeiro, M., Lima, L. (2025) MicroRNAS as Predictive Biomarkers of Therapeutic Response in Colorectal Cancer: A Systematic Review and Study Design. *3rd Young Researchers' Day* (22nd October); Porto, Portugal.

### Teaching Activity: Coordination of Curricular Units/Courses

| Member | Curricular Units | Programme | Position | Faculty/University |
|---|---|---|---|---|
| Claudia Vieira | Clinical Oncology | MSc In Oncology | Coordination and teaching | ICBAS; UP |
| Joana Assis | Research Practices in Oncology | MSc In Oncology | Teaching | ICBAS; UP |
| Joana Assis | Research Methodologies in Oncology | Continuing Training Unit | Teaching | ICBAS; UP |

### International Consortia

| Organization | Researcher |
|---|---|
| CCI4EU - Working Group on the Cancer Patient's Journey | Joana Assis |
| EUnetCCC Core Group meeting Clinical Trials | Joana Assis |

# ONCOLOGY NURSING RESEARCH UNIT

## Coordinator

Rui Costa, BSN, PhD

## Research team @31 December 2025

| Name | Academic Degree | Professional Situation | Category/position | Time % |
|---|---|---|---|---|
| Ana Cristina Rodrigues | BSN, MSc | Contract | Nurse Specialist | 20 |
| Ana Maria Almeida | BSN, PhD | External | Associate Researcher | 30 |
| Ana Maria Martins | BSN, MSc | Contract | Nurse Specialist | 20 |
| Ana Sofia Magalhães Lopes | BSN | Contract | Nurse Specialist | 20 |
| Andreia Salvini Vieira | BSN, MSc | Contract | Nurse Specialist | 20 |
| Bárbara Lamas | BSN, MSc | Contract | Nurse Specialist | 20 |
| Bruno Magalhães | BSN, PhD | External | Associate Researcher | 30 |
| Carla Rodrigues Silva | BSN, MSc | External | Associate Researcher | 30 |
| Catarina Mateus Bastos | BSN | Contract | Nurse | 20 |
| Daniela França | PhD | External | Associate Researcher | 30 |
| Diana Cristina Ramada | BSN, MSc | Contract | Nurse Specialist | 20 |
| Isabel Rocha | BSN, MSc | Contract | Nurse Specialist | 20 |
| Isabel Veiga Malta | PhD | Contract | Biomedical Sciences | 30 |
| Joana Rodrigues Lopes | BSN, MSc | Contract | Nurse Specialist | 20 |
| Luís Filipe Silva | RDN, MSc | Scholarship holder | Nutricionist / Dietitian | 30 |
| Maria Esmeralda Barreira | BSN, PhD | Contract | Nurse Specialist | 30 |
| Maria José Silva Dias | BSN, MSc | Contract | Nurse Specialist | 20 |

## Group description and objectives

The Nursing Oncology Research Unit was created in 2022 and integrates nurses, mainly from IPO Porto, who are interested in developing research in cancer nursing. It aims to contribute to patient-centred care through the understanding of the phenomena associated with the oncological disease and its treatment, as well as its impact in patient-reported outcomes. Its mission is also to stimulate and develop research in cancer nursing at IPO Porto, through the enhancement of the skills of its professionals.

## Active projects and funding

### Competitive Funding

International

- PAINLESS – "EU Pain relief in palliative care of cancer using home-based neuromodulation and predictive biomarkers WP1". The PAINLESS project is an international and multidisciplinary initiative that seeks to understand the mechanisms underlying cancer-related pain and to provide an alternative to pharmacological relief. Budget: 5 952 323.75 € (Total) € 342 250.00 (IPO Porto) (2022-2027) ID: 101057367 HORIZON-HLTH-2021-DISEASE-04 EU. [PI: Rui Medeiros (IPO Porto) Researchers: Diana Ramada].
- HENKO NET - "Innovation and digital technologies for social and palliative health care at home, is a three-year European Interreg Sudoe project involving nine partners from Spain, France and Portugal." Its objectives include creating a knowledge-sharing community, developing the AI-based platform for early detection of palliative care needs, and improving care coordination, particularly in rural areas. Budget: 146 114,61 € (2023-2026) [PI: Michael Luís; Co-PI: Sara Cruz]

National

- CAR T-Matters: A three-year research and development project focused on establishing national capacity for the development, manufacturing and clinical translation of advanced CAR T-cell therapies in Portugal. The project is led by Stemmatters and involves a multidisciplinary consortium including IPO Porto and NOVA University Lisbon. Budget: 1,846,548.48 € (2025-2028). [PI: Júlio Oliveira. Researchers: Ana Rodrigues; Diana Ramada].

### Other consortia projects

- PBE_DDI - "Evidence-Based Practice, Development, Dissemination and Implementation" (CINTESIS@RISE (2024-2025) https://i-d.esenf.pt/pbe_ddi/ [PI: Paulo Marques; Researcher: Bárbara Lamas, Ana Sofia Lopes].
- QdV_DRC5 - "Protocolo para avaliação da qualidade de vida do doente renal crónico Estadio 5 (QdV_DRC5) (2025-2031) [PI: Ana Cristina Rodrigues; Co-PI: Maximino Costa, Benvinda Amaral, Rita Calisto, Marta Rangel, Ofélia Godinho].
- QUALIS - "Prevalência de sintomas e impacto na qualidade de vida em indivíduos com doença renal crónica: um estudo transversal". BBraun Avitum, Budget: 28.189,26 € (2025 – 2026) [PI: Davide Fernandes; Co-PI: Ana Lopes]
- PLASMET - "Cânula plástica vs agulha metálica em fístula arteriovenosa: estudo de coorte retrospetivo" BBraun Avitum, Budget: 34 189,26 €. (2025 -2026) [PI: Davide Fernandes; Co-PI: Ana Lopes]

## Major achievements

- ***Cruz, S., Magalhães, B., & Fernandes, C. (2025). Family perceptions of the transition from hospital to home palliative care: a phenomenological study. Supportive care in cancer: official journal of the Multinational Association of Supportive Care in Cancer, 33(11), 1014. https://doi.org/10.1007/s00520-025-10069-9***

Home-based palliative care is increasingly essential for people with advanced disease, yet the transition from hospital to home remains a vulnerable phase associated with fragmentation of care and heightened family burden. This published study offers novel insight into the lived experience of family caregivers during this transition, uncovering emotional strain, solitary learning, and the critical role of community palliative care teams in ensuring continuity and safety. Using a rigorous descriptive phenomenological approach, the research advances the international evidence base on family-centered palliative care and highlights priority areas for clinical and policy action to support caregivers in the home environment. This work contributes meaningfully to improving palliative care quality and equity in real-world practice.

- ***Gonçalves, F., Teixeira, M.I., Rego, F., Magalhães, B. The role of spiritual care management - Needs and resources in people with amyotrophic lateral sclerosis: Insights from a mixed-methods study. Palliat Support Care. 2025;23: e111. IF 2.6***

Spirituality often provides crucial emotional support, meaning, and resilience during challenging times. Despite its importance, it is often overlooked in clinical settings. The study emphasizes the need for personalized, holistic care, which should include spiritual care support, regardless of the functional state, highlighting the importance of addressing both intrapersonal and interpersonal domains, resources and needs from early phases. Allowing to create a structured care plan that meets patients' individual spiritual needs, that can contribute to a better QoL and reduce suffering.

## Scientific output

### *a. Peer-reviewed indexed publications (final publication date in 2025)*

- **Almeida, AM,** Lima, L and Martins, T. *Monitoring Patient-Reported Outcomes in Self-management of Postsurgical Symptoms in Oncology: A Scoping Review.* Cancer Nurs. 2025;48(1): p. 31–44. IF: 2.5

- Alves, I, Moreira, AP, Sousa, T, Teles, P, **Goncalves, F, Magalhaes, BM** and Fernandes, CS. *Exergames rehabilitation program for postoperative cancer patients undergoing abdominal surgery: A quasi-experimental study.* Enferm Clin (Engl Ed). 2025;35(6): p. 502212. IF:1.1
- Alves, I, Moreira, AP, Sousa, T, Teles, P**, Magalhaes, BM**, Goncalves, F and Fernandes, CS. *Impact of Exergames on the Rehabilitation of Cancer Patients Undergoing Major Abdominal Surgery: A Randomized Controlled Trial.* Cancer Nurs. 2025;48(3): p. 239–44. IF: 2.5
- Amarelo, A, **Magalhaes, B**, Araujo, N, Capela Marques, AF and Fernandes, CS. *Effects of exercise programs on chemotherapy-induced peripheral neuropathy in cancer survivors: An umbrella systematic review.* J Bodyw Mov Ther. 2025;44: p. 655–64. IF: 1.4
- Andrade, DFS, **da Silva, CRR,** Moura, DB and Soares-Pinto, IE. *Nursing Interventions to Prevent Posttraumatic Stress Disorders in People in Intensive Care: A Scoping Review.* Dimens Crit Care Nurs. 2025;44(1): p. 36–43. IF: 1.4
- **Cruz, S,** Fernandes, C and **Magalhaes, B**. *From Hospital to Home: Health Professionals' Experiences Regarding the Needs of Palliative Patients.* J Pain Symptom Manage. 2025;70(3): p. 248–57. IF: 3.5
- **Cruz, S**, Fernandes, C and **Magalhaes, B**. *Patients' Experiences in the Transition From Hospital to Home Palliative Care: A Systematic Review and Thematic Synthesis of Qualitative Studies.* SAGE Open Nurs. 2025;11: p. 23779608251334031. IF: 2.5
- **Cruz, S, Magalhaes, B** and Fernandes, C. *Family perceptions of the transition from hospital to home palliative care: a phenomenological study.* Support Care Cancer. 2025;33(11): p. 1014. IF: 3.0
- Esteves, NEC, Filipe Lopes, HJDF, Vieira, AS, Cardoso, PAS, Soares-Pinto, IE and **da Silva, CRR**. *Nursing Assessment and Intervention in the Management of Delirium in Intensive Care: A Quantitative Study.* Revista de Enfermagem Referencia. 2025;6(4) IF: NA
- Fernandes, CS, **Magalhaes, B,** Goncalves, F, Lima, A, Silva, M, Moreira, MT, Santos, C and Ferreira, S. *Exergames for rehabilitation in stroke survivors: Umbrella review of meta-analyses.* J Stroke Cerebrovasc Dis. 2025;34(1): p. 108161. IF:1.8
- Fernandes, DMDS and **Lopes, ASM.** *nurse-led gastrostomy care: a business case.* Onco.News. 2025(51) IF: NA
- **Goncalves, F**, Teixeira, MI, Rego, F and **Magalhaes, B**. *The role of spiritual care management - Needs and resources in people with amyotrophic lateral sclerosis: Insights from a mixed-methods study.* Palliat Support Care. 2025;23: p. e111. IF: 2.1
- **Lopes, AS,** Ribeiro, AL, **Lamas, B,** Santos, D, Fernandes, D, Silva, R and Marques, P. *Oncology care humanization in adults: a scoping review protocol.* JBI Evid Synth. 2025;23(8): p. 1671–9. IF: 4.5
- Ribeiro, C, Gomes, R, Carreiro, A, Vieira, AL, Seabra, B, Conde, B, Nogueira, C, Jacome, C, Lages, J, Aguiar, M, Grafino, M, Pamplona, P, Cysneiros, A, Duraes, C, Rodrigues, C, Pimenta, C, Cristovao, C, Rodrigues, D, Ferreira, D, **Goncalves, F**, Ramos, H, Cravo, J, Silva, JP, Cunha, K, Mendez, L, Van Zeller, M, Araujo, M, Barata, M, Raposo, M, Redondo, M, Jacob, M, Araujo, MJ, Goncalves, MR, Guia, M, Faria, N, Viegas, P, Conde, S, Drummond, M and Pinto, P. *Home mechanical ventilation in adults: Clinical practice recommendations from the Portuguese Respiratory Society home mechanical ventilation assembly.* Pulmonology. 2025;31(1): p. 2598915. IF: 6.4
- Ribeiro, M, Sanches, D, Barros, S, Goncalves, M, **Castro, S,** Oliveira, T, Gasparino, R and Ribeiro, O. *Structural Empowerment of Nurses in the Hospital Setting: A Cross-Sectional Study.* Nurs Rep. 2025;15(12) IF:2.0
- Santos Ventura, FIQ, Ribeiro, VMA, Claro, IGV, Silva, ALTS, Afonso Silva, ARÁ, Gonçalves Marques, SCF, Girão, MCM, Santos, CMO, Chemela, R and **Barreira, MER**. *NURSING BEST PRACTICE RECOMMENDATIONS FOR INTRAVESICAL INSTILLATION IN BLADDER CANCER: ADAPTATION TO THE PORTUGUESE ONCOLOGICAL CARE.* Onco.News. 2025;2025-July-December(51) IF: NA
- Silva-Ferreira, M**, Cruz, S,** Luis, MS, Silva, MC, Monteiro-Reis, S, Henrique, R, Jeronimo, C, Lefevre, SC, Laplaud, A, Frasca, M, Pollet, L, Zurbanobeaskoetxea, L, Barbastro, RA, Garcia, MIH, Galan, BJ, Palau, FG, Marques, DF and Duran, RL. *Mapping study on AI-based technologies in palliative care - a scoping study.* BMC Palliat Care. 2025;24(1): p. 274. IF:3.0
- Soares-Pinto, I, Queirós, S, **Silva, C,** Alves, P, Santos, C and Brito, M. *Programa de Intervenção de Enfermagem para o Autocuidado ao Estoma de Eliminação Intestinal: Um Grupo Focal.* Revista de Enfermagem Referência. 2025;VI Série(N.º 4) IF: NA

- Ventura-Silva, JMA, Ribeiro, MP, Barros, S, **Castro, SFM**, Sanches, DMM, Trindade, LL, Teles, P, Zuge, SS and Ribeiro, O. *Quiet Quitting Scale: Adaptation and Validation for the Portuguese Nursing Context.* Nurs Rep. 2025;15(12) IF: 2.0

### *Other outputs*

#### *Book*

- Fernandes D, Santos M, **Almeida AM**. Drain 101: guia de sobrevivência para lidar com a drenagem minimamente invasiva drenagem biliar. Associação Enfermagem Oncológica Portuguesa, 2025. ISBN 978-989-35714-8-4.
- Pires A, Gato AP, Candeias, A, Subtil C, Festas C, Nunes L, **Costa R** (ed.). (ed.) História da Enfermagem em Portugal (1143-1988). UCP Editora, 2025. ISBN 9789725410943.
- Ventura F, Claro I, Ribeiro V, **Barreira E,** Afonso A, Gonçalves S, Silva, A. Instilações Intravesicais: Recomendações de Boas Práticas com a adaptação das guidelines. Associação de Enfermagem Oncológica Portuguesa, 2025. ISBN 978-989-35714-2-2.
- Santos C, **Barreira E,** Girão M, Chamela R, Afonso A. Documentos de Consensos sobre Drenagem Torácica. Associação de Enfermagem Oncológica Portuguesa, 2025. ISBN 978-989-35714-4-6.
- Machado T, **Gonçalves F**, Riveiro C. (2025). CO10: Avaliação da Sobrecarga dos Cuidadores Informais de Doentes com ELA. Abstracts from the Congresso de Pnemologia do Norte 2025: Comunicação Oral, Pulmonology, 31:sup1, 2532243, Porto, Portugal DOI: 10.1080/25310429
- **Ramada D,** Fontes F, **Rodrigues A,** Silva M, Pinto MM, Salgado N, Simões P. (Orgs.) IV Conferência de Enfermagem dos IPOs – Da prática à evidência: Enfermagem oncológica na atualidade (2025). Coimbra. ISBN 978-989-33-8549-4

#### *Book Chapters*

- **Costa R.** "E nós? Estamos satisfeitos?" Resultados de um inquérito de satisfação profissional no IPO Porto. In book: **Ramada D,** Fontes F, **Rodrigues A,** Silva M, Pinto MM, Salgado N, Simões P. (Orgs.) IV Conferência de Enfermagem dos IPOs – Da prática à evidência: Enfermagem oncológica na atualidade (2025). (pp. 90-91). Coimbra. ISBN 978-989-33-8549-4
- **Costa R.** Saberes médicos, especialização e poder. In book: Nunes JA, Duro da Costa J, Carvalho JM, Ferreira JR, Gomes, MC. (Coord.) Folhas Soltas da Pneumologia em Portugal. Sociedade Portuguesa de Pneumologia (2025). (pp. 476 – 489). Lisboa. ISBN - 978-989-36200-4-5.
- **Rodrigues A**. Idoneidade Formativa no IPO Porto: Desafios e Oportunidades. In book: Ramada D, Fontes F, Rodrigues A, Silva M, Pinto MM, Salgado N, Simões P. (Orgs.) IV Conferência de Enfermagem dos IPOs – Da prática à evidência: Enfermagem oncológica na atualidade (2025). (pp. 23-24). Coimbra. ISBN 978-989-33-8549-4

#### *Oral Communications by Invitation*

- **Almeida AM.** (2025) Oncology Nursing: From Evidence to Practice. [Enfermagem em Oncologia: da evidência à prática.] 4th International Nurses' Convention. (December); Fátima, Portugal
- **Matos M.** (2025) Gamifying knowledge: painting new scenarios. Portuguese Wound Management Association Congress. The art of (re)treatment: from sketch to masterpiece. (14th November); Gondomar, Portugal
- **Ramada D.** (2025) Nursing Research in the Field of Oncology [Investigação em Enfermagem na área da Oncologia]. International Week Master in Global Health, Imperial College London & Porto Business School (8th April); Porto, Portugal
- **Rocha I.** (2025) Issues Related to Safe Allocation in Hematology - The Importance of Safe Allocation in Bone Marrow Transplant Units. [Problemática da Dotação Segura na Hematologia - A importância da dotação segura em unidades de transplante de medula]. Annual Meeting of SHP2025, Lisbon, Portugal
- **Salvini A**. (2025) Injuries associated with surgical positioning [Lesões associadas ao posicionamento cirúrgico]. Nurses' Order in EaQ. (September) Virtual (Plataforma Digital Cisco Webex Events)

### Oral Communications in International Scientific Meetings

- **Castro S**, Ribeiro M, Ventura-Silva J, Pereira J, Gasparino, R, Trindade L, Ribeiro O. (2025). Cross-Cultural Adaptation and Content Validation of the Multidimensional Nursing Generation Questionnaire for the Portuguese Context [Adaptação transcultural e validação de conteúdo do Multidimensional Nursing Generation Questionnaire para o contexto português]. NursID Spring School 2025 (5-9th May); Porto, Portugal.
- **Cruz, S**. (2025). Caring in home palliative care: A phenomenological study. 1st International Seminar of the Oncology Nursing Research Unit (25th March); Porto, Portugal.
- **Cruz, S**. (2025). Palliative care beyond hospital walls: The role of technology in home-based palliative experience. Spring Meetings 2025 (April); Portugal.
- **Cruz, S**. (2025). HENKO NET. NursID Spring School (5-9th May); Porto, Portugal.
- **Gonçalves, F**. (2025). Artificial Inteligence – "Innovation that Cares: The Digital Health Revolution". Portuguese-Galician Palliative Care Congress (3-5th April), Viana do Castelo, Portugal.
- **Lamas B.** (2025) ADC in Breast Cancer and Management of Emerging Adverse Events. [ADC no CMa e gestão de eventos adversos emergentes]. 18th National Conference on Oncology Nursing. (29th-31st May); Peniche, Portugal.
- **Salvini A**. (2025) Interventions for pressure ulcers prevention in long-term surgeries: Nurse's approach, at the Round Table - Pressure ulcers - Up to date: Coverages and New Treatment Guidelines, 2024/2025SGAWCm2025. Sobratafe Global Advanced Wound Care Meeting (30th May); São Paulo, Brasil.

### Oral Communications in National Scientific Meetings

- **Barreira E**. (2025) Consensus on Nursing Interventions for Thoracic Drainage. [*Consensos sobre intervenções de Enfermagem em drenagem torácica*] 22nd National Oncology Congress. (26th-28th November); Braga, Portugal.
- Michael L, Paiva R, Garcia S, **Barreira E.** (2025) Early Integration of Palliative Care Consultations in Lung Cancer: Impact on Cancer Care. [*Integração precoce de consulta de cuidados paliativos no cancro do pulmão: impacto nos cuidados oncológicos*] 18th National Conference on Oncology Nursing. (29th-31st May); Peniche, Portugal.
- **Lamas B**, Sousa S, Sousa L, Almeida M. (2025) Telemedicine Nursing Consultations for Patients Undergoing Systemic Anticancer Treatment at an Outpatient Clinic: A Health Intervention Project. [*Teleconsulta de Enfermagem ao Cliente sob Tratamento Antineoplásico Sistémico em Hospital de Dia: Projeto de Intervenção em Saúde]*. 22nd National Oncology Congress (26th-28th November); Braga, Portugal.
- Machado T, **Gonçalves F,** Riveiro C. (2025). CO10: Assessment of Burden Among Informal Caregivers of Patients with ALS. [*CO10: Avaliação da Sobrecarga dos Cuidadores Informais de Doentes com ELA*. 2025 Northern Pulmonology Congress (12th-14th March); Porto, Portugal.
- Piçarra M, **Silva CR.** (2025) GreenCare Checklist: Outpatient Surgery with a Conscious Environmental Footprint [GreenCare Checklist: Cirurgia de Ambulatório com Pegada Consciente]. 14th National Congress on Outpatient Surgery. (16–17th th June); Santa Maria da Feira, Portugal.
- Piçarra M, **Silva CR**. (2025) Carbon Footprint in the Operating Room: The Perspective and Actions of the Perioperative Team [Pegada carbónica no bloco operatório: o olhar e a ação da equipa perioperatória]. 1st Alto Minho Perioperative Nursing Congress – Experiences and Practices… What Challenges? (8–9th May); Viana do Castelo, Portugal.
- **Rocha I**, Martins MM, Ferreira LM, Carvalho AP, Pires R (2025) Safe Nursing Care Allocations for Patients Undergoing Bone Marrow Transplantation – Development of a Patient Classification System Framework in the Context of Portuguese Units [Dotações Seguras de Enfermagem ao Doente submetido a Transplante De Medula Óssea – Conceção de Quadro de Sistema de Classificação de Doentes no Contexto das Unidades Portuguesas]. X Transplant Nursing Seminar 2025 (4-5th June); Porto, Portugal.
- **Rocha I**, Costa FL (2025) Nursing Education on Home Care for Informal Caregivers of Patients Who Have Undergone Bone Marrow Transplants: Preliminary Results of a Scoping Review [Ensino de Enfermagem sobre Cuidados no Domicílio aos Cuidadores Informais de Doentes submetidos a

Transplante de Medula Óssea: Resultados preliminares de Scoping Review]. X Transplant Nursing Seminar 2025 (4-5th June); Porto, Portugal.

- **Salvini A.** (2025) The Importance and Impact of Preoperative Preparation: Implementation of Innovative Projects. [*A Importância e o Impacto da Preparação PréOperatória: Implementação de Projetos Inovadores]*. 4th Beira Alta Wound Care Conference: "Surgical Wounds: From Incision to Healing: A Safe Journey on the Path to Recovery." (31st May); Mortágua, Portugal.
- Vieira B, Ferreira C, Santos G, Santos L, Glueck L, Soares M, Pereira M, **França D**, Santos J. (2025) Mental Health and Social Vulnerabilities Among College Students: A Portuguese-Brazilian Perspective.[*Saúde Mental e Vulnerabilidades Sociais em Estudantes Universitários: Uma Visão Luso-Brasileira]*. 3rd Portuguese-Brazilian Symposium (23rd -24th October); Minas Gerais, Brasil.

### *Posters in international conferences*

- **Cruz, S** (2025). Technology in home palliative care: What do mobile apps tell us? NursID Spring School (5-9th May 2025); Porto, Portugal
- **Cruz, S** (2025). iPalliumHope. OneHealth PhD Forum — 2nd Edition (12th June 2025).; Porto, Portugal.
- **França D**, Silva R, Sequeira C. (2025). Needs of Young Adult Caregivers of People with Mental Illness: Protocol for a Scoping Review [Necessidades dos cuidadores jovens adultos de pessoas com doença mental: Protocolo de uma Scoping Review]. 16th International Congress of the Portuguese Society of Mental Health Nursing (15-17 th October); Santarém, Portugal
- **Gonçalves F**, Teque P, Dias C (2025). Technological development for communication: Past, Present and Future. IV International Symposium for Innovation, Technology and Gaming in Health, ADITGames (17th June); Virtual Event
- **Lamas B,** Lopes AS, Almeida, M (2025). Implementation of a Clinical Supervision Model in a Hospital Setting: Challenges and Opportunities [Operacionalização de um Modelo de Supervisão Clínica no Contexto Hospitalar: Desafios e Oportunidades]**.** 1st APoSCE International Congress. (27th -28th Mar); Coimbra, Portugal
- **Matos M**, Alves P, Marques P (2025). Serious game in health education for radiodermatitis (RadGames). European University Alliance for Global Health (EUGLOH): 6th Annual Student Research Conference (22-24th October); Porto, Portugal
- Piçarra M, **Silva CR** (2025) Perception and behavior of the perioperative team: reducing carbon footprint in outpatient surgery. 48th IHF World Hospital Congress. (10th–13th November); Geneva, Switzerland
- **Rocha I**, Martins MM, Ferreira LM, Carvalho AP, Pires R (2025) Safe Nursing Staffing Levels in Bone Marrow Transplant Units – Design of a Patient Classification System. [Dotações Seguras de enfermagem nas Unidades de transplantação de medula óssea – conceção de sistema de classificação de doentes]. NursID Spring School 2025 (5-9th may), Porto Portugal
- **Rocha I**, Martins MM, Ferreira LM, Carvalho AP, Pires R (2025) Safe Practices in Nursing Care for Patients Undergoing Bone Marrow Transplantation: A Scoping Review, EBMT 2025 (30th march – 02 april), Florence, Italy
- **Rocha I**, Martins MM, Ferreira LM, Carvalho AP, Pires (2025) Safe Nursing Staffing Levels in Bone Marrow Transplant Units [Dotações Seguras de enfermagem nas Unidades de transplantação de medula óssea] II Health Management Administration International Congress, Paredes, Porto, Portugal
- Sanches D, Pereira S, Oliveira B, Coelho B, **Castro S,** Mendes M, Santos E, Ribeiro O. (2025). Generational Diversity Among Nurses in Professional Practice Settings: A Scoping Review. [Diversidade geracional dos enfermeiros nos ambientes de prática profissional: Scoping Review]. NursID Spring School 2025 (5th-9th May); Porto, Portugal
- Sousa S, **Lamas B**, Sousa L, Almeida M. (2025). The Role of the Nurse Manager in Talent Management: A Literature Review.[O Papel do Enfermeiro Gestor na Gestão de Talentos: uma revisão da literatura.] 15th APEGEL International Congress. (16th -18th Out); Viseu, Portugal.
- Sousa S, **Lamas B**, Sousa L, Almeida M. (2025). A Study of Nursing-Sensitive Indicators in Oncology Pain Management.[ Um Ensaio de Indicadores Sensíveis aos Cuidados de Enfermagem no Controlo

da Dor em Oncologia]. 14th National Congress and 2nd International Congress on Oncology Nursing (SPEO). (7th -8th Nov); Évora, Portugal

- **Veiga-Malta I** (2025). Reprocessing of Robotic Surgical Instruments: Implementation of an Efficient Protocol Ensuring Process Reliability. 7th IACS International Congress 2025: Challenges and Innovation in Infection Control (23rd to 34th October); Santa Maria da Feira, Portugal
- **Veiga-Malta I,** Alves J (2025). Implementation of a robotic surgical instrument reprocessing protocol: Training, standardization and challenges in hospital practice. 26th World Sterilization Congress (4th - 6th December 2025); Hog Kong, China

### *Posters in national conferences*

- **Lamas B**, Almeida M, **Lopes AS** (2025). Implementation of a Clinical Supervision Model in a Hospital Setting: Challenges and Opportunities [Operacionalização de um modelo de supervisão clínica no contexto hospitalar: desafios e oportunidades]. 1st APoSCE International Congress (March); Coimbra, Portugal
- **Lamas B**, Pereira B, Almeida M, Martins N. (2025) Oncology Literacy and the Management of Neutropenia Following Systemic Antineoplastic Therapy (SANT): Strategies for Empowering the Client. [Literacia em Oncologia e a Gestão da Neutropenia pós Tratamento Antineoplásico Sistémico (TANPS): Estratégias para empoderar o cliente]. 8th National Conference on Oncology Nursing. (30th -31th May); Peniche, Portugal
- Sousa S, **Lamas B**, Leite G, Cerqueira I, Sousa L, Carvalho C. (2025) Effectiveness of the Neutropenic Diet in Preventing Infections in Adults with Neutropenia Associated with Hematologic Disease: A Rapid Review. [Eficácia da Dieta Neutropénica na Prevenção de Infeções em Adultos com Neutropenia associada a Doença Hematológica: Uma Rapid Review]. Annual Meeting of the Portuguese Society of Hematology (SPH). (6th -8th Nov); Lisboa, Portugal
- **Lamas B**, Gonçalves S. (2025) Time-Related Toxicity in Oncology—A Narrative Review. [Toxicidade do Tempo em Oncologia - Uma Revisão Narrativa]. 22nd National Congress of Oncology. (26th -28th Nov); Braga, Portugal
- **Lamas B**, Bastos A, Nogueira A, Fernandes P, Sousa S. (2025) Outcomes of an Evaluation of Information Sharing in the Care Transition [Outcomes de uma Avaliação à Transmissão de Informação na Transição de Cuidados]. 22nd National Oncology Congress (26th -28th Nov); Braga, Portugal
- **Lopes J**, **Silva C**, **Martins A,** Martins T, Puga P. (2025). Assessment of Family Caregivers of People with an Elimination Ostomy: Development of a Tool to Assess Capacities and Skills. [Avaliação do familiar cuidador de pessoas com ostomia de eliminação: Construção de um instrument para avaliar capacidades e habilidades]. Spring Meetings 2025 (2-5 th April); Évora, Portugal
- **Martins A**, **Lopes J**, **Silva C,** Fuertes Martín A. (2025) Sexuality After Mastectomy: The Couple's Experience from a Qualitative Perspective.[Sexualidade após a Mastectomia: A vivência do casal numa prespetiva qualitativa]. Spring Meetings 2025 (2-5 th April); Évora, Portugal
- **Matos M**, Alves P, Marques P (2025). Serious game in health education for radiodermatitis (RadGames). Young Researchers Meeting of U. Porto (7-9th May); Porto, Portugal
- Nogueira D, Restivo M, Brogueira M, Vieira A, Marques J, **Matos M** (2025). Painting new possibilities in the treatment of radiodermatitis. Portuguese Wound Management Association Congress (14-15th November); Gondomar, Portugal
- Pereira L, Macedo B, Mota L, **Silva CR**, Pinto I. (2025) The person with non-Hodgkin lymphoma undergoing chemotherapy: a case study. [A pessoa com linfoma não Hodgkin em regime de quimioterapia: estudo de caso]. Spring Meetings 2025. (2–5 April); Évora, Portugal
- Pereira L, Macedo B, Mota L, **Silva CR**, Pinto I. (2025) The person with relapsed multiple myeloma in a clinical trial: a case study [A pessoa com recidiva de mieloma múltiplo em ensaio clínico: estudo de caso]. Spring Meetings 2025 (2–5 April); Évora, Portugal
- Pereira L, Mota L, Pinto I, **Silva CR**. (2025) The transition process for a patient with gastric carcinoma who underwent gastrectomy: a case study. [O processo de transição de uma pessoa com carcinoma

gástrico submetida a gastrectomia: estudo de caso]. Spring Meetings 2025 (2–5 April); Évora, Portugal

- Ribeiro D, Silva A, **Silva CR**, Lopes C. (2025) Assessment of Quality of Life in Patients Receiving Palliative Care: An Exploratory Quantitative Study. [Avaliação da qualidade de vida da pessoa em cuidados paliativos: um estudo quantitativo exploratório]. Spring Meetings 2025. (2–5 April); Évora, Portugal
- Ribeiro D, Silva A, **Silva CR**, Duarte E, Almeida M. (2025) Postoperative Complications in Patients Who Have Undergone Vulvectomy: A Narrative Review of the Literature. [Complicações no pós-operatório na pessoa submetida a vulvectomia: revisão narrativa da literatura]. Spring Meetings 2025. (2–5 April); Évora, Portugal
- Riboira M, Rodrigues L, Teixeira A, Mota L, **Silva C**, Pinto I. (2025) Meanings Attributed to Home Hospitalization by Chronic Patients: A Literature Review. [Significados atribuídos à hospitalização domiciliária por doentes crónicos: revisão da literatura]. 5th National Congress on Home Hospitalization. (19–20 September); Lagos, Portugal
- Silva A, **Silva CR**, Ribeiro D, Barbosa A. (2025) Phenomenology of allogeneic hematopoietic stem cell transplantation: a qualitative study. [Fenomenologia do alotransplante de progenitores hematopoiéticos: estudo qualitativo]. Spring Meetings 2025. (2–5 April); Évora, Portugal
- Vieira A, Esteves N, Lopes H, Cardoso P, **Silva C**, Pinto I. (2025) Advantages and Disadvantages of Open Visitation in the Intensive Care Unit: A Scoping Review. [Vantagens e desvantagens da visita aberta na unidade de cuidados intensivos: uma scoping review]. 4th International Nurses' Convention and 2nd Meeting of Nurse Managers. (4–6 December); Fátima, Portugal

### *Editorial Board Positions*

| Journal | Publishing Group | Position | Researcher |
|---|---|---|---|
| ATUA | SRNOE | Editorial council / Review Editor | Rui Costa |
| Evidências | | Review Editor | Carla Rodrigues Silva |
| Healthcare Editorial: Basel | MDPI | Reviewer Board | Bruno Magalhães |
| Onco.News | | Adjunt Director /Editorial council | Bruno Magalhães |
| Onco.News | | Editorial council | Esmeralda Barreira |
| Servir | ACEPS | Review Editor | Daniela França |
| Texto & Contexto Enfermagem | MDPI | Associate Editor | Bruno Magalhães |
| WhitePaper "Material de Penso da Ferida Cirúrgica" | APTFeridas | Review Editor | Andreia Salvini |

### *Peer Review*

African Journal of Reproductive Health (ISSN: 1118-4841), BMC Women's Health (ISSN: 1472-6874), BMJ Open (2044-6055), Cancers, CEM – Cultura, Espaço & Memória, Cultura de los Cuidados (ISSN 1699-6003), História, Ciências, Saúde – Manguinhos (ISSN printed version: 0104-5970. ISSN online version: 1678-4758), Discover Public Health (ISSN 3005-), Health & Social Care in the Community (ISSN 1365-2524) Healthcare (ISSN: 2227-9032), International journal of psychiatry in clinical practice (1365-1501), International Journal of Psychotherapy Counselling and Psychiatry Theory Research & Clinical Practice (2590-4272), JBI Evidence Synthesis (ISSN: 2689-8381), International Journal of Environmental Research and Public Health (ISSN: 660-4601), International Journal of Psychiatry in Clinical Practice (ISSN:1471-1788), International Wound Journal. Online (ISSN:1742-481X), Journal of Nursing Care Quality (ISSN 1057-3631) JBI Evidence Synthesis Nursing Reports (ISSN 2689-8381), Nutrients (ISSN: 2072-6643), One health (ISSN: 2352-7714), Onco.news (ISSN: 1646-7868), Palliative Care and Social Practice (ISSN 2632-3524) Revista Enfermería Oncológica (1576-5520), Revista de Investigação & Inovação em Saúde (ISSN: 2184-1578), Taiwanese Journal of Obstetrics and Gynecology (1028-4559), Texto & Contexto Enfermagem (ISSN printed version: 0104-0707; ISSN online version: 1980-265X) OBJN Online Brazilian Journal Nursing (ISSN: 1676-4285), Taiwanese Journal of

Obstetrics and Gynecology (ISSN: 1028-4559). Journal of Pharmaceutical Research International, Journal of Pharmaceutical Research International (ISSN: 2456-9119) (Past name: British Journal of Pharmaceutical Research; ISSN: 2231-2919)

### *Participation as Opponent in MSc Evaluation Committees*

| Student | Title | Program | Researcher |
|---|---|---|---|
| Carla Isabel Soares Brandão | Specialized care for people with cancer in an immunotherapy program: Development of specialized clinical skills in Medical-Surgical Nursing, in the Field of Nursing for People in Chronic Situations | Medical-Surgical Nursing, in the Field of Nursing for People in Chronic Situations of ESEP | Rui Costa |
| Pedro Miguel Pinto Moreira | Fadiga por Compaixão nos Enfermeiros de um Serviço de Urgência Médico-Cirúrgica | Mestrado em Enfermagem da Pessoa em Situação Crítica da ESS/UTAD | Bruno Magalhães |
| Sónia Marisa Pimenta das Neves | Prevenção da Infeção Urinária Associada a Cateter Vesical em Contexto de Serviço de Urgência | Mestrado em Enfermagem da Pessoa em Situação Crítica da ESS/UTAD | Bruno Magalhães |

### *Participation as Opponent in PhD/Aggregation Evaluation Committees*

| Student | Title | Program | Researcher |
|---|---|---|---|
| Rocío Adriana Peinado Molina | *Impact of pelvic floor dysfunction on women's health and quality of life* | Programa de Doctorado en Ciencias de la Salud por la Universidad de Jaén y la Universidad de Sevilla | Bruno Magalhães |

### *Participation in Academic Recruitment Committees*

| Call/Jury | Researcher |
|---|---|
| Santa Maria Health Scholl, ESSM<br>Call for the recruitment of Special Competition Jury for access to higher education - access regime for persons over 23 years of age<br>Appointment: Deliberation of the Scientific Technical Council (Ata nº 04.24.25 de 2025-03-21) | Daniela França |

### *Teaching Activity: Coordination of Curricular Units/Courses*

| Member | Curricular Units | Programme | Position | Faculty/University |
|---|---|---|---|---|
| Ana Maria Almeida | Nursing epistemology | Nursing degree | Coordination and Teaching | Santa Maria Health School |
| Ana Maria Almeida | Nursing: Health/illness transitions I | Nursing degree | Teaching | Santa Maria Health School |
| Ana Maria Almeida | Nursing: Fundamentals | Nursing degree | Teaching | Santa Maria Health School |
| Ana Maria Almeida | Internship with Report - Module III (Report) | Master's Degree in Medical-Surgical Nursing | Teaching | Santa Maria Health School |
| Ana Maria Almeida | Internship with Report - Module II (Post-Anesthesia Care Unit and Specialty Operating Room) | Master's Degree in Medical-Surgical Nursing | Teaching | Santa Maria Health School |

| Member | Curricular Units | Programme | Position | Faculty/University |
|---|---|---|---|---|
| Ana Maria Almeida | Internship with Report - Module I (Outpatient Units) | Master's Degree in Medical-Surgical Nursing | Teaching | Santa Maria Health School |
| Ana Maria Almeida | Geriatric Surgery | Master's Degree in Medical-Surgical Nursing | Teaching | Santa Maria Health School |
| Ana Maria Almeida | Safety and Perioperative Risk Management | Master's Degree in Medical-Surgical Nursing | Teaching | Santa Maria Health School |
| Ana Maria Almeida | Organization of Perioperative Healthcare | Master's Degree in Medical-Surgical Nursing | Teaching | Santa Maria Health School |
| Ana Maria Almeida | Perioperative Nursing II | Master's Degree in Medical-Surgical Nursing | Teaching | Santa Maria Health School |
| Ana Maria Almeida | Nursing: Profession and discipline | Master's Degree in Medical-Surgical Nursing; Master's Degree in Child and Pediatric Health Nursing + Master's Degree in Rehabilitation Nursing + Master´s Degree in Community Nursing | Teaching | Santa Maria Health School |
| Ana Maria Almeida | Postgraduate Degree in in Tissue Viability and Wound Management | Postgraduate Degree in in Tissue Viability and Wound Management | Coordination | Santa Maria Health School |
| Ana Sofia Lopes | Clinical Education: Surgery | Nursing degree | Teaching | ESEP |
| Andreia Salvini | Medical-surgical nursing care for patients in the perioperative period | Master's Degree in Medical-Surgical Nursing | Teaching | CESPU |
| Carla Rodrigues Silva | Clinical Education - Nursing Care for Adults and the Elderly - Medical Field | Nursing degree | Teaching | ESS-IPVC |
| Carla Rodrigues Silva | Research | Nursing degree | Teaching | ESS-IPVC |
| Carla Rodrigues Silva | Palliative Care Nursing | Nursing degree | Teaching | ESS-IPVC |
| Carla Rodrigues Silva | Adult Health Nursing I | Nursing degree | Teaching | ESS-IPVC |
| Carla Rodrigues Silva | Clinical Education - Fundamentals of Nursing | Nursing degree | Teaching | ESS-IPVC |
| Carla Rodrigues Silva | Palliative Care Nursing | Master's Degree in Nursing Care for Patients in Palliative Care | Teaching | ESS-IPVC |
| Carla Rodrigues Silva | Suffering and Grief in Palliative Care | Master's Degree in Nursing Care for Patients in Palliative Care | Teaching | ESS-IPVC |

| Member | Curricular Units | Programme | Position | Faculty/University |
|---|---|---|---|---|
| Carla Rodrigues Silva | Innovation, Management, and Clinical Oversight | Master's Degree in Community Nursing, specializing in Community Health and Public Health Nursing | Teaching | ESS-IPVC |
| Diana Ramada | Promotion of self-care in people with cancer | Postgraduate Degree in Oncology Nursing | Teaching | ESEP |
| Diana Ramada | Person in critical illness with compromises of cardiorepiratory system – Management of Vascular Access, | MSc in Medical-Surgical Nursing | Teaching | ESEP |
| Diana Ramada | Research Methodology in Oncology | Continuing Education Unit / Scientific Training (ICBAS) | Teaching | ICBAS/IPO Porto |
| Daniela França | Bioethics and Professional Ethics | Nursing Degree | Teaching | Santa Maria Health School |
| Daniela França | Nursing: Health-to-Illness Transition III | Nursing degree | Teaching | Santa Maria Health School |
| Daniela França | Pharmacology II | Nursing degree | Teaching | Santa Maria Health School |
| Filipe Gonçalves | Artificial Nutrition in the Support of Patients in Critical Condition | Master's Degree in Medical-Surgical Nursing | Teaching | ESEP |
| Filipe Gonçalves | Anorexia-Cachexia Syndrome | Postgraduate Course in Supportive Care in Palliative Care in Oral Oncology | Teaching | FMUP |
| Isabel Rocha | Procedures Resulting from a Prescription | Nursing degree | Teaching | ESEP |
| Maria José Dias | Clinical Teaching of Surgery | Nursing Degree | Teaching | ESEP |
| Marisa Matos | Malignant wounds and radiodermatitis | Postgraduate Degree in Advanced Wound Prevention and Treatment Interventions | Teaching | CESPU |
| Marisa Matos | Complex Wounds | Postgraduate Degree in Oncology Nursing | Teaching | ESEP |
| Marisa Matos | Wounds in oncology | Postgraduate Degree in Tissue Viability and Wounds | Teaching | Santa Maria Health School |
| Marisa Matos | Exploring interactive digital tools for clinical learning | Microcredential: Gamification, augmented and virtual reality in wound care education | Teaching | Faculty of Health Sciences and Nursing, Centre of Interdisciplinary Research in Health, Universidade Católica Portugesa |
| Sara Cruz | Nursing Care for People with Medical Conditions, Nursing Care for People Undergoing Surgical Intervention; From Assessment to Decision-Making in | Nursing degree | Teaching | CESPU |

| Member | Curricular Units | Programme | Position | Faculty/University |
|---|---|---|---|---|
| | Nursing 1 and 2; Community Nursing | | | |
| Susana Castro | Perioperative Patient Care | Master's Degree in Medical-Surgical Nursing with a Specialization in Perioperative Nursing | Teaching | CESPU |
| Susana Castro | Professional Internship with Report - Module 1 | Master's Degree in Medical-Surgical Nursing with a Specialization in Perioperative Nursing | Teaching | CESPU |
| Susana Castro | Organization and management of perioperative care | Post Graduate Program in Perioperative Nursing | Teaching | CESPU |
| Susana Castro | Perioperative Safety and Risk Management | Post Graduate Program in Perioperative Nursing | Teaching | CESPU |
| Susana Castro | Perioperative Nursing: Anesthesiology and Post-Anesthesia Care | Post Graduate Program in Perioperative Nursing | Teaching | CESPU |
| Susana Castro | Perioperative Nursing: Circulation | Post Graduate Program in Perioperative Nursing | Teaching | CESPU |

### *Prizes, Honors and Awards*

| Researcher | Prize designation | Institution | Date | Amount |
|---|---|---|---|---|
| Bárbara Lamas & Ana Sofia Lopes | Third prize - Best Poster | I Congresso Internacional da APoSCE. Coimbra, Portugal | March 2025 | 50€ |
| Bárbara Lamas | Third prize – Best Oral Communications | 22º Congresso Nacional de Oncologia. Braga, Portugal | November 2025 | 1500€ |
| Maria Esmeralda Barreira | Second prize- Oral Communication | 18.ª Conferência Nacional de Enfermagem Oncológica | May 2025 | - |
| Marisa Matos | Awarded as one of the best communications (board of distinguished) | Young Researchers Meeting of U. Porto | June 2025 | 0€ |
| Marisa Matos | Dr. José Guimarães dos Santos Research Grant | IPO Porto | June 2025 | 10000€ |
| Sara Cruz | Honourable Mention | NursID Spring School | May 2025 | - |

### *Scientific Appointments*

| Organization | Researcher |
|---|---|
| President of the Portuguese Society for the History of Nursing (SPHE) | Rui Costa |
| President of the Portuguese Society of Nursing Oncology (SPHE) | Carla Silva |

## LIST OF PUBLICATIONS

The list of the 328 publications of IPO Porto Research Center indexed in Pubmed or Scopus in 2025 is indicated below (only those with final date of publication in 2025 are included):

1. **Pan-carcinoma sialyl-Tn-targeting expands CAR therapy to solid tumors.**

*Abrantes, R, Forcados, C, Warren, DJ, Santos-Ferreira, L, Fleten, KG, Senra, E, Costa, AF, Krpina, K, Henrique, R, Liberg, AM, Rawat, P, Gelebart, P, McCormack, E, Bjorge, L, Davidson, B, Greiff, V, Costea, DE, Pinto, F, Flatmark, K, Gomes, C, Inderberg, EM, Reis, CA and Walchli, S. Cell Rep Med. 2025;6(9):102350. doi:10.1016/j.xcrm.2025.102350*

2. **An Assessment of the Sensory Function in the Maxillofacial Region: A Dual-Case Pilot Study.**

*Aguiar, JM, Machado da Silva, J, Fonseca, C and Marinho, J. Sensors (Basel). 2025;25(11)doi:10.3390/s25113355*

3. **Effect of OSEM Reconstruction Iteration Number and Monte Carlo Collimator Modeling on 166Ho Activity Quantification in SPECT/CT.**

*Albergueiro, R, Antunes, V and Santos, J. Applied Sciences. 2025;15(3)doi:10.3390/app15031589*

4. **Recent Guidelines on Anal Cancer Screening: A Systematic Review.**

*Albuquerque, A and Fontes, F. J Low Genit Tract Dis. 2025;29(2):180–5. doi:10.1097/LGT.0000000000000878*

5. **Controversies in fecal incontinence.**

*Albuquerque, A and Rao, SSC. World J Gastroenterol. 2025;31(3):97963. doi:10.3748/wjg.v31.i3.97963*

6. **Reliability and validity of the European Portuguese version of the ABILHAND questionnaire in Patients with Systemic Sclerosis.**

*Albuquerque, F, Neto, M, Patricio, R, Vieira, M, Fernandes, R, Silva, A, Santiago, T and Salvador, MJ. ARP Rheumatol. 2025;4(2):123–37. doi:10.63032/YFBG1869*

7. **Sleep, fatigue, and altered cognition in healthcare professionals: Evidence from Portugal using the fatigue and altered cognition scale.**

*Alencar, A, Abreu, F and Fernandes, C. Sleep Epidemiology. 2025;5doi:10.1016/j.sleepe.2025.100115*

8. **Monitoring Patient-Reported Outcomes in Self-management of Postsurgical Symptoms in Oncology: A Scoping Review.**

*Almeida, AM, Lima, L and Martins, T. Cancer Nurs. 2025;48(1):31–44. doi:10.1097/NCC.0000000000001250*

9. **Artificial intelligence for endoscopic grading of gastric intestinal metaplasia: advancing risk stratification for gastric cancer.**

*Almeida, E, Martins, ML, Marques, D, Delas, R, Almeida, T, Chaves, J, Libanio, D, Renna, F, Coimbra, MT and Dinis-Ribeiro, M. Endoscopy. 2025;57(11):1254–60. doi:10.1055/a-2657-9906*

10. **Leveraging known Pacific colonisation times to test models for the ancestry of Southeast Asians.**

*Almeida, M, Gandini, F, Rito, T, Foody, MG, Brandao, A, Oliveira, M, Olivieri, A, Fichera, A, Oteo-Garcia, G, Zainuddin, Z, Eng, KK, Pomat, W, Bryk, J, Pereira, L, Farr, H, Pala, M, Oppenheimer, SJ, Richards, MB and Soares, P. Sci Rep. 2025;15(1):37044. doi:10.1038/s41598-025-20856-3*

11. **"Mannose glycans as key players in trained immunity: A novel anti-tumoral catalyst".**

*Almeida, P, Alves, I, Fernandes, A, Lima, C, Freitas, R, Braga, I, Correia, J, Jeronimo, C and Pinho, SS. Biochim Biophys Acta Gen Subj. 2025;1869(5):130779. doi:10.1016/j.bbagen.2025.130779*

12. **Breaking barriers in pathology: bridging gaps in multidisciplinary collaboration.**

*Almeida, R, Boyaci, C, Braun, M, Pezzuto, F, Zens, P, Lobo, J and Tiniakos, D. Virchows Arch. 2025;487(4):733–6.*

*doi:10.1007/s00428-024-03991-6*

13. **Exosome-derived hsa-miR-200c-3p, hsa-miR-25-3p and hsa-miR-301a-3p as potential biomarkers and therapeutic targets for restoration of PTEN expression in clear cell renal cell carcinoma.**

*Alves, A, Ferreira, M, Eiras, M, Lima, L, Medeiros, R, Teixeira, AL and Dias, F. Int J Biol Macromol. 2025;302:140607. doi:10.1016/j.ijbiomac.2025.140607*

14. **Exergames rehabilitation program for postoperative cancer patients undergoing abdominal surgery: A quasi-experimental study.**

*Alves, I, Moreira, AP, Sousa, T, Teles, P, Goncalves, F, Magalhaes, BM and Fernandes, CS. Enferm Clin (Engl Ed). 2025;35(6):502212. doi:10.1016/j.enfcle.2025.502212*

15. **Impact of Exergames on the Rehabilitation of Cancer Patients Undergoing Major Abdominal Surgery: A Randomized Controlled Trial.**

*Alves, I, Moreira, AP, Sousa, T, Teles, P, Magalhaes, BM, Goncalves, F and Fernandes, CS. Cancer Nurs. 2025;48(3):239–44. doi:10.1097/NCC.0000000000001331*

16. **Long Drainers After Abdominoplasty: A Risk Analysis.**

*Alves, M, Mendes, M, Valenca-Filipe, R, Rebelo, M, Peres, H and Costa-Ferreira, A. Aesthetic Plast Surg. 2025;49(9):2525–33. doi:10.1007/s00266-025-04773-4*

17. **Effects of exercise programs on chemotherapy-induced peripheral neuropathy in cancer survivors: An umbrella systematic review.**

*Amarelo, A, Magalhaes, B, Araujo, N, Capela Marques, AF and Fernandes, CS. J Bodyw Mov Ther. 2025;44:655–64. doi:10.1016/j.jbmt.2025.06.037*

18. **Metabolic signature of renal cell carcinoma tumours and its correlation with the urinary metabolome.**

*Amaro, F, Carvalho, M, Carvalho-Maia, C, Jeronimo, C, Henrique, R, de Lourdes Bastos, M, de Pinho, PG and Pinto, J. Metabolomics. 2025;21(2):26. doi:10.1007/s11306-024-02212-0*

19. **Nursing Interventions to Prevent Posttraumatic Stress Disorders in People in Intensive Care: A Scoping Review.**

*Andrade, DFS, da Silva, CRR, Moura, DB and Soares-Pinto, IE. Dimens Crit Care Nurs. 2025;44(1):36–43. doi:10.1097/DCC.0000000000000677*

20. **Anxiety, depression, and poor sleep quality in two-year survivors of mild to severe SARS-CoV-2 infection and matched comparison groups.**

*Araujo, N, Lopes, C, Costa, A, Silva, I, Campos, P, Seco, M, Costa, AR, Calejo, MM, Pais, MJ, Pereira, S, Morais, S, Machado, JF, Ruano, L, Lunet, N and Cruz, VT. J Affect Disord. 2025;385:119344. doi:10.1016/j.jad.2025.05.004*

21. **Cognitive impairment 2 years after mild to severe SARS-CoV-2 infection in a population-based study with matched-comparison groups.**

*Araujo, N, Silva, I, Campos, P, Costa, A, Lopes, C, Seco, M, Costa, AR, Calejo, MM, Pais, MJ, Pereira, S, Morais, S, Machado, JF, Ruano, L, Lunet, N and Cruz, VT. Sci Rep. 2025;15(1):24335. doi:10.1038/s41598-025-96608-0*

22. **Recapitulation of clinical features in a patient-derived xenograft mouse model of VEXAS syndrome.**

*Arede, L, Coutinho, R, Duarte, TL, Lopes, M, Simoes, RV, Silva, S, Baptista, P, Lopes, JM, Faria, R and Duarte, D. Rheumatology (Oxford). 2025;64(9):5189–92. doi:10.1093/rheumatology/keaf284*

23. **Performance measures for upper gastrointestinal endoscopy: a European Society of Gastrointestinal Endoscopy (ESGE) Quality Improvement Initiative - Update 2025.**

*Areia, M, Esposito, G, Leclercq, P, Romanczyk, M, Zessner-Spitzenberg, J, Delgado Guillena, PG, Monged, A, Honrubia Lopez, R, Uchima, H, Ruiz Ballesteros, EJ, Panarese, A, Reis de Oliveira, LA, Afify, S, Bisschops, R, Ferlitsch, M and External Voting, P. Endoscopy.*

*2025;57(11):1268–97. doi:10.1055/a-2674-4912*

24. **The 2024 Assisi think tank on breast cancer: Focus on the use of a tumour bed boost after breast conserving therapy.**

*Arenas, M, Bolukbasi, Y, Boersma, LJ, Offersen, B, Kouloulias, V, Palumbo, I, Trigo, L, Lozza, L, Marazzi, F, Trovo, M, Rivera, S, Kaidar-Person, O, Coles, C, Meattini, I, Valentini, V, Aristei, C, Poortmans, P and Assisi Think Tank Meeting, m. Breast. 2025;80:103881. doi:10.1016/j.breast.2025.103881*

25. **Evaluating the heavy/light chain immunoglobulin biomarker for early relapse detection in multiple myeloma: A comparative study with conventional methods.**

*Azevedo, C, Fonseca, AC, Barreto, JP, Pires, AM, Faria, C, Pinto, A, Sousa, ME, Palmeira, C, Prudêncio, C, Fernandes, B, Martins, G and Ferraz, R. Clinical Immunology Communications. 2025;8:105–8. doi:10.1016/j.clicom.2025.10.003*

26. **Do (xeno)estrogens pose a risk to earthworms? Soy isoflavones and estradiol impact gonad structure and induce oxidative stress in Eisenia fetida.**

*Azevedo, T, Silva-Reis, R, Medeiros-Fonseca, B, Goncalves, M, Mendes, G, Roboredo, M, Rocha, MJ, Peixoto, F, Pinto, ML, Matos, M, Sousa, JR, Oliveira, PA and Coimbra, AM. Chemosphere. 2025;377:144315. doi:10.1016/j.chemosphere.2025.144315*

27. **Inequalities in Drug Access for Advanced Melanoma: The Prognostic Impact Resulting From the Approval Delay of the Combined Ipilimumab/Nivolumab Treatment in Portugal.**

*Baptista da Mata, D, Coelho, S, Vilas Boas, MI, Silva, MJ, Marques, D and Ferreira, P. Cureus. 2025;17(1):e78185. doi:10.7759/cureus.78185*

28. **Digital proficiency and educational needs of Portuguese radiation therapists.**

*Barbosa, B, Oliveira, C, Couto, JG, Bravo, I, Antunes, L, McFadden, S, Hughes, C, McClure, P and Dias, AG. Radiography (Lond). 2025;31(6):103176. doi:10.1016/j.radi.2025.103176*

29. **Vitamin K Epoxide Reductase Complex (VKORC1) Electrochemical Genosensors: Towards the Identification of 1639 G>A Genetic Polymorphism.**

*Barbosa, T, Morais, SL, Carvalho, R, Magalhães, JMCS, Domingues, VF, Delerue-Matos, C, Ferreira-Fernandes, H, Pinto, GR, Santos, M and Barroso, MF. Chemosensors. 2025;13(7)doi:10.3390/chemosensors13070248*

30. **Warfarin Pharmacogenomics: Designing Electrochemical DNA-Based Sensors to Detect CYP2C9*2 Gene Variation.**

*Barbosa, T, Morais, SL, Pereira, E, Magalhaes, J, Domingues, VF, Ferreira-Fernandes, H, Pinto, G, Santos, M and Barroso, MF. Genes (Basel). 2025;16(4)doi:10.3390/genes16040372*

31. **Genome-wide association study of 398,238 women unveils seven loci associated with high-grade serous ovarian cancer.**

*Barnes, DR, Tyrer, JP, Dennis, J, Leslie, G, Bolla, MK, Lush, M, Aeilts, AM, Aittomaki, K, Andrieu, N, Andrulis, IL, Anton-Culver, H, Arason, A, Arun, BK, Balmana, J, Bandera, EV, Barkardottir, RB, Berger, LPV, Berrington de Gonzalez, A, Berthet, P, Bialkowska, K, Bjorge, L, Blanco, AM, Blok, MJ, Bobolis, KA, Bogdanova, NV, Brenton, JD, Butz, H, Buys, SS, Caligo, MA, Campbell, I, Castillo, C, Claes, KBM, Colonna, SV, Cook, LS, Daly, MB, Dansonka-Mieszkowska, A, de la Hoya, M, deFazio, A, DePersia, A, Ding, YC, Doherty, JA, Domchek, SM, Dork, T, Einbeigi, Z, Engel, C, Evans, DG, Foretova, L, Fortner, RT, Fostira, F, Foti, MC, Friedman, E, Frone, MN, Ganz, PA, Gentry-Maharaj, A, Glendon, G, Godwin, AK, Gonzalez-Neira, A, Greene, MH, Gronwald, J, Guerrieri-Gonzaga, A, Hamann, U, Hansen, TVO, Harris, HR, Hauke, J, Heitz, F, Hogervorst, FBL, Hooning, MJ, Hopper, JL, Huff, CD, Huntsman, DG, Imyanitov, EN, Izatt, L, Jakubowska, A, James, PA, Janavicius, R, John, EM, Kar, S, Karlan, BY, Kennedy, CJ, Kiemeney, L, Konstantopoulou, I, Kupryjanczyk, J, Laitman, Y, Lavie, O, Lawrenson, K, Lester, J, Lesueur, F, Lopez-Pleguezuelos, C, Mai, PL, Manoukian, S, May, T,*

*McNeish, IA, Menon, U, Milne, RL, Modugno, F, Mongiovi, JM, Montagna, M, Moysich, KB, Neuhausen, SL, Nielsen, FC, Nogues, C, Olah, E, Olopade, OI, Osorio, A, Papi, L, Pathak, H, Pearce, CL, Pedersen, IS, Peixoto, A, Pejovic, T, Peng, PC, Peshkin, BN, Peterlongo, P, Powell, CB, Prokofyeva, D, Pujana, MA, Radice, P, Rashid, MU, Rennert, G, Richenberg, G, Sandler, DP, Sasamoto, N, Setiawan, VW, Sharma, P, Sieh, W, Singer, CF, Snape, K, Sokolenko, AP, Soucy, P, Southey, MC, Stoppa-Lyonnet, D, Sutphen, R, Sutter, C, Tan, YY, Teixeira, MR, Terry, KL, Thomsen, LCV, Tischkowitz, M, Toland, AE, Van Gorp, T, Vega, A, Velez Edwards, DR, Webb, PM, Weitzel, JN, Wentzensen, N, Whittemore, AS, Winham, SJ, Wu, AH, Yadav, S, Yu, Y, Ziogas, A, Berchuck, A, Couch, FJ, Goode, EL, Goodman, MT, Monteiro, AN, Offit, K, Ramus, SJ, Risch, HA, Schildkraut, JM, Thomassen, M, Simard, J, Easton, DF, Jones, MR, Chenevix-Trench, G, Gayther, SA, Antoniou, AC and Pharoah, PDP. NPJ Genom Med. 2025;10(1):73. doi:10.1038/s41525-025-00529-w*

32. **Omega-3 Polyunsaturated Fatty Acids and Cognitive Decline in Adults with Non-Dementia or Mild Cognitive Impairment: An Overview of Systematic Reviews.**

*Barros, MI, Brandao, T, Irving, SC, Alves, P, Gomes, F and Correia, M. Nutrients. 2025;17(18)doi:10.3390/nu17183002*

33. **A short questionnaire to assess changes in lifestyle-related behavior upon stressful events: translation, cultural adaptation, and validation study for the Portuguese language.**

*Bastos Pinto, EC, Carvalho da Costa, S, Irving, SC, Pereira Gomes, AM, Pimenta Martins, AS and Correia, MMA. Porto Biomed J. 2025;10(4):e295. doi:10.1097/j.pbj.0000000000000295*

34. **Private Data Incrementalization: Data-Centric Model Development for Clinical Liver Segmentation.**

*Batista, S, Couceiro, M, Filipe, R, Rachinhas, P, Isidoro, J and Domingues, I. Bioengineering (Basel). 2025;12(5)doi:10.3390/bioengineering12050530*

35. **Undetected Cribriform and Intraductal Prostate Cancer at biopsy is associated with adverse outcomes.**

*Bernardino, RM, Yin, LB, Lajkosz, K, Cockburn, JG, Wettstein, M, Sayyid, RK, Henrique, R, Pinheiro, LC, van der Kwast, T and Fleshner, NE. Prostate Cancer Prostatic Dis. 2025;28(1):187–92. doi:10.1038/s41391-024-00910-3*

36. **Intraductal Carcinoma Predicts Poor Response to Neoadjuvant Therapy in High-risk Prostate Cancer: A Retrospective Analysis of a Prospective Trial.**

*Bernardino, RM, Yin, LB, Lajkosz, K, Winquist, E, Cockburn, JG, Jenjitranant, P, Veloso, R, C, OC, Benitez, AM, Nguyen, DD, Matthiesen, R, Henrique, R, Joshua, AM, van der Kwast, T and Fleshner, NE. Eur Urol Open Sci. 2025;82:52–8. doi:10.1016/j.euros.2025.09.015*

37. **Assessment of competencies of clinical research professionals and proposals to improve clinical research in Portugal.**

*Bogas, M, Antas, J, Magalhaes, C, Revige, M, Guerra, L, Ribeiro, C, Eca, RC, Nunes, F, Lopes, A, Costa, L, Goncalves, M, Pedrosa, J, Capela, A, Gregorio, T, Dias, P, Alfaro, T, Pais, A, Soares, R, Queiros, A, Torres, T, Assis, J, Maia, J, Ferreira, M, Horta, L, Carreiro, R, Almeida, J, Meireles, MJ, Loucao, C, Antonio, S, Lopes, C, Coelho, P, Costa, R, Santana, M and Sousa, N. Front Pharmacol. 2025;16:1578955. doi:10.3389/fphar.2025.1578955*

38. **Gut dysbiosis is linked to severe steatosis and enhances its diagnostic performance in MASLD.**

*Borges-Canha, M, Centelles-Lodeiro, J, Leite, AR, Chaves, J, Lourenco, IM, Von-Hafe, M, Vale, C, Martins, D, Silva, C, Ferreira, AC, Falony, G, Liberal, R, Fragao-Marques, M, Barros, A, Miranda, I, Leite-Moreira, A, Pimentel-Nunes, P, Vieira-Silva, S and Neves, JS. eGastroenterology. 2025;3(3):e100204. doi:10.1136/egastro-2025-100204*

39. **Breast cancer in Cape Verde: a 24-year retrospective study of clinical presentation, treatment and**

**outcomes at Agostinho Neto University Hospital.**

*Borges, P, Spencer, HB, Furtado, S, Costa, V, Barbosa, C and Santos, LL. Ecancermedicalscience. 2025;19:1826. doi:10.3332/ecancer.2025.1826*

40. **Preclinical studies on the antitumor and non-toxic effect of combining pirfenidone with vinorelbine and carboplatin in non-small cell lung cancer.**

*Branco, H, Rodrigues, CA, Oliveira, J, Mendes, N, Antunes, C, Amorim, I, Santos, LL, Vasconcelos, MH and Xavier, CPR. Int J Cancer. 2025;156(9):1756–69. doi:10.1002/ijc.35276*

41. **Balancing survival rates and quality-of-life outcomes after transoral laser microsurgery for locally advanced glottic cancer.**

*Breda, E, Marques, J, Vasquez, I and Monteiro, E. Eur Arch Otorhinolaryngol. 2025;282(8):4227–36. doi:10.1007/s00405-025-09349-1*

42. **Multi-cancer early detection via a DNA methylation multiplex ddPCR-based blood test.**

*Brito-Rocha, T, Constancio, V, Leite-Silva, P, Carvalho-Maia, C, Sequeira, JP, Salta, S, Lobo, J, Machado, DI, Nunes, SP, Silva-Santos, R, Freitas, R, Goncalves Dias, C, Vieira, C, Soares, M, Henrique, R and Jeronimo, C. Int J Cancer. 2025;157(5):1006–19. doi:10.1002/ijc.35467*

43. **Advancing Non-Invasive Colorectal Cancer Screening: Exploring the Potential of Monoclonal Antibody L2A5.**

*Caldevilla, R, Eiras, M, Santos, DAR, Almeida, J, Oliveira, B, Loureiro, S, Soares, J, Gonzalez-Santos, M, Ramos, N, Videira, PA, Santos, LL, Dinis-Ribeiro, M and Lima, L. Int J Mol Sci. 2025;26(7)doi:10.3390/ijms26073070*

44. **Minimizing 3T MRI Geometric Distortions for Stereotactic Radiosurgery via Anterior–Posterior Phase Encoding–A Phantom Study.**

*Campilho, B, Silva, S, Pinto, S, Conde, P, Lencart, J, Mendes, B and Santos, J. Applied Sciences. 2025;15(18)doi:10.3390/app15189864*

45. **Characterisation of the tumour microenvironment and PD-L1 granularity reveals the prognostic value of cancer-associated myofibroblasts in non-invasive bladder cancer.**

*Canizo, CG, Guerrero-Ramos, F, Perez Escavy, M, Lodewijk, I, Suarez-Cabrera, C, Morales, L, Nunes, SP, Munera-Maravilla, E, Rubio, C, Sanchez, R, Rodriguez-Izquierdo, M, Martinez de Villarreal, J, Real, FX, Castellano, D, Martin-Arriscado, C, Lora Pablos, D, Rodriguez Antolin, A, Duenas, M, Paramio, JM and Martinez, VG. Oncoimmunology. 2025;14(1):2438291. doi:10.1080/2162402X.2024.2438291*

46. **Influence of pre-analytical factors and biological variability on the urinary volatilome.**

*Carapito, A, Amaro, F, Teixeira-Marques, A, Henrique, R, Jeronimo, C, Roque, ACA, Carvalho, F, Pinto, J and Guedes de Pinho, P. Anal Bioanal Chem. 2025;417(29):6549–66. doi:10.1007/s00216-025-06137-y*

47. **Chronic lymphocytic leukemia: criteria for first-line therapeutic choice-an opinion paper.**

*Carda, J, Martins, A, Alves, D and Gomes, M. Med Oncol. 2025;42(11):493. doi:10.1007/s12032-025-03046-z*

48. **Effects of physical exercise in reducing caregivers burden: a systematic review.**

*Cardoso, C, Lumini, MJ and Martins, T. Front Public Health. 2025;13:1474913. doi:10.3389/fpubh.2025.1474913*

49. **600- vs 400-mg First-Line Ribociclib in Hormone Receptor-Positive/ERBB2-Negative Advanced Breast Cancer: The AMALEE Randomized Clinical Trial.**

*Cardoso, F, Jacot, W, Kuemmel, S, Gupta, S, Cruz, F, Balaraman, R, Ferreira, A, Ahola, T, Chapko, Y, Zhukova, L, Chiang, W, Li, Z, Ji, Y, Kaakiou, N, Bolotova, N and Sparano, JA. JAMA Oncol. 2025;11(11):1356–63. doi:10.1001/jamaoncol.2025.3687*

50. **Leptin receptor polymorphism increases the risk of painful symptoms in Brazilian women with endometriosis.**

*Cardoso, JV, Machado, DE, de Almeida, FN, Berardo, PT, Medeiros, R and Perini, JA. Rev Bras Ginecol Obstet. 2025;47doi:10.61622/rbgo/2025rbgo43*

51. **Advanced Microfluidics for Single Cell-Based Cancer Research.**

*Carneiro, A, Aranda Palomer, M, Esteves, M, Rodrigues, C, Fernandes, JM, Oliveira, F, Teixeira, A, Honrado, C, Dieguez, L, Abalde-Cela, S and Xavier, M. Adv Sci (Weinh). 2025;12(41):e00975. doi:10.1002/advs.202500975*

52. **The Association Between Perioperative Red Blood Cell Transfusions and 1-Year Mortality After Major Cancer Surgery: An International Multicenter Observational Study.**

*Cata, JP, Guerra-Londono, JJ, Ramirez, MF, Chen, LL, Warner, MA, Guzman, LFC, Lobo, F, Uribe-Marquez, S, Huang, J, Ruscic, KJ, Chew, STH, Lanigan, M and Investigators, A-. Anesth Analg. 2025;140(4):782–94. doi:10.1213/ANE.0000000000007236*

53. **MicroRNA as a Liquid Biomarker to Detect Malignancy in Small Testicular Masses.**

*Chavarriaga, J, Langleben, C, Lobo, J, Nappi, L, Yousef, GM, Ozcan, G, Khazamipour, N, Tavares, NT, Prassas, I, Dimitrakopoulos, L, Yuan, X, Bobrowski, A, Prendeville, S, Anson-Cartwright, L, Jeronimo, C, Jarvi, K, O'Malley, M, Leao, R, Lajkosz, K and Hamilton, RJ. Eur Urol Oncol. 2025;8(6):1575–82. doi:10.1016/j.euo.2025.08.004*

54. **Sentinel lymph node biopsy without systematic pelvic lymphadenectomy in females with early-stage cervical cancer: final outcome of the SENTIX prospective, single-arm, noninferiority, international trial.**

*Cibula, D, Marnitz, S, Jarkovsky, J, Kocian, R, Dundr, P, Klat, J, Zapardiel, I, Arencibia, O, Landoni, F, Presl, J, Raspagliesi, F, Zikan, M, van Lonkhuijzen, LR, Torne, A, Slama, J, Minar, L, Ostojich, M, Pilka, R, Petiz, AF, Petzel, A, Burgetova, A, Fischerova, D, Nemejcova, K and Kohler, C. Nat Cancer. 2025;6(9):1585–94. doi:10.1038/s43018-025-01016-y*

55. **EUROVISCO Consensus Guidelines for the Use of Hyaluronic Acid Viscosupplementation in Knee Osteoarthritis Based on Patient Characteristics.**

*Conrozier, T, Raman, R, Diracoglu, D, Montfort, J, Bard, H, Baron, D, Goncalves, B, Richette, P, Migliore, A, Chevalier, X, Brittberg, M and Henrotin, Y. Cartilage. 2025;16(4):438–52. doi:10.1177/19476035241271970*

56. **Reply to: Comment on "Multi-cancer early detection via a DNA methylation multiplex ddPCR-based blood test".**

*Constancio, V, Brito-Rocha, T, Henrique, R and Jeronimo, C. Int J Cancer. 2025;157(9):1981–2. doi:10.1002/ijc.70021*

57. **Large-scale DNA methylation profiling of urological cancers identifies shared and cancer-specific methylation signatures, and reveals differentially activated pathways for therapeutic targeting.**

*Constancio, V, Lobo, J, Gomez, A, Ramalho-Carvalho, J, Carneiro, I, Freitas, R, Esteller, M, Henrique, R and Jeronimo, C. Clin Transl Med. 2025;15(10):e70488. doi:10.1002/ctm2.70488*

58. **Prostate cancer epigenetics - from pathophysiology to clinical application.**

*Constancio, V, Lobo, J, Sequeira, JP, Henrique, R and Jeronimo, C. Nat Rev Urol. 2025;22(7):447–69. doi:10.1038/s41585-024-00991-8*

59. **[Recommendations for Contraception in Women with Gynecologic Cancer: From Diagnosis to Post-Treatment].**

*Correia, L, Teves, M, Pires, M, Pacheco, A and Palma, F. Acta Med Port. 2025;38(9):579–87. doi:10.20344/amp.22396*

60. **Systemic Arterial Supply to a Congenital Pulmonary Airway Malformation: Imaging of a rare Hybrid BPS/CPAM Lesion.**

*Correia, MR, Coelho, F, Carvalho, F and Pauperio, G. Port J Card Thorac Vasc Surg. 2025;32(3):63. doi:10.48729/pjctvs.539*

61. **Deep Learning Can Accurately Predict the Prognosis of Gynecologic Smooth Muscle Tumors of**

**Uncertain Malignant Potential: A Multicenter Pilot Study.**

*Costa, J, Le, VL, De Leo, A, Ravaioli, C, Velasco, V, Davidson, B, Skeie-Jensen, T, Devouassoux-Shisheboran, M, Trecourt, A, Bartosch, C, Rios, E, Genestie, C, Pautier, P, Lebreton, C, Guyon, F, Babin, G, Coindre, JM, Le Loarer, F, Saut, O and Croce, S. Lab Invest. 2025;105(10):104211. doi:10.1016/j.labinv.2025.104211*

62. **Venous Thrombogenesis and Cervical Cancer: Plasma MicroRNAs as Prognostic Indicators of Tumor Behavior.**

*Costa, MT, Neto, BV, da Silva, JB, Carvalho, L, Salgado, L, Pereira, D, Adega, F, Tavares, V and Medeiros, R. Int J Mol Sci. 2025;26(19)doi:10.3390/ijms26199796*

63. **Stereotactic body radiation therapy for lung metastases from colorectal cancer: outcomes and prognostic factors in a series of 109 patients.**

*Costa, SPF, Sousa, F, Leite-Silva, P, Gomes, D and Sousa, O. Rep Pract Oncol Radiother. 2024;29(6):700–9. doi:10.5603/rpor.103527*

64. **E-selectin affinity glycoproteomics reveals neuroendocrine proteins and the secretin receptor as a poor-prognosis signature in colorectal cancer.**

*Cotton, S, Ferreira, D, Relvas-Santos, M, Brandao, A, Afonso, LP, Miranda, A, Ferreira, E, Santos, B, Goncalves, M, Lopes, P, Santos, LL, Silva, AMN and Ferreira, JA. Mol Oncol. 2025;19(3):635–58. doi:10.1002/1878-0261.13733*

65. **NTRK3-rearranged spindle cell neoplasm of the skin: diagnostic pitfalls of an emerging entity, a case report.**

*Coutada, A, Di Loreto, C, Matjasic, A and Luzar, B. Acta Dermatovenerol Alp Pannonica Adriat. 2025;34(3):147–9. doi:10.15570/actaapa.2025.3*

66. **Immunobridging Trials: An Important Tool to Protect Vulnerable and Immunocompromised Patients Against Evolving Pathogens.**

*Cruz, P, Lam, JM, Abdalla, J, Bell, S, Bytyci, J, Brosh-Nissimov, T, Gill, J, Haidar, G, Hoerger, M, Maor, Y, Pagliuca, A, Raffi, F, Samuels, F, Segev, D, Ying, Y, Lee, LYW and Global Immunocompromised Health, C. Vaccines (Basel). 2024;13(1)doi:10.3390/vaccines13010019*

67. **From Hospital to Home: Health Professionals' Experiences Regarding the Needs of Palliative Patients.**

*Cruz, S, Fernandes, C and Magalhaes, B. J Pain Symptom Manage. 2025;70(3):248–57. doi:10.1016/j.jpainsymman.2025.05.012*

68. **Patients' Experiences in the Transition From Hospital to Home Palliative Care: A Systematic Review and Thematic Synthesis of Qualitative Studies.**

*Cruz, S, Fernandes, C and Magalhaes, B. SAGE Open Nurs. 2025;11:23779608251334031. doi:10.1177/23779608251334031*

69. **Family perceptions of the transition from hospital to home palliative care: a phenomenological study.**

*Cruz, S, Magalhaes, B and Fernandes, C. Support Care Cancer. 2025;33(11):1014. doi:10.1007/s00520-025-10069-9*

70. **Endoscopic Sustainability PrimAry Reporting Essentials (E-SPARE): European Society of Gastrointestinal Endoscopy (ESGE) Position Statement.**

*Cunha Neves, JA, Baddeley, R, Pohl, H, Pioche, M, Lorenzo-Zuniga, V, Albeniz Arbizu, E, Mihai Voiosu, A, Rommele, C, Donnelly, L, Elli, L, Lopez-Munoz, P, Henniger, D, Khalaf, K, Bruno, MJ, Arvanitakis, M, Bisschops, R, Hassan, C, Messmann, H, Gralnek, IM, Siersema, PD, Thomas-Gibson, S, Hayee, B, Rodriguez de Santiago, E and Dinis-Ribeiro, M. Endoscopy. 2025;57(6):674–88. doi:10.1055/a-2543-0400*

71. **X-Tackling the Path to Closure: Post-Endoscopic Submucosal Dissection Defect Resolution Strategies.**

*Cunha Neves, JA, Chaves, J, Dinis-Ribeiro, M and Libanio, D. GE Port J Gastroenterol. 2025;32(2):127–30. doi:10.1159/000541865*

72. **Contributions of the nursing consultation in performing Magnetic Resonance Imaging without anesthesia in pediatric patients.**

*da Silva Sousa, EH, Monteiro, CCC and Moreira, RAMS. Onco.News. 2025(50)doi:10.31877/on.2025.50.07*

73. **Characteristics, Treatment Patterns and Clinical Outcomes of Women with Maghreb Origin and Diagnosis of Breast Cancer: A Single-Center, Retrospective Cohort Study.**

*Dauccia, C, Martins-Branco, D, Moreau, M, Ameye, L, Agostinetto, E, Arecco, L, Lobo-Martins, S, Skoporc, A, Vilas-Boas, I, Auprih, M, Awada, A, Debien, V and de Azambuja, E. Clin Breast Cancer. 2025;25(8):e1092–e9 e11. doi:10.1016/j.clbc.2025.06.011*

74. **Translation and cross-cultural adaptation of the Get Active Questionnaire for Pregnancy ("Questionário Seja Ativa durante a Gravidez") into Portugal and Brazil Portuguese.**

*de Carvalho, CG, Casseb, SG, Silva, M-RG, Castro, B, Szumilewicz, A, Davenport, MH and Santos-Rocha, R. Apunts Sports Medicine. 2025;60(228)doi:10.1016/j.apunsm.2025.100493*

75. **Characterization of testicular embryonic-type neuroectodermal tumor and embryonic-type neuroectodermal tissue admixed with mature neuro-glial tissue using a broad immunohistochemical panel.**

*Di Sciascio, L, Orsatti, A, Ambrosi, F, Franchini, E, Massari, F, Mollica, V, Bianchi, FM, Colecchia, M, De Leo, A, Acosta, AM, Lobo, J, Fiorentino, M and Ricci, C. Virchows Arch. 2025;487(1):221–6. doi:10.1007/s00428-024-03911-8*

76. **Uncommon Extrapyramidal Reaction to Ondansetron.**

*Dias, CS, Moreira, C, Gaspar, J and Santos, M. Cureus. 2025;17(3):e80362. doi:10.7759/cureus.80362*

77. **Case Report: Effective methotrexate removal by combined hemodialysis and polymeric resin hemoadsorption.**

*Dias, MR, Nicolau, C, Ferreira, H, Chacim, S, Oliveira, I, de Camara Negalha, G, Mariz, JM and Costa, JM. Front Nephrol. 2025;5:1644079. doi:10.3389/fneph.2025.1644079*

78. **Unveiling the TGF-beta/Smad signaling in renal carcinoma progression: Prognostic and therapeutic insights.**

*Dias, V, Alves, A, Medeiros, R, Teixeira, AL and Dias, F. Biochim Biophys Acta Rev Cancer. 2025;1880(4):189372. doi:10.1016/j.bbcan.2025.189372*

79. **A scoping review of TSR analysis in colorectal cancer: implications for automated solutions.**

*Dikland, FA, Fekih, C, Wellenstein, MRJ, Souza da Silva, R, Machado-Neves, R, Fraga, J, Oliveira, D, Montezuma, D, Pinto, IM and Woodburn, J. Oncol Rev. 2025;19:1605383. doi:10.3389/or.2025.1605383*

80. **Professor Lars Aabakken: A Visionary in GI Endoscopy and Medical Education.**

*Dinis-Ribeiro, M. United European Gastroenterol J. 2025;13(8):1597–9. doi:10.1002/ueg2.70082*

81. **How to improve the quality of upper gastrointestinal diagnostic endoscopy?**

*Dinis-Ribeiro, M and Areia, M. Clin Endosc. 2025;58(5):633–7. doi:10.5946/ce.2024.339*

82. **Management of epithelial precancerous conditions and early neoplasia of the stomach (MAPS III): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG) and European Society of Pathology (ESP) Guideline update 2025.**

*Dinis-Ribeiro, M, Libanio, D, Uchima, H, Spaander, MCW, Bornschein, J, Matysiak-Budnik, T, Tziatzios, G, Santos-Antunes, J, Areia, M, Chapelle, N, Esposito, G, Fernandez-Esparrach, G, Kunovsky, L, Garrido, M, Tacheci, I, Link, A, Marcos, P, Marcos-Pinto, R, Moreira, L, Pereira, AC, Pimentel-Nunes, P, Romanczyk, M, Fontes, F, Hassan, C, Bisschops, R, Feakins, R, Schulz, C, Triantafyllou, K, Carneiro, F and Kuipers, EJ. Endoscopy. 2025;57(5):504–54. doi:10.1055/a-2529-5025*

83. **Predicting Grades in the "Introduction to Clinical Databases" Course: Dataset**

**Creation, Pipeline Design, and Model Evaluation.**

*Domingues, I. Artificial Intelligence in Education Technologies: New Development and Innovative Practices. Lecture Notes on Data Engineering and Communications Technologies. 2282025. p. 255–67. doi:10.1007/978-981-97-9255-9_17*

84. **The Effects of Social Feedback Through the "Like" Feature on Brain Activity: A Systematic Review.**

*Dores, AR, Peixoto, M, Fernandes, C, Marques, A and Barbosa, F. Healthcare (Basel). 2025;13(1)doi:10.3390/healthcare13010089*

85. **CAR-NK cells: harnessing the power of natural killers for advanced cancer therapy.**

*Dos Reis, FD, Saidani, Y, Martin-Rubio, P, Sanz-Pamplona, R, Stojanovic, A and Correia, MP. Front Immunol. 2025;16:1603757. doi:10.3389/fimmu.2025.1603757*

86. **Addressing Ancestral Underrepresentation in Oncobiology: The Need for Sub-Saharan African-Specific In Vitro Models.**

*Dos Santos, CS, Magalhaes, AC, Pinto, RJ, Carrilho, C, Pereira, C, Miguel, F, Borges, P, Santos, LL and Pereira, L. Genes (Basel). 2025;16(12)doi:10.3390/genes16121403*

87. **Medication review improves pain management and quality of life in chronic pain: a pilot randomized controlled study.**

*Duarte, N, Martins, JP, Garcia-Domingo, M, Garcia-Pedraza, JA and Santos, M. Sci Rep. 2025;15(1):44689. doi:10.1038/s41598-025-28475-8*

88. **Ten-year analgesic utilization patterns and economic implications in Portugal.**

*Duarte, N, Martins, JP, Garcia-Pedraza, JA and Santos, M. Br J Clin Pharmacol. 2025;91(3):866–81. doi:10.1111/bcp.16333*

89. **The Global Reading Room: Performing a Breast Localization Procedure.**

*Elmaadawy, MM, Pires-Goncalves, L, Shimpi, T and Singla, V. AJR Am J Roentgenol. 2025;225(1):e2432282. doi:10.2214/AJR.24.32282*

90. **Regional differences in the daily consumption of smoked and smokeless tobacco among adults (25-64 years) in Mozambique: 2005 versus 2014/2015.**

*Enjo-Barreiro, JR, Fontes, F, Tualufo, S, Silva-Matos, C, Damasceno, A and Lunet, N. Cad Saude Publica. 2025;40(12):e00029024. doi:10.1590/0102-311XEN029024*

91. **STAndardization of Reports (the STAR project) Upper gastrointestinal endoscopy: European Society of Gastrointestinal Endoscopy (ESGE) Quality Improvement Initiative.**

*Esposito, G, Areia, M, Ching, HL, Afify, S, Guillena, PGD, Lopez, RH, Leclercq, P, Monged, A, Panarese, A, Reis De Oliveira, LA, Romanczyk, M, Ballesteros, EJR, Uchima, HI, Zessner-Spitzenberg, J, Eross, B, Hopper, A, Lux, T, McGettigan, N, Oguntoye, OO, Tai, FWD, Gralnek, IM, Hassan, C, Bisschops, R, Ferlitsch, M and External voting, p. Endoscopy. 2025;57(11):1298–308. doi:10.1055/a-2652-8941*

92. **The Gastroscopy RAte of Cleanliness Evaluation (GRACE) Scale: an international reliability and validation study.**

*Esposito, G, Dilaghi, E, Costa-Santos, C, Ligato, I, Annibale, B, Dinis-Ribeiro, M, Areia, M and Investigators, G. Endoscopy. 2025;57(4):312–20. doi:10.1055/a-2422-0856*

93. **EHMT2/G9a and EZH2: Epimarkers in testicular germ cell tumors.**

*Estevao-Pereira, H, Guimaraes-Teixeira, C, Flores, BCT, Moreira-Silva, F, Tavares, NT, Guimaraes, R, Braga, I, Mauricio, J, Henrique, R, Jeronimo, C and Lobo, J. Andrology. 2025;13(2):286–95. doi:10.1111/andr.13604*

94. **Nursing Assessment and Intervention in the Management of Delirium in Intensive Care: A Quantitative Study.**

*Esteves, NEC, Filipe Lopes, HJDF, Vieira, AS, Cardoso, PAS, Soares-Pinto, IE and da Silva, CRR. Revista de Enfermagem Referencia. 2025;6(4)doi:10.12707/rvi24.37425*

95. **Extended pharmacological thromboprophylaxis and clinically relevant venous thromboembolism after major abdominal and pelvic surgery: international, prospective, propensity score-weighted cohort study.**

*EuroSurg, C and Collaborative, ST. Br J Surg. 2025;112(3)doi:10.1093/bjs/znaf005*

96. **Effects of Glucagon-Like Peptide-1 Receptor Agonists on Upper Gastrointestinal Endoscopy: A Meta-Analysis.**

*Facciorusso, A, Ramai, D, Dhar, J, Samanta, J, Chandan, S, Gkolfakis, P, Crino, SF, Maida, M, Anderloni, A, Boskoski, I, Triantafyllou, K, Dinis-Ribeiro, M, Hassan, C, Fuccio, L and Arvanitakis, M. Clin Gastroenterol Hepatol. 2025;23(5):715–25 e3. doi:10.1016/j.cgh.2024.07.021*

97. **INTERLINK-1: A Phase III, Randomized, Placebo-Controlled Study of Monalizumab plus Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma.**

*Fayette, J, Licitra, L, Harrington, K, Haddad, R, Siu, LL, Liu, YC, Tahara, M, Machiels, JP, Rischin, D, Seiwert, TY, Ferris, RL, Keilholz, U, Psyrri, A, Keam, B, Bossi, P, Metcalf, R, Hsieh, CY, Clement, PMJ, Isaev, P, Mudunov, A, Dinis, J, Hoeben, A, Kasper, S, Klinghammer, K, Hwang, M, Blando, J, Serrano, O, Ruscica, D, Cohen, RB and investigators, I-. Clin Cancer Res. 2025;31(13):2617–27. doi:10.1158/1078-0432.CCR-25-0073*

98. **Cellular dynamics of cervical remodelling: insights from preterm and term labour.**

*Felix, J, Matias, A and Bartosch, C. Arch Gynecol Obstet. 2025;311(6):1553–60. doi:10.1007/s00404-024-07902-7*

99. **Identification of novel biomarkers in renal cell carcinoma.**

*Fernandes-Pontes, F, Lobo, J, Jeronimo, C and Henrique, R. Expert Rev Mol Diagn. 2025;25(8):465–77. doi:10.1080/14737159.2025.2518134*

100. **Portuguese real-world experience with ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma.**

*Fernandes, C, Costa e Sousa, R, Santos, P, Almeida, C, Roque, A, Pinto, AL, Monteiro, J, Neves, A, Ramos, MJ, Coutinho, R, Mousinho, F, Fernandes, ML, Badior, M, João, C, Leocádio, S, Tomé, AL, Carrolo, M, Dias, S, da Silva, MG and Fernandes, JP. Frontiers in Hematology. 2025;4doi:10.3389/frhem.2025.1702446*

101. **Reply to Gao et al.**

*Fernandes, C and Dinis-Ribeiro, M. Endoscopy. 2025;57(11):1321–2. doi:10.1055/a-2702-3082*

102. **Adenoma detection rate by colonoscopy in real-world population-based studies: a systematic review and meta-analysis.**

*Fernandes, C, Estevinho, M, Marques Cruz, M, Frazzoni, L, Rodrigues, PP, Fuccio, L and Dinis-Ribeiro, M. Endoscopy. 2025;57(1):49–61. doi:10.1055/a-2382-5795*

103. **Exergames for rehabilitation in stroke survivors: Umbrella review of meta-analyses.**

*Fernandes, CS, Magalhaes, B, Goncalves, F, Lima, A, Silva, M, Moreira, MT, Santos, C and Ferreira, S. J Stroke Cerebrovasc Dis. 2025;34(1):108161. doi:10.1016/j.jstrokecerebrovasdis.2024.108161*

104. **nurse-led gastrostomy care: a business case.**

*Fernandes, DMDS and Lopes, ASM. Onco.News. 2025(51)doi:10.31877/on.2025.51.06*

105. **Interventional Radiology Nursing: an Evolving competence.**

*Fernandes, DMS. Onco.News. 2025;2025-January-June(50)doi:10.31877/on.2024.50.02*

106. **[Practical Guidance on the Detection of NTRK Fusions in Sarcomas: Current Status and Diagnostic Challenges].**

*Fernandes, I, Macedo, D, Gouveia, E, Ferreira, A, Lima, J, Lopez, D, Melo-Alvim, C, Carvalho, A, Tavares, P, Rodrigues-Santos, P, Cardoso, P, Magalhaes, M, Vieira, P,*

*Brito, J, Mendes, C, Rodrigues, J, Netto, E, Oliveira, V, Sousa, C, Henriques Abreu, M, Pina, F and Vasques, H. Acta Med Port. 2025;38(4):266–75. doi:10.20344/amp.21925*

107. **Time perception of attractive male faces and voices: The role of women's menstrual cycle.**

*Fernandes, N, Soares, S, Arantes, M and Arantes, J. PLoS One. 2025;20(4):e0321956. doi:10.1371/journal.pone.0321956*

108. **Factors Associated With Prolonged Survival in Colorectal Cancer Patients Admitted to Palliative Care: An Exploratory Study.**

*Ferraz-Goncalves, JA, Lima, A, Silva, AJ and Calisto, R. Am J Hosp Palliat Care. 2025;42(12):1278–83. doi:10.1177/10499091241313224*

109. **Hypercalcemia in a patient with small bowel gastrointestinal stromal tumor: a quiz.**

*Ferreira, A, Ferreira, H and Costa, JM. J Nephrol. 2025;38(5):1525–7. doi:10.1007/s40620-025-02275-9*

110. **Pharmacological nephrotoxicity profile in a comprehensive cancer center: What changed in two decades and predictors for the need for haemodialysis and mortality.**

*Ferreira, A, Reis, M, Chuva, T, Ferreira, H, Coelho, I, Paiva, A and Costa, JM. Nefrologia (Engl Ed). 2025;45(6):501332. doi:10.1016/j.nefroe.2025.501332*

111. **The Role of Dupilumab in Atopic Dermatitis-Like Graft-Versus-Host Disease.**

*Ferreira Costa, I, Pinto, D, Teixeira, F, Maia, I, Ferreira, RB, Inacio, I and Araujo, AR. Cureus. 2025;17(7):e88293. doi:10.7759/cureus.88293*

112. **Trimmed N-glycans define aggressive gastric cancer and predict clinical outcomes.**

*Ferreira, D, Marinho-Santos, B, Relvas-Santos, M, Orr, B, Brandao, A, Afonso, LP, Santos, LL and Ferreira, JA. Theranostics. 2025;15(18):9375–98. doi:10.7150/thno.111670*

113. **Early-Stage Colon Cancer Surveillance: Pattern and Timing of Recurrence and the Role of 5-Year Surveillance.**

*Ferreira Pinto, P, Peyroteo, M, Baia, C, Marques, M, Cardoso, MJ, Videira, JF and Abreu de Sousa, J. GE Port J Gastroenterol. 2025;32(2):109–17. doi:10.1159/000540338*

114. **Let-7b, miR-29b, and miR-125b as Potential Biomarkers for Differentiating Canine Mammary Carcinoma Histological Types.**

*Ferreira, T, Dias, F, Alves, A, Gama, A, Mano, JF, Oliveira, PA and Medeiros, R. Animals (Basel). 2024;15(1)doi:10.3390/ani15010020*

115. **Hormone receptor discrepancy and molecular subtype changes in canine mammary carcinomas and synchronous lymph node metastasis.**

*Ferreira, T, Machado, AT, Medeiros, R, Mano, JF, Oliveira, PA and Gama, A. Res Vet Sci. 2025;194:105816. doi:10.1016/j.rvsc.2025.105816*

116. **Rapid Determination of Colistin Susceptibility by Flow Cytometry Directly from Positive Urine Samples-Preliminary Results.**

*Fonseca-Silva, D, Gomes, R, Martins-Oliveira, I, Silva-Dias, A, Ramos, MH and Pina-Vaz, C. Int J Mol Sci. 2025;26(3)doi:10.3390/ijms26030883*

117. **Adherence to clinical practice guidelines for Management of epithelial precancerous conditions and lesions in the stomach in Europe.**

*Fontes, F, Kapteijn, NEA, Hassan, C, Deane, C, Cristiano, M, Fernandes-Mendes, H, Luzko, I, Cavlina Sevo, M, Kelly, O, Esposito, G, Holster, IL, van der Horst, MPJ, Kweldam, CF, Voiosu, A, Pinto, RM, Almeida, N, O'Morain, C, Moreira, L, Bornschein, J, Spaander, MCW and Dinis-Ribeiro, M. Endoscopy. 2025;57(12):1338–47. doi:10.1055/a-2695-1376*

118. **External Radiotherapy in Mozambique: Report of the First Five Years of Activity of the Radiotherapy Service of the Maputo Central Hospital.**

*Fontes, F, Morais, AG, Nhampule, J, Navarro, S, Sitoe, N, Amisse, L, Tulsidas, S, Lorenzoni, C, Carrilho, C and Lunet, N. Cancer Med. 2025;14(17):e71199. doi:10.1002/cam4.71199*

119. **Consensus-Based Guidelines for Best Practices in the Selection and Use of Examination Gloves in Healthcare Settings.**

*Freitas, J, Lomba, A, Sousa, S, Goncalves, V, Brois, P, Nunes, E, Veloso, I, Peres, D and Alves, P. Nurs Rep. 2025;15(1)doi:10.3390/nursrep15010009*

120. **Glycan-based therapeutic approaches for bladder cancer: Overcoming clinical barriers.**

*Freitas, R, Peixoto, A, Santos, LL and Ferreira, JA. Biochim Biophys Acta Rev Cancer. 2025;1880(3):189327. doi:10.1016/j.bbcan.2025.189327*

121. **Epidemiological profile of women with moderate-risk breast cancer mutations.**

*Galama, R, Ribeiro, C, Silva, J and de Sousa, JA. Cir Esp (Engl Ed). 2025;103(1):55–6. doi:10.1016/j.cireng.2024.09.008*

122. **Imiquimod for Anal High Grade Intraepithelial Neoplasia: A Systematic Review.**

*Gallio, N, Preti, M, Casetta, E, Albuquerque, A, Vieira-Baptista, P, Borella, F, Bevilacqua, F, Cavallero, C, Mistrangelo, M and Revelli, A. Curr Oncol Rep. 2025;27(7):833–43. doi:10.1007/s11912-025-01675-1*

123. **Occupational Stress and Sleep of Military Police Officers From Rio de Janeiro, Brazil.**

*Garcia, LOR, Moreira, R and Silva, MG. Am J Hum Biol. 2025;37(1):e24184. doi:10.1002/ajhb.24184*

124. **Sexual function and dysfunction in the LGBTQIA+ community-including before and after gender-affirming surgery: recommendations from the Fifth International Consultation on Sexual Medicine (ICSM 2024).**

*Garcia, MM, Peixoto, MM, Armstrong, HL, Kelley, E, Knudson, G, Mattawanon, N and Wheldon, CW. Sex Med Rev. 2025;13(3):283–300. doi:10.1093/sxmrev/qeaf024*

125. **External multicenter validation of the FAMISH score for predicting metachronous gastric lesions after endoscopic submucosal dissection.**

*Garrido, M, Almeida, TC, Kuttner-Magalhaes, R, Marcos-Pinto, R, Archer, S, Pinho, R, Estevinho, MM, Santos-Antunes, J, Morais, R, Barreiro, P, Simao, I, Bourke, M, Wang, H, Amaro, P, Gravito-Soares, E, Kuvaev, R, Kashin, S, Areia, M, Viegas, MI, Koch, AD, Spaander, MCW, Provoost, N, Manfredi, G, Esposito, G, Losurdo, G, Lemmers, A, Fernandez-Esparrach, G, Santiago, ER, Dinis-Ribeiro, M and Libanio, D. Scand J Gastroenterol. 2025;60(8):1–9. doi:10.1080/00365521.2025.2522464*

126. **Allogeneic hematopoietic cell transplantation for older patients with Philadelphia-positive acute lymphoblastic leukemia. A study by the Acute Leukemia Working Party of the EBMT.**

*Giebel, S, Labopin, M, Swoboda, R, Blaise, D, Yakoub-Agha, I, Nguyen, S, Wagner-Drouet, EM, Castilla-Llorente, C, Kottaridis, P, Schroeder, T, Fanin, R, Passweg, J, Versluis, J, Crawley, C, Gabellier, L, Mielke, S, Poire, X, Nur, E, Vaz, CP, Eder, M, Nozzoli, C, Dreger, P, Peric, Z, Mohty, M and Ciceri, F. Bone Marrow Transplant. 2025;60(10):1325–32. doi:10.1038/s41409-025-02667-2*

127. **Applicability of the Scottish screen-detected polyp cancer study (SSPoCS) algorithm in a multicentric cohort in the management of malignant colorectal polyps.**

*Goncalves, AR, Azevedo Silva, M, Sequeira, C, Mascarenhas, A, Costa, M, Pinto Pais, T, Barreiro, P, Almeida, N, Rama, N, Fernandes, A, Eliseu, L, Dinis-Ribeiro, M and Vasconcelos, H. Scand J Gastroenterol. 2025;60(1):122–9. doi:10.1080/00365521.2024.2445699*

128. **Risk and survival of third primary cancers in a population-based cohort of patients with a cervical, endometrial, or ovarian cancer.**

*Goncalves, E, Fontes, F, Rodrigues, JR, Calisto, R, Bento,*

*MJ, Lunet, N and Morais, S. J Obstet Gynaecol Res. 2025;51(5):e16297. doi:10.1111/jog.16297*

129. **The role of spiritual care management - Needs and resources in people with amyotrophic lateral sclerosis: Insights from a mixed-methods study.**

*Goncalves, F, Teixeira, MI, Rego, F and Magalhaes, B. Palliat Support Care. 2025;23:e111. doi:10.1017/S1478951525000495*

130. **Early diagnosis of gastric cancer: Endoscopy and artificial intelligence.**

*Goncalves, N, Chaves, J, Marques-Sa, I, Dinis-Ribeiro, M and Libanio, D. Best Pract Res Clin Gastroenterol. 2025;75:101979. doi:10.1016/j.bpg.2025.101979*

131. **A Functional Polymorphism in IL-36beta Modulates Macrophage Antifungal Effector Functions and Increases Susceptibility to Invasive Pulmonary Aspergillosis.**

*Goncalves, SM, Leite, L, de Vasconcelos, P, Pereira, I, Dewi, IMW, Mercier, T, Aerts, R, Ligeiro, D, Mendes, F, Freitas, F, Condeco, J, Vieira, J, Espada, E, Lagrou, K, Maertens, JA, Gresnigt, MS, Dinarello, CA, Lacerda, JF, Pinho Vaz, C, Cunha, C, Carvalho, A and van de Veerdonk, FL. J Infect Dis. 2025;232(5):1208–19. doi:10.1093/infdis/jiaf301*

132. **Unusual Location of a Bronchogenic Cyst.**

*Graca, LL, Lopes, S, Leite, F and Pauperio, G. Port J Card Thorac Vasc Surg. 2025;31(4):55. doi:10.48729/pjctvs.440*

133. **[Congenital Sideroblastic Anemia and Iron Overload in Older Age].**

*Gradim, M and Ferreira, F. Acta Med Port. 2025;38(4):279–80. doi:10.20344/amp.22803*

134. **[Not Available].**

*Gradim, M and Ferreira, F. Acta Med Port. 2025;38(5):354–5. doi:10.20344/amp.22802*

135. **[Lipemia in Blood Donation: What are the Implications?].**

*Gradim, M, Quelhas, M, Carvalho, C and Rosales, M. Acta Med Port. 2025;38(11):748–9. doi:10.20344/amp.23537*

136. **Super-Resolution Microscopy Reveals Alterations in Clathrin Structure in Human Cancer Tissue.**

*Greig, A, Henrique, R, Xie, B, Thrasivoulou, C, Millar, M and Ahmed, A. Am J Pathol. 2025;195(9):1619–26. doi:10.1016/j.ajpath.2025.05.008*

137. **European Cancer Organisation Essential Requirements for Quality Cancer Care: Hematological malignancies.**

*Gribben, JG, Quintanilla-Martinez, L, Crompton, S, Arends, J, Bardin, C, Becker, H, Castinetti, F, Csaba, DL, D'Anastasi, M, Frese, T, Geissler, J, Matuzeviciene, R, Mayerhoefer, ME, Medeiros, R, Morgan, K, Narbutas, S, Nier, S, Ricardi, U, Arjona, ET, Ungan, M, Warwick, L and Zucca, E. Hemasphere. 2025;9(4):e70108. doi:10.1002/hem3.70108*

138. **Controversies in NEN: An ENETS position statement on nutritional support in neuroendocrine neoplasms.**

*Grozinsky-Glasberg, S, Hofland, J, Alband, S, de Lima, YC, Croitoru, A, Geilvoet, W, Igaz, P, Kos-Kudla, B, Krejs, GJ, Laviano, A, Panzuto, F, Sadanandam, A, Santos, AP, Welin, S and Srirajaskanthan, R. J Neuroendocrinol. 2025;37(12):e70062. doi:10.1111/jne.70062*

139. **Prolonged Responses to Cemiplimab in Advanced Cutaneous Squamous Cell Carcinoma: A Case Series.**

*Guedes, AP, Fernandes, CL, Freitas, IB, Ferreira, PC and Vilas Boas, MI. Cureus. 2025;17(9):e92346. doi:10.7759/cureus.92346*

140. **The role of multi-organ cancer predisposition genes in the risk of inherited and histologically diverse gastric cancer.**

*Guerra, J, Estrada-Florez, AP, Lott, PC, Pinto, C, Pinheiro, M, Chiu, KA, Montoya, DJ, Zhang, H, Polanco-Echeverry, GM, Pinto, P, Peixoto, A, Santos, C, Barbosa, A, Silva, J, Suarez-Olaya, J, Castro-Valencia, F, Molina, G, Corvalan, AH, Della Valle, A, Castelao, JE, Fernandez-Fernandez, N, Cid, L, Rios-Sarabia, N, Medrano, R, Mantilla, A, Echeverry de*

*Polanco, MM, Rivera-Herrera, AL, Riano-Moreno, J, Parra-Medina, R, Gonzalez-Castrillon, LM, Dominguez, R, Isidoro, AR, Silva, F, Morgan, DR, Cock-Rada, AM, Sanabria-Salas, MC, Bohorquez, MH, Torres, J, Teixeira, MR, Carvajal-Carmona, LG, Consorcio, G and Hispanic Gastric Cancer Genetics Collaborative, G. EBioMedicine. 2025;116:105759. doi:10.1016/j.ebiom.2025.105759*

141. **In situ radiotherapy for gastric cancer: The role of gold and other inorganic nanoparticles.**

*Guerreiro, SFC, Dias, AG, Dias, JR and Granja, PL. Acta Biomater. 2025;202:27–44. doi:10.1016/j.actbio.2025.06.044*

142. **Polycaprolactone (PCL)-Gelatin Electrospun Meshes for Accelerated Gastric Wound Healing.**

*Guerreiro, SFC, Leal, F, Dias, AG, Granja, PL and Dias, JR. Colloids Surf B Biointerfaces. 2025;250:114572. doi:10.1016/j.colsurfb.2025.114572*

143. **Can optical evaluation distinguish between T1a and T1b esophageal adenocarcinoma: an international expert interobserver agreement study.**

*Gupta, S, Mandarino, FV, Shahidi, N, Hourigan, LF, Messmann, H, Wallace, MB, Repici, A, Dinis-Ribeiro, M, Haber, GB, Taylor, ACF, Waxman, I, Siersema, PD, Pouw, RE, Lemmers, A, Bisschops, R, Mosko, JD, Teshima, C, Ragunath, K, Rosch, T, Pech, O, Beyna, T, Sharma, P, Lee, EYT, Burgess, NG, Bourke, MJ and study working, g. Endoscopy. 2025;57(3):200–7. doi:10.1055/a-2399-1401*

144. **Atezolizumab in High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck: A Randomized Clinical Trial.**

*Haddad, R, Fayette, J, Teixeira, M, Prabhash, K, Mesia, R, Kawecki, A, Dechaphunkul, A, Dinis, J, Guo, Y, Masuda, M, Hsieh, CY, Ghi, MG, Vaz de Melo Sette, C, Harrington, K, Tahara, M, Saba, NF, Lau, A, Jiang, T, Yan, Y, Ballinger, M, Kaul, M, Matheny, C, Cuchelkar, V and Wong, DJ. JAMA. 2025;333(18):1599–607. doi:10.1001/jama.2025.1483*

145. **A comprehensive assessment of the existing landscape of personalized cancer medicine in the European Union, on behalf of the PCM4EU consortium.**

*Haj Mohammad, SF, van der Pol, H, Vrdoljak, E, Lassen, U, Ojamaa, K, Jalkanen, K, Verlingue, L, Stenzinger, A, Patocs, A, Curigliano, G, Baltruskeviciene, E, Helland, A, Russnes, HG, Lugowska, I, Mainoli, B, Edsjo, A, Lonardi, E, Tasken, K and Gelderblom, H. ESMO Open. 2025;10(11):105872. doi:10.1016/j.esmoop.2025.105872*

146. **The Helicobacter pylori AI-clinician harnesses artificial intelligence to personalise H. pylori treatment recommendations.**

*Higgins, K, Nyssen, OP, Southern, J, Laponogov, I, Aida, C, Veselkov, D, Gisbert, JP, Kanonnikoff, TF and Veselkov, K. Nat Commun. 2025;16(1):6472. doi:10.1038/s41467-025-61329-5*

147. **Endoscopic papillectomy versus surgical ampullectomy for adenomas and early cancers of the papilla: a retrospective Pancreas2000/European Pancreatic Club analysis.**

*Hollenbach, M, Heise, C, Abou-Ali, E, Gulla, A, Auriemma, F, Soares, K, Leung, G, Schattner, MA, Jarnagin, WR, Wang, T, Caillol, F, Giovannini, M, Dahel, Y, Hackert, T, Paik, WH, Zerbi, A, Nappo, G, Napoleon, B, Arnelo, U, Haraldsson, E, Halimi, A, Waldthaler, A, Will, U, Saadeh, R, Masaryk, V, van der Wiel, SE, Bruno, MJ, Perez-Cuadrado-Robles, E, Deprez, P, Sauvanet, A, Bolm, L, Keck, T, Souche, R, Fabre, JM, Musquer, N, Kahler, G, Seyfried, S, Petrone, MC, Mariani, A, Zaccari, P, Belfiori, G, Crippa, S, Falconi, M, Partelli, S, Yilmaz, B, Demir, IE, Ceyhan, GO, Satoi, S, Regimbeau, JM, Gagniere, J, Repici, A, Anderloni, A, Vollmer, C, Casciani, F, Del Chiaro, M, Oba, A, Schulick, RD, Berger, A, Maggino, L, Salvia, R, Schemmer, P, Wichmann, D, Inoue, Y, Dinis-Ribeiro, M, Laranjo, A, Libanio, D, Kleemann, T, Sandru, V, Ilie, M, Ahola, R, Laukkarinen, J, Schumacher, B, Albers, D, Curdia Goncalves, T, Barbier, L, Salame, E, Weismuller, TJ, Heling, D, Alves, A, Karam, E, Regenet, N, Dugic, A, Muehldorfer, S, Truant, S, Caca, K, Meier, B, Miutescu, BP, Tantau, M, Birnbaum, D,*

*Miksch, RC, Wedi, E, Salzmann, K, Bruzzi, M, Lupinacci, RM, David, P, De Ponthaud, C, Schmidt, A, Regner, S, Gaujoux, S and group, Es. Gut. 2025;74(3):397–409. doi:10.1136/gutjnl-2022-327996*

148. **Preface to special edition: Screening and Early diagnosis of upper gastrointestinal neoplastic lesions.**

*Honing, J and Dinis-Ribeiro, M. Best Pract Res Clin Gastroenterol. 2025;75:101983. doi:10.1016/j.bpg.2025.101983*

149. **Investigating the role of neurotransmitter system and neurotrophic factor-related genes in human papillomavirus-associated cervical lesions.**

*Inácio, Â, Aguiar, L, Caldeira, J, Gato, M, Carrilho, R, Pires, P, Ferreira, J, Coelho, L, Medeiros, R, Bicho, M and Clara Bicho, M. Eurasian Journal of Medicine and Oncology. 2025;9(2):250–60. doi:10.36922/ejmo025100047*

150. **Altered NRF2 signalling in systemic redox imbalance: Insights from non-communicable diseases.**

*Jakubowska, M, Costa, VM, Krzeptowski, W, Dominkus, PP, Santos, M, Demirdogen, BC, Genc, S, Trougakos, IP, Kanninen, KM, Winklhofer-Roob, BM, Copple, IM, Cuadrado, A, Dolzan, V and Morgenstern, C. Redox Biol. 2025;87:103891. doi:10.1016/j.redox.2025.103891*

151. **Unmet supportive care needs among head and neck cancer survivors beyond 5 years after diagnosis: a multinational cohort study.**

*Jansen, F, Eerenstein, SE, Taylor, KJ, Amdal, CD, Bjordal, K, Astrup, GL, Herlofson, BB, Duprez, F, Gama, RR, Jacinto, AA, Hammerlid, E, Scricciolo, M, Fanetti, G, Guntinas-Lichius, O, Inhestern, J, Dragan, T, Fabian, A, Boehm, A, Wohner, U, Kiyota, N, Kruger, M, Bonomo, P, Pinto, M, Nuyts, S, Silva, JC, Stromberger, C, Specenier, P, Tramacere, F, Bushnak, A, Perotti, P, Plath, M, Paderno, A, Stempler, N, Kanellopoulou, A, Singer, S and Verdonck-de Leeuw, IM. Lancet Reg Health Eur. 2025;59:101495. doi:10.1016/j.lanepe.2025.101495*

152. **CRISPR-Cas9 and Its Bioinformatics Tools: A Systematic Review.**

*Jasieniecka, A and Domingues, I. Curr Issues Mol Biol. 2025;47(5)doi:10.3390/cimb47050307*

153. **Exploring the Chemopreventive and Antioxidant Effects of Spearmint Leaf Hydroethanolic Extract in HPV16-transgenic Mice.**

*Jesus, TM, Azevedo, T, Silva-Reis, R, Ferreira, T, Nascimento-Goncalves, E, Medeiros, C, Ferreira, J, Gama, A, Gaivao, I, Pires, MJ, Lanzarin, G, Felix, L, Venancio, C, Medeiros, R, Bastos, M, Finimundy, TC, Barros, L, Gil, DACRM and Oliveira, PA. In Vivo. 2025;39(3):1303–13. doi:10.21873/invivo.13934*

154. **Supporting the early development of decentralised oncology units in Portuguese-speaking African countries: initial results of the GONCO program in Angola and Cape Verde.**

*Juliao, I, Costa, T, Antunes, L, Almeida, P, Salamanca, P, Borges, H and Santos, LL. Ecancermedicalscience. 2025;19:2050. doi:10.3332/ecancer.2050*

155. **H&E to IHC virtual staining methods in breast cancer: an overview and benchmarking.**

*Klockner, P, Teixeira, J, Montezuma, D, Fraga, J, Horlings, HM, Cardoso, JS and Oliveira, SP. NPJ Digit Med. 2025;8(1):384. doi:10.1038/s41746-025-01741-9*

156. **Lymph node tuberculosis after occupational exposure in a Portuguese physician.**

*Lagoa, M, Ramos, AS, Leite, CO, Bento, J and Pires, L. Rev Bras Med Trab. 2025;23(2):e20251361. doi:10.47626/1679-4435-2025-1361*

157. **Oral squamous cell carcinoma identification by FTIR spectroscopy of oral biofluids.**

*Lapa, T, Pascoa, R, Coimbra, F, Medeiros, L and Gomes, PS. Oral Dis. 2025;31(3):729–40. doi:10.1111/odi.15128*

158. **Endoscopic submucosal dissection for gastric neuroendocrine**

**neoplasms: A multicenter retrospective study.**

*Lazaridis, N, Rimondi, A, Chacchi-Cahuin, R, Lemmers, A, Costa, D, Bucalau, AM, Mandair, D, Gupta, S, Tantau, M, Pioche, M, Rivory, J, Santos-Antunes, J, Marques, M, Ramos Zabala, F, Barbaro, F, Pimentel-Nunes, P, Uchima, H, Albeniz, E, Dinis-Ribeiro, M, Costamagna, G, Spada, C, Bourke, M, Caplin, M, Toumpanakis, C, Despott, EJ and Murino, A. J Neuroendocrinol. 2025;37(9):e70064. doi:10.1111/jne.70064*

159. **Concerning the TNM 9th edition - Go forth and validate.**

*Leite, F. Port J Card Thorac Vasc Surg. 2025;32(1):9–11. doi:10.48729/pjctvs.559*

160. **Glycemic variability and entero-pancreatic hormones signatures after different bariatric surgery procedures: a cross-sectional study.**

*Lobato, CB, Pereira, SS, Guimaraes, M, Soares, B, Hartmann, B, Nora, M, Holst, JJ and Monteiro, MP. Int J Obes (Lond). 2025;49(10):2042–50. doi:10.1038/s41366-025-01865-8*

161. **Cytological Features of the Emerging Entity Papillary Renal Neoplasm with Reverse Polarity: A Case Report Highlighting the Relevance of Fine-Needle Aspiration in Renal Masses.**

*Lobo, J, Castro, J, Azevedo, J, Lobo, C, Rodrigues, A, Braga, I, Freitas, R, Silva-Santos, R, Peixoto, A, Henrique, R, Leca, L and Lobo, J. Pathobiology. 2025;92(5):288–93. doi:10.1159/000545894*

162. **Primary Ewing Sarcoma of the Kidney: Clinicopathologic and Molecular Study of 24 Patients Including a Rare EWSR1::ETV4 Fusion.**

*Lobo, J, He, H, Ahmed, R, Zein-Sabatto, B, Winokur, T, Wei, S, Harada, S, McKenney, JK, Myles, JL, Nguyen, JK, Przybycin, CG, Williamson, SR, Magi-Galluzzi, C and Alaghehbandan, R. Am J Surg Pathol. 2025;49(10):1078–89. doi:10.1097/PAS.0000000000002427*

163. **Diagnosis of Papillary Renal Cell Carcinoma – the Current Perspective.**

*Lobo, J, Ohashi, R and Moch, H. Kidney Cancer. 2025;9(1 Special Issue: Updates in Kidney Tumor Classification, Morphology, and Molecular Alterations):16–26. doi:10.3233/KCA-230022*

164. **Phenotypic and Molecular Features of Somatically Derived "Yolk Sac Tumors": Similarities and Differences With Counterparts of Germ Cell Origin.**

*Lobo, J, Tavares, NT, Fernandes-Pontes, F, Fonseca, D, Jeronimo, C, Henrique, R, Ricci, C, de Leo, A, Collins, K, Idrees, MT, Ulbright, TM, Gupta, S and Acosta, AM. Mod Pathol. 2025;38(9):100807. doi:10.1016/j.modpat.2025.100807*

165. **MicroRNA-371-373 cluster and methylome analysis suggests that a subset of 'somatic-type' malignancies arising in germ cell tumors may originate in yolk sac tumor components.**

*Lobo, J, Tavares, NT, Fonseca, D, Jeronimo, C, Henrique, R, Wyvekens, N, Yang, Y, Snuderl, M, Maclean, F, Gordetsky, J, Fletcher, CD, Hirsch, MS, Hornick, JL, Idrees, MT, Collins, K, Warmke, L, Ulbright, TM and Acosta, AM. J Pathol. 2025;266(2):160–76. doi:10.1002/path.6412*

166. **Digital and Computational Pathology Applications in Bladder Cancer: Novel Tools Addressing Clinically Pressing Needs.**

*Lobo, J, Zein-Sabatto, B, Lal, P and Netto, GJ. Mod Pathol. 2025;38(1):100631. doi:10.1016/j.modpat.2024.100631*

167. **Practical Guidelines for the Treatment of Gestational Trophoblastic Disease: Collaboration of the European Organisation for the Treatment of Trophoblastic Disease (EOTTD)-European Society of Gynaecologic Oncology (ESGO)-Gynecologic Cancer InterGroup (GCIG)-International Society for the Study of Trophoblastic Diseases (ISSTD).**

*Lok, C, van Trommel, N, Braicu, EI, Planchamp, F, Berkowitz, R, Seckl, M and Committee, E-E-G-IG. J Clin Oncol. 2025;43(18):2119–28. doi:10.1200/JCO-24-02326*

168. **Treatment strategies in human papillomavirus-related advanced penile cancer.**

*Longoni, M, Fankhauser, CD, Negri, F, Salonia, A, Basile, G, Johnstone, PAS, Bandini, M, Penile, E-Y and Testis Cancer Working, G. Nat Rev Urol. 2025;22(7):427–38. doi:10.1038/s41585-025-00994-z*

169. **Oncology care humanization in adults: a scoping review protocol.**

*Lopes, AS, Ribeiro, AL, Lamas, B, Santos, D, Fernandes, D, Silva, R and Marques, P. JBI Evid Synth. 2025;23(8):1671–9. doi:10.11124/JBIES-24-00295*

170. **Saliva-derived transcriptomic signature for gastric cancer detection using machine learning and leveraging publicly available datasets.**

*Lopes, C, Brandao, A, Teixeira, MR, Dinis-Ribeiro, M and Pereira, C. Sci Rep. 2025;15(1):18491. doi:10.1038/s41598-025-96864-0*

171. **Advances towards gastric cancer screening: Novel devices and biomarkers.**

*Lopes, C and Pereira, C. Best Pract Res Clin Gastroenterol. 2025;75:102009. doi:10.1016/j.bpg.2025.102009*

172. **An Overview of the Therapeutic Potential of Dimeric Flavonoids for Targeting Cancer Hallmarks.**

*Lopes, I, Meireles, I, Rocha, R, Medeiros, R and Cerqueira, F. BioChem. 2025;5(1)doi:10.3390/biochem5010002*

173. **Implications of tendinopathy on the sports career: Epidemiological and clinical profile of high-performance athletes.**

*Lopes, LR, Machado, DE, Goes, RA, Amaral, MVG, Dias, F, Tavares, V, Medeiros, R and Perini, JA. Phys Ther Sport. 2025;72:59–68. doi:10.1016/j.ptsp.2025.02.003*

174. **A Systematic Review and Meta-Analysis on Aerobic Fitness Dynamics in Post-COVID-19 Athletes: Implications in the Return-to-Play Performance.**

*Lopes, LR, Medeiros, R, Tavares, V, Dias, F, Amaral, MVG, Goes, RA, Matheus Guimaraes, JA and Perini, JA. Sports (Basel). 2025;13(2)doi:10.3390/sports13020040*

175. **A systematic review of the effectiveness of leaded glasses for ensuring safety among healthcare professionals in fluoroscopy.**

*Lopes, R, Teles, P and Santos, J. J Med Imaging Radiat Sci. 2025;56(2):101848. doi:10.1016/j.jmir.2024.101848*

176. **A systematic review on the occupational health impacts of ionising radiation exposure among healthcare professionals.**

*Lopes, R, Teles, P and Santos, J. J Radiol Prot. 2025;45(2)doi:10.1088/1361-6498/added2*

177. **Artificial Intelligence in Thoracic Surgery: Transforming Diagnostics, Treatment, and Patient Outcomes.**

*Lopes, S, Mascarenhas, M, Fonseca, J, Fernandes, MGO and Leite-Moreira, AF. Diagnostics (Basel). 2025;15(14)doi:10.3390/diagnostics15141734*

178. **Unveiling the Algorithm: The Role of Explainable Artificial Intelligence in Modern Surgery.**

*Lopes, S, Mascarenhas, M, Fonseca, J, Fernandes, MGO and Leite-Moreira, AF. Healthcare (Basel). 2025;13(24)doi:10.3390/healthcare13243208*

179. **Neighborhood Socioeconomic Deprivation and Gender Disparities in Children with Excessive Body Weight in a Southern European Municipality.**

*Lourenco, AC, Nogueira, HG, Rodrigues, D, Gama, A, Machado-Rodrigues, AM, Silva, MRG and Padez, C. Children (Basel). 2025;12(3)doi:10.3390/children12030321*

180. **3d Model For Chest Wall Reconstruction - Utility Survey.**

*Lourenco Graca, L, Leite, F and Pauperio, G. Port J Card Thorac Vasc Surg. 2025;32(3):25–31. doi:10.48729/pjctvs.521*

181. **Asthenia.**

*Luís, MS. Medical Oncology Compendium2025. p. 709–13. doi:10.1016/b978-0-443-15609-0.00045-3*

182. **Efficacy of digital technology-based**

**interventions for reducing caregiver burden and stress: a systematic review and meta-analysis.**

*Lumini, MJ, Franca, D, Sousa, MR, Araujo, F, Cardoso, C, Sa, M, Lopes, M, Peixoto, MJ and Martins, T. Front Digit Health. 2025;7:1636084. doi:10.3389/fdgth.2025.1636084*

183. **Decoding MUC1 and AR axis in a radiation-induced neuroendocrine prostate cancer cell-subpopulation unveils novel therapeutic targets.**

*Macedo-Silva, C, Albuquerque-Castro, A, Carrico, I, Lencart, J, Carneiro, I, Altucci, L, Lobo, J, Miranda-Goncalves, V, Henrique, R, Correia, MP and Jeronimo, C. Cell Death Discov. 2025;11(1):306. doi:10.1038/s41420-025-02597-4*

184. **Exploring hyperglycemia's impact on embryonic development: Insights from the chicken embryo model.**

*Machado-Costa, D, Miranda, G, Correia-Pinto, J and Moura, RS. Tissue Cell. 2025;95:102925. doi:10.1016/j.tice.2025.102925*

185. **Circulating cell-free DNA methylation as biomarker for lung cancer detection: a systematic review and meta-analysis of diagnostic studies.**

*Machado, DI, Brito-Rocha, T, Salta, S, Monjardino, T, Henrique, R and Jeronimo, C. Syst Rev. 2025;14(1):120. doi:10.1186/s13643-025-02860-w*

186. **Attention Deficit/Hyperactivity Disorder in Adults: Position of Portuguese Experts on Diagnosis and Treatment.**

*Madeira, N, Franca, G, Jesus, G, Fernandes, JM, Almeida, SS and Filipe, CN. Acta Med Port. 2025;38(3):187–96. doi:10.20344/amp.22149*

187. **Pediatric Renal Transplantation: A 10-Year Single-Center Experience.**

*Magalhaes, M, Oliveira, B, Goncalves, G, Sousa, H, Vinagre, N, Pinto, AM, Nunes-Carneiro, D, Ramos, MS and Fraga, A. Transplant Proc. 2025;57(7):1277–80. doi:10.1016/j.transproceed.2025.07.014*

188. **Usefulness of Mixed Reality in Surgical Treatment: Delphi Study.**

*Magalhaes, R, Lima, AC, Marques, A, Pereira, J and Santos, LL. J Med Internet Res. 2025;27:e69964. doi:10.2196/69964*

189. **Sodium 2-Mercaptoethanesulfonate (MESNA), Ifosfamide, Mitoxantrone, and Etoposide (MINE) in Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Is the Old Regimen Still Gold?**

*Maia Moco, L, Hortas, AM, Ramos, I, Fontoura, A, de Camara Negalha, G, Bras, G and Mariz, M. Cureus. 2025;17(7):e87128. doi:10.7759/cureus.87128*

190. **The role of generative language systems in increasing patient awareness of colon cancer screening.**

*Maida, M, Ramai, D, Mori, Y, Dinis-Ribeiro, M, Facciorusso, A, Hassan, C and and the, AICWG. Endoscopy. 2025;57(3):262–8. doi:10.1055/a-2388-6084*

191. **High burden and multi-parasite profile of gastrointestinal infections in cattle from Limpopo District, Southern Mozambique: Epidemiology, risk factors, and One Health implications.**

*Manave, EC, Nchowela, GA, Miguel, AR, Matuassa, CC, Muadica, AS, Machanja, B, Fernandes, L, Mavilingue, OM, Simbine, I, Tsamba, P, Manuel, IF, Muchanga, IJ, Deta, T, Ualema, EM, Cortes, H and Alfredo, C. Vet World. 2025;18(12):3994–4008. doi:10.14202/vetworld.2025.3994-4008*

192. **SUCCOR 10 years: a decade's perspective on radical hysterectomy outcomes in cervical cancer.**

*Manzour, N, Chiva, L, Zanagnolo, V, Capilna, ME, Bizzarri, N, Mom, CH, Klasa, L, Arencibia, O, Malzoni, M, Narducci, F, Raspagliesi, F, Poka, R, Golub, D, Tavares, M, Tsolakidis, D, Shamistan, A, Perrone, AM, Pete, I, Aluloski, I, Bernardino, M, Vujic, G, Jedryka, M, Maenpaa, M, Ponce, J, Povolotskaya, N, Roldan Rivas, F, Feron, JG, Van Gorp, T, Alonso-Espias, M, Fruscio, R, Vorgias, G, Diez Garcia, J, Herrero, S, Kavallaris, A, Luyckx, M, Yezhova, I, Mitrovic, M, Ferrero, A, Saaron, R, Sukhin, V and Group, SYS. Int J Gynecol Cancer. 2025;35(5):101690. doi:10.1016/j.ijgc.2025.101690*

193. **Standardizing endoscopic protocols increases detection of gastric cancer during surveillance of patients with precancerous conditions: a systematic review and meta-analysis.**

*Marcos, P, Goncalves, N, Gama, J, Areia, M and Dinis-Ribeiro, M. Dig Liver Dis. 2025;57(8):1588–602. doi:10.1016/j.dld.2025.04.047*

194. **Combination of MLo-1508 with sunitinib for the experimental treatment of papillary renal cell carcinoma.**

*Marques-Magalhaes, A, Moreira-Silva, F, Graca, I, Dias, PC, Correia, MP, Alzamora, MA, Henrique, R, Lopez, M, Arimondo, PB, Miranda-Goncalves, V and Jeronimo, C. Front Oncol. 2025;15:1399956. doi:10.3389/fonc.2025.1399956*

195. **Laparoscopic colorectal bypass for colorectal anastomosis stricture-A video vignette.**

*Marques, M, Martins, P, Lencastre, L, Videira, F and de Sousa, JA. Colorectal Dis. 2025;27(12):e70351. doi:10.1111/codi.70351*

196. **Influence of Artisanal Mining and Environmental Pollutants on Food Security in Southern Africa: A Systematic Review.**

*Marrufo, TJ, Capece, BPS and Silva, MRG. Food and Energy Security. 2025;14(2)doi:10.1002/fes3.70080*

197. **Immunogenicity as a Predictor of Influenza Vaccine Efficacy: A Systematic Review.**

*Martins, AM, Valero Juan, LF, Santos, M and Martins, JP. Vaccines (Basel). 2025;13(8)doi:10.3390/vaccines13080859*

198. **Adverse reactions mediated by (99m)Tc-tetrofosmin: Literature review and analysis of post-marketing reports.**

*Martins, S, Costa, S, Sousa, M, Moreira, F, Martin-Suarez, A and Jesus, A. Rev Esp Med Nucl Imagen Mol (Engl Ed). 2025;44(6):500166. doi:10.1016/j.remnie.2025.500166*

199. **Biomarker-Directed Radiotherapy in Breast Cancer: A Narrative Review.**

*Meattini, I, Coles, CE, Tramm, T, Borghesi, S, Krug, D, Montero, A, Nardone, V, Salvestrini, V, Valzano, M, Valentini, V, Aristei, C, Poortmans, P and Assisi Think Tank Meeting, I. JAMA Oncol. 2025;11(3):329–39. doi:10.1001/jamaoncol.2024.5780*

200. **Epidemiological characterization of chronic myeloid leukaemia patients at an oncologic centre: A retrospective observational study.**

*Meireles, AM, Calisto, R, Bento, MJ, Gouveia, PM, Bizarro, S, Teixeira, M, Moreira, C, Santo, AE and Mariz, M. Hematol Transfus Cell Ther. 2025;47(3):103935. doi:10.1016/j.htct.2025.103935*

201. **Effects of fludarabine dosage on transplant-related outcomes in hematopoietic stem cell transplantation.**

*Meireles, AM, Oliveira Rodrigues Amarante, ACD, Marques Catita, BMC, Abilheira Monjardino, M, de Abreu Gouveia, PMG, Rocha Moreira, CSD, Jesus Leite, LC, Coutinho, R, Santos Ferreira, RB, Bras, GP, Guerreiro, M, Vaz, CP and Mariz, JM. Leuk Lymphoma. 2025;66(10):1942–6. doi:10.1080/10428194.2025.2509701*

202. **Epigenetic Alterations in Glioblastoma Multiforme as Novel Therapeutic Targets: A Scoping Review.**

*Meleiro, M and Henrique, R. Int J Mol Sci. 2025;26(12)doi:10.3390/ijms26125634*

203. **Immunohistochemical expression of EZH2 in germ cell tumors of the testis: New insights into the genesis and epigenetic reprogramming of these fascinating tumors.**

*Melotti, S, Ambrosi, F, Franceschini, T, Giunchi, F, Vasuri, F, Orsatti, A, Di Sciascio, L, Grillini, A, Franchini, E, Massari, F, Mollica, V, Marchetti, A, Mineo Bianchi, F, Colecchia, M, Acosta, AM, Lobo, J, Fiorentino, M and Ricci, C. Am J Clin Pathol. 2025;164(5):739–45. doi:10.1093/ajcp/aqaf098*

204. **Colorectal Endoscopic Full-Thickness Resection: A Portuguese Multicenter Experience Based on a Retrospective Cohort.**

*Mendes, RR, Mascarenhas, A, Correia, J, Estevinho, MM, Pereira Rodrigues, J, Conceicao, D, Saraiva, S, Mao De Ferro, S, Nascimento, CN, Loureiro, R, Costa, MS, Gravito-Soares, E, Chaves, J, Libanio, D, Dinis Ribeiro, M, Archer, S, Kuttner Magalhaes, R, Bronze, S, Noronha Ferreira, C, Tarrio, I, Araujo, T and Barreiro, P. GE Port J Gastroenterol. 2025;32(4):264–72. doi:10.1159/000541642*

205. **Immune-Related Esophagitis and Durable Response to Second-Line Treatment With Nivolumab in Stage IV Squamous Cell Esophageal Carcinoma.**

*Meneses, O, Alzamora, M, Dias, C, Ortigao, R and Marques, D. Cureus. 2025;17(12):e98324. doi:10.7759/cureus.98324*

206. **The RNA-binding protein YTHDF3 affects gastric cancer cell migration and response to paclitaxel by regulating EZRIN.**

*Mesquita, P, Coelho, A, Ribeiro, AS, Povoas, LFC, de Oliveira, C, Leca, N, Silva, S, Ferreira, D, Padua, D, Coelho, R, Jeronimo, C, Paredes, J, Conde, C, Pereira, B and Almeida, R. Gastric Cancer. 2025;28(5):760–75. doi:10.1007/s10120-025-01620-y*

207. **Testicular adult granulosa cell tumour: discussing assessment of risk, microRNA-371a-3p levels and FOXL2 testing in a single case.**

*Mesquita, S, Azevedo, J, Silva-Santos, R, Tavares, NT, Santos, C, Rodrigues, A, Henrique, R, Braga, I, Acosta, AM, Freitas, R and Lobo, J. Histopathology. 2025;87(5):773–6. doi:10.1111/his.15515*

208. **Renal Juxtaglomerular Cell Tumors Exhibit Distinct Genomic and Epigenomic Features and Lack Recurrent Gene Fusions: Comprehensive Molecular Analysis of a Multi-institutional Series.**

*Michalova, K, Martinek, P, Mezencev, R, Gupta, S, Williamson, S, Wasco, M, Mohanty, S, Magi-Galluzzi, C, Canete-Portillo, S, Aron, M, Kandukuri, S, Lobo, J, Barkan, GA, Kilic, I, Strakova-Peterikova, A, Pivovarcikova, K, Michal, M, Michal, M, Ulbright, TM and Acosta, AM. Am J Surg Pathol. 2025;49(3):217–26. doi:10.1097/PAS.0000000000002344*

209. **Evaluation of Nectin-4 and Trop-2: Implications for Patient Outcomes and Therapy in Penile Cancer.**

*Mink, JN, Eckstein, M, Khalmurzaev, O, Pryalukhin, A, Geppert, C, Lohse, S, Bende, K, Lobo, J, Henrique, R, Loertzer, H, Steffens, J, Jeronimo, C, Wunderlich, H, Heinzelbecker, J, Bohle, RM, Stockle, M, Matveev, V, Hartmann, A and Junker, K. Mod Pathol. 2025;38(8):100781. doi:10.1016/j.modpat.2025.100781*

210. **Bioengineered Tumor-Stroma Prostate Cancer In Vitro Models for Screening Therapeutics.**

*Monteiro, MV, Moreira-Silva, F, Lagarto, M, Ferreira, LP, Ramalhinho, C, Duarte, IF, Jeronimo, C, Gaspar, VM and Mano, JF. Biotechnol Bioeng. 2025;122(6):1541–53. doi:10.1002/bit.28971*

211. **Male Breast Cancer in Portugal: A Descriptive Analysis of a 20-Year Cohort.**

*Montenegro, MA, Domingues, TD, Garcia, TM, Ferreira, RQ, Furtado, IT, Escaleira, R, Verdasca, FR, Simao, DC, Fernandes, L and Oliveira, SD. Eur J Breast Health. 2025;21(2):154–61. doi:10.4274/ejbh.galenos.2025.2025-2-2*

212. **Annotation Practices in Computational Pathology: A European Society of Digital and Integrative Pathology (ESDIP) Survey Study.**

*Montezuma, D, Oliveira, SP, Tolkach, Y, Boor, P, Haragan, A, Carvalho, R, Della Mea, V, Kiehl, TR, Leh, S, Yousif, M, Ameisen, D, Mircea-Sebastian, S, Zerbe, N and L'Imperio, V. Lab Invest. 2025;105(3):102203. doi:10.1016/j.labinv.2024.102203*

213. **Unbiased Artificial Intelligence: Addressing Bias in Computational Pathology.**

*Montezuma, D, Porz, R, Ameisen, D, L'Imperio, V, Serbanescu, MS, Temprana-Salvador, J, Zerbe, N, Khalili, N, Zlobec, I, European Society of, D and Integrative, P. Mayo Clin Proc Digit Health. 2025;3(4):100302. doi:10.1016/j.mcpdig.2025.100302*

214. **Natural History of Primary Retroperitoneal Extra-Visceral Perivascular Epithelioid Cell Tumors (PEC): A Study from Transatlantic and Australasian Retroperitoneal Sarcoma Working Group (TARPSWG).**

*Mor, E, Apte, S, Mitchell, C, Nessim, C, Almond, M, Vincenzi, B, Lopez, JAG, Cranmer, L, Wagner, MJ, Nissan, A, Abreu, MH, Albertsmeier, M, Knoblauch, M, Barlow, A, Keung, EZ, Grignani, G, Hornick, JL, Gronchi, A and Gyorki, DE. Ann Surg Oncol. 2025;32(10):7817–28. doi:10.1245/s10434-025-17787-8*

215. **Deep Learning Techniques for Detecting Morphed Face Images: A Literature Review.**

*Morais, P, Domingues, I and Bernardino, J. IEEE Access. 2025;13:105952–81. doi:10.1109/access.2025.3578199*

216. **Cost-utility and clinical impact of endoscopic screening for esophageal and gastric neoplasia in patients with head and neck neoplasms.**

*Morais, R, Afonso, J, Sousa, N, Sousa-Pinto, B, Libanio, D, Marinho, B, Sacramento, ML, Simplicio, M, Faria-Ramos, I, Azevedo, L, Marques, M, Silveira, H, Gullo, I, Carneiro, F, Santos-Antunes, J and Macedo, G. Eur J Gastroenterol Hepatol. 2025;37(7):815–25. doi:10.1097/MEG.0000000000002988*

217. **Translating G9a epigenetics' role: From cell machinery to cancer therapy.**

*Moreira-Silva, F, Macedo-Silva, C, Jeronimo, C and Julio, MK. Gene. 2025;968:149681. doi:10.1016/j.gene.2025.149681*

218. **Ensuring safety in cytotoxic drug preparation: A systematic review of guidelines addressing education for pharmacy professionals.**

*Moreira, F, Jesus, A, Pinho, C, Santos, M, Serdoura, M and Cruz, A. J Am Pharm Assoc (2003). 2025;65(3):102352. doi:10.1016/j.japh.2025.102352*

219. **Experimental characterization of the non-linear viscoelastic properties of human female perineal tissue.**

*Moura, R, D, AO, M, RC, Pirker, TM, Hammer, N, M, PLP and Vom Scheidt, A. Sci Rep. 2025;15(1):42483. doi:10.1038/s41598-025-26576-y*

220. **Effectiveness of Gastric Cancer Endoscopic Screening in Intermediate-Risk Countries-A Systematic Review and Meta-Analysis.**

*Mourato, MB, Pratas, N, Branco Pereira, A, Chanca, R, Fronteira, I, Dinis, R and Areia, M. United European Gastroenterol J. 2025;13(9):1715–29. doi:10.1002/ueg2.70084*

221. **Gastric Cancer Endoscopic Screening in an Intermediate-Risk Country-A Dual-Center Pilot Program.**

*Mourato, MB, Pratas, N, Branco Pereira, A, Costa Pinto, F, Dinis, R, Fronteira, I and Areia, M. Helicobacter. 2025;30(4):e70061. doi:10.1111/hel.70061*

222. **Current practices in HPV-related anogenital neoplasia care in Europe - a survey analysis.**

*Nathan, M, Chatzistamatiou, K, Gallio, N, Cappello, C, Loughlin, P, Bock, S, Blanco, JL, Sendagorta, E, Etienney, I, Albuquerque, A, Vieira-Baptista, P, Schmidt, PT, Gultekin, M, Surmont, M, Ahmad, S, Bowring, J, Lyons, D, Cuming, T, Preti, M, Cruickshank, ME and Group, AS. BMC Cancer. 2025;25(1):1223. doi:10.1186/s12885-025-14564-4*

223. **Reliability and validity of the European Portuguese version of the EULAR Systemic Sclerosis Impact of Disease (ScleroID) questionnaire.**

*Neto, M, Albuquerque, F, Patricio, R, Vieira, M, Fernandes, R, Silva, A, Salvador, MJ and Santiago, T. ARP Rheumatol. 2025;4(3):194–205. doi:10.63032/DBOO2665*

224. **The Potential of Parkia platycephala from Use to Cure.**

*Nunes, J, Medeiros, R, Melonio, MC, da Rocha, CQ and Cerqueira, F. Compounds. 2025;5(4)doi:10.3390/compounds5040047*

225. **A survey on cell nuclei instance segmentation**

**and classification: Leveraging context and attention.**

*Nunes, JD, Montezuma, D, Oliveira, D, Pereira, T and Cardoso, JS. Med Image Anal. 2025;99:103360. doi:10.1016/j.media.2024.103360*

226. **Bridging Domain Gaps in Computational Pathology: A Comparative Study of Adaptation Strategies.**

*Nunes, JD, Montezuma, D, Oliveira, D, Pereira, T, Zlobec, I, Pinto, IM and Cardoso, JS. Sensors (Basel). 2025;25(9)doi:10.3390/s25092856*

227. **Testicular germ cell tumors and infertility: Exploring epigenetic dysregulation in the journey of the male germ cell towards new biomarkers and therapeutics.**

*Oliveira-Lopes, B, Tavares, NT, Henrique, R, Jeronimo, C and Lobo, J. Biochim Biophys Acta Rev Cancer. 2025;1880(5):189437. doi:10.1016/j.bbcan.2025.189437*

228. **The Inflammatory Footprint of Anti-Breast Cancer Treatments and Psychosocial Factors in Women Undergoing Chemotherapy.**

*Oliveira, MA, Almeida, SS, Martins, G, Godinho, I, Palmeira, C, Sousa, ME, Fernandes, L, Medeiros, R and Guerra, MP. Biomedicines. 2025;13(10)doi:10.3390/biomedicines13102563*

229. **Improved biosynthesis and characteristics of silver nanoparticles using marine endophytic fungi exposed to hypo-osmotic stress.**

*Oliveira, MAM, Calado, ML, Guerreiro, SFC, Dias, JR, Campos, MJ, Murray, PG and Novais, SC. Sci Rep. 2025;15(1):16327. doi:10.1038/s41598-025-98978-x*

230. **Pennisetum glaucum (L.) Oral Supplementation Mitigates Multi-Organic Dysfunction Associated with Carcinogenesis in HPV16-Transgenic Mice.**

*Oliveira, PA, Hajri, L, Moreno, AVP, Santos, CED, Brito, HO, Bastos, M, Medeiros, R, Ghodbane, S, Ammari, M, Gil da Costa, RM and Faustino-Rocha, AI. Curr Issues Mol Biol. 2025;47(10)doi:10.3390/cimb47100858*

231. **The Impact of a Rectal Spacer in VMAT Dosimetry in the Treatment of Prostate Cancer.**

*Oliveira, S, Fernandes, R, Baylina, P, Santos, J, Vieira, G, Faria, I and Pereira, N. Applied Sciences. 2025;15(17)doi:10.3390/app15179414*

232. **Evolution of the use, effectiveness and safety of bismuth-containing quadruple therapy for Helicobacter pylori infection between 2013 and 2021: results from the European registry on H. pylori management (Hp-EuReg).**

*Olmedo, L, Calvet, X, Gene, E, Bordin, DS, Voynovan, I, Castro-Fernandez, M, Pabon-Carrasco, M, Keco-Huerga, A, Perez-Aisa, A, Lucendo, AJ, Rodrigo, L, Sarsenbaeva, AS, Khlinov, IB, Fadieienko, G, Zaytsev, O, Lanas, A, Martinez-Dominguez, SJ, Alfaro, E, Jonaitis, L, Nunez, O, Pellicano, R, Hernandez, L, Gridnyev, O, Kupcinskas, J, Gasbarrini, A, Boltin, D, Niv, Y, Babayeva, G, Marcos-Pinto, R, Tepes, B, Venerito, M, Papp, V, Lerang, F, Leja, M, Phull, PS, Marlicz, W, Doulberis, M, Smith, SM, Milivojevic, V, Kunovsky, L, Mestrovic, A, Matysiak-Budnik, T, Simsek, H, Cano-Catala, A, Puig, I, Moreira, L, Parra, P, Nyssen, OP, Megraud, F, O'Morain, C, Gisbert, JP and Hp-EuReg, i. Gut. 2024;74(1):15–25. doi:10.1136/gutjnl-2024-332804*

233. **Methylation Status of the Telomerase Reverse Transcriptase Promoter in Parotid Tumours and Adjacent Parotid Gland Tissue: A Pilot Study on the Implications for Recurrence and Development of Malignancy.**

*Paiva-Correia, A, Apolonio, J, Nadal, A, Brandao, JR, Silva, N, Machado, B, Archilla, I, Castelo-Branco, P and Hellquist, H. Curr Oncol. 2025;32(6)doi:10.3390/curroncol32060312*

234. **EGFR-STAT3 activation provides a therapeutic rationale for targeting aggressive ETV1-positive prostate cancer.**

*Paiva, EG, Orr, B, Azeredo, A, Brandao, A, Teixeira, MR and Paulo, P. Mol Oncol. 2025;19(11):3287–304. doi:10.1002/1878-0261.70069*

235. **Management of Small Testicular Masses: A Delphi Consensus Study.**

*Pang, KH, Fallara, G, Lobo, J, Alnajjar, HM, Sangar, V, von Stempel, C, Huang, DY, Parnham, A, Cazzaniga, W, Giganti, F, Haider, A, Sachdeva, A, Albersen, M, Alifrangis, C, Bandini, M, Castiglione, F, De Vries, HM, Fankhauser, C, Heffernan Ho, D, Nicol, D, Shamash, J, Thomas, A, Walkden, M, Freeman, A, Muneer, A, Penile, E-Y and Testis Cancer Working, G. Eur Urol Oncol. 2025;8(1):152–63. doi:10.1016/j.euo.2024.10.010*

236. **Multilevel plasticity and altered glycosylation drive aggressiveness in hypoxic and glucose-deprived bladder cancer cells.**

*Peixoto, A, Ferreira, D, Miranda, A, Relvas-Santos, M, Freitas, R, Veth, TS, Brandao, A, Ferreira, E, Paulo, P, Cardoso, M, Gaiteiro, C, Cotton, S, Soares, J, Lima, L, Teixeira, F, Ferreira, R, Palmeira, C, Heck, AJR, Oliveira, MJ, Silva, AMN, Santos, LL and Ferreira, JA. iScience. 2025;28(2):111758. doi:10.1016/j.isci.2025.111758*

237. **Prevalence and sociodemographic correlates of sexual difficulties and sexual dissatisfaction in Portuguese men and women: a community-based online study.**

*Peixoto, MM, Pereira, TJ, Lopes, J, Pinto, V and Sousa, F. Sexual and Relationship Therapy. 2025;40(3):677–94. doi:10.1080/14681994.2025.2507790*

238. **Impact of prognostic nutritional index on oncological outcomes and mortality among advanced gastric cancer patients: European GASTRODATA registry analysis.**

*Pelc, Z, Sedlak, K, Mlak, R, Endo, Y, Gockel, I, van Sandick, J, Baiocchi, GL, Wijnhoven, B, Gisbertz, S, Pera, M, Morgagni, P, Framarini, M, Hoelscher, A, Moenig, S, Kolodziejczyk, P, Piessen, G, Eveno, C, da Costa, PM, Baker, C, Davies, A, Allum, W, Romario, UF, Rosati, R, Reim, D, Santos, LL, D'Ugo, D, de Manzoni, G, Kielan, W, Schneider, P, Pawlik, TM, Polkowski, W and Rawicz-Pruszynski, K. Int J Cancer. 2025;157(8):1734–45. doi:10.1002/ijc.35489*

239. **Metastatic Mammary-Like Adenocarcinoma of the Vulva Responding to Cyclin-Dependent Kinase (CDK) Inhibitor: A Case Report and Literature Review.**

*Pereira, F, Pimenta, JL, Rei, M, Dias, CR and Pereira, D. Cureus. 2025;17(9):e93598. doi:10.7759/cureus.93598*

240. **Antibody blockade of the PSGL-1 immune checkpoint enhances T-cell responses to B-cell lymphoma.**

*Pereira, JL, Arede, L, Ferreira, F, Matos, A, Pereira, D, Santos, RF, Carmo, AM, Oliveira, MJ, Machado, JC, Duarte, D and Dos Santos, NR. Leukemia. 2025;39(1):178–88. doi:10.1038/s41375-024-02446-w*

241. **Consensus on drivers of maintenance treatment choice and patterns of care in advanced ovarian cancer.**

*Perez-Fidalgo, A, Schmalfeldt, B, George, A, Gourley, C, Pignata, S, Lorusso, D, Barretina-Ginesta, MP, Romero, I, Grimm, C, Van Gorp, T, Rossing, M, Collins, DC, Fernebro, J, Bjorge, L, Leary, A, Rouge, TM, Harter, P, Kurzeder, C, Savva-Bordalo, J and You, B. Int J Gynecol Cancer. 2025;35(7):101863. doi:10.1136/ijgc-2024-005497*

242. **Follicular Helper T-cell Lymphoma With Hodgkin/Reed-Sternberg-Like Cells Versus Classic Hodgkin Lymphoma: A Comparative Study.**

*Petronilho, S, Poullot, E, Andre, A, Robe, C, Nouhoum, S, Fataccioli, V, Quintela, JM, Claudel, A, Briere, J, Lechapt, E, Lemonnier, F, Henrique, R, de Leval, L and Gaulard, P. Am J Surg Pathol. 2025;49(3):273–83. doi:10.1097/PAS.0000000000002345*

243. **Optimized reconstruction of the absorption spectra of kidney tissues from the spectra of tissue components using the least squares method.**

*Pinheiro, MR, Fernandes, LE, Carneiro, IC, Carvalho, SD, Henrique, RM, Tuchin, VV, Oliveira, HP and Oliveira, LM. J Biophotonics. 2025;18(12):e202300466. doi:10.1002/jbio.202300466*

244. **Social Representations of Sexual**

**Assistance Services for People with Physical Disabilities in the Context of Portugal.**

*Pinho, AR, Carvalhaes, S, Rodrigues, L, Peixoto, MM, de Oliveira, JM and Nogueira, C. Int J Sex Health. 2025;37(3):411–25. doi:10.1080/19317611.2025.2536260*

245. **The surface proteome of rabbit spermatozoa.**

*Pinto-Pinho, P, Impens, F, Dufour, S, Van Haver, D, Pinto-Leite, R, Howl, J, Fardilha, M and Colaco, B. Anim Reprod Sci. 2025;276:107834. doi:10.1016/j.anireprosci.2025.107834*

246. **The Surface Proteome of Bovine Unsexed and Sexed Spermatozoa.**

*Pinto-Pinho, P, Quelhas, J, Impens, F, Dufour, S, Van Haver, D, Lopes, G, Rocha, A, Pinto-Leite, R, Fardilha, M and Colaco, B. Animals (Basel). 2025;15(4)doi:10.3390/ani15040484*

247. **Coding and regulatory somatic profiling of triple-negative breast cancer in Sub-Saharan African patients.**

*Pinto, RJ, Ferreira, D, Salamanca, P, Miguel, F, Borges, P, Barbosa, C, Costa, V, Lopes, C, Santos, LL and Pereira, L. Sci Rep. 2025;15(1):10325. doi:10.1038/s41598-025-94707-6*

248. **Invasive lobular carcinoma subgroup analysis of the MIPA study: real-world prospective data on preoperative MRI impact across the globe.**

*Pires-Goncalves, L. Eur Radiol. 2025;35(7):3987–9. doi:10.1007/s00330-025-11414-6*

249. **Prospective Evaluation of Contrast-enhanced Mammography for Early Prediction of Pathologic Response after Neoadjuvant Therapy.**

*Pires-Goncalves, L, Aguiar, AT, Leal, C, Guimaraes-Santos, A, Abreu, M and Henrique, R. Radiol Imaging Cancer. 2025;7(3):e240117. doi:10.1148/rycan.240117*

250. **Multiple Myeloma Laboratory Diagnostics Made Simple: Practical Insights and Key Recommendations.**

*Pires, AM, Barreto, JP, Caetano, J, Soares, MJ, Geraldes, C, Fernandes, B, Coucelo, M, Chacim, S, Coelho, H, Correia, C, Cruz, AP, Cunha, M, Cunha, MR, Cunha, N, Ferraz, P, Freitas, JG, Henrique, R, Lisboa, S, Lucio, P, Paiva, A, Pedrosa, C, Ramos, I, Sarmento-Ribeiro, AB, Seabra, P, Sevilha, J, Sousa, MJR, Sousa, S, Sousa, T, Tavares, M, Trigo, F, Roque, A, Bergantim, R, Joao, C and On Behalf Of The Portuguese Multiple Myeloma, G. J Clin Med. 2025;14(19)doi:10.3390/jcm14197115*

251. **[Diagnosis and Laboratory Follow-Up of Patients with Multiple Myeloma: Guidelines from the Portuguese Multiple Myeloma Group].**

*Pires, AM, Barreto, JP, Caetano, J, Soares, MJ, Geraldes, C, Fernandes, B, Coucelo, M, Chacim, S, Coelho, H, Correia, C, Cruz, AP, Cunha, M, Cunha, MR, Cunha, N, Ferraz, P, Freitas, JG, Henrique, R, Lisboa, S, Lucio, P, Paiva, A, Pedrosa, C, Ramos, I, Sarmento, AB, Seabra, P, Sevilha, J, Rego de Sousa, MJ, Sousa, S, Sousa, T, Tavares, M, Trigo, F, Bergantim, R, Roque, A and Joao, C. Acta Med Port. 2025;38(10):654–68. doi:10.20344/amp.22909*

252. **Identification of novel candidate predisposing genes in familial nonmedullary thyroid carcinoma implicating DNA damage repair pathways.**

*Pires, C, Marques, IJ, Saramago, A, Moura, MM, Pojo, M, Cabrera, R, Santos, C, Rosario, F, Lousa, D, Vicente, JB, Bandeiras, TM, Teixeira, MR, Leite, V and Cavaco, BM. Int J Cancer. 2025;156(1):130–44. doi:10.1002/ijc.35159*

253. **Um flash do processo de cuidados de reabilitação dos enfermeiros especialistas numa instituição portuguesa.**

*Porcelis Vargas, C, Maria Manuela, M, Soraia Dornelles, S, Lucas, A and Rute Salomé da Silva, P. Revista Portuguesa de Enfermagem de Reabilitação. 2025;8(3)doi:10.33194/rper.2025.39026*

254. **Safe and transparent introduction and evaluation of targeted axillary dissection in patients with node-positive breast cancer undergoing primary surgery: international consensus process.**

*Potter, S, Mullan, R, Cain, H, St John, ER, Barry, P, Massanat, Y, Harvey, J, Fairhurst, K, Morgan, A, Perkins, M, Mann, GB, Lippey, J, Cowan, K, Blencowe, N, McIntosh, SA, Group, TTM and the, T-TC. BJS Open. 2025;9(6)doi:10.1093/bjsopen/zraf121*

255. **Association of DNA Methylation and Oral Cancer Risk: A Systematic Review and Meta-Analysis.**

*Rapado-Gonzalez, O, Sevilla-Garcia, CI, Pizcueta-Leiros, J, Salgado-Barreira, A, Pineiro-Lamas, M, De Carlos-Villafranca, F, Lopez-Lopez, R and Suarez-Cunqueiro, MM. J Evid Based Dent Pract. 2025;25(4):102169. doi:10.1016/j.jebdp.2025.102169*

256. **A Rare Cause of Female Virilization: A Case Report.**

*Realista, R, Neves, B, Pereira, J and Pinto, AR. Cureus. 2025;17(11):e96744. doi:10.7759/cureus.96744*

257. **Ultrasound in endometrial cancer: evaluating the impact of pre-surgical staging.**

*Rei, M, Bernardes, JF and Costa, A. Oncol Rev. 2025;19:1446850. doi:10.3389/or.2025.1446850*

258. **Glycomics and Glycoproteomics Reveal Distinct Oligomannose Carriers Across Bladder Cancer Stages.**

*Relvas-Santos, M, Ferreira, D, Brandao, A, Afonso, LP, Santos, LL, Silva, AMN and Ferreira, JA. Int J Mol Sci. 2025;26(10)doi:10.3390/ijms26104891*

259. **Kidney Disease and Hematopoietic Stem Cell Transplantation.**

*Renaghan, AD, Costa, JM and Esteves, A. Kidney360. 2025;6(2):317–30. doi:10.34067/KID.0000000692*

260. **Home mechanical ventilation in adults: Clinical practice recommendations from the Portuguese Respiratory Society home mechanical ventilation assembly.**

*Ribeiro, C, Gomes, R, Carreiro, A, Vieira, AL, Seabra, B, Conde, B, Nogueira, C, Jacome, C, Lages, J, Aguiar, M, Grafino, M, Pamplona, P, Cysneiros, A, Duraes, C, Rodrigues, C, Pimenta, C, Cristovao, C, Rodrigues, D, Ferreira, D, Goncalves, F, Ramos, H, Cravo, J, Silva, JP, Cunha, K, Mendez, L, Van Zeller, M, Araujo, M, Barata, M, Raposo, M, Redondo, M, Jacob, M, Araujo, MJ, Goncalves, MR, Guia, M, Faria, N, Viegas, P, Conde, S, Drummond, M and Pinto, P. Pulmonology. 2025;31(1):2598915. doi:10.1080/25310429.2025.2598915*

261. **Structural Empowerment of Nurses in the Hospital Setting: A Cross-Sectional Study.**

*Ribeiro, M, Sanches, D, Barros, S, Goncalves, M, Castro, S, Oliveira, T, Gasparino, R and Ribeiro, O. Nurs Rep. 2025;15(12)doi:10.3390/nursrep15120444*

262. **Volumetric and Linear Imaging Response After Stereotactic Radiotherapy for Vestibular Schwannoma.**

*Rocha, EM, Costa, PT, Arantes, M, Aguiar, A, Pires, A and Conde, S. Cureus. 2025;17(12):e98252. doi:10.7759/cureus.98252*

263. **GPT-4 generates accurate and readable patient education materials aligned with current oncological guidelines: A randomized assessment.**

*Rodler, S, Cei, F, Ganjavi, C, Checcucci, E, De Backer, P, Rivero Belenchon, I, Taratkin, M, Puliatti, S, Veccia, A, Piazza, P, Baekelandt, L, Kowalewski, KF, Gomez Rivas, J, Fankhauser, CD, Moschini, M, Gandaglia, G, Campi, R, De Castro Abreu, A, Russo, GI, Cocci, A, Maruccia, S, Cacciamani, GE and Collaborators, YAU. PLoS One. 2025;20(6):e0324175. doi:10.1371/journal.pone.0324175*

264. **Management of typical and atypical metastatic lung carcinoids: present and future perspectives.**

*Rodrigues, A, Henrique, R, Jeronimo, C and Araujo, A. Clin Transl Oncol. 2025;27(3):816–23. doi:10.1007/s12094-024-03607-0*

265. **Characterization of the Population, Treatment Patterns, and Outcomes of Patients with Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) with Epidermal Growth Factor Receptor Mutation (EGFRm): A Retrospective Cohort Study from IPO Porto.**

*Rodrigues, A, Pina, M, Calisto, R, Leite-Silva, P, Medeiros, P, Silva, C, Silva, AS, Redondo, P, Ramalho-Carvalho, J, Santos, SF and Bento, MJ. Curr Oncol. 2025;32(8)doi:10.3390/curroncol32080414*

266. **Improving Clinically Significant Prostate Cancer Detection with a Multimodal Machine Learning Approach: A Large-Scale Multicenter Study.**

*Rodrigues, AC, de Almeida, JG, Rodrigues, N, Moreno, R, Castro Verde, AS, Mascarenhas Gaivao, A, Bilreiro, C, Santiago, I, Ip, J, Beliao, S, Silva, S, Domingues, I, Tsiknakis, M, Marias, K, Regge, D, Papanikolaou, N and Pro, C-IC. Radiol Imaging Cancer. 2025;7(5):e240507. doi:10.1148/rycan.240507*

267. **Utilisation patterns of radiotherapy among older patients: Insights from Portuguese National Cancer Registry data.**

*Rodrigues, ED, Bento, MJ, Calisto, R, Rodrigues, J, Almeida, P, Lopez, E and Teixeira, L. J Cancer Policy. 2025;43:100522. doi:10.1016/j.jcpo.2024.100522*

268. **Is Progesterone Receptor a Neglected Feature in Breast Cancer? A Retrospective Study Analysing the Clinicopathological Characteristics of Breast Cancer Based on Progesterone Receptor Status.**

*Rodrigues, I, Fernandes, R, Ferreira, A, Pereira, D, Fernandes, R, Soares, R and Luis, C. Clin Breast Cancer. 2025;25(4):e331–e40. doi:10.1016/j.clbc.2024.11.018*

269. **The clinicopathological characteristics, oncologic outcomes and costs of "HER2-low" early breast cancer compared to HER2-zero and HER2-positive: a single-centre retrospective analysis.**

*Rodrigues, PR, Lopes-Conceicao, L, Sousa, V, Coutada, A, Bento, MJ, Coimbra, N, Leal, C, Pereira, D and Magalhaes Ferreira, A. Front Oncol. 2025;15:1579602. doi:10.3389/fonc.2025.1579602*

270. **A Rare Case of Benign Phyllodes Tumor of the Breast Responding to Anastrozole.**

*Rodrigues, PR, Mata, D, Brito-da-Silva, J, Duque, CP and Ferreira, A. Cureus. 2025;17(1):e77277. doi:10.7759/cureus.77277*

271. **Exploring the feasibility of protein phosphatase 1-docking motif-mimetic cell-penetrating peptides for modulating prostate carcinogenesis.**

*Rodrigues, RM, Felgueiras, J, Jones, S, Camilo, V, Matos, B, Jeronimo, C, Howl, J and Fardilha, M. JNCI Cancer Spectr. 2025;9(6)doi:10.1093/jncics/pkaf101*

272. **Endoscopic grading of gastric intestinal metaplasia using blue light imaging in a low-risk population: Multicenter cross-sectional validation study.**

*Rodriguez-Carrasco, M, Esposito, G, Dilaghi, E, Manfredi, G, Alicante, S, Buscarini, E, Annibale, B and Dinis-Ribeiro, M. Endosc Int Open. 2025;13:a25003748. doi:10.1055/a-2500-3748*

273. **Model organisms for investigating the functional involvement of NRF2 in non-communicable diseases.**

*Rojo, AI, Buttari, B, Cadenas, S, Carlos, AR, Cuadrado, A, Falcao, AS, Lopez, MG, Georgiev, MI, Grochot-Przeczek, A, Gumeni, S, Jimenez-Villegas, J, Horbanczuk, JO, Konu, O, Lastres-Becker, I, Levonen, AL, Maksimova, V, Michaeloudes, C, Mihaylova, LV, Mickael, ME, Milisav, I, Miova, B, Rada, P, Santos, M, Seabra, MC, Strac, DS, Tenreiro, S, Trougakos, IP and Dinkova-Kostova, AT. Redox Biol. 2025;79:103464. doi:10.1016/j.redox.2024.103464*

274. **Reply to Mussetto et al.**

*Rosa, B, Curdia Goncalves, T, Moreira, MJ, Dias de Castro, F, Sousa-Pinto, B, Dinis-Ribeiro, M and Cotter, J. Endoscopy. 2025;57(4):426–7. doi:10.1055/a-2464-1297*

275. **Immune-Mediated Thrombocytopenia Induced by Niraparib: A Clinically Relevant Case.**

*Roxo, F, Duarte, D and Abreu, MH. Cureus. 2025;17(11):e97299. doi:10.7759/cureus.97299*

276. **Impact of Obesity and Ageing on the Expression of Key Mediators of SARS-CoV-2 Infection in Human Adipose Tissue.**

*Salazar, M, Ferreira, M, Oliveira, SM, Saraiva, F, Pinho, C, Jarnalo, M, Correia-Sa, I, Falcao-Pires, I, Leite-Moreira, A, Neves, D, Almeida, H, Rodrigues, AR and Gouveia, AM. Int J Mol Sci. 2025;26(15)doi:10.3390/ijms26157313*

277. **Methylation-Specific Droplet Digital PCR: Testing a Novel Triage Tool for HrHPV-Positive Women in the Cervical Cancer Screening Program of Northern Portugal.**

*Salta, S, Sequeira, JP, Amorim-Fernandes, B, Lobo, J, Baldaque, I, Monteiro, P, Tavares, F, Taly, V, Henrique, R and Jeronimo, C. MedComm (2020). 2025;6(7):e70203. doi:10.1002/mco2.70203*

278. **Breast Primary Follicular Lymphoma: Two Cases of a Rare Entity Treated With Radical Radiotherapy and Rituximab.**

*Samarao, L, Mariz, JM, Goncalves, J, Martins, A and Castro, C. Cureus. 2025;17(11):e95870. doi:10.7759/cureus.95870*

279. **A preliminary assessment of a stool-based microRNA profile for early colorectal cancer screening.**

*Santos, DAR, Eiras, M, Gonzalez-Santos, M, Santos, M, Pereira, C, Santos, LL, Dinis-Ribeiro, M and Lima, L. Sci Rep. 2025;15(1):28597. doi:10.1038/s41598-025-14485-z*

280. **NURSING BEST PRACTICE RECOMMENDATIONS FOR INTRAVESICAL INSTILLATION IN BLADDER CANCER: ADAPTATION TO THE PORTUGUESE ONCOLOGICAL CARE.**

*Santos Ventura, FIQ, Ribeiro, VMA, Claro, IGV, Silva, ALTS, Afonso Silva, ARÁ, Gonçalves Marques, SCF, Girão, MCM, Santos, CMO, Chemela, R and Barreira, MER. Onco.News. 2025;2025-July-December(51)doi:10.31877/on.2025.51.03*

281. **Hallmarks of Cancer Cachexia: Sexual Dimorphism in Related Pathways.**

*Satari, S, Mota, INR, Silva, ACL, Brito, HO, Oliveira, PA, Gil da Costa, RM and Medeiros, R. Int J Mol Sci. 2025;26(9)doi:10.3390/ijms26093952*

282. **Staging Laparoscopy in Gastric Cancer Patients Treated with Curative Intent: A European GASTRODATA Cohort Study.**

*Sedlak, K, Kobialka, S, Pelc, Z, Endo, Y, Gockel, I, van Sandick, J, Baiocchi, GL, Wijnhoven, B, Gisbertz, S, Pera, M, Morgagni, P, Framarini, M, Hoelscher, A, Moenig, S, Kolodziejczyk, P, Piessen, G, Eveno, C, da Costa, PM, Davies, A, Allum, W, Romario, UF, Rosati, R, Reim, D, Santos, LL, D'Ugo, D, De Manzoni, G, Kielan, W, Schneider, PM, Pawlik, TM, Polkowski, W and Rawicz-Pruszynski, K. Ann Surg Oncol. 2025;32(10):7615–26. doi:10.1245/s10434-025-17905-6*

283. **Molecular characterisation of Mozambican patients diagnosed with colorectal adenocarcinoma.**

*Selemane, C, Ferreira, D, Veiga, I, Rocha, P, Jamisse, L, Buane, L, Guisseve, A, Carrilho, C, Ismail, M, Teixeira, MR and Santos, LL. J Gastrointest Oncol. 2025;16(3):1025–37. doi:10.21037/jgo-24-677*

284. **Moderate to Severe Short Stature and Joint Involvement in Individuals With ACAN Deletions.**

*Sentchordi-Montane, L, Diaz-Gonzalez, F, Modamio-Hoybjor, S, Nevado, J, Machado-Fernandes, F, Carcavilla, A, Salcedo, M, Saraiva, J, Kant, SG, de Bruin, C, van Duyvenvoorde, HA, Gonzalez-Cabaleiro, I, Rey-Cordo, L, Chamorro-Martin, JL, Cancela-Muniz, V, Alcon-Saez, JJ, Parron-Pajares, M, Sousa, SB and Heath, KE. Clin Endocrinol (Oxf). 2025;103(2):177–84. doi:10.1111/cen.15237*

285. **European Cancer Organisation Essential Requirements for Quality Cancer Care for ovarian cancer: Focus on the multidisciplinary team.**

*Sessa, C, Travado, L, Calaminus, G, Cunha, TM, Delgado Bolton, RC, van Driel, W, Fernandes, A, Hutka, M, Lemley, B, Luczak, N, Medeiros, R, Oberst, S, Ottevanger, N, Papadia, A, Pereira, P, Rodrigues, M, Stolnicu, S, Vandecasteele, K, Costa, A, Poortmans, P and Peccatori, F. Tumori. 2025;111(1):11–9. doi:10.1177/03008916241303022*

286. **Endoscopic stratification of gastric**

**intestinal metaplasia: where are we, where do we want to go and how do we get there?**

*Shah, SC and Dinis-Ribeiro, M. Gut. 2025;74(5):867–8. doi:10.1136/gutjnl-2024-333977*

287. **Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer.**

*Shitara, K, Van Cutsem, E, Gumus, M, Lonardi, S, de la Fouchardiere, C, Coutzac, C, Dekervel, J, Hochhauser, D, Shen, L, Mansoor, W, Liu, B, Fornaro, L, Ryu, MH, Lee, J, Faustino, C, Metges, JP, Tabernero, J, Franke, F, Janjigian, YY, Souza, F, Jukofsky, L, Zhao, Y, Kamio, T, Zaanan, A, Pietrantonio, F and Investigators, DE-GT. N Engl J Med. 2025;393(4):336–48. doi:10.1056/NEJMoa2503119*

288. **Mapping study on AI-based technologies in palliative care - a scoping study.**

*Silva-Ferreira, M, Cruz, S, Luis, MS, Silva, MC, Monteiro-Reis, S, Henrique, R, Jeronimo, C, Lefevre, SC, Laplaud, A, Frasca, M, Pollet, L, Zurbanobeaskoetxea, L, Barbastro, RA, Garcia, MIH, Galan, BJ, Palau, FG, Marques, DF and Duran, RL. BMC Palliat Care. 2025;24(1):274. doi:10.1186/s12904-025-01909-w*

289. **Competencies of nurses in clinical trials: Integrative review of literature.**

*Silva, A, Cruz, M and Araújo, N. Onco.News. 2025;2025-January-June(50)doi:10.31877/on.2024.50.03*

290. **Author's reply: "Improving screening participation: The need for socioeconomic considerations and psychological interventions in colorectal cancer programs".**

*Silva, JC, Dinis-Ribeiro, M and Libanio, D. Dig Liver Dis. 2025;57(6):1333–4. doi:10.1016/j.dld.2025.02.016*

291. **Adherence, risk perception, and attitudes towards colorectal cancer screening: A road to individualized screening?**

*Silva, JC, Dinis-Ribeiro, M, Tavares, F and Libanio, D. Dig Liver Dis. 2025;57(6):1162–70. doi:10.1016/j.dld.2024.11.027*

292. **Exploring the Perceived Risk of Complications in Endoscopic Screening Procedures.**

*Silva, JC, Dinis-Ribeiro, M, Tavares, F and Libanio, D. GE Port J Gastroenterol. 2025;32(6):404–13. doi:10.1159/000543180*

293. **Impact of a FIT Based Colorectal Cancer Screening Program on Gastric Cancer Incidence, Early Diagnosis and Patients' Survival.**

*Silva, JC, Leite-Silva, P, Tavares, F, Bento, MJ, Libanio, D and Dinis-Ribeiro, M. Helicobacter. 2025;30(5):e70071. doi:10.1111/hel.70071*

294. **Long-Term Persistent Headache After SARS-CoV-2 Infection: A Follow-Up Population-Based Study.**

*Silva, L, Fernandes, J, Lopes, R, Costa, S, Malheiro, S, Aires, E, Pereira, D, Fonte, J, Dias, A, Oliveira, V, Cavaco, S, Magalhaes, R, Correia, M, Andrade, C and Maia, LF. Eur J Neurol. 2025;32(5):e70130. doi:10.1111/ene.70130*

295. **Anaesthetic Management of Advanced Late-Onset Pompe Disease: Challenges in a Major Abdominal Surgery.**

*Silva, M, Santos, MF and Cardoso, G. Cureus. 2025;17(9):e93349. doi:10.7759/cureus.93349*

296. **Sociodemographic Characteristics Associated With Food-Insecure Households With Preschool and School Children: Findings From the ObesInCrisis Study.**

*Silva, MG, Rodrigues, D, Machado-Rodrigues, AM, Nogueira, H, Gama, A and Padez, C. Am J Hum Biol. 2025;37(6):e70080. doi:10.1002/ajhb.70080*

297. **Domino synthesis of a new class of red-shifted and antimicrobial imidazole-based azo dyes from 5-aminoimidazole-4-carboxamidrazones.**

*Silva, MP, Silva, B, Costa, I, Coutinho, PJG, Cerqueira, F, Pinto, E and Dias, AM. Org Biomol Chem. 2025;23(20):4983–96. doi:10.1039/d5ob00463b*

298. **A família e a vivência da deficiência física adquirida: desafios e estratégias no cuidado.**

*Silva Pereira, RS, Martins, MM, Machado, WCA, Lourenço, MdC, Vargas, CP and Schoeller, SD. Revista Portuguesa de Enfermagem de Reabilitação. 2025;8(2)doi:10.33194/rper.2025.40611*

299. **Programa de Intervenção de Enfermagem para o Autocuidado ao Estoma de Eliminação Intestinal: Um Grupo Focal.**

*Soares-Pinto, I, Queirós, S, Silva, C, Alves, P, Santos, C and Brito, M. Revista de Enfermagem Referência. 2025;VI Série(N.º 4)doi:10.12707/rvi25.16.39839*

300. **Immune Checkpoint Inhibitor-Induced Hepatitis: A Case Report of Challenging Management.**

*Soldin, I, Teixeira, R, Ortigao, R, Lapa, A and Lima, S. Cureus. 2025;17(1):e77331. doi:10.7759/cureus.77331*

301. **Cytokine-based immunotherapy in hematolymphoid malignancies.**

*Sousa-Pimenta, M and Dos Santos, NR. Int Rev Cell Mol Biol. 2025;396:55–79. doi:10.1016/bs.ircmb.2025.01.003*

302. **Completeness Evaluation of Adult-Population-Based Cancer Registries: A Systematic Review.**

*Sousa, MP, Monjardino, T, Santos, CC, Lara, L and Bento, MJ. Cancers (Basel). 2025;17(7)doi:10.3390/cancers17071123*

303. **Cellulose-Based Colorimetric Test Strips for SARS-CoV-2 Antibody Detection.**

*Sousa, MP, Pereira, AC, Correia, B, do Carmo, A, Matos, AM, Cruz, MT and Moreira, FTC. Biosensors (Basel). 2025;15(6)doi:10.3390/bios15060390*

304. **Beam data commissioning, validation and clinical implementation of SRS gyroscopic system.**

*Souto, C, Aguilar, B, Dias, V, Pascual, E, Farinha, G, Marcelino, C, Rodrigues, C, Teles, P, Perez-Rozos, A, Sallabanda, M and Sallabanda, K. Phys Med. 2025;133:104952. doi:10.1016/j.ejmp.2025.104952*

305. **Multi-Observer Study on the Assessment of Pediatric Gonadal Tumors Using Higher Harmonic Generation Microscopy as Compared to Conventional Histology.**

*Spies, S, Nazarian, E, Bremmer, F, Gonzalez, IA, Lobo, J, Reyes-Mugica, M, Zambrano, E, Hulsker, CCC, Mavinkurve-Groothuis, AMC, de Krijger, RR and Groot, ML. Cancers (Basel). 2025;17(10)doi:10.3390/cancers17101636*

306. **Extracellular vesicles derived-microRNAs predicting enzalutamide-resistance in 3D spheroid prostate Cancer model.**

*Tavares, I, Morais, M, Dias, F, Ferreira, M, Martins, G, Fernandes, R, Bidarra, SJ, Medeiros, R and Teixeira, AL. Int J Biol Macromol. 2025;284(Pt 1):137993. doi:10.1016/j.ijbiomac.2024.137993*

307. **Current Role of MicroRNAs in the Diagnosis and Clinical Management of Germ Cell Tumors.**

*Tavares, NT, Henrique, R, Jeronimo, C and Lobo, J. Surg Pathol Clin. 2025;18(1):91–100. doi:10.1016/j.path.2024.08.003*

308. **MicroRNA-371-373 cluster extracellular vesicle-based communication in testicular germ cell tumors.**

*Tavares, NT, Lourenco, C, Constancio, V, Fernandes-Pontes, F, Fonseca, D, Silva-Santos, R, Braga, I, Mauricio, J, Henrique, R, Liu, M, Weiss, RS, Bagrodia, A, Jeronimo, C and Lobo, J. Cell Commun Signal. 2025;23(1):252. doi:10.1186/s12964-025-02250-8*

309. **Genetic markers of thrombophilia as predictors of outcome in colorectal cancer.**

*Tavares, V, Lopes, C, Macedo-Silva, C, Farinha, M, Costa, J, Vilas-Boas, MI, Pinelas, S, Assis, J, Dinis-Ribeiro, M, Pereira, D, Pereira, C and Medeiros, R. J Thromb Thrombolysis. 2025;58(5):663–78. doi:10.1007/s11239-025-03106-1*

310. **Heritable Genetic Variability in Ovarian Tumours: Exploring Venous Thromboembolism Susceptibility and Cancer Prognosis in a Hospital-Based Study.**

*Tavares, V, Savva-Bordalo, J, Rei, M, Liz-Pimenta, J, Assis, J, Pereira, D and Medeiros, R. Gene. 2025;950:149378. doi:10.1016/j.gene.2025.149378*

311. **Characteristics and Mortality of Patients With Cancer Diagnosed With SARS-CoV-2 in Northern Portugal.**

*Taveira-Barbosa, J, Garcia, T, Lebre, A, Fontes, F, Brandao, M, Calisto, R, Ture, R, Bento, MJ, Lunet, N, Morais, S and Lopes-Conceicao, L. Anticancer Res. 2025;45(4):1749–60. doi:10.21873/anticanres.17555*

312. **Second primary cancers among males with a first primary prostate cancer: a population-based study in Northern Portugal.**

*Taveira-Barbosa, J, Morais, S, Garcia, T, Bento, MJ and Lunet, N. Clin Exp Med. 2025;25(1):122. doi:10.1007/s10238-025-01654-7*

313. **Toxicities in long-term survivors of head and neck cancer-A multi-national cross-sectional analysis.**

*Taylor, KJ, Amdal, CD, Bjordal, K, Astrup, GL, Herlofson, BB, Duprez, F, Gama, RR, Jacinto, A, Hammerlid, E, Scricciolo, M, Jansen, F, Verdonck-de Leeuw, IM, Fanetti, G, Guntinas-Lichius, O, Inhestern, J, Dragan, T, Fabian, A, Boehm, A, Wohner, U, Kiyota, N, Kruger, M, Bonomo, P, Pinto, M, Nuyts, S, Silva, JC, Stromberger, C, Specenier, P, Tramacere, F, Bushnak, A, Perotti, P, Plath, M, Paderno, A, Stempler, N, Kouri, M, Gregoire, V, Tribius, S, Singer, S, Group, EQoL, the, EH and Neck, G. Int J Cancer. 2025;157(10):2061–70. doi:10.1002/ijc.70033*

314. **Editorial: Exploring HPV's role in genitourinary cancers beyond cervical cancer.**

*Teixeira, AL, Dias, F and Gil da Costa, RM. Front Oncol. 2025;15:1658619. doi:10.3389/fonc.2025.1658619*

315. **Treatment of Locally Advanced and Metastatic Salivary Gland Cancer: A 10-year Experience of an Oncology Center in Portugal.**

*Teixeira, AR, Agostinho, C, Dias, C, Soares, R, Pina, M, Dinis, J, Lopes-Conceicao, L and Vieira, C. Acta Med Port. 2025;38(10):608–18. doi:10.20344/amp.22800*

316. **Short Hydration Regimen in Cisplatin-Based Chemotherapy and Its Impact on Nephrotoxicity: A Unicentric Prospective Study.**

*Teixeira, AR, Mata, D, Ferreira, H, Paiva, A, Pelayo, MJ, Rafael, C, Mauricio, J, Calisto, R and Cassiano Neves, M. Cureus. 2025;17(2):e79774. doi:10.7759/cureus.79774*

317. **Local DRL estimation and effective dose calculation in paediatric interventional cardiology using measurements and Monte Carlo simulations.**

*Teles, P, Costa, R, Bettio, T, Pinheiro, T, Loupa, T, Santos, J, Pinto, F, Gil, OM, Ferrari, P and Zankl, M. Phys Med. 2025;135:105023. doi:10.1016/j.ejmp.2025.105023*

318. **Controversies in NEN: An ENETS position statement on the management of locally advanced neuroendocrine neoplasia of the small intestine and pancreas without distant metastases.**

*Tesselaar, MET, Partelli, S, Braat, A, Croitoru, A, Soares Santos, AP, Schrader, J, Welin, S, Christ, E, Falconi, M and Bartsch, DK. J Neuroendocrinol. 2025;37(12):e70083. doi:10.1111/jne.70083*

319. **Case Report: Hypercalcemic small-cell carcinoma of the ovary during pregnancy: diagnostic and therapeutic challenges.**

*Tripepi, M, da Costa, AG, Albergaria, D, Costa, A, Catarino, A, Duarte, AL, Bartosch, C, Schuler, V, Oliveira, J, Lima, J and Casanova, J. Front Oncol. 2025;15:1648580. doi:10.3389/fonc.2025.1648580*

320. **Impact of postoperative complications on clinical outcomes after gastrectomy for cancer: multicentre study.**

*van Hootegem, SJM, van der Linde, M, Schneider, MA, Kim, J, Berlth, F, Sugita, Y, Grimminger, PP, Baiocchi, GL, De Manzoni, G, Bencivenga, M, Gisbertz, S, Nunobe, S, Yang, HK, Gutschow,*

*CA, Lagarde, SM, Lingsma, HF, Wijnhoven, BPL, GastroBenchmark, C and Consortium, G. Br J Surg. 2025;112(4)doi:10.1093/bjs/znaf043*

321. **Quiet Quitting Scale: Adaptation and Validation for the Portuguese Nursing Context.**

*Ventura-Silva, JMA, Ribeiro, MP, Barros, S, Castro, SFM, Sanches, DMM, Trindade, LL, Teles, P, Zuge, SS and Ribeiro, O. Nurs Rep. 2025;15(12)doi:10.3390/nursrep15120411*

322. **Effectiveness of First-Line Empirical Treatment in Portugal: Data from the European Registry on Helicobacter pylori Management.**

*Viegas, MI, Areia, M, Elvas, L, Marcos-Pinto, R, Fernandes-Mendes, H, Alves, S, Brito, D, Saraiva, S, Cadime, AT, Cano-Catala, A, Parra, P, Moreira, L, Megraud, F, O'Morain, C, O, PN, Gisbert, JP and Hp-EuReg, i. GE Port J Gastroenterol. 2025;32(5):339–49. doi:10.1159/000543179*

323. **Self-perception of oropharyngeal cancer patients regarding the impacts of chemoradiotherapy treatments on swallowing and voice functions.**

*Vieira, D, Barreira, S, Dinis-Ribeiro, M and Monteiro, E. Revista de Logopedia, Foniatría y Audiología. 2025;45(2)doi:10.1016/j.rlfa.2025.100518*

324. **Patient and Healthcare Professional Perceptions.**

*Vieira, D, Sousa, ECT, Laranja, A, Soares, A, Dinis-Ribeiro, M and Monteiro, E. Holistic Approaches to Health Recovery2025. p. 291–320. doi:10.4018/979-8-3693-6432-1.ch010*

325. **External validation of a prediction model for bleeding events in anticoagulated cancer patients with venous thromboembolism (PredictAI).**

*Vinuela-Beneitez, MC, Iglesias Perez, C, Ortega Moran, L, Garcia Escobar, I, Cacho Lavin, D, Porta, IBR, Garcia Adrian, S, Carmona Campos, M, Benitez Lopez, G, Santiago Crespo, JA, Lobo de Mena, M, Perez Altozano, J, Gallardo Diaz, E, Tejerina Peces, J, Ochoa Rivas, P, Ortiz Morales, MJ, Castellon Rubio, VE, Diez Pedroche, C, Rosales Sueiro, M, Goncalves, F, Sanchez-Canovas, M, Ruiz, MA, Munoz-Langa, J, Perez Segura, P, de Castro, EM, Carmona-Bayonas, A, Jimenez-Fonseca, P and Munoz Martin, AJ. Clin Transl Oncol. 2025;27(10):4031–9. doi:10.1007/s12094-025-03890-5*

326. **Mandibular Follicular Lymphoma: A Rare Extranodal Presentation With Initial Facial Bone Involvement.**

*Vital, C, Leite, PM, Martins, M and Gomes, P. Cureus. 2025;17(10):e94289. doi:10.7759/cureus.94289*

327. **Systematic Review of Phylogenetic Analysis Techniques for RNA Viruses Using Bioinformatics.**

*Wadas, I and Domingues, I. Int J Mol Sci. 2025;26(5)doi:10.3390/ijms26052180*

328. **Overall Survival with Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC.**

*Yang, JC, Lu, S, Hayashi, H, Felip, E, Spira, AI, Girard, N, Kim, YJ, Lee, SH, Ostapenko, Y, Danchaivijitr, P, Liu, B, Alip, A, Korbenfeld, E, Mourao Dias, J, Besse, B, Passaro, A, Lee, KH, Xiong, H, How, SH, Cheng, Y, Chang, GC, Yoshioka, H, Thomas, M, Nguyen, D, Ou, SI, Mukhedkar, S, Prabhash, K, D'Arcangelo, M, Alatorre-Alexander, J, Vazquez Limon, JC, Alves, S, Stroyakovskiy, D, Peregudova, M, Sendur, MAN, Yazici, O, Califano, R, Gutierrez Calderon, V, de Marinis, F, Kim, SW, Gadgeel, SM, Owen, S, Xie, J, Sun, T, Mehta, J, Venkatasubramanian, R, Ennis, M, Fennema, E, Daksh, M, Roshak, A, Man, J, Knoblauch, RE, Bauml, JM, Baig, M, Shah, S, Sethi, S, Cho, BC and Investigators, M. N Engl J Med. 2025;393(17):1681–93. doi:10.1056/NEJMoa2503001*

# IPO PORTO RESEARCH CENTER @ NEWS

## Media




Comprehensive Cancer Center Presentation with an interview and video with several IPO Porto Research Center Researchers by CCDR NORTE




Interview to SIC Notícias from Prof. Rui Medeiros about the HPV Awareness Day (2nd March 2025)




News about of nomination of Prof. Lúcio Lara Santos as Portugal representative in the IARC/WHO (29th May 2025)




IPO Porto Researchers developed a vaccine prototype to treat cancer (25th June 2025)




Interview to Jornal de Notícias by Prof. Rui Henrique about Precision Medicine (6th July 2025)




Interview to the RISE Associate Lab Online platforms by Dr. Carina Pereira about the use of saliva to gastric cancer detection (31st July 2025)




Creation Comprehensive Cancer Infrastructure of Northen Portugal (18th September 2025)




Creation of a prototherapy center at IPO Porto (24th October 2025)




Interview to Público highlighting the Maria de Sousa Award and the scientific contribution to gastric cancer research (4th November 2025)

## Social Media




IPO Porto attributed 10 grants for collaborative projects – Dr. José Guimarães dos Santos Grants (22nd April 2025)




IPO Porto Researchers among the World best scientists (21st August 2025)




Open Day IPO Porto Research Center – 2nd Edition




Prof. Rui Henrique elected European Academy of Cancer Sciences (EACS) Fellow




IPO Porto Research Center collaborated to the Researchers European Night 2025




Beatriz Matos, a PhD Student was awarded with a CMU Portugal Grant

# 2025 ACTIVITY REPORT